---
title: 标准化建设（三）
author: charlie
date: 2025-12-05T00:00:00.000Z
cover: /uploads/download.jpg
summary: 国内外相关医学影像标准情况简介
tags:
  - 标准化建设
---

# ACR-AC 章节化文档

* 来源文件: `ACR_data/ACR_final_with_codes.csv`
* 生成时间: 2025-12-04T23:37:41
* 数据行数: 1014

## 统计概览

* 科室（Panel）数量: 1
* 主题（Topic）数量: 17
* 变体（Variant）场景数: 126
* 检查推荐条目总数: 1014

## 内容说明

* 本文件从原始表格构建，包含英中双语字段。
* 章节结构为 `Panel → Topic → Variant`。
* 每个 Variant 下聚合了所有相关的检查项目推荐，按评分降序排列。
* 编码列格式：`P:检查编码` `R:推荐编码`。

### 字段清单

* 临床科室 (Panel)
* 临床主题 (Topic)
* 临床场景 (Variant)
* 适宜性类别
* 评分
* 中位数
* 检查项目（英文/中文）
* 推荐说明（英文/中文）
* 证据强度
* 辐射风险 (Adult/Peds)
* 相关编码

## 目录

* [P0001 Breast | 乳腺外科](#p0001-breast---乳腺外科)
  * [T0001 Breast Imaging During Pregnancy | 妊娠期乳腺影像学检查](#p0001-breast---乳腺外科-t0001-breast-imaging-during-pregnancy---妊娠期乳腺影像学检查)
  * [T0002 Breast Imaging of Lactating Women | 哺乳期女性乳腺影像学检查](#p0001-breast---乳腺外科-t0002-breast-imaging-of-lactating-women---哺乳期女性乳腺影像学检查)
  * [T0003 Breast Implant Evaluation | 乳腺植入物评估](#p0001-breast---乳腺外科-t0003-breast-implant-evaluation---乳腺植入物评估)
  * [T0004 Breast Pain | 乳腺疼痛](#p0001-breast---乳腺外科-t0004-breast-pain---乳腺疼痛)
  * [T0005 Evaluation of Nipple Discharge | 乳头溢液评估](#p0001-breast---乳腺外科-t0005-evaluation-of-nipple-discharge---乳头溢液评估)
  * [T0006 Evaluation of the Symptomatic Male Breast | 有症状男性乳腺评估](#p0001-breast---乳腺外科-t0006-evaluation-of-the-symptomatic-male-breast---有症状男性乳腺评估)
  * [T0007 Female Breast Cancer Screening | 女性乳腺癌筛查](#p0001-breast---乳腺外科-t0007-female-breast-cancer-screening---女性乳腺癌筛查)
  * [T0008 Imaging after Breast Surgery | 乳腺术后影像学检查](#p0001-breast---乳腺外科-t0008-imaging-after-breast-surgery---乳腺术后影像学检查)
  * [T0009 Imaging after Mastectomy and Breast Reconstruction | 乳腺切除与重建术后影像学检查](#p0001-breast---乳腺外科-t0009-imaging-after-mastectomy-and-breast-reconstruction---乳腺切除与重建术后影像学检查)
  * [T0010 Imaging of Ductal Carcinoma in Situ (DCIS) | 乳腺导管原位癌（DCIS）影像学检查](#p0001-breast---乳腺外科-t0010-imaging-of-ductal-carcinoma-in-situ--dcis----乳腺导管原位癌-dcis-影像学检查)
  * [T0011 Imaging of Invasive Breast Cancer | 浸润性乳腺癌影像学检查](#p0001-breast---乳腺外科-t0011-imaging-of-invasive-breast-cancer---浸润性乳腺癌影像学检查)
  * [T0012 Imaging of the Axilla | 腋窝影像学检查](#p0001-breast---乳腺外科-t0012-imaging-of-the-axilla---腋窝影像学检查)
  * [T0013 Male Breast Cancer Screening | 男性乳腺癌筛查](#p0001-breast---乳腺外科-t0013-male-breast-cancer-screening---男性乳腺癌筛查)
  * [T0014 Monitoring Response to Neoadjuvant Systemic Therapy for Breast Cancer | 乳腺癌新辅助全身治疗疗效监测](#p0001-breast---乳腺外科-t0014-monitoring-response-to-neoadjuvant-systemic-therapy-for-breast-cancer---乳腺癌新辅助全身治疗疗效监测)
  * [T0015 Palpable Breast Masses | 可触及乳腺肿块](#p0001-breast---乳腺外科-t0015-palpable-breast-masses---可触及乳腺肿块)
  * [T0016 Supplemental Breast Cancer Screening Based on Breast Density | 基于乳腺密度的补充性乳腺癌筛查](#p0001-breast---乳腺外科-t0016-supplemental-breast-cancer-screening-based-on-breast-density---基于乳腺密度的补充性乳腺癌筛查)
  * [T0017 Transgender Breast Cancer Screening | 跨性别乳腺癌筛查](#p0001-breast---乳腺外科-t0017-transgender-breast-cancer-screening---跨性别乳腺癌筛查)

## 章节化文本

### P0001 Breast | 乳腺外科

* 科室编码: P0001

#### T0001 Breast Imaging During Pregnancy | 妊娠期乳腺影像学检查

* 主题编码: T0001

##### S0001 Variant: Variant 1:  Pregnant female. Age 40 years or older. Breast cancer screening. Any risk. | 妊娠期女性，≥40岁，乳腺癌筛查，任何风险。

检查推荐列表：

* 检查项目: Mammography Screening / MG双侧乳腺钼靶
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0010
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Mammography is considered safe during pregnancy \[2,17]. Scatter radiation to the fetus is negligible \[2]. 妊娠期进行乳腺X线摄影被认为是安全的\[2,17]。散射辐射对胎儿的影响可忽略不计\[2]。
* 检查项目: Digital Breast Tomosynthesis Screening / MG双侧乳腺钼靶(筛查)
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0001 / R:CR000001
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Mammography is considered safe for screening for breast cancer for pregnant women ≥40 years of age. Tomosynthesis with mammography may provide added benefit of detection in denser breast tissue of pregnancy \[3,8]. Scatter radiation to the fetus is negligible \[2]. 乳腺X线摄影被认为是40岁及以上孕妇筛查乳腺癌的安全方法。乳腺X线断层合成技术可为妊娠期致密乳腺组织提供额外的检测优势\[3,8]。胎儿受到的散射辐射可忽略不计\[2]。
* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 5
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0003 / R:CR000003
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: During pregnancy the breasts undergo considerable physiological changes. No studies to date have evaluated the usefulness of screening whole-breast ultrasound (US) (handheld or automated) during pregnancy \[2]. 妊娠期间乳房会发生显著的生理变化。迄今为止，尚无研究评估妊娠期全乳房超声筛查（手持式或自动式）的有效性\[2]。
* 检查项目: Mammography With IV Contrast / MG双侧乳腺钼靶导管造影
  * 评分: 2
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0004 / R:CR000004
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Diagnostic iodinated contrast media crosses the placenta and enters the fetus. There are no available data regarding potential harm to the fetus exposed to maternal iodinated contrast media \[11]. 诊断用碘造影剂可穿过胎盘进入胎儿体内。目前尚无关于母体接触碘造影剂对胎儿潜在危害的数据\[11]。
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000007
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no evidence to support the use of noncontrast breast MRI for screening of breast cancer in pregnancy. 目前尚无证据支持在妊娠期使用非对比增强乳腺MRI进行乳腺癌筛查。
* 检查项目: MRI Breast Without IV Contrast Abbreviated / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000007
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no evidence to support the use of noncontrast breast MRI for screening of breast cancer in pregnancy. 目前尚无证据支持在妊娠期使用非对比增强乳腺MRI进行乳腺癌筛查。
* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000005
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: Contrast-enhanced MRI is not recommended during pregnancy because IV gadolinium crosses the placenta and enters fetal circulation \[3,7]. Within the amniotic fluid, the gadolinium may dissociate into toxic free gadolinium 不推荐在妊娠期使用对比增强MRI，因为静脉注射钆剂会穿过胎盘进入胎儿循环\[3,7]。在羊水中，钆剂可能解离成有毒性的游离钆。
* 检查项目: MRI Breast Without and With IV Contrast Abbreviated / MR乳腺(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000005
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: Contrast-enhanced MRI is not recommended during pregnancy because IV gadolinium crosses the placenta and enters fetal circulation \[3,7]. Within the amniotic fluid, the gadolinium may dissociate into toxic free gadolinium ions \[7]. The ACR Manual on Contrast Media \[11] outlines the guidelines for the use of gadolinium in pregnancy. 妊娠期不建议使用增强MRI，因为静脉注射钆剂会穿过胎盘进入胎儿循环\[3,7]。在羊水中，钆剂可能解离为有毒性的游离钆离子\[7]。《ACR造影剂使用手册》\[11]详细说明了妊娠期钆剂使用指南。
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000009
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: Molecular breast imaging (MBI) is contraindicated in breast cancer screening in pregnancy. Tc-99m sestamibi crosses the placenta and thus exposes the fetus to unnecessary radiation \[18,19]. 妊娠期乳腺癌筛查禁用分子乳腺成像（MBI）。锝-99m司他米易通过胎盘屏障，导致胎儿遭受不必要的辐射暴露\[18,19]。

##### S0002 Variant: Variant 2:  Pregnant female. Age less than 25 years. Breast cancer screening. Higher-than-average risk. | 妊娠期女性，\<25岁，乳腺癌筛查，高于平均风险。

检查推荐列表：

* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 5
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0003 / R:CR000010
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: During pregnancy, the breasts undergo considerable physiological changes. No studies to date have evaluated the US could be considered supplemental in pregnancy (based on results seen in nonpregnant women) for those at high risk of breast cancer \[20,21]. 妊娠期间乳房经历显著的生理变化。迄今尚无研究评估超声在妊娠期的应用，对于乳腺癌高风险人群（基于非妊娠女性数据）可考虑将超声作为补充手段\[20,21]。
* 检查项目: Mammography Screening / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Mammography is not advised for screening for breast cancer in women \<25 years of age. Screening mammography is generally not performed before the age of 30 in high-risk patients. 不建议对25岁以下女性进行乳腺癌筛查的乳腺X线摄影检查。对于高风险患者，通常在30岁之前不进行筛查性乳腺X线摄影。
* 检查项目: Digital Breast Tomosynthesis Screening / MG双侧乳腺钼靶(筛查)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0001 / R:CR000011
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Mammography is not advised for screening for breast cancer in women \<25 years of age. Digital breast tomosynthesis (DBT) is generally not performed before the age of 30 in high-risk patients. 不建议对25岁以下女性采用乳腺X线摄影进行乳腺癌筛查。高风险患者通常在30岁前不进行数字乳腺断层合成（DBT）检查。
* 检查项目: Mammography With IV Contrast / MG双侧乳腺钼靶导管造影
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0004 / R:CR000013
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Diagnostic iodinated contrast media crosses the placenta and enters the fetus. There are no available data regarding potential harm to the fetus exposed to maternal iodinated contrast media \[11]. 诊断用碘造影剂可穿过胎盘进入胎儿体内。目前尚无关于母体接触碘造影剂对胎儿潜在危害的数据\[11]。
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000016
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no evidence to support the use of noncontrast breast MRI for the screening of breast cancer in pregnancy. 目前尚无证据支持在妊娠期使用非对比增强乳腺MRI进行乳腺癌筛查。
* 检查项目: MRI Breast Without IV Contrast Abbreviated / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000016
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no evidence to support the use of noncontrast breast MRI for the screening of breast cancer in pregnancy. 目前尚无证据支持在妊娠期使用非对比增强乳腺MRI进行乳腺癌筛查。
* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000014
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: Contrast-enhanced MRI is not recommended during pregnancy because IV gadolinium crosses the placenta and enters fetal circulation \[3,7]. Within the amniotic fluid, the gadolinium may dissociate into toxic free gadolinium ions \[7]. The ACR Manual on Contrast Media \[11] outlines the guidelines for the use of gadolinium in pregnancy. 妊娠期不建议使用增强MRI，因为静脉注射钆剂会穿过胎盘进入胎儿循环\[3,7]。在羊水中，钆剂可能解离为有毒性的游离钆离子\[7]。《ACR造影剂使用手册》\[11]详细说明了妊娠期钆剂使用指南。
* 检查项目: MRI Breast Without and With IV Contrast Abbreviated / MR乳腺(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000014
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: Contrast-enhanced MRI is not recommended during pregnancy because IV gadolinium crosses the placenta and enters fetal circulation \[3,7]. Within the amniotic fluid, the gadolinium may dissociate into toxic free gadolinium ions \[7]. The ACR Manual on Contrast Media \[11] outlines the guidelines for the use of gadolinium in pregnancy. 妊娠期不建议使用增强MRI，因为静脉注射钆剂会穿过胎盘进入胎儿循环\[3,7]。在羊水中，钆剂可能解离为有毒性的游离钆离子\[7]。《ACR造影剂使用手册》\[11]详细说明了妊娠期钆剂使用指南。
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000018
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: MBI is contraindicated in breast cancer screening in pregnancy. Tc-99m sestamibi crosses the placenta and thus exposes the fetus to unnecessary radiation \[18,19]. 妊娠期乳腺癌筛查禁用MBI。Tc-99m甲氧异腈可透过胎盘屏障，导致胎儿受到不必要的辐射暴露\[18,19]。

##### S0003 Variant: Variant 3:  Pregnant female. Age 25 years or older. Breast cancer screening. Higher-than-average risk. | 妊娠期女性。≥25岁。乳腺癌筛查。风险高于平均水平。

检查推荐列表：

* 检查项目: Mammography Screening / MG双侧乳腺钼靶
  * 评分: 8
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0010
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Mammography is considered safe in pregnancy. Scatter radiation to the fetus is negligible \[2]. For patients who are at higher than average risk, the benefits need to be weighed against the risks. 乳腺X线摄影在妊娠期被认为是安全的。胎儿受到的散射辐射可忽略不计\[2]。对于风险高于平均水平的患者，需权衡其利弊。
* 检查项目: Digital Breast Tomosynthesis Screening / MG双侧乳腺钼靶(筛查)
  * 评分: 8
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0001 / R:CR000019
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Mammography is considered safe in pregnancy. Scatter radiation to the fetus is negligible \[2]. For patients who are at higher than average risk, the benefits need to be weighed against the risks. Tomosynthesis with mammography may provide added benefit of detection in denser breast tissue of pregnancy \[3,8]. 妊娠期乳腺X线摄影被认为是安全的。胎儿受到的散射辐射可忽略不计\[2]。对于风险高于平均水平的患者，需权衡利弊。乳腺X线断层合成摄影可为妊娠期致密乳腺组织的检测提供额外优势\[3,8]。
* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 5
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0003 / R:CR000021
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: During pregnancy, the breasts undergo considerable physiologic changes. No studies to date have evaluated the usefulness of screening whole-breast US (handheld or automated) during pregnancy \[2]. Screening whole-breast US could be considered supplemental in pregnancy (based on results seen in nonpregnant women) for those at high risk of breast cancer \[20,21]. 妊娠期间，乳房会发生显著的生理变化。迄今为止，尚无研究评估孕期全乳超声筛查（手持式或自动式）的有效性\[2]。对于乳腺癌高风险人群，可考虑将全乳超声筛查作为妊娠期的补充检查手段（基于非妊娠女性的研究结果）\[20,21]。
* 检查项目: Mammography With IV Contrast / MG双侧乳腺钼靶导管造影
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0004 / R:CR000022
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Diagnostic iodinated contrast media crosses the placenta and enters the fetus. There are no available data regarding potential harm to the fetus exposed to maternal iodinated contrast media. 诊断用碘造影剂可穿过胎盘进入胎儿体内。目前尚无关于母体接触碘造影剂对胎儿潜在危害的数据。
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000025
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no evidence to support the use of noncontrast breast MRI for the screening of breast cancer in pregnancy. 目前尚无证据支持在妊娠期使用非对比增强乳腺MRI进行乳腺癌筛查。
* 检查项目: MRI Breast Without IV Contrast Abbreviated / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000025
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no evidence to support the use of noncontrast breast MRI for the screening of breast cancer in pregnancy. 目前尚无证据支持在妊娠期使用非对比增强乳腺MRI进行乳腺癌筛查。
* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000023
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: Contrast-enhanced MRI is not recommended during pregnancy because IV gadolinium crosses the placenta and enters fetal circulation. Within the amniotic fluid, the gadolinium may dissociate into toxic free gadolinium ions \[7]. The ACR Manual on Contrast Media \[11] outlines the guidelines for the use of gadolinium in pregnancy. 妊娠期不建议进行增强MRI检查，因为静脉注射的钆剂会通过胎盘进入胎儿循环。在羊水中，钆剂可能解离为具有毒性的游离钆离子\[7]。《ACR造影剂使用手册》\[11]详细阐述了妊娠期钆剂使用的相关指南。
* 检查项目: MRI Breast Without and With IV Contrast Abbreviated / MR乳腺(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000023
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: Contrast-enhanced MRI is not recommended during pregnancy because IV gadolinium crosses the placenta and enters fetal circulation \[3,7]. Within the amniotic fluid, the gadolinium may dissociate into toxic free gadolinium ions \[7]. The ACR Manual on Contrast Media \[11] outlines the guidelines for the use of gadolinium in pregnancy. 妊娠期不建议使用增强MRI，因为静脉注射钆剂会穿过胎盘进入胎儿循环\[3,7]。在羊水中，钆剂可能解离为有毒性的游离钆离子\[7]。《ACR造影剂使用手册》\[11]详细说明了妊娠期钆剂使用指南。
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000027
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: MBI is contraindicated in breast cancer screening in pregnancy \[18,19]. Tc-99m sestamibi crosses the placenta and thus exposes the fetus to unnecessary radiation \[18,19]. 妊娠期乳腺癌筛查禁用MBI检查\[18,19]。锝-99m司他米易通过胎盘屏障，导致胎儿受到不必要的辐射暴露\[18,19]。

##### S0004 Variant: Variant 4:  Pregnant female. Age less than 30 years. Focal pain or palpable breast mass. Initial imaging. | 妊娠期女性。\<30岁。局灶性疼痛或可触及乳腺肿块。初始影像学检查。

检查推荐列表：

* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0003 / R:CR000028
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: US is the first-line imaging in the evaluation of a palpable lump in pregnant patients younger than 30. It can detect both benign and malignant masses. US is reported to have a 100% sensitivity and a 100% negative predictive value for detecting PABC \[7,24]. US has a high sensitivity for both benign and malignant abnormalities. It can evaluate for focal pain or palpable finding in pregnancy \[2,7]. Due to the changes of the breast during pregnancy, some benign masses can appear suspicious \[10]. 超声检查是评估30岁以下孕妇可触及肿块的首选影像学方法，可同时检出良性和恶性肿块。据报道，超声对妊娠相关乳腺癌（PABC）的检测具有100%的敏感度和100%的阴性预测值\[7,24]。该检查对良恶性病变均具有高敏感性，可用于评估妊娠期局部疼痛或可触及的异常发现\[2,7]。由于妊娠期乳房变化，部分良性肿块可能呈现可疑征象\[10]。
* 检查项目: Digital Breast Tomosynthesis Diagnostic / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000029
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: According to the ACR Appropriateness Criteria ® for Palpable Breast Masses , DBT should not be the initial imaging modality in this patient population \[22]. However, mammography is considered safe in pregnancy. Scatter radiation breast tissue of pregnancy \[3,8,23]. It may be a useful adjunct to US findings for focal pain or a palpable mass, especially if US findings are suspicious. 根据ACR适宜性标准®关于可触及乳腺肿块的建议，DBT不应作为该患者群体的初始影像学检查方式\[22]。然而， mammography在妊娠期被认为是安全的。妊娠期乳腺组织会受到散射辐射\[3,8,23]。对于局灶性疼痛或可触及肿块，尤其是超声检查结果可疑时， mammography可作为超声检查的有用辅助手段。
* 检查项目: Mammography Diagnostic / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000029
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: According to the ACR Appropriateness Criteria ® for Palpable Breast Masses , mammography should not be the initial imaging modality in this patient population \[22]. However, mammography is considered safe during pregnancy. Scatter radiation to the fetus is negligible \[2]. Diagnostic mammography may be a useful adjunct to US findings for focal pain or a palpable mass. Sensitivity of mammography is less than US, 74% to 100% \[2,10]. 根据美国放射学会（ACR）关于可触及乳腺肿块的适宜性标准®，乳腺X线摄影不应作为该患者群体的首选影像学检查方式\[22]。然而，妊娠期进行乳腺X线摄影被认为是安全的，胎儿受到的散射辐射可忽略不计\[2]。对于局部疼痛或可触及肿块的患者，诊断性乳腺X线摄影可作为超声检查的有益补充。其敏感性低于超声检查，为74%至100%\[2,10]。
* 检查项目: Mammography With IV Contrast / MG双侧乳腺钼靶导管造影
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0004 / R:CR000031
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Diagnostic iodinated contrast media crosses the placenta and enters the fetus. There are no available data regarding potential harm to the fetus exposed to maternal iodinated contrast media \[11]. Mammography with IV contrast would not be expected to be used in pregnancy for the evaluation of focal pain or palpable mass. 诊断用碘造影剂可穿过胎盘进入胎儿体内。目前尚无关于母体使用碘造影剂对胎儿潜在危害的数据\[11]。妊娠期评估局灶性疼痛或可触及肿块时，预计不会使用静脉注射造影剂的乳腺X线摄影检查。
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000033
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no evidence to support the use of noncontrast breast MRI for the evaluation of pain or palpable breast mass in pregnancy. 目前尚无证据支持在妊娠期使用非对比增强乳腺MRI评估乳房疼痛或可触及肿块。
* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000032
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: Contrast-enhanced MRI is not recommended during pregnancy because IV gadolinium crosses the placenta and enters fetal circulation \[3,7]. Within the amniotic fluid, the gadolinium may dissociate into toxic free gadolinium ions \[7]. The ACR Manual on Contrast Media \[11] outlines the guidelines for the use of gadolinium in pregnancy. 妊娠期不建议使用增强MRI，因为静脉注射钆剂会穿过胎盘进入胎儿循环\[3,7]。在羊水中，钆剂可能解离为有毒性的游离钆离子\[7]。《ACR造影剂使用手册》\[11]详细说明了妊娠期钆剂使用指南。
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000034
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: MBI is contraindicated in pregnant patients \[18,19]. Tc-99m sestamibi crosses the placenta and thus exposes the fetus to unnecessary radiation \[18,19]. 孕妇禁用MBI检查\[18,19]。锝-99m甲氧异腈可通过胎盘屏障，导致胎儿接受不必要的辐射暴露\[18,19]。

##### S0005 Variant: Variant 5:  Pregnant female. Age 30 years or older. Focal pain or palpable breast mass. Initial imaging. | 妊娠期女性，≥30岁，局灶性疼痛或可触及乳腺肿块，初始影像学检查。

检查推荐列表：

* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0003 / R:CR000035
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: As per the ACR Appropriateness Criteria ® for Palpable Breast Masses , breast US may be used in conjunction with DBT/mammography \[22]. US has a high sensitivity for both benign and malignant abnormalities. It can evaluate for focal pain or palpable finding in pregnancy regardless of patient age \[2,7]. US can distinguish between cystic and solid masses. Because of the changes of the breast during pregnancy, some benign masses can appear suspicious \[10]. 根据美国放射学会（ACR）关于可触及乳腺肿块的适用标准®，乳腺超声可与数字乳腺断层合成摄影（DBT）/乳腺X线摄影联合使用\[22]。超声对良恶性病变均具有高敏感性，可评估妊娠期局灶性疼痛或可触及的异常发现，不受患者年龄限制\[2,7]。超声能有效鉴别囊性与实性肿块。由于妊娠期乳腺组织变化，部分良性肿块可能呈现可疑征象\[10]。
* 检查项目: Digital Breast Tomosynthesis Diagnostic / MG双侧乳腺钼靶
  * 评分: 8
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0010 / R:CR000036
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Mammography is considered safe in pregnancy. Scatter radiation to the fetus is negligible \[2]. For adult women who are ≥40 years of age, DBT/mammography should be the initial imaging assessment \[22]. For adult women 30 to 39 years of age, according to the ACR Appropriateness Criteria ® for Palpable Breast Masses , diagnostic mammography (DM), DBT, or US may be used as the initial imaging study \[22] Tomosynthesis with mammography may provide added benefit of detection in denser breast tissue of pregnancy \[3,8,23]. 妊娠期乳腺X线摄影被认为是安全的。对胎儿的散射辐射可忽略不计\[2]。对于40岁及以上的成年女性，数字乳腺断层合成（DBT）/乳腺X线摄影应作为初始影像学评估\[22]。对于30至39岁的成年女性，根据ACR《可触及乳腺肿块适宜性标准》，诊断性乳腺X线摄影（DM）、DBT或超声可作为初始影像学检查\[22]。乳腺断层合成联合X线摄影可为妊娠期致密乳腺组织的检出提供额外优势\[3,8,23]。
* 检查项目: Mammography Diagnostic / MG双侧乳腺钼靶
  * 评分: 8
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0010 / R:CR000036
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Mammography is considered safe during pregnancy. Scatter radiation to the fetus is negligible \[2]. For adult women who are ≥40 years of age, DBT/mammography should be the initial imaging assessment \[22]. For adult women 30 to 39 years of age, according to the ACR Appropriateness Criteria ® for Palpable Breast Masses , 乳腺X线摄影在妊娠期被认为是安全的。对胎儿的散射辐射可忽略不计\[2]。对于年龄≥40岁的成年女性，DBT/乳腺X线摄影应作为初始影像学评估方法\[22]。对于30至39岁的成年女性，根据ACR适宜性标准®可触及乳腺肿块指南，
* 检查项目: Mammography With IV Contrast / MG双侧乳腺钼靶导管造影
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0004 / R:CR000038
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Diagnostic iodinated contrast media crosses the placenta and enters the fetus. There are no available data regarding potential harm to the fetus exposed to maternal iodinated contrast media \[11]. Mammography with IV contrast would not be expected to be used in pregnancy for the evaluation of focal pain or palpable mass. 诊断用碘造影剂可穿过胎盘进入胎儿体内。目前尚无关于母体使用碘造影剂对胎儿潜在危害的数据\[11]。妊娠期评估局灶性疼痛或可触及肿块时，预计不会使用静脉注射造影剂的乳腺X线摄影检查。
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000040
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no evidence to support the use of noncontrast breast MRI for the evaluation of pain or palpable breast mass in pregnancy. 目前尚无证据支持在妊娠期使用非对比增强乳腺MRI评估乳房疼痛或可触及肿块。
* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000039
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: Contrast-enhanced MRI is not recommended during pregnancy because IV gadolinium crosses the placenta and enters fetal circulation \[3,7]. Within the amniotic fluid, the gadolinium may dissociate into toxic free gadolinium ions \[7]. The ACR Manual on Contrast Media \[11] outlines the guidelines for the use of gadolinium in pregnancy. 妊娠期不建议使用增强MRI，因为静脉注射钆剂会穿过胎盘进入胎儿循环\[3,7]。在羊水中，钆剂可能解离为有毒性的游离钆离子\[7]。《ACR造影剂使用手册》\[11]详细说明了妊娠期钆剂使用指南。
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000041
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: MBI is contraindicated in pregnant patients \[18,19]. Tc-99m sestamibi crosses the placenta and thus exposes the fetus to unnecessary radiation \[18,19]. 孕妇禁用MBI检查\[18,19]。锝-99m甲氧异腈可通过胎盘屏障，导致胎儿接受不必要的辐射暴露\[18,19]。

##### S0006 Variant: Variant 6:  Pregnant female. Age less than 30 years. Clinically suspicious nipple discharge. Initial imaging. | 妊娠期女性。\<30岁。临床可疑乳头溢液。初始影像学检查。

检查推荐列表：

* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0003 / R:CR000042
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: US can evaluate suspicious nipple discharge finding in pregnancy \[2,7]. US of the subareolar region can be used to identify duct ectasia or intraductal filling defects. Suspicious US findings can aid in any further intervention \[2]. 超声可用于评估妊娠期可疑乳头溢液\[2,7]。乳晕下区域超声检查可识别导管扩张或导管内充盈缺损。可疑超声表现有助于进一步干预\[2]。
* 检查项目: Digital Breast Tomosynthesis Diagnostic / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000043
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Mammography is considered safe in pregnancy. Scatter radiation to the fetus is negligible \[2]. DBT should not be the initial imaging modality in this patient population \[22]. Tomosynthesis with mammography may provide added benefit of detection in denser breast tissue of pregnancy \[3,8,23]. It may be a useful adjunct to US findings for suspicious nipple discharge, especially if US findings are suspicious. Mammography may reveal suspicious calcifications. 妊娠期乳腺X线摄影被认为是安全的，胎儿受到的散射辐射可忽略不计\[2]。对于此类患者群体，数字乳腺断层合成（DBT）不应作为首选影像学检查方式\[22]。乳腺X线摄影联合断层合成技术可为妊娠期致密乳腺组织的病灶检出提供额外获益\[3,8,23]。对于可疑乳头溢液病例，该技术可作为超声检查的有益补充，尤其在超声结果可疑时。乳腺X线摄影可检出可疑钙化灶。
* 检查项目: Mammography Diagnostic / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000043
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Mammography is considered safe during pregnancy. Scatter radiation to the fetus is negligible \[2]. Mammography should not be the initial imaging modality in this patient population \[22]. It may be a useful adjunct to US findings for suspicious nipple discharge, especially if the US findings are suspicious. Sensitivity of mammography is less than US, 74% to 100% \[2,10]. Mammography may reveal suspicious calcifications. 妊娠期进行乳腺X线摄影被认为是安全的。胎儿受到的散射辐射可忽略不计\[2]。乳腺X线摄影不应作为该患者群体的首选影像学检查方法\[22]。对于可疑乳头溢液病例，在超声检查结果可疑时，乳腺X线摄影可作为超声检查的有益补充。其敏感性(74%-100%)低于超声检查\[2,10]。乳腺X线摄影可检出可疑钙化灶。
* 检查项目: Mammography With IV Contrast / MG双侧乳腺钼靶导管造影
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0004 / R:CR000045
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Diagnostic iodinated contrast media crosses the placenta and enters the fetus. There are no available data regarding potential harm to the fetus exposed to maternal iodinated contrast media \[11]. Mammography with IV contrast would not be expected to be used in pregnancy for the evaluation of suspicious nipple discharge. 诊断用碘造影剂可穿过胎盘进入胎儿体内。目前尚无关于母体碘造影剂对胎儿潜在危害的数据\[11]。妊娠期评估可疑乳头溢液时，预计不会使用静脉注射造影剂的乳腺X线摄影。
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000047
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no evidence to support the use of noncontrast breast MRI for evaluation of nipple discharge in pregnancy. 目前尚无证据支持在妊娠期使用非增强乳腺MRI评估乳头溢液。
* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000046
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: Contrast-enhanced MRI is not recommended during pregnancy because IV gadolinium crosses the placenta and enters fetal circulation \[3,7]. Within the amniotic fluid, the gadolinium may dissociate into toxic free gadolinium ions \[7]. The ACR Manual on Contrast Media \[11] outlines the guidelines for the use of gadolinium in pregnancy. 妊娠期不建议使用增强MRI，因为静脉注射钆剂会穿过胎盘进入胎儿循环\[3,7]。在羊水中，钆剂可能解离为有毒性的游离钆离子\[7]。《ACR造影剂使用手册》\[11]详细说明了妊娠期钆剂使用指南。
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000048
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: MBI is contraindicated in pregnant patients \[18,19]. Tc-99m sestamibi crosses the placenta and thus exposes the MBI检查禁忌用于妊娠患者\[18,19]。锝99m司他比可通过胎盘屏障从而导致

##### S0007 Variant: Variant 7:  Pregnant female. Age 30 years or older. Clinically suspicious nipple discharge. Initial imaging. | 妊娠期女性，≥30岁，临床可疑乳头溢液，初始影像学检查。

检查推荐列表：

* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0003 / R:CR000049
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: US can evaluate suspicious nipple discharge finding in pregnancy \[2,7]. Breast US may serve as a useful adjunct to DBT/mammography. US of the subareolar region can be used to identify duct ectasia or intraductal filling defects. Suspicious US findings can aid in any further intervention \[2]. 超声可评估妊娠期可疑乳头溢液\[2,7]。乳腺超声可作为数字乳腺断层合成摄影/乳腺X线摄影的有效辅助手段。乳晕下区超声可用于识别导管扩张或导管内充盈缺损。可疑超声表现有助于进一步干预\[2]。
* 检查项目: Digital Breast Tomosynthesis Diagnostic / MG双侧乳腺钼靶
  * 评分: 8
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0010 / R:CR000050
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Mammography is considered safe in pregnancy. Scatter radiation to the fetus is negligible \[2]. For adult women who are ≥40 years of age, DBT/mammography should be the initial imaging assessment in the evaluation of suspicious nipple discharge (see the ACR Appropriateness Criteria ® topic on “ Evaluation of Nipple Discharge ” \[25]). For adult women 30 to 39 years of age, according to the ACR Appropriateness Criteria ® topic on “ Evaluation of Nipple Discharge, ” DM, DBT, or US may be used as the initial imaging study \[25]. Tomosynthesis with mammography may provide added benefit of detection in denser breast tissue of pregnancy \[3,8,23]. Mammography may reveal suspicious calcifications. 妊娠期乳腺X线摄影被认为是安全的。胎儿受到的散射辐射可忽略不计\[2]。对于40岁及以上的成年女性，在评估可疑乳头溢液时，DBT/乳腺X线摄影应作为初始影像学检查（参见ACR适宜性标准®关于“乳头溢液评估”的主题\[25]）。对于30至39岁的成年女性，根据ACR适宜性标准®关于“乳头溢液评估”的主题，数字乳腺摄影（DM）、数字乳腺断层合成（DBT）或超声（US）均可作为初始影像学检查\[25]。断层合成联合乳腺X线摄影可为妊娠期致密乳腺组织的检出提供额外优势\[3,8,23]。乳腺X线摄影可显示可疑钙化灶。
* 检查项目: Mammography Diagnostic / MG双侧乳腺钼靶
  * 评分: 8
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0010 / R:CR000050
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Mammography is considered safe during pregnancy. Scatter radiation to the fetus is negligible \[2]. For adult women who are ≥40 years of age, DBT/mammography should be the initial imaging assessment in the evaluation of suspicious nipple discharge (see the ACR Appropriateness Criteria ® topic on “ Evaluation of Nipple Discharge ” \[25]). For adult women 30 to 39 years of age, according to the ACR Appropriateness Criteria ® topic on “ Evaluation of Nipple Discharge ,” DM, DBT, or US may be used as the initial imaging study \[25]. Mammography may reveal suspicious calcifications. 妊娠期进行乳腺X线摄影被认为是安全的。胎儿受到的散射辐射可忽略不计\[2]。对于年龄≥40岁的成年女性，在评估可疑乳头溢液时，DBT/乳腺X线摄影应作为初始影像学检查（参见ACR适宜性标准®关于“乳头溢液评估”的主题\[25]）。对于30至39岁的成年女性，根据ACR适宜性标准®关于“乳头溢液评估”的主题，数字乳腺摄影（DM）、DBT或超声（US）均可作为初始影像学检查\[25]。乳腺X线摄影可能检出可疑钙化灶。
* 检查项目: Mammography With IV Contrast / MG双侧乳腺钼靶导管造影
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0004 / R:CR000052
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Diagnostic iodinated contrast media crosses the placenta and enters the fetus. There are no available data regarding potential harm to the fetus exposed to maternal iodinated contrast media \[11]. Mammography with IV contrast would not be expected to be used in pregnancy for the evaluation of suspicious nipple discharge. 诊断用碘造影剂可穿过胎盘进入胎儿体内。目前尚无关于母体碘造影剂对胎儿潜在危害的数据\[11]。妊娠期评估可疑乳头溢液时，预计不会使用静脉注射造影剂的乳腺X线摄影。
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000054
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no evidence to support the use of noncontrast breast MRI for evaluation of nipple discharge in pregnancy. 目前尚无证据支持在妊娠期使用非增强乳腺MRI评估乳头溢液。
* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000053
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: Contrast-enhanced MRI is not recommended during pregnancy because IV gadolinium crosses the placenta and enters fetal circulation \[3,7]. Within the amniotic fluid, the gadolinium may dissociate into toxic free gadolinium ions \[7]. The ACR Manual on Contrast Media \[11] outlines the guidelines for use of gadolinium in pregnancy. 妊娠期不建议使用增强MRI，因为静脉注射钆剂会穿过胎盘进入胎儿循环\[3,7]。在羊水中，钆剂可能解离为有毒性的游离钆离子\[7]。《ACR造影剂使用手册》\[11]详细说明了妊娠期钆剂使用指南。
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000055
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: MBI is contraindicated in pregnant patients \[18,19]. Tc-99m sestamibi crosses the placenta and thus exposes the fetus to unnecessary radiation \[18,19]. 孕妇禁用MBI检查\[18,19]。锝-99m甲氧异腈可通过胎盘屏障，导致胎儿接受不必要的辐射暴露\[18,19]。

##### S0008 Variant: Variant 8:  Pregnant female. Newly diagnosed breast cancer. Locoregional staging. | 妊娠期女性。新诊断乳腺癌。局部区域分期。

检查推荐列表：

* 检查项目: Digital Breast Tomosynthesis Diagnostic / MG双侧乳腺钼靶
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0010 / R:CR000056
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Mammography is considered safe in pregnancy. Scatter radiation to the fetus is negligible \[2]. Tomosynthesis with mammography may provide added benefit of detection in denser breast tissue of pregnancy \[3,8,23]. After the detection of a new breast cancer, it can be used to evaluate the rest of the breast for any additional masses or suspicious calcifications. 妊娠期乳腺X线摄影被认为是安全的，对胎儿的散射辐射可忽略不计\[2]。乳腺X线断层合成技术可为妊娠期致密乳腺组织的检测提供额外益处\[3,8,23]。在检出新发乳腺癌后，该技术可用于评估乳腺其余部位是否存在其他肿块或可疑钙化灶。
* 检查项目: Mammography Diagnostic / MG双侧乳腺钼靶
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0010 / R:CR000056
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Mammography is considered safe during pregnancy. Scatter radiation to the fetus is negligible \[2]. After the detection of a new breast cancer, it can be used to evaluate the rest of the breast for any additional masses or suspicious calcifications. 妊娠期进行乳腺X线摄影检查被认为是安全的。胎儿受到的散射辐射可忽略不计\[2]。在发现新发乳腺癌后，该检查可用于评估乳腺其他部位是否存在额外肿块或可疑钙化灶。
* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0003 / R:CR000059
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: Breast US may be a useful adjunct to DBT/mammography. US can be used to evaluate a palpable mass \[2,7], additional lesions seen on mammography, and aid in the management of any further intervention \[2]. There is a lack of evidence to support whole-breast US during locoregional staging of newly diagnosed breast cancer in pregnant patients \[3,8]. 乳腺超声可作为DBT/乳腺X线摄影的有益辅助检查。超声可用于评估可触及肿块\[2,7]、乳腺X线摄影中发现的额外病灶，并有助于指导进一步干预措施的实施\[2]。目前缺乏证据支持在妊娠期乳腺癌患者新确诊时进行局部区域分期时采用全乳超声检查\[3,8]。
* 检查项目: US Axilla / US腋窝淋巴结常规超声检查
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0012 / R:CR000058
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: US of the ipsilateral axilla may be performed to evaluate the morphology of the lymph nodes \[26,27]. Level I lymph nodes are lateral to the pectoral is minor muscle, level II lymph nodes are posterior to the pectoralis minor muscle, and level III lymph nodes are medial to the pectoralis minor muscle. Identification of abnormal lymph nodes may facilitate clinical management. 可对同侧腋窝进行超声检查以评估淋巴结形态\[26,27]。I级淋巴结位于胸小肌外侧，II级淋巴结位于胸小肌后方，III级淋巴结位于胸小肌内侧。识别异常淋巴结有助于临床治疗决策。
* 检查项目: Mammography With IV Contrast / MG双侧乳腺钼靶导管造影
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0004 / R:CR000060
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Diagnostic iodinated contrast media crosses the placenta and enters the fetus. There are no available data regarding potential harm to the fetus exposed to maternal iodinated contrast media \[11]. 诊断用碘造影剂可穿过胎盘进入胎儿体内。目前尚无关于母体接触碘造影剂对胎儿潜在危害的数据\[11]。
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000062
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no evidence to support the use of noncontrast breast MRI in the evaluation of breast cancer in pregnancy. 目前尚无证据支持在妊娠期乳腺癌评估中使用非对比增强乳腺MRI。
* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000061
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: Contrast-enhanced MRI is not recommended during pregnancy because IV gadolinium crosses the placenta and enters fetal circulation \[3,7]. Within the amniotic fluid, the gadolinium may dissociate into toxic free gadolinium ions \[7]. The ACR Manual on Contrast Media \[11] outlines the guidelines for the use of gadolinium in pregnancy. 妊娠期不建议使用增强MRI，因为静脉注射钆剂会穿过胎盘进入胎儿循环\[3,7]。在羊水中，钆剂可能解离为有毒性的游离钆离子\[7]。《ACR造影剂使用手册》\[11]详细说明了妊娠期钆剂使用指南。
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000063
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: MBI is contraindicated in pregnant patients \[18,19]. Tc-99m sestamibi crosses the placenta and thus exposes the fetus to unnecessary radiation \[18,19]. 孕妇禁用MBI检查\[18,19]。锝-99m甲氧异腈可通过胎盘屏障，导致胎儿接受不必要的辐射暴露\[18,19]。

##### S0009 Variant: Variant 9:  Pregnant female. Breast infection or abscess suspected. Initial imaging. | 妊娠期女性。疑似乳腺感染或脓肿。初始影像学检查。

检查推荐列表：

* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0003 / R:CR000064
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: US can evaluate a palpable mass or possible infection \[2,7]. If warranted, it can guide intervention or future surveillance. 超声可评估可触及的肿块或可能的感染\[2,7]。如有必要，可指导干预或后续监测。
* 检查项目: Digital Breast Tomosynthesis Diagnostic / MG双侧乳腺钼靶
  * 评分: 6
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0010 / R:CR000065
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Mammography is considered safe in pregnancy. Scatter radiation to the fetus is negligible \[2]. Tomosynthesis with mammography may provide added benefit as an adjunct to US imaging. 妊娠期乳腺X线摄影被认为是安全的，胎儿受到的散射辐射可忽略不计\[2]。作为超声成像的辅助手段，乳腺X线断层合成技术可能提供额外益处。
* 检查项目: Mammography Diagnostic / MG双侧乳腺钼靶
  * 评分: 6
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0010 / R:CR000065
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Mammography is considered safe in pregnancy. Scatter radiation to the fetus is negligible \[2]. Mammography may provide added benefit as an adjunct to US imaging. 妊娠期乳腺X线摄影被认为是安全的，胎儿受到的散射辐射可忽略不计\[2]。作为超声成像的辅助手段，乳腺X线摄影可提供额外诊断价值。
* 检查项目: Mammography With IV Contrast / MG双侧乳腺钼靶导管造影
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0004 / R:CR000067
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Diagnostic iodinated contrast media crosses the placenta and enters the fetus. There are no available data regarding potential harm to the fetus exposed to maternal iodinated contrast media \[11]. Mammography with IV contrast 诊断用碘对比剂可穿过胎盘进入胎儿体内。目前尚无关于母体使用碘对比剂对胎儿潜在危害的数据\[11]。静脉注射对比剂乳腺摄影
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000069
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no evidence to support the use of noncontrast breast MRI for the evaluation of infection of the breast cancer in pregnancy. 目前尚无证据支持在妊娠期乳腺癌感染评估中使用非对比增强乳腺MRI。
* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000068
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: Contrast-enhanced MRI is not recommended during pregnancy because IV gadolinium crosses the placenta and enters fetal circulation \[3,7]. Within the amniotic fluid, the gadolinium may dissociate into toxic free gadolinium ions \[7]. The ACR Manual on Contrast Media \[11] outlines the guidelines for the use of gadolinium in pregnancy. 妊娠期不建议使用增强MRI，因为静脉注射钆剂会穿过胎盘进入胎儿循环\[3,7]。在羊水中，钆剂可能解离为有毒性的游离钆离子\[7]。《ACR造影剂使用手册》\[11]详细说明了妊娠期钆剂使用指南。
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000070
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: MBI is contraindicated in pregnant patients \[18,19]. Tc-99m sestamibi crosses the placenta and thus exposes the fetus to unnecessary radiation \[18,19]. 孕妇禁用MBI检查\[18,19]。锝-99m甲氧异腈可通过胎盘屏障，导致胎儿接受不必要的辐射暴露\[18,19]。

##### S0010 Variant: Variant 10:  Pregnant female. Palpable breast mass. US findings are probably benign. Next imaging study. | 妊娠期女性。可触及乳腺肿块。超声检查结果可能为良性。下一步影像学检查。

检查推荐列表：

* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0003 / R:CR000071
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: US can evaluate a palpable mass \[2,7]. It may be used in continued surveillance of probably benign masses. Masses (fibroadenomas) that are assessed as probably benign (BI-RADS 3) warrant US follow-up to assess for progression \[28]. 超声可评估可触及的肿块\[2,7]，适用于对可能良性肿块的持续监测。被评估为可能良性（BI-RADS 3类）的肿块（如纤维腺瘤）需通过超声随访以评估进展情况\[28]。
* 检查项目: Mammography Diagnostic / MG双侧乳腺钼靶
  * 评分: 2
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000074
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Mammography is considered safe during pregnancy. Scatter radiation to the fetus is negligible \[2]. It may be a useful adjunct to US findings. 妊娠期进行乳腺X线摄影被认为是安全的。胎儿受到的散射辐射可忽略不计\[2]。该检查可作为超声检查结果的有益补充。
* 检查项目: Image-Guided Core Biopsy Breast / 影像引导下乳腺穿刺活检术
  * 评分: 2
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0013 / R:CR000072
  * 证据强度: LimitedReferences
  * Adult RRL: Varies
  * Peds RRL: Varies
  * 推荐说明: Probably benign breast lesions are safe to observe and follow during pregnancy. Core needle biopsies can be safely performed during pregnancy if indicated. They have increased risks of bleeding due to the breast vascularization and ductal dilatation \[2]. During pregnancy, the risk of developing a milk fistula is low, except it increases the closer to delivery. 妊娠期可能为良性的乳腺病变可安全观察随访。如有指征，妊娠期可安全进行空心针穿刺活检，但因乳腺血管化和导管扩张，出血风险增加\[2]。除临近分娩时风险上升外，妊娠期发生乳瘘的风险较低。
* 检查项目: Digital Breast Tomosynthesis Diagnostic / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000074
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Mammography is considered safe in pregnancy. Scatter radiation to the fetus is negligible \[2]. Tomosynthesis with mammography may provide added benefit of detection in denser breast tissue of pregnancy \[3,8,23]. It may be a useful adjunct to US findings, especially if US findings are suspicious. 妊娠期乳腺X线摄影被认为是安全的。胎儿受到的散射辐射可忽略不计\[2]。乳腺X线断层合成技术可为妊娠期致密乳腺组织的检测提供额外益处\[3,8,23]。该技术可作为超声检查的有益补充，尤其当超声结果可疑时。
* 检查项目: Mammography With IV Contrast / MG双侧乳腺钼靶导管造影
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0004 / R:CR000076
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Diagnostic iodinated contrast media crosses the placenta and enters the fetus. There are no available data regarding potential harm to the fetus exposed to maternal iodinated contrast media \[11]. 诊断用碘造影剂可穿过胎盘进入胎儿体内。目前尚无关于母体接触碘造影剂对胎儿潜在危害的数据\[11]。
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000078
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no evidence to support the use of noncontrast breast MRI for evaluating probably benign lesions in pregnancy. 无证据支持使用非增强乳腺MRI评估妊娠期可能良性病变。
* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000077
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: Contrast-enhanced MRI is not recommended during pregnancy because IV gadolinium crosses the placenta and enters fetal circulation \[3,7]. Within the amniotic fluid, the gadolinium may dissociate into toxic free gadolinium ions \[7]. The ACR Manual on Contrast Media \[11] outlines the guidelines for the use of gadolinium in pregnancy. 妊娠期不建议使用增强MRI，因为静脉注射钆剂会穿过胎盘进入胎儿循环\[3,7]。在羊水中，钆剂可能解离为有毒性的游离钆离子\[7]。《ACR造影剂使用手册》\[11]详细说明了妊娠期钆剂使用指南。
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000079
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: MBI is contraindicated in pregnant patients \[18,19]. Tc-99m sestamibi crosses the placenta and thus exposes the MBI检查禁忌用于妊娠患者\[18,19]。锝99m司他比可通过胎盘屏障从而导致
* 检查项目: US Axilla / US腋窝淋巴结常规超声检查
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0012 / R:CR000080
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: Imaging of the axilla for probably benign lesions has little or no value. 腋窝影像学检查对于可能为良性病变的价值很小或没有价值。
* 检查项目: Image-Guided Fine Needle Aspiration Breast / 影像引导下乳腺细针穿刺抽吸
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0014 / R:CR000075
  * 证据强度: LimitedReferences
  * Adult RRL: Varies
  * Peds RRL: Varies
  * 推荐说明: It is safe to perform fine needle aspirations; however, because of the histologic features between neoplasia and cellular changes of the breast during pregnancy, it may lead to false-positive diagnosis for malignancy \[3]. Probably benign breast lesions are safe to observe and follow during pregnancy. 细针穿刺活检是安全的；然而，由于妊娠期乳腺肿瘤与细胞变化的组织学特征相似，可能导致恶性肿瘤的假阳性诊断\[3]。妊娠期观察和随访可能为良性的乳腺病变是安全的。

##### S0011 Variant: Variant 11:  Pregnant female. Palpable breast mass. US findings are suspicious or highly suggestive of malignancy. Next imaging study. | 妊娠期女性。可触及乳腺肿块。超声检查结果可疑或高度提示恶性。下一步影像学检查。

检查推荐列表：

* 检查项目: Digital Breast Tomosynthesis Diagnostic / MG双侧乳腺钼靶
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0010 / R:CR000081
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Mammography is considered safe in pregnancy. Scatter radiation to the fetus is negligible \[2]. Tomosynthesis with mammography may provide added benefit of detection in denser breast tissue of pregnancy \[3,8,23]. It may be a useful adjunct to US findings, especially if US findings are suspicious. Mammography may reveal suspicious calcifications. 妊娠期乳腺X线摄影被认为是安全的。胎儿受到的散射辐射可忽略不计\[2]。乳腺X线断层合成技术可为妊娠期致密乳腺组织的检测提供额外优势\[3,8,23]。该技术可作为超声检查的有益补充，尤其当超声结果可疑时。乳腺X线摄影可检出可疑钙化灶。
* 检查项目: Mammography Diagnostic / MG双侧乳腺钼靶
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0010 / R:CR000081
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Mammography is considered safe during pregnancy. Scatter radiation to the fetus is negligible \[2]. It may be a useful adjunct to US findings. 妊娠期进行乳腺X线摄影被认为是安全的。胎儿受到的散射辐射可忽略不计\[2]。该检查可作为超声检查结果的有益补充。
* 检查项目: US Axilla / US腋窝淋巴结常规超声检查
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0012 / R:CR000084
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: If a suspicious mass is identified, evaluation of the ipsilateral axilla for nodal pathology could assist with clinical management. 如发现可疑肿块，评估同侧腋窝淋巴结病变有助于临床处理。
* 检查项目: Image-Guided Core Biopsy Breast / 影像引导下乳腺穿刺活检术
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0013 / R:CR000082
  * 证据强度: LimitedReferences
  * Adult RRL: Varies
  * Peds RRL: Varies
  * 推荐说明: Core needle biopsies can be safely performed during pregnancy. They have increased risks of bleeding due to the breast vascularization and ductal dilatation \[2]. There is also a risk of a milk fistula, but this risk is greater during lactation. 核心针穿刺活检可在妊娠期安全进行。由于乳房血管化和导管扩张，其出血风险增加\[2]。此外还存在乳瘘风险，但哺乳期该风险更高。
* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 8
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0003 / R:CR000085
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: US can evaluate a palpable mass \[2,7] and provide information on the morphology, size, and characterize the mass 超声可评估可触及肿块\[2,7]，并提供形态学、尺寸信息及肿块特征描述。
* 检查项目: Image-Guided Fine Needle Aspiration Breast / 影像引导下乳腺细针穿刺抽吸
  * 评分: 5
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0014 / R:CR000086
  * 证据强度: LimitedReferences
  * Adult RRL: Varies
  * Peds RRL: Varies
  * 推荐说明: It is safe to perform fine needle aspirations; however, due to the difficulty in evaluating the histologic features between neoplasia and cellular changes of the breast during pregnancy, it is less advised and may lead to a false- positive diagnosis for malignancy \[3]. 可安全进行细针穿刺；然而，由于难以评估妊娠期乳腺肿瘤与细胞学改变的组织学特征，较少建议采用此方法，可能导致恶性肿瘤的假阳性诊断\[3]。
* 检查项目: Mammography With IV Contrast / MG双侧乳腺钼靶导管造影
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0004 / R:CR000087
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Diagnostic iodinated contrast media crosses the placenta and enters the fetus. There are no available data regarding potential harm to the fetus exposed to maternal iodinated contrast media \[11]. 诊断用碘造影剂可穿过胎盘进入胎儿体内。目前尚无关于母体接触碘造影剂对胎儿潜在危害的数据\[11]。
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000089
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no evidence to support the use of noncontrast breast MRI for evaluating breast cancer in pregnancy. 目前尚无证据支持在妊娠期使用非对比增强乳腺MRI评估乳腺癌。
* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000088
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: Contrast-enhanced MRI is not recommended during pregnancy because IV gadolinium crosses the placenta and enters fetal circulation \[3,7]. Within the amniotic fluid, the gadolinium may dissociate into toxic free gadolinium ions \[7]. The ACR Manual on Contrast Media \[11] outlines the guidelines for the use of gadolinium in pregnancy. 妊娠期不建议使用增强MRI，因为静脉注射钆剂会穿过胎盘进入胎儿循环\[3,7]。在羊水中，钆剂可能解离为有毒性的游离钆离子\[7]。《ACR造影剂使用手册》\[11]详细说明了妊娠期钆剂使用指南。
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000090
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: MBI is contraindicated in pregnant patients \[18,19]. Tc-99m sestamibi crosses the placenta and thus exposes the fetus to unnecessary radiation \[18,19]. 孕妇禁用MBI检查\[18,19]。锝-99m甲氧异腈可通过胎盘屏障，导致胎儿接受不必要的辐射暴露\[18,19]。

#### T0002 Breast Imaging of Lactating Women | 哺乳期女性乳腺影像学检查

* 主题编码: T0002

##### S0012 Variant: Variant 1:  Breast cancer screening during lactation. Initial imaging. | 哺乳期乳腺癌筛查。初始影像学检查。

检查推荐列表：

* 检查项目: Mammography screening / MG双侧乳腺钼靶
  * 评分: 8
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0010
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Mammography screening is usually appropriate for breast cancer screening during lactation as the initial imaging modality. While lactation increases breast density and may reduce mammographic sensitivity, mammography remains a valuable screening tool when performed with technical adjustments, including adequate compression and thorough imaging of all breast tissue. The lactating breast may demonstrate benign changes such as prominent ducts and generalized increased density, which should be distinguished from suspicious findings. Although ultrasound may serve as an adjunct for diagnostic evaluation of specific concerns, screening mammography provides a baseline assessment and can detect microcalcifications and architectural distortions that might indicate malignancy. Patients should be counseled that the test may have reduced sensitivity during lactation, and any persistent clinical concerns despite negative imaging warrant further investigation. The benefits of early cancer detection generally outweigh the limitations imposed by lactational changes. 哺乳期乳腺癌筛查中，乳腺X线摄影作为初始影像学检查通常是合适的。虽然哺乳会增加乳腺密度并可能降低乳腺X线摄影的敏感性，但通过技术调整（包括充分压迫和全面成像所有乳腺组织）后，它仍是一种有价值的筛查工具。哺乳期乳腺可能显示良性变化，如导管明显和普遍密度增加，这些应与可疑发现相区分。尽管超声可作为辅助手段用于特定问题的诊断评估，但筛查性乳腺X线摄影能提供基线评估，并可检测可能指示恶性的微钙化和结构扭曲。应告知患者该检查在哺乳期敏感性可能降低，且任何影像学阴性后持续的临床 concerns 需进一步调查。早期癌症检测的益处通常超过哺乳期变化带来的限制。
* 检查项目: Digital breast tomosynthesis screening / MG双侧乳腺钼靶(筛查)
  * 评分: 8
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0001 / R:CR000091
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Digital breast tomosynthesis screening is usually appropriate for breast cancer screening during lactation in asymptomatic women. While lactation increases breast density and parenchymal changes that may reduce mammographic sensitivity, tomosynthesis provides superior lesion detection compared to digital mammography alone by minimizing tissue superimposition. Lactating patients should be encouraged to nurse or pump immediately prior to imaging to reduce breast engorgement and improve compression, though technical challenges may persist due to inherent breast density and composition changes. Radiologists should be aware that lactational changes may mimic or obscure malignancies, potentially requiring additional evaluation with ultrasound for complete assessment. This modality represents a reasonable initial imaging approach for screening in this population, balancing the need for early cancer detection with the technical limitations imposed by the lactating state. 数字乳腺断层合成筛查通常适用于哺乳期无症状女性的乳腺癌筛查。虽然哺乳会增加乳腺密度和实质变化，可能降低乳腺X线摄影的敏感性，但断层合成通过最小化组织重叠，提供了比单独数字乳腺X线摄影更优的病变检测能力。应鼓励哺乳期患者在成像前立即哺乳或泵奶，以减少乳房充盈并改善压迫效果，尽管由于固有的乳腺密度和组成变化，技术挑战可能持续存在。放射科医生应注意哺乳期变化可能模仿或掩盖恶性肿瘤，可能需要超声进行额外评估以完成全面评估。该模态代表了在这一人群中进行筛查的合理初始成像方法，平衡了早期癌症检测的需求与哺乳状态带来的技术限制。
* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 5
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0003 / R:CR000093
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There are no studies specifically evaluating hand-held or automated whole-breast US screening in women who are breastfeeding. Given the increased mammographic density during lactation, screening US could be considered as a supplemental screening option in lactating women at intermediate and high risk for breast cancer. It is, however, important to keep in mind that screening US may increase the false-positive rate and prompt additional biopsies 目前尚无研究专门评估手持式或自动化全乳超声筛查在哺乳期女性中的应用。鉴于哺乳期乳腺X线密度增加，对于中、高乳腺癌风险的哺乳期女性，筛查性超声可考虑作为补充筛查选项。然而，必须注意筛查性超声可能会增加假阳性率并导致额外的活检。
* 检查项目: MRI breast without and with IV contrast / MR乳腺(平扫+增强)
  * 评分: 3
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000094
  * 证据强度: StrongReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明:
* 检查项目: MRI breast without IV contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000095
  * 证据强度: StrongReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明:
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000096
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no role for molecular breast imaging (MBI) in breast cancer screening during lactation. 哺乳期乳腺癌筛查中不建议使用分子乳腺成像（MBI）。

#### T0003 Breast Implant Evaluation | 乳腺植入物评估

* 主题编码: T0003

##### S0013 Variant: Variant 1:  Adult of any age. Female or transfeminine. Evaluation of saline breast implants. Asymptomatic. Initial imaging. | 任何年龄成人。女性或跨性别女性。评估盐水乳房假体。无症状。初始影像学检查。

检查推荐列表：

* 检查项目: Mammography Screening / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no role for screening mammography for implant evaluation in asymptomatic patients with saline implants. However, female and transfeminine patients should follow breast cancer screening protocols as outlined in the ACR Appropriateness Criteria ® topics on “ Breast Cancer Screening ” \[14] and “ Transgender Breast Cancer Screening ” \[15]. A collapsed implant shell of a ruptured saline implant may be seen at mammography. The saline from the 对于无症状盐水假体患者，筛查性乳腺X线摄影在假体评估中无应用价值。然而，女性及跨女性患者应遵循ACR Appropriateness Criteria®中"乳腺癌筛查"\[14]与"跨性别乳腺癌筛查"\[15]专题所述的乳腺癌筛查方案。破裂盐水假体的塌陷假体壳可能在乳腺X线摄影中可见。盐水假体中的生理盐水
* 检查项目: Digital Breast Tomosynthesis Screening / MG双侧乳腺钼靶(筛查)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0001 / R:CR000097
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no role for DBT screening for implant evaluation in asymptomatic patients with saline implants. However, female and transfeminine patients should follow breast cancer screening protocols as outlined in the ACR Appropriateness Criteria ® topics on “ Breast Cancer Screening ” \[14] and “ Transgender Breast Cancer Screening ” \[15]. A collapsed implant shell of a ruptured saline implant may be seen at DBT. The saline from the implant is resorbed by the body without significant sequelae or secondary findings in the breast. 对于无症状的盐水假体患者，数字乳腺断层合成（DBT）筛查在假体评估中并无作用。但女性和跨性别女性患者应遵循美国放射学会（ACR）适宜性标准中“乳腺癌筛查”\[14]和“跨性别乳腺癌筛查”\[15]专题所述的乳腺癌筛查方案。破裂的盐水假体其塌陷的假体外壳可能在DBT中可见。假体内的盐水会被人体吸收，不会在乳房内产生显著后遗症或继发表现。
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000100
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no role for MRI without IV contrast for implant evaluation in asymptomatic patients with saline implants \[16]. The saline from the implant is resorbed by the body without significant sequelae or secondary findings in the breast. 对于无症状的盐水假体患者，无需使用无静脉对比剂的MRI进行假体评估\[16]。假体中的盐水会被人体吸收，不会在乳房中产生显著后遗症或继发表现。
* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000099
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no role for MRI without and with intravenous (IV) contrast for implant evaluation in asymptomatic patients with saline implants \[16]. The saline from the implant is resorbed by the body without significant sequelae or secondary findings in the breast. 对于无症状的生理盐水假体患者，无需使用未增强及静脉注射（IV）对比剂的MRI进行假体评估\[16]。假体中的生理盐水会被人体吸收，不会在乳房中产生显著后遗症或次要发现。
* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0003 / R:CR000101
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no role for US for implant evaluation in asymptomatic patients with saline implants. The saline from the implant is resorbed by the body without significant sequelae or secondary findings in the breast. 对于无症状的盐水假体植入患者，超声检查在假体评估中无应用价值。植入的盐水会被人体吸收，不会在乳房内造成显著后遗症或继发表现。

##### S0014 Variant: Variant 2:  Adult younger than 30 years of age. Female or transfeminine. Evaluation of saline breast implants. Clinical examination equivocal for implant rupture. Initial imaging. | 年龄\<30岁成人。女性或跨性别女性（男跨女）。评估盐水乳房假体。临床检查提示假体破裂不明确。初始影像学检查。

检查推荐列表：

* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 8
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0003 / R:CR000102
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: In cases of saline implant rupture, the collapsed implant shell is visible by US, and for patients \<30 years of age, an US is helpful as the initial examination. If a patient is uncertain which type of implant is in place, the implant type can be determined at US by examining the implant at its margin and witnessing the effect the implant has on surrounding normal tissue \[18]. Because the speed of sound through silicone (997 m/sec) is slower than that through soft tissues and saline (1,540 m/sec), it will take longer for sound waves to travel through a silicone implant compared with through a saline-filled implant, causing a step-off appearance in silicone implants, which is not seen in saline implants \[18]. 对于生理盐水假体破裂的情况，超声检查可观察到塌陷的假体外壳，且对于30岁以下患者，超声作为初始检查手段具有价值。若患者不确定植入假体类型，可通过超声检查假体边缘并观察其对周围正常组织的影响来确定假体类型\[18]。由于声波在硅胶中的传播速度（997米/秒）低于在软组织和生理盐水中的速度（1,540米/秒），声波穿过硅胶假体所需时间较生理盐水填充假体更长，导致硅胶假体呈现阶梯状外观特征，而这一现象在生理盐水假体中不会出现\[18]。
* 检查项目: Mammography Diagnostic / MG双侧乳腺钼靶
  * 评分: 3
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000104
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Rupture of saline implants is usually clinically evident because the saline is resorbed by the body over a period of days and the patient experiences a change in breast size and shape \[16,17]. Although diagnostic mammography may be useful in patients with suspected saline implant rupture and equivocal clinical findings, diagnostic mammography is typically not performed as the initial imaging study in patients \<30 years of age. 盐水假体破裂通常在临床上较为明显，因为盐水会在数日内被人体吸收，患者会感受到乳房大小和形状的变化\[16,17]。尽管对于临床检查结果不明确且疑似盐水假体破裂的患者，诊断性乳腺X线摄影可能有所帮助，但通常不会对30岁以下的患者首选进行此项影像学检查。
* 检查项目: Digital Breast Tomosynthesis Diagnostic / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000104
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Rupture of saline implants is usually clinically evident because the saline is resorbed by the body over a period of days and the patient experiences a change in breast size and shape \[16,17]. Although DBT may be useful in patients with suspected saline implant rupture and equivocal clinical findings, DBT is typically not performed as the initial imaging study in patients \<30 years of age. 盐水假体破裂通常在临床上较为明显，因为盐水会在数天内被人体吸收，患者会感受到乳房大小和形状的变化\[16,17]。尽管对于临床检查结果不明确且怀疑盐水假体破裂的患者，数字乳腺断层合成摄影（DBT）可能有所帮助，但通常不建议对30岁以下的患者进行DBT作为初始影像学检查。
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000106
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no role for MRI without IV contrast in the evaluation of saline implants \[16]. 在评估盐水假体时，无静脉注射对比剂的MRI检查无临床价值\[16]。
* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000105
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no role for MRI without and with IV contrast in the evaluation of saline implants \[16]. 在评估盐水假体时，无需使用无对比剂及静脉注射对比剂的MRI检查\[16]。

##### S0015 Variant: Variant 3:  Adult 30 to 39 years of age. Female or transfeminine. Evaluation of saline breast implants. Clinical examination equivocal for implant rupture. Initial imaging. | 成人30至39岁。女性或跨性别女性。评估盐水乳房假体。临床检查提示假体破裂不明确。初始影像学检查。

检查推荐列表：

* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 8
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0003 / R:CR000107
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: For patients 30 to 39 years of age, US may be complementary to diagnostic mammography or diagnostic DBT. In cases of saline implant rupture, the collapsed implant shell is visible by US. If a patient is uncertain which type of implant is in place, the implant type can be determined at US by examining the implant at its margin and witnessing the effect the implant has on surrounding normal tissue \[18]. Because the speed of sound through silicone (997 m/sec) is slower than that through soft tissues and saline (1,540 m/sec), it will take longer for sound waves to travel through a silicone implant compared with through a saline-filled implant, causing a step-off appearance in silicone implants, which is not seen in saline implants \[18]. 对于30至39岁的患者，超声可作为诊断性乳腺X线摄影或诊断性数字乳腺断层合成（DBT）的补充检查。在生理盐水假体破裂的情况下，超声可观察到塌陷的假体外壳。若患者不确定植入假体的类型，可通过超声检查假体边缘并观察其对周围正常组织的影响来确定假体类型\[18]。由于声波在硅胶中的传播速度（997米/秒）低于在软组织和生理盐水中的速度（1,540米/秒），声波穿过硅胶假体的时间较生理盐水填充假体更长，导致硅胶假体呈现阶梯状外观，而生理盐水假体则无此特征\[18]。
* 检查项目: Digital Breast Tomosynthesis Diagnostic / MG双侧乳腺钼靶
  * 评分: 5
  * 适宜性: May be appropriate (Disagreement) / 可能适宜（存在争议）
  * 编码: P:PR0010 / R:CR000108
  * 证据强度: Expert OpinionReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: For patients 30 to 39 years of age, DBT may be complementary to US. Rupture of saline implants is usually clinically evident because the saline is resorbed by the body over a period of days and the patient experiences a change in breast size and shape \[16,17]. However, DBT may be useful in patients with suspected saline implant rupture and equivocal clinical findings. Findings on DBT are diagnostic, in which a collapsed implant shell is visible. 对于30至39岁的患者，数字乳腺断层合成（DBT）可作为超声检查的补充手段。生理盐水假体破裂通常具有明显的临床表现，因为生理盐水会在数日内被人体吸收，患者会感受到乳房大小和形态的变化\[16,17]。但对于临床检查结果不明确且疑似生理盐水假体破裂的患者，DBT可能具有诊断价值。DBT检查可见假体外壳塌陷的特征性表现，具有确诊意义。
* 检查项目: Mammography Diagnostic / MG双侧乳腺钼靶
  * 评分: 5
  * 适宜性: May be appropriate (Disagreement) / 可能适宜（存在争议）
  * 编码: P:PR0010 / R:CR000108
  * 证据强度: Expert OpinionReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: For patients 30 to 39 years of age, diagnostic mammography may be complementary to US. Rupture of saline implants is usually clinically evident because the saline is resorbed by the body over a period of days and the patient experiences a change in breast size and shape \[16,17]. However, diagnostic mammography may be useful in patients with suspected saline implant rupture and equivocal clinical findings. Findings on mammography are diagnostic, in 对于30至39岁患者，诊断性乳腺X线摄影可作为超声的补充检查。盐水假体破裂通常具有明显临床表现，因为盐水在数日内被人体吸收导致患者乳房大小和形态改变 \[16,17]。但对于临床疑似盐水假体破裂而体征不明确的患者，诊断性乳腺X线摄影可能有价值。其影像学表现具有诊断意义，
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000111
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no role for MRI without IV contrast in the evaluation of saline implants \[16]. 在评估盐水假体时，无静脉注射对比剂的MRI检查无临床价值\[16]。
* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000110
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no role for MRI without and with IV contrast in the evaluation of saline implants \[16]. 在评估盐水假体时，无需使用无对比剂及静脉注射对比剂的MRI检查\[16]。

##### S0016 Variant: Variant 4:  Adult age 40 years or older. Female or transfeminine. Evaluation of saline breast implants. Clinical examination equivocal for implant rupture. Initial imaging. | ≥40岁成人，女性或跨性别女性，评估盐水乳房假体，临床检查提示假体破裂不明确，初始影像学检查。

检查推荐列表：

* 检查项目: Digital Breast Tomosynthesis Diagnostic / MG双侧乳腺钼靶
  * 评分: 8
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0010 / R:CR000112
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: For patients ≥40 years of age, DBT would typically be performed for an area of clinical concern and could be complementary with US. Rupture of saline implants is usually clinically evident because the saline is resorbed by the body over a period of days and the patient experiences a change in breast size and shape \[16,17]. However, DBT may be useful in patients with suspected saline implant rupture and equivocal clinical findings. Findings on DBT are diagnostic when a collapsed implant shell is visible. 对于40岁及以上患者，数字乳腺断层合成摄影（DBT）通常针对临床关注区域进行，并可与超声检查互补。生理盐水假体破裂通常具有明显临床表现，因生理盐水在数日内被机体吸收，患者可感知乳房大小及形态改变\[16,17]。但对于临床疑似生理盐水假体破裂而体征不明确的患者，DBT仍具应用价值。当观察到假体包膜塌陷时，DBT检查结果具有诊断意义。
* 检查项目: Mammography Diagnostic / MG双侧乳腺钼靶
  * 评分: 8
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0010 / R:CR000112
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: For patients ≥40 years of age, diagnostic mammography would typically be performed for an area of clinical concern and could be complementary with US. Rupture of saline implants is usually clinically evident because the saline is resorbed by the body over a period of days and the patient experiences a change in breast size and shape \[16,17]. However, diagnostic mammography may be useful in patients with suspected saline implant rupture and equivocal clinical findings. Findings on mammography are diagnostic, in which a collapsed implant shell is visible. 对于40岁及以上患者，通常针对临床关注区域进行诊断性乳腺X线摄影，并可联合超声检查。生理盐水假体破裂通常具有明显临床表现，因生理盐水在数日内被机体吸收，患者可感知乳房大小及形态改变\[16,17]。但对于疑似生理盐水假体破裂且临床表现不明确的患者，诊断性乳腺X线摄影仍具应用价值。乳腺X线摄影若观察到假体外壳塌陷的影像学表现，即可确诊。
* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 6
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0003 / R:CR000114
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: For patients ≥40 years of age, US would typically be performed for an area of clinical concern and could be complementary with diagnostic mammography or diagnostic DBT. In patients with suspected saline implant rupture, US may be useful if the mammographic findings are equivocal or the patient is unable to undergo mammography. In cases of saline implant rupture, the collapsed implant shell is visible by US. For patients ≥40 years of age unable to undergo mammography, US may be used as an alternative option. 对于40岁及以上患者，超声检查通常针对临床关注区域进行，并可作为诊断性乳腺X线摄影或诊断性数字乳腺断层合成（DBT）的辅助手段。若患者疑似生理盐水假体破裂且乳腺X线检查结果不明确或无法接受乳腺X线检查时，超声检查具有应用价值。在生理盐水假体破裂情况下，超声可观察到塌陷的假体外壳。对于40岁及以上无法接受乳腺X线检查的患者，超声检查可作为替代选择方案。
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000116
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no role for MRI without IV contrast in the evaluation of saline implants \[16]. 在评估盐水假体时，无静脉注射对比剂的MRI检查无临床价值\[16]。
* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000115
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no role for MRI without and with IV contrast in evaluation of saline implants \[16]. 评估盐水假体时无需进行无和有静脉注射对比剂的MRI检查\[16]。

##### S0017 Variant: Variant 5:  Adult of any age. Female or transfeminine. Evaluation of silicone breast implants. Asymptomatic. Less than 5 years after implant placement. Initial imaging. | 任何年龄成人，女性或跨性别女性。评估硅胶乳房植入体。无症状。植入术后不足5年。初始影像学检查。

检查推荐列表：

* 检查项目: Digital Breast Tomosynthesis Diagnostic / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000117
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no role for diagnostic DBT for implant evaluation in asymptomatic patients with silicone implants. However, female and transfeminine patients should follow breast cancer screening protocols as outlined in the ACR Appropriateness Criteria ® topics on “ Breast Cancer Screening ” \[14] and “ Transgender Breast Cancer Screening ” \[15]. The diagnosis of silicone implant rupture can be challenging, with clinical examination known to be unreliable \[19]. In cases of extracapsular silicone implant rupture, the diagnosis is often made with DBT in which high-density silicone is seen outside the implant contour. DBT does not detect intracapsular silicone implant rupture. Both standard craniocaudal and mediolateral oblique and implant-displaced views should be obtained. DBT has a low sensitivity for the detection of implant rupture due to the silicone implant appearing extremely radiopaque \[18]. Silicone implants are normally oval, smooth, and uniformly dense at mammography, preventing any internal substructural evaluation, so with the limited ability to evaluate implants internally, intracapsular ruptures go unseen \[18]. Although internal evaluation of the implant is impeded at mammography, the contour of a silicone implant time, such as the appearance of undulations, which potentially indicate a problem with implant integrity \[18]. Frank bulges or herniations represent areas of weakening of the fibrous capsule and potential weak points of the elastomer shell \[18]. An implant that becomes more rounded in appearance may signify the presence of capsular contracture rather than implying a problem with implant integrity. Calcifications along the fibrous capsule, thought to arise as a consequence of a chronic inflammatory response, are more frequently encountered in older implants that have been in place for multiple years. Capsular calcifications correlate with implant age, but calcifications alone do not necessarily imply capsular contracture or implant rupture. Although insensitive for identifying intracapsular rupture, DBT is useful in detecting extracapsular silicone. When silicone escapes the confines of the fibrous capsule and enters the surrounding breast parenchyma, DBT can often reveal the high-density free silicone. In the absence of a prior history of implant rupture or revision, the presence of silicone outside the expected contour of the implant signifies extracapsular rupture and, by extension, intracapsular rupture \[18,20]. 对于无症状硅胶假体患者，诊断性DBT在假体评估中无应用价值。然而，女性及跨女性患者应遵循ACR Appropriateness Criteria®中"乳腺癌筛查"\[14]与"跨性别乳腺癌筛查"\[15]专题所述的乳腺癌筛查方案。硅胶假体破裂的诊断具有挑战性，已知临床检查不可靠\[19]。对于包膜外硅胶假体破裂，诊断常通过DBT实现，可见假体轮廓外的高密度硅胶。DBT无法检测包膜内硅胶假体破裂。应同时获取标准头尾位、内外斜位及假体位移位投照。因硅胶假体呈极高放射密度，DBT对假体破裂的检测敏感性较低\[18]。硅胶假体在乳腺X线摄影中通常呈卵圆形、光滑且均匀致密，阻碍内部亚结构评估，故因内部评估能力有限，包膜内破裂难以被发现\[18]。虽然乳腺X线摄影中假体内部评估受限，但硅胶假体轮廓值得仔细检查\[18]。与既往乳腺X线摄影对比有助于识别随时间出现的细微轮廓变化，如波纹状外观可能提示假体完整性异常\[18]。明显凸起或疝出代表纤维囊薄弱区及弹性体外壳的潜在薄弱点\[18]。外观趋于圆形的假体可能意味着包膜挛缩而非假体完整性问题。沿纤维囊的钙化被认为由慢性炎症反应引起，更常见于植入多年的老旧假体。包膜钙化与假体植入时长相关，但仅钙化本身未必意味着包膜挛缩或假体破裂。尽管对识别包膜内破裂不敏感，DBT可有效检测包膜外硅胶。当硅胶突破纤维囊限制进入周围乳腺实质时，DBT常可显示高密度游离硅胶。若无假体破裂或修正术既往史，假体预期轮廓外出现硅胶意味着包膜外破裂，进而提示包膜内破裂\[18,20]。
* 检查项目: Mammography Diagnostic / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000117
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no role for diagnostic mammography for implant evaluation in asymptomatic patients with silicone implants. However, female and transfeminine patients should follow breast cancer screening protocols as outlined in the ACR Appropriateness Criteria ® topics on “ Breast Cancer Screening ” \[14] and “ Transgender Breast Cancer Screening ” \[15]. The diagnosis of silicone implant rupture can be challenging, with clinical examination known to be unreliable \[19]. In cases of extracapsular silicone implant rupture, the diagnosis is often made with mammography in which high-density silicone is seen outside the implant contour. Mammography does not detect intracapsular silicone implant rupture. Both standard craniocaudal and mediolateral oblique and implant-displaced views should be obtained. Mammography has low sensitivity for detection of implant rupture due to the silicone implant appearing extremely radiopaque \[18]. Silicone implants are normally oval, smooth, and uniformly dense at mammography, preventing any internal substructural evaluation, so with the limited ability to evaluate implants internally, intracapsular ruptures go unseen \[18]. Although internal evaluation of the implant is impeded at mammography, the contour of a silicone implant merits close inspection \[18]. Comparison with prior mammograms is useful to identify subtle contour changes over time, such as the appearance of undulations, which potentially indicate a problem with implant integrity \[18]. Frank bulges or herniations represent areas of weakening of the fibrous capsule and potential weak points of the elastomer shell \[18]. An implant that becomes more rounded in appearance may signify the presence of capsular contracture rather than implying a problem with implant integrity. Calcifications along the fibrous capsule, thought to arise as a consequence of a chronic inflammatory response, are more frequently encountered in older implants that have been in place for multiple years. Capsular calcifications correlate with implant age, but calcifications alone do not necessarily imply capsular contracture or implant rupture. Although insensitive for identifying intracapsular rupture, mammography is useful in detecting extracapsular silicone. When silicone escapes the confines of the fibrous capsule and enters the surrounding breast parenchyma, mammography can often reveal the high-density free silicone. In the absence of a prior history of implant rupture or revision, the presence of silicone outside the expected contour of the implant signifies extracapsular rupture and, by extension, intracapsular rupture \[18,20]. 对于无症状的硅胶假体患者，诊断性乳腺X线摄影在假体评估中无作用。然而，女性和跨女性患者应遵循ACR适宜性标准®中“乳腺癌筛查”\[14]和“跨性别者乳腺癌筛查”\[15]专题所述的乳腺癌筛查方案。硅胶假体破裂的诊断可能具有挑战性，已知临床检查不可靠\[19]。对于囊外硅胶假体破裂，诊断通常通过乳腺X线摄影做出，可见假体轮廓外的高密度硅胶。乳腺X线摄影无法检测囊内硅胶假体破裂。应同时获取标准的头尾位、内外斜位及假体位移位投照。由于硅胶假体呈现极度不透X线，乳腺X线摄影对假体破裂的检测敏感性较低\[18]。硅胶假体在乳腺X线摄影中通常呈椭圆形、光滑且密度均匀，阻碍了任何内部亚结构评估，因此由于评估假体内部的能力有限，囊内破裂无法被发现\[18]。尽管在乳腺X线摄影中假体的内部评估受到阻碍，但硅胶假体的轮廓值得仔细检查\[18]。与既往乳腺X线摄影片对比有助于识别随时间推移的细微轮廓变化，例如波纹状外观的出现，这可能提示假体完整性问题\[18]。明显的凸起或疝出代表纤维囊薄弱区域和弹性体外壳的潜在薄弱点\[18]。外观变得更圆的假体可能意味着存在包膜挛缩，而非暗示假体完整性问题。沿纤维囊的钙化，被认为是慢性炎症反应的结果，更常见于已植入多年的较老旧假体中。包膜钙化与假体使用年限相关，但仅凭钙化不一定意味着包膜挛缩或假体破裂。尽管对识别囊内破裂不敏感，乳腺X线摄影在检测囊外硅胶方面是有用的。当硅胶突破纤维囊的限制进入周围乳腺实质时，乳腺X线摄影常能显示高密度的游离硅胶。在没有假体破裂或翻修既往史的情况下，假体预期轮廓外出现硅胶意味着囊外破裂，并进而意味着囊内破裂\[18,20]。
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000120
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support the use of MRI without IV contrast in the evaluation of asymptomatic silicone implants less than 5 years after implant placement. Note that in the updated FDA recommendations for asymptomatic patients with silicone implants, the first US or MRI should be performed at 5 to 6 years postoperatively, then every 2 to 3 years thereafter \[1]. 目前尚无相关文献支持在硅胶假体植入术后5年内对无症状患者进行无静脉对比剂的MRI评估。需注意，根据美国食品药品监督管理局（FDA）最新指南，无症状硅胶假体患者的首次超声或MRI检查应于术后5至6年进行，此后每2至3年复查一次\[1]。
* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000119
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support the use of MRI without and with IV contrast in the evaluation of asymptomatic silicone implants less than 5 years after implant placement. 目前尚无相关文献支持在植入术后5年内对无症状硅胶假体患者进行无静脉造影剂及增强MRI检查的评估。
* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0003 / R:CR000121
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support the role of US breast in the evaluation of an asymptomatic patient with silicone implants that have been in place less than 5 years. Note that in the updated FDA recommendations for asymptomatic patients with silicone implants, the first US or MRI should be performed at 5 to 6 years 目前尚无相关文献支持对置入时间不足5年的硅胶假体无症状患者使用乳腺超声进行评估。需注意，根据FDA更新的硅胶假体无症状患者随访建议，首次超声或MRI检查应在置入后5至6年进行。

##### S0018 Variant: Variant 6:  Adult of any age. Female or transfeminine. Evaluation of silicone breast implants. Asymptomatic. Initial imaging at 5 to 6 years after implant placement and follow-up imaging every 2 to 3 years after initial negative imaging. | 任何年龄成人，女性或跨性别女性。评估硅胶乳房植入体。无症状。植入术后5至6年行初始影像学检查，初次阴性后每2至3年随访影像学检查。

检查推荐列表：

* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0007 / R:CR000122
  * 证据强度: StrongReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: MRI without IV contrast is helpful for imaging silicone implants. The FDA updated guidance recommends that for asymptomatic patients, the first US or MRI should be performed at 5 to 6 years postoperatively, then every 2 to 3 years thereafter \[1]. T1- and T2-weighted, short tau inversion recovery, and silicone-suppressed sequences allow for optimal imaging of implant integrity \[16]. There is currently no consensus on whether ruptured implants require surgery in asymptomatic patients, and the benefits of screening for implant rupture are controversial. Some authors \[21] have advocated a patient-centered approach with shared decision making between the patient and surgeon rather than generalized recommendations for all patients with silicone implants. Most studies focused on symptomatic women, in whom the expected prevalence of rupture would be higher than among asymptomatic women. In addition, numerous studies evaluating the rupture rate of more modern implants have shown this rate to be low \[22-25]. Studies of asymptomatic women have reported sensitivities and specificities of 64% and 77% \[26], accuracy of 94% \[27], sensitivity of 89%, specificity of 97%, accuracy of 92%, positive predictive value (PPV) of 99%, and negative predictive value (NPV) of 79% \[28]. 不注射静脉对比剂的MRI有助于硅胶假体的成像。美国FDA更新的指南建议，对于无症状患者，首次超声或MRI检查应在术后5至6年进行，之后每2至3年复查一次\[1]。T1加权、T2加权、短时反转恢复序列及硅胶抑制序列可实现对假体完整性的最佳成像\[16]。目前对于无症状患者的假体破裂是否需手术尚无共识，筛查假体破裂的获益也存在争议。部分学者\[21]主张采用以患者为中心的个体化决策模式，由患者与外科医生共同制定方案，而非对所有硅胶假体患者给出普适性建议。多数研究聚焦于有症状女性群体，该人群的假体破裂预期发生率高于无症状女性。此外，多项针对现代假体的破裂率评估研究显示其发生率较低\[22-25]。针对无症状女性的研究报道显示：灵敏度64%与特异度77%\[26]、准确率94%\[27]、灵敏度89%/特异度97%/准确率92%/阳性预测值(PPV)99%/阴性预测值(NPV)79%\[28]。
* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 7
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0003 / R:CR000123
  * 证据强度: StrongReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: In the updated FDA recommendations, for asymptomatic patients with silicone implants, the first US or MRI should be performed at 5 to 6 years postoperatively, then every 2 to 3 years thereafter \[1]. A single-lumen silicone implant is most often featureless and anechoic, which provides reliable US evidence that the implant remains intact and undamaged. A normal implant exhibits a smooth contour outlined by a trilaminar margin, which corresponds to the capsule-shell complex. Implants will often infold on themselves within the surgical pocket created by the plastic surgeon. These radial folds are a common feature of implants and should be recognized as a normal infolding of the elastomer shell rather than mistaken for evidence of intracapsular rupture. Most silicone implant ruptures are intracapsular. Numerous US findings of intracapsular silicone implant rupture, including the stepladder sign, keyhole, noose, or subcapsular sign, have been described \[18,29-31], but the variability in reported accuracy of sonographic findings \[26,27,32-34], combined with the well-known user dependence of this technology, often makes sonographic findings somewhat equivocal. Several US intracapsular- rupture mimics exist and include reverberation artifact, radial folds, or silicone implant impurities creating spurious echoes within the implant, which can give a false impression of intracapsular rupture \[18]. At US, extracapsular silicone demonstrates a classic “snowstorm” appearance that is characterized by a highly echogenic pattern of scattered and reverberating echoes with a well-defined anterior margin and loss of detail posteriorly. The FDA recommendations regarding evaluation for implant rupture do not replace additional imaging that may be warranted based upon each patient’s underlying medical history or circumstances \[1]. Breast cancer screening recommendations for feminine and transfeminine patients are outlined in the ACR Appropriateness Criteria ® topics on “ Breast Cancer Screening ” \[14] and “ Transgender Breast Cancer Screening ” \[15]. 根据FDA最新建议，对于无症状的硅胶假体植入患者，首次超声或MRI检查应在术后5至6年进行，之后每2至3年复查一次\[1]。单腔硅胶假体通常表现为无特征性结构且无回声，这为假体完整无损提供了可靠的超声证据。正常假体呈现由三层结构边缘勾勒的光滑轮廓，对应囊-壳复合体。假体常会在整形外科医生创建的手术腔隙内形成自折叠。这些放射状皱褶是假体的常见特征，应识别为弹性体外壳的正常折叠，而非误认为囊内破裂证据。大多数硅胶假体破裂为囊内型。超声检查中囊内破裂的多种表现已被描述，包括阶梯征、钥匙孔征、套索征或囊下征\[18,29-31]，但由于超声表现报告准确性的差异\[26,27,32-34]以及该技术对操作者的依赖性，超声结果常具有一定不确定性。存在多种可能被误判为囊内破裂的超声伪像，包括混响伪影、放射状皱褶或假体内硅胶杂质产生的虚假回声\[18]。超声下囊外硅胶呈现典型的"暴风雪"征象，表现为界限清晰的前缘伴后方细节丢失的强回声散射及混响模式。FDA关于假体破裂评估的建议并不取代基于患者个体病史或特殊情况可能需要的其他影像检查\[1]。女性和
* 检查项目: Digital Breast Tomosynthesis Diagnostic / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000124
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no role for diagnostic DBT for implant evaluation in asymptomatic patients with silicone implants. However, female and transfeminine patients should follow breast cancer screening protocols as outlined in the ACR Appropriateness Criteria ® topics on “ Breast Cancer Screening ” \[14] and “ Transgender Breast Cancer Screening ” \[15]. The diagnosis of silicone implant rupture can be challenging, with clinical examination known to be unreliable \[19]. In cases of extracapsular silicone implant rupture, the diagnosis is often made with DBT in which high-density silicone is seen outside the implant contour. DBT does not detect intracapsular silicone implant rupture. Both standard craniocaudal and mediolateral oblique and implant-displaced views should be obtained. DBT has low sensitivity for the detection of implant rupture due to the silicone implant appearing extremely radiopaque \[18]. Silicone implants are normally oval, smooth, and uniformly dense at mammography, preventing any internal substructural evaluation, so with the limited ability to evaluate implants internally, intracapsular ruptures go unseen \[18]. Although internal evaluation of the implant is impeded at mammography, the contour of a silicone implant merits close inspection \[18]. Comparison with prior mammograms is useful to identify subtle contour changes over time, such as the appearance of undulations, which potentially indicate a problem with implant integrity \[18]. Frank bulges or herniations represent areas of weakening of the fibrous capsule and potential weak points of the elastomer shell \[18]. An implant that becomes more rounded in appearance may signify the presence of capsular contracture rather than implying a problem with implant integrity. Calcifications along the fibrous capsule, thought to arise as a consequence of a chronic inflammatory response, are more frequently encountered in older implants that have been in place for multiple years. Capsular calcifications correlate with implant age, but calcifications alone do not necessarily imply capsular contracture or implant rupture. Although insensitive for identifying intracapsular rupture, DBT is useful in detecting extracapsular silicone. When silicone escapes the confines of the fibrous capsule and enters the surrounding breast parenchyma, DBT can often reveal the high-density free silicone. In the absence of a history of implant rupture or revision, the presence of silicone outside the expected contour of the implant signifies extracapsular rupture and, by extension, intracapsular rupture \[18,20]. 对于无症状硅胶假体患者，诊断性DBT不适用于假体评估。然而，女性及跨女性患者应遵循ACR适宜性标准专题《乳腺癌筛查》\[14]与《跨性别者乳腺癌筛查》\[15]所述的乳腺癌筛查方案。硅胶假体破裂的诊断具有挑战性，已知临床检查不可靠\[19]。对于囊外型硅胶假体破裂，DBT常可作出诊断，表现为假体轮廓外出现高密度硅胶影。DBT无法检测囊内型硅胶假体破裂。应同时获取标准头尾位、内外斜位及假体位移位投照。因硅胶假体呈极高放射密度，DBT对假体破裂的检测灵敏度较低\[18]。硅胶假体在乳腺X线摄影中通常呈卵圆形、光滑且均匀致密，阻碍了对内部亚结构的评估，由于内部评估能力有限，囊内破裂难以被发现\[18]。虽然乳腺X线摄影对假体内部的评估受限，但硅胶假体的轮廓值得仔细检查\[18]。与既往乳腺X线片对比有助于识别随时间出现的细微轮廓变化，如波浪状外观可能提示假体完整性受损\[18]。明显凸起或疝出代表纤维囊薄弱区及弹性体外壳的潜在薄弱点\[18]。假体外观变圆可能意味着包膜挛缩而非假体完整性问题。沿纤维囊的钙化被认为由慢性炎症反应引起，更常见于植入多年的老旧假体。包膜钙化与假体植入时长相关，但仅凭钙化不一定意味着包膜挛缩或假体破裂。尽管对识别囊内破裂不敏感，DBT可有效检测囊外硅胶。当硅胶突破纤维囊进入周围乳腺实质时，DBT常可显示高密度游离硅胶。若无假体破裂或修整史，假体预期轮廓外出现硅胶意味着囊外破裂，进而提示囊内破裂\[18,20]。
* 检查项目: Mammography Diagnostic / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000124
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no role for diagnostic mammography for implant evaluation in asymptomatic patients with silicone implants. However, female and transfeminine patients should follow breast cancer screening protocols as outlined in the ACR Appropriateness Criteria ® topics on “ Breast Cancer Screening ” \[14] and “ Transgender Breast Cancer Screening ” \[15]. The diagnosis of silicone implant rupture can be challenging, with clinical examination known to be unreliable \[19]. In cases of extracapsular silicone implant rupture, the diagnosis is often made with mammography in which high-density silicone is seen outside the implant contour. Mammography does not detect intracapsular silicone implant rupture. Both standard craniocaudal and mediolateral oblique and implant-displaced views should be obtained. Mammography has low sensitivity for the detection of implant rupture due to the silicone implant appearing extremely radiopaque \[18]. Silicone implants are normally oval, smooth, and uniformly dense at mammography, preventing any internal substructural evaluation, so with the limited ability to evaluate implants internally, intracapsular ruptures go unseen \[18]. Although internal evaluation of the implant is impeded at mammography, the contour of a silicone implant merits close inspection \[18]. Comparison with prior mammograms is useful to identify subtle contour changes over time, such as the appearance of undulations, which potentially indicate a problem with implant integrity \[18]. Frank bulges or herniations represent areas of weakening of the fibrous capsule and potential weak points of the elastomer shell \[18]. An implant that becomes more rounded in appearance may signify the presence of capsular contracture rather than implying a problem with implant integrity. Calcifications along the fibrous capsule, thought to arise as a consequence of a chronic inflammatory response, are more frequently encountered in older implants that have been in place for multiple years. Capsular calcifications correlate with implant age, but calcifications alone do not necessarily imply capsular contracture or implant rupture. Although insensitive for identifying intracapsular rupture, mammography is useful in detecting extracapsular silicone. When silicone escapes the confines of the fibrous capsule and enters the surrounding breast parenchyma, mammography can often reveal the high-density free silicone. In the absence of a history of implant rupture or revision, the presence of silicone outside the expected contour of the implant signifies extracapsular rupture and, 对于无症状硅胶假体患者，诊断性乳腺X线摄影在假体评估中无应用价值。然而，女性及跨女性患者应遵循ACR Appropriateness Criteria®中"乳腺癌筛查"\[14]与"跨性别乳腺癌筛查"\[15]专题所述的乳腺癌筛查方案。硅胶假体破裂的诊断具有挑战性，已知临床检查不可靠\[19]。对于包膜外硅胶假体破裂，诊断常通过乳腺X线摄影实现，可见假体轮廓外的高密度硅胶。乳腺X线摄影无法检测包膜内硅胶假体破裂。应同时获取标准头尾位、内外斜位及假体位移位投照。因硅胶假体呈极高放射密度，乳腺X线摄影对假体破裂的检测敏感性较低\[18]。硅胶假体在乳腺X线摄影中通常呈卵圆形、光滑且均匀致密，阻碍内部亚结构评估，故因内部评估能力有限，包膜内破裂难以被发现\[18]。虽然乳腺X线摄影中假体内部评估受限，但硅胶假体轮廓值得仔细检查\[18]。与既往乳腺X线摄影对比有助于识别随时间出现的细微轮廓变化，如波纹状外观可能提示假体完整性异常\[18]。明显凸起或疝出代表纤维囊薄弱区及弹性体外壳的潜在薄弱点\[18]。外观趋于圆形的假体可能意味着包膜挛缩而非假体完整性问题。沿纤维囊的钙化被认为由慢性炎症反应引起，更常见于植入多年的老旧假体。包膜钙化与假体植入时长相关，但仅钙化本身未必意味着包膜挛缩或假体破裂。尽管对识别包膜内破裂不敏感，乳腺X线摄影可有效检测包膜外硅胶。当硅胶突破纤维囊限制进入周围乳腺实质时，乳腺X线摄影常可显示高密度游离硅胶。若无假体破裂或修正术既往史，假体预期轮廓外出现硅胶意味着包膜外破裂。
* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000126
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support the use of MRI without and with IV contrast in the evaluation of asymptomatic silicone implants. The FDA recommendations regarding evaluation for implant rupture do not replace additional imaging that may be warranted based upon each patient’s underlying medical history or circumstances \[1]. Breast cancer screening recommendations for feminine and transfeminine patients are outlined in the ACR Appropriateness Criteria ® topics on “ Breast Cancer Screening ” \[14] and “ Transgender Breast Cancer Screening ” \[15]. 目前尚无相关文献支持在评估无症状硅胶假体时使用无静脉对比剂及增强MRI检查。FDA关于假体破裂评估的建议并不取代根据患者具体病史或情况可能需要进行的额外影像学检查\[1]。女性和跨性别女性患者的乳腺癌筛查建议详见ACR适宜性标准®专题“乳腺癌筛查”\[14]和“跨性别乳腺癌筛查”\[15]。

##### S0019 Variant: Variant 7:  Adult younger than 30 years of age. Female or transfeminine. Evaluation of silicone breast implants. Suspected implant complication. Initial imaging. | 年龄\<30岁成人。女性或跨性别女性（男跨女）。评估硅胶乳房假体。疑似假体并发症。初始影像学检查。

检查推荐列表：

* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0007 / R:CR000127
  * 证据强度: StrongReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: In symptomatic patients with silicone breast implants or patients with equivocal US results for rupture at any time postoperatively, an MRI is recommended by the FDA \[1]. MRI without IV contrast is particularly helpful in identifying intracapsular ruptures, which are not evident on mammography and can be difficult to diagnose by US. Most implant ruptures are intracapsular, and these are most often asymptomatic. MRI findings of both intracapsular and extracapsular rupture have been described \[16,29,31,32,35]. An incomplete intracapsular rupture has been referred to by a variety of names, including the “inverted-loop sign,” “keyhole sign,” “teardrop sign,” or “hang noose sign.” A complete intracapsular rupture has been called the “linguini” or “wavy-line” sign and is the most specific sign of intracapsular implant rupture. Pooled data from a meta-analysis \[37] showed a sensitivity of 87% and a specificity of 89.9% for MRI. Of note, most studies in the meta-analysis focused on symptomatic women, in whom the expected prevalence of rupture would be higher than among asymptomatic women. Studies of asymptomatic women have reported sensitivities and specificities of 64% and 77% \[26], accuracy of 94% \[27], accuracy of 92%, sensitivity of 89%, specificity of 97%, PPV of 99%, and NPV of 79% \[28]. In symptomatic patients \[38], MRI sensitivity of 96%, specificity of 77%, PPV of 90%, NPV of 90%, and accuracy of 90% have been reported. 对于有症状的硅胶乳房植入患者或术后任何时期超声检查结果不确定是否破裂的患者，美国食品药品监督管理局（FDA）推荐进行磁共振成像（MRI）检查\[1]。无静脉对比剂的MRI特别有助于识别包膜内破裂，这种情况在乳腺X线摄影中不明显，且超声诊断较为困难。大多数植入物破裂为包膜内破裂，且通常无症状。文献已描述了包膜内及包膜外破裂的MRI表现\[16,29,31,32,35]。不完全包膜内破裂有多种命名，包括“倒环征”、“钥匙孔征”、“泪滴征”或“绞索征”。完全包膜内破裂被称为“面条征”或“波浪线征”，是包膜内植入物破裂最具特异性的征象。荟萃分析汇总数据显示\[37]，MRI的敏感性为87%，特异性为89.9%。值得注意的是，该荟萃分析中大多数研究针对有症状女性，其破裂预期发生率高于无症状女性。针对无症状女性的研究报告敏感性为64%、特异性为77%\[26]，准确率为94%\[27]，准确率92%、敏感性89%、特异性97%、阳性预测值（PPV）99%、阴性预测值（NPV）79%\[28]。对于有症状患者\[38]，研究报道MRI敏感性96%、特异性77%、PPV 90%、NPV 90%、准确率90%。
* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 5
  * 适宜性: May be appropriate (Disagreement) / 可能适宜（存在争议）
  * 编码: P:PR0003 / R:CR000128
  * 证据强度: Expert OpinionReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: In symptomatic patients with silicone breast implants, an MRI is recommended by the FDA to evaluate for rupture In patients without prior explantation of silicone implants, this finding is diagnostic of extracapsular rupture. However, in patients who have had prior silicone implants, this may represent residual silicone rather than rupture of the new implants. A single-lumen silicone implant is most often featureless and anechoic, which provides reliable US evidence that the implant remains intact and undamaged. A normal implant exhibits a smooth contour outlined by a trilaminar margin, which corresponds to the capsule-shell complex. Implants will often infold on themselves within the surgical pocket created by the plastic surgeon. These radial folds are a common feature of implants and should be recognized as a normal infolding of the elastomer shell rather than mistaken for evidence of intracapsular rupture. Most silicone implant ruptures are intracapsular. Numerous US findings of intracapsular silicone implant rupture, including the stepladder sign, keyhole, noose, or subcapsular sign, have been described \[18,29-31], but the variability in reported accuracy of sonographic findings \[26,27,32-34], combined with the well-known user dependence of this technology, often makes sonographic findings somewhat equivocal. Several US intracapsular- rupture mimics exist and include reverberation artifact, radial folds, or silicone implant impurities creating spurious echoes within the implant, which can give a false impression of intracapsular rupture \[18]. At US, extracapsular silicone demonstrates a classic “snowstorm” appearance that is characterized by a highly echogenic pattern of scattered and reverberating echoes with a well-defined anterior margin and loss of detail posteriorly. Sonographic findings of intracapsular rupture have been described \[29-31], including a “stepladder” appearance of the collapsed implant shell. Some authors have reported excellent agreement of US with MRI and surgical findings \[32,33]. However, other studies have reported much lower sensitivities and accuracies for US diagnosis of intracapsular silicone implant rupture \[26,27,34], with an accuracy of 72%, sensitivity of 30%, and specificity of 77%. For the assessment of appropriateness, it is assumed the procedure is performed and interpreted by an expert. In a more recent study by Rukanskiene et al \[39], US was very accurate in the evaluation of implant integrity, with diagnostic accuracy of 94.7%, sensitivity of 98.3%, specificity of 89.2%, and NPV of 97.1%. In the case of an intact implant, all 3 signs of implant integrity on US (even implant shell, homogeneous content, and normal axillary lymph nodes) were observed most frequently at 93.6% \[39]. In cases of ruptured implants, more than 2 signs of implant rupture on US were observed in 82.8% and only 1 sign of implant rupture on US was documented in 15.5% (abnormal implant shell) \[39]. Therefore, these results suggest that if more than 2 signs of a ruptured implant are 对于有症状的硅胶乳房植入物患者，FDA推荐采用MRI评估破裂情况。在未既往取出硅胶植入物的患者中，此发现可诊断囊外破裂。然而，在既往有硅胶植入物的患者中，这可能代表残留硅胶而非新植入物的破裂。单腔硅胶植入物通常表现为无内部结构且无回声，这为超声判断植入物完整无损提供了可靠依据。正常植入物呈现由三层结构边缘勾勒的光滑轮廓，对应囊壳复合体。植入物常在整形外科医生
* 检查项目: Digital Breast Tomosynthesis Diagnostic / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000129
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: In symptomatic patients with silicone breast implants, an MRI is recommended by the FDA to evaluate for rupture \[1]. DBT is typically not performed as the initial imaging study in patients under the age of 30. Extracapsular silicone implant ruptures, although only a minority of all implant ruptures, frequently present with palpable findings or other symptoms. The diagnosis of silicone implant rupture can be challenging, however, with clinical examination known to be unreliable \[19]. DBT can identify extracapsular silicone \[20,29,31,35], which presents as high-density material outside the confines of the implant shell. In patients without prior explantation of silicone may represent residual silicone rather than rupture of the new implants, and comparison with priors is critical. Intracapsular silicone implant rupture is frequently asymptomatic and may not be reliably diagnosed with DBT. The FDA recommendations regarding evaluation for implant rupture do not replace additional imaging that may be warranted based upon each patient’s underlying medical history or circumstances \[1]. Breast cancer screening recommendations for feminine and transfeminine patients are outlined in the ACR Appropriateness Criteria ® topics on “ Breast Cancer Screening ” \[14] and “ Transgender Breast Cancer Screening ” \[15]. Imaging recommendations for areas of clinical concern unrelated to suspected implant complications may be found in the ACR Appropriateness Criteria ® topic on “ Palpable Breast Masses ” \[36]. 对于有症状的硅胶乳房假体患者，FDA推荐采用MRI评估假体破裂\[1]。30岁以下患者通常不将DBT作为初始影像学检查。尽管囊外硅胶假体破裂仅占所有假体破裂的少数，但常表现为可触及的异常或其他症状。然而硅胶假体破裂的诊断具有挑战性，已知临床检查不可靠\[19]。DBT可识别囊外硅胶\[20,29,31,35]，其表现为假体外壳外的高密度物质。对于既往未取出硅胶假体的患者，这可能代表残留硅胶而非新假体破裂，与既往影像对比至关重要。囊内硅胶假体破裂常无症状，且DBT可能无法可靠诊断。FDA关于假体破裂评估的建议并不取代基于患者个体基础病史或情况所需进行的额外影像学检查\[1]。女性和跨女性患者的乳腺癌筛查建议详见ACR适宜性标准专题"乳腺癌筛查"\[14]和"跨性别乳腺癌筛查"\[15]。与疑似假体并发症无关的临床关注区域的影像学建议可参考ACR适宜性标准专题"可触及乳腺肿块"\[36]。
* 检查项目: Mammography Diagnostic / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000129
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: In symptomatic patients with silicone breast implants, an MRI is recommended by the FDA to evaluate for rupture \[1]. Diagnostic mammography is typically not performed as the initial imaging study in patients under the age of 30. Extracapsular silicone implant ruptures, although only a minority of all implant ruptures, frequently present with palpable findings or other symptoms. The diagnosis of silicone implant rupture can be challenging, with clinical examination known to be unreliable \[19]. In cases of extracapsular silicone implant rupture, the diagnosis is often made with mammography in which high-density silicone is seen outside the implant contour. Mammography does not detect intracapsular silicone implant rupture. Both standard craniocaudal and mediolateral oblique and implant-displaced views should be obtained. Mammography can identify extracapsular silicone \[20,29,31,35], which presents as high-density material outside the confines of the implant shell. In patients without prior explantation of silicone implants, this is diagnostic of extracapsular rupture. However, in patients who have had prior silicone implants, this may represent residual silicone rather than rupture of the new implants, and comparison with priors is critical. The FDA recommendations regarding evaluation for implant rupture do not replace additional imaging that may be warranted based upon each patient’s underlying medical history or circumstances \[1]. Breast cancer screening recommendations for feminine and transfeminine patients are outlined in the ACR Appropriateness Criteria ® topics on “ Breast Cancer Screening ” \[14] and “ Transgender Breast Cancer Screening ” \[15]. Imaging recommendations for areas of clinical concern unrelated to suspected implant complications may be found in the ACR Appropriateness Criteria ® topic on “ Palpable Breast Masses ” \[36]. 对于有症状的硅胶乳房假体患者，美国食品药品监督管理局（FDA）推荐采用MRI评估假体破裂情况\[1]。30岁以下患者通常不将诊断性乳腺X线摄影作为初始影像学检查。尽管囊外硅胶假体破裂仅占所有假体破裂的少数，但常表现为可触及的异常或其他症状。硅胶假体破裂的诊断可能具有挑战性，已知临床检查并不可靠\[19]。在囊外硅胶假体破裂病例中，诊断通常通过乳腺X线摄影进行，可见假体轮廓外的高密度硅胶。乳腺X线摄影无法检测囊内硅胶假体破裂。应同时获取标准头尾位、内外斜位及假体位移位投照。乳腺X线摄影可识别囊外硅胶\[20,29,31,35]，表现为假体包膜外的高密度物质。对于既往未取出硅胶假体的患者，此表现可确诊为囊外破裂。但对于曾植入硅胶假体的患者，这可能代表残留硅胶而非新假体破裂，与既往影像对比至关重要。FDA关于假体破裂评估的建议并不取代根据患者具体病史或情况可能需要进行的其他影像学检查\[1]。女性和跨女性患者的乳腺癌筛查建议详见ACR适宜性标准®专题《乳腺癌筛查》\[14]和《跨性别者乳腺癌筛查》\[15]。与疑似假体并发症无关的临床关注区域的影像学
* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000131
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support the use of MRI without and with IV contrast in the evaluation of symptomatic silicone implants. Breast cancer screening recommendations for feminine and transfeminine patients are outlined in the ACR Appropriateness Criteria ® topics on “ Breast Cancer Screening ” \[14] and “ Transgender Breast Cancer Screening ” \[15]. Imaging recommendations for areas of clinical concern unrelated to suspected implant complications may be found in the ACR Appropriateness Criteria ® topic on “ Palpable Breast Masses ” \[36]. 目前尚无相关文献支持在评估有症状的硅胶假体时使用无静脉造影剂与增强MRI的检查方案。针对女性和跨女性患者的乳腺癌筛查建议，请参阅ACR适宜性标准®专题《乳腺癌筛查》\[14]和《跨性别者乳腺癌筛查》\[15]。对于与可疑假体并发症无关的临床关注区域，其影像学检查建议可参考ACR适宜性标准®专题《可触及乳腺肿块》\[36]。

##### S0020 Variant: Variant 8:  Adult 30 to 39 years of age. Female or transfeminine. Evaluation of silicone breast implants. Suspected implant complication. Initial imaging. | 成人30至39岁。女性或跨性别女性。评估硅胶乳房假体。疑似假体并发症。初始影像学检查。

检查推荐列表：

* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 8
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0007 / R:CR000132
  * 证据强度: StrongReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: In symptomatic patients with silicone breast implants or patients with equivocal US results for rupture at any time postoperatively, an MRI is recommended by the FDA \[1]. MRI without IV contrast is particularly helpful in identifying intracapsular ruptures, which are not evident on mammography and can be difficult to diagnose by US. Most implant ruptures are intracapsular, and these are most often asymptomatic. MRI findings of both intracapsular and extracapsular rupture have been described \[16,29,31,32,35]. An incomplete intracapsular rupture has been referred to by a variety of names, including the “inverted-loop sign,” “keyhole sign,” “teardrop sign,” or “hang noose sign.” A complete intracapsular rupture has been called the “linguini” or “wavy-line” sign and is the most specific sign of intracapsular implant rupture. Pooled data from a meta-analysis \[37] showed a sensitivity of 87% and a specificity of 89.9% for MRI. Of note, most studies in the meta-analysis focused on symptomatic women, in whom the expected prevalence of rupture would be higher than among asymptomatic women. Studies of asymptomatic women have reported sensitivities and specificities of 64% and 77% \[26], accuracy of 94% \[27], accuracy of 92%, sensitivity of 89%, specificity of 97%, PPV of 99%, and NPV of 79% \[28]. In symptomatic patients \[38], MRI sensitivity of 96%, specificity of 77%, PPV of 90%, NPV of 90%, and accuracy of 90% have been reported. 对于有症状的硅胶乳房植入患者或术后任何时期超声检查结果不确定是否破裂的患者，美国食品药品监督管理局（FDA）推荐进行磁共振成像（MRI）检查\[1]。无静脉对比剂的MRI特别有助于识别包膜内破裂，这种情况在乳腺X线摄影中不明显，且超声诊断较为困难。大多数植入物破裂为包膜内破裂，且通常无症状。文献已描述了包膜内及包膜外破裂的MRI表现\[16,29,31,32,35]。不完全包膜内破裂有多种命名，包括“倒环征”、“钥匙孔征”、“泪滴征”或“绞索征”。完全包膜内破裂被称为“面条征”或“波浪线征”，是包膜内植入物破裂最具特异性的征象。荟萃分析汇总数据显示\[37]，MRI的敏感性为87%，特异性为89.9%。值得注意的是，该荟萃分析中大多数研究针对有症状女性，其破裂预期发生率高于无症状女性。针对无症状女性的研究报告敏感性为64%、特异性为77%\[26]，准确率为94%\[27]，准确率92%、敏感性89%、特异性97%、阳性预测值（PPV）99%、阴性预测值（NPV）79%\[28]。对于有症状患者\[38]，研究报道MRI敏感性96%、特异性77%、PPV 90%、NPV 90%、准确率90%。
* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 5
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0003 / R:CR000133
  * 证据强度: StrongReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: In symptomatic patients with silicone breast implants, an MRI is recommended by the FDA to evaluate for rupture \[1]. However, US can identify extracapsular silicone \[20,29,31,35], which presents as a classic “snowstorm” pattern. In patients without prior explantation of silicone implants, this finding is diagnostic of extracapsular rupture. However, in patients who have had prior silicone implants, this may represent residual silicone rather than rupture A single-lumen silicone implant is most often featureless and anechoic, which provides reliable US evidence that the implant remains intact and undamaged. A normal implant exhibits a smooth contour outlined by a trilaminar margin, which corresponds to the capsule-shell complex. Implants will often infold on themselves within the surgical pocket created by the plastic surgeon. These radial folds are a common feature of implants and should be recognized as a normal infolding of the elastomer shell rather than mistaken for evidence of intracapsular rupture. Most silicone implant ruptures are intracapsular. Numerous US findings of intracapsular silicone implant rupture, including the stepladder sign, keyhole, noose, or subcapsular sign, have been described \[18,29-31], but the variability in reported accuracy of sonographic findings \[26,27,32-34], combined with the well-known user dependence of this technology, often makes sonographic findings somewhat equivocal. Several US intracapsular- rupture mimics exist and include reverberation artifact, radial folds, or silicone implant impurities creating spurious echoes within the implant, which can give a false impression of intracapsular rupture \[18]. At US, extracapsular silicone demonstrates a classic “snowstorm” appearance that is characterized by a highly echogenic pattern of scattered and reverberating echoes with a well-defined anterior margin and loss of detail posteriorly. Sonographic findings of intracapsular rupture have been described \[29-31], including a “stepladder” appearance of the collapsed implant shell. Some authors have reported excellent agreement of US with MRI and surgical findings \[32,33]. However, other studies have reported much lower sensitivities and accuracies for US diagnosis of intracapsular silicone implant rupture \[26,27,34], with an accuracy of 72%, sensitivity of 30%, and specificity of 77%. For the assessment of appropriateness, it is assumed the procedure is performed and interpreted by an expert. In a more recent study by Rukanskiene et al \[39], US was very accurate in the evaluation of implant integrity, with a diagnostic accuracy of 94.7%, sensitivity of 98.3%, specificity of 89.2%, and NPV of 97.1%. In the case of an intact implant, all 3 signs of implant integrity on US (even implant shell, homogeneous content, and normal axillary lymph nodes) were observed most frequently at 93.6% \[39]. In cases of ruptured implants, more than 2 signs of implant rupture on US were observed in 82.8% and only 1 sign of implant rupture on US was documented in 15.5% 对于有症状的硅胶乳房假体患者，FDA推荐采用MRI评估假体破裂\[1]。但US可识别囊外硅胶\[20,29,31,35]，其表现为典型的"暴风雪"模式。对于既往未取出硅胶假体的患者，该表现可诊断囊外破裂。但对于既往有硅胶假体的患者，这可能代表残留硅胶而非破裂。单腔硅胶假体多表现为无特征性且无回声，这为假体完整未损提供了可靠的US证据。正常假体呈现由三层结构边缘勾勒的光滑轮廓，对应囊壳复合体。假体常在整形外科医生创建的手术囊袋内自行折叠。这些放射状褶皱是假体的常见特征，应识别为弹性体外壳的正常折叠，而非误认为囊内破裂证据。多数硅胶假体破裂为囊内型。尽管已描述多种囊内硅胶假体破裂的US表现（包括阶梯征、锁眼征、套索征或囊下征）\[18,29,31]，但报道的超声检查准确性存在变异\[26,
* 检查项目: Digital Breast Tomosynthesis Diagnostic / MG双侧乳腺钼靶
  * 评分: 5
  * 适宜性: May be appropriate (Disagreement) / 可能适宜（存在争议）
  * 编码: P:PR0010 / R:CR000134
  * 证据强度: Expert OpinionReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: In symptomatic patients with silicone breast implants, an MRI is recommended by the FDA to evaluate for rupture \[1]. However, DBT can identify extracapsular silicone. Extracapsular silicone implant ruptures, although only a minority of all implant ruptures, frequently present with palpable findings or other symptoms. The diagnosis of silicone implant rupture can be challenging, with clinical examination known to be unreliable \[19]. In cases of extracapsular silicone implant rupture, the diagnosis is often made with DBT in which high-density silicone is seen outside the implant contour. DBT does not detect intracapsular silicone implant rupture. Both standard craniocaudal and mediolateral oblique and implant-displaced views should be obtained. DBT will identify extracapsular silicone, which presents as high-density material outside the confines of the implant shell. In patients without prior explantation of silicone implants, this is diagnostic of extracapsular rupture. However, in patients who have had prior silicone implants, this may represent residual silicone rather than rupture of the new implants, and comparison with priors is critical. The FDA recommendations regarding evaluation for implant rupture do not replace additional imaging that may be warranted based upon each patient’s underlying medical history or circumstances \[1]. Breast cancer screening on “ Breast Cancer Screening ” \[14] and “ Transgender Breast Cancer Screening ” \[15]. Imaging recommendations for areas of clinical concern unrelated to suspected implant complications may be found in the ACR Appropriateness Criteria ® topic on “ Palpable Breast Masses ” \[36]. 对于有症状的硅胶乳房假体患者，FDA推荐采用MRI评估假体破裂\[1]。但DBT可识别囊外硅胶。尽管囊外硅胶假体破裂仅占所有假体破裂的少数，但常表现为可触及的异常或其他症状。硅胶假体破裂的诊断具有挑战性，已知临床检查不可靠\[19]。对于囊外硅胶假体破裂病例，常通过DBT诊断，可见假体轮廓外的高密度硅胶。DBT不能检测囊内硅胶假体破裂。应同时获取标准头尾位、内外斜位及假体移位位图像。DBT可识别囊外硅胶，其表现为假体外壳外的高密度物质。对于既往未取出硅胶假体的患者，该表现可诊断囊外破裂。但对于既往有硅胶假体的患者，这可能代表残留硅胶而非新假体破裂，与既往影像对比至关重要。FDA关于假体破裂评估的建议并不取代基于患者个体基础病史或情况所需进行的额外影像学检查\[1]。乳腺癌筛查建议详见"乳腺癌筛查"\[14]和"跨性别乳腺癌筛查"\[15]。与疑似假体并发症无关的临床关注区域的影像学建议可参考ACR适宜性标准专题"可触及乳腺肿块"\[36]。
* 检查项目: Mammography Diagnostic / MG双侧乳腺钼靶
  * 评分: 5
  * 适宜性: May be appropriate (Disagreement) / 可能适宜（存在争议）
  * 编码: P:PR0010 / R:CR000134
  * 证据强度: Expert OpinionReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: In symptomatic patients with silicone breast implants, an MRI is recommended by the FDA to evaluate for rupture \[1]. However, diagnostic mammography can identify extracapsular silicone. Extracapsular silicone implant ruptures, although only a minority of all implant ruptures, frequently present with palpable findings or other symptoms. The diagnosis of silicone implant rupture can be challenging, with clinical examination known to be unreliable \[19]. In cases of extracapsular silicone implant rupture, the diagnosis is often made with mammography in which high-density silicone is seen outside the implant contour. Mammography does not detect intracapsular silicone implant rupture. Both standard craniocaudal and mediolateral oblique and implant-displaced views should be obtained. Mammography can identify extracapsular silicone \[20,29,31,35], which presents as high-density material outside the confines of the implant shell. In patients without prior explantation of silicone implants, this is diagnostic of extracapsular rupture. However, in patients who have had prior silicone implants, this may represent residual silicone rather than rupture of the new implants, and comparison with priors is critical. The FDA recommendations regarding evaluation for implant rupture do not replace additional imaging that may be warranted based upon each patient’s underlying medical history or circumstances \[1]. Breast cancer screening recommendations for feminine and transfeminine patients are outlined in the ACR Appropriateness Criteria ® topics on “ Breast Cancer Screening ” \[14] and “ Transgender Breast Cancer Screening ” \[15]. Imaging recommendations for areas of clinical concern unrelated to suspected implant complications may be found in the ACR Appropriateness Criteria ® topic on “ Palpable Breast Masses ” \[36]. 对于有症状的硅胶乳房假体患者，美国食品药品监督管理局（FDA）推荐通过MRI评估假体破裂情况\[1]。然而，诊断性乳腺X线摄影可识别包膜外硅胶渗漏。虽然包膜外假体破裂仅占所有假体破裂的少数，但常表现为可触及的异常或其他症状。硅胶假体破裂的诊断具有挑战性，已知临床检查并不可靠\[19]。对于包膜外硅胶假体破裂，通常通过乳腺X线摄影诊断，可见假体轮廓外的高密度硅胶影。乳腺X线摄影无法检测包膜内假体破裂，需同时获取标准头尾位、内外斜位及假体位移位投照。该检查可识别包膜外硅胶渗漏\[20,29,31,35]，表现为假体外壳边界外的高密度物质。对于未取出过硅胶假体的患者，此表现可确诊包膜外破裂。但既往有硅胶假体植入史者，此类表现可能为残留硅胶而非新假体破裂，与既往影像对比至关重要。FDA关于假体破裂评估的建议并不取代根据患者具体病史或情况所需的其他影像检查\[1]。女性和跨性别女性患者的乳腺癌筛查建议详见ACR适宜性标准®专题《乳腺癌筛查》\[14]及《跨性别者乳腺癌筛查》\[15]。与可疑假体并发症无关的临床关注区域影像建议
* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000136
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support the use of MRI without and with IV contrast in the evaluation of symptomatic silicone implants. The FDA recommendations regarding evaluation for implant rupture do not replace additional imaging that may be warranted based upon each patient’s underlying medical history or circumstances \[1]. Breast cancer screening recommendations for feminine and transfeminine patients are outlined in the ACR Appropriateness Criteria ® topics on “ Breast Cancer Screening ” \[14] and “ Transgender Breast Cancer Screening ” \[15]. Imaging recommendations for areas of clinical concern unrelated to suspected implant complications may be found in the ACR Appropriateness Criteria ® topic on “ Palpable Breast Masses ” \[36]. 目前尚无相关文献支持在评估有症状的硅胶假体时采用不注射和注射静脉对比剂的MRI检查。FDA关于假体破裂评估的建议并不能替代根据患者具体病史或情况可能需要进行的额外影像学检查\[1]。针对女性和跨性别女性患者的乳腺癌筛查建议详见ACR适宜性标准®专题“乳腺癌筛查”\[14]和“跨性别乳腺癌筛查”\[15]。与可疑假体并发症无关的临床关注区域的影像学检查建议可参考ACR适宜性标准®专题“可触及乳腺肿块”\[36]。

##### S0021 Variant: Variant 9:  Adult age 40 years or older. Female or transfeminine. Evaluation of silicone breast implants. Suspected implant complication. Initial imaging. | ≥40岁成人，女性或跨性别女性，评估硅胶乳房假体，疑似假体并发症，初始影像学检查。

检查推荐列表：

* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0007 / R:CR000137
  * 证据强度: StrongReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: In symptomatic patients with silicone breast implants or patients with equivocal US results for rupture at any time postoperatively, an MRI is recommended by the FDA \[1]. MRI without IV contrast is generally a helpful imaging study for evaluation of silicone implant rupture. It is particularly helpful in identifying intracapsular ruptures, which are not evident on mammography and can be difficult to diagnose by US. Most implant ruptures are intracapsular, and these are most often asymptomatic. MRI findings of both intracapsular and extracapsular rupture have been described \[16,29,31,32,35]. An incomplete intracapsular rupture has been referred to by a variety of names, including the “inverted-loop sign,” “keyhole sign,” “teardrop sign,” or “hang noose sign.” A complete intracapsular rupture has been called the “linguini” or “wavy-line” sign and is the most specific sign of intracapsular implant rupture. Pooled data from a meta-analysis \[37] showed a sensitivity of 87% and a specificity of 89.9% for MRI. Of note, most studies in the meta-analysis focused on symptomatic women, in whom the expected prevalence of rupture would be higher than among asymptomatic women. Studies of asymptomatic women have reported sensitivities and specificities of 64% and 77% \[26], accuracy of 94% \[27], accuracy of 92%, sensitivity of 89%, specificity of 97%, PPV of 99%, and NPV of 79% \[28]. In symptomatic patients \[38], an MRI sensitivity of 96%, specificity of 77%, PPV of 90%, NPV of 90%, and accuracy of 90% have been reported. 对于术后任何时期出现症状的硅胶乳房假体患者或超声检查结果不确定是否破裂的患者，美国食品药品监督管理局（FDA）推荐进行磁共振成像（MRI）检查\[1]。无静脉对比剂的MRI通常是评估硅胶假体破裂的有效影像学手段，尤其有助于识别乳腺X线摄影无法显示且超声难以诊断的包膜内破裂。大多数假体破裂为包膜内型，且通常无症状。文献已描述了包膜内及包膜外破裂的MRI表现\[16,29,31,32,35]。不完全性包膜内破裂有多种命名，包括"反折环征"、"锁眼征"、"泪滴征"或"绞索征"；完全性包膜内破裂则被称为"面条征"或"波浪线征"，是包膜内假体破裂最具特异性的征象。荟萃分析汇总数据显示\[37]，MRI诊断的敏感性为87%，特异性为89.9%。值得注意的是，该荟萃分析中大多数研究针对有症状女性，其破裂预期发生率高于无症状人群。针对无症状女性的研究报道敏感性64%与特异性77%\[26]、准确率94%\[27]、准确率92%/敏感性89%/特异性97%/阳性预测值99%/阴性预测值79%\[28]。而有症状患者的研究显示\[38]，MRI敏感性96%、特异性77%、阳性预测值90%、阴性预测值90%、准确率90%。
* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 5
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0003 / R:CR000138
  * 证据强度: StrongReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: In symptomatic patients with silicone breast implants, an MRI is recommended by the FDA to evaluate for rupture \[1]. However, US can identify extracapsular silicone. Extracapsular rupture is disruption of both the polymer and fibrous capsules with leak of silicone into the breast tissue. Rupture of silicone implants, however, may be asymptomatic, especially if the rupture is intracapsular (contained by the fibrous shell formed by the body around the implant). If the rupture is extracapsular, patients may present with palpable masses or changes in breast contour. Diagnosis of extracapsular rupture of silicone implants is often made with mammography and/or US, in which high- density silicone is identified outside the confines of the implant shell. The rate of implant ruptures increases with time, and most of them do not cause any clinical symptoms. Once an implant ruptures, free silicone can migrate. identify extracapsular silicone \[20,29,31,35], which presents as a classic “snowstorm” pattern and may be useful if mammographic findings are equivocal or the patient cannot undergo mammography. Sonographic findings of intracapsular rupture have been described \[29-31], including a “stepladder” appearance of the collapsed implant shell. Some authors have reported excellent agreement of US with MRI and surgical findings \[32,33]. However, other studies have reported much lower sensitivities and accuracies for US diagnosis of intracapsular silicone implant rupture \[26,27,34], showing an accuracy of 72%, sensitivity of 30%, and specificity of 77%. For the assessment of appropriateness, it is assumed the procedure is performed and interpreted by an expert. In a more recent study by Rukanskiene et al, US was very accurate in the evaluation of implant integrity, with a diagnostic accuracy of 94.7%, sensitivity of 98.3%, specificity of 89.2%, and NPV of 97.1%. In the case of an intact implant, all 3 signs of implant integrity on US (even implant shell, homogeneous content, and normal axillary lymph nodes) were observed most frequently at 93.6% \[39]. In cases of ruptured implants, more than 2 signs of implant rupture on US were observed in 82.8%, and only 1 sign of implant rupture on US was documented in 15.5% (abnormal implant shell) \[39]. Therefore, these results suggest that if more than 2 signs of a ruptured implant are detected on US, US findings can be acted upon; if only 1 sign of a ruptured implant are found, MRI can be helpful \[39]. The FDA recommendations regarding evaluation for implant rupture do not replace additional imaging that may be warranted based upon each patient’s underlying medical history or circumstances \[1]. Breast cancer screening recommendations for feminine and transfeminine patients are outlined in the ACR Appropriateness Criteria ® topics on “ Breast Cancer Screening ” \[14] and “ Transgender Breast Cancer Screening ” \[15]. Imaging recommendations for areas of clinical concern unrelated to suspected implant complications may be found in the ACR 对于有症状的硅胶乳房假体患者，FDA推荐采用MRI评估假体破裂\[1]。然而，超声可识别囊外硅胶。囊外破裂指聚合物与纤维包膜同时破裂，导致硅胶渗入乳腺组织。但硅胶假体破裂可能无症状，尤其当破裂为囊内性时（即被机体在假体周围形成的纤维壳包裹）。若发生囊外破裂，患者可能出现可触及肿块或乳房轮廓改变。硅胶假体囊外破裂的诊断常通过乳腺X线摄影和/或超声实现，可观察到假体壳外的高密度硅胶。假体破裂率随时间增加，但多数不引起临床症状。一旦假体破裂，游离硅胶可能迁移。超声可识别囊外硅胶\[20,29,31,35]，表现为典型"暴风雪"征象，在乳腺X线摄影结果不明确或患者无法接受乳腺X线摄影时可能有价值。囊内破裂的超声表现已有描述\[2931]，包括假体壳塌陷形成的"阶梯征"。部分研究者报道超声与MRI及手术结果高度一致\[32,33]。但其他研究报道超声诊断硅胶假体囊内破裂的敏感性和准确性较低\[26,27,34]，准确性为72%，敏感性为30%，特异性为77%。在适宜性评估中，假定检查由专家操作和判读。Rukanskiene等最新研究表明超声评估假体完整性非常准确，诊断准确性达94.7%，敏感性98.3%，特异性89.2%，阴性预测值97.1%。对于完整假体，超声所有三项完整性征象（平整假体壳、均匀内容物及正常腋窝淋巴结）的出现频率最高达93.6%\[39]。对于破裂假体，82.8%病例观察到超过两项超声破裂征象，15.5%病例仅记录到一项超声破裂征象（异常假体壳）\[39]。因此这些结果表明若超声检测到超过两项假体破裂征象，可依据超声结果采取行动；若仅发现一项破裂征象，MRI可能有帮助\[39]。FDA关于假体破裂评估的建议不替代根据患者具体病史或情况可能需要的额外影像学检查\[1]。女性和跨女性患者的乳腺癌筛查建议详见ACR适宜性标准专题"乳腺癌筛查"\[14]和"跨性别乳腺癌筛查"\[15]。与疑似假体并发症无关的临床关注区域的影像学建议可见ACR
* 检查项目: Digital Breast Tomosynthesis Diagnostic / MG双侧乳腺钼靶
  * 评分: 5
  * 适宜性: May be appropriate (Disagreement) / 可能适宜（存在争议）
  * 编码: P:PR0010 / R:CR000139
  * 证据强度: Expert OpinionReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: In symptomatic patients with silicone breast implants, an MRI is recommended by the FDA to evaluate for rupture \[1]. However, DBT can identify extracapsular silicone. DBT can be useful in the evaluation of suspected extracapsular silicone implant rupture, which frequently presents with palpable findings or other symptoms. The diagnosis of silicone implant rupture can be challenging, with clinical examination known to be unreliable \[19]. In cases of extracapsular silicone implant rupture, the diagnosis is often made with DBT in which high-density silicone is seen outside the implant contour. DBT does not detect intracapsular silicone implant rupture. Both standard craniocaudal and mediolateral oblique and implant-displaced views should be obtained. DBT can identify extracapsular silicone \[20,29-31,35], which presents as high-density material outside the confines of the implant shell. In patients without prior explantation of silicone implants, this finding is diagnostic of extracapsular rupture. However, in patients who have had prior silicone implants, this may represent residual silicone rather than rupture of the new implants, and comparison with priors is critical. The FDA recommendations regarding evaluation for implant rupture do not replace additional imaging that may be warranted based upon each patient’s underlying medical history or circumstances \[1]. Breast cancer screening recommendations for feminine and transfeminine patients are outlined in the ACR Appropriateness Criteria ® topics on “ Breast Cancer Screening ” \[14] and “ Transgender Breast Cancer Screening ” \[15]. Imaging recommendations for areas of clinical concern unrelated to suspected implant complications may be found in the ACR 对于有症状的硅胶乳房假体患者，FDA推荐采用MRI评估假体破裂\[1]。但DBT可识别囊外硅胶。DBT有助于评估疑似囊外硅胶假体破裂，此类破裂常表现为可触及的异常或其他症状。硅胶假体破裂的诊断具有挑战性，已知临床检查不可靠\[19]。对于囊外硅胶假体破裂病例，常通过DBT诊断，可见假体轮廓外的高密度硅胶。DBT不能检测囊内硅胶假体破裂。应同时获取标准头尾位、内外斜位及假体移位位图像。DBT可识别囊外硅胶\[20,29,31,35]，其表现为假体外壳外的高密度物质。对于既往未取出硅胶假体的患者，该表现可诊断囊外破裂。但对于既往有硅胶假体的患者，这可能代表残留硅胶而非新假体破裂，与既往影像对比至关重要。FDA关于假体破裂评估的建议并不取代基于患者个体基础病史或情况所需进行的额外影像学检查\[1]。女性和跨女性患者的乳腺癌筛查建议详见ACR适宜性标准专题"乳腺癌筛查"\[14]和"跨性别乳腺癌筛查"\[15]。与疑似假体并发症无关的临床关注区域的影像学建议可参考ACR适宜性标准专题"可触及乳腺肿块"\[36]。
* 检查项目: Mammography Diagnostic / MG双侧乳腺钼靶
  * 评分: 5
  * 适宜性: May be appropriate (Disagreement) / 可能适宜（存在争议）
  * 编码: P:PR0010 / R:CR000139
  * 证据强度: Expert OpinionReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: In symptomatic patients with silicone breast implants, an MRI is recommended by the FDA to evaluate for rupture \[1]. However, diagnostic mammography can identify extracapsular silicone. Diagnostic mammography can be useful in the evaluation of suspected extracapsular silicone implant rupture, which frequently presents with palpable findings or other symptoms. The diagnosis of silicone implant rupture can be challenging, with clinical examination known to be unreliable \[19]. In cases of extracapsular silicone implant rupture, the diagnosis is often made with mammography in which high-density silicone is seen outside the implant contour. Mammography does not detect intracapsular silicone implant rupture. Both standard craniocaudal and mediolateral oblique and implant-displaced views should be obtained. Mammography can identify extracapsular silicone \[20,29-31,35], which presents as high- density material outside the confines of the implant shell. In patients without prior explantation of silicone implants, this finding is diagnostic of extracapsular rupture. However, in patients who have had prior silicone implants, this may represent residual silicone rather than rupture of the new implants, and comparison with priors is critical. The FDA recommendations regarding evaluation for implant rupture do not replace additional imaging that may be warranted based upon each patient’s underlying medical history or circumstances \[1]. Breast cancer screening recommendations for feminine and transfeminine patients are outlined in the ACR Appropriateness Criteria ® topics on “ Breast Cancer Screening ” \[14] and “ Transgender Breast Cancer Screening ” \[15]. Imaging recommendations for areas of clinical concern unrelated to suspected implant complications may be found in the ACR Appropriateness Criteria ® topic on “ Palpable Breast Masses ” \[36]. 对于有症状的硅胶乳房假体患者，美国食品药品监督管理局（FDA）建议通过磁共振成像（MRI）评估假体破裂情况\[1]。然而，诊断性乳腺X线摄影可识别包膜外硅胶渗漏。该检查对评估疑似包膜外硅胶假体破裂具有重要价值，此类破裂常表现为可触及的异常或其他症状。硅胶假体破裂的诊断具有挑战性，已知临床检查结果并不可靠\[19]。在包膜外硅胶假体破裂病例中，诊断通常通过乳腺X线摄影实现，可见假体轮廓外的高密度硅胶影。但乳腺X线摄影无法检测包膜内假体破裂。应同时获取标准头尾位、内外斜位及假体位移位投照。乳腺X线摄影可识别表现为假体外壳边界外高密度物质的包膜外硅胶渗漏\[20,29-31,35]。对于未接受过假体取出术的患者，该表现可确诊包膜外破裂。但对于既往植入过硅胶假体的患者，此征象可能代表残留硅胶而非新假体破裂，此时与既往影像对比至关重要。FDA关于假体破裂评估的建议并不取代根据患者具体病史或情况所需的其他影像学检查\[1]。女性和跨女性患者的乳腺癌筛查建议详见ACR适宜性标准®专题《乳腺癌筛查》\[14]与《跨性别者乳腺癌筛查》\[
* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000141
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support the use of MRI without and with IV contrast in the evaluation of symptomatic silicone implants. The FDA recommendations regarding evaluation for implant rupture do not replace additional imaging that may be warranted based upon each patient’s underlying medical history or circumstances \[1]. Breast cancer screening recommendations for feminine and transfeminine patients are outlined in the ACR Appropriateness Criteria ® topics on “ Breast Cancer Screening ” \[14] and “ Transgender Breast Cancer Screening ” \[15]. Imaging recommendations for areas of clinical concern unrelated to suspected implant complications may be found in the ACR Appropriateness Criteria ® topic on “ Palpable Breast Masses ” \[36]. 目前尚无相关文献支持在评估有症状的硅胶假体时采用不注射和注射静脉对比剂的MRI检查。FDA关于假体破裂评估的建议并不能替代根据患者具体病史或情况可能需要进行的额外影像学检查\[1]。针对女性和跨性别女性患者的乳腺癌筛查建议详见ACR适宜性标准®专题“乳腺癌筛查”\[14]和“跨性别乳腺癌筛查”\[15]。与可疑假体并发症无关的临床关注区域的影像学检查建议可参考ACR适宜性标准®专题“可触及乳腺肿块”\[36]。

##### S0022 Variant: Variant 10:  Adult younger than 30 years of age. Female or transfeminine. Evaluation of unexplained axillary adenopathy. Silicone breast implants (current or prior). Initial imaging. | 年龄\<30岁成人。女性或跨性别女性（男跨女）。评估不明原因腋窝淋巴结肿大。目前或既往有硅胶乳房假体。初始影像学检查。

检查推荐列表：

* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0003 / R:CR000142
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: For patients \<30 years of age with unexplained axillary adenopathy in this clinical scenario, US can be helpful in diagnosing silicone adenitis, in which a “snowstorm” \[30] appearance will be seen in the axillary nodes containing free silicone. In addition, US can identify morphologically abnormal lymph nodes that may represent metastatic disease from a previously unsuspected breast cancer or may be from a variety of other causes such as lymphoma, 对于此临床背景下30岁以下不明原因腋窝淋巴结病患者，超声有助于诊断硅酮性淋巴结炎，表现为含游离硅酮的腋窝淋巴结呈现"暴风雪征"\[30]。此外，超声可识别形态异常淋巴结，可能提示既往未发现的乳腺癌转移灶，或源于淋巴瘤等多种其他病因，
* 检查项目: Digital Breast Tomosynthesis Diagnostic / MG双侧乳腺钼靶
  * 评分: 2
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000143
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: DBT is typically not performed as the initial imaging study in patients under the age of 30. DBT may be useful as a complementary imaging modality to evaluate unexplained axillary adenopathy in patients \<30 years of age when suspicious sonographic findings are identified. Silicone within low axillary nodes may also be seen on DBT. 30岁以下患者通常不将DBT作为初始影像学检查。当发现可疑超声表现时，DBT可作为补充影像学手段用于评估30岁以下患者不明原因的腋窝淋巴结病变。低腋窝淋巴结内的硅胶也可通过DBT观察到。
* 检查项目: Mammography Diagnostic / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000143
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Diagnostic mammography is typically not performed as the initial imaging study in patients under the age of 30. Diagnostic mammography may be useful as a complementary imaging modality to evaluate for unexplained axillary adenopathy in patients \<30 years of age when suspicious sonographic findings are identified. Silicone within low axillary nodes may also be seen on diagnostic mammography. 30岁以下患者通常不将诊断性乳腺X线摄影作为初始影像学检查。当发现可疑超声表现时，诊断性乳腺X线摄影可作为辅助影像手段用于评估30岁以下患者不明原因的腋窝淋巴结病。诊断性乳腺X线摄影还可显示低位腋窝淋巴结内的硅胶物质。
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000146
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support MRI without IV contrast in evaluation of unexplained axillary adenopathy in patients \<30 years of age because its primary function would be to identify silicone in the lymph nodes as an explanation for the adenopathy. 目前尚无相关文献支持在不使用静脉造影剂的情况下，通过MRI评估30岁以下患者不明原因腋窝淋巴结病的有效性，因为其主要功能是检测淋巴结中的硅胶物质以解释淋巴结病的病因。
* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000145
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support MRI without and with IV contrast as the initial imaging study in this setting. However, it is needed if biopsy shows axillary metastatic disease from a mammographically and sonographically occult primary breast carcinoma. 目前尚无相关文献支持在此情况下将无和有静脉注射对比剂的MRI作为初始影像学检查。然而，若活检显示腋窝转移性病变来自乳腺X线摄影和超声检查未发现的原发性乳腺癌，则需进行此项检查。

##### S0023 Variant: Variant 11:  Adult 30 to 39 years of age. Female or transfeminine. Evaluation of unexplained axillary adenopathy. Silicone breast implants (current or prior). Initial imaging. | 成人30至39岁。女性或跨性别女性。评估不明原因腋窝淋巴结肿大。目前或既往有硅胶乳房假体。初始影像学检查。

检查推荐列表：

* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0003 / R:CR000147
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: US may be considered for patients 30 to 39 years of age with unexplained axillary adenopathy. The second most common place for free silicone migration is regional lymph nodes (axillary lymph nodes), and silicone aggregates in lymph nodes can also mimic malignant processes. Occasionally, free silicone travels to distant regions (arm/forearm, thoracic cavity, abdominal wall, legs, back). To avoid these complications, it is of crucial importance to detect implant rupture as soon as possible and to remove or replace a ruptured implant \[39]. US can diagnose silicone adenitis, in which a “snowstorm” \[30] appearance will be seen in the axillary nodes containing free silicone. In addition, US can identify morphologically abnormal lymph nodes that may represent metastatic disease from a previously unsuspected breast cancer or may be from a variety of other causes, such as lymphoma, infection, or systemic illnesses including autoimmune diseases. If morphologically abnormal lymph nodes are identified, further evaluation of the breast parenchyma is indicated. For patients 30 to 39 years of age, this often includes mammography or DBT and US. 对于30至39岁不明原因腋窝淋巴结肿大的患者，可考虑采用超声检查。游离硅胶迁移的第二常见部位是区域淋巴结（腋窝淋巴结），而淋巴结中的硅胶聚集也可能与恶性病变相似。偶尔，游离硅胶会迁移至远处区域（手臂/前臂、胸腔、腹壁、腿部、背部）。为避免这些并发症，尽早发现植入物破裂并移除或更换破裂的植入物至关重要\[39]。超声可诊断硅胶性淋巴结炎，表现为含有游离硅胶的腋窝淋巴结呈现“暴风雪”样特征\[30]。此外，超声还能识别形态异常的淋巴结，这些淋巴结可能提示既往未被怀疑的乳腺癌转移，或由其他多种原因引起，如淋巴瘤、感染或包括自身免疫性疾病在内的全身性疾病。若发现形态异常的淋巴结，需进一步评估乳腺实质。对于30至39岁的患者，通常包括乳腺X线摄影或数字乳腺断层合成摄影（DBT）及超声检查。
* 检查项目: Digital Breast Tomosynthesis Diagnostic / MG双侧乳腺钼靶
  * 评分: 8
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0010 / R:CR000148
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: DBT may help to evaluate unexplained axillary adenopathy in patients 30 to 39 years of age. Silicone within low axillary nodes may be seen on DBT. When DBT is performed, axillary US is complementary and may be performed at the same time. 数字乳腺断层摄影（DBT）可用于评估30至39岁患者不明原因的腋窝淋巴结病变。DBT可显示低位腋窝淋巴结内的硅胶。进行DBT检查时，腋窝超声可作为补充检查并同时进行。
* 检查项目: Mammography Diagnostic / MG双侧乳腺钼靶
  * 评分: 8
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0010 / R:CR000148
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Diagnostic mammography may help to evaluate unexplained axillary adenopathy in patients 30 to 39 years of age. Silicone within low axillary nodes may be seen on mammography and DBT. When mammography is performed, axillary US is complementary and may be performed at the same time. 诊断性乳腺X线摄影有助于评估30至39岁患者不明原因的腋窝淋巴结病变。乳腺X线摄影和数字乳腺断层合成（DBT）可观察到低位腋窝淋巴结内的硅胶。进行乳腺X线检查时，腋窝超声可作为补充检查并同时进行。
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 2
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000150
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: MRI without IV contrast is of limited value in evaluation of unexplained axillary adenopathy in patients 30 to 39 years of age because its primary function would be to identify silicone in the lymph nodes as an explanation for the adenopathy. 对于30至39岁患者不明原因腋窝淋巴结病的评估，无静脉注射对比剂的MRI检查价值有限，因其主要功能是检测淋巴结中的硅胶物质以解释淋巴结病。
* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000151
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support MRI without and with IV contrast in this setting as the initial imaging study in this setting. However, it is needed if biopsy shows axillary metastatic disease from a mammographically and sonographically occult primary breast carcinoma. 目前尚无相关文献支持在此情况下将无和有静脉注射对比剂的MRI作为初始影像学检查。然而，若活检显示腋窝转移性病变源自乳腺X线摄影和超声检查未发现的隐匿性乳腺癌，则需进行此项检查。

##### S0024 Variant: Variant 12:  Adult age 40 years or older. Female or transfeminine. Evaluation of unexplained axillary adenopathy. Silicone breast implants (current or prior). Initial imaging. | ≥40岁成人，女性或跨性别女性，评估不明原因腋窝淋巴结肿大，目前或既往有硅胶乳房假体，初始影像学检查。

检查推荐列表：

* 检查项目: Digital Breast Tomosynthesis Diagnostic / MG双侧乳腺钼靶
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0010 / R:CR000152
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: DBT can evaluate for unexplained axillary adenopathy in patients ≥40 years of age and may identify a breast cancer that has metastasized to the axilla. Silicone within low axillary nodes may also be seen on DBT. US is complementary and may be done in conjunction with DBT during evaluation, regardless of findings on mammography or DBT. DBT可评估40岁及以上患者不明原因的腋窝淋巴结病变，并可能识别已转移至腋窝的乳腺癌。DBT还可观察到低位腋窝淋巴结内的硅胶。超声检查可作为补充手段，在评估过程中可与DBT联合进行，无论乳腺X线摄影或DBT检查结果如何。
* 检查项目: Mammography Diagnostic / MG双侧乳腺钼靶
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0010 / R:CR000152
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Mammography can evaluate for unexplained axillary adenopathy in patients ≥40 years of age and may identify a breast cancer that has metastasized to the axilla. Silicone within low axillary nodes may also be seen on mammography. US is complementary and may be done in conjunction with mammography during evaluation, regardless of findings on mammography or DBT. 乳腺X线摄影可用于评估40岁及以上患者不明原因的腋窝淋巴结病变，并可能识别已转移至腋窝的乳腺癌。低位腋窝淋巴结内的硅胶也可通过乳腺X线摄影观察到。超声检查作为补充手段，在评估过程中可与乳腺X线摄影联合进行，无论乳腺X线摄影或数字乳腺断层合成摄影（DBT）的检查结果如何。
* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0003 / R:CR000154
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: US is complementary to mammography or DBT and can diagnose silicone adenitis, in which a “snowstorm” \[30] appearance will be seen in the axillary nodes containing free silicone. In addition, US can identify morphologically abnormal lymph nodes that may represent metastatic disease from primary breast cancer or may be from a variety of other causes, such as lymphoma, infection, or systemic illnesses, including autoimmune diseases. If morphologically abnormal lymph nodes are identified, further evaluation of the breast parenchyma is indicated. This often begins with diagnostic mammography or DBT and may include targeted US of any suspicious findings. The second most common place for free silicone migration is regional lymph nodes (axillary lymph nodes), and silicone aggregates in lymph nodes can also mimic malignant processes. Occasionally, free silicone travels to distant regions (arm/forearm, thoracic cavity, abdominal wall, legs, back). To avoid these complications, it is of crucial importance to detect implant rupture as soon as possible and to remove or replace a ruptured implant \[39]. 超声检查可作为乳腺X线摄影或数字乳腺断层合成摄影（DBT）的补充手段，用于诊断硅胶性淋巴结炎——此时含游离硅胶的腋窝淋巴结会呈现"暴风雪征"\[30]。此外，超声能识别形态异常的淋巴结，这些异常可能提示原发性乳腺癌转移，也可能源于淋巴瘤、感染或包括自身免疫性疾病在内的多种全身性疾病。若发现形态异常淋巴结，需进一步评估乳腺实质，通常从诊断性乳腺X线摄影或DBT开始，并对可疑病灶进行针对性超声检查。游离硅胶迁移的第二常见部位是区域淋巴结（腋窝淋巴结），淋巴结中的硅胶聚集也可能被误认为恶性病变。少数情况下，游离硅胶会迁移至远处区域（手臂/前臂、胸腔、腹壁、腿部、背部）。为避免这些并发症，尽早发现假体破裂并及时取出或更换破裂假体至关重要\[39]。
* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 2
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000155
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: MRI without and with IV contrast may not be ideal in this setting. However, it is needed if biopsy shows axillary metastatic disease from a mammographically and sonographically occult primary breast carcinoma. 在此情况下，不注射和注射静脉对比剂的MRI可能并非理想选择。然而，若活检显示腋窝转移性病灶源自乳腺X线摄影和超声检查未能发现的原发性乳腺癌，则需进行此项检查。
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000156
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: MRI without IV contrast is of limited value in evaluation of unexplained axillary adenopathy in patients ≥40 years of age because its primary function would be to identify silicone in the lymph nodes as an explanation for the 非增强MRI在评估≥40岁患者不明原因腋窝淋巴结病变时价值有限，因其主要功能在于检测淋巴结内硅胶沉积以解释

##### S0025 Variant: Variant 13:  Adult of any age. Female or transfeminine. Suspected breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) (delayed seroma, swelling, mass, pain, but no erythema, warmth, or skin changes that would raise concern for inflammatory breast cancer or mastitis). Breast implant of any type. Initial imaging. | 任何年龄成人，女性或跨性别女性。疑似乳房植入体相关间变性大细胞淋巴瘤（BIAALCL）（迟发性血清肿、肿胀、肿块、疼痛，但无红斑、皮温升高或皮肤改变等提示炎性乳腺癌或乳腺炎的表现）。任何类型乳房植入体。初始影像学检查。

检查推荐列表：

* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0003 / R:CR000157
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: Initial workup may include US evaluation for fluid collection, breast masses, and enlarged regional lymph nodes (axillary, supraclavicular, and internal mammary) \[8,11,43]. Other symptoms can include breast enlargement, skin be made from cytological analysis of the fluid, and patients with disease limited to the implant capsule have a much better prognosis than those with an associated mass or systemic disease \[8,11,44-48]. US will frequently identify a fluid collection or mass if present and provides image guidance for diagnostic aspiration of the fluid for cytology or core biopsy of a mass lesion \[4]. In cases in which a mass (or masses) is present, it most commonly appears as an oval, hypoechoic, and well-circumscribed solid mass, without hypervascularity, although a complex-cystic mass has also been observed \[13]. Adrada et al \[11] reported an 84% sensitivity for detection of effusion and a 46% sensitivity for detection of a mass, with a corresponding specificity of 75% and 100%, respectively. Periprosthetic effusions should undergo fine needle aspiration, and any suspicious mass should undergo tissue biopsy; specimens should be sent for cytology \[4,8]. Ideally, a minimum of 50 mL of fluid should be sent to the laboratory with a specific request to evaluate for BIA-ALCL \[8]. Before fluid collection or tissue sampling, the radiologist should consider contacting colleagues within pathology to discuss how best to collect and send the fluid and tissue samples for the specific analyses required for diagnosis of BIA-ALCL \[8,9]. A multidisciplinary team of plastic surgeons, surgical oncologists, hematologists, and pathologists should be assemble for the diagnosis and management of BIA-ALC. Abnormal ipsilateral axillary lymph nodes with cortical thickening or diffusely hypoechoic lymph node(s) without evident fatty hilus may be present in the setting of BIA-ALCL \[42]. 初步检查可包括US评估积液、乳腺肿块及区域淋巴结（腋窝、锁骨上及内乳区）增大\[8,11,43]。其他症状可包括乳房增大、皮肤改变等。积液细胞学分析可明确诊断，且病变局限于假体包膜的患者预后远优于伴有肿块或全身性疾病者\[8,11,4448]。US常可识别积液或肿块，并为积液诊断性抽吸细胞学检查或肿块粗针活检提供影像引导\[4]。存在单发或多发肿块时，多表现为卵圆形、低回声、边界清晰的实性肿块，无血管增生征象，但也可见复杂性囊实性肿块\[13]。Adrada等\[11]报道US检测积液的敏感性为84%、特异性为75%，检测肿块的敏感性为46%、特异性为100。假体周围积液应行细针抽吸，任何可疑肿块应行组织活检；标本需送检细胞学\[4,8]。理想情况下应至少送检50 mL液体至实验室，并特别要求进行BIAALCL检测\[8]。在采集液体或组织样本前，放射科医师应考虑联系病理科同事，商讨如何最优采集和送检样本以满足BIAALCL诊断所需的特殊分析要求\[8,9]。应组建由整形外科、肿瘤外科、血液科和病理科专家组成的多学科团队负责BIAALCL的诊断与管理。BIAALCL患者可能出现同侧腋窝淋巴结异常，表现为皮质增厚或淋巴结弥漫性低回声伴脂肪门消失\[42]。
* 检查项目: Digital Breast Tomosynthesis Diagnostic / MG双侧乳腺钼靶
  * 评分: 5
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0010 / R:CR000158
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: If the patient is >40 years of age, DBT may be considered. DBT has a low sensitivity and specificity for BIA-ALCL, but it may be used to assess for any potential mimics or masses and other diagnoses including in situ and invasive primary breast malignancy \[11,40]. In cases of BIA-ALCL, the capsule may be thickened and the membrane contour may be disrupted \[11]. In general, DBT findings include nonspecific capsular thickening, circumferential asymmetry around the implant, or irregular mass \[13]. DBT may detect a change in implant appearance related to a new fluid collection or an associated mass. Distinguishing between fluid and solid tissue typically requires US. One meta-analysis \[11] reported a sensitivity of 73% and a specificity of 50% for mammography in the detection of an abnormality. 若患者年龄超过40岁，可考虑采用数字乳腺断层摄影（DBT）。该技术对乳房假体相关间变性大细胞淋巴瘤（BIA-ALCL）的敏感性和特异性较低，但可用于评估其他可能的类似病变或肿块，包括原位和浸润性原发性乳腺癌等鉴别诊断\[11,40]。BIA-ALCL病例中可见包膜增厚及膜轮廓中断\[11]。DBT通常表现为非特异性包膜增厚、假体周围不对称性改变或不规则肿块\[13]。该技术可检测与新增积液或相关肿块有关的假体形态改变，但区分液体与实性组织通常需借助超声检查。一项荟萃分析\[11]显示乳腺X线摄影检测异常的敏感性为73%，特异性为50%。
* 检查项目: Mammography Diagnostic / MG双侧乳腺钼靶
  * 评分: 5
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0010 / R:CR000158
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: If the patient is >40 years of age, mammography may be considered. Mammography has a low sensitivity and specificity for BIA-ALCL, but it may be used to assess for any potential mimics or masses and other diagnoses including in situ and invasive primary breast malignancy \[11,40]. In cases of BIA-ALCL, the capsule may be thickened and the membrane contour may be disrupted \[11]. In general, diagnostic mammography findings include nonspecific capsular thickening, circumferential asymmetry around the implant, or irregular mass \[13]. Diagnostic mammography may detect a change in implant appearance related to a new fluid collection or an associated mass. Distinguishing between fluid and solid tissue typically requires US. One meta-analysis \[11] reported a sensitivity of 73% and a specificity of 50% for mammography in detection of an abnormality. 若患者年龄超过40岁，可考虑进行乳腺X线摄影检查。该检查对乳房植入物相关间变性大细胞淋巴瘤（BIA-ALCL）的敏感性和特异性较低，但可用于评估可能的类似病变或肿块，以及其他诊断包括原位和浸润性原发性乳腺癌\[11,40]。在BIA-ALCL病例中，可能出现包膜增厚和膜轮廓破坏\[11]。通常诊断性乳腺X线摄影表现为非特异性包膜增厚、假体周围不对称增厚或不规则肿块\[13]。诊断性乳腺X线摄影可检测到与新增积液或相关肿块有关的假体形态改变。区分液体与实性组织通常需借助超声检查。一项荟萃分析\[11]报告乳腺X线摄影检测异常的敏感性为73%，特异性为50%。
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 5
  * 适宜性: May be appropriate (Disagreement) / 可能适宜（存在争议）
  * 编码: P:PR0007 / R:CR000161
  * 证据强度: Expert OpinionReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: MRI without IV contrast may identify a fluid collection associated with the implant but is of limited value in the detection of an associated mass. US provides an easier means to assess for effusion and has the added benefit of guiding aspiration for cytologic diagnosis. MRI breast without IV contrast may serve to evaluate for the presence of implant rupture when there is a silicone implant \[13]. 不注射静脉对比剂的MRI可识别与植入物相关的积液，但对检测相关肿块的敏感性有限。超声检查为评估积液提供了更简便的方法，并具有引导穿刺进行细胞学诊断的额外优势。对于硅胶植入物患者，不注射静脉对比剂的乳腺MRI可用于评估植入物破裂情况\[13]。
* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 5
  * 适宜性: May be appropriate (Disagreement) / 可能适宜（存在争议）
  * 编码: P:PR0005 / R:CR000160
  * 证据强度: Expert OpinionReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: MRI without and with IV contrast is the second imaging test of choice and may be needed when US yields indeterminate results \[9,41,42]. MRI has reported sensitivity of 82% for the detection of effusion and 50% for detection of a mass, with corresponding specificities of 33% and 93%, respectively \[11]. MRI breast can be considered if US is equivocal or nondiagnostic. MRI findings include peri-implant tissue edema and effusion, as well as peri-implant mass lesions, including small volume mass components not detected with US \[41,42]. The principal MRI signs seen in the Rotili et al \[41] study included liquid-serous effusion, peri-implant and capsule related masses, enhancement of the capsule, irregular thickness of the capsule, and subcutaneous nodules of local recurrence of ALCL after capsulectomy. 不注射和注射静脉对比剂的MRI是第二选择的影像学检查，当超声检查结果不确定时可能需要使用\[9,41,42]。据报道，MRI检测积液的敏感性为82%，检测肿块的敏感性为50%，相应的特异性分别为33%和93%\[11]。如果超声检查结果不明确或无法诊断，可以考虑进行乳腺MRI检查。MRI表现包括植入物周围组织水肿和积液，以及植入物周围肿块病变，包括超声未检测到的小体积肿块成分\[41,42]。Rotili等人\[41]研究中观察到的主要MRI征象包括液体-浆液性积液、植入物周围及包膜相关肿块、包膜强化、包膜不规则增厚以及包膜切除术后ALCL局部复发的皮下结节。

#### T0004 Breast Pain | 乳腺疼痛

* 主题编码: T0004

##### S0026 Variant: Variant 1:  Female with clinically insignificant breast pain (nonfocal \[greater than one quadrant], diffuse, or cyclical) without other suspicious clinical finding. Any age. Initial imaging. | 女性，临床非显著性乳房疼痛（非局灶性\[大于一个象限]、弥漫性或周期性），无其他可疑临床发现，任何年龄，初始影像学检查

检查推荐列表：

* 检查项目: Digital breast tomosynthesis diagnostic / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000162
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明:
* 检查项目: Mammography diagnostic / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000162
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明:
* 检查项目: MRI breast without IV contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000165
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明:
* 检查项目: MRI breast without and with IV contrast / MR乳腺(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000164
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明:
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000166
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature regarding the use of molecular breast imaging (MBI) in the evaluation of nonfocal or cyclical breast pain. 目前尚无关于分子乳腺成像（MBI）用于评估非局灶性或周期性乳腺疼痛的相关文献。
* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0003 / R:CR000167
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is scant literature specifically evaluating the use of ultrasound (US) imaging in patients with nonfocal or cyclical breast pain. In a retrospective review of 236 patients with breast pain, authors found no mammographic or sonographic correlate in the 10 patients who had cyclical breast pain \[8]. A prospective study of 76 patients younger than age 30 who presented with cyclical breast pain as their only complaint and underwent US found no malignancy \[35]. A limitation of this study was the lack of follow-up. 目前专门评估超声成像在非局灶性或周期性乳房疼痛患者中应用的文献较少。一项针对236例乳房疼痛患者的回顾性研究发现，10例周期性乳房疼痛患者的乳腺X线摄影或超声检查均未发现相关异常\[8]。另一项前瞻性研究纳入76例30岁以下仅主诉周期性乳房疼痛并接受超声检查的患者，结果未发现恶性病变\[35]。该研究的局限性在于缺乏随访数据。

##### S0027 Variant: Variant 2:  Female with clinically significant breast pain (focal and noncyclical). Age less than 30. Initial imaging. | 女性，临床显著乳房疼痛（局灶性非周期性）。年龄\<30岁。初始影像学检查。

检查推荐列表：

* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 7
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0003 / R:CR000168
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: The literature regarding the efficacy of US in evaluation of breast pain is somewhat limited by lack of age-group- specific results. Most authors have found that cancer is a rare cause of focal, clinically significant breast pain \[12,35], and that US has a high negative predictive value (NPV), sensitivity, and specificity for evaluation of breast pain. Leddy et al \[11] performed a retrospective review of 257 patients who underwent US after presenting with focal breast pain and found cancer in 1.2% of patients, with a sensitivity of 100%, specificity of 92.5%, positive predictive value of 13.6%, and NPV of 100%. Loving et al \[37] found a 100% NPV and sensitivity in their retrospective study of 830 patients less than 30 years of age with focal breast signs or symptoms (not limited to but including breast pain). Some authors suggest that, despite the low incidence of malignancy, US may be useful in that it could potentially find treatable causes of breast pain, such as cysts \[9]. On the other hand, a prospective, observational follow-up small cysts \[14]. The authors argued that in the absence of a palpable abnormality, any cyst that may be found by US would be unlikely to be large enough to cause pain or benefit from aspiration. 关于US评估乳腺疼痛效能的文献在一定程度上受限于缺乏按年龄分层的研究结果。多数学者发现癌症是局灶性临床显著性乳腺疼痛的罕见病因\[12,35]，且US对乳腺疼痛评估具有较高的阴性预测值（NPV）、敏感性和特异性。Leddy等\[11]对257例因局灶性乳腺疼痛接受US检查的患者进行回顾性分析，发现癌症检出率为1.2%，敏感性达100%，特异性92.5%，阳性预测值13.6%，NPV为100%。Loving等\[37]在830例30岁以下具有局灶性乳腺体征或症状（不限于但包括乳腺疼痛）患者的回顾性研究中发现100%的NPV和敏感性。部分学者提出，尽管恶性病变发生率低，US仍可能通过发现可治疗的乳腺疼痛病因（如囊肿）而具有价值\[9]。另一方面，一项前瞻性观察性随访研究显示\[14]，作者认为当无可触及异常时，US发现的任何囊肿均不太可能大到引起疼痛或从抽吸术中获益的程度。
* 检查项目: Digital breast tomosynthesis diagnostic / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000169
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明:
* 检查项目: Mammography diagnostic / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000169
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明:
* 检查项目: MRI breast without IV contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000172
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明:
* 检查项目: MRI breast without and with IV contrast / MR乳腺(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000171
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明:
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000173
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature regarding the use of MBI in the evaluation of focal and noncyclical breast pain. 目前尚无关于使用MBI评估局灶性和非周期性乳房疼痛的相关文献。

##### S0028 Variant: Variant 3:  Female with clinically significant breast pain (focal and noncyclical). Age 30 to 39. Initial imaging. | 女性，临床显著乳房疼痛（局灶性非周期性）。年龄30至39岁。初始影像学检查。

检查推荐列表：

* 检查项目: Digital breast tomosynthesis diagnostic / MG双侧乳腺钼靶
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0010 / R:CR000174
  * 证据强度: StrongReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Digital breast tomosynthesis diagnostic is usually appropriate for initial imaging evaluation in females aged 30 to 39 presenting with clinically significant focal and noncyclical breast pain. This modality provides superior lesion detection and characterization compared to conventional mammography by reducing tissue overlap through acquisition of thin-section images, which is particularly valuable in younger patients who often have dense breast tissue. Tomosynthesis enhances the ability to identify underlying benign or malignant causes of focal pain, such as cysts, fibroadenomas, or carcinomas, while reducing recall rates and improving diagnostic confidence. However, it should be noted that breast pain is rarely associated with malignancy, and imaging is primarily performed to exclude underlying pathology and provide reassurance. The procedure should be tailored to the clinical presentation, and supplemental ultrasound may be considered based on findings or persistent symptoms, though the decision for additional imaging should be guided by tomosynthesis results and clinical assessment. 对于30至39岁女性出现临床显著的局灶性非周期性乳腺疼痛的初始影像学评估，数字乳腺断层合成诊断通常适用。该模态通过获取薄层图像减少组织重叠，相比传统乳腺X线摄影提供更优的病变检测和特征分析能力，对于常伴有致密乳腺组织的年轻患者尤其有价值。断层合成增强了对局灶性疼痛潜在良性或恶性原因（如囊肿、纤维腺瘤或癌）的识别能力，同时降低召回率并提高诊断信心。但需注意乳腺疼痛罕与恶性肿瘤相关，影像学检查主要用于排除潜在病变和提供 reassurance。该检查应根据临床表现进行调整，基于发现或持续症状可考虑补充超声检查，但额外影像学决策应遵循断层合成结果和临床评估。
* 检查项目: Mammography diagnostic / MG双侧乳腺钼靶
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0010 / R:CR000174
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: For females aged 30 to 39 presenting with clinically significant focal and noncyclical breast pain, diagnostic mammography is usually appropriate as an initial imaging evaluation. This modality is recommended to evaluate for underlying structural abnormalities such as benign cysts, fibroadenomas, or other masses that may be contributing to the pain, and to assess for any suspicious findings that could indicate malignancy, though cancer is an uncommon cause of isolated breast pain. Diagnostic mammography, as opposed to screening mammography, allows for tailored imaging with additional views and potential magnification to better characterize the area of concern. It is important to note that mammographic sensitivity may be limited in younger patients due to denser breast tissue, and thus correlation with clinical examination and potentially supplemental imaging such as ultrasound may be necessary for a comprehensive assessment. The procedure should be performed in accordance with ACR practice parameters to ensure optimal image quality and interpretation. 对于30至39岁出现临床显著的局灶性非周期性乳房疼痛的女性，诊断性乳腺X线摄影通常适合作为初始影像学评估。该方式被推荐用于评估可能导致疼痛的潜在结构性异常，如良性囊肿、纤维腺瘤或其他肿块，并评估任何可能提示恶性的可疑发现，尽管癌症是孤立性乳房疼痛的罕见原因。与筛查性乳腺X线摄影不同，诊断性乳腺X线摄影允许通过额外投照和可能的放大进行定制成像，以更好地表征关注区域。需要注意的是，由于乳腺组织较致密，乳腺X线摄影对年轻患者的敏感性可能有限，因此可能需要与临床检查以及潜在的补充成像（如超声）相关联以进行全面评估。该程序应按照ACR实践参数执行，以确保最佳的图像质量和解读。
* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 7
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0003 / R:CR000176
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: While there are few studies evaluating US independently of mammography in the setting of focal and noncyclical breast pain, the existing literature suggests that US may be useful to exclude malignancy in these cases. A retrospective review of 110 cases of focal breast pain evaluated by US found no imaging abnormality in 85 cases (77.3%) \[12] and there were no malignancies. In 15 cases (13.6%), cysts were identified, and 3 patients (2.7%) had solid masses, all of which were benign. Fluid collections and edema were seen in the remaining cases. Several studies have evaluated the usefulness of US in addition to mammography in cases of focal, noncyclical breast pain and concluded that in the setting of a negative mammogram, US may not be indicated, especially in patients with nondense breasts. A retrospective study of 206 patients with focal breast pain as their only symptom evaluated with US after a mammogram found that US resulted in 8 additional biopsies and 14 additional 6-month follow-up examinations without detecting any additional cancers \[11]. Another retrospective study found 76 imaging abnormalities in 413 cases of focal pain, with 46 (61%) seen on US alone, for a specificity of 82%. While there were no malignancies, US found a benign lesion in 40 of 56 cases in which mammography was negative in patients with dense breasts and found a benign lesion in 6 of 20 cases with a negative mammogram and nondense breasts. The specificity of US was 95% for nondense breasts and 87% for dense breasts \[9]. Some authors suggest that, despite the low incidence of malignancy, US may be useful in that it could potentially find treatable causes of breast pain, such as cysts \[9]. On the other hand, a prospective, observational follow-up study of 987 patients with breast pain alone found benign findings in 8.6% of cases, which consisted mostly of small cysts \[14]. The authors argued that in the absence of a palpable abnormality, any cyst that may be found by US would be unlikely to be large enough to cause pain or benefit from aspiration. 目前针对局灶性非周期性乳腺疼痛单独使用超声评估的研究较少，但现有文献表明超声可能有助于排除此类情况下的恶性病变。一项回顾性研究对110例局灶性乳腺疼痛患者的超声检查发现，85例（77.3%）未发现影像学异常\[12]，且均未检出恶性肿瘤。15例（13.6%）检出囊肿，3例（2.7%）发现实性肿块（均为良性），其余病例可见积液或水肿表现。多项研究评估了超声联合乳腺X线摄影对局灶性非周期性乳腺疼痛的诊断价值，结论指出在乳腺X线摄影阴性时，尤其对非致密型乳腺患者，超声检查可能无必要。一项针对206例以局灶性疼痛为唯一症状患者的研究显示，乳腺X线摄影后追加超声检查虽导致8例追加活检和14例6个月后复查，但未额外检出恶性肿瘤\[11]。另一项回顾性研究在413例局灶性疼痛中发现76处影像学异常，其中46处（61%）仅由超声检出，特异性为82%。虽未发现恶性病变，但在56例致密型乳腺X线摄影阴性患者中，超声检出40例良性病灶；20例非致密型乳腺X线摄影阴性患者中检出6例。超声对非致密型乳腺的特异性达95%，致密型为87%\[9]。有学者指出，尽管恶性病变发生率
* 检查项目: MRI breast without IV contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000178
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明:
* 检查项目: MRI breast without and with IV contrast / MR乳腺(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000177
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明:
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000179
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature regarding the use of MBI in the evaluation of focal and noncyclical breast pain. 目前尚无关于使用MBI评估局灶性和非周期性乳房疼痛的相关文献。

##### S0029 Variant: Variant 4:  Female with clinically significant breast pain (focal and noncyclical). Age greater than or equal to 40. Initial imaging. | 女性，临床显著乳房疼痛（局灶性非周期性）。年龄≥40岁。初始影像学检查。

检查推荐列表：

* 检查项目: Digital breast tomosynthesis diagnostic / MG双侧乳腺钼靶
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0010 / R:CR000180
  * 证据强度: StrongReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Digital breast tomosynthesis diagnostic is usually appropriate for females aged 40 years or older presenting with clinically significant focal and noncyclical breast pain during initial imaging evaluation. This modality provides superior lesion detection and characterization compared to conventional 2D mammography by reducing tissue superposition through thin-section tomographic imaging, which is particularly valuable for assessing focal symptoms. The procedure should be performed as a diagnostic examination with additional tailored views as needed to thoroughly evaluate the painful area. While tomosynthesis enhances cancer detection rates and improves diagnostic confidence, it remains limited in its ability to definitively characterize all palpable findings, and suspicious or equivocal findings may require supplemental ultrasound for complete assessment. The use of tomosynthesis aligns with the goal of comprehensive evaluation in symptomatic patients within this age group, where underlying malignancy must be considered despite breast pain being an uncommon presenting symptom of breast cancer. 对于40岁及以上患有临床显著的局灶性非周期性乳腺疼痛的女性进行初始影像学评估时，数字乳腺断层合成诊断通常适用。该模态通过薄层断层成像减少组织重叠，相比传统二维乳腺X线摄影能提供更优异的病灶检测和特征分析能力，特别适用于评估局灶性症状。应作为诊断性检查实施，并根据需要增加定制投照位以彻底评估疼痛区域。虽然断层合成提高了癌症检出率并增强诊断信心，但其在明确表征所有可触及 findings 方面仍存在局限，可疑或不确定的发现可能需要补充超声进行完整评估。在该年龄组有症状患者的全面评估目标中，使用断层合成是合理的，尽管乳腺疼痛并非乳腺癌的常见表现症状，但仍需考虑潜在恶性肿瘤的可能性。
* 检查项目: Mammography diagnostic / MG双侧乳腺钼靶
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0010 / R:CR000180
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: For females aged 40 years or older presenting with clinically significant focal and noncyclical breast pain, mammography diagnostic is usually appropriate as the initial imaging evaluation. This modality is recommended due to its established role in detecting underlying breast pathology, including malignancies, which may manifest as pain in this demographic. Diagnostic mammography provides high-resolution imaging that can identify suspicious calcifications, masses, or architectural distortions that might be causative. While breast pain is often benign and not commonly associated with cancer, its focal and noncyclical nature in women ≥40 years warrants imaging to exclude malignancy or other significant conditions such as fibroadenomas, cysts, or inflammatory processes. The procedure should be tailored with additional views as needed to evaluate the painful area thoroughly. Limitations include reduced sensitivity in dense breast tissue, where complementary ultrasound may be considered, but mammography remains the cornerstone for initial assessment in this age group to ensure comprehensive evaluation. 对于40岁或以上出现临床显著的局灶性非周期性乳房疼痛的女性，诊断性乳腺X线摄影通常适合作为初始影像学评估。推荐此方法是因为其在检测潜在乳腺病理（包括恶性肿瘤）方面已确立作用，恶性肿瘤在该人群可能表现为疼痛。诊断性乳腺X线摄影提供高分辨率成像，可识别可疑钙化、肿块或结构扭曲等可能病因。虽然乳房疼痛通常为良性且与癌症不常见相关，但其在≥40岁女性中呈现局灶性和非周期性特征，需进行影像学检查以排除恶性肿瘤或其他重要病症，如纤维腺瘤、囊肿或炎症过程。该程序应根据需要调整附加投照位以彻底评估疼痛区域。局限性包括在致密乳腺组织中敏感性降低，此时可考虑辅助超声检查，但乳腺X线摄影仍是该年龄组初始评估的基石，以确保全面评估。
* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 7
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0003 / R:CR000182
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: While there are few studies evaluating US independently of mammography in the setting of focal and noncyclical breast pain, the existing literature suggests that US may be useful to exclude malignancy in these cases. A retrospective review of 110 cases of focal breast pain evaluated by US found no imaging abnormality in 85 cases (77.3%) \[12], and there were no malignancies. In 15 cases (13.6%), cysts were identified, and of those, 3 patients (2.7%) had solid masses, all of which were benign. Fluid collections and edema were seen in the remaining cases. Several studies have evaluated the usefulness of US in addition to mammography in cases of focal, noncyclical breast pain and concluded that in the setting of a negative mammogram, US may not be indicated, especially in patients with nondense breasts. A retrospective study of 206 patients with focal breast pain as their only symptom evaluated with US after a mammogram, found that US resulted in 8 additional biopsies and 14 additional 6-month follow-up examinations without detecting any additional cancers \[11]. Another retrospective study found 76 imaging abnormalities in 413 cases of focal pain, with 46 (61%) seen on US alone, for a specificity of 82%. While there were no malignancies, US found a benign lesion in 40 of 56 cases in which mammography was negative in patients with dense breasts and found a benign lesion in 6 of 20 cases with a negative mammogram and nondense breasts. The specificity of US was 95% for nondense breasts and 87% for dense breasts \[9]. Some authors suggest that, despite the low incidence of malignancy, US may be useful in that it could potentially find treatable causes of breast pain, such as cysts \[9]. On the other hand, a prospective, observational follow-up study of 987 patients with breast pain alone found benign findings in 8.6% of cases, which consisted mostly of small cysts \[14]. The authors argued that in the absence of a palpable abnormality, any cyst that may be found by US would unlikely be large enough to cause pain or benefit from aspiration. If a mammogram has been obtained within the last 3 to 6 months, the patient may proceed directly to US. 尽管在局灶性非周期性乳腺疼痛背景下单独评估超声的研究较少，但现有文献表明超声可能有助于排除此类病例的恶性肿瘤。一项对110例局灶性乳腺疼痛超声评估的回顾性分析发现，85例（77.3%）无影像学异常\[12]，且均无恶性肿瘤。15例（13.6%）发现囊肿，其中3例（2.7%）存在实性肿块，均为良性。其余病例可见液性聚集和水肿。多项研究评估了超声联合乳腺X线摄影在局灶性非周期性乳腺疼痛中的效用，结论表明在乳腺X线摄影阴性时，尤其非致密乳腺患者，可能无需进行超声检查。一项对206例以局灶性乳腺疼痛为唯一症状患者的回顾性研究显示，乳腺X线摄影后行超声检查导致额外8例活检和14例6个月随访检查，但未发现额外癌症\[11]。另一项回顾性研究发现413例局灶性疼痛中存在76处影像学异常，其中46处（61%）仅超声可见，特异性为82%。虽无恶性肿瘤，但超声在56例致密乳腺且乳腺X线摄影阴性的病例中发现40例良性病变，在20例非致密乳腺且乳腺X线摄影阴性的病例中发现6例良性病变。超声对非致密乳腺的特异性为95%，对致密乳腺为87%\[9]。部分学者认为，尽管恶性肿瘤发生率低，超声仍可能有价值，因其可能发现可治疗的乳腺疼痛原因（如囊肿）\[9]。另一方面，一项针对987例单纯乳腺疼痛患者的前瞻性观察性随访研究发现，8.6%的病例存在良性表现（主要为小囊肿）\[14]。
* 检查项目: MRI breast without IV contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000184
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明:
* 检查项目: MRI breast without and with IV contrast / MR乳腺(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000183
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明:
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000185
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature regarding the use of MBI in the evaluation of focal and noncyclical breast pain. 目前尚无关于使用MBI评估局灶性和非周期性乳房疼痛的相关文献。

#### T0005 Evaluation of Nipple Discharge | 乳头溢液评估

* 主题编码: T0005

##### S0030 Variant: Variant 1:  Adult female or male or transfeminine (male-to-female) or transmasculine (female-to-male). Physiologic nipple discharge. Initial imaging. | 成人女性或男性或跨性别女性（男跨女）或跨性别男性（女跨男）。生理性乳头溢液。初始影像学检查。

检查推荐列表：

* 检查项目: Digital Breast Tomosynthesis Diagnostic / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000186
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: If patient history and physical examination demonstrate physiologic nipple discharge and routine screening mammography is up to date, no further radiologic investigation is needed \[28,29]. 若患者病史和体格检查显示为生理性乳头溢液且常规筛查乳腺X线摄影检查结果及时更新，则无需进一步影像学检查\[28,29]。
* 检查项目: Mammography Diagnostic / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000186
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: If patient history and physical examination demonstrate physiologic nipple discharge and routine screening mammography is up to date, no further radiologic investigation is needed \[28,29]. 若患者病史和体格检查显示为生理性乳头溢液且常规筛查乳腺X线摄影检查结果及时更新，则无需进一步影像学检查\[28,29]。
* 检查项目: MRI breast without IV contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000193
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明:
* 检查项目: MRI breast without and with IV contrast / MR乳腺(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000192
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明:
* 检查项目: FDG-PET Breast Dedicated / PET/CT局部(胸部)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0016 / R:CR000188
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: If patient history and physical examination demonstrate physiologic nipple discharge and routine screening mammography is up to date, no further radiologic investigation is needed \[28,29]. 若患者病史和体格检查显示为生理性乳头溢液且常规筛查乳腺X线摄影检查结果及时更新，则无需进一步影像学检查\[28,29]。
* 检查项目: Ductography / RF乳腺导管造影
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0015 / R:CR000187
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: If patient history and physical examination demonstrate physiologic nipple discharge and routine screening mammography is up to date, no further radiologic investigation is needed \[28,29]. 若患者病史和体格检查显示为生理性乳头溢液且常规筛查乳腺X线摄影检查结果及时更新，则无需进一步影像学检查\[28,29]。
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000194
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: If patient history and physical examination demonstrate physiologic nipple discharge and routine screening mammography is up to date, no further radiologic investigation is needed \[28,29]. Therefore, if the clinical findings are consistent with physiologic nipple discharge and a women’s health 若患者病史和体格检查显示为生理性乳头溢液，且常规筛查性乳腺X线摄影检查为最新，则无需进一步影像学检查\[28,29]。因此，若临床表现符合生理性乳头溢液且女性健康
* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0003 / R:CR000195
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: If patient history and physical examination demonstrate physiologic nipple discharge and routine screening mammography is up to date, no further radiologic investigation is needed \[28,29]. 若患者病史和体格检查显示为生理性乳头溢液且常规筛查乳腺X线摄影检查结果及时更新，则无需进一步影像学检查\[28,29]。
* 检查项目: Image-guided Core Biopsy Breast / 影像引导下乳腺穿刺活检术
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0013 / R:CR000189
  * 证据强度: Expert Consensus
  * Adult RRL: Varies
  * Peds RRL: Varies
  * 推荐说明: Image-guided core biopsy is not required for the evaluation of physiologic nipple discharge in the female patient. 影像引导下的核心针活检不适用于女性生理性乳头溢液的评估。
* 检查项目: Image-Guided Fine Needle Aspiration Breast / 影像引导下乳腺细针穿刺抽吸
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0014 / R:CR000190
  * 证据强度: Expert Consensus
  * Adult RRL: Varies
  * Peds RRL: Varies
  * 推荐说明: Image-guided fine-needle aspiration (FNA) is not required for the evaluation of physiologic nipple discharge in the female patient. 影像引导下细针穿刺抽吸（FNA）不适用于女性生理性乳头溢液的评估。

##### S0031 Variant: Variant 2:  Adult male or female 40 years of age or older. Pathologic nipple discharge. Initial imaging. | 成人≥40岁。病理性乳头溢液。初始影像学检查。

检查推荐列表：

* 检查项目: Digital Breast Tomosynthesis Diagnostic / MG双侧乳腺钼靶
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0010 / R:CR000196
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Although there is no relevant literature to support the use of DBT alone in assessing nipple discharge, mammography is useful for evaluating pathologic nipple discharge in male and female patients in this age group \[30]. Early studies with DBT demonstrate promise is assessing the symptomatic breast \[35,36]. 尽管目前尚无相关文献支持单独使用数字乳腺断层摄影（DBT）评估乳头溢液，但乳腺X线摄影对于该年龄段男女患者的病理性乳头溢液评估具有实用价值\[30]。早期关于DBT的研究表明其在症状性乳腺评估中具有应用潜力\[35,36]。
* 检查项目: Mammography Diagnostic / MG双侧乳腺钼靶
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0010 / R:CR000196
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Mammography is the first-line imaging modality for evaluation of pathologic nipple discharge in male and female patients in this age group \[30]. Although 3% to 29% of pathologic nipple discharge is due to an underlying breast cancer, full-field mammography often does not demonstrate these lesions because they may be very small, contain no calcifications, or are completely intraductal \[1-3]. To better evaluate the subareolar breast in patients with an asymmetry/focal asymmetry or suspicious microcalcifications, additional mammographic views with spot compression and magnification may be needed \[31]. Most cases of pathologic nipple discharge are due to a benign intraductal papilloma \[32]. When visible on mammography, imaging findings of papilloma include asymmetrically dilated ducts, a circumscribed benign- appearing subareolar mass, or grouped microcalcifications \[1]. Up to 12% of patients with ductal carcinoma in situ (DCIS) present with nipple discharge \[33]. DCIS is usually detected mammographically as fine, linear, discontinuous, and branching microcalcifications in linear, ductal, or segmental distribution and less often as a mass, asymmetry/focal asymmetry, or architectural distortion on mammography \[11]. The mammographic features of invasive carcinomas are well known, including a mass of various margin characteristics with or without microcalcifications or an asymmetry, focal asymmetry, or architectural distortion \[34]. For detection of malignancy (DCIS and invasive cancer), the reported sensitivity of mammography varies widely between 15% and 68%, with a specificity between 38% and 98% \[3,9,23,28]. In one study, the positive predictive value (PPV) was 42%, and the negative predictive value (NPV) was 90% \[23]. Malignant and high-risk lesions are identified by mammography with a reported sensitivity of 10% to 26%, specificity of 94% to 95%, PPV of 18%, and NPV of 88% \[3,16]. The possible causes of the wide variation in reported sensitivity include differences in imaging technology (digital versus film-screen mammography) and varied breast density among different cohorts of patients. In a study of 106 patients >30 years of age with pathologic nipple discharge, Gray et al \[28] showed the risk of carcinoma to be 3% with a negative mammogram and 0% when both mammogram and subareolar US were negative. Although low in sensitivity and PPV, mammography remains useful in the evaluation of pathologic nipple discharge because of its high specificity and high NPV. 乳腺X线摄影是该年龄组男性和女性患者评估病理性乳头溢液的首选影像学检查方式\[30]。尽管3%至29%的病理性乳头溢液由潜在乳腺癌引起，但全视野乳腺X线摄影常无法显示这些病变，因为它们可能非常微小、不含钙化或完全位于导管内\[13]。为更好地评估存在不对称/局灶性不对称或可疑微钙化患者的乳晕下乳腺区域，可能需要采用点压迫和放大技术的附加投照位\[31]。多数病理性乳头溢液病例由良性导管内乳头状瘤引起\[32]。乳腺X线摄影可见的乳头状瘤影像学表现包括不对称扩张的导管、边界清晰的良性外观乳晕下肿块或成簇微钙化\[1]。高达12%的导管原位癌（DCIS）患者以乳头溢液为首发症状\[33]。DCIS通常在乳腺X线摄影中表现为细线样、不连续、分支状微钙化，呈线性、导管性或节段性分布，较少表现为肿块、不对称/局灶性不对称或结构扭曲\[11]。浸润性癌的乳腺X线摄影特征已明确，包括具有不同边缘特征的肿块（伴或不伴微钙化）、不对称、局灶性不对称或结构扭曲\[34]。对于恶性肿瘤（DCIS和浸润癌）的检测，报道的乳腺X线摄影敏感性差异较大（15%至68%），特异性介于38%至98%之间\[3,9,23,28]。一项研究显示阳性预测值（PPV）为42%，阴性预测值（NPV）为90%\[23]。乳腺X线摄影对恶性和高风险病变的检出敏感性为10%至26%，特异性为94%至95%，PPV为18%，NPV为88%\[3,16]。报道敏感性存在广泛差异的可能原因包括成像技术差异（数字与胶片乳腺摄影）以及不同患者群体的乳腺密度差异。Gray等\[28]对106例30岁病理性乳头溢液患者的研究显示，乳腺X线摄影阴性时癌变风险为3%，而当乳腺摄影与乳晕下超声均阴性时风险为0%。尽管敏感性和PPV较低，但由于其高特异性和高NPV，乳腺X线摄影在病理性乳头溢液评估中仍具有重要价值。
* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0003 / R:CR000198
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: US is useful in identifying invasive cancer and assessing extent of disease but has a diminished sensitivity for detecting DCIS \[9,12,37,38]. In patients with pathologic nipple discharge, US identifies lesions not visible on mammography 63% to 69% of the time \[30,39]. US adds specificity for some lesions when compared with mammography if it identifies the mammographic finding as a simple cyst or duct ectasia. US expands on ductography in its ability to visualize and detect abnormalities in multiple rather than single ducts \[24]. US alone has a reported sensitivity (56%–80%), specificity (61%–75%), PPV (29%–39%), and NPV (90%–91%) for detection of underlying malignancy in patients with pathologic nipple discharge \[3,9,23]. The wide variation in reported performance can be explained by differences in the definition of pathologic nipple discharge and variation in US technique \[9]. Although more sensitive than mammography, US suffers from lower specificity in differentiating benign versus malignant lesions \[9]. False-positive US results may be due to volume averaging with the ductal wall in a tortuous duct, intraductal and periductal fibrosis, adherent blood clots, or inspissated debris \[31]. Previous studies have also reported mammography and US to be unreliable in predicting histology in patients with pathologic nipple discharge, which underscores the necessity of histological diagnosis \[17,23]. In male and female patients, US is useful in identifying and assessing lesions and for biopsy guidance \[40]. 超声检查有助于识别浸润性癌并评估疾病范围，但对检测导管原位癌的敏感性较低\[9,12,37,38]。在病理性乳头溢液患者中，超声检查在63%至69%的情况下可发现乳腺X线摄影未显示的病灶\[30,39]。与乳腺X线摄影相比，若超声将X线发现确认为单纯性囊肿或导管扩张，则可提高对某些病变的特异性诊断。超声检查扩展了导管造影的能力，可对多支导管（而非单支导管）的异常进行可视化检测\[24]。据报道，单纯超声检查对病理性乳头溢液患者潜在恶性肿瘤的检出敏感度（56%-80%）、特异度（61%-75%）、阳性预测值（29%-39%）和阴性预测值（90%-91%）存在差异\[3,9,23]。这种性能指标的广泛差异可归因于病理性乳头溢液定义的差异及超声技术的不同\[9]。虽然超声比乳腺X线摄影更敏感，但在区分良恶性病变方面特异性较低\[9]。超声假阳性结果可能源于迂曲导管壁的体积效应、导管内及导管周围纤维化、黏附血块或浓缩分泌物\[31]。既往研究也报道称，乳腺X线摄影和超声在预测病理性乳头溢液患者组织学特征方面不可靠，这强调了组织学诊断的必要性\[17,23]。对于男女患者，超声检查在病灶识别
* 检查项目: MRI breast without IV contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000204
  * 证据强度: StrongReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明:
* 检查项目: MRI breast without and with IV contrast / MR乳腺(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000203
  * 证据强度: StrongReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明:
* 检查项目: FDG-PET Breast Dedicated / PET/CT局部(胸部)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0016 / R:CR000200
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: High-resolution cameras specifically designed for breast imaging have improved detection of small and noninvasive carcinomas. However, specific research evaluating women with nipple discharge is lacking \[41,53]. Currently, there is no relevant literature for the use of fluorine-18-2-fluoro-2-deoxy-D-glucose (FDG)-PET in the evaluation of a male or female patient with pathologic nipple discharge. 专为乳腺成像设计的高分辨率摄像头提高了对小癌灶和非浸润性癌的检出率。然而，目前尚缺乏针对乳头溢液患者的专项研究\[41,53]。目前尚无关于使用氟-18-2-氟-2-脱氧-D-葡萄糖(FDG)-PET评估病理性乳头溢液患者（无论男女）的相关文献。
* 检查项目: Ductography / RF乳腺导管造影
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0015 / R:CR000199
  * 证据强度: StrongReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Ductography may demonstrate small lesions and localize the duct responsible for the nipple discharge. Ductography is minimally invasive, may be uncomfortable, and can be time-consuming. The procedure is technically challenging the day of ductography so that a cannula can be placed in the appropriate duct. Failure to cannulate the discharging duct may lead to a false negative \[43]. Ductography is not recommended in lactating women or patients with active mastitis. Known hypersensitivity to iodinated contrast agents is a relative contraindication. Findings on ductography suggestive of malignant or papillary lesions include intraductal filling defect, partial or complete obstruction of a duct, duct expansion or distortion, and duct wall irregularity \[1]. In patients with pathologic nipple discharge and a negative mammogram and US, Morrogh et al \[44] reported the PPV and NPV of ductography for detection of cancer and high-risk lesions to be 19% and 63%, respectively. In the setting of negative standard evaluations, ductography localized 76% of otherwise occult malignant/high-risk lesions and 91% of benign lesions \[39]. When the standard evaluation is positive, ductography facilitated preoperative localization of the causative lesion in 78% of cases \[39]. For detection of cancer in patients with pathologic nipple discharge, 2 studies showed the sensitivity, specificity, PPV, and NPV of ductography to be 75% to 100%, 6% to 49%, 16% to 18%, and 93% to 100%, respectively \[16,23]. For detection of high-risk lesions, Adepoju et al \[16] reported the sensitivity, specificity, PPV, and NPV of ductography to be 75%, 53%, 22%, and 92%, respectively. Ductography is more sensitive than mammography and US but has lower specificity than both modalities. A negative ductogram does not reliably exclude an underlying cancer or high-risk lesion, with the false-negative rate reported to be as high as 20% to 30% \[44]. As such, the primary value of ductography is to localize intraductal lesions and assist in surgery \[45]. A study found that patients who underwent ductography-guided operations or any other surgical procedure with image guidance of the lesion were significantly more likely to have a specific underlying lesion identified than patients who underwent central duct excision alone \[23,42]. 导管造影可显示微小病变并对引流的导管进行定位。导管造影是微创的，但可能引起不适且耗时。该操作在技术上有挑战性，通常需要术前进行超声检查，以便在导管造影当天将插管置入相应的导管。未能对引流导管进行插管可能导致假阴性结果\[43]。不建议对哺乳期妇女或活动性乳腺炎患者进行导管造影。已知对碘造影剂过敏是相对禁忌症。导管造影上提示恶性或乳头状病变的发现包括导管内充盈缺损、导管部分或完全梗阻、导管扩张或扭曲以及导管壁不规则\[1]。在病理性乳头溢液且乳腺X线摄影和超声检查阴性的患者中，Morrogh等\[44]报告导管造影检测癌症和高风险病变的阳性预测值和阴性预测值分别为19%
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000205
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of molecular breast imaging (MBI) in the evaluation of a male or female patient with pathologic nipple discharge. 目前尚无相关文献支持分子乳腺成像（MBI）用于评估病理性乳头溢液的男性或女性患者。
* 检查项目: Image-Guided Core Biopsy Breast / 影像引导下乳腺穿刺活检术
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0013 / R:CR000201
  * 证据强度: StrongReferences
  * Adult RRL: Varies
  * Peds RRL: Varies
  * 推荐说明: Previous studies showed that mammography, US, and ductography are unreliable in predicting histology in patients with pathologic nipple discharge \[17,23,44], which underscores the importance of histological diagnosis of lesions identified on imaging. The biopsy procedures may be guided by stereotactic mammography, US, ductography, or MRI, depending on the imaging modality that best depicts the lesion. CNB is preferred over FNA because the larger localization and excision if the biopsied lesion yields malignant or high-risk histology. Vacuum-assisted CNB is particularly useful in assuring complete sampling of small intraductal papillary lesions \[24]. Although biopsy is a diagnostic procedure, the process of removing enough of the intraductal papillary lesion during vacuum-assisted core biopsy may be therapeutic and will lead to permanent cessation of nipple discharge in 90% to 97.2% of patients \[24,56]. However, Reiner et al \[57] cautioned that ductography-guided 11-gauge vacuum-assisted stereotactic biopsy should not be used as a substitute for surgical duct excision in cases of pathologic nipple discharge with abnormalities on ductography because of the high underestimation rate (50%) for high-risk lesions and DCIS, false- negative rate (7%), and histopathological detection of lesion remnants in every case. Papillomas are historically considered high-risk lesions, with reported rates of upgrade to malignancy between 3% and 14% \[58,59]. The management of papillomas diagnosed on CNB is controversial and varies by institution \[60]. Because papillomas diagnosed on CNB are often excised, excisional biopsy instead of CNB may be useful when a papillary lesion is anticipated based on imaging findings. A recent study suggests that patients with nonbloody pathologic nipple discharge, a benign CNB, or normal imaging (cancer risk \<2%) may be considered for nonoperative management if they do not have risk factors such as prior ipsilateral breast cancer, BRCA mutation, or atypia on CNB \[61]. According to the surgical literature, major duct excision remains the reference standard to exclude malignancy in patients with unremarkable imaging, when even a negative ductogram (NPV 63%–82%) \[17,30] or MRI (NPV 87%–100%) \[44,52] does not exclude an underlying cancer or high-risk lesion \[13,39,44]. In addition, US does not reliably distinguish between benign and malignant small intraductal lesions \[9]. Therefore, the decision to perform percutaneous biopsy versus major duct excision should involve the patient and their health care provider. Image-guided CNB is equally useful in male patients for obtaining tissue diagnosis and assisting in patient management \[40]. Image-guided CNB is not indicated as the initial examination to evaluate pathologic nipple discharge. 既往研究表明，对于病理性乳头溢液患者，乳腺X线摄影、超声及导管造影在预测组织学结果方面不可靠\[17,23,44]，这凸显了对影像学发现病变进行组织学诊断的重要性。活检操作可在立体定向乳腺X线摄影、超声、导管造影或MRI引导下进行，具体取决于最佳显示病变的影像模式。核心针活检（CNB）优于细针抽吸（FNA），因后者若提示恶性或高风险组织学结果仍需手术定位切除。真空辅助CNB尤其有助于确保完全取样小的导管内乳头状病变\[24]。尽管活检是诊断性操作，真空辅助核心针活检过程中切除足够多的导管内乳头状病变可能具有治疗作用，可使90%至97.2%患者的乳头溢液永久停止\[24,56]。然而，Reiner等\[57]提醒：对于导管造影显示异常的病理性乳头溢液，不应以导管造影引导的11G真空辅助立体定向活检替代手术导管切除，因其对高风险病变和导管原位癌（DCIS）的高低估率（50%）、假阴性率（7%）以及所有病例中均存在病变残留的组织病理学检测结果。乳头状瘤历来被视为高风险病变，报道的恶变升级率为3%至14%\[58,59]。CNB诊断的乳头状瘤处理存在争议且因机构而异\[60]。鉴于CNB诊断的乳头状瘤常被切除，当影像学提示乳头状病变时，直接行切除活检而非CNB可能更为合适。近期研究表明，对于非血性病理性乳头溢液、CNB良性或影像学正常（癌症风险\<2%）且无同侧乳腺癌史、BRCA突变或CNB不典型增生等风险因素者，可考虑非手术治疗\[61]。外科学文献指出，即使导管造影（阴性预测值63%–82%）\[17,30]或MRI（阴性预测值87%–100%）\[44,52]阴性亦不能排除潜在癌症或高风险病变\[13,39,44]，主要导管切除仍是排除影像学无异常患者恶性肿瘤的金标准。此外，超声无法可靠区分良恶性小导管内病变\[9]。因此，选择经皮活检还是主要导管切除应医患共同决策。影像引导CNB同样适用于男性患者获取组织学诊断及辅助治疗决策\[40]。影像引导CNB不推荐作为评估病理性乳头溢液的初始检查。
* 检查项目: Image-Guided Fine Needle Aspiration Breast / 影像引导下乳腺细针穿刺抽吸
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0014 / R:CR000202
  * 证据强度: LimitedReferences
  * Adult RRL: Varies
  * Peds RRL: Varies
  * 推荐说明: Once a suspicious lesion that is likely responsible for the pathologic nipple discharge is identified on imaging, image-guided FNA or CNB can be performed for histological diagnosis. Although some institutions demonstrate good results using FNA, larger series have shown that core biopsy is superior to FNA in terms of sensitivity, specificity, and correct histological grading of a lesion \[54,55]. Image-guided FNA is not indicated as the initial examination to evaluate pathologic nipple discharge. 一旦影像学检查发现可能导致病理性乳头溢液的疑似病变，可进行影像引导下的细针穿刺抽吸（FNA）或空心针穿刺活检（CNB）以获取组织学诊断。尽管部分机构报道细针穿刺取得良好效果，但更大规模研究显示，在病变的敏感性、特异性及正确组织学分级方面，空心针活检优于细针穿刺\[54,55]。影像引导下的细针穿刺抽吸不推荐作为评估病理性乳头溢液的初始检查手段。

##### S0032 Variant: Variant 3:  Adult male or female 30 to 39 years of age. Pathologic nipple discharge. Initial imaging. | 成人30至39岁。病理性乳头溢液。初始影像学检查。

检查推荐列表：

* 检查项目: Digital Breast Tomosynthesis Diagnostic / MG双侧乳腺钼靶
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0010 / R:CR000206
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Although there is no relevant literature to support the use of DBT alone in assessing nipple discharge, mammography is useful for evaluating pathologic nipple discharge in male and female patients in this age group \[30]. Early studies with DBT demonstrate promise is assessing the symptomatic breast \[35,36]. 尽管目前尚无相关文献支持单独使用数字乳腺断层摄影（DBT）评估乳头溢液，但乳腺X线摄影对于该年龄段男女患者的病理性乳头溢液评估具有实用价值\[30]。早期关于DBT的研究表明其在症状性乳腺评估中具有应用潜力\[35,36]。
* 检查项目: Mammography Diagnostic / MG双侧乳腺钼靶
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0010 / R:CR000206
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: The sensitivity of US for palpable or nonpalpable breast cancer is higher than that of mammography (95.7% versus 60.9%) for women 30 to 39 years of age \[63,64]. Either mammography or US may be used as the initial imaging modality, on the basis of institutional preference and case-by-case consideration. However, mammography has its value in detecting suspicious microcalcifications, given the high incidence of patients with DCIS presenting with nipple discharge. Because of the high incidence (23%–57%) of breast cancer in male patients with nipple discharge \[19,65], imaging with mammography is indicated as an initial study per the ACR Appropriateness Criteria ® topic on “ Evaluation of 对于30至39岁女性，超声对可触及或不可触及乳腺癌的敏感性高于乳腺X线摄影（95.7%对比60.9%）\[63,64]。根据机构偏好和个案情况，可选择乳腺X线摄影或超声作为初始影像学检查方式。然而，鉴于表现为乳头溢液的DCIS患者发生率较高，乳腺X线摄影在检测可疑微钙化方面具有重要价值。由于男性乳头溢液患者乳腺癌发生率较高（23%–57%）\[19,65]，根据ACR适宜性标准专题"乳头溢液评估"建议，乳腺X线摄影应作为初始影像学检查。
* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0003 / R:CR000208
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: The sensitivity of US for palpable or nonpalpable breast cancer is higher than that of mammography (95.7% versus 60.9%) for women 30 to 39 years of age \[63,64]. Hence, US may be useful as the initial imaging modality, with mammography added when necessary. 超声对30至39岁女性可触及或不可触及乳腺癌的敏感性高于乳腺X线摄影（95.7%对60.9%）\[63,64]。因此，超声可作为首选影像学检查方法，必要时辅以乳腺X线摄影。
* 检查项目: Ductography / RF乳腺导管造影
  * 评分: 2
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0015 / R:CR000209
  * 证据强度: StrongReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Ductography may demonstrate small lesions and localize the duct responsible for the nipple discharge. Ductography is minimally invasive, may be uncomfortable, and can be time-consuming. The procedure is technically challenging with 10% to 15% of cases resulting in inadequate or incomplete results \[41,42]. The discharge must be present on the day of ductography so that a cannula can be placed in the appropriate duct. Failure to cannulate the discharging duct may lead to a false negative \[43]. Ductography is not recommended in lactating women or patients with active mastitis. Known hypersensitivity to iodinated contrast agents is a relative contraindication. Findings on ductography suggestive of malignant or papillary lesions include intraductal filling defect, partial or complete obstruction of a duct, duct expansion or distortion, and duct wall irregularity \[1]. In patients with pathologic nipple discharge and a negative mammogram and US, Morrogh et al \[44] reported the PPV and NPV of ductography for the detection of cancer and high-risk lesions to be 19% and 63%, respectively. In the setting of negative standard evaluations, ductography localized 76% of otherwise occult malignant/high-risk lesions and 91% of benign lesions \[39]. When the standard evaluation is positive, ductography facilitated preoperative localization of the causative lesion in 78% of cases \[39]. For detection of cancer in patients with pathologic nipple discharge, 2 studies showed the sensitivity, specificity, PPV, and NPV of ductography to be 75% to 100%, 6% to 49%, 16% to 18%, and 93% to 100%, respectively \[16,23]. For detection of high-risk lesions, Adepoju et al \[16] reported the sensitivity, specificity, PPV, and NPV of ductography to be 75%, 53%, 22%, and 92%, respectively. Ductography is more sensitive than mammography and US but has a lower specificity than both modalities. A negative ductogram does not reliably exclude an underlying cancer or high-risk lesion, with the false-negative rate reported to be as high as 20% to 30% \[44]. As such, the primary value of ductography is to localize intraductal lesions and assist in surgery \[45]. A study found that patients who underwent ductography-guided operations or any other surgical procedure with image guidance of the lesion were significantly more likely to have a specific underlying lesion identified than patients who underwent central duct excision alone \[23,42]. At this time, there is no relevant literature available for use of ductography for evaluation of a male patient with nipple discharge. 导管造影可显示微小病灶并定位导致乳头溢液的导管。该检查具有微创性，但可能引起不适且耗时较长。其操作技术要求较高，10%至15%的病例无法获得充分或完整的检查结果\[41,42]。检查当日必须存在溢液方可进行导管插管。若未能成功插管可能导致假阴性结果\[43]。哺乳期妇女或活动性乳腺炎患者不推荐行导管造影。对碘对比剂已知过敏属相对禁忌证。导管造影中提示恶性或乳头状病变的征象包括：导管内充盈缺损、导管部分或完全梗阻、导管扩张或扭曲、以及管壁不规则\[1]。Morrogh等\[44]报道，在病理性乳头溢液伴乳腺X线摄影和US检查阴性的患者中，导管造影检测癌症和高风险病变的PPV和NPV分别为19%和63%。在标准评估阴性的情况下，导管造影定位了76%的隐匿性恶性/高风险病变和91%的良性病变\[39]。当标准评估呈阳性时，导管造影在78%的病例中实现了致病性病灶的术前定位\[39]。针对病理性乳头溢液患者的癌症检测，两项研究显示导管造影的敏感性、特异性、PPV和NPV分别为75%至100%、6%至49%、16%至18%和93%至100%\[16,23]。对于高风险病变的检测，Adepoju等\[16]报道导管造影的敏感性、特异性、PPV和NPV分别为75%、53%、22%和92%。导管造影较乳腺X线摄影和US更具敏感性，但特异性低于这两种检查。阴性导管造影结果不能可靠排除潜在癌症或高风险病变，其假阴性率据报道高达20%至30%\[44]。因此，导管造影的主要价值在于定位导管内病变并辅助手术\[45]。一项研究发现，接受导管造影引导手术或任何其他影像引导下病灶切除术的患者，其特异性病灶检出率显著高于单纯接受中央导管切除术的患者\[23,42]。目前尚无相关文献支持导管造影用于评估男性乳头溢液患者。
* 检查项目: MRI breast without IV contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000213
  * 证据强度: StrongReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明:
* 检查项目: MRI breast without and with IV contrast / MR乳腺(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000212
  * 证据强度: StrongReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明:
* 检查项目: FDG-PET Breast Dedicated / PET/CT局部(胸部)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0016 / R:CR000210
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: High-resolution cameras specifically designed for breast imaging have improved detection of small and noninvasive carcinomas. However, specific research evaluating women with nipple discharge is lacking \[41,53]. Currently, there is no relevant literature for the use of FDG-PET in the evaluation of a male or female patient with pathologic nipple discharge. 专为乳腺成像设计的高分辨率摄像头提高了对小癌灶和非浸润性癌的检出率。然而，目前缺乏针对乳头溢液患者的具体研究\[41,53]。目前尚无相关文献支持FDG-PET用于评估病理性乳头溢液的男性或女性患者。
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000214
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of MBI in the evaluation of a male or female patient with pathologic 目前尚无相关文献支持在患有病理改变的男性或女性患者评估中使用MBI。
* 检查项目: Image-Guided Fine Needle Aspiration Breast / 影像引导下乳腺细针穿刺抽吸
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0014 / R:CR000211
  * 证据强度: LimitedReferences
  * Adult RRL: Varies
  * Peds RRL: Varies
  * 推荐说明: Once a suspicious lesion that is likely responsible for the pathologic nipple discharge is identified on imaging, image-guided FNA or CNB can be performed for histological diagnosis. Although some institutions demonstrate good results using FNA, larger series have shown that core biopsy is superior to FNA in terms of sensitivity, specificity, and correct histological grading of a lesion \[54,55]. Image-guided FNA is not indicated as the initial examination to evaluate pathological nipple discharge. 一旦影像学检查发现可能导致病理性乳头溢液的疑似病变，可进行影像引导下的细针穿刺抽吸（FNA）或空心针穿刺活检（CNB）以获取组织学诊断。尽管部分机构报道细针穿刺取得良好效果，但更大规模研究显示，空心针活检在敏感性、特异性及病变组织学分级准确性方面均优于细针穿刺\[54,55]。影像引导下的细针穿刺抽吸不推荐作为评估病理性乳头溢液的初始检查手段。

##### S0033 Variant: Variant 4:  Adult male younger than 30 years of age. Pathologic nipple discharge. Initial imaging. | 成人男性\<30岁。病理性乳头溢液。初始影像学检查。

检查推荐列表：

* 检查项目: Digital Breast Tomosynthesis Diagnostic / MG双侧乳腺钼靶
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0010 / R:CR000215
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Although there is no relevant literature to support the use of DBT alone in assessing nipple discharge, mammography is useful for evaluating pathologic nipple discharge in male and female patients in this age group \[30]. Early studies with DBT demonstrate promise in assessing the symptomatic breast \[35,36]. 尽管目前尚无相关文献支持单独使用数字乳腺断层摄影（DBT）评估乳头溢液，但乳腺X线摄影对于该年龄段男女患者的病理性乳头溢液评估具有实用价值\[30]。早期关于DBT的研究显示其在评估症状性乳房病变方面具有应用潜力\[35,36]。
* 检查项目: Mammography Diagnostic / MG双侧乳腺钼靶
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0010 / R:CR000215
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Diagnostic mammography is useful in distinguishing malignancy from benign breast conditions in symptomatic male patients with nipple discharge \[1,2]. Please refer to the ACR Appropriateness Criteria ® topic on “ Evaluation of the Symptomatic Male Breast ” \[40] for additional details. 诊断性乳腺X线摄影有助于区分有乳头溢液症状的男性患者中的恶性与良性乳腺疾病\[1,2]。更多详情请参阅ACR适宜性标准®中关于"有症状男性乳腺评估"的主题\[40]。
* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0003 / R:CR000217
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: In conjunction with mammography or DBT, US is often useful in assisting with management decisions and to facilitate US core biopsy \[3]. Please refer to the ACR Appropriateness Criteria ® topic on “ Evaluation of the Symptomatic Male Breast ” \[40] for additional details. 结合乳腺X线摄影或数字乳腺断层合成摄影（DBT），超声检查通常有助于辅助制定治疗决策并便于进行超声引导下核心针活检\[3]。更多详细信息，请参阅美国放射学会（ACR）适宜性标准®专题“有症状男性乳腺的评估”\[40]。
* 检查项目: MRI breast without IV contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000223
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明:
* 检查项目: MRI breast without and with IV contrast / MR乳腺(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000222
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明:
* 检查项目: FDG-PET Breast Dedicated / PET/CT局部(胸部)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0016 / R:CR000219
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of FDG-PET for the evaluation of male patients with nipple discharge. 目前尚无相关文献支持使用FDG-PET评估男性乳头溢液患者。
* 检查项目: Ductography / RF乳腺导管造影
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0015 / R:CR000218
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of ductography for the evaluation of male patients with nipple discharge. 目前尚无相关文献支持使用导管造影术评估男性乳头溢液患者。
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000224
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of MBI for the evaluation of male patients with nipple discharge. 目前尚无相关文献支持使用MBI评估男性乳头溢液患者。
* 检查项目: Image-guided Core Biopsy Breast / 影像引导下乳腺穿刺活检术
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0013 / R:CR000220
  * 证据强度: Expert Consensus
  * Adult RRL: Varies
  * Peds RRL: Varies
  * 推荐说明: There is no relevant literature to support the use of core biopsy for the evaluation of male patients with nipple discharge. However, if an imaging abnormality is identified, US may be used to direct biopsy. 目前尚无相关文献支持采用核心针活检评估男性乳头溢液患者。但若发现影像学异常，可采用超声引导下活检。
* 检查项目: Image-Guided Fine Needle Aspiration Breast / 影像引导下乳腺细针穿刺抽吸
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0014 / R:CR000221
  * 证据强度: Expert Consensus
  * Adult RRL: Varies
  * Peds RRL: Varies
  * 推荐说明: There is no relevant literature to support the use of image-guided FNA for the evaluation of male patients with nipple discharge. 目前尚无相关文献支持使用影像引导下的细针抽吸活检评估男性乳头溢液患者。

##### S0034 Variant: Variant 5:  Adult female younger than 30 years of age. Pathologic nipple discharge. Initial imaging. | 成人女性，\<30岁。病理性乳头溢液。初始影像学检查。

检查推荐列表：

* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0003 / R:CR000225
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: Yue et al \[69] studied 955 women \<25 years of age who presented with breast symptoms including palpable mass, pain, and nipple discharge. US was performed in 692 patients and was normal/negative in 671 patients and indeterminate in 21 patients. No cancer was found in this group via biopsy or clinical follow-up. However, it is unknown how many of these patients had pathologic or physiologic discharge. 岳等人\[69]研究了955名25岁以下出现乳房症状（包括可触及肿块、疼痛和乳头溢液）的女性。其中692例患者接受了超声检查，671例检查结果正常/阴性，21例不确定。通过活检或临床随访，该组未发现癌症病例。但尚不清楚其中有多少患者存在病理性或生理性溢液。
* 检查项目: Digital Breast Tomosynthesis Diagnostic / MG双侧乳腺钼靶
  * 评分: 3
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000226
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Although there is no relevant literature to support the use of DBT alone in assessing nipple discharge, mammography is useful for evaluating pathologic nipple discharge in male and female patients in this age group 尽管尚无相关文献支持单独使用DBT评估乳头溢液，但乳腺X线摄影对于该年龄段男女患者的病理性乳头溢液评估具有价值
* 检查项目: Mammography Diagnostic / MG双侧乳腺钼靶
  * 评分: 3
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000226
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Most breast lesions in young women are not visualized on mammography \[67,68] because of the low incidence of breast cancer (0.4% or lower) in women \<30 years of age. US is most useful for initial imaging in this population; however, diagnostic mammography may be useful when US shows a suspicious finding. 年轻女性乳腺病变在钼靶检查中大多无法显影\[67,68]，因为30岁以下女性乳腺癌发病率较低（0.4%或更低）。超声是该人群首选的影像学检查方法；但当超声发现可疑病灶时，诊断性钼靶检查仍具重要价值。
* 检查项目: MRI breast without IV contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000233
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明:
* 检查项目: MRI breast without and with IV contrast / MR乳腺(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000232
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明:
* 检查项目: FDG-PET Breast Dedicated / PET/CT局部(胸部)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0016 / R:CR000229
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of FDG-PET in women \<30 years of age with symptoms of pathologic nipple discharge. 目前尚无相关文献支持在30岁以下出现病理性乳头溢液症状的女性中使用FDG-PET检查。
* 检查项目: Ductography / RF乳腺导管造影
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0015 / R:CR000228
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of ductography in women \<30 years of age with symptoms of pathologic nipple discharge. 目前尚无相关文献支持对30岁以下出现病理性乳头溢液症状的女性进行乳腺导管造影检查。
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000234
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of MBI in women \<30 years of age with symptoms of pathologic nipple discharge. 目前尚无相关文献支持在30岁以下出现病理性乳头溢液症状的女性中使用乳腺钼靶检查。
* 检查项目: Image-guided Core Biopsy Breast / 影像引导下乳腺穿刺活检术
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0013 / R:CR000230
  * 证据强度: Expert Consensus
  * Adult RRL: Varies
  * Peds RRL: Varies
  * 推荐说明: There is no relevant literature to support the use of image-guided core biopsy in women \<30 years of age with symptoms of pathologic nipple discharge. However, if an imaging abnormality is identified, US may be used to direct biopsy. 目前尚无相关文献支持对30岁以下有病理性乳头溢液症状的女性进行影像引导下的空心针穿刺活检。但若发现影像学异常，可采用超声引导下活检。
* 检查项目: Image-Guided Fine Needle Aspiration Breast / 影像引导下乳腺细针穿刺抽吸
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0014 / R:CR000231
  * 证据强度: Expert Consensus
  * Adult RRL: Varies
  * Peds RRL: Varies
  * 推荐说明: There is no relevant literature to support the use of image-guided FNA in women \<30 years of age with symptoms of pathologic nipple discharge. 目前尚无相关文献支持对30岁以下出现病理性乳头溢液症状的女性使用影像引导下的细针抽吸活检。

##### S0035 Variant: Variant 6:  Adult transfeminine (male-to-female) patient 30 years of age or older. Pathologic nipple discharge. Initial imaging. | 成人跨性别女性（男跨女）患者，年龄≥30岁。病理性乳头溢液。初始影像学检查。

检查推荐列表：

* 检查项目: Digital Breast Tomosynthesis Diagnostic / MG双侧乳腺钼靶
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0010 / R:CR000235
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Although there is no relevant literature to support the use of DBT alone in assessing nipple discharge, mammography is useful for evaluating pathologic nipple discharge in male and female patients in this age group \[30]. Early studies with DBT demonstrate promise is assessing the symptomatic breast \[35,36]. 尽管目前尚无相关文献支持单独使用数字乳腺断层摄影（DBT）评估乳头溢液，但乳腺X线摄影对于该年龄段男女患者的病理性乳头溢液评估具有实用价值\[30]。早期关于DBT的研究表明其在症状性乳腺评估中具有应用潜力\[35,36]。
* 检查项目: Mammography Diagnostic / MG双侧乳腺钼靶
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0010 / R:CR000235
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Diagnostic mammography is useful in distinguishing malignancy from benign breast conditions in symptomatic transfeminine patients \[1,2]. Please refer to the ACR Appropriateness Criteria ® topic on “ Evaluation of the Symptomatic Male Breast ” \[40] for additional details. 诊断性乳腺X线摄影有助于区分有症状的跨女性患者的恶性与良性乳腺病变\[1,2]。更多详情请参阅ACR适宜性标准®中关于"有症状男性乳腺评估"的主题\[40]。
* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0003 / R:CR000237
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: In conjunction with mammography or DBT, US is often useful in assisting with management decisions and to facilitate US core biopsy \[3]. Please refer to the ACR Appropriateness Criteria ® topic on “ Evaluation of the Symptomatic Male Breast ” \[40] for additional details. 结合乳腺X线摄影或数字乳腺断层合成摄影（DBT），超声检查通常有助于辅助制定治疗决策并便于进行超声引导下核心针活检\[3]。更多详细信息，请参阅美国放射学会（ACR）适宜性标准®专题“有症状男性乳腺的评估”\[40]。
* 检查项目: MRI breast without IV contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000243
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明:
* 检查项目: MRI breast without and with IV contrast / MR乳腺(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000242
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明:
* 检查项目: FDG-PET Breast Dedicated / PET/CT局部(胸部)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0016 / R:CR000239
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of FDG-PET for evaluation of transgender patients with nipple discharge. 目前尚无相关文献支持使用FDG-PET评估伴有乳头溢液的跨性别患者。
* 检查项目: Ductography / RF乳腺导管造影
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0015 / R:CR000238
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of ductography for evaluation of transgender patients with nipple discharge. 目前尚无相关文献支持使用导管造影术评估跨性别患者的乳头溢液情况。
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000244
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of MBI for evaluation of transgender patients with nipple discharge. 目前尚无相关文献支持使用MBI评估伴有乳头溢液的跨性别患者。
* 检查项目: Image-guided Core Biopsy Breast / 影像引导下乳腺穿刺活检术
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0013 / R:CR000240
  * 证据强度: Expert Consensus
  * Adult RRL: Varies
  * Peds RRL: Varies
  * 推荐说明: There is no relevant literature to support the use of image-guided core biopsy for evaluation of transgender patients with nipple discharge. However, if an imaging abnormality is identified, US may be used to direct biopsy. 目前尚无相关文献支持使用影像引导下空心针活检评估跨性别患者的乳头溢液。但若发现影像学异常，可采用超声引导下活检。
* 检查项目: Image-Guided Fine Needle Aspiration Breast / 影像引导下乳腺细针穿刺抽吸
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0014 / R:CR000241
  * 证据强度: Expert Consensus
  * Adult RRL: Varies
  * Peds RRL: Varies
  * 推荐说明: There is no relevant literature to support the use of image-guided FNA for evaluation of transgender patients with nipple discharge. 目前尚无相关文献支持使用影像引导下的细针抽吸活检来评估有乳头溢液的跨性别患者。

##### S0036 Variant: Variant 7:  Adult transfeminine (male-to-female) patient younger than 30 years of age. Pathologic nipple discharge. Initial imaging. | 成人跨性别女性（男跨女）患者，年龄\<30岁。病理性乳头溢液。初始影像学检查。

检查推荐列表：

* 检查项目: Digital Breast Tomosynthesis Diagnostic / MG双侧乳腺钼靶
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0010 / R:CR000245
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Although there is no relevant literature to support the use of DBT alone in assessing nipple discharge, mammography is useful for evaluating pathologic nipple discharge in male and female patients in this age group \[30]. Early studies with DBT demonstrate promise is assessing the symptomatic breast \[35,36]. 尽管目前尚无相关文献支持单独使用数字乳腺断层摄影（DBT）评估乳头溢液，但乳腺X线摄影对于该年龄段男女患者的病理性乳头溢液评估具有实用价值\[30]。早期关于DBT的研究表明其在症状性乳腺评估中具有应用潜力\[35,36]。
* 检查项目: Mammography Diagnostic / MG双侧乳腺钼靶
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0010 / R:CR000245
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Diagnostic mammography is useful in distinguishing malignancy from benign breast conditions in symptomatic transfeminine patients with nipple discharge \[1,2]. Please refer to the ACR Appropriateness Criteria ® topic on “ Evaluation of the Symptomatic Male Breast ” \[40] for additional details. 诊断性乳腺X线摄影有助于区分有乳头溢液症状的跨性别女性患者的恶性与良性乳腺病变\[1,2]。更多详情请参阅ACR适宜性标准®专题"男性症状性乳腺评估"\[40]。
* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0003 / R:CR000247
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: In conjunction with mammography or DBT, US is often useful in assisting with management decisions and to facilitate US core biopsy \[3]. Please refer to the ACR Appropriateness Criteria ® topic on “ Evaluation of the Symptomatic Male Breast ” \[40] for additional details. 结合乳腺X线摄影或数字乳腺断层合成摄影（DBT），超声检查通常有助于辅助制定治疗决策并便于进行超声引导下核心针活检\[3]。更多详细信息，请参阅美国放射学会（ACR）适宜性标准®专题“有症状男性乳腺的评估”\[40]。
* 检查项目: MRI breast without IV contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000253
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明:
* 检查项目: MRI breast without and with IV contrast / MR乳腺(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000252
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明:
* 检查项目: FDG-PET Breast Dedicated / PET/CT局部(胸部)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0016 / R:CR000249
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of FDG-PET for evaluation of transgender patients with nipple discharge. 目前尚无相关文献支持使用FDG-PET评估伴有乳头溢液的跨性别患者。
* 检查项目: Ductography / RF乳腺导管造影
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0015 / R:CR000248
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of ductography for evaluation of transgender patients with nipple discharge. 目前尚无相关文献支持使用导管造影术评估跨性别患者的乳头溢液情况。
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000254
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明:
* 检查项目: Image-guided Core Biopsy Breast / 影像引导下乳腺穿刺活检术
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0013 / R:CR000250
  * 证据强度: Expert Consensus
  * Adult RRL: Varies
  * Peds RRL: Varies
  * 推荐说明: There is no relevant literature to support the use of core biopsy for evaluation of transgender patients with nipple discharge. However, if an imaging abnormality is identified, US may be used to direct biopsy. 目前尚无相关文献支持采用核心活检评估跨性别患者的乳头溢液。但若发现影像学异常，可采用超声引导活检。
* 检查项目: Image-Guided Fine Needle Aspiration Breast / 影像引导下乳腺细针穿刺抽吸
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0014 / R:CR000251
  * 证据强度: Expert Consensus
  * Adult RRL: Varies
  * Peds RRL: Varies
  * 推荐说明: There is no relevant literature to support the use of image-guided FNA for evaluation of transgender patients with nipple discharge. 目前尚无相关文献支持使用影像引导下的细针抽吸活检来评估有乳头溢液的跨性别患者。

#### T0006 Evaluation of the Symptomatic Male Breast | 有症状男性乳腺评估

* 主题编码: T0006

##### S0037 Variant: Variant 1:  Male patient of any age with symptoms of gynecomastia and physical examination consistent with gynecomastia or pseudogynecomastia. Initial imaging. | 任何年龄男性，有男性乳房发育症症状且体格检查符合男性乳房发育症或假性男性乳房发育症。初始影像学检查。

检查推荐列表：

* 检查项目: Digital breast tomosynthesis diagnostic / MG双侧乳腺钼靶
  * 评分: 2
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000255
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明:
* 检查项目: Mammography diagnostic / MG双侧乳腺钼靶
  * 评分: 2
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000255
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明:
* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 2
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0003 / R:CR000257
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: In men with clinical findings consistent with gynecomastia or pseudogynecomastia, ultrasound (US) is not routinely indicated. When US is performed, gynecomastia may appear mass-like and demonstrate vascularity on color Doppler \[16-18]. Comparison with the contralateral side may be helpful on real-time imaging, as synchronous bilateral breast carcinoma in males is rare. Chen et al \[19] evaluated the incremental clinical value of US in 327 symptomatic male patients where mammography was negative or revealed only gynecomastia and found no additional malignancies. However, in that series, US did lead to additional unnecessary benign biopsies. Tangerud et al \[20], in a study of 350 men with mammographic findings diagnostic of gynecomastia, did not identify any patients with male breast cancer when US, fine needle aspiration, or core biopsy was performed in conjunction with mammography. When performed for suspected gynecomastia, US may demonstrate a lack of breast tissue in men with pseudogynecomastia and obviate further unnecessary interventions for falsely presumed gynecomastia (eg, altering medications) \[12,21-23]. 对于临床表现符合男性乳房发育症或假性男性乳房发育症的男性患者，超声检查（US）通常不作为常规检查项目。当进行超声检查时，男性乳房发育症可能呈现肿块样外观，并在彩色多普勒上显示血流信号\[16-18]。实时成像时与对侧乳房对比可能有所帮助，因为男性双侧同步乳腺癌较为罕见。Chen等\[19]评估了超声在327例有症状男性患者中的增量临床价值（这些患者乳腺X线摄影结果为阴性或仅显示男性乳房发育症），未发现额外恶性肿瘤。然而在该系列研究中，超声确实导致了更多不必要的良性病变活检。Tangerud等\[20]在一项针对350例乳腺X线摄影确诊为男性乳房发育症患者的研究中发现，当超声、细针穿刺或空心针活检与乳腺X线摄影联合应用时，未检出任何男性乳腺癌病例。对于疑似男性乳房发育症的检查，超声可显示假性男性乳房发育症患者缺乏乳腺组织，从而避免对误判为男性乳房发育症进行不必要干预（如调整用药）\[12,21-23]。
* 检查项目: MRI breast without IV contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000259
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明:
* 检查项目: MRI breast without and with IV contrast / MR乳腺(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000258
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明:

##### S0038 Variant: Variant 2:  Male younger than 25 years of age with indeterminate palpable breast mass. Initial imaging. | \<25岁男性，可触及性质不确定乳腺肿块。初始影像学检查。

检查推荐列表：

* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 8
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0003 / R:CR000260
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: Some authors suggest that using US is useful as the initial imaging modality in the young male who is unlikely to have breast cancer and who presents with an indeterminate physical symptom \[3]. However, gynecomastia and oil cysts can have a suspicious appearance on US but can typically be diagnosed as benign on mammography or DBT. Therefore, if there are suspicious features on US, mammography or DBT should be performed before a 有学者建议对乳腺癌低危且表现为不确定躯体症状的年轻男性首选US作为初始影像学检查\[3]。然而，男性乳腺发育和油性囊肿在US上可能呈现可疑表现，但通常可通过乳腺X线摄影或DBT诊断为良性。因此若US发现可疑特征，应在进行
* 检查项目: Digital breast tomosynthesis diagnostic / MG双侧乳腺钼靶
  * 评分: 5
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0010 / R:CR000261
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Digital breast tomosynthesis diagnostic may be appropriate for the initial imaging evaluation of an indeterminate palpable breast mass in a male younger than 25 years of age. While mammographic techniques are less commonly utilized in young males due to lower breast cancer prevalence and typically dense breast tissue that may limit sensitivity, tomosynthesis can offer improved lesion characterization compared to conventional 2D mammography by reducing tissue superimposition. This modality may be considered when ultrasound findings are equivocal or discordant with physical examination, or if there is a strong clinical suspicion warranting further delineation of mammographic findings. However, ultrasound remains the primary initial imaging modality for palpable masses in males of all ages due to its high sensitivity, lack of ionizing radiation, and ability to characterize solid versus cystic lesions. The use of tomosynthesis should be weighed against the radiation exposure, particularly in younger patients, and is typically reserved for cases where additional information is clinically necessary after initial ultrasound evaluation. 对于25岁以下男性不确定的可触及乳房肿块进行初始影像学评估时，数字乳腺断层合成诊断检查可能是合适的。虽然乳腺摄影技术在年轻男性中较少使用（因为乳腺癌患病率较低且通常乳腺组织致密可能限制敏感性），但与传统二维乳腺摄影相比，断层合成通过减少组织重叠可提供更好的病变特征显示。当超声检查结果不明确或与体格检查不一致时，或者存在强烈临床怀疑需要进一步明确乳腺摄影发现时，可考虑使用该 modality。然而，超声仍然是所有年龄段男性可触及肿块的主要初始影像学检查方式，因其敏感性高、无电离辐射且能够区分实性与囊性病变。使用断层合成时应权衡辐射暴露风险（尤其在年轻患者中），通常保留用于初始超声评估后需要额外临床信息的病例。
* 检查项目: Mammography diagnostic / MG双侧乳腺钼靶
  * 评分: 5
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0010 / R:CR000261
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Mammography diagnostic may be appropriate for the initial imaging evaluation of an indeterminate palpable breast mass in a male younger than 25 years of age. While the dense glandular tissue typical in younger males can limit mammographic sensitivity, it can still be a useful initial tool to characterize a mass and may demonstrate features suggestive of gynecomastia, which is a common benign etiology in this demographic. However, its utility must be weighed against the very low pretest probability of breast carcinoma in this age group. Ultrasound is often considered the primary initial imaging modality for palpable masses in young males due to its lack of ionizing radiation and superior ability to differentiate solid from cystic lesions in dense tissue. Therefore, the decision to proceed with diagnostic mammography should be made judiciously, considering clinical factors and often in conjunction with or following ultrasound, to provide a more comprehensive assessment and potentially obviate the need for mammography if a definitive benign diagnosis is established sonographically. 对于25岁以下男性不确定的可触及乳房肿块进行初始影像学评估时，诊断性乳腺X线摄影可能是合适的。尽管年轻男性通常具有致密的腺体组织可能限制乳腺X线摄影的敏感性，但它仍可作为初步评估工具来表征肿块，并可能显示男性乳房发育症的特征（该年龄段常见的良性病因）。然而，必须权衡其效用与该年龄段极低的乳腺癌预测试概率。超声通常被认为是年轻男性可触及肿块的主要初始影像学检查方式，因为它无电离辐射且在致密组织中区分实性与囊性病变的能力更优。因此，是否进行诊断性乳腺X线摄影应谨慎决定，需考虑临床因素，并常与超声联合使用或在其后进行，以提供更全面的评估，若超声能明确良性诊断则可能无需进行乳腺X线摄影。
* 检查项目: MRI breast without IV contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000264
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明:
* 检查项目: MRI breast without and with IV contrast / MR乳腺(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000263
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明:

##### S0039 Variant: Variant 3:  Male 25 years of age or older with indeterminate palpable breast mass. Initial imaging. | ≥25岁男性，可触及乳房肿块性质待定，初始影像学检查。

检查推荐列表：

* 检查项目: Digital breast tomosynthesis diagnostic / MG双侧乳腺钼靶
  * 评分: 8
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0010 / R:CR000265
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Digital breast tomosynthesis diagnostic is usually appropriate as the initial imaging modality for males 25 years of age or older presenting with an indeterminate palpable breast mass. This three-dimensional imaging technique provides superior tissue delineation compared to conventional mammography by reducing tissue superposition, which is particularly valuable in the typically limited breast tissue of male patients. It allows for improved characterization of mass margins, architecture, and associated features such as microcalcifications, thereby enhancing diagnostic confidence in distinguishing benign entities like gynecomastia from suspicious lesions requiring biopsy. While tomosynthesis improves cancer detection and reduces recall rates in female breasts, its specific performance in male breast evaluation derives from extrapolated data and technical advantages in tissue visualization. Limitations include potential need for additional ultrasound evaluation for complete assessment, particularly in cases with dense tissue or posterior lesions. This modality should be performed with proper clinical correlation and radiologist expertise in male breast imaging. 数字乳腺断层合成诊断成像通常适用于25岁或以上男性出现不确定可触及乳腺肿块的初始影像学检查。这种三维成像技术通过减少组织重叠，相比传统乳腺X线摄影提供更优越的组织 delineation，对于男性患者通常有限的乳腺组织特别有价值。它能够改善肿块边缘、结构及相关特征（如微钙化）的表征，从而增强区分良性病变（如男性乳腺发育）与需要活检的可疑病变的诊断信心。虽然断层合成在女性乳腺中提高了癌症检出率并降低了召回率，但其在男性乳腺评估中的具体性能源于推断数据和组织可视化的技术优势。局限性包括可能需要对致密组织或后方病变进行额外超声评估以完成全面评估。该检查应在适当的临床关联和放射科医生男性乳腺成像专业知识下进行。
* 检查项目: Mammography diagnostic / MG双侧乳腺钼靶
  * 评分: 8
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0010 / R:CR000265
  * 证据强度: StrongReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Mammography diagnostic is usually appropriate as the initial imaging modality for males 25 years of age or older presenting with an indeterminate palpable breast mass. This procedure serves as the primary imaging tool to evaluate the symptomatic male breast due to its ability to characterize palpable abnormalities, differentiate between benign and malignant etiologies, and provide guidance for further management. It is particularly effective in identifying features suggestive of gynecomastia, which is a common benign cause, or in detecting suspicious findings that may indicate malignancy, such as breast cancer. Diagnostic mammography should be performed with tailored techniques, including spot compression and magnification views as needed, to optimize evaluation of the palpable area. Limitations include reduced sensitivity in extremely dense breast tissue, which is less common in males, and the potential need for supplemental imaging with ultrasound if mammographic findings are inconclusive or discordant with clinical examination. The examination should be interpreted by radiologists experienced in breast imaging to ensure accurate assessment and appropriate triage. 对于25岁及以上患有不确定可触及乳房肿块的男性，诊断性乳腺X线摄影通常适合作为初始影像学检查。该程序是评估有症状男性乳房的主要影像工具，因其能够表征可触及异常、区分良恶性病因，并为进一步管理提供指导。它在识别提示男性乳房发育症（常见良性原因）的特征或检测可能表明恶性肿瘤（如乳腺癌）的可疑发现方面特别有效。诊断性乳腺X线摄影应采用定制技术，包括必要时使用点压迫和放大视图，以优化对可触及区域的评估。局限性包括在极度致密乳腺组织（男性中较少见）中敏感性降低，以及如果乳腺X线摄影结果不确定或与临床检查不符，可能需要超声补充成像。检查应由具有乳腺影像经验的放射科医生解读，以确保准确评估和适当分流。
* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 5
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0003 / R:CR000267
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: If the mammogram is indeterminate or suspicious, US can assist in clinical management and guide biopsy \[3]. 若乳腺X线摄影结果不确定或可疑，超声检查可辅助临床管理并指导活检\[3]。
* 检查项目: MRI breast without IV contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000269
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明:
* 检查项目: MRI breast without and with IV contrast / MR乳腺(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000268
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明:

##### S0040 Variant: Variant 4:  Male 25 years of age or older with indeterminate palpable breast mass. Mammography or digital breast tomosynthesis indeterminate or suspicious. | ≥25岁男性，可触及乳房肿块性质待定，乳腺X线摄影或数字乳腺断层融合成像结果不确定或可疑。

检查推荐列表：

* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0003 / R:CR000270
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: If the mammogram is indeterminate or suspicious, US is usually appropriate as the next imaging modality because US can assist in lesion characterization and guide biopsy \[3]. Performance of breast US in men may be more variable than mammography. Carrasco et al \[3], in their series of 638 patients, reported a lower sensitivity of US for distinguishing benign from malignant disease (88.9% compared to 95% for mammography) but a similar, high specificity of 95%. However, Patterson et al \[28], in a series of 166 patients, reported US to have the same sensitivity as mammography (100%) but lower specificity (74%). 若乳腺X线摄影结果不确定或可疑，超声通常适合作为后续影像学检查手段，因其可协助病灶特征分析并引导活检\[3]。男性乳腺超声检查的表现可能较乳腺X线摄影更具变异性。Carrasco等\[3]在638例患者系列研究中报告，超声鉴别良恶性病变的敏感性较低（88.9%，而乳腺X线摄影为95%），但特异性同样高达95%。然而Patterson等\[28]在166例患者系列研究中指出，超声与乳腺X线摄影具有相同敏感性（100%），但特异性较低（74%）。
* 检查项目: MRI breast without and with IV contrast / MR乳腺(平扫+增强)
  * 评分: 2
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000271
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明:
* 检查项目: MRI breast without IV contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000272
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明:

##### S0041 Variant: Variant 5:  Male of any age with physical examination suspicious for breast cancer (suspicious palpable breast mass, axillary adenopathy, nipple discharge, or nipple retraction). Initial imaging. | 任何年龄男性，体格检查疑似乳腺癌（可疑可触及乳腺肿块、腋窝淋巴结肿大、乳头溢液或乳头回缩）。初始影像学检查。

检查推荐列表：

* 检查项目: Digital breast tomosynthesis diagnostic / MG双侧乳腺钼靶
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0010 / R:CR000273
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Digital breast tomosynthesis diagnostic is usually appropriate as the initial imaging modality for males of any age with physical examination findings suspicious for breast cancer, including suspicious palpable breast mass, axillary adenopathy, nipple discharge, or nipple retraction. This three-dimensional imaging technique provides superior lesion characterization compared to conventional mammography by reducing tissue superposition, which is particularly valuable in the typically limited breast tissue of male patients. Tomosynthesis allows for improved visualization of mass margins, architectural distortions, and associated features that may indicate malignancy. While male breast cancer is rare, imaging evaluation remains crucial when clinical suspicion exists, as benign conditions such as gynecomastia may also present with similar findings. The procedure should be performed with appropriate technique modifications for male breast imaging, and any suspicious findings should prompt tissue diagnosis through biopsy. Negative or benign-appearing imaging results should be correlated with clinical findings, as false negatives can occur, and persistent clinical concern may warrant further evaluation. 数字乳腺断层合成诊断通常适用于任何年龄男性出现可疑乳腺癌体格检查结果（包括可疑可触及乳腺肿块、腋窝淋巴结肿大、乳头溢液或乳头回缩）的初始影像学检查。这种三维成像技术通过减少组织重叠，相比传统乳腺X线摄影能提供更优异的病变特征显示，对于男性患者通常有限的乳腺组织尤其有价值。断层合成能够改善肿块边缘、结构扭曲及相关恶性特征的显示。虽然男性乳腺癌罕见，但当存在临床怀疑时影像学评估仍然至关重要，因为良性情况如男性乳房发育症也可能出现类似表现。该检查应采用适合男性乳腺成像的技术调整，任何可疑发现应通过活检进行组织学诊断。阴性或良性表现的影像结果应与临床发现相结合，因为可能存在假阴性，持续临床关注可能需进一步评估。
* 检查项目: Mammography diagnostic / MG双侧乳腺钼靶
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0010 / R:CR000273
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Mammography is usually appropriate as the initial imaging modality for symptomatic males with physical examination findings suspicious for breast cancer, including a suspicious palpable breast mass, axillary adenopathy, nipple discharge, or nipple retraction. Diagnostic mammography provides high-resolution evaluation of breast tissue and can effectively characterize palpable abnormalities, distinguish between benign and malignant etiologies, and guide further management. It is particularly valuable for detecting microcalcifications and assessing the features of a mass. While male breast cancer is rare, mammography remains the primary imaging tool for its evaluation due to its high sensitivity in this population, which typically has less dense breast tissue compared to females. Limitations include the potential for false-negative results in very small lesions or those obscured by overlying structures. If mammography is equivocal or negative despite strong clinical suspicion, supplemental breast ultrasound should be considered for further assessment. 对于体格检查提示可能为乳腺癌（包括可疑可触及乳房肿块、腋窝淋巴结肿大、乳头溢液或乳头回缩）的有症状男性，乳腺X线摄影通常适合作为初始影像学检查手段。诊断性乳腺X线摄影可提供乳腺组织的高分辨率评估，能有效表征可触及异常、区分良恶性病因并指导进一步管理。其在检测微钙化和评估肿块特征方面尤其有价值。尽管男性乳腺癌罕见，但由于该人群通常比女性乳腺组织致密度更低，乳腺X线摄影仍是其主要评估工具，因其在此群体中具有高敏感性。局限性包括对非常小的病灶或被重叠结构遮挡的病变可能出现假阴性结果。若乳腺X线摄影结果不明确或呈阴性但临床高度怀疑，应考虑补充乳腺超声进行进一步评估。
* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 8
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0003 / R:CR000275
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: Mammography is recommended as the initial imaging study because of its high sensitivity, specificity, and NPV, and the performance of breast US in men may be more variable than mammography \[3,9,12,16]. Carrasco et al \[3], in their series of 638 patients, reported a lower sensitivity of US for distinguishing benign from malignant disease (88.9% compared to 95% for mammography) but a similar, high specificity of 95.3%. However, Patterson et al \[28] in a series of 166 patients reported US to have the same sensitivity as mammography (100%) but lower specificity (74%). In conjunction with mammography or DBT, US is often useful in assisting with management decisions and to facilitate US core biopsy \[3]. Male breast cancers typically manifest as hypoechoic solid masses with irregular borders; however, cystic or circumscribed masses in men should also be viewed with suspicion unless definitely correlative benign findings (eg, oil cyst) are identified on mammography \[3,11,24,30,31]. Lapid et al \[32] in a series of 557 male patients demonstrated that mammography and/or US imaging in combination had an NPV of 99.8%, and a complex cystic and solid mass on US was the only false-negative examination. 推荐将乳腺X线摄影作为首选影像学检查，因其具有高敏感性、特异性及阴性预测值，且男性乳腺超声检查的表现可能较乳腺X线摄影更具变异性\[3,9,12,16]。Carrasco等\[3]在638例患者系列研究中报告超声鉴别良恶性病变的敏感性较低（88.9%，而乳腺X线摄影为95%），但特异性同样高达95.3%。然而Patterson等\[28]在166例患者系列研究中指出超声与乳腺X线摄影敏感性相同（100%），但特异性较低（74%）。联合乳腺X线摄影或数字乳腺断层合成摄影时，超声常有助于辅助制定诊疗决策并引导超声空心针活检\[3]。男性乳腺癌典型表现为边界不规则的低回声实性肿块；但对男性囊性或边界清晰的肿块也应保持警惕，除非乳腺X线摄影明确提示良性相关表现（如油性囊肿）\[3,11,24,30,31]。Lapid等\[32]在557例男性患者系列研究中证实，乳腺X线摄影和/或超声联合检查的阴性预测值达99.8%，而超声显示的复杂囊实性肿块是唯一假阴性病例。
* 检查项目: MRI breast without and with IV contrast / MR乳腺(平扫+增强)
  * 评分: 3
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000276
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明:
* 检查项目: MRI breast without IV contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000277
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明:

#### T0007 Female Breast Cancer Screening | 女性乳腺癌筛查

* 主题编码: T0007

##### S0042 Variant: Variant 1:  Adult female. Breast cancer screening. Average risk. | 成年女性，乳腺癌筛查，平均风险。

检查推荐列表：

* 检查项目: Mammography Screening / MG双侧乳腺钼靶
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0010
  * 证据强度: StrongReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: To date, mammography is the only screening modality shown to decrease breast cancer mortality. Multiple randomized controlled trials demonstrate that invitation to screening mammography results in at least a 22% reduction in breast cancer mortality \[38]. For example, after 29 years of follow-up, the Swedish Two-County trial demonstrated a 27% to 31% reduction in breast cancer mortality in 133,065 females 40 to 74 years of age invited screenings \[1]. Randomized controlled trials of screening mammography in which advanced stage breast cancers decreased by 20% or more demonstrate even greater reductions in breast cancer mortality \[11]. Observational studies, including those from population-based service screening programs, also demonstrate larger reductions in breast cancer mortality (≥40%) in females who were actually screened \[11,38]. In addition to mortality reduction, screening mammography decreases treatment morbidity, because screen-detected tumors are typically lower stage (eg, smaller and more likely to be node-negative), compared to breast cancers detected by palpation \[2,11]. Despite these benefits, screening mammograms also have risks. The most common perceived risks include false-positive recalls and biopsies, overdiagnosis, and patient anxiety \[5,7,35]. Approximately 10% of screening mammograms result in a recall for additional imaging, although \<2% result in a recommendation for percutaneous biopsy following additional imaging \[11]. Overdiagnosis refers to breast cancers that are detected by screening that would not have otherwise become apparent during the patient’s lifetime. The reported frequency of overdiagnosis varies widely in the published literature due to important underlying differences in study methodology. Overdiagnosis estimates that do not account for breast cancer risk, trends in breast cancer incidence, or lead time bias range from 0% to 54%, whereas adjusted estimates range from 1% to 10% \[39,40]. Overdiagnosis estimates increase with age at screening \[39,40]. Although the risks of screening may impact uptake and adherence to screening mammography, prior research has shown that females value early detection of breast cancer over false-positives and screening-related anxiety \[11]. Despite the established mortality benefit, published guidelines differ in their recommendations for screening mammography due to variations in the perceptions of the relative risks and benefits \[5,41]. The degree of breast cancer mortality reduction from screening mammography varies with different screening regimens. Mortality reduction is greater when screening begins at 40 years of age rather than 45 or 50 years of age and when screening is done more frequently (annually rather than biennially) \[9-11,34]. Annual screening mammography for females 40 to 84 years of age decreases mortality by 40% (12 lives per 1,000 females screened), whereas biennial screening mammography for females 50 to 74 years of age only decreases mortality by 23% (7 lives per 1,000 females 迄今为止，钼靶摄影是唯一被证明可降低乳腺癌死亡率的筛查方式。多项随机对照试验表明，邀请进行筛查性钼靶摄影可使乳腺癌死亡率至少降低22%\[38]。例如，经过29年随访，瑞典双县试验在133,065名40至74岁受邀筛查的女性中证实乳腺癌死亡率降低了27%至31%，尽管采用了单视图钼靶摄影且后续筛查间隔为24至33个月\[1]。在晚期乳腺癌减少20%或以上的筛查性钼靶摄影随机对照试验中，乳腺癌死亡率的降低更为显著\[11]。观察性研究，包括基于人群的服务筛查项目，也显示实际接受筛查的女性乳腺癌死亡率降低幅度更大（≥40%）\[11,38]。除降低死亡率外，筛查性钼靶摄影还可降低治疗相关发病率，因为与触诊发现的乳腺癌相比，筛查检测出的肿瘤通常分期较低（例如，体积更小且更可能为淋巴结阴性）\[2,11]。尽管有这些益处，筛查性钼靶摄影也存在风险。最常见的感知风险包括假阳性召回和活检、过度诊断\[5,7,35]以及患者焦虑。约10%的筛查性钼靶摄影会导致召回进行额外影像学检查，但其中\<2%会在额外影像学检查后建议进行经皮活检\[11]。过度诊断指的是通过筛查检测出的、在患者有生之年本不会显现的乳腺癌。由于研究方法存在重要差异，已发表文献中报告的过度诊断频率差异很大。未考虑乳腺癌风险、乳腺癌发病率趋势或领先时间偏倚的过度诊断估计值范围在0%至54%之间，而调整后的估计值范围在1%至10%之间\[39,40]。过度诊断估计值随筛查年龄增加而升高\[39,40]。尽管筛查风险可能影响筛查性钼靶摄影的接受度和依从性，但先前研究表明，女性更重视乳腺癌的早期检测，而非假阳性和筛查相关焦虑\[11]。尽管已确立死亡率益处，但由于对相对风险和益处的认知存在差异，已发布的指南在筛查性钼靶摄影的建议上有所不同\[5,41]。筛查性钼靶摄影对乳腺癌死亡率的降低程度因筛查方案不同而异。当筛查始于40岁而非45或50岁，且筛查频率更高（每年一次而非每两年一次）时，死亡率降低幅度更大\[911,34]。对40至84岁女性进行年度筛查性钼靶摄影可使死亡率降低40%（每筛查1000名女性挽救12条生命），而对50至74岁女性进行每两年一次的筛查性钼靶摄影仅使死亡率降低23%（每筛查1000名女性挽救7条生命）。
* 检查项目: Digital Breast Tomosynthesis Screening / MG双侧乳腺钼靶(筛查)
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0001 / R:CR000278
  * 证据强度: StrongReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Digital breast tomosynthesis (DBT) displays reconstructed stacked images of the breast in combination with digital mammographic views, which may be synthetic mammograms reconstructed from the acquired tomosynthesis data set or full-field digital mammograms (FFDM). Compared to FFDM or synthetic mammograms alone, most studies demonstrate that DBT increases cancer detection rate (CDR) and decreases recall rates \[17-25]; although some studies have not reached statistical significance \[26] or have found less compelling results in subsets of females, such as those with extremely dense breasts \[27,28]. Dense breast tissue decreases the sensitivity of mammography \[29] and is an independent risk factor for developing breast cancer \[30]. Compared to average breast density (near the threshold between heterogeneously dense and scattered areas of fibroglandular density), the relative risks for developing breast cancer are 1.2 for heterogeneously dense and 2.1 for extremely dense breasts \[31]. Some health care providers may therefore consider females with extremely dense breasts to no longer be average risk. Irrespective of risk category, meta-analyses have demonstrated an incremental increase in CDR of 1.6 to 3.2 per 1,000 screening DBT examinations and a 2.2% pooled decrease in recall rate compared to digital mammography \[21,32,33]. The degree of breast cancer mortality reduction from screening mammography varies with different screening regimens. Mortality reduction is greater when screening begins at 40 years of age rather than 45 or 50 years of age and when screening is done more frequently (annually rather than biennially) \[9-11,34]. Annual screening with DBT led to greater reductions in mortality compared with biennial screening, with 37% median reduction with screening annually from 40 to 75 years of age \[10]. Beginning screening at an earlier age and more frequent screening result in a greater number of imaging studies performed, so these screening regimens may also increase the number of false-positive examinations and biopsies \[9-11,35]. To maximize the benefits, the ACR recommends screening DBT in average-risk females each year beginning at 40 years of age. Although randomized controlled trials of screening mammography did not enroll females >74 years of age, observational studies demonstrate that some females ≥75 years of age may continue to benefit from screening mammography \[11,35]. There is no upper age limit agreed upon for screening mammography \[5,6,11,35]. Because mortality reduction from screening mammography requires years before being fully attained, screening recommendations should be based upon life expectancy and competing comorbidities, rather than age alone \[11,35-37]. Females should continue screening mammography as long as they remain in overall good health and are willing to undergo the examination and subsequent testing or biopsy, if an abnormality is identified \[5,11]. Because screening mammography decreases breast cancer mortality, screening mammography or screening DBT 数字乳腺断层合成（DBT）显示结合数字乳腺X线摄影视图的重建乳腺断层图像，这些视图可以是从采集的断层合成数据集重建的合成乳腺X线摄影图像或全视野数字乳腺X线摄影（FFDM）图像。与单独使用FFDM或合成乳腺X线摄影相比，大多数研究表明DBT提高了癌症检出率（CDR）并降低了召回率\[1725]；尽管一些研究未达到统计学显著性\[26]或在某些女性亚组（如致密乳腺女性）中发现结果说服力较低\[27,28]。致密乳腺组织降低乳腺X线摄影的敏感性\[29]并且是发生乳腺癌的独立危险因素\[30]。与平均乳腺密度（接近不均匀致密和散在纤维腺体密度区域的阈值）相比，不均匀致密和极度致密乳腺发生乳腺癌的相对风险分别为1.2和2.1\[31]。因此，一些医疗保健提供者可能认为极度致密乳腺女性不再属于平均风险。无论风险类别如何，荟萃分析表明，与数字乳腺X线摄影相比，每1,000次DBT筛查检查的CDR增量增加为1.6至3.2，召回率合并降低2.2%\[21,32,33]。筛查乳腺X线摄影对乳腺癌死亡率的降低程度因不同筛查方案而异。从40岁开始筛查而非45或50岁，以及更频繁筛查（每年而非每两年）时死亡率降低幅度更大\[911,34]。与两年一次筛查相比，每年进行DBT筛查导致死亡率降低幅度更大，从40岁至75岁每年筛查的中位降低率为37%\[10]。更早开始筛查和更频繁筛查导致执行的影像学检查数量增加，因此这些筛查方案也可能增加假阳性检查和活检的数量\[911,35]。为最大化获益，ACR建议平均风险女性从40岁开始每年进行DBT筛查。尽管筛查乳腺X线摄影的随机对照试验未纳入74岁女性，但观察性研究表明一些≥75岁女性可能继续从筛查乳腺X线摄影中获益\[11,35]。筛查乳腺X线摄影没有公认的年龄上限\[5,6,11,35]。由于筛查乳腺X线摄影对死亡率的降低需要多年才能完全实现，筛查建议应基于预期寿命和合并症，而非仅基于年龄\[11,3537]。只要女性总体健康状况良好，并且愿意接受检查以及后续的检测或活检（如果发现异常），就应继续筛查乳腺X线摄影\[5,11]。由于筛查乳腺X线摄影降低了乳腺癌死亡率，筛查乳腺X线摄影或筛查DBT
* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 5
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0005 / R:CR000280
  * 证据强度: StrongReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: Although data are limited regarding the use of breast MRI without and with IV contrast for screening females at average risk, a study has demonstrated that breast MRI demonstrates incremental cancer detection (15-16 cancers per 1,000 breast MRI examinations) over screening mammography with or without screening ultrasound (US) in average-risk females irrespective of breast density \[45]. Breast MRI also decreases interval cancers \[45,46]. In the DENSE trial, breast MRI significantly reduced interval cancers within females with extremely dense breast tissue and normal mammography, so the European Society of Breast Imaging now recommends screening breast MRI every 2 to 4 years in females 50 to 70 years of age with extremely dense breasts \[46,47]. Compared to average breast density (near the threshold between heterogeneously dense and scattered areas of fibroglandular density), the relative risks for developing breast cancer are 1.2 for heterogeneously dense and 2.1 for extremely dense breasts \[31]. Some health care providers may therefore consider females with extremely dense breasts to no longer be average risk. For supplemental screening recommendations based upon breast density, please refer to the ACR Appropriateness Criteria ® topic on “ Supplemental Breast Cancer Screening Based on Breast Density ” \[13]. 尽管关于不使用和联合静脉注射对比剂进行乳腺MRI筛查平均风险女性的数据有限，但一项研究表明，无论乳腺密度如何，乳腺MRI相比单独或联合超声的乳腺X线筛查能额外检出癌症（每1000次乳腺MRI检查发现15-16例癌症）\[45]。乳腺MRI还能降低间期癌发生率\[45,46]。DENSE试验证实，乳腺MRI能显著降低乳腺组织极度致密且X线检查正常女性的间期癌风险，因此欧洲乳腺影像学会现建议50至70岁乳腺极度致密女性每2至4年接受一次乳腺MRI筛查\[46,47]。相较于平均乳腺密度（接近不均匀致密与散在纤维腺体密度的临界值），不均匀致密和极度致密乳腺发生乳腺癌的相对风险分别为1.2和2.1\[31]。因此部分医疗机构可能认为乳腺极度致密女性不再属于平均风险人群。基于乳腺密度的补充筛查建议请参阅ACR适宜性标准专题《基于乳腺密度的补充乳腺癌筛查》\[13]。
* 检查项目: MRI Breast Without and With IV Contrast Abbreviated / MR乳腺(平扫+增强)
  * 评分: 5
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0005 / R:CR000280
  * 证据强度: ModerateReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: Data are limited regarding the use of abbreviated breast MRI without and with IV contrast for screening females at average risk. The ECOG-ACRIN abbreviated MRI trial demonstrated a significantly higher CDR for abbreviated breast MRI without and with IV contrast (15 cancers per 1,000) compared with DBT (6 cancers per 1,000), although the study recruited females with dense breasts \[48]. In addition to dense breasts, females enrolled in the trial had variable 5 and 10 year risk profiles based upon the Breast Cancer Surveillance Consortium risk calculator and 19% reported 1 or more first degree relatives with breast cancer \[48]. Compared to average breast density (near the threshold between heterogeneously dense and scattered areas of fibroglandular density), the relative risks for developing breast cancer are 1.2 for heterogeneously dense and 2.1 for extremely dense breasts \[31]. Some health care providers may therefore consider females with extremely dense breasts to no longer be average risk. For supplemental screening recommendations based upon breast density, please refer to the ACR Appropriateness Criteria ® topic on “ Supplemental Breast Cancer Screening Based on Breast Density ” \[13]. 关于使用无和有静脉注射对比剂的简化乳腺MRI对平均风险女性进行筛查的数据有限。ECOG-ACRIN简化MRI试验显示，与数字乳腺断层合成（DBT）（每1000例检出6例癌症）相比，无和有静脉注射对比剂的简化乳腺MRI的癌症检出率（CDR）显著更高（每1000例检出15例癌症），尽管该研究招募的是致密型乳腺女性\[48]。除致密型乳腺外，参与试验的女性基于乳腺癌监测联盟风险计算器具有不同的5年和10年风险特征，且19%报告有1名或更多一级亲属患有乳腺癌\[48]。与平均乳腺密度（接近不均匀致密和散在纤维腺体密度的阈值）相比，不均匀致密乳腺和极度致密乳腺发生乳腺癌的相对风险分别为1.2和2.1\[31]。因此，一些医疗保健提供者可能认为极度致密乳腺女性不再属于平均风险。有关基于乳腺密度的补充筛查建议，请参阅ACR适宜性标准®专题“基于乳腺密度的补充乳腺癌筛查”\[13]。
* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 5
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0003 / R:CR000282
  * 证据强度: StrongReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: Most studies evaluating the utility of screening with breast US have focused on females with dense breast tissue with or without other risk factors. Dense breast tissue decreases the sensitivity of mammography \[29] and is an independent risk factor for developing breast cancer \[30]. Screening breast US in females with mammographically dense breasts, including those with risk factors placing them at increased breast cancer risk, identifies mammographically occult, small, node-negative invasive tumors with an increased CDR of 1.8 to 4.6 cancers per 1,000 females screened \[43,52]. Although supplemental screening US in females with dense breasts results in an increased CDR, US also increases recall rate, false-positive examinations, and false-positive biopsies \[29,52-58]. For supplemental screening recommendations based upon breast density, please refer to the ACR Appropriateness Criteria ® topic on “ Supplemental Breast Cancer Screening Based on Breast Density ” \[13]. Data regarding supplemental screening US in average-risk females with nondense breasts is less compelling. In a study of 1,526 average-risk females without mammographic abnormalities, screening with US demonstrated an overall incremental CDR of 3.3 per 1,000, with 5.1 per 1,000 examinations in dense breasts and 0 per 1,000 in nondense breasts compared to digital mammography \[59]. In another study of 1,003 average-risk females, US yielded an overall incremental CDR of 3.2 per 1,000 examinations, with 0 per 1,000 in nondense breasts, compared to DBT with or without digital mammography \[56]. 大多数评估乳腺超声筛查效用的研究主要针对伴有致密乳腺组织（无论是否合并其他风险因素）的女性。致密乳腺组织会降低乳腺X线摄影的敏感性\[29]，同时也是乳腺癌发生的独立风险因素\[30]。对乳腺X线摄影显示致密乳腺的女性（包括存在其他乳腺癌高风险因素者）进行超声筛查，可检出X线摄影隐匿性的小型无淋巴结转移浸润性肿瘤，其额外癌症检出率（CDR）为每筛查1000名女性增加1.8至4.6例癌症\[43,52]。尽管致密乳腺女性的补充超声筛查能提高CDR，但也会导致召回率、假阳性检查及假阳性活检的增加\[29,52-58]。关于基于乳腺密度的补充筛查建议，请参阅ACR适宜性标准®专题《基于乳腺密度的补充乳腺癌筛查》\[13]。对于非致密乳腺的平均风险女性，补充超声筛查的数据支持力较弱。一项针对1526名无乳腺X线异常的普通风险女性的研究表明，与数字乳腺X线摄影相比，超声筛查的总体增量CDR为每1000例检查3.3例（致密乳腺组5.1例/1000，非致密乳腺组0例/1000）\[59]。另一项针对1003名普通风险女性的研究显示，与数字乳腺断层合成摄影（DBT）联合/不联合数字乳腺X线摄影相比，超声
* 检查项目: Mammography With IV Contrast / MG双侧乳腺钼靶导管造影
  * 评分: 3
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0004 / R:CR000283
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Data are limited regarding the use of mammography with intravenous (IV) contrast for screening females at average risk. Most published studies evaluated mammography with IV contrast in females with dense breasts and elevated risk, so results specific to females at average risk, especially those without dense breasts, are not currently available. For supplemental screening recommendations based upon breast density, please refer to the ACR Appropriateness Criteria ® topic on “ Supplemental Breast Cancer Screening Based on Breast Density ” \[13]. 关于静脉注射（IV）对比剂乳腺X线摄影用于一般风险女性筛查的数据有限。大多数已发表的研究评估了静脉注射对比剂乳腺X线摄影在乳腺致密且风险升高的女性中的应用，因此目前尚无针对一般风险女性（尤其是非致密乳腺者）的具体结果。基于乳腺密度的补充筛查建议，请参阅ACR适宜性标准®专题“基于乳腺密度的乳腺癌补充筛查”\[13]。
* 检查项目: MRI breast without IV contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000284
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明:
* 检查项目: MRI Breast Without IV Contrast Abbreviated / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000284
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support the use of abbreviated MRI without IV contrast for screening females at average risk. 目前尚无相关文献支持在不使用静脉对比剂的情况下采用简化MRI对平均风险女性进行筛查。
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000286
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: Data are limited regarding the use of sestamibi molecular breast imaging (MBI) for screening females at average risk. Most studies have focused upon females with dense breasts and variable risk profiles. One of the larger studies published to date of 1,696 females with recent negative or benign mammographic examinations showed that sestamibi MBI yielded an incremental CDR of 7.7 cancers per 1,000 examinations; however, all 13 cancers were detected in females with dense breasts \[49]. Although 92% of the females within the study had \<20% estimated lifetime risk, the estimates ranged from 6.1% to 17.2% \[49]. Additional retrospective and prospective studies have demonstrated similar incremental CDR for sestamibi MBI of 6.5 to 9 per 1,000 over mammography \[43,50]. Sestamibi MBI demonstrates similar sensitivity, better specificity, and lower recall rate compared to supplemental screening US in females with dense breasts \[50,51]. 关于使用司他比锝分子乳腺成像（MBI）对平均风险女性进行筛查的数据有限。大多数研究集中于乳腺致密且风险特征各异的女性群体。迄今发表的一项较大规模研究（纳入1,696名近期乳腺X线检查阴性或良性的女性）显示，司他比锝MBI可额外检出7.7例/1000次检查的癌症检出率（CDR）；但所有13例癌症均发现于乳腺致密的女性\[49]。尽管该研究中92%的女性终生风险预估\<20%，但具体风险估值范围为6.1%至17.2%\[49]。其他回顾性和前瞻性研究也表明，与乳腺X线摄影相比，司他比锝MBI可带来6.5至9例/1000次检查的额外CDR提升\[43,50]。对于乳腺致密女性，司他比锝MBI作为补充筛查手段与超声相比，具有相似的敏感性、更优的特异性及更低的召回率\[50,51]。

##### S0043 Variant: Variant 2:  Adult female. Breast cancer screening. Intermediate risk. | 成年女性，乳腺癌筛查，中等风险。

检查推荐列表：

* 检查项目: Mammography Screening / MG双侧乳腺钼靶
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0010
  * 证据强度: StrongReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: To date, mammography is the only screening modality shown to decrease breast cancer mortality. Multiple randomized controlled trials demonstrate that invitation to screening mammography results in at least a 22% reduction in breast cancer mortality \[38]. For example, after 29 years of follow-up, the Swedish Two-County trial demonstrated a 27% to 31% reduction in breast cancer mortality in 133,065 females 40 to 74 years of age invited to screening despite use of single view mammography and the 24 to 33 month interval between subsequent screenings \[1]. Randomized controlled trials of screening mammography in which advanced stage breast cancers decreased by 20% or more demonstrate even greater reductions in breast cancer mortality \[11]. Observational studies, including those from population-based service screening programs, also demonstrate larger reductions in breast cancer mortality (≥40%) in females who were actually screened \[11,38]. In addition to mortality reduction, screening mammography decreases treatment morbidity, because screen-detected tumors are typically lower stage (eg, smaller and more likely to be node-negative) compared to breast cancers detected by palpation \[2,11]. Despite these benefits, screening mammograms also have risks. The most common perceived risks include false-positive recalls and biopsies, overdiagnosis \[5,7,35], and patient anxiety. Approximately 10% of screening mammograms result in a recall for additional imaging, although \<2% result in a that are detected by screening that would not have otherwise become apparent during the patient’s lifetime. The reported frequency of overdiagnosis varies widely in the published literature, due to important underlying differences in study methodology. Overdiagnosis estimates that do not account for breast cancer risk, trends in breast cancer incidence, or lead time bias range from 0% to 54%, whereas adjusted estimates range from 1% to 10% \[39,40]. Overdiagnosis estimates increase with age at screening \[39,40]. Although the risks of screening may impact uptake and adherence to screening mammography, prior research has shown that females value early detection of breast cancer over false-positives and screening-related anxiety \[11]. Despite the established mortality benefit, published guidelines differ in their recommendations for screening mammography due to variations in the perceptions of the relative risks and benefits \[5,41]. The degree of breast cancer mortality reduction from screening mammography varies with different screening regimens. Mortality reduction is greater when screening begins 40 years of age rather than 45 or 50 years of age and when screening is done more frequently (annually rather than biennially) \[9-11,34]. Annual screening mammography for females 40 to 84 years of age decreases mortality by 40% (12 lives per 1,000 females screened), whereas biennial screening mammography for females 50 to 74 years of age only decreases mortality by 23% (7 lives per 1,000 females 迄今为止，乳腺X线摄影是唯一被证明可降低乳腺癌死亡率的筛查方法。多项随机对照试验表明，接受筛查乳腺X线摄影邀请可使乳腺癌死亡率至少降低22%\[38]。例如，经过29年随访，瑞典双县试验显示，在133,065名40至74岁接受筛查的女性中，尽管采用单视图乳腺X线摄影且筛查间隔为24至33个月，乳腺癌死亡率降低了27%至31%\[1]。在高级别乳腺癌减少20%或以上的筛查乳腺X线摄影随机对照试验中，乳腺癌死亡率的降低幅度更大\[11]。观察性研究（包括基于人群的服务筛查项目）也显示，实际接受筛查的女性乳腺癌死亡率降低幅度更大（≥40%）\[11,38]。除降低死亡率外，筛查乳腺X线摄影还可降低治疗相关发病率，因为与触诊发现的乳腺癌相比，筛查发现的肿瘤通常分期更低（例如体积更小且更可能淋巴结阴性）\[2,11]。尽管存在这些益处，筛查性乳腺X线摄影也存在风险。最常见的感知风险包括假阳性召回和活检、过度诊断\[5,7,35]以及患者焦虑。约10%的筛查性乳腺X线摄影会导致召回进行额外影像学检查，尽管其中仅\<2%需要在额外影像学检查后建议经皮活检\[11]。过度诊断指通过筛查检测出、否则在患者有生之年不会显现的乳腺癌。由于研究方法学存在重要差异，已发表文献中报道的过度诊断频率差异很大。未考虑乳腺癌风险、乳腺癌发病率趋势或领先时间偏倚的过度诊断估计值范围为0%至54%，而经调整的估计值范围为1%至10%\[39,40]。过度诊断估计值随筛查年龄增加而升高\[39,40]。尽管筛查风险可能影响筛查乳腺X线摄影的接受度和依从性，既往研究表明女性更重视乳腺癌的早期检测而非假阳性和筛查相关焦虑\[11]。尽管已明确死亡率获益，由于对相对风险和益处的认知存在差异，已发布的指南对筛查乳腺X线摄影的建议有所不同\[5,41]。筛查乳腺X线摄影对乳腺癌死亡率的降低程度因筛查方案不同而异。从40岁开始筛查而非45或50岁、以及更频繁筛查（每年而非每两年）时死亡率降低幅度更大\[911,34]。对40至84岁女性进行年度筛查乳腺X线摄影可使死亡率降低40%（每筛查1000名女性挽救12条生命），而对50至74岁女性进行两年一次筛查仅使死亡率降低23%（每筛查1000名女性挽救7条生命）——
* 检查项目: Digital Breast Tomosynthesis Screening / MG双侧乳腺钼靶(筛查)
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0001 / R:CR000287
  * 证据强度: StrongReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: DBT displays reconstructed stacked images of the breast in combination with digital mammographic views, which may be synthetic mammograms reconstructed from the acquired tomosynthesis dataset or FFDM. Compared to FFDM or synthetic mammograms alone, most studies demonstrate that DBT increases CDR and decreases recall rate \[17-25]; although, some studies have not reached statistical significance \[26] or have found less compelling results in subsets of females, such as those with extremely dense breasts \[27,28]. Dense breast tissue decreases the sensitivity of mammography \[29] and is an independent risk factor for developing breast cancer \[30]. Compared to average breast density (near the threshold between heterogeneously dense and scattered areas of fibroglandular density), the relative risks for developing breast cancer are 1.2 for heterogeneously dense and 2.1 for extremely dense breasts \[31]. Some health care providers may therefore consider females with extremely dense breasts to no longer be average risk. Irrespective of risk category, meta-analyses have demonstrated an incremental increase in CDR of 1.6 to 3.2 per 1,000 screening DBT examinations and a 2.2% pooled decrease in recall rate compared to digital mammography \[21,32,33]. The degree of breast cancer mortality reduction from screening mammography varies with different screening regimens. Mortality reduction is greater when screening begins at 40 years of age rather than 45 or 50 years of age and when screening is done more frequently (annually rather than biennially) \[9-11,34]. Beginning screening at an earlier age and more frequent screening, result in a greater number of imaging studies performed, so these screening regimens also increase the number of false-positive examinations and biopsies \[9-11,35]. Although randomized controlled trials of screening mammography did not enroll females >74 years of age, observational studies demonstrate that some females ≥75 years of age may continue to benefit from screening mammography \[11,35]. There is no upper age limit agreed upon for screening mammography \[5,6,11,35]. Because mortality reduction from screening mammography requires years before being fully attained, screening recommendations should be based upon life expectancy and competing comorbidities, rather than age alone \[11,35-37]. Females should continue screening mammography as long as they remain in overall good health and are willing to undergo the examination and subsequent testing or biopsy, if an abnormality is identified \[5,11]. Within the limited studies of females at elevated risk due to personal and/or family history of breast cancer, DBT decreased recall rate without a significant increase in CDR compared to FFDM; however, small sample sizes restrict analyses \[3,43]. Because screening mammography decreases breast cancer mortality, screening mammography or screening DBT is still performed in females undergoing supplemental screening studies \[3,11,38]. The ACR recommends annual 数字乳腺断层合成成像（DBT）结合数字乳腺X线摄影视图显示乳腺的重建层叠图像，这些视图可能是从采集的断层合成数据集或全视野数字乳腺X线摄影（FFDM）重建的合成乳腺X线图像。与单独使用FFDM或合成乳腺X线图像相比，多数研究表明DBT可提高癌症检出率（CDR）并降低召回率\[1725]；尽管部分研究未达到统计学显著性\[26]，或在特定女性亚组（如致密乳腺极度致密者）中发现结果说服力较弱\[27,28]。致密乳腺组织会降低乳腺X线摄影的敏感性\[29]，并且是发生乳腺癌的独立危险因素\[30]。与平均乳腺密度（接近不均匀致密与散在纤维腺体密度的临界值）相比，不均匀致密和极度致密乳腺发生乳腺癌的相对风险分别为1.2和2.1\[31]。因此，部分医疗从业者可能认为极度致密乳腺女性不再属于平均风险人群。无论风险类别如何，荟萃分析表明，与数字乳腺X线摄影相比，每1,000次DBT筛查可增加1.6至3.2的CDR，且召回率合并降低2.2%\[21,32,33]。筛查性乳腺X线摄影对乳腺癌死亡率的降低程度因筛查方案而异。从40岁开始筛查相比45或50岁开始筛查、以及更频繁筛查（每年而非每两年）可更大程度降低死亡率\[911,34]。更早开始筛查和更频繁筛查会导致影像学检查次数增加，因此这些筛查方案也会增加假阳性检查和活检的数量\[911,35]。尽管筛查性乳腺X线摄影的随机对照试验未纳入74岁女性，但观察性研究表明部分≥75岁女性可能继续从筛查性乳腺X线摄影中获益\[11,35]。筛查性乳腺X线摄影尚无公认的年龄上限\[5,6,11,35]。由于筛查性乳腺X线摄影对死亡率的降低需多年才能完全实现，筛查建议应基于预期寿命和合并症，而非仅基于年龄\[11,3537]。只要女性总体健康状况良好且愿意接受检查以及后续检测或活检（若发现异常），就应继续接受筛查性乳腺X线摄影\[5,11]。在针对因个人和/或家族乳腺癌史而风险升高的女性的有限研究中，与FFDM相比，DBT降低了召回率但未显著提高CDR；然而，小样本量限制了分析\[3,43]。由于筛查性乳腺X线摄影可降低乳腺癌死亡率，接受补充筛查研究的女性仍进行筛查性乳腺X线摄影或筛查性DBT\[3,11,38]。美国放射学会建议每年
* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 6
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0005 / R:CR000289
  * 证据强度: StrongReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: MRI has a higher CDR than mammography alone, DBT, or mammography/DBT combined with US \[67-70]. The incremental CDR of MRI in elevated-risk females ranges from 8 to 29 per 1,000 females, with lower CDR estimates in intermediate-risk females compared to high-risk BRCA mutation carriers \[67-69,71,72]. In an study, breast MRI CDR was 15 per 1,000 in females with a prior biopsy demonstrating a high-risk lesion compared to 8 per 1,000 in females reporting a family history \[71]. In females with a personal history of breast cancer, a meta-analysis estimated a CDR of 9 to 15 per 1,000 breast MRI \[73]. Breast MRI detects small, node-negative invasive cancers at earlier tumor stages compared to mammography, as well as ductal carcinoma in situ \[74,75]. Screening MRI also reduces interval cancers \[75]. However, breast MRI has a higher recall rate than mammography (15.1% versus 6.4%) \[76], higher frequency of BI-RADS category 3 assessment than mammography (14.8% versus 11.8%), and greater frequency of image-guided biopsies than mammography (11.8% versus 2.4%) \[69]. 与单独乳腺X线摄影、数字乳腺断层合成（DBT）或乳腺X线摄影/DBT联合超声检查相比，MRI具有更高的癌症检出率（CDR）\[67-70]。在高危女性中，MRI的增量CDR为每1000人8至29例，中危女性的CDR估值低于携带BRCA突变的高危人群\[67-69,71,72]。一项研究显示，既往活检证实为高风险病变的女性中，乳腺MRI的CDR为每1000人15例，而仅报告家族史的女性为每1000人8例\[71]。对于有乳腺癌个人史的女性，一项荟萃分析估计乳腺MRI的CDR为每1000人9至15例\[73]。与乳腺X线摄影相比，乳腺MRI能更早检出肿瘤分期更早的小型无淋巴结转移浸润癌以及导管原位癌\[74,75]。MRI筛查还可降低间期癌发生率\[75]。然而，乳腺MRI的召回率高于乳腺X线摄影（15.1%对6.4%）\[76]，BI-RADS 3类评估频率更高（14.8%对11.8%），且影像引导活检实施率更高（11.8%对2.4%）\[69]。
* 检查项目: MRI Breast Without and With IV Contrast Abbreviated / MR乳腺(平扫+增强)
  * 评分: 6
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0005 / R:CR000289
  * 证据强度: StrongReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: Data are limited regarding the use of abbreviated breast MRI without and with IV contrast in intermediate-risk females. In an cohort of females deemed at “mildly to moderately increased risk” abbreviated breast MRI demonstrated an incremental cancer detection yield of 18 cancers per 1,000 and a high negative predictive value \[77,78]. In intermediate-risk females, abbreviated breast MRI yields a lower CDR (7 per 1,000) compared to high- risk females (29 per 1,000) \[56]. Multiple studies have demonstrated similar diagnostic accuracy for abbreviated protocol MRI compared to conventional full protocol breast MRI \[79-81] . The ECOG-ACRIN abbreviated MRI trial demonstrated a significantly higher CDR for abbreviated breast MRI without and with IV contrast (15 cancers per 1,000) compared with DBT (6 cancers per 1,000) in females with dense breasts \[48]. In addition to dense breasts, females enrolled in the trial had variable 5 and 10 year risk profiles based upon the Breast Cancer Surveillance Consortium risk calculator, and 19% reported 1 or more first degree relatives with breast cancer \[48]. 关于在中危女性中应用不联合及联合静脉对比剂的简化乳腺MRI检查，现有数据有限。在一项针对“轻度至中度风险升高”女性群体的研究中，简化乳腺MRI显示出每1000例额外检出18例癌症的增量收益，并具有较高的阴性预测值\[77,78]。与高风险女性（29例/1000例）相比，简化乳腺MRI在中危女性中的癌症检出率（CDR）较低（7例/1000例）\[56]。多项研究表明，与传统全序列乳腺MRI相比，简化方案MRI具有相似的诊断准确性\[79-81]。ECOG-ACRIN简化MRI试验证实，在致密型乳腺女性中，不联合及联合静脉对比剂的简化乳腺MRI（15例/1000例）相比数字乳腺断层摄影（DBT）（6例/1000例）具有显著更高的CDR\[48]。除致密型乳腺外，该试验入组女性基于乳腺癌监测联盟风险计算工具具有不同的5年及10年风险特征，其中19%报告有1名或以上一级亲属罹患乳腺癌\[48]。
* 检查项目: Mammography With IV Contrast / MG双侧乳腺钼靶导管造影
  * 评分: 5
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0004 / R:CR000291
  * 证据强度: StrongReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Data are limited regarding the use of mammography with IV contrast for breast cancer screening in intermediate- risk females. To date, published studies have predominantly included females with dense breasts and other risk factors resulting in intermediate- or high-risk profiles. Compared to mammography alone, mammography with IV contrast increases cancer detection (incremental CDR = 6.6-13 per 1,000) in females at elevated risk \[62-66]. 关于静脉注射造影剂乳腺X线摄影用于中等风险女性乳腺癌筛查的数据有限。迄今为止，已发表的研究主要纳入乳腺致密且存在其他风险因素导致中高风险特征的女性。与单独乳腺X线摄影相比，静脉注射造影剂乳腺X线摄影可提高高风险女性的癌症检出率（增量CDR=6.6-13/1000）\[62-66]。
* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 5
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0003 / R:CR000292
  * 证据强度: StrongReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: Most studies evaluating the utility of screening with breast US have focused on females with dense breast tissue with or without other risk factors. Dense breast tissue decreases the sensitivity of mammography \[29] and is an independent risk factor for developing breast cancer \[30]. Screening breast US in females with mammographically dense breasts, including those with risk factors placing them at increased breast cancer risk, identifies predominantly mammographically occult, small, node-negative invasive tumors with an increased CDR of 1.8 to 4.6 cancers per 1,000 females screened \[43,52]. Although supplemental screening US in females with dense breasts results in an increased CDR, US also increases recall rate, false-positive examinations, and false-positive biopsies \[29,52-58]. In females undergoing annual mammography plus annual supplemental screening MRI, the addition of supplemental screening with US does not identify additional cancers and is therefore not routinely performed. For supplemental screening recommendations based upon breast density, please refer to the ACR Appropriateness Criteria ® topic on “ Supplemental Breast Cancer Screening Based on Breast Density ” \[13]. The ACRIN 6666 trial enrolled females with dense breast tissue and at least 1 other breast cancer risk factor \[67]. Compared to mammography alone, screening US detected 5.3 cancers per 1,000 in year 1, 3.7 cancers per 1,000 in years 2 and 3, and resulted in a larger number of false-positive examinations and false-positive biopsies each year \[67]. In a prospective study limited to intermediate-risk females, sensitivity of mammography was 57%, US was 24.5%, and mammography combined with biannual US demonstrated 80.4% sensitivity \[82]. In females with a personal history of breast cancer, supplemental US screening results in an incremental CDR of 2.4 to 2.9 cancers per 1,000 examinations over mammography alone; however, US screening has lower specificity \[13,72]. 大多数评估乳腺超声筛查效用的研究主要针对具有致密乳腺组织（伴或不伴其他风险因素）的女性。致密乳腺组织会降低乳腺X线摄影的敏感性\[29]，并且是罹患乳腺癌的独立风险因素\[30]。对乳腺X线摄影显示致密乳腺的女性（包括存在其他乳腺癌风险因素者）进行超声筛查，主要可发现乳腺X线摄影隐匿性、小型、淋巴结阴性的浸润性肿瘤，其癌症检出率（CDR）增加至每筛查1000名女性检出1.8至4.6例癌症\[43,52]。尽管对致密乳腺女性进行补充超声筛查可提高CDR，但超声也会增加召回率、假阳性检查及假阳性活检率\[29,52-58]。对于每年接受乳腺X线摄影联合补充MRI筛查的女性，额外增加超声筛查并未发现更多癌症病例，因此不作为常规检查。关于基于乳腺密度的补充筛查建议，请参阅ACR适宜性标准®专题《基于乳腺密度的补充乳腺癌筛查》\[13]。ACRIN 6666试验纳入了具有致密乳腺组织且至少存在1项其他乳腺癌风险因素的女性\[67]。与单纯乳腺X线摄影相比，超声筛查在第一年检出率为每1000人5.3例癌症，第二、三年为每1000人3.7例，但每年均导致更多假阳性检查和假阳性活检\[67]。一项针对
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 3
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000293
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: Data are limited regarding the use of sestamibi MBI for screening females at intermediate risk. Most studies have focused upon females with dense breasts and variable risk profiles. Retrospective and prospective studies have demonstrated similar incremental CDR for sestamibi MBI of 6.5 to 9 over mammography, with a study history of breast cancer \[43,50]. Sestamibi MBI demonstrates similar sensitivity, better specificity, and lower recall rate compared to supplemental screening US in females with dense breasts \[50,51]. 关于使用司他比锝 MBI 对中危女性进行筛查的数据有限。大多数研究聚焦于致密乳腺且风险特征各异的女性群体。回顾性和前瞻性研究表明，在有乳腺癌病史的研究中，司他比锝 MBI 相较于乳腺 X 线摄影可带来相似的增量癌症检出率（CDR），增幅为 6.5 至 9 \[43,50]。在致密乳腺女性中，与补充性筛查超声（US）相比，司他比锝 MBI 显示出相似的敏感性、更好的特异性及更低的召回率 \[50,51]。
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000294
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support the use of breast MRI without IV contrast for screening females at intermediate risk. 目前尚无相关文献支持在不使用静脉造影剂的情况下，采用乳腺MRI对中等风险女性进行筛查。
* 检查项目: MRI Breast Without IV Contrast Abbreviated / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000294
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support the use of abbreviated breast MRI without IV contrast for screening females at intermediate risk. 目前尚无相关文献支持在不使用静脉对比剂的情况下采用简化乳腺MRI对中等风险女性进行筛查。

##### S0044 Variant: Variant 3:  Adult female 30 years of age or older. Breast cancer screening. High risk. | ≥30岁成人女性，乳腺癌筛查，高风险。

检查推荐列表：

* 检查项目: Mammography Screening / MG双侧乳腺钼靶
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0010
  * 证据强度: StrongReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: To date, mammography is the only screening modality shown to decrease breast cancer mortality. Multiple randomized controlled trials demonstrate that invitation to screening mammography results in at least a 22% reduction in breast cancer mortality \[38]. For example, after 29 years of follow-up, the Swedish Two-County trial demonstrated a 27% to 31% reduction in breast cancer mortality in 133,065 females 40 to 74 years of age invited to screening despite use of single view mammography and the 24 to 33 month interval between subsequent screenings \[1]. Randomized controlled trials of screening mammography in which advanced stage breast cancers studies, including those from population-based service screening programs, also demonstrate larger reductions in breast cancer mortality (≥40%) in females who were actually screened \[11,38]. In addition to mortality reduction, screening mammography decreases treatment morbidity, because screen-detected tumors are typically lower stage (eg, smaller and more likely to be node-negative), compared to breast cancers detected by palpation \[2,11]. Despite these benefits, screening mammograms also have risks. The most common perceived risks include false-positive recalls and biopsies, overdiagnosis \[5,7,35], and patient anxiety. Approximately 10% of screening mammograms result in a recall for additional imaging, although \<2% result in a recommendation for percutaneous biopsy following additional imaging \[11]. Overdiagnosis refers to breast cancers that are detected by screening that would not have otherwise become apparent during the patient’s lifetime. The reported frequency of overdiagnosis varies widely in the published literature due to important underlying differences in study methodology. Overdiagnosis estimates that do not account for breast cancer risk, trends in breast cancer incidence, or lead time bias range from 0% to 54%, whereas adjusted estimates range from 1% to 10% \[39,40]. Overdiagnosis estimates increase with age at screening \[39,40]. Although the risks of screening may impact uptake and adherence to screening mammography, prior research has shown that females value early detection of breast cancer over false-positives and screening-related anxiety \[11]. Despite the established mortality benefit, published guidelines differ in their recommendations for screening mammography due to variations in the perceptions of the relative risks and benefits \[5,41]. The degree of breast cancer mortality reduction from screening mammography varies with different screening regimens. Mortality reduction is greater when screening begins 40 years of age rather than 45 or 50 years of age and when screening is done more frequently (annually rather than biennially) \[9-11,34]. Annual screening mammography for females 40 to 84 years of age decreases mortality by 40% (12 lives per 1,000 females screened), whereas biennial screening mammography for females 50 to 74 years of age only decreases mortality by 23% (7 lives per 1,000 females 迄今为止， mammography 是唯一被证明可降低乳腺癌死亡率的筛查方式。多项随机对照试验表明，接受筛查性 mammography 可使乳腺癌死亡率至少降低 22% \[38]。例如，经过 29 年随访，瑞典双县试验在 133,065 名 40 至 74 岁受邀接受筛查的女性中，尽管采用单视图 mammography 且筛查间隔为 24 至 33 个月，仍证明了乳腺癌死亡率降低了 27% 至 31% \[1]。对筛查性 mammography 进行的随机对照试验（包括基于人群的服务筛查项目的研究）中，针对晚期乳腺癌的研究也表明，实际接受筛查的女性乳腺癌死亡率降低幅度更大（≥40%）\[11,38]。除了降低死亡率外，筛查性 mammography 还可降低治疗发病率，因为与触诊发现的乳腺癌相比，筛查检测出的肿瘤通常分期较低（例如，更小且更可能为淋巴结阴性）\[2,11]。尽管有这些益处，筛查性 mammography 也存在风险。最常见的感知风险包括假阳性召回和活检、过度诊断 \[5,7,35] 以及患者焦虑。大约 10% 的筛查性 mammography 会导致召回进行额外成像，但其中 \<2% 会在额外成像后建议进行经皮活检 \[11]。过度诊断指的是通过筛查检测出的、在患者有生之年本不会显现的乳腺癌。由于研究方法的根本性重要差异，已发表文献中报道的过度诊断频率差异很大。未考虑乳腺癌风险、乳腺癌发病率趋势或领先时间偏倚的过度诊断估计值范围在 0% 至 54% 之间，而调整后的估计值范围在 1% 至 10% 之间 \[39,40]。过度诊断估计值随筛查年龄的增加而增加 \[39,40]。尽管筛查风险可能影响筛查性 mammography 的接受度和依从性，但先前研究表明，女性更重视乳腺癌的早期检测，而非假阳性和筛查相关焦虑 \[11]。尽管已确立了死亡率益处，但由于对相对风险和益处的认知存在差异，已发布的指南对筛查性 mammography 的建议有所不同 \[5,41]。筛查性 mammography 对乳腺癌死亡率的降低程度因不同筛查方案而异。从 40 岁开始筛查而非 45 或 50 岁，以及更频繁地进行筛查（每年而非每两年）时，死亡率降低幅度更大 \[911,34]。对 40 至 84 岁女性进行年度筛查性 mammography 可使死亡率降低 40%（每筛查 1000 名女性挽救 12 条生命），而对 50 至 74 岁女性进行两年一次筛查性 mammography 仅使死亡率降低 23%（每筛查 1000 名女性挽救 7 条生命）。
* 检查项目: Digital Breast Tomosynthesis Screening / MG双侧乳腺钼靶(筛查)
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0001 / R:CR000296
  * 证据强度: StrongReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: DBT displays reconstructed stacked images of the breast in combination with digital mammographic views, which may be synthetic mammograms reconstructed from the acquired tomosynthesis data set or FFDM. Compared to rate \[17-25]; although, some studies have not reached statistical significance \[26] or have found less compelling results in subsets of females, such as those with extremely dense breasts \[27,28]. Dense breast tissue decreases the sensitivity of mammography \[29] and is an independent risk factor for developing breast cancer \[30]. Irrespective of risk category, meta-analyses have demonstrated an incremental increase in CDR of 1.6 to 3.2 per 1,000 screening DBT examinations and a 2.2% pooled decrease in recall rate compared to digital mammography \[21,32,33]. The degree of breast cancer mortality reduction from screening mammography varies with different screening regimens. Mortality reduction is greater when screening begins at 40 years of age rather than 45 or 50 years of age and when screening is done more frequently (annually rather than biennially) \[9-11,34]. Annual screening with DBT led to greater reductions in mortality compared with biennial screening, with 37% median reduction with screening annually from ages 40 to 75 years \[10]. Beginning screening at an earlier age and more frequent screening result in a greater number of imaging studies performed, so these screening regimens also increase the number of false-positive examinations and biopsies \[9-11,35]. Although randomized controlled trials of screening mammography did not enroll females >74 years of age, observational studies demonstrate that some females ≥75 years of age may continue to benefit from screening mammography \[11,35]. There is no upper age limit agreed upon for screening mammography \[5,6,11,35]. Because mortality reduction from screening mammography requires years before being fully attained, screening recommendations should be based upon life expectancy and competing comorbidities, rather than age alone \[11,35-37]. Females should continue screening mammography as long as they remain in overall good health and are willing to undergo the examination and subsequent testing or biopsy, if an abnormality is identified \[5,11]. Within the limited studies of females at elevated risk due to personal and/or family history of breast cancer, DBT decreased recall rate without a significant increase in CDR compared to FFDM; however, small sample sizes restrict analyses \[3,43]. High-risk females due to familial or genetic factors should begin annual screening mammography at age 30 or 10 years prior to the youngest family member who had breast cancer, but generally not before age 30 \[3]. Approximately -third of breast cancers may only be detected on mammography in BRCA2 mutation carriers who are \<40 years of age \[88]. An early modeling study showed that mammography had more risk than benefit in younger females with BRCA mutations thought to be due to dense breast tissues and weakened DNA repair \[89]. DBT显示结合数字乳腺X线摄影视图的重建乳腺断层图像，这些图像可能是从采集的断层合成数据集或FFDM重建的合成乳腺X线照片。与比率相比\[1725]；然而，一些研究未达到统计学显著性\[26]，或在某些女性亚组中发现结果不太令人信服，例如具有极度致密乳腺的女性\[27,28]。致密乳腺组织降低乳腺X线摄影的敏感性\[29]，并且是发生乳腺癌的独立危险因素\[30]。无论风险类别如何，荟萃分析表明，与数字乳腺X线摄影相比，每1,000次DBT筛查检查的CDR增加1.6至3.2，召回率合并降低2.2%\[21,32,33]。筛查乳腺X线摄影对乳腺癌死亡率的降低程度因不同筛查方案而异。从40岁开始筛查而非45或50岁开始筛查，以及更频繁筛查（每年而非每两年一次）时，死亡率降低更大\[911,34]。与每两年一次筛查相比，每年进行DBT筛查导致死亡率降低更大，从40岁到75岁每年筛查的中位降低率为37%\[10]。更早开始筛查和更频繁筛查导致进行的影像学检查数量增加，因此这些筛查方案也增加了假阳性检查和活检的数量\[911,35]。尽管筛查乳腺X线摄影的随机对照试验未纳入74岁女性，但观察性研究表明，一些≥75岁的女性可能继续从筛查乳腺X线摄影中获益\[11,35]。对于筛查乳腺X线摄影没有商定的年龄上限\[5,6,11,35]。因为筛查乳腺X线摄影对死亡率的降低需要多年才能完全实现，筛查建议应基于预期寿命和共存合并症，而非仅基于年龄\[11,3537]。只要女性总体健康状况良好，并且愿意接受检查和后续检测或活检（如果发现异常），就应继续筛查乳腺X线摄影\[5,11]。在针对因个人和/或家族乳腺癌史而风险升高的女性的有限研究中，与FFDM相比，DBT降低了召回率，但CDR没有显著增加；然而，小样本量限制了分析\[3,43]。因家族或遗传因素而高风险的女性应在30岁或比最年轻乳腺癌家族成员发病年龄早10年开始每年筛查乳腺X线摄影，但通常不早于30岁\[3]。在\<40岁的BRCA2突变携带者中，大约三分之一的乳腺癌可能仅在乳腺X线摄影中检测到\[88]。一项早期模型研究表明，对于具有BRCA突变的年轻女性，乳腺X线摄影的风险大于益处，认为这是由于致密乳腺组织和减弱的DNA修复所致\[89]。
* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0005 / R:CR000298
  * 证据强度: StrongReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: MRI has a higher CDR than mammography alone, DBT, or mammography/DBT combined with US \[67-70]. In high-risk females, supplemental screening MRI combined with mammography yields a 91% to 98% sensitivity, although the reported specificity of MRI is typically lower than mammography \[43,96]. The incremental CDR of MRI in elevated-risk females ranges from 8 to 29 per 1,000 females, with higher CDR (26 per 1,000) in BRCA mutation carriers \[67-69,71,72]. Breast MRI detects small, node-negative invasive cancers at earlier tumor stages compared to mammography, as well as ductal carcinoma in situ \[74,75]. Screening MRI also reduces interval cancers \[75]. However, breast MRI has a higher recall rate than mammography (15.1% versus 6.4%) \[76], higher frequency of BI-RADS category 3 assessment than mammography (14.8% versus 11.8%), and a greater frequency In females with a personal history of breast cancer, early detection of second breast cancers improves survival; however, mammographic sensitivity is lower, and interval cancer rates are higher, prompting investigations into supplemental screening regimens in breast cancer survivors \[3,43,72]. In females previously diagnosed with breast cancer \[3], a recent meta-analysis estimated a CDR of 9 to 15 per 1,000 breast MRI \[73]. Due to heterogeneity in the risk of second breast cancer diagnoses, recommendations for supplemental screening MRI vary. Based upon limited modeling data, females with a personal history of breast cancer who were diagnosed before \<50 years of age or females with a personal history of breast cancer and dense breast tissue may have a >20% estimated lifetime risk of a subsequent breast cancer diagnosis and may therefore be considered high risk, warranting supplemental screening breast MRI on an annual basis \[3]. In a prospective observational study of females ≤50 years of age who had undergone breast conservation therapy, supplemental screening MRI increased CDR (8.2 versus 4.4 per 1,000) but had decreased specificity, compared to mammography \[72]. Childhood leukemia or sarcoma survivors treated without chest radiation are also at elevated breast cancer risk; early initiation of annual mammography and breast MRI \<40 years of age would avert 52.6% to 64.3% of breast cancer deaths \[93,95]. Increased risk of breast cancer from other childhood cancers such as non–Hodgkin lymphoma, Wilms tumors, and neuroblastomas has been observed, likely a combination of treatment effects and patient’s underlying genetic factors \[93]. Since 2007, the American Cancer Society has recommended annual breast MRI for breast cancer screening in high- risk females \[4]. The ACR recommends annual breast MRI in high-risk females beginning as early as 25 years of age \[3] . MRI的癌症检出率（CDR）高于单独乳腺X线摄影、数字乳腺断层合成（DBT）或乳腺X线摄影/DBT联合US\[6770]。在高风险女性中，补充筛查MRI联合乳腺X线摄影可达到91%至98%的敏感性，尽管报道的MRI特异性通常低于乳腺X线摄影\[43,96]。高风险女性中MRI的增量CDR为每1000名女性8至29例，其中BRCA突变携带者的CDR更高（每1000名26例）\[6769,71,72]。与乳腺X线摄影相比，乳腺MRI可检测到更早肿瘤分期的小型淋巴结阴性浸润癌以及导管原位癌\[74,75]。筛查MRI还可减少间期癌\[75]。然而，乳腺MRI的召回率高于乳腺X线摄影（15.1%对比6.4%）\[76]，BIRADS 3类评估频率高于乳腺X线摄影（14.8%对比11.8%），且图像引导活检频率更高（11.8%对比2.4%）\[69]。在有个人乳腺癌史的女性中，早期检测第二原发乳腺癌可提高生存率；然而，乳腺X线摄影敏感性较低，间期癌率较高，促使对乳腺癌幸存者的补充筛查方案进行研究\[3,43,72]。在既往诊断为乳腺癌的女性中\[3]，一项近期荟萃分析估计乳腺MRI的CDR为每1000次检查9至15例\[73]。由于第二原发乳腺癌诊断风险的异质性，补充筛查MRI的建议各不相同。基于有限的模型数据，50岁前确诊或有个人乳腺癌史且致密乳腺组织的女性，其后续乳腺癌诊断的预估终生风险可能达20%，因此可视为高风险，需每年进行补充筛查乳腺MRI\[3]。在一项针对≤50岁接受保乳治疗女性的前瞻性观察研究中，与乳腺X线摄影相比，补充筛查MRI提高了CDR（每1000人8.2例对比4.4例），但特异性降低\[72]。未接受胸部放射治疗的儿童期白血病或肉瘤幸存者的乳腺癌风险也升高；40岁前早期开始年度乳腺X线摄影和乳腺MRI可避免52.6%至64.3%的乳腺癌死亡\[93,95]。已观察到其他儿童期癌症（如非霍奇金淋巴瘤、Wilms瘤和神经母细胞瘤）导致乳腺癌风险增加，这可能是治疗效果和患者潜在遗传因素共同作用的结果\[93]。自2007年起，美国癌症协会建议高风险女性每年进行乳腺MRI用于乳腺癌筛查\[4]。ACR建议高风险女性从25岁开始每年进行乳腺MRI\[3]。
* 检查项目: MRI Breast Without and With IV Contrast Abbreviated / MR乳腺(平扫+增强)
  * 评分: 7
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0005 / R:CR000298
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: Data are limited regarding the use of abbreviated breast MRI without and with IV contrast for screening in high- risk females. Following the publication of the American Cancer Society guidelines for supplemental screening breast MRI in 2007, high-risk females have traditionally undergone conventional full protocol breast MRI without and with IV contrast \[3,4]. However, multiple studies have demonstrated similar diagnostic accuracy for abbreviated protocol MRI compared to conventional full protocol breast MRI \[79-81]. In a study evaluating 3,037 abbreviated breast MRI in 1,975 high-risk females, the CDR was 29 per 1,000, the interval cancer rate was 0.66 per 1,000, and all cancers missed by abbreviated breast MRI were node negative early-stage invasive malignancies \[78]. 关于不采用和采用静脉注射对比剂的简化乳腺MRI用于高风险女性筛查的数据有限。自2007年美国癌症协会发布补充性乳腺MRI筛查指南以来，高风险女性传统上接受的是不采用和采用静脉注射对比剂的传统完整乳腺MRI检查\[3,4]。然而，多项研究表明，简化方案MRI与传统完整乳腺MRI相比具有相似的诊断准确性\[79-81]。在一项针对1,975名高风险女性进行的3,037次简化乳腺MRI评估研究中，癌症检出率为每1,000例29例，间期癌症发生率为每1,000例0.66例，且所有被简化乳腺MRI漏诊的癌症均为淋巴结阴性的早期浸润性恶性肿瘤\[78]。
* 检查项目: Mammography With IV Contrast / MG双侧乳腺钼靶导管造影
  * 评分: 5
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0004 / R:CR000300
  * 证据强度: StrongReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Data are limited regarding the use of mammography with IV contrast for breast cancer screening in high-risk females. To date, published studies have predominantly included females with dense breasts and other risk factors resulting in intermediate- or high-risk profiles. Compared to mammography alone, mammography with IV contrast increases sensitivity and cancer detection (incremental CDR = 6.6-13 per 1,000) in females at elevated risk \[62-66]. A recent prospective single institution study of 466 females at elevated risk age 35 years and older who underwent mammography with IV contrast had an incremental cancer detection rate of 23.9 per 1,000 at the prevalence round \[97]. Mammography with IV contrast may be useful in high-risk females as an alternative to MRI. 关于静脉注射造影剂乳腺X线摄影用于高风险女性乳腺癌筛查的数据有限。迄今为止，已发表的研究主要纳入乳腺致密且具有其他风险因素导致中高风险特征的女性。与单纯乳腺X线摄影相比，静脉注射造影剂乳腺X线摄影可提高高风险女性的敏感性和癌症检出率（增量CDR=6.6-13/1000）\[62-66]。近期一项前瞻性单机构研究对466名35岁及以上高风险女性进行静脉注射造影剂乳腺X线摄影，在基线筛查轮次中增量癌症检出率达23.9/1000\[97]。静脉注射造影剂乳腺X线摄影可作为MRI的替代方案用于高风险女性。
* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 5
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0003 / R:CR000301
  * 证据强度: StrongReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: In high-risk females undergoing annual mammography plus annual supplemental screening MRI, the addition of supplemental screening with US does not identify additional cancers and is therefore not routinely performed. Screening US may be useful in high-risk patients as an alternative to MRI. However, high-risk females who do not undergo supplemental screening MRI should be counseled that the CDR of US is inferior to MRI. MRI has a higher CDR than mammography, DBT, or mammography/DBT combined with US \[67-70]. The ACRIN 6666 trial enrolled females with elevated breast cancer risk \[67]. Compared to mammography alone, screening US detected 5.3 cancers per 1,000 in year 1 and 3.7 cancers per 1,000 in years 2 and 3 and resulted in a larger number of false- positive examinations and false-positive biopsies each year \[67]. After 3 consecutive rounds of mammography plus US, the incremental CDR of MRI was 14.7 per 1,000, although false-positive examinations also increased \[67]. In a prospective multicenter study of 687 high-risk females who underwent clinical breast examination, mammography, US, and MRI for screening, the combination of MRI plus mammography maximized the breast for mammography plus US, 14.9 per 1,000 for MRI, 14.9 per 1,000 for MRI plus US, 16 per 1,000 for mammography plus MRI, and 16 per 1,000 for mammography plus US plus MRI \[68]. In a prospective study of BRCA mutation carriers and high-risk females, sensitivity of mammography was 25% and 66% whereas US was 23% and 34%, respectively \[82]. In the high-risk group, mammography combined with biannual US demonstrated 100% sensitivity \[82]; however, MRI was not performed. In a subset analysis of BRCA mutation carriers, MRI sensitivity was 94% \[82]. In another study of 529 high-risk females suspected or proven to carry a deleterious BRCA mutation, the performance of US was also inferior to MRI \[98]. The sensitivity of mammography was 33%, US was 40%, mammography plus US was 49%, and MRI was 91% \[98]. In females with a personal history of breast cancer, supplemental US screening results in an incremental CDR of 2.4 to 2.9 cancers per 1,000 examinations over mammography alone; however, US screening has lower specificity \[13,72]. 对于接受年度乳腺X线摄影加年度补充性MRI筛查的高危女性群体，额外增加超声筛查并不能提高癌症检出率，故不作为常规操作。筛查超声可作为MRI的替代方案用于高危患者。但应告知未接受补充性MRI筛查的高危女性：超声的癌症检出率低于MRI。MRI的癌症检出率高于乳腺X线摄影、数字乳腺断层合成摄影（DBT）或乳腺X线摄影/DBT联合超声\[6770]。ACRIN 6666试验纳入了乳腺癌风险升高的女性\[67]。与单纯乳腺X线摄影相比，筛查超声在第一年检出5.3‰的癌症，第二三年各检出3.7‰的癌症，但每年均导致更多假阳性检查和假阳性活检\[67]。经过三轮乳腺X线摄影联合超声检查后，MRI的增量癌症检出率达14.7‰，尽管假阳性检查也有所增加\[67]。一项对687名高危女性进行临床乳腺检查、乳腺X线摄影、超声和MRI筛查的前瞻性多中心研究显示，MRI联合乳腺X线摄影实现了最高检出率：乳腺X线摄影联合超声为14.9‰，单独MRI为14.9‰，MRI联合超声为14.9‰，乳腺X线摄影联合MRI为16‰，三者联合为16‰\[68]。针对BRCA突变携带者和高危女性的前瞻性研究中，乳腺X线摄影的敏感性分别为25%和66%，而超声分别为23%和34%\[82]。在高危组中，乳腺X线摄影联合半年期超声筛查显示出100%的敏感性\[82]；但该研究未实施MRI。在BRCA突变携带者的亚组分析中，MRI敏感性达94%\[82]。另一项针对529名疑似或确诊携带有害BRCA突变的高危女性的研究也表明超声性能逊于MRI\[98]。乳腺X线摄影敏感性为33%，超声为40%，两者联合为49%，MRI达91%\[98]。对于有乳腺癌个人史的女性，补充超声筛查相比单纯乳腺X线摄影可增加2.42.9‰的增量癌症检出率，但其特异性较低\[13,72]。
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 3
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000302
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: Data are limited regarding the use of sestamibi MBI for screening females at high risk. Most studies have focused upon females with dense breasts and variable risk profiles. Retrospective and prospective studies have demonstrated similar incremental CDR for sestamibi MBI of 6.5 to 9 over mammography, with a study demonstrating an incremental CDR of 16.5 per 1,000 in females at increased risk primarily due to family or personal history of breast cancer \[43,50]. Sestamibi MBI demonstrates similar sensitivity, better specificity, and lower recall rate compared to supplemental screening US in females with dense breasts \[50,51]. 关于使用司他比锝MBI对高风险女性进行筛查的数据有限。大多数研究集中在乳腺致密且风险特征各异的女性群体。回顾性和前瞻性研究显示，与乳腺X线摄影相比，司他比锝MBI可额外检出6.5至9例癌症/千人，其中一项研究证实，在主要因乳腺癌家族史或个人史导致风险增加的女性中，额外检出率达16.5例/千人\[43,50]。对于乳腺致密女性，与补充性超声筛查相比，司他比锝MBI具有相似的敏感性、更优的特异性及更低的召回率\[50,51]。
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000303
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support the use of MRI without IV contrast for screening females at high risk. 目前尚无相关文献支持在不使用静脉造影剂的情况下采用MRI对高风险女性进行筛查。
* 检查项目: MRI Breast Without IV Contrast Abbreviated / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000303
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support the use of abbreviated breast MRI without IV contrast for screening females at high risk. 目前尚无相关文献支持在不使用静脉对比剂的情况下采用简化乳腺MRI对高风险女性进行筛查。

##### S0045 Variant: Variant 4:  Adult female younger than 30 years of age. Breast cancer screening. High risk. | 成人女性，\<30岁。乳腺癌筛查。高风险。

检查推荐列表：

* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 8
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0005 / R:CR000305
  * 证据强度: StrongReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: MRI has a higher CDR than mammography alone, DBT, or mammography/DBT combined with US \[67-70]. In high-risk females, supplemental screening MRI combined with mammography yields a 91% to 98% sensitivity, although the reported specificity of MRI is typically lower than mammography \[43,96]. The incremental CDR of mutation carriers \[67-69,71,72]. Breast MRI detects small, node-negative invasive cancers at earlier tumor stages compared to mammography, as well as ductal carcinoma in situ \[74,75]. Screening MRI also reduces interval cancers \[75]. However, breast MRI has a higher recall rate than mammography (15.1% versus 6.4%) \[76], higher frequency of BI-RADS category 3 assessment than mammography (14.8% versus 11.8%), and a greater frequency of image-guided biopsies than mammography (11.8 versus 2.4%) \[69]. In females with a personal history of breast cancer, early detection of second breast cancers improves survival; however, mammographic sensitivity is lower, and interval cancer rates are higher, prompting investigations into supplemental screening regimens in breast cancer survivors \[3,43,72]. In females previously diagnosed with breast cancer \[3], a recent meta-analysis estimated a CDR of 9 to 15 per 1,000 breast MRI \[73]. Due to heterogeneity in the risk of second breast cancer diagnoses, recommendations for supplemental screening MRI vary. Based upon limited modeling data, females with a personal history of breast cancer who were diagnosed before \<50 years of age or females with a personal history of breast cancer and dense breast tissue may have a >20% estimated lifetime risk of a subsequent breast cancer diagnosis and may therefore be considered high risk, warranting supplemental screening breast MRI on an annual basis \[3]. In a prospective observational study of females ≤50 years of age who had undergone breast conservation therapy, supplemental screening MRI increased CDR (8.2 versus 4.4 per 1,000) but had decreased specificity, compared to mammography \[72]. Childhood leukemia or sarcoma survivors treated without chest radiation are also at elevated breast cancer risk; early initiation of annual mammography and breast MRI \<40 years of age would avert 52.6% to 64.3% of breast cancer deaths \[93,95]. Increased risk of breast cancer from other childhood cancers such as non–Hodgkin lymphoma, Wilms tumors, and neuroblastomas has been observed, likely a combination of treatment effects and patient’s underlying genetic factors \[93]. Since 2007, the American Cancer Society has recommended annual breast MRI for breast cancer screening in high- risk females \[4]. The ACR recommends annual breast MRI in high-risk females beginning as early as 25 years of age \[3] . MRI也被研究用于睾丸癌的分期和监测，以识别转移性腹膜后淋巴结病\[4146]。来自单机构研究的有限证据表明，其检测腹膜后淋巴结病的效能与CT相当，且 notably 无需钆基对比剂（GBCAs）\[41,43]。关于MRI检测转移性腹膜后淋巴结病的文献局限性在于研究较旧且未纳入弥散加权成像（DWI）。DWI可显著改善淋巴结识别；2020年一项研究显示，包含DWI且省略GBCAs的MRI与CT在检测睾丸生殖细胞肿瘤转移性腹膜后淋巴结方面具有相当准确性\[47]。
* 检查项目: MRI Breast Without and With IV Contrast Abbreviated / MR乳腺(平扫+增强)
  * 评分: 7
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0005 / R:CR000305
  * 证据强度: Expert OpinionReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: Data are limited regarding the use of abbreviated breast MRI without and with IV contrast for screening in high- risk females. The studies that have included high-risk females \<30 years of age have not stratified results on this subset of young patients. Following the publication of the American Cancer Society guidelines for supplemental screening breast MRI in 2007, high-risk females have traditionally undergone conventional full protocol breast MRI without and with IV contrast \[3,4]. However, multiple studies have demonstrated similar diagnostic accuracy for abbreviated protocol MRI compared to conventional full protocol breast MRI \[79-81]. In a study evaluating 3,037 abbreviated breast MRI in 1,975 high-risk females, the CDR was 29 per 1,000, the interval cancer rate was 0.66 per 1,000, and all cancers missed by abbreviated breast MRI were node negative early-stage invasive malignancies \[78]. 关于不注射和注射静脉对比剂的简化乳腺MRI用于高风险女性筛查的数据有限。纳入30岁以下高风险女性的研究尚未对这一年轻患者亚群的结果进行分层分析。自2007年美国癌症协会发布补充性乳腺MRI筛查指南以来，高风险女性传统上接受的是不注射和注射静脉对比剂的标准全序列乳腺MRI检查\[3,4]。然而，多项研究表明简化序列MRI与传统全序列乳腺MRI具有相似的诊断准确性\[79-81]。一项针对1,975名高风险女性进行的3,037例简化乳腺MRI研究中，癌症检出率为每1,000例29例，间期癌发生率为每1,000例0.66例，且所有被简化乳腺MRI漏诊的癌症均为淋巴结阴性的早期浸润性恶性肿瘤\[78]。
* 检查项目: Mammography Screening / MG双侧乳腺钼靶
  * 评分: 5
  * 适宜性: May be appropriate (Disagreement) / 可能适宜（存在争议）
  * 编码: P:PR0010
  * 证据强度: Expert OpinionReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: To date, mammography is the only screening modality shown to decrease breast cancer mortality. Multiple randomized controlled trials demonstrate that invitation to screening mammography results in at least a 22% reduction in breast cancer mortality \[38]. For example, after 29 years of follow-up, the Swedish Two-County trial demonstrated a 27% to 31% reduction in breast cancer mortality in 133,065 females 40 to 74 years of age invited to screening despite use of single view mammography and the 24 to 33 month interval between subsequent screenings \[1]. Randomized controlled trials of screening mammography in which advanced stage breast cancers decreased by 20% or more demonstrate even greater reductions in breast cancer mortality \[11]. Observational studies, including those from population-based service screening programs, also demonstrate larger reductions in breast cancer mortality (≥40%) in females who were actually screened \[11,38]. In addition to mortality reduction, screening mammography decreases treatment morbidity, because screen-detected tumors are typically lower stage (eg, smaller and more likely to be node-negative), compared to breast cancers detected by palpation \[2,11]. Despite these benefits, screening mammograms also have risks. The most common perceived risks include false-positive recalls and biopsies, overdiagnosis \[5,7,35], and patient anxiety. Approximately 10% of screening mammograms result in a recall for additional imaging, although \<2% result in a recommendation for percutaneous biopsy following additional imaging \[11]. Overdiagnosis refers to breast cancers that are detected by screening that would not have otherwise become apparent during the patient’s lifetime. The reported frequency of overdiagnosis varies widely in the published literature due to important underlying differences in study methodology. Overdiagnosis estimates that do not account for breast cancer risk, trends in breast cancer incidence, or lead time bias range from 0% to 54%, whereas adjusted estimates range from 1% to 10% \[39,40]. Overdiagnosis estimates increase with age at screening \[39,40]. Although the risks of screening may impact uptake and adherence to screening mammography, prior research has shown that females value early detection of breast cancer over false-positives and screening-related anxiety \[11]. Despite the established mortality benefit, published guidelines differ in their recommendations for screening mammography due to variations in the perceptions of the relative risks and benefits \[5,41]. Annual screening mammography results in a greater reduction in mortality compared to biennial screening \[10,11]. In females 40 to 84 years of age, annual screening reduces mortality by 40%, compared to a 32% reduction for biennial screening \[35]. With regular screening, interval breast cancers do occur with a higher frequency in females decreased in some groups of females, including those with dense breasts \[43]. Dense breast tissue decreases the 迄今为止，乳腺X线摄影是唯一被证明可降低乳腺癌死亡率的筛查方法。多项随机对照试验表明，接受筛查乳腺X线摄影邀请可使乳腺癌死亡率至少降低22%\[38]。例如，经过29年随访，瑞典双县试验显示，在133,065名40至74岁接受筛查的女性中，尽管采用单视图乳腺X线摄影且筛查间隔为24至33个月，乳腺癌死亡率降低了27%至31%\[1]。在高级别乳腺癌减少20%或以上的筛查乳腺X线摄影随机对照试验中，乳腺癌死亡率的降低幅度更大\[11]。观察性研究（包括基于人群的服务筛查项目）也显示，实际接受筛查的女性乳腺癌死亡率降低幅度更大（≥40%）\[11,38]。除降低死亡率外，筛查乳腺X线摄影还可降低治疗相关发病率，因为与触诊发现的乳腺癌相比，筛查发现的肿瘤通常分期更低（例如体积更小且更可能淋巴结阴性）\[2,11]。尽管存在这些益处，筛查性乳腺X线摄影也存在风险。最常见的感知风险包括假阳性召回和活检、过度诊断\[5,7,35]以及患者焦虑。约10%的筛查性乳腺X线摄影会导致召回进行额外影像学检查，尽管其中仅\<2%需要在额外影像学检查后建议经皮活检\[11]。过度诊断指通过筛查检测出、否则在患者有生之年不会显现的乳腺癌。由于研究方法学存在重要差异
* 检查项目: Digital Breast Tomosynthesis Screening / MG双侧乳腺钼靶(筛查)
  * 评分: 5
  * 适宜性: May be appropriate (Disagreement) / 可能适宜（存在争议）
  * 编码: P:PR0001 / R:CR000307
  * 证据强度: Expert OpinionReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: DBT displays reconstructed stacked images of the breast in combination with digital mammographic views, which may be synthetic mammograms reconstructed from the acquired tomosynthesis data set or FFDM. Compared to FFDM or synthetic mammograms alone, most studies demonstrate that DBT increases CDR and decreases recall rate \[17-25]; although, some studies have not reached statistical significance \[26] or have found less compelling results in subsets of females, such as those with extremely dense breasts \[27,28]. Dense breast tissue decreases the sensitivity of mammography \[29] and is an independent risk factor for developing breast cancer \[30]. Irrespective of risk category, meta-analyses have demonstrated an incremental increase in CDR of 1.6 to 3.2 per 1,000 screening DBT examinations and a 2.2% pooled decrease in recall rate compared to digital mammography \[21,32,33]. Data regarding mortality reduction from screening mammography in females \<30 years of age is limited and extrapolated from available data for older age groups. Within the limited studies of females at elevated risk due to personal and/or family history of breast cancer, DBT decreased recall rate without a significant increase in CDR compared to FFDM; however, small sample sizes restrict High-risk females due to familial or genetic factors should begin annual screening mammography at age 30 or 10 years prior to the youngest family member who had breast cancer, but generally not before age 30 \[3]. Approximately -third of breast cancers may only be detected on mammography in BRCA2 mutation carriers who are \<40 years of age \[88]. An early modeling study showed that mammography had more risk than benefit in younger females with BRCA mutations thought to be due to dense breast tissues and weakened DNA repair \[89]. In a prospective cohort study including 8,782 high-risk females, the benefit of adding mammography to MRI in mutation carriers 30 to 39 years of age was small, as the sensitivity of mammography plus MRI was comparable to MRI alone (100% versus 96.8%) in mutation carriers \[90]. In females 50 to 69 years of age, combining MRI and mammography statistically significantly increased sensitivity compared with MRI alone (96.3% versus 90.9%) \[90]. In a study of 2,157 females 25 to 75 years of age, >15% lifetime risk, including 599 mutation carriers, MRI sensitivity was much higher than mammography in 24 BRCA1 patients (67% versus 25%) and slightly higher in 13 BRCA2 patients (69% versus 62%) \[91]. Therefore, in some mutation carriers, some referring providers use mammography or DBT beginning at 40 years of age if patients undergo annual MRI \[92]. High-risk females due to thoracic or upper abdominal radiation therapy at an early age should begin screening mammography 8 years after radiation therapy but not before 25 years of age \[3,93,94]. Childhood leukemia or sarcoma survivors treated without chest radiation are also at elevated breast cancer risk; early initiation of annual mammography and breast MRI \<40 years of age would avert 52.6% to 64.3% of breast cancer deaths \[93,95]. 数字乳腺断层合成（DBT）结合数字乳腺X线摄影视图显示重建的乳腺分层图像，这些视图可能是从采集的断层合成数据集重建的合成乳腺X线影像或全视野数字乳腺X线摄影（FFDM）。与单独使用FFDM或合成乳腺X线影像相比，多数研究表明DBT可提高癌症检出率（CDR）并降低召回率\[1725]；尽管部分研究未达到统计学显著性\[26]或在某些亚组女性（如乳腺极度致密者）中发现结果说服力较低\[27,28]。致密乳腺组织会降低乳腺X线摄影的敏感性\[29]且是发生乳腺癌的独立风险因素\[30]。不论风险类别如何，荟萃分析表明与数字乳腺X线摄影相比，DBT筛查的增量CDR为每千例1.6至3.2例，召回率汇总降低2.2%\[21,32,33]。关于30岁以下女性筛查乳腺X线摄影降低死亡率的数据有限，系从老年组可用数据外推而来。在因个人和/或家族乳腺癌史而风险升高的女性有限研究中，与FFDM相比，DBT降低了召回率但未显著增加CDR；然而小样本量限制了结论。因家族或遗传因素所致高风险女性应从30岁或比最年轻家族乳腺癌患者发病年龄早10年开始年度筛查乳腺X线摄影，但通常不早于30岁\[3]。约三分之一乳腺癌在40岁以下BRCA2突变携带者中可能仅通过乳腺X线摄影检测\[88]。早期模型研究表明，对于具有BRCA突变的年轻女性，乳腺X线摄影的风险大于获益，认为与致密乳腺组织和DNA修复能力减弱有关\[89]。一项包含8,782名高风险女性的前瞻性队列研究表明，在30至39岁突变携带者中，乳腺X线摄影
* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 5
  * 适宜性: May be appropriate (Disagreement) / 可能适宜（存在争议）
  * 编码: P:PR0003 / R:CR000309
  * 证据强度: Expert OpinionReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: In high-risk females undergoing annual mammography plus annual supplemental screening MRI, the addition of supplemental screening with US does not identify additional cancers and is therefore not routinely performed. The studies that have included high risk females less than age 30 have had small numbers of patients less than age 30 and have not stratified data by this subset. Screening US may be useful in high-risk patients as an alternative to MRI. However, high-risk females who do not undergo supplemental screening MRI should be counseled that the CDR of US is inferior to MRI. MRI has a higher CDR than mammography, DBT, or mammography/DBT combined with US \[67-70]. The ACRIN 6666 trial 5.3 cancers per 1,000 in year 1 and 3.7 cancers per 1,000 in years 2 and 3 and resulted in a larger number of false- positive examinations and false-positive biopsies each year \[67]. After 3 consecutive rounds of mammography plus US, the incremental CDR of MRI was 14.7 per 1,000, although false-positive examinations also increased \[67]. In a prospective multicenter study of 687 high-risk females who underwent clinical breast examination, mammography, US, and MRI for screening, the combination of MRI plus mammography maximized the breast cancers detected \[68]. Mammography identified 5 cancers per 1,000 compared to 6 per 1,000 for US, 7.7 per 1,000 for mammography plus US, 14.9 per 1,000 for MRI, 14.9 per 1,000 for MRI plus US, 16 per 1,000 for mammography plus MRI, and 16 per 1,000 for mammography plus US plus MRI \[68]. In a prospective study of BRCA mutation carriers and high-risk females, sensitivity of mammography was 25% and 66% whereas US was 23% and 34%, respectively \[82]. In the high-risk group, mammography combined with biannual US demonstrated 100% sensitivity \[82]; however, MRI was not performed. In a subset analysis of BRCA mutation carriers, MRI sensitivity was 94% \[82]. In another study of 529 high-risk females suspected or proven to carry a deleterious BRCA mutation, the performance of US was also inferior to MRI \[98]. The sensitivity of mammography was 33%, US was 40%, mammography plus US was 49%, and MRI was 91% \[98]. In females with a personal history of breast cancer, supplemental US screening results in an incremental CDR of 2.4 to 2.9 cancers per 1,000 examinations over mammography alone; however, US screening has lower specificity \[13,72]. 对于接受年度乳腺X线摄影加年度补充性MRI筛查的高危女性，额外增加超声补充筛查并不能发现更多癌症，因此不作为常规操作。纳入30岁以下高危女性的研究样本量较小，且未按此亚组进行数据分层。对于高危患者，筛查超声可作为MRI的替代方法。然而，应向未接受补充性MRI筛查的高危女性说明超声的癌症检出率（CDR）低于MRI。MRI的CDR高于乳腺X线摄影、数字乳腺断层合成（DBT）或乳腺X线摄影/DBT联合超声\[6770]。ACRIN 6666试验显示第一年每1000例检出5.3例癌症，第二和第三年每1000例检出3.7例癌症，但每年均导致大量假阳性检查和假阳性活检\[67]。在连续三轮乳腺X线摄影联合超声筛查后，MRI的增量CDR为每1000例14.7例，但假阳性检查也有所增加\[67]。一项对687名高危女性进行临床乳腺检查、乳腺X线摄影、超声和MRI筛查的前瞻性多中心研究中，MRI联合乳腺X线摄影最大程度地检测出乳腺癌\[68]。乳腺X线摄影每1000例检出5例癌症，超声为6例，乳腺X线摄影联合超声为7.7例，MRI为14.9例，MRI联合超声为14.9例，乳腺X线摄影联合MRI为16例，乳腺X线摄影联合超声加MRI为16例\[68]。一项针对BRCA突变携带者和高危女性的前瞻性研究中，乳腺X线摄影的敏感性分别为25%和66%，而超声分别为23%和34%\[82]。在高危组中，乳腺X线摄影联合半年一次超声显示100%的敏感性\[82]；但未进行MRI。在BRCA突变携带者的亚组分析中，MRI敏感性为94%\[82]。另一项针对529名疑似或证实携带有害BRCA突变的高危女性的研究中，超声的性能也逊于MRI\[98]。乳腺X线摄影的敏感性为33%，超声为40%，乳腺X线摄影联合超声为49%，MRI为91%\[98]。在有个人乳腺癌史的女性中，补充超声筛查相比单独乳腺X线摄影每1000次检查可增加2.4至2.9例癌症的增量CDR；但超声筛查的特异性较低\[13,72]。
* 检查项目: Mammography With IV Contrast / MG双侧乳腺钼靶导管造影
  * 评分: 2
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0004 / R:CR000310
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of mammography with IV contrast for screening females at high risk \<30 year of age. 目前尚无相关文献支持对30岁以下高风险女性使用静脉造影乳腺X线摄影进行筛查。
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000311
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support the use of MRI without IV contrast for screening females at high risk less than age 30. 目前尚无相关文献支持对30岁以下高风险女性使用无静脉注射对比剂的MRI进行筛查。
* 检查项目: MRI Breast Without IV Contrast Abbreviated / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000311
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support the use of abbreviated breast MRI without IV contrast for screening females at high risk less than age 30. 目前尚无相关文献支持对30岁以下高风险女性使用无静脉对比剂的简化乳腺MRI进行筛查。
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000313
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of sestamibi MBI for screening females at high risk less than age 30. 目前尚无相关文献支持将司他比锝MBI用于30岁以下高风险女性的筛查。

#### T0008 Imaging after Breast Surgery | 乳腺术后影像学检查

* 主题编码: T0008

##### S0046 Variant: Variant 1:  Female. Age 40 years or older. Postsurgical excision with nonmalignant pathology. Asymptomatic. Initial imaging. | 女性，≥40岁，术后切除且病理学良性，无症状，初始影像学检查。

检查推荐列表：

* 检查项目: Mammography Screening / MG双侧乳腺钼靶
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0010 / R:CR000317
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: The ACR and SBI recommend all asymptomatic women ≥40 years of age undergo annual screening mammography, even if they are average risk \[1,8,17]. Please refer to the ACR Appropriateness Criteria ® topic on “ Breast Cancer Screening ” \[8]. Women in this clinical scenario should undergo annual screening mammography. One study of more than 2 million screening mammograms in nearly 800,000 women, with 15% having a self- reported history of prior benign percutaneous or excisional breast biopsy, showed no difference in mammographic sensitivity; however, there was decreased in specificity and mammographic performance, which was attributed to tissue characteristics rather than the biopsy itself \[18]. Another study comparing patients with history of proliferative lesions with atypia with matched screenings based on age, density, and breast cancer family history also found no differences in mammographic sensitivity or proportion of interval cancers; however, they also reported lower specificity in the atypical proliferative lesions group \[19]. 美国放射学会（ACR）和乳腺影像学会（SBI）建议所有≥40岁的无症状女性每年接受乳腺X线筛查，即使其风险水平为平均风险\[1,8,17]。具体请参阅ACR适宜性标准®中关于"乳腺癌筛查"的专题内容\[8]。本临床情境中的女性应每年进行乳腺X线筛查。一项针对近80万女性（其中15%有自述的经皮或切除乳腺良性活检史）的200多万次乳腺X线筛查研究表明：虽然乳腺X线敏感度无差异，但特异度和检查效能有所降低——这归因于组织特性而非活检本身\[18]。另一项针对非典型增生性病变患者（根据年龄、乳腺密度及乳腺癌家族史进行匹配筛查）的研究同样显示：乳腺X线敏感度和间期癌比例无差异，但非典型增生性病变组的特异度较低\[19]。
* 检查项目: Digital Breast Tomosynthesis Screening / MG双侧乳腺钼靶(筛查)
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0001 / R:CR000314
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: The ACR and Society of Breast Imaging (SBI) recommend all asymptomatic women ≥40 years of age undergo annual screening mammography, even if they are average risk \[1,8,17]. Please refer to the ACR Appropriateness Criteria ® topic on “ Breast Cancer Screening ” \[8]. Women in this clinical scenario should undergo annual screening mammography. One study of more than 2 million screening mammograms in nearly 800,000 women, with 15% having a self- reported history of prior benign percutaneous or excisional breast biopsy, showed no difference in mammographic sensitivity; however, there was decreased specificity and mammographic performance, which was attributed to tissue characteristics rather than the biopsy itself \[18]. Another study comparing patients with history of proliferative lesions with atypia with matched screenings based on age, density, and breast cancer family history also found no differences in mammographic sensitivity or proportion of interval cancers; however, they also reported lower specificity in the atypical proliferative lesions group \[19]. 美国放射学会（ACR）与乳腺影像学会（SBI）建议所有40岁以上无症状女性每年接受乳腺X线筛查，即使其属于平均风险人群\[1,8,17]。具体可参阅ACR适用标准中"乳腺癌筛查"专题\[8]。本临床情境中的女性应进行年度乳腺X线筛查。一项针对近80万女性（其中15%有自述良性经皮或切除性乳腺活检史）超过200万次乳腺X线筛查的研究显示：乳腺X线敏感度无差异，但特异度和检查效能降低，这与组织特性（而非活检本身）相关\[18]。另一项针对非典型增生性病变患者（根据年龄、乳腺密度及乳腺癌家族史进行匹配筛查）的研究同样发现：乳腺X线敏感度或间期癌比例无统计学差异，但非典型增生组特异度较低\[19]。
* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 5
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0005 / R:CR000316
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support the routine use of MRI breast without and with intravenous (IV) contrast in an average-risk patient. Some benign breast diseases, especially atypical ductal hyperplasia and lobular neoplasia can increase a woman’s overall risk for developing breast cancer. In these situations, the use of MRI breast without and with IV contrast may be warranted. Please refer to the ACR Appropriateness Criteria ® topics on “ Breast Cancer Screening ” \[8] and “ Supplemental Breast Cancer Screening Based on Breast Density ” \[9] and the ACR recommendations on screening in women at higher-than-average risk \[10]. 目前尚无相关文献支持对一般风险患者常规使用无静脉注射（IV）对比剂及含IV对比剂的乳腺MRI检查。某些良性乳腺疾病（尤其是不典型导管增生和小叶肿瘤）可能增加女性罹患乳腺癌的总体风险。此类情况下，可考虑采用无IV对比剂及含IV对比剂的乳腺MRI检查。请参阅ACR适宜性标准®专题《乳腺癌筛查》\[8]、《基于乳腺密度的补充乳腺癌筛查》\[9]以及ACR针对高于平均风险女性的筛查建议\[10]。
* 检查项目: Digital Breast Tomosynthesis Diagnostic / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000317
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the routine use of diagnostic digital breast tomosynthesis (DBT) in this clinical scenario. Women in this clinical scenario are asymptomatic and should undergo screening mammography or tomosynthesis \[8]. Some benign breast diseases, with or without other factors, can increase a woman’s risk to higher-than-average risk. For screening guidelines based on overall risk for breast cancer, please refer to the ACR Appropriateness Criteria ® topics on “ Breast Cancer Screening ” \[8] and “ Supplemental Breast Cancer Screening Based on Breast Density ” \[9] and the ACR recommendations on screening in women at higher-than-average risk \[10]. Although there are no relevant studies examining mammographic follow-up intervals of benign breast disease following surgical biopsy, there are some studies examining imaging intervals following benign core biopsy. In populations with nonproliferative lesions or proliferative lesions without atypia, imaging intervals of 6 months compared to routine annual screening did not improve cancer detection rates or change invasive cancer rates, stage, tumor size, or nodal status \[11,12]. The studies on proliferative lesions with atypia, examining the need for excision and, if not excised, need for short interval follow-up, are varied \[13-16] and are outside the scope of this document. Atypical ductal hyperplasia on core biopsy typically warrants surgical consultation and/or multidisciplinary discussion regarding the benefits and risks of subsequent excision. There is more varied practice in management of atypical lobular hyperplasia, LCIS, and flat epithelial atypia found on core biopsy. 目前尚无相关文献支持在此临床情境中常规使用诊断性数字乳腺断层合成摄影（DBT）。该临床情境中的女性无症状，应接受乳腺X线筛查或断层合成摄影检查\[8]。某些良性乳腺疾病（无论是否合并其他因素）可能使女性的乳腺癌风险升高至高于平均水平。关于基于乳腺癌总体风险的筛查指南，请参阅ACR适宜性标准®专题《乳腺癌筛查》\[8]、《基于乳腺密度的补充乳腺癌筛查》\[9]以及ACR针对高于平均风险女性的筛查建议\[10]。虽然尚无相关研究探讨手术活检后良性乳腺疾病的乳腺X线随访间隔，但已有部分研究评估了良性空心针活检后的影像学随访间隔。对于非增生性病变或无非典型性的增生性病变人群，6个月的影像学随访间隔与常规年度筛查相比，并未提高癌症检出率或改变浸润性癌发生率、分期、肿瘤大小或淋巴结状态\[11,12]。关于伴非典型性的增生性病变（探讨是否需要手术切除，若未切除则是否需要短期随访）的研究结果各异\[13-16]，不在本文件讨论范围内。空心针活检发现非典型导管增生通常需要外科会诊和/或多学科讨论以评估后续切除的获益与风险。对于空心针活检发现的非典型小叶增生、小叶原位癌及平坦型上皮非典型性的处理方式则存在更大差异。
* 检查项目: Mammography Diagnostic / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000317
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the routine use of diagnostic mammography in this clinical scenario. Women in this clinical scenario are asymptomatic and should undergo screening mammography or tomosynthesis \[8]. Some benign breast diseases, with or without other factors, can increase a woman’s risk to higher-than-average risk. For screening guidelines based on overall risk for breast cancer, please refer to the ACR Appropriateness Criteria ® topics on “ Breast Cancer Screening ” \[8] and “ Supplemental Breast Cancer Screening Based on Breast Density ” \[9] and the ACR recommendations on screening in women at higher-than-average risk \[10]. Although there are no relevant studies examining mammographic follow-up intervals of benign breast disease following surgical biopsy, there are some studies examining imaging intervals following benign core biopsy. In populations with nonproliferative lesions or proliferative lesions without atypia, imaging intervals of 6 months compared with routine annual screening did not improve cancer detection rates or change invasive cancer rates, excision and, if not excised, the need for short interval follow-up, are varied \[13-16,20] and are outside the scope of this document. A majority agree that there is a need for surgical excision when atypical ductal hyperplasia is found on core biopsy. There is more varied practice in management of atypical lobular hyperplasia, LCIS, and flat epithelial atypia found on core biopsy. 目前尚无相关文献支持在此临床情境中常规使用诊断性乳腺X线摄影。该临床情境中的女性无症状，应接受筛查性乳腺X线摄影或断层合成摄影\[8]。某些良性乳腺疾病，无论是否伴有其他因素，都可能使女性风险升高至高于平均水平。关于基于乳腺癌总体风险的筛查指南，请参阅ACR适宜性标准专题“乳腺癌筛查”\[8]和“基于乳腺密度的补充性乳腺癌筛查”\[9]，以及ACR关于高于平均风险女性筛查的建议\[10]。尽管尚无相关研究探讨外科活检后良性乳腺疾病的乳腺X线随访间隔，但存在一些研究探讨良性空心针活检后的影像学随访间隔。在非增生性病变或无非典型性的增生性病变人群中，6个月的影像学间隔与常规年度筛查相比，并未提高癌症检出率或改变浸润癌发生率；切除指征以及未切除时是否需要短期间隔随访存在差异\[1316,20]，且超出本文档范围。多数共识认为空心针活检发现非典型导管增生时需要手术切除。对于空心针活检发现的非典型小叶增生、小叶原位癌和平坦上皮非典型性的处理方式则存在较大差异。
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000320
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support the use of MRI breast without IV contrast for screening in this clinical scenario. 目前尚无相关文献支持在此临床情况下使用无静脉对比剂的乳腺MRI进行筛查。
* 检查项目: FDG-PET Breast Dedicated / PET/CT局部(胸部)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0016 / R:CR000318
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of fluorine-18-2-fluoro-2-deoxy-D-glucose (FDG)-PET breast imaging in this clinical scenario. 目前尚无相关文献支持氟-18-2-氟-2-脱氧-D-葡萄糖（FDG）-PET乳腺显像在该临床场景中的应用。
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000321
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of Tc-99m sestamibi molecular breast imaging (MBI) in this clinical scenario. 目前尚无相关文献支持在此临床情境下使用锝-99m甲氧异丁基异腈（Tc-99m sestamibi）分子乳腺成像（MBI）。
* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0003 / R:CR000322
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support the routine use of breast ultrasound (US) in this clinical scenario. Some benign breast disease, especially atypical ductal hyperplasia and lobular neoplasia can increase a woman’s overall risk for developing breast cancer. Please refer to the ACR Appropriateness Criteria ® topics on “ Breast Cancer Screening ” \[8] and “ Supplemental Breast Cancer Screening Based on Breast Density ” \[9] and the ACR recommendations on screening in women at higher-than-average risk \[10]. 目前尚无相关文献支持在此临床情况下常规使用乳腺超声检查。某些良性乳腺疾病，尤其是非典型导管增生和小叶肿瘤，可能增加女性罹患乳腺癌的总体风险。请参阅ACR适宜性标准®中关于"乳腺癌筛查"\[8]和"基于乳腺密度的补充乳腺癌筛查"\[9]的主题，以及ACR对高于平均风险女性的筛查建议\[10]。

##### S0047 Variant: Variant 2:  Female. Age 30 to 39 years. Postsurgical excision with nonmalignant pathology. Asymptomatic. Initial imaging. | 女性，年龄30至39岁。术后切除伴非恶性病理。无症状。初始影像学检查。

检查推荐列表：

* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 5
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0005 / R:CR000323
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support the routine use of MRI breast without and with IV contrast in an average- risk patient. Some benign breast disease, especially atypical ductal hyperplasia and lobular neoplasia can increase a woman’s overall risk for developing breast cancer. In these situations, the use of MRI breast without and with IV contrast may be warranted. Please refer to the ACR Appropriateness Criteria ® topics on “ Breast Cancer Screening ” \[8] and “ Supplemental Breast Cancer Screening Based on Breast Density ” \[9] and the ACR recommendations on screening in women at higher-than-average risk \[10]. 目前尚无相关文献支持对一般风险患者常规使用无静脉注射对比剂及静脉注射对比剂的乳腺MRI检查。某些良性乳腺疾病（尤其是不典型导管增生和小叶肿瘤）可能增加女性罹患乳腺癌的总体风险。在此类情况下，可考虑采用无静脉注射对比剂及静脉注射对比剂的乳腺MRI检查。请参阅ACR适宜性标准®专题《乳腺癌筛查》\[8]和《基于乳腺密度的补充乳腺癌筛查》\[9]，以及ACR关于高于平均风险女性筛查的建议\[10]。
* 检查项目: Mammography Screening / MG双侧乳腺钼靶
  * 评分: 4
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0010 / R:CR000326
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the routine use of screening mammography in an average-risk patient. The ACR and SBI recommend asymptomatic average-risk women undergo annual screening mammography starting at age 40 \[1,8,17]. Women in this clinical scenario should undergo age and risk appropriate screening. Some benign breast diseases, with or without other risk factors, can increase a woman’s risk to higher-than-average risk. In these patients, mammography may be warranted at an earlier age before 40. For screening guidelines based on overall risk for breast cancer, please refer to the ACR Appropriateness Criteria ® topics on “ Breast Cancer Screening ” \[8] and “ Supplemental Breast Cancer Screening Based on Breast Density ” \[9] and the ACR recommendations on screening in women at higher-than-average risk \[10]. 目前尚无相关文献支持对平均风险患者常规进行乳腺X线筛查。美国放射学会（ACR）和乳腺影像学会（SBI）建议无症状平均风险女性从40岁开始每年接受乳腺X线筛查\[1,8,17]。此类临床情况下的女性应根据年龄和风险程度接受相应筛查。某些良性乳腺疾病（无论是否伴有其他风险因素）可能使女性的乳腺癌风险高于平均水平。对于这类患者，可能需要提前至40岁前进行乳腺X线检查。关于基于乳腺癌总体风险的筛查指南，请参阅ACR适宜性标准®专题《乳腺癌筛查》\[8]和《基于乳腺密度的补充乳腺癌筛查》\[9]，以及ACR针对高于平均风险女性的筛查建议\[10]。
* 检查项目: Digital Breast Tomosynthesis Screening / MG双侧乳腺钼靶(筛查)
  * 评分: 4
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0001 / R:CR000324
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the routine use of screening DBT in an average-risk patient. The ACR and SBI recommend asymptomatic average-risk women undergo annual screening mammography starting at age 40 \[1,8,17]. Women in this clinical scenario should undergo age and risk appropriate screening. Some benign breast diseases, with or without other risk factors, can increase a woman’s risk to higher-than-average risk. In these patients, mammography may be warranted at an earlier age before 40. For screening guidelines based on overall risk for breast cancer, please refer to the ACR Appropriateness Criteria ® topics on “ Breast Cancer Screening ” \[8] and “ Supplemental Breast Cancer Screening Based on Breast Density ” \[9] and the ACR recommendations on screening in women at higher-than-average risk \[10]. 目前尚无相关文献支持对平均风险患者常规使用筛查性数字乳腺断层合成摄影（DBT）。美国放射学会（ACR）和乳腺影像学会（SBI）建议无症状平均风险女性从40岁开始每年进行筛查性乳腺X线摄影检查\[1,8,17]。此类临床情况下的女性应接受与年龄和风险相匹配的筛查。某些良性乳腺疾病（无论是否伴有其他风险因素）可能使女性的乳腺癌风险升高至高于平均水平。对于这类患者，可能需要考虑在40岁之前提前开始乳腺X线检查。关于基于乳腺癌总体风险的筛查指南，请参阅ACR适宜性标准®专题《乳腺癌筛查》\[8]和《基于乳腺密度的补充性乳腺癌筛查》\[9]，以及ACR针对高于平均风险女性的筛查建议\[10]。
* 检查项目: Digital Breast Tomosynthesis Diagnostic / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000326
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the routine use of diagnostic DBT in this clinical scenario. Diagnostic imaging is not typically used for asymptomatic women. Women in this clinical scenario should undergo age- and risk-appropriate screening. Some benign breast diseases, with or without other risk factors, can increase a woman’s risk to higher-than-average risk. In these patients, mammography may be warranted at an earlier age before 40. For screening guidelines based on overall risk for breast cancer, please refer to the ACR Appropriateness Criteria ® topics on “ Breast Cancer Screening ” \[8] and “ Supplemental Breast Cancer Screening Based on Breast Density ” \[9] and the ACR recommendations on screening in women at higher-than-average \[10]. 目前尚无相关文献支持在此临床情况下常规使用诊断性数字乳腺断层合成摄影（DBT）。诊断性影像学检查通常不适用于无症状女性。此类临床情况下的女性应接受与其年龄和风险相适应的筛查。某些良性乳腺疾病（无论是否伴有其他风险因素）可能使女性的风险高于平均水平。对于这些患者，可能在40岁之前就需要进行乳腺X线摄影检查。关于基于乳腺癌总体风险的筛查指南，请参阅美国放射学会（ACR）适宜性标准®中关于"乳腺癌筛查"\[8]和"基于乳腺密度的补充乳腺癌筛查"\[9]的主题，以及ACR对高于平均风险女性的筛查建议\[10]。
* 检查项目: Mammography Diagnostic / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000326
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the routine use of diagnostic mammography in this clinical scenario. Diagnostic imaging is not typically used for asymptomatic women. Women in this clinical scenario should undergo age- and risk-appropriate screening. Some benign breast diseases, with or without other risk factors, can increase a woman’s risk to higher-than-average risk. In these patients, mammography may be warranted at an earlier age before 40. For screening guidelines based on overall risk for breast cancer, please refer to the ACR Appropriateness Criteria ® topics on “ Breast Cancer Screening ” \[8] and “ Supplemental Breast Cancer Screening Based on Breast Density ” \[9] and the ACR recommendations on screening in women at higher-than-average risk \[10]. 目前尚无相关文献支持在此临床情况下常规使用诊断性乳腺X线摄影。诊断性影像学检查通常不适用于无症状女性。此类临床情况下的女性应接受与其年龄和风险相适应的筛查。某些良性乳腺疾病，无论是否伴有其他风险因素，可能使女性的乳腺癌风险高于平均水平。对于这些患者，可能需要在40岁之前更早开始乳腺X线摄影检查。关于基于乳腺癌总体风险的筛查指南，请参阅ACR适宜性标准®中"乳腺癌筛查"\[8]和"基于乳腺密度的补充乳腺癌筛查"\[9]专题，以及ACR对高于平均风险女性的筛查建议\[10]。
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000329
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support the use of MRI breast without IV contrast for screening in this clinical scenario. 目前尚无相关文献支持在此临床情况下使用无静脉对比剂的乳腺MRI进行筛查。
* 检查项目: FDG-PET Breast Dedicated / PET/CT局部(胸部)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0016 / R:CR000327
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of FDG-PET breast in this clinical scenario. 目前尚无相关文献支持在此临床情况下使用FDG-PET乳腺检查。
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000330
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of Tc-99m sestamibi MBI in this clinical scenario. 目前尚无相关文献支持在此临床情境中使用锝-99m甲氧异丁基异腈（MBI）。
* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0003 / R:CR000331
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support the routine use of breast US for surveillance in this clinical scenario. Some risk for developing breast cancer. Please refer to the ACR Appropriateness Criteria ® topics on “ Breast Cancer Screening ” \[8] and “ Supplemental Breast Cancer Screening Based on Breast Density ” \[9] and the ACR recommendations on screening in women at higher-than-average risk \[10]. 目前尚无相关文献支持在此临床情境中常规使用乳腺超声进行监测。存在一定的乳腺癌发生风险。请参阅ACR适宜性标准专题“乳腺癌筛查”\[8]和“基于乳腺密度的补充性乳腺癌筛查”\[9]，以及ACR关于高于平均风险女性筛查的建议\[10]。

##### S0048 Variant: Variant 3:  Adult female younger than 30 years of age. Postsurgical excision with nonmalignant pathology. Asymptomatic. Initial imaging. | 成人女性，\<30岁。术后切除且病理为非恶性。无症状。初始影像学检查。

检查推荐列表：

* 检查项目: Digital Breast Tomosynthesis Diagnostic / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000332
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the routine use of diagnostic DBT in this clinical scenario. Diagnostic imaging is not typically used for asymptomatic women. Women in this clinical scenario should undergo age- and risk-appropriate screening. For screening guidelines based on overall risk for breast cancer, please refer to the ACR Appropriateness Criteria ® topics on “ Breast Cancer Screening ” \[8] and “ Supplemental Breast Cancer Screening Based on Breast Density ” \[9] and the ACR recommendations on screening in women at higher-than-average risk \[10]. 目前尚无相关文献支持在此临床情境中常规使用诊断性数字乳腺断层合成技术（DBT）。诊断性影像学检查通常不适用于无症状女性。此类临床情境下的女性应接受与其年龄和风险相适应的筛查。有关基于乳腺癌总体风险的筛查指南，请参阅美国放射学会（ACR）适宜性标准®中关于"乳腺癌筛查"\[8]和"基于乳腺密度的补充乳腺癌筛查"\[9]的主题，以及ACR针对高于平均风险女性的筛查建议\[10]。
* 检查项目: Mammography Diagnostic / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000332
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the routine use of diagnostic mammography in this clinical scenario. Diagnostic imaging is not typically used for asymptomatic women. Women in this clinical scenario should undergo age- and risk-appropriate screening. For screening guidelines based on overall risk for breast cancer, please refer to the ACR Appropriateness Criteria ® topics on “ Breast Cancer Screening ” \[8] and “ Supplemental Breast Cancer Screening Based on Breast Density ” \[9] and the ACR recommendations on screening in women at higher-than- average risk \[10]. 目前尚无相关文献支持在此临床情况下常规使用诊断性乳腺X线摄影。诊断性影像学检查通常不适用于无症状女性。此类临床情况下的女性应接受与年龄和风险相匹配的筛查。关于基于乳腺癌总体风险的筛查指南，请参阅ACR适宜性标准®中"乳腺癌筛查"\[8]和"基于乳腺密度的补充乳腺癌筛查"\[9]专题，以及ACR针对高于平均风险女性的筛查建议\[10]。
* 检查项目: Mammography Screening / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000332
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the routine use of screening mammography in an average-risk patient. The ACR and SBI recommend asymptomatic average-risk women undergo annual screening mammography starting at age 40 \[1,8,17]. For screening guidelines based on overall risk for breast cancer, please refer to the ACR Appropriateness Criteria ® topics on “ Breast Cancer Screening ” \[8] and “ Supplemental Breast Cancer Screening Based on Breast Density ” \[9] and the ACR recommendations on screening in women at higher-than-average risk \[10]. 目前尚无相关文献支持对一般风险患者常规进行乳腺X线筛查。美国放射学会（ACR）和乳腺影像学会（SBI）建议无症状的一般风险女性从40岁开始每年接受乳腺X线筛查\[1,8,17]。关于基于乳腺癌总体风险的筛查指南，请参阅ACR适宜性标准®专题《乳腺癌筛查》\[8]和《基于乳腺密度的补充乳腺癌筛查》\[9]，以及ACR针对高于平均风险女性的筛查建议\[10]。
* 检查项目: Digital Breast Tomosynthesis Screening / MG双侧乳腺钼靶(筛查)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0001 / R:CR000333
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the routine use of screening DBT in an average-risk patient. The ACR and SBI recommend asymptomatic average-risk women undergo annual screening mammography starting at age 40 \[1,8,17]. For screening guidelines based on overall risk for breast cancer, please refer to the ACR Appropriateness Criteria ® topics on “ Breast Cancer Screening ” \[8] and “ Supplemental Breast Cancer Screening Based on Breast Density ” \[9] and the ACR recommendations on screening in women at higher-than-average risk \[10]. 目前尚无相关文献支持对平均风险患者常规使用筛查性数字乳腺断层合成技术（DBT）。美国放射学会（ACR）和乳腺影像学会（SBI）建议无症状平均风险女性从40岁开始每年进行筛查性乳腺X线摄影检查\[1,8,17]。关于基于乳腺癌总体风险的筛查指南，请参阅ACR适宜性标准®专题《乳腺癌筛查》\[8]和《基于乳腺密度的补充乳腺癌筛查》\[9]，以及ACR针对高于平均风险女性的筛查建议\[10]。
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000338
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support the use of MRI breast without IV contrast for screening in this clinical scenario. 目前尚无相关文献支持在此临床情况下使用无静脉对比剂的乳腺MRI进行筛查。
* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000337
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support the routine use of MRI breast without and with IV contrast in an average- a woman’s overall risk for developing breast cancer. In these situations, the use of MRI breast without and with IV contrast may be warranted. Please refer to the ACR Appropriateness Criteria ® topics on “ Breast Cancer Screening ” \[8] and “ Supplemental Breast Cancer Screening Based on Breast Density ” \[9] and the ACR recommendations on screening in women at higher-than-average risk \[10]. 目前尚无相关文献支持对乳腺癌平均风险的女性常规使用平扫及增强MRI乳腺检查。在此类情况下，可能需要使用平扫及增强MRI乳腺检查。请参阅ACR适宜性标准中"乳腺癌筛查"\[8]和"基于乳腺密度的补充性乳腺癌筛查"\[9]专题，以及ACR对高于平均风险女性筛查的建议\[10]。
* 检查项目: FDG-PET Breast Dedicated / PET/CT局部(胸部)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0016 / R:CR000334
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of FDG-PET breast in this clinical scenario. 目前尚无相关文献支持在此临床情况下使用FDG-PET乳腺检查。
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000339
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of Tc-99m sestamibi MBI in this clinical scenario. 目前尚无相关文献支持在此临床情境中使用锝-99m甲氧异丁基异腈（MBI）。
* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0003 / R:CR000340
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support the routine use of breast US for surveillance in this clinical scenario. Some benign breast disease, especially atypical hyperplasia and lobular neoplasia can increase a woman’s overall risk for developing breast cancer. Please refer to the ACR Appropriateness Criteria ® topics on “ Breast Cancer Screening ” \[8] and “ Supplemental Breast Cancer Screening Based on Breast Density ” \[9] and the ACR recommendations on screening in women at higher-than-average risk \[10]. 目前尚无相关文献支持在此临床情况下常规使用乳腺超声进行监测。某些良性乳腺疾病，尤其是非典型增生和小叶肿瘤，可能增加女性罹患乳腺癌的总体风险。请参阅ACR适宜性标准®中关于"乳腺癌筛查"\[8]和"基于乳腺密度的补充乳腺癌筛查"\[9]的主题，以及ACR对高于平均风险女性的筛查建议\[10]。

##### S0049 Variant: Variant 4:  Adult female. Postsurgical excision for breast cancer. Positive margins. Asymptomatic. Initial imaging. | 成人女性，乳腺癌术后切除，切缘阳性，无症状，初始影像学检查。

检查推荐列表：

* 检查项目: Mammography Diagnostic / MG双侧乳腺钼靶
  * 评分: 5
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0010 / R:CR000343
  * 证据强度: StrongReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is insufficient evidence to support the routine use of diagnostic mammography in this clinical scenario. However, it can be helpful in a subset of patients in which there is concern for residual microcalcifications, which are better visualized on magnification mammograms rather than DBT. One small retrospective study evaluated postexcision mammography and MRI to assess for residual disease. Of 51 patients with malignant calcifications (32 with and 19 without residual disease), mammography sensitivity, specificity, and accuracy were 78.1%, 42.1%, and 62.7%, respectively. MRI was better than mammography, especially in the setting of low background parenchymal enhancement, in which sensitivity, specificity, and accuracy were 88.8%, 57.1%, and 76.5%, respectively \[24]. Another small single institution study of 281 patients with ductal carcinoma in situ, of which 144 underwent postexcision preirradiation mammography, found postexcision preirradiation mammography resulted in a change in surgical management in 7% (10/144) and removal of residual ductal carcinoma in situ in 4% (6/144) of patients. More importantly there was no significant change in 10-year local recurrence-free survival (95% versus 92%, with and without postexcision preirradiation mammography) \[25]. 现有证据不足以支持在此临床情境中常规使用诊断性乳腺X线摄影。然而，对于部分疑似残留微钙化的患者群体，该检查仍具价值——放大乳腺摄影较数字乳腺断层合成技术能更清晰显示此类病变。一项小型回顾性研究评估了术后乳腺X线摄影与MRI对残留病灶的检测效能：在51例恶性钙化患者中（32例存在残留病灶，19例无残留），乳腺摄影的敏感性、特异性及准确率分别为78.1%、42.1%和62.7%。MRI表现优于乳腺摄影，尤其在背景实质强化较低的情况下，其敏感性、特异性及准确率分别达88.8%、57.1%和76.5%\[24]。另一项单中心小规模研究纳入281例导管原位癌患者，其中144例接受术后放疗前乳腺摄影，结果显示该检查导致7%（10/144）患者手术方案变更，并使4%（6/144）患者的残留导管原位癌得以切除。更重要的是，无论是否采用术后放疗前乳腺摄影，两组患者的10年局部无复发生存率均无显著差异（95%对比92%）\[25]。
* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 5
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0005 / R:CR000342
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is insufficient evidence to support the routine use of MRI breast without and with IV contrast in this clinical scenario. MRI, when performed, is generally done before initial surgery. However, it may be performed following initial surgery in the setting of unsuspected positive margins. Evaluating residual disease in the surgical cavity is limited with MRI because of associated benign enhancement of the borders of the resection cavity obscuring residual disease. MRI may be helpful in identification of more widespread disease or remote disease \[26,27]. This information can guide surgical planning for re-excision or need for mastectomy. One small retrospective study evaluated postexcision mammography and MRI to assess for residual disease in 51 patients with malignant calcifications (32 with and 19 without residual disease). MRI was better than mammography, especially in the setting of low background parenchymal enhancement, where sensitivity, specificity, and accuracy were 88.8%, 57.1%, and 76.5%, respectively. However higher background parenchymal enhancement did reduce sensitivity and accuracy \[24]. 现有证据不足以支持在该临床情况下常规使用无静脉注射对比剂及增强MRI乳腺检查。MRI检查通常在初次手术前进行，但若术后发现意外阳性切缘，也可考虑实施。由于手术腔边缘的良性强化可能掩盖残留病灶，MRI在评估手术腔内残余病变方面存在局限性。然而，MRI有助于识别更广泛的病灶或远处转移\[26,27]，这些信息可指导再次切除手术规划或判断是否需要乳房切除术。一项小型回顾性研究对51例恶性钙化患者（32例存在残余病灶，19例无残余病灶）的术后乳腺X线摄影和MRI检查进行了评估，结果显示MRI优于乳腺X线摄影——尤其在背景实质强化较低的情况下，其敏感性、特异性和准确率分别为88.8%、57.1%和76.5%。但较高的背景实质强化确实会降低敏感性和准确率\[24]。
* 检查项目: Digital Breast Tomosynthesis Diagnostic / MG双侧乳腺钼靶
  * 评分: 5
  * 适宜性: May be appropriate (Disagreement) / 可能适宜（存在争议）
  * 编码: P:PR0010 / R:CR000343
  * 证据强度: Expert Opinion
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the routine use of diagnostic DBT in this clinical scenario. When diagnostic mammography is performed in this scenario, it is typically for evaluation of residual calcifications, which are better visualized on magnification mammograms rather than DBT. One small retrospective study evaluated postexcision mammography and MRI to assess for residual disease. Of 51 patients with malignant calcifications (32 with and 19 without residual disease), mammography sensitivity, specificity, and accuracy were 78.1%, 42.1%, and 62.7%, respectively. MRI was better than mammography, especially in the setting of low background parenchymal enhancement, in which sensitivity, specificity, and accuracy were 88.8%, 57.1%, and 76.5%, respectively \[24]. Another small single institution study of 281 patients with ductal carcinoma in situ, of which 144 underwent postexcision preirradiation mammography, found postexcision preirradiation mammography resulted in a change in surgical management in 7% (10/144) and removal of residual ductal carcinoma in situ in 4% (6/144) of patients. More importantly there was no significant change in 10-year local recurrence-free survival (95% versus 92%, with and without postexcision preirradiation mammography) \[25]. 目前尚无相关文献支持在此临床情境中常规使用诊断性数字乳腺断层合成摄影（DBT）。在此情况下进行诊断性乳腺X线摄影，通常是为了评估残余钙化灶，而放大乳腺X线摄影对此的显示效果优于DBT。一项小型回顾性研究评估了术后乳腺X线摄影和MRI对残余病灶的检测效果：在51例恶性钙化患者中（32例存在残余病灶，19例无残余病灶），乳腺X线摄影的敏感性、特异性和准确率分别为78.1%、42.1%和62.7%。MRI表现优于乳腺X线摄影，尤其在背景实质强化较低的情况下，其敏感性、特异性和准确率分别达到88.8%、57.1%和76.5%\[24]。另一项单中心小规模研究纳入281例导管原位癌患者，其中144例接受了切除术后放疗前乳腺X线检查，结果显示该检查使7%（10/144）的患者手术方案发生变更，并使4%（6/144）的患者切除了残余导管原位癌。更重要的是，无论是否接受切除术后放疗前乳腺X线检查，患者的10年局部无复发生存率均无显著差异（95% vs 92%）\[25]。
* 检查项目: Mammography Screening / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000343
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of screening mammography in this clinical scenario. 目前尚无相关文献支持在此临床情况下使用乳腺X线筛查。
* 检查项目: Digital Breast Tomosynthesis Screening / MG双侧乳腺钼靶(筛查)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0001 / R:CR000344
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of screening DBT in this clinical scenario. 目前尚无相关文献支持在此临床情况下使用筛查数字乳腺断层合成技术（DBT）。
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000347
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support the use of MRI breast without IV contrast for screening in this clinical scenario. 目前尚无相关文献支持在此临床情况下使用无静脉对比剂的乳腺MRI进行筛查。
* 检查项目: FDG-PET breast dedicated / PET/CT局部(胸部)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0016 / R:CR000345
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明:
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000348
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of Tc-99m sestamibi MBI in this clinical scenario. 目前尚无相关文献支持在此临床情境中使用锝-99m甲氧异丁基异腈（MBI）。
* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0003 / R:CR000349
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support the use of breast US in this clinical scenario. 目前尚无相关文献支持在此临床情况下使用乳腺超声检查。

##### S0050 Variant: Variant 5:  Adult female. Surveillance following completion of breast conservation therapy for breast cancer. Negative margins. With or without radiation. Asymptomatic. | 成人女性，乳腺癌保乳治疗完成后随访，切缘阴性，伴或不伴放疗，无症状。

检查推荐列表：

* 检查项目: Mammography Diagnostic / MG双侧乳腺钼靶
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0010 / R:CR000353
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Annual mammography is the best imaging test for surveillance in this clinical scenario, with reduction of mortality compared to women with history of breast cancer who do not get annual mammography \[40,41]. The most common presentation of a recurrent or second breast cancer in patients with a personal history of breast cancer is an abnormal mammogram in an otherwise asymptomatic patient \[22,34,36]. The ACR practice parameters allows asymptomatic women with a personal history of breast cancer to undergo diagnostic mammography \[42]. A survey of radiologists showed variability in recommendation of diagnostic versus screening mammography for women treated with breast conservation therapy. Most (79%) recommended at least 1 diagnostic mammogram, with 49% recommending diagnostic mammography up to 2 years and 33% recommending diagnostic mammography from 2 to 5 years \[43]. This is supported by the fact that most locoregional recurrences occur within 5 years after diagnosis \[34,35,44], with recurrence risk greatest 2 to 3 years after initial therapy \[23,28,33,37]. There is suboptimal compliance of annual mammography in select patients with a history of breast cancer. Groups most impacted are younger women \<45 to 50 years of age, older women >65 years of age, African Americans and other underrepresented minorities, and women who did not have a recent physician visit \[34,45-50]. The ASTRO and NCCN guidelines both recommend annual mammographic surveillance for women who have completed radiation therapy as part of breast conservation therapy, with the first imaging performed at 6 to 12 months \[51,52]. Other studies have found imaging before 12 months is not beneficial and/or leads to unnecessary additional imaging due to acute breast changes, supporting the first mammogram to be at 12 months after the last mammogram \[30,53-56]. More frequent imaging of the ipsilateral affected breast beyond annual surveillance mammography, at 6-month intervals for the first 2 to 5 years, has also been studied. Two groups showed no benefits to this more frequent imaging \[30,56]. One study found a lower stage of recurrence in women undergoing 6-month surveillance compared with annual surveillance; however, this may be secondary to decreased compliance with imaging recommendations in the annual surveillance group, and follow-up was insufficient to assess for any mortality differences \[57]. The addition of DBT to 2-D digital mammography or 2-D synthetic images in the surveillance of patients with prior breast cancer history has been shown to reduce recall rates and indeterminate findings \[58-61], without significant change in cancer detection rate \[60,61]. 在此临床场景中，年度乳腺X线摄影是最佳影像学监测手段，与未接受年度乳腺X线摄影的乳腺癌病史女性相比可降低死亡率\[40,41]。乳腺癌个人史患者复发或第二原发乳腺癌最常见表现为无症状患者的乳腺X线摄影异常\[22,34,36]。ACR实践参数允许无症状乳腺癌个人史女性接受诊断性乳腺X线摄影\[42]。放射科医师调查显示，对保乳治疗女性推荐诊断性与筛查性乳腺X线摄影存在差异：多数（79%）推荐至少1次诊断性检查，其中49%推荐持续至2年，33%推荐持续25年\[43]。这得到多数局部区域复发发生在
* 检查项目: Mammography Screening / MG双侧乳腺钼靶
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0010 / R:CR000353
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Annual mammography is the best imaging test for surveillance in this clinical scenario, with reduction of mortality compared with women with history of breast cancer who do not get annual mammography \[40,41]. The most common presentation of a recurrent or second breast cancer in patients with a personal history of breast cancer is an abnormal mammogram in an otherwise asymptomatic patient \[22,34,36]. The ACR practice parameters state asymptomatic women previously treated for breast cancer may undergo annual screening or diagnostic mammography, as determined by the imaging facility \[42]. The most common factor influencing this decision is the number of years since cancer diagnosis and treatment. A survey of radiologists showed variability in recommendation of diagnostic versus screening mammography for women treated with breast conservation therapy. Most (79%) recommended at least 1 diagnostic mammogram, with 49% recommending diagnostic mammography up to 2 years and 33% recommending diagnostic mammography from 2 to 5 years \[43]. Most locoregional recurrences occur within 5 years after diagnosis \[34,35,44], with recurrence risk greatest 2 to 3 There is suboptimal compliance of annual screening mammography in select patients with a history of breast cancer. Groups most impacted are younger women \<45 to 50 years of age, older women >65 years of age, African Americans and other underrepresented minorities, and women who did not have a recent physician visit \[34,45-50]. The ASTRO and NCCN guidelines both recommend annual mammographic surveillance for women who have completed radiation therapy as part of breast conservation therapy, with the first imaging performed at 6 to 12 months \[51,52]. Other studies have found imaging before 12 months is not beneficial and/or leads to unnecessary additional imaging due to acute breast changes, supporting the first mammogram to be at 12 months after the last mammogram \[30,53-56]. More frequent imaging of the ipsilateral affected breast beyond annual surveillance mammography, at 6-month intervals for the first 2 to 5 years, has also been studied. Two groups showed no benefits to this more frequent imaging \[30,56]. One study found lower stage of recurrence in women undergoing 6-month surveillance compared with annual surveillance; however, this may be secondary to decreased compliance with imaging recommendations in the annual surveillance group and follow-up was insufficient to assess for any mortality differences \[57]. The addition of DBT to 2-D digital mammography or 2-D synthetic images in the surveillance of patients with prior breast cancer history, has been shown to reduce recall rates and indeterminate findings \[58-61], without significant change in cancer detection rate \[60,61]. 年度乳腺X线摄影是该临床场景下最佳的影像学监测检查，与未进行年度乳腺X线摄影的有乳腺癌病史的女性相比可降低死亡率\[40,41]。有个人乳腺癌病史的患者出现复发或第二乳腺癌的最常见表现是无症状患者的异常乳腺X线摄影结果\[22,34,36]。ACR实践参数指出，既往接受乳腺癌治疗的无症状女性可根据影像机构的决定接受年度筛查或诊断性乳腺X线摄影\[42]。影响该决定的最常见因素是自癌症诊断和治疗以来的年数。一项对放射科医师的调查显示，对于接受保乳治疗女性推荐诊断性与筛查性乳腺X线摄影存在差异。大多数（79%）推荐至少1次诊断性乳腺X线摄影，其中49%推荐诊断性乳腺X线摄影至多2年，33%推荐诊断性乳腺X线摄影2至5年\[43]。大多数局部区域复发发生在诊断后5年内\[34,35,44]，复发风险在初始治疗后2至3年最高\[23,28,33,37]。部分有乳腺癌病史的患者对年度筛查乳腺X线摄影的依从性欠佳。受影响最大的群体是年龄\<45至50岁的较年轻女性、65岁的较年长女性、非洲裔美国人及其他代表性不足的少数族裔，以及近期未就诊的女性\[34,4550]。ASTRO和NCCN指南均推荐已完成作为保乳治疗一部分的放疗的女性进行年度乳腺X线摄影监测，首次成像在6至12个月进行\[51,52]。其他研究发现12个月前的成像无益和/或因急性乳腺改变导致不必要的额外成像，支持首次乳腺X线摄影在上次检查后12个月进行\[30,5356]。也有研究探讨了较年度监测乳腺X线摄影更频繁的对同侧受累乳腺成像，即前2至5年每6个月一次。两个研究组显示这种更频繁的成像无益处\[30,56]。一项研究发现接受6个月监测的女性复发分期低于年度监测组；然而，这可能是因为年度监测组对成像建议的依从性降低，且随访不足以评估任何死亡率差异\[57]。在既往有乳腺癌病史患者的监测中，将DBT加入2D数字乳腺X线摄影或2D合成图像已被证明可降低召回率和不明确发现\[5861]，且癌症检出率无显著变化\[60,61]。
* 检查项目: Digital Breast Tomosynthesis Screening / MG双侧乳腺钼靶(筛查)
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0001 / R:CR000350
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Annual mammography is the best imaging test for surveillance in this clinical scenario, with reduction of mortality compared with women with history of breast cancer who do not get annual mammography \[40,41]. The most common presentation of a recurrent or second breast cancer in patients with a personal history of breast cancer is an abnormal mammogram in an otherwise asymptomatic patient \[22,34,36]. The ACR practice parameters state asymptomatic women previously treated for breast cancer may undergo annual screening or diagnostic mammography, as determined by the imaging facility \[42]. The most common factor influencing this decision is the number of years since cancer diagnosis and treatment. A survey of radiologists showed variability in recommendation of diagnostic versus screening mammography for women treated with breast conservation therapy. Most (79%) recommended at least 1 diagnostic mammogram, with 49% recommending diagnostic mammography up to 2 years and 33% recommending diagnostic mammography from 2 to 5 years \[43]. This is supported by the fact that most locoregional recurrences occur within 5 years after diagnosis \[34,35,44], with recurrence risk greatest 2 to 3 years after initial therapy \[23,28,33,37]. There is suboptimal compliance of annual screening mammography in select patients with a history of breast cancer. Groups most impacted are younger women \<45 to 50 years of age, older women >65 years of age, African Americans and other underrepresented minorities, and women who did not have a recent physician visit \[34,45-50]. The ASTRO and NCCN guidelines both recommend annual mammographic surveillance for women who have completed radiation therapy as part of breast conservation therapy, with the first imaging performed at 6 to 12 months \[51,52]. Other studies have found imaging before 12 months is not beneficial and/or leads to unnecessary additional imaging due to acute breast changes, supporting the first mammogram to be at 12 months after the last More frequent imaging of the ipsilateral affected breast beyond annual surveillance mammography, at 6-month intervals for the first 2 to 5 years, has also been studied. Two groups showed no benefits to this more frequent imaging \[30,56]. One study found lower stage of recurrence in women undergoing 6-month surveillance compared to annual surveillance; however, this may be secondary to decreased compliance with imaging recommendations in the annual surveillance group and follow-up was insufficient to assess for any mortality differences \[57]. The addition of DBT to 2-D digital mammography or 2-D synthetic images in the surveillance of patients with prior breast cancer history has been shown to reduce recall rates and indeterminate findings \[58-61], without significant change in cancer detection rate \[60,61]. 年度乳腺X线摄影是该临床场景下最佳的影像学监测检查，与未进行年度乳腺X线摄影的有乳腺癌病史的女性相比可降低死亡率\[40,41]。有个人乳腺癌病史的患者出现复发或第二乳腺癌的最常见表现是无症状患者的异常乳腺X线摄影结果\[22,34,36]。ACR实践参数指出，既往接受乳腺癌治疗的无症状女性可根据影像机构的决定接受年度筛查或诊断性乳腺X线摄影\[42]。影响该决定的最常见因素是自癌症诊断和治疗以来的年数。一项对放射科医师的调查显示，对于接受保乳治疗女性推荐诊断性与筛查性乳腺X线摄影存在差异。大多数（79%）推荐至少1次诊断性乳腺X线摄影，其中49%推荐诊断性乳腺X线摄影至多2
* 检查项目: Digital Breast Tomosynthesis Diagnostic / MG双侧乳腺钼靶
  * 评分: 8
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0010 / R:CR000353
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Annual mammography is the best imaging test for surveillance in this clinical scenario, with reduction of mortality compared with women with history of breast cancer who do not get annual mammography \[40,41]. The most common presentation of a recurrent or second breast cancer in patients with a personal history of breast cancer is an abnormal mammogram in an otherwise asymptomatic patient \[22,34,36]. This ACR practice parameter allows asymptomatic women with a personal history of breast cancer to undergo diagnostic mammography \[42]. A survey of radiologists showed variability in recommendation of diagnostic versus screening mammography for women treated with breast conservation therapy. Most (79%) recommended at least 1 diagnostic mammogram, with 49% recommending diagnostic mammography up to 2 years and 33% recommending diagnostic mammography from 2 to 5 years \[43]. This is supported by the fact that most locoregional recurrences occur within 5 years after diagnosis \[34,35,44], with recurrence risk greatest 2 to 3 years after initial therapy \[23,28,33,37]. There is suboptimal compliance of annual mammography in select patients with a history of breast cancer. Groups most impacted are younger women \<45 to 50 years of age, older women >65 years of age, African Americans and other underrepresented minorities, and women who did not have a recent physician visit \[34,45-50]. The American Society of Radiology Oncology (ASTRO) and National Comprehensive Cancer Network (NCCN) both recommend annual mammographic surveillance for women who have completed radiation therapy as part of breast conservation therapy, with the first imaging performed at 6 to 12 months \[51,52]. Other studies have found imaging before 12 months is not beneficial and/or leads to unnecessary additional imaging because of acute breast changes, supporting the first mammogram to be at 12 months after the last mammogram \[30,53-56]. More frequent imaging of the ipsilateral affected breast beyond annual surveillance mammography, at 6-month intervals for the first 2 to 5 years, has also been studied. Two groups showed no benefits to this more frequent imaging \[30,56]. One study found lower stage of recurrence in women undergoing 6-month surveillance compared with annual surveillance; however, this may be secondary to decreased compliance with imaging recommendations in the annual surveillance group and follow-up was insufficient to assess for any mortality differences \[57]. The addition of DBT to 2-D digital mammography or 2-D synthetic images in the surveillance of patients with prior breast cancer history has been shown to reduce recall rates and indeterminate findings \[58-61], without significant change in cancer detection rate \[60,61]. 年度乳腺X线摄影是此临床场景下最佳的影像学监测手段，与未接受年度乳腺X线摄影
* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 5
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0005 / R:CR000354
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is insufficient literature to support the routine use of MRI breast without and with IV contrast in this clinical scenario. The utility for breast MRI surveillance in patients with a personal history of breast cancer depends upon associated risk factors of the studied populations, as well as institutional protocols. The ACR recommends annual breast MRI surveillance for any woman with a lifetime risk of breast cancer of \~20% or greater \[8,10]. Annual breast MRI is recommended for women with a personal history of breast cancer and dense breasts as well as women diagnosed with breast cancer before 50 years of age \[10], because these risk factor combinations likely result in a \~20% or greater estimated lifetime risk of developing breast cancer \[10,62,63]. Annual breast MRI is also recommended for women with a mammographically occult primary breast cancer \[62,63]. A large observational study from BCSC data of 812,164 women compared mammographic and MRI performance in women with and without a personal history of breast cancer. They found MRI was more likely to be performed in patients with a family history of breast cancer and personal history of breast cancer and in women with dense breast tissue. There were higher biopsy rates with MRI (6.3%) compared with mammography (2.2%), with lower cancer yield (19.5% versus 34.7%, respectively) \[64]. The findings of higher cancer detection rates with MRI compared with mammography, with lower specificity and positive predictive value were confirmed \[65,66]. Another large community-based study from BCSC data of 13,266 women with a personal history of breast cancer compared surveillance with MRI and mammography to mammography alone. The group with breast MRI had higher biopsy rates (odds ratio, 2.2) and cancer detection rates (odds ratio, 1.7), with no significant difference in sensitivity or interval cancers. This study did not control for confounders and suggested subgroup analysis was warranted to better delineate risks and benefits of breast MRI in this patient population \[67]. Other single institution studies of patients with personal history of breast cancer assessed time of cancer detection with MRI. These studies found the use of MRI yielded lower new cancer detection rates in the first 3 years following breast cancer surgery, with greater MRI cancer detection rates beyond 3 years following breast cancer therapy \[67- 71]. 现有文献不足以支持在此临床场景中常规使用平扫及增强MRI乳腺检查。乳腺MRI监测对于有乳腺癌个人史患者的效用取决于研究人群的相关风险因素及机构规范。ACR建议对终身乳腺癌风险约20%或更高的所有女性进行年度乳腺MRI监测\[8,10]。对于有乳腺癌个人史且致密乳腺的女性，以及50岁前确诊乳腺癌的女性，推荐年度乳腺MRI检查\[10]，因为这些风险因素组合可能导致约20%或更高的终身罹患乳腺癌风险\[10,62,63]。对乳腺X线摄影隐匿性原发性乳腺癌女性也推荐年度乳腺MRI\[62,63]。一项基于BCSC数据包含812,164名女性的大型观察性研究比较了有/无乳腺癌个人史女性的乳腺X线摄影与MRI表现。研究发现有乳腺癌家族史、个人史及致密乳腺组织的女性更可能接受MRI检查。MRI活检率（6.3%）高于乳腺X线摄影（2.2%），但癌症检出率较低（分别为19.5% versus 34.7%）\[64]。研究证实MRI较乳腺X线摄影具有更高癌症检出率，但特异性和阳性预测值较低\[65,66]。另一项基于BCSC数据包含13,266名有乳腺癌个人史女性的大型社区研究比较了MRI联合乳腺X线摄影监测与单独乳腺X线摄影。MRI组活检率（比值比2.2）和癌症检出率（比值比1.7）更高，但敏感性和间期癌无显著差异。该研究未控制混杂因素，建议进行亚组分析以更好界定该人群乳腺MRI的风险与收益\[67]。其他针对乳腺癌个人史患者的单机构研究评估了MRI检测癌症的时间，发现乳腺癌术后前3年MRI的新癌检出率较低，而乳腺癌治疗3年后MRI癌症检出率更高\[6771]。
* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 4
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0003 / R:CR000355
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is insufficient evidence to support the routine use of breast US for routine surveillance in this clinical scenario. Whole-breast US, using handheld or automated technique, may be used as a supplemental screening examination Appropriateness Criteria ® topics on “ Breast Cancer Screening ” \[8] and “ Supplemental Breast Cancer Screening Based on Breast Density ” \[9]. Studies of women with a prior history of breast cancer who underwent US evaluation in addition to mammography for surveillance imaging found increased cancer detection rate or slightly earlier recurrence detection \[72-76]; however, those studies also had associated increases in overall biopsy rates and false positives \[76,77]. None of these studies showed improved breast cancer mortality. In addition, in a large study of 6,584 USs in Asian women with personal history of breast cancer and negative mammogram, high interval cancer rates were seen in women \<50 years of age and women with dense breasts, suggesting the need for additional supplemental imaging beyond US in select populations \[73]. 目前尚无充分证据支持在此临床场景中常规使用乳腺US进行常规监测。全乳腺US（采用手持或自动化技术）可作为补充筛查检查，具体参见ACR适宜性标准专题《乳腺癌筛查》\[8]和《基于乳腺密度的补充性乳腺癌筛查》\[9]。针对有乳腺癌既往史的女性在乳腺X线摄影基础上加用US监测影像学的研究发现，其癌症检出率有所提高或复发检测时间略微提前\[7276]；但这些研究也伴随总体活检率和假阳性率的升高\[76,77]。所有研究均未显示乳腺癌死亡率的改善。此外，一项针对6,584例亚洲女性（有乳腺癌个人史且乳腺X线摄影阴性）的大型US研究发现，50岁以下女性和致密乳腺女性的间期癌发生率较高，提示特定人群需要US之外的补充影像学检查\[73]。
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000357
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support the use of MRI breast without IV contrast in this clinical scenario. 目前尚无相关文献支持在此临床情况下使用无静脉对比剂的乳腺MRI检查。
* 检查项目: FDG-PET Breast Dedicated / PET/CT局部(胸部)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0016 / R:CR000356
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of FDG-PET breast in this clinical scenario. 目前尚无相关文献支持在此临床情况下使用FDG-PET乳腺检查。
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000358
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of Tc-99m sestamibi MBI in this clinical scenario. 目前尚无相关文献支持在此临床情境中使用锝-99m甲氧异丁基异腈（MBI）。

#### T0009 Imaging after Mastectomy and Breast Reconstruction | 乳腺切除与重建术后影像学检查

* 主题编码: T0009

##### S0051 Variant: Variant 1:  Female. Breast cancer screening. History of cancer, mastectomy side(s), no reconstruction. | 女性 乳腺癌筛查 既往癌症史 乳房切除术侧未重建

检查推荐列表：

* 检查项目: Mammography Screening / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Annual screening with 2-D mammography or DBT is recommended for the contralateral native breast. There is insufficient evidence to support screening with 2-D mammography of the postmastectomy side. Although one small retrospective study has shown a small increase in cancer detection with mammography in postmastectomy patients \[16], another study has demonstrated no benefit \[8]. 建议每年对健侧乳腺进行二维乳腺X线摄影或数字乳腺断层合成摄影筛查。目前证据不足以支持对乳房切除术后患侧进行二维乳腺X线摄影筛查。虽然一项小型回顾性研究显示乳房切除术后患者接受乳腺X线摄影可略微提高癌症检出率\[16]，但另一项研究显示该方法并无获益\[8]。
* 检查项目: Digital Breast Tomosynthesis Screening / MG双侧乳腺钼靶(筛查)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0001 / R:CR000359
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of digital breast tomosynthesis (DBT) for screening the postmastectomy side. However, annual screening with 2-D mammography or DBT is recommended for the contralateral native breast. DBT addresses some of the limitations encountered with standard 2-D mammographic views. In addition to planar images, DBT allows for creation and viewing of thin-section reconstructed images that may decrease the lesion-masking effect of overlapping normal tissue and reveal the true nature of potential false- positive findings. See the ACR Appropriateness Criteria ® topic on “ Breast Cancer Screening ” \[15] for further guidance. 目前尚无相关文献支持使用数字乳腺断层合成摄影（DBT）对乳房切除术后患侧进行筛查。但建议每年对健侧自然乳房进行二维乳腺X线摄影或DBT筛查。DBT可解决标准二维乳腺摄影视图的部分局限性——除平面图像外，DBT还能生成并显示薄层重建图像，从而减少正常组织重叠对病灶的遮蔽效应，并揭示潜在假阳性结果的真实性质。更多指导请参阅ACR适宜性标准®专题《乳腺癌筛查》\[15]。
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000363
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support the use of MRI breast without intravenous (IV) contrast for screening in this clinical setting. 目前尚无相关文献支持在此临床情况下使用无静脉注射（IV）对比剂的乳腺MRI进行筛查。
* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000362
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support the use of MRI without and with IV contrast, specifically for screening the postmastectomy nonreconstructed breast. However, based on breast cancer risk, including factors such as age at cancer diagnosis, breast density, and family history, women with a personal history of cancer may undergo MRI for the contralateral native breast \[17]. In this setting, the postmastectomy breast may be imaged and evaluated on MRI with potential for malignancy detection and characterization \[18]. 目前尚无相关文献支持在乳房切除术后未重建的乳腺筛查中单独使用MRI或联合静脉注射造影剂的MRI检查。然而，根据乳腺癌风险因素（包括确诊年龄、乳腺密度及家族史等），具有癌症病史的女性可对健侧乳腺进行MRI检查\[17]。在此情况下，乳房切除术后乳腺可通过MRI成像评估，以发现潜在恶性病变并进行特征分析\[18]。
* 检查项目: FDG-PET Breast Dedicated / PET/CT局部(胸部)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0016 / R:CR000360
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of fluorine-18-2-fluoro-2-deoxy-D-glucose (FDG)-PET breast for screening in this clinical setting. 目前尚无相关文献支持在此临床情况下使用氟-18-2-氟-2-脱氧-D-葡萄糖（FDG）-PET乳腺检查作为筛查手段。
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000364
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of Tc-99m sestamibi molecular breast imaging (MBI) for screening in this clinical setting. 目前尚无相关文献支持在此临床情境下使用锝-99m甲氧基异丁基异腈（Tc-99m sestamibi）分子乳腺成像（MBI）进行筛查。
* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0003 / R:CR000365
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is insufficient evidence to support the use of ultrasound (US) for screening in this setting. There is a paucity of evidence-based literature \[16,18-20], with only a few small retrospective studies finding utility in screening with US in this setting. A subset of a retrospective study evaluated 67 women postmastectomy who had suspected recurrence and underwent US imaging; although some of these women were symptomatic, 7 recurrent impalpable cancers were detected only on US in the cohort \[16]. This study also found 3/61 cancers detected only on mammography and not on US. A study of 1,796 US examinations in 874 asymptomatic patients (median follow-up of 37 months) found 15 clinically occult recurrences detected with US in 15 patients (cancer detection rate of 1.7% per patient and 0.8% per examination) \[19]. Lee et al \[20] evaluated 1,180 consecutive screening USs of the mastectomy site and the ipsilateral axillary fossa in 468 asymptomatic women and found 10 malignancies with a 当前证据不足以支持在此情况下采用超声作为筛查手段。循证文献匮乏\[16,1820]，仅少数小型回顾性研究发现超声筛查在此场景下具有效用。一项回顾性研究亚组评估了67例乳房切除术后疑似复发并接受超声检查的女性：尽管部分患者有症状，该队列中仍通过超声检出7例不可触及的复发癌灶\[16]。该研究同时发现3/61的癌灶仅由乳腺X线摄影检出而超声未发现。一项对874名无症状患者（中位随访37个月）进行的1,796次超声检查研究发现，15例患者通过超声检出15处临床隐匿性复发（患者癌症检出率1.7%，单次检查检出率0.8%）\[19]。Lee等\[20]评估468名无症状女性连续进行的1,180次乳房切除部位及同侧腋窝筛查超声，发现10例恶性肿瘤...

##### S0052 Variant: Variant 2:  Female. Breast cancer screening. History of cancer, autologous reconstruction side(s) with or without implant. | 女性 乳腺癌筛查 既往癌症史 自体重建侧伴或不伴假体

检查推荐列表：

* 检查项目: Mammography Screening / MG双侧乳腺钼靶
  * 评分: 5
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0010
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Evidence is limited, but a few retrospective studies suggest a benefit to screening women with autologous reconstruction after mastectomy for cancer in the reconstruction side. Helvie et al \[27] looked at 214 consecutive screening mammograms in 113 women with TRAM flap reconstructions, 106 (94%) of which were performed after mastectomy for cancer. The cancer detection rate was 0.9% per screen and 1.9% per patient (2/106, 95% confidence interval \[CI]: 0.33%, 7.32%) and positive predictive value (PPV) of biopsy was 33% (95% CI: 6%, 76%). Noroozian et al \[10] in a larger study of 515 women and 618 mastectomies with reconstruction, 485 of which were performed for cancer, found the cancer detection rate of screening mammography to be 1.5/1,000 screening mammograms, comparable to that for one native breast of age-matched women. However, Freyvogel et al \[28] retrospectively evaluated 541 postmastectomy and autologous reconstruction patients. Of these, 397 patients had screening mammography and 537 patients underwent routine clinical examination. Of the patients in the cohort, 26 of 27 (96.3%) had a clinically detectable recurrence, and the two cancers detected on screening were also palpable on follow-up clinical examination. Lee et al \[29] evaluated 554 mammograms (265 TRAM flap reconstructions); no cancers were detected through screening and no interval nonpalpable recurrent breast cancers missed at mammography were identified, yielding a 0% rate of detection (exact 95% CI: 0.0%, 1.4%). The authors concluded that screening this population is less effective than screening average-risk women in their 40s, although it should be noted that the upper end of the CI is in line with the rates reported by the other studies mentioned above. Of note, there are no studies specifically evaluating decrease in mortality from screening women in this setting. 现有证据有限，但几项回顾性研究表明对乳房切除术后自体重建的癌症患者进行重建侧筛查可能获益。Helvie等\[27]研究了113例TRAM皮瓣重建患者的214次连续筛查 mammograms，其中106例(94%)为癌症术后患者。每次筛查的癌症检出率为0.9%，每位患者为1.9%(2/106，95%置信区间\[CI]：0.33%，7.32%)，活检阳性预测值(PPV)为33%(95%CI：6%，76%)。Noroozian等\[10]在515例女性618例乳房切除重建术(其中485例为癌症手术)的大样本研究中发现，筛查 mammography 的癌症检出率为1.5/1000次检查，与同龄女性自然乳房的检出率相当。然而Freyvogel等\[28]回顾性评估了541例乳房切除术后自体重建患者，其中397例接受筛查 mammography，537例接受常规临床检查。队列中27例复发患者中有26例(96.3%)为临床可触及复发，筛查发现的两例癌症在后续临床检查中也可触及。Lee等\[29]评估了554次 mammograms检查(265例TRAM皮瓣重建)，未通过筛查检出癌症，也未发现 mammography 漏诊的不可触及间隔期复发乳腺癌，检出率为0%(精确95%CI：0.0%，1.
* 检查项目: Digital Breast Tomosynthesis Screening / MG双侧乳腺钼靶(筛查)
  * 评分: 4
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0001 / R:CR000367
  * 证据强度: StrongReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Although insufficient studies have been performed to assess the utility of DBT in this setting, multiple investigations have demonstrated that DBT is helpful in the screening setting of the native breast, thus decreasing recall rates and increasing cancer detection rates compared to a conventional mammographic workup \[21-26]. 尽管目前评估数字乳腺断层合成（DBT）在此场景中应用价值的研究尚不充分，但多项研究已证实DBT在自然乳腺筛查中具有积极作用，与传统乳腺X线检查方案相比，可降低召回率并提高癌症检出率\[21-26]。
* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 3
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000368
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is insufficient evidence to support the use of MRI without and with IV contrast for screening in this setting. Based on breast cancer risk, including factors such as age at cancer diagnosis, breast density, and family history, women with a personal history of cancer may undergo MRI for the contralateral native breast \[17]. In this setting, MRI will also allow for evaluation of the reconstructed breast and may be able to demonstrate recurrent malignancy, although the literature is scant with only several small studies and case reports \[30,31]. Reiber et al \[31], for example, used MRI to evaluate 41 patients with flap reconstructions, finding one mammographically and sonographically occult cancer in a patient with a latissimus dorsi flap. However, MRI also generated three false- positive biopsies. 目前尚无充分证据支持在此情况下使用无静脉注射对比剂及增强MRI进行筛查。根据乳腺癌风险因素（包括确诊年龄、乳腺密度及家族史等），有癌症病史的女性可对侧自然乳腺行MRI检查\[17]。在此情境下，MRI还可评估重建乳房，或能显示恶性肿瘤复发，但相关文献较少，仅见数项小型研究及病例报告\[30,31]。例如Reiber等\[31]采用MRI评估41例皮瓣重建患者，在背阔肌皮瓣患者中发现1例乳腺X线及超声检查隐匿的癌症，但MRI也导致了3例假阳性活检。
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000370
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support the use of MRI of the breast without IV contrast for screening in this clinical setting. 目前尚无相关文献支持在此临床情况下使用无静脉对比剂的乳腺MRI进行筛查。
* 检查项目: FDG-PET Breast Dedicated / PET/CT局部(胸部)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0016 / R:CR000369
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of FDG-PET breast for screening in this clinical setting. 目前尚无相关文献支持在此临床情况下使用FDG-PET乳腺进行筛查。
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000371
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of Tc-99m sestamibi MBI for screening in this clinical setting. 目前尚无相关文献支持在此临床情况下使用锝-99m甲氧异丁基异腈（MBI）进行筛查。
* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0003 / R:CR000372
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support the use of US for screening in this clinical setting. 目前尚无相关文献支持在此临床情况下使用超声进行筛查。

##### S0053 Variant: Variant 3:  Female. Breast cancer screening. History of cancer, nonautologous (implant) reconstruction sides(s). | 女性 乳腺癌筛查 既往癌症史 非自体（假体）重建侧

检查推荐列表：

* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 2
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000373
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is insufficient evidence to support screening women specifically to evaluate the postmastectomy breast with implant reconstruction. A small retrospective study of 45 breast MRI surveillance examinations performed in women who underwent mastectomy for either cancer or prophylaxis and had either implant, flap, or mixed reconstruction found no locoregional recurrences that were not also clinically suspected \[33]. Golan et al \[34] evaluated 159 women status post bilateral mastectomy and reconstruction who underwent 415 surveillance MRI examinations. In this study, the majority of the women (90%) had implant reconstruction. Of these, 405 (98%; 95% CI: 96%–99%) of the studies were negative, and one breast recurrence was found on MRI (cancer detection rate 2.4 per 1,000 MRI examinations, 95% CI: 0.4–13) in a woman who was also found to have metastatic disease. In addition, the false-positive rate was 90% (95% CI: 54%–99%). The interval cancer rate in this group was 5/1000 (95% CI: 1.3–17), and 4 women were diagnosed with metastatic disease. However, based on breast cancer risk, including factors such as age at cancer diagnosis, breast density, and family history, women with a personal history of cancer may undergo MRI for the contralateral native breast \[17]. 目前证据不足以支持对乳房切除术后植入物重建的女性进行专门筛查。一项针对45例因癌症或预防性原因接受乳房切除术并行植入物、皮瓣或混合重建的女性进行乳腺MRI监测的小型回顾性研究发现，所有局部区域复发均伴有临床可疑表现\[33]。Golan等\[34]评估了159例双侧乳房切除术后重建女性接受的415次MRI监测检查，其中大多数（90%）为植入物重建。结果显示405次检查呈阴性（98%；95%CI：96%-99%），仅1例通过MRI检出乳房复发（癌症检出率2.4/1000次MRI检查，95%CI：0.4-13），该患者同时发现转移性疾病。此外，假阳性率达90%（95%CI：54%-99%）。该组间期癌症发生率为5/1000（95%CI：1.3-17），另有4例确诊转移性疾病。但基于乳腺癌风险因素（包括确诊年龄、乳腺密度及家族史等），有癌症个人史的女性可考虑对健侧自然乳腺进行MRI检查\[17]。
* 检查项目: Mammography Screening / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of mammography for screening in this clinical setting. 目前尚无相关文献支持在此临床情况下使用乳腺X线摄影进行筛查。
* 检查项目: Digital Breast Tomosynthesis Screening / MG双侧乳腺钼靶(筛查)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0001 / R:CR000374
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of DBT for screening in this clinical setting. 目前尚无相关文献支持在此临床情况下使用数字乳腺断层摄影（DBT）进行筛查。
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000377
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support the use of MRI without IV contrast for screening in this clinical setting. 目前尚无相关文献支持在此临床情况下使用无静脉对比剂的MRI进行筛查。
* 检查项目: FDG-PET Breast Dedicated / PET/CT局部(胸部)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0016 / R:CR000375
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of FDG-PET breast for screening in this clinical setting. 目前尚无相关文献支持在此临床情况下使用FDG-PET乳腺进行筛查。
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000378
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of Tc-99m sestamibi MBI for screening in this clinical setting. 目前尚无相关文献支持在此临床情况下使用锝-99m甲氧异丁基异腈（MBI）进行筛查。
* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0003 / R:CR000379
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support the use of US for screening in this clinical setting. 目前尚无相关文献支持在此临床情况下使用超声进行筛查。

##### S0054 Variant: Variant 4:  Female. Breast cancer screening. High-risk, bilateral prophylactic mastectomy, no reconstruction. | 女性 乳腺癌筛查 高风险 双侧预防性乳房切除术 未重建

检查推荐列表：

* 检查项目: Mammography Screening / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of mammography for screening in this clinical setting. 目前尚无相关文献支持在此临床情况下使用乳腺X线摄影进行筛查。
* 检查项目: Digital Breast Tomosynthesis Screening / MG双侧乳腺钼靶(筛查)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0001 / R:CR000380
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of DBT for screening in this clinical setting. 目前尚无相关文献支持在此临床情况下使用数字乳腺断层摄影（DBT）进行筛查。
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000384
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support the use of MRI without IV contrast for screening in this clinical setting. 目前尚无相关文献支持在此临床情况下使用无静脉对比剂的MRI进行筛查。
* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000383
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is insufficient evidence to support the use of MRI without and with IV contrast for breast cancer screening in this setting. 目前尚无充分证据支持在此情况下使用无静脉注射对比剂及含静脉注射对比剂的MRI进行乳腺癌筛查。
* 检查项目: FDG-PET Breast Dedicated / PET/CT局部(胸部)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0016 / R:CR000381
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of FDG-PET breast for screening in this clinical setting. 目前尚无相关文献支持在此临床情况下使用FDG-PET乳腺进行筛查。
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000385
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of Tc-99m sestamibi MBI for screening in this clinical setting. 目前尚无相关文献支持在此临床情况下使用锝-99m甲氧异丁基异腈（MBI）进行筛查。
* 检查项目: US breast / US乳腺常规超声检查
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0003 / R:CR000386
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明:

##### S0055 Variant: Variant 5:  Female. Breast cancer screening. High-risk, bilateral prophylactic mastectomy with autologous reconstructions. | 女性，乳腺癌筛查，高风险，双侧预防性乳房切除术伴自体重建。

检查推荐列表：

* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 2
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000387
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: Although there may be residual breast glandular tissue after mastectomy and MRI may be useful in delineating the amount of this residual tissue in women after prophylactic mastectomy \[35], there is insufficient evidence to support the use of MRI breast without and with IV contrast for breast cancer screening in this population. A small retrospective study of breast MRI surveillance examinations performed in a subset of women who underwent bilateral mastectomy for either cancer or prophylaxis and had either implant, flap, or mixed reconstructions found no cancers that were not also evident on clinical examinations \[33]. 尽管乳房切除术后可能残留乳腺组织，且MRI有助于评估预防性乳房切除术后女性残留组织的量\[35]，但目前尚无充分证据支持在该人群中使用无静脉对比剂及增强MRI进行乳腺癌筛查。一项针对因癌症或预防性原因接受双侧乳房切除（植入物、皮瓣或混合重建）的女性进行乳腺MRI监测的小型回顾性研究发现，所有临床检查中明显的癌症在MRI检查中均未漏诊\[33]。
* 检查项目: Mammography Screening / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is insufficient evidence to support the use of mammography for breast cancer screening in this population. A recent study by Noroozian et al \[10] found no evidence to support the use of screening mammography in women who had undergone bilateral prophylactic mastectomy with autologous reconstruction. Of 133 prophylactic mastectomies with autologous reconstruction (805 mammograms), the cancer detection rate with mammography was 0%. 目前尚无充分证据支持在该人群中使用乳腺X线摄影进行乳腺癌筛查。Noroozian等人\[10]的最新研究发现，对于接受双侧预防性乳房切除并自体重建的女性，没有证据支持使用筛查性乳腺X线摄影。在133例自体重建的预防性乳房切除术（共805次乳腺X线检查）中，乳腺X线摄影的癌症检出率为0%。
* 检查项目: Digital Breast Tomosynthesis Screening / MG双侧乳腺钼靶(筛查)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0001 / R:CR000388
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of DBT for screening in this clinical setting. 目前尚无相关文献支持在此临床情况下使用数字乳腺断层摄影（DBT）进行筛查。
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000391
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support the use of MRI without IV contrast for screening in this clinical setting. 目前尚无相关文献支持在此临床情况下使用无静脉对比剂的MRI进行筛查。
* 检查项目: FDG-PET Breast Dedicated / PET/CT局部(胸部)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0016 / R:CR000389
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of FDG-PET breast for screening in this clinical setting. 目前尚无相关文献支持在此临床情况下使用FDG-PET乳腺进行筛查。
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000392
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of Tc-99m sestamibi MBI for screening in this clinical setting. 目前尚无相关文献支持在此临床情况下使用锝-99m甲氧异丁基异腈（MBI）进行筛查。
* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0003 / R:CR000393
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support the use of US for screening in this clinical setting. 目前尚无相关文献支持在此临床情况下使用超声进行筛查。

##### S0056 Variant: Variant 6:  Female. Breast cancer screening. High-risk, bilateral prophylactic mastectomy with nonautologous (implant) reconstructions. | 女性，乳腺癌筛查，高风险，双侧预防性乳房切除术伴非自体（假体）重建。

检查推荐列表：

* 检查项目: Mammography Screening / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of mammography for screening in this clinical setting. 目前尚无相关文献支持在此临床情况下使用乳腺X线摄影进行筛查。
* 检查项目: Digital Breast Tomosynthesis Screening / MG双侧乳腺钼靶(筛查)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0001 / R:CR000394
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of DBT for screening in this clinical setting. 目前尚无相关文献支持在此临床情况下使用数字乳腺断层摄影（DBT）进行筛查。
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000398
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support the use of MRI without IV contrast for screening in this clinical setting. 目前尚无相关文献支持在此临床情况下使用无静脉对比剂的MRI进行筛查。
* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000397
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is insufficient evidence to support screening for women with prophylactic mastectomy and implant reconstruction. It has been suggested that the yield of screening in this setting is especially low in the setting of retropectoral implant placement, in which recurrences are most likely to be clinically palpable \[33,34]. A small retrospective study of breast MRI in 48 women status post bilateral mastectomy with and without reconstruction, some of whom underwent surveillance MRI, found no malignancy that was not also evident on clinical examination \[33]. A retrospective study of 159 women status post bilateral mastectomy and reconstruction and undergoing MRI 目前缺乏足够证据支持对预防性乳房切除联合假体重建术后的女性进行筛查。研究表明，在胸肌后假体置入的情况下，筛查检出率尤其低，因为复发灶最可能通过临床触诊发现\[33,34]。一项针对48例双侧乳房切除（含重建与未重建）术后女性的乳腺MRI小型回顾性研究显示，在临床检查未发现异常的人群中，监测MRI未检出恶性肿瘤\[33]。一项对159例双侧乳房切除及重建术后接受MRI检查女性的回顾性研究表明...
* 检查项目: FDG-PET Breast Dedicated / PET/CT局部(胸部)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0016 / R:CR000395
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of FDG-PET breast for screening in this clinical setting. 目前尚无相关文献支持在此临床情况下使用FDG-PET乳腺进行筛查。
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000399
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of Tc-99m sestamibi MBI for screening in this clinical setting. 目前尚无相关文献支持在此临床情况下使用锝-99m甲氧异丁基异腈（MBI）进行筛查。
* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0003 / R:CR000400
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support the use of US for screening in this clinical setting. 目前尚无相关文献支持在此临床情况下使用超声进行筛查。

##### S0057 Variant: Variant 7:  Female. Palpable lump or clinically significant pain on the side of the mastectomy without reconstruction. Initial imaging. | 女性，乳房切除未重建术后同侧可触及肿块或临床显著疼痛，初始影像学检查。

检查推荐列表：

* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0003 / R:CR000401
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: A retrospective evaluation of 118 palpable lumps in 101 patients, 9% of whom were status postmastectomy found 13 cancers in the mastectomy bed in women with a history of cancer. US had a high NPV of 97% and a PPV of 27% \[39]. Gweon et al \[41] evaluated both palpable and nonpalpable US BI-RADS categorization of lesions 4a and above at the mastectomy site and found 9/20 (45%) malignancies among palpable lesions; they also found that 100% of all BI-RADS 4c and BI-RADS 5 lesions proved to be malignant. In the event of an indeterminate US finding or an US finding suggestive of fat necrosis, diagnostic mammography or DBT may be helpful for lesion characterization and may preclude the need for biopsy if a clearly benign finding such as an oil cyst is identified. 对101例患者的118个可触及肿块进行回顾性评估，其中9%为乳房切除术后状态，发现既往有癌症史的女性乳房切除床中有13例癌症。超声检查的阴性预测值（NPV）高达97%，阳性预测值（PPV）为27%\[39]。Gweon等\[41]评估了乳房切除部位可触及及不可触及超声BI-RADS 4a及以上分类的病灶，发现可触及病灶中9/20（45%）为恶性；他们还发现所有BI-RADS 4c和BI-RADS 5类病灶100%被证实为恶性。若超声结果不确定或提示脂肪坏死，诊断性乳腺X线摄影或数字乳腺断层合成成像（DBT）可能有助于病灶特征分析，若明确为油性囊肿等良性表现，则可避免活检。
* 检查项目: Digital Breast Tomosynthesis Diagnostic / MG双侧乳腺钼靶
  * 评分: 5
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0010 / R:CR000402
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is insufficient evidence to support the use of DBT as the initial imaging modality in women with palpable lumps or clinically significant pain on the side of the mastectomy. However, DBT can be useful in the diagnostic setting. It is known to improve lesion characterization in noncalcified lesions and to improve cancer detection when compared to conventional mammographic workup \[36-38]. 目前尚无充分证据支持将DBT作为乳房切除术后可触及肿块或临床显著疼痛侧的首选影像学检查方法。然而，DBT在诊断场景中具有应用价值。与传统乳腺X线检查相比，已知DBT可改善非钙化性病变的特征描述，并提高癌症检出率\[36-38]。
* 检查项目: Mammography Diagnostic / MG双侧乳腺钼靶
  * 评分: 5
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0010 / R:CR000402
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is limited evidence to support the use of diagnostic mammography as the initial imaging modality in this clinical setting. A study of 67 women who underwent mastectomy and were suspected of recurrence found 3/61 cancers detected only on mammography and not on US \[16]. Another study evaluating palpable lumps in 101 patients who had undergone mastectomy, the majority of whom (69%) had reconstruction with implants, demonstrated that mammography could be useful to confirm benign findings such as fat necrosis and benign calcifications identified on US \[39]. However, diagnostic mammography yielded no additional cancers beyond those depicted on US. 目前支持将诊断性乳腺X线摄影作为该临床情境下首选影像学检查的证据有限。一项针对67例接受乳房切除术后疑似复发患者的研究显示，61例癌症中有3例仅通过乳腺X线摄影检出而超声未能发现\[16]。另一项研究评估了101例乳房切除术后触及肿块的患者（其中69%接受假体重建术），证实乳腺X线摄影有助于确认超声发现的良性病变（如脂肪坏死和良性钙化）\[39]。但除超声已检出的病灶外，诊断性乳腺X线摄影并未发现额外恶性肿瘤。
* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 3
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000404
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no evidence to support the use of MRI breast without and with IV contrast as the initial imaging modality in women with palpable lump or clinically significant pain on the mastectomy side. However, MRI may help characterize malignancy once identified and has been found to be more accurate than US in delineating extent of disease, although there is a paucity of evidence-based literature \[18]. 目前尚无证据支持在乳房切除术后出现可触及肿块或临床显著疼痛的女性中，将无和有静脉对比剂的乳腺MRI作为初始影像学检查手段。然而，一旦发现恶性肿瘤，MRI可能有助于其特性描述，并且在界定疾病范围方面比超声更准确，尽管基于证据的文献较少\[18]。
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 2
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000405
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There are a few small retrospective studies evaluating the use of Tc-99m sestamibi MBI in the context of a clinically suspicious lump. For example, Usmani et al \[40] looked at 41 consecutive postmastectomy patients and found a sensitivity of 89%, specificity of 92%, PPV of 96%, negative predictive value (NPV) of 80%, and accuracy of 90% with Tc-99m sestamibi MBI. This was compared to US, which had a lower sensitivity of 86%, specificity of 77%, PPV of 89%, NPV of 71%, and accuracy of 83% ( P = .001). The authors found that the combined sensitivity was 100%, specificity 77%, PPV 90%, NPV 100%, and accuracy 93%. However, there is insufficient evidence to support the use of Tc-99m sestamibi MBI as the initial imaging modality in this setting. 目前已有少量回顾性研究评估了锝-99m甲氧基异丁基异腈（MBI）在临床可疑肿块中的应用。例如Usmani等\[40]对41例连续收治的乳房切除术后患者进行分析，发现Tc-99m MBI的敏感性为89%、特异性92%、阳性预测值（PPV）96%、阴性预测值（NPV）80%、准确率90%。与之相比，超声检查的敏感性较低（86%），特异性77%、PPV 89%、NPV 71%、准确率83%（P=0.001）。研究者发现联合检测时敏感性达100%、特异性77%、PPV 90%、NPV 100%、准确率93%。但现有证据尚不足以支持将Tc-99m MBI作为此类情况的首选影像学检查方法。
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000407
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support the use of MRI without IV contrast in this clinical setting. 无相关文献支持在此临床情况下使用无静脉注射对比剂的MRI检查。
* 检查项目: FDG-PET Breast Dedicated / PET/CT局部(胸部)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0016 / R:CR000406
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of FDG-PET breast in this clinical setting. 目前尚无相关文献支持在此临床情况下使用FDG-PET乳腺检查。

##### S0058 Variant: Variant 8:  Female. Palpable lump or clinically significant pain on the side of the mastectomy with reconstruction (autologous or nonautologous). Initial imaging. | 女性，乳房切除重建术后（自体或非自体）同侧可触及肿块或临床显著疼痛，初始影像学检查。

检查推荐列表：

* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0003 / R:CR000408
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There are a few small studies to support the use of US this setting. Dashevsky et al \[39] looked at 118 palpable lumps in 101 patients postmastectomy (85% of whom were also postreconstruction). In total, 14 palpable lumps in 12 patients were malignant, and 104 palpable lumps in 89 patients were nonmalignant. Thirteen cancers were identified on US with only two false-positives (NPV 97%, PPV 27%). Edeiken et al \[42] evaluated 20 women with autologous flap reconstruction after mastectomy who presented with palpable lumps; US ultimately identified 39 of 39 (100%) of cancers, 18 of which were palpable and 21 of which were occult. In the event of an indeterminate US finding, or an US finding suggestive of fat necrosis, diagnostic mammography or DBT may be helpful for lesion characterization and may preclude the need for biopsy if a clearly benign finding such as an oil cyst is identified. 目前有少量小型研究支持在此情况下使用超声检查。Dashevsky等\[39]对101例乳房切除术后患者（其中85%同时接受乳房重建）的118个可触及肿块进行了研究：12例患者的14个可触及肿块为恶性，89例患者的104个可触及肿块为良性。超声检出13例恶性肿瘤，仅出现2例假阳性（阴性预测值97%，阳性预测值27%）。Edeiken等\[42]评估了20例乳房切除术后自体皮瓣重建出现可触及肿块的女性患者，超声最终检出39例恶性肿瘤（检出率100%），其中18例为可触及肿块，21例为隐匿性肿块。若超声检查结果不确定或提示脂肪坏死，诊断性乳腺X线摄影或数字乳腺断层合成成像（DBT）可能有助于病灶特征评估；若明确检出油性囊肿等良性表现，则可避免活检。
* 检查项目: Digital Breast Tomosynthesis Diagnostic / MG双侧乳腺钼靶
  * 评分: 5
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0010 / R:CR000409
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is insufficient evidence to support the use of DBT as the initial imaging modality for women with palpable lumps or clinically significant pain on the side of the mastectomy with reconstruction. However, DBT can be useful in the diagnostic setting. It is known to improve lesion characterization in noncalcified lesions and to improve cancer detection when compared to conventional mammographic workup \[36-38]. 目前证据不足以支持将数字乳腺断层合成（DBT）作为乳房切除重建术后出现可触及肿块或临床显著疼痛侧的首选影像学检查方法。然而，DBT在诊断场景中具有应用价值。研究表明，与传统乳腺X线检查相比，DBT能提高非钙化性病变的特征显示能力，并提升乳腺癌检出率\[36-38]。
* 检查项目: Mammography Diagnostic / MG双侧乳腺钼靶
  * 评分: 5
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0010 / R:CR000409
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is limited evidence to support the use of diagnostic mammography as the initial imaging modality in this clinical setting. Mammography may be helpful in identifying a benign postsurgical etiology of a palpable concern such as fat necrosis or oil cyst. For example, a study evaluating palpable lumps in 101 patients who had undergone mastectomy, the majority of whom (69%) had reconstruction with implants, demonstrated that mammography could be useful to confirm benign findings such as fat necrosis and benign calcifications identified on US \[39]. However, the study also showed that diagnostic mammography yielded no additional cancers beyond those depicted on US. In another small study, Edeiken et al \[42] found that mammography depicted only 14 of 25 (56%) of the recurrences visualized on US in women who had undergone autogenous myocutaneous flaps after mastectomy. 现有证据有限，不足以支持将诊断性乳腺X线摄影作为该临床情况的首选影像学检查手段。乳腺X线摄影可能有助于识别可触及病变的良性术后病因（如脂肪坏死或油性囊肿）。例如，一项针对101例乳房切除术后患者（其中69%接受假体重建）可触及肿块的研究表明，乳腺X线摄影可有效确认超声发现的良性病变（如脂肪坏死和良性钙化）\[39]。但该研究同时显示，诊断性乳腺X线摄影未能检出超出超声发现的额外恶性肿瘤。另一项小规模研究中，Edeiken等\[42]发现，对于乳房切除术后接受自体肌皮瓣重建的女性患者，乳腺X线摄影仅能检出超声所发现25例复发中的14例（56%）。
* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 3
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000411
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is insufficient evidence for MRI without and with IV contrast as the initial imaging modality in this setting. There are a few small studies evaluating MRI in women with symptomatic concerns and breast reconstruction. Devon et al \[43] evaluated 24 TRAM reconstructions in 22 women with the majority of cases (64%) presenting with palpable abnormality or pain. Sixteen women in the study had MRI without mammography or US. In 4 of 24 cases (17%), MRI detected recurrent breast cancer, including axillary nodal recurrence. Of note, tissue expanders may be a contraindication to breast MRI \[44]. 在此情况下，将无和有静脉注射对比剂的MRI作为初始影像学检查方式的证据不足。目前仅有少量小型研究评估了MRI在有症状担忧和乳房重建女性中的应用。Devon等人\[43]评估了22名女性的24例TRAM重建，其中大多数病例（64%）表现为可触及异常或疼痛。研究中有16名女性仅接受了MRI检查，未进行乳腺X线摄影或超声检查。在24例病例中，有4例（17%）通过MRI检测出乳腺癌复发，包括腋窝淋巴结复发。值得注意的是，组织扩张器可能是乳腺MRI的禁忌症\[44]。
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000413
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no role for MRI without IV contrast as the initial imaging modality in this clinical setting. For evaluation of implant integrity, please see the ACR Appropriateness Criteria ® topic on “ Breast Implant Evaluation ” \[32]. 在此临床情况下，无需使用无静脉对比剂的MRI作为初始影像学检查手段。如需评估植入物完整性，请参阅ACR适宜性标准®中关于“乳房植入物评估”的主题\[32]。
* 检查项目: FDG-PET Breast Dedicated / PET/CT局部(胸部)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0016 / R:CR000412
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of FDG-PET breast as the initial imaging modality in this clinical setting. 目前尚无相关文献支持在此临床情况下将FDG-PET乳腺显像作为首选影像学检查手段。
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000414
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of Tc-99m sestamibi MBI as the initial imaging modality in this clinical setting. 目前尚无相关文献支持在此临床情况下将锝-99m甲氧异腈（MIBI）作为首选影像学检查方法。

#### T0010 Imaging of Ductal Carcinoma in Situ (DCIS) | 乳腺导管原位癌（DCIS）影像学检查

* 主题编码: T0010

##### S0059 Variant: Variant 1:  Adult. Newly diagnosed DCIS. Initial imaging. | 成人。新发导管原位癌。初始影像学检查。

检查推荐列表：

* 检查项目: Digital Breast Tomosynthesis Diagnostic / MG双侧乳腺钼靶
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0010 / R:CR000415
  * 证据强度: StrongReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: DCIS presents as mammographically identified suspicious calcifications in approximately 80% of cases \[3]. Pure DCIS presents with suspicious calcifications in 73% to 98% of cases, which can be identified mammographically independent of the density of the fibroglandular breast tissue \[35-38]. Approximately half of DCIS calcifications will have fine pleomorphic morphologic characteristics and a grouped distribution \[3,39]. Microcalcifications associated with high-grade DCIS and DCIS with necrosis appear as fine pleomorphic or fine-linear branching \[40]. Mammography findings associated with low and intermediate-grade DCIS include round/punctate calcifications or Diagnostic mammography can evaluate lesion size and extent of disease and can be assisted by ultrasound (US). The typical appearance of suspicious calcifications in isolated DCIS may be more commonly assessed as BI-RADS 5, highly suggestive of malignancy with mammography (87%) than with US (33%) \[36]. For DCIS, mammographic size demonstrates high correlation with pathologic size \[43]. It should be noted that measurement of the DCIS component of malignancies as seen on imaging may differ from estimates reported by pathology \[44,45]. A European multicenter retrospective reading study of 7,060 examinations compared digital mammography, digital breast tomosynthesis (DBT), digital mammography plus DBT, and synthetic mammography plus DBT found similar sensitivity in detecting DCIS across all modalities and improvement in specificity of DBT plus 2-D compared with 2-D mammography alone \[46]. A recent analysis of 166 breast lesions in 130 patients found similar performance in detecting DCIS across synthetic 2-D mammography, DBT alone, DBT supplemented with US, and contrast-enhanced digital mammography \[47]. For detecting high-grade DCIS, the sensitivity of mammography may be lower than for breast MRI. A study of 167 women diagnosed with pure DCIS that had preoperative mammography and breast MRI found that 56% of the DCIS cases were diagnosed by mammography and 92% by breast MRI. Forty-eight percent of the high-grade DCIS lesions were diagnosed on breast MRI and not apparent on mammography \[48]. DCIS在大约80%的病例中表现为乳腺X线摄影识别的可疑钙化\[3]。纯DCIS在73%至98%的病例中表现为可疑钙化，这可以通过乳腺X线摄影识别，且与纤维腺体组织的密度无关\[3538]。大约一半的DCIS钙化将具有细多形性形态学特征和成组分布\[3,39]。与高级别DCIS和伴有坏死的DCIS相关的微钙化表现为细多形性或细线样分支\[40]。与低级别和中级别DCIS相关的乳腺X线摄影表现包括圆形/点状钙化或诊断性乳腺X线摄影可以评估病变大小和疾病范围，并可借助US辅助。孤立性DCIS中可疑钙化的典型外观更常被评估为BIRADS 5类，乳腺X线摄影高度提示恶性（87%）高于US（33%）\[36]。对于DCIS，乳腺X线摄影大小与病理大小高度相关\[43]。应注意的是，影像学上所见恶性肿瘤的DCIS成分的测量可能与病理学报告的估计值不同\[44,45]。一项欧洲多中心回顾性读片研究，涉及7,060次检查，比较了数字乳腺X线摄影、数字乳腺断层合成（DBT）、数字乳腺X线摄影加DBT以及合成乳腺X线摄影加DBT，发现所有模态在检测DCIS方面敏感性相似，并且DBT加2D与单独2D乳腺X线摄影相比特异性有所提高\[46]。最近一项对130名患者中166个乳腺病变的分析发现，合成2D乳腺X线摄影、单独DBT、DBT辅以US以及对比增强数字乳腺X线摄影在检测DCIS方面性能相似\[47]。对于检测高级别DCIS，乳腺X线摄影的敏感性可能低于乳腺MRI。一项针对167名诊断为纯DCIS并接受了术前乳腺X线摄影和乳腺MRI的女性研究发现，56%的DCIS病例通过乳腺X线摄影诊断
* 检查项目: Mammography Diagnostic / MG双侧乳腺钼靶
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0010 / R:CR000415
  * 证据强度: StrongReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: DCIS presents as mammographically identified suspicious calcifications in approximately 80% of cases \[3]. Pure DCIS presents with suspicious calcifications in 73% to 98% of cases, which can be identified mammographically independent of the density of the fibroglandular breast tissue \[35-38]. Approximately half of DCIS calcifications will have fine pleomorphic morphologic characteristics and a grouped distribution \[3,39]. Microcalcifications associated with high-grade DCIS and DCIS with necrosis appear as fine pleomorphic or fine-linear branching \[40]. Mammography findings associated with low and intermediate-grade DCIS include round/punctate calcifications or an asymmetry without calcifications \[40-42]. Diagnostic mammography can evaluate lesion size and extent of disease and can be assisted by US. The typical appearance of suspicious calcifications in isolated DCIS may be more commonly assessed as BI-RADS 5, highly suggestive of malignancy with mammography (87%) than with US (33%) \[36]. Mammography has been demonstrated to be more sensitive in detecting DCIS overall than US. In a prospective study of 111 consecutive women with newly diagnosed breast cancer, 2-D mammography was found to be more sensitive than US in detecting DCIS (55% versus 47%, P \< .01) \[52]. For DCIS, mammographic size demonstrates high correlation with pathologic size \[43]. It should be noted that measurement of the DCIS component of malignancies as seen on imaging may differ from estimates reported by pathology \[44,45]. A European multicenter retrospective reading study of 7,060 examinations compared digital mammography, DBT, across all modalities and improvement in specificity of DBT plus 2-D compared with 2-D mammography alone \[46]. A recent analysis of 166 breast lesions in 130 patients found similar performance in detecting DCIS across synthetic 2-D mammography, DBT alone, DBT supplemented with US, and contrast-enhanced digital mammography \[47]. For detecting high-grade DCIS, the sensitivity of mammography may be lower than for breast MRI. A study of 167 women diagnosed with pure DCIS who had preoperative mammography and breast MRI found that 56% of the DCIS cases were diagnosed by mammography and 92% by breast MRI. Forty-eight percent of the high-grade DCIS lesions were diagnosed on breast MRI and not apparent on mammography \[48]. 导管原位癌（DCIS）在约80%的病例中表现为乳腺X线摄影发现的可疑钙化\[3]。纯DCIS在73%至98%的病例中呈现可疑钙化，这种钙化可在乳腺X线摄影中被识别，且与纤维腺体组织密度无关\[3538]。约半数DCIS钙化具有细多形性形态特征和簇状分布\[3,39]。与高级别DCIS及伴坏死的DCIS相关的微钙化表现为细多形性或细线样分支状\[40]。与低级别和中级别DCIS相关的乳腺X线摄影表现包括圆形/点状钙化或无非钙化的不对称影\[4042]。诊断性乳腺X线摄影可评估病灶大小和疾病范围，并可辅以US检查。孤立性DCIS中可疑钙化的典型表现在乳腺X线摄影中更常被评估为BIRADS 5类（高度提示恶性，87%），而US仅为33%\[36]。研究证实乳腺X线摄影总体检测DCIS的敏感性高于US。一项对111例连续新诊断乳腺癌患者的前瞻性研究发现，二维乳腺X线摄影检测DCIS的敏感性高于US（55%对比47%，P \< 0.01）\[52]。对于DCIS，乳腺X线摄影测量的尺寸与病理尺寸高度相关\[43]。需注意影像学显示的恶性肿瘤DCIS成分测量可能与病理报告评估存在差异\[44,45]。一项欧洲多中心回顾性读片研究对7,060次检查进行比较，发现数字乳腺X线摄影、数字乳腺断层合成（DBT）在所有模态中均表现优异，且DBT联合二维乳腺X线摄影的特异性优于单独二维乳腺X线摄影\[46]。最近一项对130患者166个乳腺病灶的分析发现，合成二维乳腺X线摄影、单独DBT、DBT联合US以及对比增强数字乳腺X线摄影在检测DCIS方面性能相似\[47]。对于检测高级别DCIS，乳腺X线摄影的敏感性可能低于乳腺MRI。一项针对167例术前接受乳腺X线摄影和乳腺MRI的纯DCIS患者的研究发现，56%的DCIS病例通过乳腺X线摄影诊断，92%通过乳腺MRI诊断。48%的高级DCIS病灶通过乳腺MRI诊断而在乳腺X线摄影中不明显\[48]。
* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 6
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0005 / R:CR000417
  * 证据强度: StrongReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: DCIS typically presents on MRI breast with IV contrast as nonmass enhancement, mass, or focus \[59-62]. Morphology of DCIS on breast MRI is significantly correlated with enhancement kinetics, with nonmass enhancement more likely demonstrating medium and persistent kinetics, and foci or masses demonstrating rapid and plateau or washout kinetics \[59,63]. DCIS lesions \<1.5 cm are more likely to have rapid initial enhancement ( P = .004) \[59]. Both calcified and noncalcified DCIS demonstrate similar appearances on breast MRI \[59]. Several important shifts in breast MRI have increased the sensitivity of breast MRI in detecting DCIS to 85% to 92%, including a shift to high temporal from high spatial imaging, evolution from primarily interpreting diagnostic studies to screening of high-risk patients, and an increased understanding of nonmass enhancement \[48,64-66]. Contrast-enhanced breast MRI can identify most pure DCIS lesions, may identify multifocal or multicentric disease, and can predict upgrade to invasive cancer \[67,68]. A study of 51 patients with biopsy proven DCIS who underwent breast MRI with IV contrast found that MRI depicted 88% of DCIS lesions, predicted upgrade to invasive disease in 82% of cases, and predicted multicentricity in 90% of cases \[68]. Contrast-enhanced breast MRI may also be useful in identifying patients with high-grade DCIS, particularly those that could be mammographically occult \[48,69]. For detecting high-grade DCIS, the sensitivity of mammography may be lower than for breast MRI. A study of 167 women diagnosed with pure DCIS who had preoperative mammography and breast MRI found that 56% of the DCIS cases were diagnosed by mammography, 92% by breast MRI, and 48% of high-grade DCIS Breast MRI may be useful for patients with newly diagnosed DCIS by detecting additional areas of ipsilateral or contralateral breast DCIS, by more accurately estimating lesion size, and by predicting upgrade to invasive cancer \[67]. A secondary analyses of a multicenter prospective clinical trial from the Eastern Cooperative Oncology Group- American College of Radiology Imaging Network (ECOG-ACRIN) Cancer Research group of 339 women with DCIS diagnosed with conventional imaging (mammography and US) confirmed via CNB who underwent MRI found that MRI showed nonmass enhancement in 58% patients. MRI exams showed larger median tumor size than mammograms and yielded an additional cancer detection rate of 6.2% (16 additional ipsilateral malignant lesions found and 5 contralateral malignant lesions detected) with a false-positive rate of 14.2% \[67]. Because mammography has been reported to underestimate the extent of DCIS, breast MRI may be especially useful for evaluating patients with DCIS \[58]. When used in conjunction with mammography, breast MRI has the potential to guide clinical management of DCIS, however, long-term clinical outcome data are lacking \[67,68,70,71]. Although breast MRI does increase the detection of breast cancer, long-term outcome data do not support the routine 导管原位癌（DCIS）在静脉注射对比剂的乳腺MRI上通常表现为非肿块样强化、肿块或焦点样强化\[5962]。乳腺MRI上DCIS的形态学与强化动力学显著相关，非肿块样强化更可能表现为中等持续强化动力学，而焦点或肿块则表现为快速平台期或流出型动力学\[59,63]。小于1.5 cm的DCIS病灶更可能出现快速初始强化（P = 0.004）\[59]。钙化和非钙化DCIS在乳腺MRI上表现相似\[59]。乳腺MRI的若干重要进展将其检测DCIS的敏感性提高至85%至92%，包括从高空间成像向高时间分辨率成像的转变、从主要解读诊断性研究向高风险患者筛查的演变，以及对非肿块样强化认识的深化\[48,6466]。对比增强乳腺MRI可识别大多数纯DCIS病灶，可能发现多灶性或多中心性疾病，并可预测升级为浸润性癌\[67,68]。一项对51例经活检证实DCIS并接受静脉对比剂乳腺MRI的研究发现，MRI显示了88%的DCIS病灶，预测了82%病例升级为浸润性疾病，并预测了90%病例的多中心性\[68]。对比增强乳腺MRI也可能有助于识别高级别DCIS患者，特别是那些乳腺X线摄影隐匿的病例\[48,69]。对于检测高级别DCIS，乳腺X线摄影的敏感性可能低于乳腺MRI。一项针对167例术前接受乳腺X线摄影和乳腺MRI的纯DCIS患者的研究发现，56%的DCIS病例通过乳腺X线摄影诊断，92%通过乳腺MRI诊断，48%的高级DCIS通过乳腺MRI检测。乳腺MRI可能对新诊断DCIS患者有用，可通过检测同侧或对侧乳腺额外DCIS区域、更准确评估病灶大小以及预测升级为浸润性癌来指导治疗\[67]。东部肿瘤协作组美国放射学会影像网络（ECOGACRIN）癌症研究组一项多中心前瞻性临床试验的二次分析纳入339例经传统影像学（乳腺X线摄影和US）诊断并通过CNB证实DCIS的女性，发现MRI显示58%的患者存在非肿块样强化。MRI检查显示的中位肿瘤尺寸大于乳腺X线摄影，并带来6.2%的额外癌症检出率（发现16个额外同侧恶性病灶和5个对侧恶性病灶），假阳性率为14.2%\[67]。由于据报道乳腺X线摄影会低估DCIS范围，乳腺MRI可能特别适用于评估DCIS患者\[58]。
* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 5
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0003 / R:CR000418
  * 证据强度: StrongReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: Diagnostic mammography, and possibly US, are often used to evaluate tumor size and extent of disease during the initial diagnostic workup and before pathological diagnosis. DCIS may present on US as a mass, nonmass lesion, or ductal dilatation. US most commonly demonstrates pure DCIS lesions (86%), including 13% of cases of clinically and mammographically occult pure DCIS \[77]. Approximately 6% to 23% of DCIS lesions are not detected by DCIS with microcalcifications on mammography demonstrate US findings in 80% of cases, most commonly heterogeneous hyper- or isoechoic parenchyma with intralesional microcalcifications and without posterior acoustic features \[77]. DCIS without microcalcifications on mammography has shown positive US findings in 98% of cases, most commonly masses with round or oval shape, microlobulated margins, parallel orientation, heterogeneous mild hypoechogenicity, and posterior acoustic features \[77]. Ductal dilatation and intralesional cystic foci were present in 18% and 24% of pure DCIS, respectively \[77]. In an analysis of 809 DCIS lesions surgically treated across 16 institutions, 705 (87%) were seen by US, with the most common US imaging findings of DCIS being nonmass abnormalities (64%), such as hypoechoic areas in the mammary gland (49%) and ductal abnormalities (10%), followed by masses (36%) \[79]. Given the increased awareness of the limited sensitivity of screening mammography for women with dense breasts, whole breast screening US has emerged as a supplemental screening tool \[80]. This section was previously described in the ACR Appropriateness Criteria ® topic on “ Supplemental Breast Cancer Screening Based on Breast Density ” \[81]. The increasing use of breast US in screening has resulted in DCIS being detected by US alone. In this clinical scenario, DCIS commonly presents as cystic or solid localized lesions, often of low grade \[82]. The incremental cancer detection of US appears to be maintained after patients undergo tomosynthesis. A trial of 3,231 women found that screening US identified 3.4 per 1,000 cancers after patients underwent tomosynthesis, with 4% of these lesions being DCIS \[83]. A trial of 7,146 paired tomosynthesis and US examinations found a supplemental cancer detection rate after tomosynthesis of 2.4 per 1,000 (positive predictive value 19.8%), with 4% of these lesions being DCIS \[84]. US has demonstrated a lower sensitivity than breast MRI for the detection of DCIS ( P \< .001) and a lower sensitivity for the detection of DCIS compared to invasive carcinoma \[52]. 诊断性乳腺X线摄影以及可能的超声检查常用于初始诊断检查期间及病理诊断前评估肿瘤大小和疾病范围。导管原位癌在超声上可表现为肿块、非肿块性病变或导管扩张。超声最常显示纯导管原位癌病灶（86%），包括13%临床和乳腺X线摄影隐匿的纯导管原位癌病例\[77]。约6%至23%的导管原位癌病灶未被乳腺X线摄影检出。伴有微钙化的导管原位癌在80%的病例中显示超声异常，最常见表现为异质性高回声或等回声实质伴病灶内微钙化且无后方声学特征\[77]。乳腺X线摄影无微钙化的导管原位癌在98%的病例中显示阳性超声表现，最常见表现为圆形或椭圆形肿块、微小叶状边缘、平行方位、异质性轻度低回声及后方声学特征\[77]。纯导管原位癌分别存在18%和24%的导管扩张和病灶内囊性灶\[77]。对16个机构手术治疗的809例导管原位癌病灶分析显示，705例（87%）经超声发现，导管原位癌最常见的超声影像学表现是非肿块异常（64%），如乳腺腺体中的低回声区（49%）和导管异常（10%），其次为肿块（36%）\[79]。鉴于对致密乳腺女性筛查性乳腺X线摄影敏感性有限的认识提高，全乳腺筛查超声已成为补充性筛查工具\[80]。本节先前在ACR适宜性标准®“基于乳腺密度的补充性乳腺癌筛查”专题中已有描述\[81]。超声在筛查中的应用日益增加导致导管原位癌可单独经超声检出。在此临床情境下，导管原位癌通常表现为囊性或实性局灶性病变，常为低级别\[82]。增量癌症检出率在患者接受断层合成摄影后似乎得以维持。一项对3,231名女性的试验发现，筛查超声在患者接受断层合成摄影后检出3.4/1000的癌症，其中4%为导管原位癌\[83]。一项对7,146次配对断层合成摄影和超声检查的试验发现，断层合成摄影后的补充癌症检出率为2.4/1000（阳性预测值19.8%），其中4%为导管原位癌\[84]。超声对导管原位癌的检出敏感性低于乳腺MRI（P \< .001），且对导管原位癌的检出敏感性低于浸润癌\[52]。
* 检查项目: Mammography With IV Contrast / MG双侧乳腺钼靶导管造影
  * 评分: 2
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0004 / R:CR000419
  * 证据强度: StrongReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is insufficient evidence to support routine use of mammography with IV contrast for initial imaging of newly diagnosed DCIS. Few studies have evaluated the use of mammography with IV contrast for the evaluation of DCIS. Mammography with IV contrast protocols require performance of a standard 2-D mammogram that should be interpreted in addition to the contrast-enhanced image. The standard 2-D mammogram can detect the microcalcifications often associated with DCIS. DCIS demonstrates varied appearances on mammography with IV contrast, such as enhancement at site of suspicious calcifications, no enhancement at site of suspicious calcifications, and enhancement at a site remote to suspicious calcifications \[53,54]. Small studies have demonstrated enhancement of DCIS-associated calcifications seen on mammography with IV contrast ranging from 67% to 84% \[55-57]. A review of 95 women found that, although 12 cases of suspicious calcifications were identified, 4 showed no enhancement despite biopsy results demonstrating DCIS and invasive lobular cancer \[57]. A review of 94 biopsied lesions found that 16 of 19 (84%) cases of DCIS showed enhancement \[55]. A study of 147 women undergoing mammography with IV contrast found that 81% (27 of 33) pure DCIS lesions demonstrated enhancement \[56]. These findings suggest that the absence of enhancement is insufficient to exclude DCIS, but the presence of enhancement raises the suspicion for malignancy. The usefulness of mammography with IV contrast arises from identifying nonmass enhancement or an enhancing mass that suggests malignancy, noting that the absence of enhancement tends to favor benignity or low-grade DCIS \[54]. In a small study that included 8 cases of biopsy-proven DCIS, measurements of the digital mammography was found to underestimate tumor size derived by histopathologic findings by 7 mm and mammography with IV contrast overestimated tumor size by 11 mm \[58]. Because of technical limitations, mammography with IV contrast may be unable to identify some lesions in the far posterior breast and in the axilla. 现有证据不足以支持常规使用静脉对比剂乳腺X线摄影作为新诊断DCIS的初始影像学检查。少数研究评估了静脉对比剂乳腺X线摄影在DCIS评估中的应用。静脉对比剂乳腺X线摄影方案需执行标准二维乳腺X线摄影，其影像应连同增强图像共同解读。标准二维乳腺X线摄影可检测常与DCIS相关的微钙化。静脉对比剂乳腺X线摄影中DCIS表现多样，如可疑钙化位点强化、可疑钙化位点无强化、以及远离可疑钙化位点的强化\[53,54]。小型研究显示静脉对比剂乳腺X线摄影中DCIS相关钙化强化率为67%至84%\[5557]。一项95例女性回顾性研究发现，虽识别出12例可疑钙化，其中4例无强化但活检结果显示DCIS与浸润性小叶癌\[57]。一项94例活检病变回顾发现19例DCIS中16例（84%）显示强化\[55]。一项147例接受静脉对比剂乳腺X线摄影的女性研究发现81%（33例
* 检查项目: CT Chest With IV Contrast / CT胸部(增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0017 / R:CR000420
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明: There is no evidence to support the use of CT chest with intravenous (IV) contrast for initial imaging of newly diagnosed DCIS. The American Society of Clinical Oncology (ASCO) published Choosing Wisely guidelines advises against routine performance of PET, CT, and radionuclide bone scans in the staging of early breast cancer at low risk for metastasis, given the lack of evidence demonstrating a benefit in asymptomatic individuals with newly identified DCIS, or clinical stage I or II disease, because unnecessary imaging can lead to harm through unnecessary radiation exposure, misdiagnosis, unnecessary invasive procedures, overtreatment, and treatment-related complications \[34]. 目前尚无证据支持对新诊断的导管原位癌（DCIS）患者初始影像学检查采用静脉注射造影剂的胸部CT扫描。美国临床肿瘤学会（ASCO）发布的明智选择指南明确指出：鉴于缺乏证据表明对无症状的新发DCIS患者或临床I/II期乳腺癌患者有益，不推荐在低转移风险的早期乳腺癌分期中常规使用PET、CT及放射性核素骨扫描检查。不必要的影像学检查可能因辐射暴露、误诊、非必要侵入性操作、过度治疗及相关并发症而对患者造成伤害\[34]。
* 检查项目: CT Chest Without IV Contrast / CT胸部(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0019 / R:CR000422
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明: There is no evidence to support the use of CT chest without IV contrast for initial imaging of newly diagnosed DCIS. The ASCO published Choosing Wisely guidelines advises against routine performance of PET, CT, and radionuclide bone scans in the staging of early breast cancer at low risk for metastasis, given the lack of evidence demonstrating a benefit in asymptomatic individuals with newly identified DCIS, or clinical stage I or II disease, because unnecessary imaging can lead to harm through unnecessary radiation exposure, misdiagnosis, unnecessary invasive procedures, overtreatment, and treatment-related complications \[34]. 无证据支持对新诊断的导管原位癌（DCIS）进行初始影像学检查时使用无静脉注射对比剂的胸部CT。美国临床肿瘤学会（ASCO）发布的明智选择指南建议，在低转移风险的早期乳腺癌分期中，不常规进行PET、CT和放射性核素骨扫描，因为缺乏证据表明这些检查对新确诊的无症状DCIS或临床I期、II期患者有益。不必要的影像学检查可能通过不必要的辐射暴露、误诊、不必要的侵入性操作、过度治疗及治疗相关并发症造成伤害\[34]。
* 检查项目: CT Chest Without and With IV Contrast / CT胸部(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0018 / R:CR000421
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明: There is no evidence to support the use of CT chest without and with IV contrast for initial imaging of newly diagnosed DCIS. The ASCO published Choosing Wisely guidelines advises against routine performance of PET, CT, and radionuclide bone scans in the staging of early breast cancer at low risk for metastasis, given the lack of evidence demonstrating a benefit in asymptomatic individuals with newly identified DCIS, or clinical stage I or II disease, because unnecessary imaging can lead to harm through unnecessary radiation exposure, misdiagnosis, unnecessary invasive procedures, overtreatment, and treatment-related complications \[34]. 无证据支持对新诊断的导管原位癌（DCIS）初始影像学检查采用胸部CT平扫+增强扫描。美国临床肿瘤学会（ASCO）发布的明智选择指南指出：鉴于缺乏证据表明影像学检查能为新确诊DCIS或临床I/II期乳腺癌的无症状患者带来获益，且不必要检查可能因辐射暴露、误诊、非必要有创操作、过度治疗及治疗相关并发症造成伤害，故不推荐对低转移风险的早期乳腺癌患者常规进行PET、CT及放射性核素骨扫描等分期检查\[34]。
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000424
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no evidence to support the use of MRI breast without IV contrast for initial imaging of newly diagnosed DCIS. 无证据支持对新诊断的导管原位癌（DCIS）初始影像学检查使用无静脉注射对比剂的乳腺MRI。
* 检查项目: FDG-PET Breast Dedicated / PET/CT局部(胸部)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0016 / R:CR000423
  * 证据强度: StrongReferences
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no evidence to support the use of fluorine-18-2-fluoro-2-deoxy-D-glucose (FDG)-PET breast dedicated for initial imaging of newly diagnosed DCIS. Limited studies have suggested that FDG-PET dedicated breast may allow for identification of some forms of DCIS, yet there are insufficient data to substantiate routine use of FDG-PET \[49,50]. In a study consisting of 139 surgery- confirmed pure DCIS cases (50 high-risk and 89 low-risk DCIS), the reported sensitivity and specificity of dedicated breast PET to differentiate between indolent and potentially aggressive DCIS were 90% (95% confidence interval \[CI], 77%-96%) and 92% (95% CI, 84%-97%), respectively \[51]. The ASCO published Choosing Wisely guidelines advises against routine performance of PET, CT, and radionuclide bone scans in the staging of early breast cancer at low risk for metastasis, given the lack of evidence demonstrating a benefit in asymptomatic individuals with newly identified DCIS, or clinical stage I or II disease, because unnecessary imaging can lead to harm through unnecessary radiation exposure, misdiagnosis, unnecessary invasive procedures, overtreatment, and treatment-related complications \[34]. 目前尚无证据支持将氟-18-2-氟-2-脱氧-D-葡萄糖（FDG）-PET乳腺专用显像用于新诊断DCIS的初始影像学评估。有限研究表明FDG-PET乳腺专用显像可能识别某些类型的DCIS，但现有数据不足以证实其常规应用的合理性\[49,50]。一项包含139例经手术证实的单纯DCIS病例（50例高风险和89例低风险DCIS）的研究显示，乳腺专用PET鉴别惰性与潜在侵袭性DCIS的敏感性和特异性分别为90%（95%置信区间\[CI]，77%-96%）和92%（95%CI，84%-97%）\[51]。美国临床肿瘤学会（ASCO）发布的明智选择指南不建议对转移风险低的早期乳腺癌患者常规进行PET、CT和放射性核素骨扫描分期，因为在无症状的新确诊DCIS或临床I/II期患者中缺乏获益证据，不必要的影像学检查可能通过辐射暴露、误诊、不必要的有创操作、过度治疗及治疗相关并发症造成伤害\[34]。
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000425
  * 证据强度: ModerateReferences
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: Currently, there is insufficient evidence to support the use of sestamibi molecular breast imaging (MBI) for initial imaging of newly diagnosed DCIS; however, there is developing data from small studies and the science is evolving. The sensitivity of MBI in detecting DCIS may be similar to mammography and breast MRI. A meta-analysis of 19 studies evaluating MBI used as an adjunct to mammography found a pooled sensitivity of 88% for detecting DCIS, similar to mammography and breast MRI \[74]. In a retrospective study of 33 patients, the pattern of uptake for DCIS lesions at MBI correlated well with mammography, with MBI demonstrating improved assessment of local disease extent \[75]. Regarding use of MBI to evaluate for residual disease, MBI may show similar disease extent as breast MRI before neoadjuvant chemotherapy (NAC), and MBI may be an alternative to breast MRI \[76]. Defining the extent of residual disease compared with pathologic evaluation also was limited after NAC for both breast MRI and MBI. A study of patients after NAC found that 56 women had residual invasive disease or DCIS, and post–NAC findings were positive in 82% of MRI patients and 59% of MBI examinations, yielding false-negative rates of 18% by MRI and 41% by MBI \[76]. Neither breast MRI nor MBI showed sufficient accuracy after NAC in predicting breast pathologic complete response to obviate tissue diagnosis to assess for residual invasive disease \[76]. 目前尚无充分证据支持使用司他比锝分子乳腺成像（MBI）对新诊断的导管原位癌（DCIS）进行初始影像学检查；但来自小型研究的数据正在积累，相关科学认识也在不断发展。MBI检测DCIS的灵敏度可能与乳腺X线摄影和乳腺MRI相当。一项针对19项评估MBI作为乳腺X线摄影辅助手段研究的荟萃分析发现，其检测DCIS的综合灵敏度为88%，与乳腺X线摄影和乳腺MRI相似\[74]。一项包含33例患者的回顾性研究显示，MBI对DCIS病灶的摄取模式与乳腺X线摄影高度一致，且MBI在局部病变范围评估方面更具优势\[75]。关于MBI用于评估残留病灶，新辅助化疗（NAC）前MBI显示的病变范围可能与乳腺MRI相似，MBI可作为乳腺MRI的替代选择\[76]。在NAC后，无论是乳腺MRI还是MBI，与病理评估相比对残留病灶范围的界定均存在局限性。一项针对NAC后患者的研究发现，56例女性存在残留浸润性病灶或DCIS，NAC后MRI检查阳性率为82%，MBI检查为59%，导致MRI和MBI的假阴性率分别为18%和41%\[76]。NAC后，乳腺MRI和MBI在预测乳腺病理完全缓解方面均未显示出足够准确性，因此仍需通过组织学诊断来评估残留浸润性病灶\[76]。

##### S0060 Variant: Variant 2:  Adult. Newly diagnosed DCIS. No surgical intervention. Active surveillance. | 成人。新发导管原位癌。未行手术干预。主动监测。

检查推荐列表：

* 检查项目: Digital Breast Tomosynthesis Diagnostic / MG双侧乳腺钼靶
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0010 / R:CR000426
  * 证据强度: ModerateReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: In a retrospective study consisting of 29 patients with DCIS who underwent active surveillance \[86], the 29 patients were divided into 2 groups. Group 1 consisted of 22 (75.9%) nontrial active surveillance patients who refused surgery or were not surgical candidates, and of those patients 16 (72.7%) received hormonal therapy (9 letrozole, 7 diagnostic mammography with a mean long-axis length of 3.4 cm (range 0.3-8.0 cm). Two of the DCIS cases were detected on high-risk screening MRI that presented as clumped morphologies and multiple or regional distributions. Group 2 consisted of 7 (24.1%) patients who were enrolled in a trial of letrozole and deferred surgical excision for 6 to 12 months. In Group 2, all patients presented with calcifications and the mean long-axis length was 4.7 cm (range 2.6-10.4 cm). The authors reported that the imaging follow-up in Group 1 was nonstandardized, but all patients underwent at least a yearly 2-D mammography with a directed US (50%, 11/22) or an MRI (55%, 12/22) performed at the discretion of the surgical oncologist or radiologist \[86]. In Group 2, all patients were scheduled for mammography and MRI according to the study protocol \[87]. The median follow-up for Group 1 was 2.7 years (range 0.6-13.9 years). Of the patients in Group 1, 15 (68%) had stable imaging, whereas 7 (32%) patients underwent additional biopsies that yielded invasive ductal carcinoma in 2 patients after 3.9 and 3.6 years who developed increasing calcifications and new masses, respectively. On surgical excision, 1 (14%) patient in Group 2 was upstaged to DCIS with microinvasion, whereas the other 6 patients had only DCIS on final pathology. Between the patients in both groups with mammographic calcifications (n = 26), there was no progression to invasive disease among those with stable (50%, 13/26) or decreased (19%, 5/26) calcifications \[86]. A total of 79 patients were enrolled in a phase II single-arm multicenter cooperative-group (CALGB 40903) trial conducted in postmenopausal patients diagnosed with ER-positive DCIS without invasion and treated with letrozole 2.5 mg/day for 6 months before surgery \[87]. Mammography (digital 2-view bilateral mammograms for each breast with additional images as deemed necessary by the breast radiologist) was obtained at baseline and repeated after 6 months or within 4 weeks before surgical excision. Assessment of mammographic disease was based exclusively on total extent of calcifications (patients with a mass associated with DCIS were excluded from the trial). As part of the study protocol, contrast-enhanced bilateral breast MRI was also obtained at baseline and repeated after 3 months and 6 months. The results demonstrated that, in 54 patients with both baseline and 6-month mammograms, the median reduction in extent of disease was 5.0 mm (14.5%; interquartile range 10.8; P = .007). In 67 patients with data from all MRI study time points, the baseline MRI volumes ranged from 0.004 to 26.3 cm 3 . Median reductions from baseline MRI volume (1.4 cm 3 ) were 0.6 cm 3 (61.0%) at 3 months ( P \< .001) and 0.8 cm 3 (71.7%) 一项回顾性研究纳入了29例接受主动监测的DCIS患者\[86]，该研究将患者分为两组。第1组包含22例（75.9%）非试验性主动监测患者（拒绝手术或不适合手术），其中16例（72.7%）接受激素治疗（9例来曲唑，7例他莫昔芬），6例（27.3%）未接受治疗。该组86%（19/22）的患者在诊断性乳腺X线摄影中表现为钙化灶，平均长轴长度为3.4 cm（范围0.38.0 cm）。其中2例DCIS通过高危筛查MRI发现，表现为簇状形态及多发性或区域性分布。第2组包含7例（24.1%）参与来曲唑试验并延迟手术切除6至12个月的患者。该组所有患者均表现为钙化灶，平均长轴长度为4.7 cm（范围2.610.4 cm）。作者报告第1组的影像学随访未标准化，但所有患者至少每年接受一次二维乳腺X线摄影，并根据肿瘤外科医师或放射科医师的判断补充定向US（50%，11/22）或MRI（55%，12/22）\[86]。第2组所有患者均按研究方案安排乳腺X线摄影和MRI检查\[87]。第1组中位随访时间为2.7年（范围0.613.9年）。该组15例（68%）患者影像学表现稳定，7例（32%）接受了额外活检，其中2例分别在3.9年和3.6年后进展为浸润性导管癌（分别出现钙化灶增多和新发肿块）。手术切除后，第2组中1例（14%）患者分期升级为伴微浸润的DCIS，其余6例术后病理仅为DCIS。在两组合并的乳腺X线钙化灶患者（n=26）中，钙化稳定（50%，13/26）或减少（19%，5/26）者均未进展为浸润性疾病\[86]。
* 检查项目: Mammography Diagnostic / MG双侧乳腺钼靶
  * 评分: 8
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0010 / R:CR000426
  * 证据强度: ModerateReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: In a retrospective study consisting of 29 patients with DCIS who underwent active surveillance \[86], the 29 patients were divided into 2 groups. Group 1 consisted of 22 (75.9%) nontrial active surveillance patients who refused surgery or were not surgical candidates, and of those patients 16 (72.7%) received hormonal therapy (9 letrozole, 7 tamoxifen) and 6 (27.3%) did not. In Group 1, 86% (19/22) of the patients presented with calcifications on diagnostic mammography with a mean long-axis length of 3.4 cm (range 0.3-8.0 cm). Two of the DCIS cases were detected on high-risk screening MRI that presented as clumped morphologies and multiple or regional distributions. Group 2 consisted of 7 (24.1%) patients who were enrolled in a trial of letrozole and deferred surgical excision for 6 to 12 months. In Group 2, all patients presented with calcifications and the mean long-axis length was 4.7 cm (range 2.6-10.4 cm). The authors reported that the imaging follow-up in Group 1 was nonstandardized, but all patients underwent at least a yearly 2-D mammography with a directed US (50%, 11/22) or an MRI (55%, 12/22) performed at the discretion of the surgical oncologist or radiologist \[86]. In Group 2, all patients were scheduled for mammography and MRI according to the study protocol \[87]. The median follow-up for Group 1 was 2.7 years (range 0.6-13.9 years). Of the patients in Group 1, 15 (68%) had stable imaging, whereas 7 (32%) patients underwent additional biopsies that yielded invasive ductal carcinoma in 2 patients after 3.9 and 3.6 years who developed increasing calcifications and new masses, respectively. On surgical excision, 1 (14%) patient in Group 2 was upstaged to DCIS with microinvasion, whereas the other 6 patients had only DCIS on final pathology. Between the patients in both groups with mammographic calcifications (n = 26), there was no progression to A total of 79 patients were enrolled in a phase II single-arm multicenter cooperative-group (CALGB 40903) trial conducted in postmenopausal patients diagnosed with ER-positive DCIS without invasion and treated with letrozole 2.5 mg/day for 6 months before surgery \[87]. Mammography (digital 2-view bilateral mammograms for each breast with additional images as deemed necessary by the breast radiologist) was obtained at baseline and repeated after 6 months or within 4 weeks before surgical excision. Assessment of mammographic disease was based exclusively on total extent of calcifications (patients with a mass associated with DCIS were excluded from the trial). As part of the study protocol, contrast-enhanced bilateral breast MRI was also obtained at baseline and repeated after 3 months and 6 months. The results demonstrated that in 54 patients with both baseline and 6-month mammograms, the median reduction in extent of disease was 5.0 mm (14.5%; interquartile range 10.8; P = .007). In 67 patients with data from all MRI study time points, the baseline MRI volumes ranged from 0.004 to 26.3 cm 3 . Median 一项II期单臂多中心协作组（CALGB 40903）试验纳入了79例绝经后ER阳性无浸润DCIS患者，术前接受来曲唑2.5 mg/天治疗6个月\[87]。基线及术后6个月（或术前4周内）行乳腺X线摄影（双侧乳腺数字双视图摄片，必要时由乳腺放射科医师补充投照）。乳腺X线病变评估仅基于钙化灶总范围（合并肿块的DCIS患者被排除）。根据研究方案，基线、3个月和6个月时均行对比剂增强双侧乳腺MRI。结果显示：54例同时拥有基线和6个月乳腺X线数据的患者中，病变范围中位减少值为5.0 mm（14.5%；四分位距10.8；P=0.007）。67例拥有全部MRI时间点数据的患者中，基线MRI体积范围为0.00426.3 cm³。与基线MRI体积（1.4 cm³）相比，3个月时中位减少0.6 cm³（61.0%）（P\<0.001），6个月时中位减少0.8 cm³（71.7%）。
* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 5
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0005 / R:CR000428
  * 证据强度: StrongReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is limited evidence to support the use of breast MRI without and with IV contrast in active surveillance in patients with newly diagnosed DCIS. A total of 79 patients were enrolled in a phase II single-arm multicenter cooperative-group (CALGB 40903) trial conducted in postmenopausal patients diagnosed with ER-positive DCIS without invasion and treated with letrozole 2.5 mg/day for 6 months before surgery \[87]. Mammography (digital 2-view bilateral mammograms for each breast with additional images as deemed necessary by the breast radiologist) was obtained at baseline and repeated after 6 months or within 4 weeks before surgical excision. Assessment of mammographic disease was based exclusively on total extent of calcifications (patients with a mass associated with DCIS were excluded from the trial). As part of the study protocol, contrast-enhanced bilateral breast MRI was also obtained at baseline and repeated after 3 months and 6 months. The results demonstrated that, in 54 patients with both baseline and 6-month mammograms, the median reduction in extent of disease was 5.0 mm (14.5%; interquartile range 10.8; P = .007). In 67 patients with data from all MRI study time points, the baseline MRI volumes ranged from 0.004 to 26.3 cm 3 . Median reductions from baseline MRI volume (1.4 cm 3 ) were 0.6 cm 3 (61.0%) at 3 months ( P \< .001) and 0.8 cm 3 (71.7%) at 6 months ( P \< .001) \[88]. Of the 59 patients who underwent surgery per study protocol, 50 (85%) patients had residual DCIS, invasive cancer was detected in 6 (10%) patients, and 9 (15%) patients had pathologic complete response on final pathology \[88]. There was no significant correlation observed between baseline mammographic maximum extent and pathologic DCIS size or between baseline MRI maximum diameter and pathologic DCIS size. However, significant correlation was observed between 6-month MRI maximum diameter and pathologic DCIS size ( P = .001) \[88]. Because mammography has been reported to underestimate the extent of DCIS, breast MRI may be especially useful for evaluating patients with DCIS \[58]. When used in conjunction with mammography, breast MRI has the potential to guide clinical management of DCIS, however, long-term clinical outcome data are lacking \[67,68,70,71]. 支持在新诊断DCIS患者主动监测中使用无对比剂及对比增强乳腺MRI的证据有限。一项II期单臂多中心协作组试验（CALGB 40903）纳入了79例绝经后患者，这些患者被诊断为ER阳性无浸润DCIS，并在手术前接受来曲唑2.5 mg/天治疗6个月\[87]。基线时进行乳腺X线摄影（双侧乳腺数字双视图 mammogram，必要时由乳腺放射科医师追加投照），并在6个月后或手术切除前4周内重复检查。乳腺X线影像评估仅基于钙化总范围（伴有肿块的DCIS患者被排除出试验）。根据研究方案，基线时还进行了对比增强双侧乳腺MRI，并在3个月和6个月后重复。结果显示，在54例同时拥有基线和6个月乳腺X线影像的患者中，病变范围中位减少值为5.0 mm（14.5%；四分位距10.8；P = 0.007）。在67例拥有所有MRI时间点数据的患者中，基线MRI体积范围为0.004至26.3 cm³。与基线MRI体积（1.4 cm³）相比，3个月时中位减少0.6 cm³（61.0%）（P \< 0.001），6个月时减少0.8 cm³（71.7%）（P \< 0.001）\[88]。在59例按研究方案接受手术的患者中，50例（85%）存在残留DCIS，6例（10%）检出浸润癌，9例（15%）在最终病理学上达到病理学完全缓解\[88]。未观察到基线乳腺X线摄影最大范围与病理DCIS大小之间存在显著相关性，基线MRI最大直径与病理DCIS大小之间也无显著相关性。然而，6个月MRI最大直径与病理DCIS大小之间存在显著相关性（P = 0.001）\[88]。由于据报道乳腺X线摄影会低估DCIS范围，乳腺MRI可能对评估DCIS患者特别有用\[58]。当与乳腺X线摄影联合使用时，乳腺MRI有潜力指导DCIS的临床管理，但缺乏长期临床结局数据\[67,68,70,71]。
* 检查项目: Mammography With IV Contrast / MG双侧乳腺钼靶导管造影
  * 评分: 2
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0004 / R:CR000429
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no evidence to support the use of mammography with IV contrast in active surveillance in patients with newly diagnosed DCIS. 没有证据支持在新诊断的导管原位癌患者进行主动监测时使用静脉造影乳腺X线摄影。
* 检查项目: CT Chest With IV Contrast / CT胸部(增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0017 / R:CR000430
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明: There is no evidence to support the use of CT of the chest with IV contrast in active surveillance in patients with newly diagnosed DCIS. 没有证据支持在新诊断的导管原位癌患者进行主动监测时使用静脉注射对比剂的胸部CT检查。
* 检查项目: CT Chest Without IV Contrast / CT胸部(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0019 / R:CR000432
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明: There is no evidence to support the use of CT of the chest without IV contrast in active surveillance in patients with newly diagnosed DCIS. 没有证据支持在新诊断的导管原位癌患者主动监测中使用无静脉注射对比剂的胸部CT检查。
* 检查项目: CT Chest Without and With IV Contrast / CT胸部(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0018 / R:CR000431
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明: There is no evidence to support the use of CT of the chest without and with IV contrast in active surveillance in patients with newly diagnosed DCIS. 没有证据支持在新诊断DCIS患者的主动监测中使用无和有静脉注射对比剂的胸部CT检查。
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000434
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no evidence to support the use of breast MRI without IV contrast in active surveillance in patients with newly diagnosed DCIS. 没有证据支持在新诊断的导管原位癌患者主动监测中使用无静脉造影剂的乳腺MRI。
* 检查项目: FDG-PET Breast Dedicated / PET/CT局部(胸部)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0016 / R:CR000433
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no evidence to support the use of dedicated FDG-PET of the breast in active surveillance in patients with newly diagnosed DCIS. 没有证据支持在新诊断的导管原位癌患者进行主动监测时使用专用的乳腺FDG-PET检查。
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000435
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no evidence to support the use of sestamibi MBI in active surveillance in patients with newly diagnosed DCIS. 没有证据支持在新诊断的导管原位癌患者主动监测中使用司他比锝MIBI。
* 检查项目: US breast / US乳腺常规超声检查
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0003 / R:CR000436
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明:

##### S0061 Variant: Variant 3:  Adult. Evaluation for local recurrence in patient with history of breast conservation therapy for DCIS. Routine surveillance. | 成人。既往因导管原位癌行保乳治疗，评估局部复发。常规监测。

检查推荐列表：

* 检查项目: Digital Breast Tomosynthesis Diagnostic / MG双侧乳腺钼靶
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0010 / R:CR000437
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: This section was previously described in the ACR Appropriateness Criteria ® topic on “ Imaging After Breast Surgery ” \[99]. NCCN and American Society of Radiology Oncology (ASTRO) guidelines advise surveillance/imaging follow-up of postsurgical DCIS, which includes mammography every 12 months with the first mammogram occurring 6 to 12 months after breast conservation therapy \[27]. Patients treated with breast- conserving therapy should have their first posttreatment mammogram no earlier than 6 months after definitive RT. Subsequent mammograms should be obtained every 6 to 12 months for surveillance of abnormalities. The ASCO Practice Guidelines for Breast Cancer Follow-Up and Management After Primary Treatment advise that mammography should be performed yearly if stability of mammographic findings is achieved after completion of locoregional therapy \[100,101]. For this clinical scenario, annual mammography is a helpful surveillance imaging test because it is associated with a reduction of mortality compared to patients who do not undergo annual mammography \[102,103]. For patients with a personal history of breast cancer, the most common presentation of a recurrent or second breast cancer is an abnormal mammogram in an otherwise asymptomatic patient \[99,104-106]. Mammography detects approximately 91% to 97% of cases of recurrent DCIS after BCS and can be used for the routine surveillance for local recurrence in a patient with a history of breast conservation therapy for DCIS \[89]. Of these, 75% of cases of recurrent DCIS presented mammographically as microcalcifications, and 80% of the patients whose initial DCIS presented with microcalcifications will have a recurrence manifested by microcalcifications \[89]. In 94%, the recurrent tumor calcifications had a morphology similar to the initial DCIS \[89]. In 60% to 90% of cases, recurrences are in the same quadrant \[89,90]. The ACR Practice Parameter for the Performance of Screening and Diagnostic Mammography provides guidance for patients with a history of breast cancer \[107]. Surveyed radiologists varied on their recommendation of diagnostic versus screening mammography for patients treated with breast conservation therapy with most (79%) recommending at least 1 diagnostic mammogram, 49% recommending diagnostic mammography up to 2 years, and 33% recommending diagnostic mammography from for 2 to 5 years \[108]. 本节内容先前已在ACR适宜性标准®专题“腋窝影像学检查”中阐述\[88]。Z0011试验表明，对于肿瘤尺寸＜5 cm且无临床可触及淋巴结、前哨淋巴结活检显示≤2个阳性腋窝淋巴结宏转移的女性，可避免腋窝淋巴结清扫而不影响生存率\[89]。US是评估临床或影像学发现可疑淋巴结后最成熟的腋窝无创影像学检查方法。与恶性可能性较高的US特征包括短轴淋巴结尺寸≥1 cm、皮质厚度≥0.3 cm及脂肪门缺失\[9093]。腋窝US的敏感性和特异性报告范围广泛，且这些影像学特征均不足以避免组织学取样需求。敏感性范围为26.4%至94%，特异性范围为53%至98%\[9497]。尽管单独腋窝US排除转移性疾病的NPV相对较低\[36,98]，但与低负荷患者（即符合Z0011试验腋窝保留条件者）相比，腋窝影像学检查在pN23疾病患者中检出转移性病变的可能性显著更高。因此，淋巴结病变检测有助于识别可从新辅助全身治疗中获益的患者，以实现降期、降低腋窝手术范围并避免腋窝淋巴结清扫。然而，与导管型相比，影像学检测浸润性小叶癌转移的敏感性较低\[140]。一项包含21项研究的荟萃分析显示，US联合穿刺活检将敏感性从61%提高至79%\[99101]。在一项针对1,353例新诊断浸润性乳腺癌患者的荟萃分析中，US引导空芯针活检优于US引导FNA，其报告敏感性分别为空芯针活检88%、FNA 74%\[102]。另一项研究中，腋窝US与MRI评估腋窝淋巴结性能相当\[103]。一项针对9,212例乳腺癌患者9,232次术前腋窝分期操作的荟萃分析显示，术前腋窝US引导活检可识别约50%的腋窝受累女性，但假阴性率为25%\[141]。另一项荟萃分析报告了相似结果\[100]。NCCN确实建议在术前全身治疗前考虑行腋窝US，若进行活检则需放置标记物\[126]。
* 检查项目: Mammography Screening / MG双侧乳腺钼靶
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0010 / R:CR000437
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: This section was previously described in the ACR Appropriateness Criteria ® topic on “ Imaging After Breast Surgery ” \[99]. NCCN and ASTRO guidelines advise surveillance/imaging follow-up of postsurgical DCIS which includes mammography every 12 months with the first mammogram occurring 6 to 12 months after breast conservation therapy \[27]. Patients treated with breast-conserving therapy should have their first posttreatment mammogram no earlier than 6 months after definitive RT. Subsequent mammograms should be obtained every 6 to 12 months for surveillance of abnormalities. The ASCO Practice Guidelines for Breast Cancer Follow-Up and Management After Primary Treatment advise that mammography should be performed yearly if stability of mammographic findings is achieved after completion of locoregional therapy \[100,101]. For this clinical scenario, annual mammography is a helpful surveillance imaging test because it is associated with a reduction of mortality compared to women who do not undergo annual mammography \[102,103]. For patients with a personal history of breast cancer, the most common presentation of a recurrent or second breast cancer is an abnormal mammogram in an otherwise asymptomatic patient \[99,104-106]. Mammography detects approximately 91% to 97% of cases of recurrent DCIS after BCS and can be used for the routine surveillance for local recurrence in a patient with history of breast conservation therapy for DCIS \[89]. Of these, 75% of cases of recurrent DCIS presented mammographically as microcalcifications, and 80% of the patients whose initial DCIS presented with calcifications had a morphology similar to the initial DCIS \[89]. In 60% to 90% of cases, recurrences are in the same quadrant \[89,90]. The ACR Practice Parameter for the Performance of Screening and Diagnostic Mammography provides guidance for patients with a history of breast cancer \[107]. Surveyed radiologists varied on their recommendation of diagnostic versus screening mammography for patients treated with breast conservation therapy with most (79%) recommending at least 1 diagnostic mammogram, 49% recommending diagnostic mammography up to 2 years, and 33% recommending diagnostic mammography from for 2 to 5 years \[108]. For patients with invasive breast cancer, there is limited data to support more frequent imaging of the ipsilateral breast, with a study suggesting diagnosis of second cancer at a lower stage, but this could have been to less than expected compliance of the annual surveillance group \[113]. The addition of DBT to 2-D digital mammography or 2-D synthetic images in the surveillance of patients with breast cancer history has been shown to reduce recall rates and indeterminate findings and no significant change in cancer detection rate \[109-111]. 本节内容先前已在ACR适宜性标准®专题“乳腺术后影像学检查”中阐述\[99]。NCCN和ASTRO指南建议对术后DCIS进行监测/影像学随访，包括每12个月进行一次乳腺X线摄影，首次检查应在保乳治疗后6至12个月内进行\[27]。接受保乳治疗的患者，其首次治疗后乳腺X线检查不应早于根治性放疗后6个月。后续应每6至12个月进行乳腺X线摄影以监测异常。ASCO乳腺癌初级治疗后随访和管理实践指南建议，若在完成局部区域治疗后乳腺X线检查结果趋于稳定，则应每年进行乳腺X线摄影\[100,101]。在此临床情境下，年度乳腺X线摄影是一种有用的监测影像学检查，因为与未接受年度检查的女性相比，其可降低死亡率\[102,103]。对于有个人乳腺癌病史的患者，复发或第二原发乳腺癌最常见的表现是无症状患者的乳腺X线异常\[99,104106]。乳腺X线摄影可检测约91%至97%的保乳手术（BCS）后DCIS复发案例，可用于有DCIS保乳治疗史患者的局部复发常规监测\[89]。其中，75%的DCIS复发案例在乳腺X线上表现为微钙化，且80%初始DCIS表现为钙化的患者，其复发钙化形态与初始DCIS相似\[89]。60%至90%的复发位于同一象限\[89,90]。ACR筛查和诊断性乳腺X线摄影执行实践参数为有乳腺癌病史的患者提供了指导\[107]。接受调查的放射科医生对保乳治疗后患者推荐诊断性 versus 筛查性乳腺X线摄影的意见不一：多数（79%）建议至少进行1次诊断性检查，49%建议诊断性检查持续至多2年，33%建议诊断性检查持续2至5年\[108]。对于浸润性乳腺癌患者，支持更频繁同侧乳腺影像学
* 检查项目: Digital Breast Tomosynthesis Screening / MG双侧乳腺钼靶(筛查)
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0001 / R:CR000438
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: This section was previously described in the ACR Appropriateness Criteria ® topic on “ Imaging After Breast Surgery ” \[99]. NCCN and ASTRO guidelines advise surveillance/imaging follow-up of postsurgical DCIS, which includes mammography every 12 months with the first mammogram occurring 6 to 12 months after breast conservation therapy \[27]. Patients treated with breast-conserving therapy should have their first posttreatment mammogram no earlier than 6 months after definitive RT. Subsequent mammograms should be obtained every 6 to 12 months for surveillance of abnormalities. The ASCO Practice Guidelines for Breast Cancer Follow-Up and Management After Primary Treatment advise that mammography should be performed yearly if stability of mammographic findings is achieved after completion of locoregional therapy \[100,101]. For this clinical scenario, annual mammography is a helpful surveillance imaging test because it is associated with a reduction of mortality compared to patients who do not undergo annual mammography \[102,103]. For patients with a personal history of breast cancer, the most common presentation of a recurrent or second breast cancer is an abnormal mammogram in an otherwise asymptomatic patient \[99,104-106]. Mammography detects approximately 91% to 97% of cases of recurrent DCIS after BCS and can be used for the routine surveillance for local recurrence in a patient with a history of breast conservation therapy for DCIS \[89]. Of these, 75% of cases of recurrent DCIS presented mammographically as microcalcifications, and 80% of the patients whose initial DCIS presented with microcalcifications will have a recurrence manifested by microcalcifications \[89]. In 94%, the recurrent tumor calcifications had a morphology similar to the initial DCIS \[89]. In 60% to 90% of cases, recurrences are in the same quadrant \[89,90]. The ACR Practice Parameter for the Performance of Screening and Diagnostic Mammography provides guidance for patients with a history of breast cancer \[107]. Surveyed radiologists varied on their recommendation of diagnostic versus screening mammography for patients treated with breast conservation therapy with most (79%) recommending at least 1 diagnostic mammogram, 49% recommending diagnostic mammography up to 2 years, and 33% recommending diagnostic mammography from for 2 to 5 years \[108]. The addition of DBT to 2-D digital mammography or 2-D synthetic images in the surveillance of patients with breast cancer history has been shown to reduce recall rates and indeterminate findings and no significant change in 本部分内容先前已在ACR适宜性标准®“乳腺术后影像学检查”专题中阐述\[99]。NCCN与ASTRO指南建议对术后DCIS进行监测/影像学随访，包括每12个月进行一次乳腺X线摄影，首次检查应在保乳治疗后6至12个月内进行\[27]。接受保乳治疗的患者应在根治性放疗后至少6个月进行首次治疗后乳腺X线摄影。后续应每6至12个月进行乳腺X线摄影以监测异常情况。ASCO乳腺癌初级治疗后随访与管理实践指南建议，若在完成局部区域治疗后乳腺X线检查结果趋于稳定，则应每年进行乳腺X线摄影\[100,101]。在此临床情境下，年度乳腺X线摄影是一种有效的监测影像学检查手段，因为与未接受年度检查的患者相比，其可降低死亡率\[102,103]。对于有乳腺癌个人史的患者，复发或第二原发乳腺癌最常见的表现是无症状患者的异常乳腺X线检查结果\[99,104106]。乳腺X线摄影可检测约91%至97%的保乳手术后DCIS复发病例，可用于DCIS保乳治疗史患者的常规局部复发监测\[89]。其中75%的DCIS复发病例在乳腺X线摄影中表现为微钙化，且80%初始DCIS表现为微钙化的患者复发时也会呈现微钙化\[89]。94%的复发肿瘤钙化形态与初始DCIS相似\[89]。60%至90%的复发位于同一象限\[89,90]。ACR筛查与诊断性乳腺X线摄影实践参数为有乳腺癌史的患者提供了指导\[107]。接受调查的放射科医生对保乳治疗后患者应行诊断性还是筛查性乳腺X线摄影的建议存在差异：多数（79%）建议至少进行1次诊断性乳腺X线摄影，49%建议诊断性检查持续至多2年，33%建议诊断性检查持续2至5年\[108]。在乳腺癌史患者的监测中，将DBT与2D数字乳腺X线摄影或2D合成图像结合已被证明可降低召回率和不确定发现，且对癌症检出率无显著影响。
* 检查项目: Mammography Diagnostic / MG双侧乳腺钼靶
  * 评分: 8
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0010 / R:CR000437
  * 证据强度: StrongReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: This section was previously described in the ACR Appropriateness Criteria ® topic on “ Imaging After Breast Surgery ” \[99]. NCCN and ASTRO guidelines advise surveillance/imaging follow-up of postsurgical DCIS, which includes mammography every 12 months with the first mammogram occurring 6 to 12 months after breast conservation therapy \[27]. Patients treated with breast-conserving therapy should have their first posttreatment mammogram no earlier than 6 months after definitive RT. Subsequent mammograms should be obtained every 6 to 12 months for surveillance of abnormalities. The ASCO Practice Guidelines for Breast Cancer Follow-Up and Management After Primary Treatment advise that mammography should be performed yearly if stability of mammographic findings is achieved after completion of locoregional therapy \[100,101]. For this clinical scenario, annual mammography is a helpful surveillance imaging test because it is associated with a reduction of mortality compared to patients who do not undergo annual mammography \[102,103]. For patients with a personal history of breast cancer, the most common presentation of a recurrent or second breast cancer is an abnormal mammogram in an otherwise asymptomatic patient \[99,104-106]. Mammography detects approximately 91% to 97% of cases of recurrent DCIS after BCS and can be used for the routine surveillance for local recurrence in a patient with history of breast conservation therapy for DCIS \[89]. Of these, 75% of cases of recurrent DCIS presented mammographically as microcalcifications, and 80% of the patients whose initial DCIS presented with microcalcifications will have a recurrence manifested by microcalcifications \[89]. In 94%, the recurrent tumor calcifications had a morphology similar to the initial DCIS \[89]. Detection of a tumor recurrence on mammography alone has been associated with a lower tumor stage after treatment for early stage invasive breast cancers, and toward noninvasive histology and longer disease-free survival \[112]. In 60% to 90% of cases, recurrences are in the same quadrant \[89,90]. The ACR Practice Parameter for the Performance of Screening and Diagnostic Mammography provides guidance for patients with a history of breast cancer \[107]. Surveyed radiologists varied on their recommendation of diagnostic versus screening mammography for patients treated with breast conservation therapy with most (79%) recommending at least 1 diagnostic mammogram, 49% recommending diagnostic mammography up to 2 years, and 33% recommending diagnostic mammography from for 2 to 5 years \[108]. For patients with invasive breast cancer, there is limited data to support more frequent imaging of the ipsilateral breast, with a study suggesting diagnosis of second cancer at a lower stage, but this could have been to less than expected compliance of the annual surveillance group \[113]. The addition of DBT to 2-D digital mammography or 2-D synthetic images in the surveillance of patients with breast cancer history has been shown to reduce recall rates 本节内容先前已在ACR适宜性标准®专题“乳腺术后影像学检查”中阐述\[99]。NCCN与美国放射肿瘤学会（ASTRO）指南建议对术后DCIS进行监测/影像学随访，包括每12个月进行一次乳腺X线摄影，首次检查应在保乳治疗后6至12个月内进行\[27]。接受保乳治疗的患者应在根治性放疗后至少6个月进行首次治疗后乳腺X线检查。后续应每6至12个月进行乳腺X线摄影以监测异常。ASCO原发性乳腺癌治疗后随访与管理实践指南建议，若在完成局部区域治疗后乳腺X线检查结果趋于稳定，则应每年进行乳腺X线摄影\[100,101]。在此临床情境下，年度乳腺X线摄影是一种有效的监测影像学检查手段，因为与未接受年度检查的患者相比，其可降低死亡率\[102,103]。对于有乳腺癌个人史的患者，复发或第二原发乳腺癌最常见的表现是无症状患者的异常乳腺X线影像\[99,104106]。乳腺X线摄影可检测约91%至97%的BCS术后DCIS复发案例，适用于有DCIS保乳治疗史患者的局部复发常规监测\[89]。其中75%的DCIS复发案例在影像上表现为微钙化，且80%初始DCIS表现为微钙化的患者复发时仍会呈现微钙化\[89]。94%的复发肿瘤钙化形态与初始DCIS相似\[89]。单纯通过乳腺X线摄影检测肿瘤复发与早期浸润性乳腺癌治疗后较低肿瘤分期、非浸润性组织学类型及更长无病生存期相关\[112]。60%至90%的复发位于同一象限\[89,90]。ACR筛查与诊断性乳腺X线摄影实践参数为有乳腺癌病史的患者提供了指导\[107]。接受调查的放射科医师对保乳治疗患者推荐诊断性 versus 筛查性乳腺X线摄影的意见存在差异：多数（79%）建议至少进行1次诊断性检查，49%建议诊断性检查持续至2年，33%建议持续2至5年\[108]。
* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 5
  * 适宜性: May be appropriate (Disagreement) / 可能适宜（存在争议）
  * 编码: P:PR0005 / R:CR000441
  * 证据强度: Expert OpinionReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is insufficient literature to support the routine use of MRI breast without and with IV contrast in this clinical scenario. However, high-risk patients who have undergone breast conservation therapy for DCIS may benefit from MRI high-risk surveillance of the breast, see the ACR Practice Parameter for the Performance of Contrast-Enhanced Magnetic Resonance Imaging (MRI) of the Breast \[114]. 现有文献不足以支持在此临床情境中常规使用无和有静脉注射对比剂的乳腺MRI检查。然而，接受过导管原位癌保乳治疗的高风险患者可能受益于乳腺MRI高风险监测，参见《ACR乳腺对比增强磁共振成像（MRI）操作实践参数》\[114]。
* 检查项目: Mammography With IV Contrast / MG双侧乳腺钼靶导管造影
  * 评分: 2
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0004 / R:CR000442
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is insufficient evidence to support routine use of mammography with IV contrast for routine surveillance evaluation for local recurrence in patients with a history of breast conservation therapy for DCIS. Mammography with IV contrast performs a low-energy mammogram equivalent to a mammogram without IV contrast, which can identify most cases of recurrent DCIS after BCS. However, only a few studies have evaluated the use of mammography with IV contrast for the routine evaluation for local recurrence in patients with history of breast conservation therapy for DCIS. 目前证据不足，无法支持常规使用静脉造影乳腺X线摄影对接受过DCIS保乳治疗的患者进行局部复发常规监测评估。静脉造影乳腺X线摄影的低能成像效果等同于无造影剂乳腺X线摄影，可检出保乳手术后大多数DCIS复发病例。但仅有少数研究评估了静脉造影乳腺X线摄影在DCIS保乳治疗患者局部复发常规监测中的应用价值。
* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 2
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0003 / R:CR000443
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no evidence to support the routine use of breast US for routine surveillance evaluation for local recurrence in patients with history of breast conservation therapy for DCIS. 没有证据支持常规使用乳腺超声对接受过保乳治疗的DCIS患者进行局部复发的常规监测评估。
* 检查项目: CT Chest With IV Contrast / CT胸部(增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0017 / R:CR000444
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明: There is no evidence to support the use of CT chest with IV contrast for routine surveillance evaluation for local recurrence in patients with a history of breast conservation therapy for DCIS. 没有证据支持使用静脉注射对比剂的胸部CT作为常规监测手段，用于评估曾接受保乳治疗的DCIS患者局部复发情况。
* 检查项目: CT Chest Without IV Contrast / CT胸部(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0019 / R:CR000446
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明: There is no evidence to support the use of CT chest without IV contrast for routine surveillance evaluation for local 没有证据支持使用无静脉对比剂的胸部CT进行常规局部 surveillance 评估。
* 检查项目: CT Chest Without and With IV Contrast / CT胸部(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0018 / R:CR000445
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明: There is no evidence to support the use of CT chest without and with IV contrast for routine surveillance evaluation for local recurrence in patients with a history of breast conservation therapy for DCIS. 无证据支持对接受过保乳治疗的DCIS患者常规使用无静脉造影剂及增强CT胸部检查来监测局部复发情况。
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000448
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no evidence to support the use of MRI breast without IV contrast for routine surveillance evaluation for local recurrence in patients with history of breast conservation therapy for DCIS. 无证据支持对接受过DCIS保乳治疗的患者在常规局部复发监测评估中使用无静脉造影剂的乳腺MRI。
* 检查项目: FDG-PET Breast Dedicated / PET/CT局部(胸部)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0016 / R:CR000447
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no evidence to support the use of FDG-PET breast dedicated for routine surveillance evaluation for local recurrence in patients with a history of breast conservation therapy for DCIS. 目前尚无证据支持将FDG-PET乳腺专用显像常规用于导管原位癌保乳治疗术后患者的局部复发监测评估。
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000449
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no evidence to support the use of sestamibi MBI for routine surveillance evaluation for local recurrence in patients with a history of breast conservation therapy for DCIS. 没有证据支持使用司他比锝MBI对接受过DCIS保乳治疗的患者进行常规局部复发监测评估。

##### S0062 Variant: Variant 4:  Adult. Evaluation for ipsilateral local recurrence in a patient with history of mastectomy for DCIS. Routine surveillance. | 成人。既往因导管原位癌行乳房切除术，评估同侧局部复发。常规监测。

检查推荐列表：

* 检查项目: CT Chest With IV Contrast / CT胸部(增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0017 / R:CR000450
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明: In asymptomatic patients with a history of mastectomy for DCIS, there is no evidence to support the use of CT chest with IV contrast for evaluation of local recurrence. ASCO, NCCN, and European Socitey for Medical Oncology (ESMO) all recommend against the use of CT imaging \[100,121,122] to screen for local recurrence after mastectomy. 对于曾因导管原位癌（DCIS）接受乳房切除术的无症状患者，目前无证据支持使用静脉注射对比剂的胸部CT评估局部复发。美国临床肿瘤学会（ASCO）、美国国家综合癌症网络（NCCN）及欧洲肿瘤内科学会（ESMO）均不建议采用CT影像学检查\[100,121,122]筛查乳房切除术后的局部复发。
* 检查项目: CT Chest Without IV Contrast / CT胸部(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0019 / R:CR000452
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明: In asymptomatic patients with a history of mastectomy for DCIS, there is no evidence to support the use of CT chest without IV contrast for evaluation of local recurrence. ASCO, NCCN, and ESMO all recommend against the use of CT imaging \[100,121,122] to screen for local recurrence after mastectomy. 对于曾因导管原位癌接受乳房切除术的无症状患者，目前无证据支持使用非静脉增强胸部CT评估局部复发。美国临床肿瘤学会（ASCO）、美国国家综合癌症网络（NCCN）及欧洲肿瘤内科学会（ESMO）均不建议采用CT影像学检查\[100,121,122]作为乳房切除术后局部复发的筛查手段。
* 检查项目: CT Chest Without and With IV Contrast / CT胸部(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0018 / R:CR000451
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明: In asymptomatic patients with a history of mastectomy for DCIS, there is no evidence to support the use of CT chest without and with IV contrast for evaluation of local recurrence. ASCO, NCCN, and ESMO all recommend against the use of CT imaging \[100,121,122] to screen for local recurrence after mastectomy. 对于曾因导管原位癌接受乳房切除术的无症状患者，目前无证据支持采用非增强及静脉增强胸部CT评估局部复发。美国临床肿瘤学会（ASCO）、美国国家综合癌症网络（NCCN）及欧洲肿瘤内科学会（ESMO）均不建议采用CT影像学检查\[100,121,122]作为乳房切除术后局部复发的筛查手段。
* 检查项目: Mammography Screening / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no evidence to support the use of mammography screening to evaluate for local recurrence after mastectomy. 没有证据支持使用乳腺X线摄影筛查来评估乳房切除术后局部复发情况。
* 检查项目: Digital Breast Tomosynthesis Screening / MG双侧乳腺钼靶(筛查)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0001 / R:CR000453
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no evidence to support the use of DBT to evaluate for local recurrence after mastectomy. 没有证据支持使用数字乳腺断层合成技术（DBT）评估乳房切除术后局部复发情况。
* 检查项目: Mammography With IV Contrast / MG双侧乳腺钼靶导管造影
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0004 / R:CR000456
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no evidence to support the use of mammography with IV contrast to evaluate for local recurrence after mastectomy. 没有证据支持使用静脉造影乳腺X线摄影来评估乳房切除术后局部复发情况。
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000458
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no evidence to support the use of breast MRI without IV contrast to evaluate for local recurrence after mastectomy. ASCO, NCCN, and ESMO all recommend against the use of MRI \[100,121,122] to screen for local recurrence after mastectomy. 目前无证据支持在不使用静脉造影剂的情况下采用乳腺MRI评估乳房切除术后局部复发。ASCO、NCCN和ESMO均不建议使用MRI筛查乳房切除术后局部复发\[100,121,122]。
* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000457
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is insufficient literature to support the use of breast MRI to evaluate for local recurrence after mastectomy. A single, retrospective study consisting of 402 asymptomatic mastectomy cases that underwent MRI, the cancer detection rate in the asymptomatic mastectomy side was 10/1,000. The reported sensitivity, specificity, positive predictive value, and negative predictive value of surveillance MRI was 66.7%, 99.2%, 57.1%, and 99.5%, respectively \[123] . None of the recurrences were in the 33% patients who underwent mastectomy for DCIS \[123]. ASCO, NCCN, and ESMO all recommend against the use of MRI \[100,121,122] to screen for local recurrence after mastectomy. 目前文献不足以支持使用乳腺MRI评估乳房切除术后局部复发。一项包含402例无症状乳房切除术后接受MRI检查的回顾性研究显示，无症状乳房切除侧的癌症检出率为10/1000。监测MRI的敏感性、特异性、阳性预测值和阴性预测值分别为66.7%、99.2%、57.1%和99.5%\[123]。在因DCIS接受乳房切除术的33%患者中未发现复发\[123]。ASCO、NCCN和ESMO均不建议使用MRI\[100,121,122]筛查乳房切除术后局部复发。
* 检查项目: FDG-PET Breast Dedicated / PET/CT局部(胸部)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0016 / R:CR000454
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no evidence to support the use of dedicated breast FDG-PET to evaluate for local recurrence after mastectomy. 目前尚无证据支持使用专用乳腺FDG-PET评估乳房切除术后局部复发情况。
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000459
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no evidence to support the use of sestamibi MBI to evaluate for local recurrence after mastectomy. 无证据支持使用司他比锝MBI评估乳房切除术后局部复发情况。
* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0003 / R:CR000460
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: One study consisting of 1,180 consecutive US screenings were performed for mastectomy sites and ipsilateral axillary fossae in 468 asymptomatic patients who had undergone mastectomy for breast cancer. Of the 468 patients, 19 (4.1%) had “suspicious for malignant nodules”; of these lesions, 10 (52.6%) were malignant. The sensitivity and specificity were 90.9% and 98.0%, respectively. The biopsy positive predictive value was 52.6%. The cancer detection rates with US screening of the mastectomy site and ipsilateral axillary fossae were 2.1%. The US features most common of occult recurrence at the mastectomy sites were irregular shape, not circumscribed, and hypoechoic mass with intratumoral vascularity. In addition, the authors reported that most recurrences were within the deep muscle layer \[124]. 一项研究对468例因乳腺癌接受乳房切除术后无症状患者进行了连续1180次超声筛查，检查部位包括乳房切除区域及同侧腋窝。468例患者中，19例（4.1%）存在“可疑恶性结节”；其中10例（52.6%）为恶性。敏感性和特异性分别为90.9%和98.0%。活检阳性预测值为52.6%。乳房切除区域及同侧腋窝的超声筛查癌症检出率为2.1%。乳房切除区域隐匿性复发最常见的超声特征为形态不规则、边界不清的低回声肿块伴瘤内血管形成。此外，作者报告多数复发位于深肌层内\[124]。

##### S0063 Variant: Variant 5:  Adult. Suspected local recurrence based on symptoms, physical examination, or laboratory value in patient with history of breast conservation therapy for DCIS. Initial imaging. | 成人。有DCIS保乳治疗史患者，基于症状、体格检查或实验室值疑似局部复发。初始影像学检查。

检查推荐列表：

* 检查项目: Digital Breast Tomosynthesis Diagnostic / MG双侧乳腺钼靶
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0010 / R:CR000461
  * 证据强度: StrongReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: The conventional workup usually involves an overview examination evaluating both breasts, commonly performed as a diagnostic bilateral mammogram or DBT examination, followed by US for more focused evaluation of the area of concern, when applicable. This topic was previously described in the ACR Appropriateness Criteria ® topics on “ Palpable Breast Masses ” \[125] and “ Breast Pain ” \[126]. Palpable DCIS is visible on mammography in approximately 81% of cases; compared with ER-positive noncalcified DCIS, ER-negative noncalcified DCIS is less likely to be visible on mammography \[42]. The typical appearance of suspicious calcifications in isolated DCIS may be more commonly assessed as BI-RADS 5 (highly suggestive of malignancy) on mammography (87%) compared to on US (33%) \[36]. Compared to invasive breast cancer, mammographic size of DCIS demonstrates high correlation with pathologic size \[43]. It should be noted that measurement of the DCIS component of malignancies as seen on imaging may differ from estimates reported by pathology because pathology measurements may not include the DCIS components seen on 常规检查通常包括双侧乳房概览检查（常采用诊断性双侧乳腺X线摄影或DBT检查），随后酌情对关注区域进行针对性US检查。该内容先前在ACR适宜性标准专题“可触及乳腺肿块”\[125]与“乳腺疼痛”\[126]中已有阐述。可触及DCIS在乳腺X线摄影中的可见率约为81%；与ER阳性非钙化DCIS相比，ER阴性非钙化DCIS在乳腺X线摄影中更不易显现\[42]。孤立性DCIS中可疑钙化的典型表现在乳腺X线摄影中较US更常被评估为BIRADS 5类（高度提示恶性）（87%对33%）\[36]。与浸润性乳腺癌相比，DCIS的乳腺X线摄影尺寸与病理尺寸高度相关\[43]。需注意影像学所见恶性肿瘤DCIS成分的测量可能与病理报告存在差异，因病理测量可能未包含影像所见的DCIS成分。
* 检查项目: Mammography Diagnostic / MG双侧乳腺钼靶
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0010 / R:CR000461
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: The conventional workup usually involves an overview examination evaluating both breasts, commonly performed as a diagnostic bilateral mammogram or DBT examination, followed by US for more focused evaluation of the area of concern, when applicable. This topic was previously described in the ACR Appropriateness Criteria ® topics on “ Palpable Breast Masses ” \[125] and “ Breast Pain ” \[126]. Diagnostic mammography is highly accurate in identifying local recurrence in patients with a history of breast conservation therapy for DCIS. A meta-analysis of 9 studies evaluating the diagnostic accuracy of surveillance mammography for detecting ipsilateral breast tumor recurrence and metachronous contralateral breast cancer in patients previously treated for primary breast cancer found the sensitivity of mammography for routine surveillance ranged from 64% to 67% and specificity ranged from 85% to 97%, but was lower, 50% to 83% and 57% to 75%, respectively for patients undergoing nonsurveillance imaging after having a test suspicious for recurrence. Authors noted that although mammography is associated with high sensitivity and specificity, MRI is the most accurate test for detecting ipsilateral breast tumor recurrence and metachronous contralateral breast cancer in women previously treated for primary breast cancer \[128]. 常规检查通常包括对双侧乳房进行全面评估，一般采用诊断性双侧乳腺X线摄影或数字乳腺断层合成（DBT）检查，必要时辅以超声对可疑区域进行针对性评估。相关内容此前已在ACR适宜性标准®专题"可触及乳腺肿块"\[125]和"乳房疼痛"\[126]中阐述。对于曾接受保乳治疗的DCIS患者，诊断性乳腺X线摄影在识别局部复发方面具有高度准确性。一项纳入9项研究的荟萃分析评估了乳腺X线摄影监测对原发性乳腺癌治疗后患者同侧乳房肿瘤复发和异时性对侧乳腺癌的诊断准确性，结果显示常规监测中乳腺X线摄影的敏感度为64%-67%，特异度为85%-97%；但对于复发可疑检查后接受非监测性影像学检查的患者，其敏感度和特异度分别降至50%-83%和57%-75%。研究者指出，虽然乳腺X线摄影具有较高的敏感度和特异度，但对于原发性乳腺癌治疗后女性，MRI才是检测同侧乳房肿瘤复发和异时性对侧乳腺癌最准确的检查方法\[128]。
* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 8
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0003 / R:CR000463
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: Diagnostic mammography, and possibly US, are often used to evaluate tumor size and extent of disease during the diagnostic workup of a clinically suspicious finding and prior to pathological diagnosis. US breast demonstrates a high sensitivity in evaluating palpable clinical findings and can identify masses, nonmass lesions, or ductal dilatation associated with recurrent cancer. The sensitivity and specificity of US breast may vary widely in the evaluation of the postoperative breast. A meta-analysis of 9 studies evaluating the diagnostic accuracy of US breast for detecting ipsilateral breast tumor recurrence and metachronous contralateral breast cancer in patients previously treated for primary breast cancer found the sensitivity of US breast to range from 43% to 87% and specificity from 31% to 73% for patients undergoing nonsurveillance imaging after having a test suspicious for recurrence \[128]. 在临床可疑发现的诊断检查及病理诊断前，诊断性乳腺X线摄影（必要时结合超声）常用于评估肿瘤大小及疾病范围。乳腺超声在评估可触及的临床病变时表现出高敏感性，可识别与复发癌相关的肿块、非肿块性病变或导管扩张。乳腺超声在术后乳腺评估中的敏感性和特异性可能存在较大差异。一项针对9项研究的荟萃分析评估了乳腺超声在检测既往接受原发性乳腺癌治疗患者同侧乳腺肿瘤复发及异时性对侧乳腺癌中的诊断准确性，结果显示：对于因疑似复发接受非监测性影像学检查的患者，乳腺超声的敏感性范围为43%-87%，特异性范围为31%-73%\[128]。
* 检查项目: Mammography With IV Contrast / MG双侧乳腺钼靶导管造影
  * 评分: 3
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0004 / R:CR000464
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is insufficient evidence to support routine use of mammography with IV contrast for initial imaging in setting of suspected local recurrence based on symptoms, physical examination, or laboratory value in patients with history of breast conservation therapy for DCIS. 现有证据不足以支持对曾接受保乳治疗的导管原位癌患者，在出现疑似局部复发的症状、体格检查或实验室检查结果时，常规使用静脉造影乳腺X线摄影作为初始影像学检查手段。
* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 2
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000465
  * 证据强度: StrongReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: Although MRI does have a higher sensitivity for malignancy than diagnostic mammography, evidence does not support the use of MRI in cases of a palpable breast mass without corresponding suspicious finding on mammography or US \[129-131]. DCIS typically presents on MRI breast with IV contrast as nonmass enhancement (60%) but may also be seen as a mass (31%) or focus (9%) \[59]. Morphology of DCIS on breast MRI is significantly correlated with enhancement kinetics, with nonmass enhancement more likely demonstrating medium and persistent kinetics, and foci or masses demonstrating rapid and plateau or washout kinetics ( P \< .05) \[59]. DCIS lesions \<1.5 cm are more likely to have rapid initial enhancement ( P = .004) \[59]. Both calcified and noncalcified DCIS demonstrate similar appearances on breast MRI \[59]. Because mammography has been reported to underestimate the extent of DCIS, breast MRI may be especially useful for evaluating patients with DCIS \[58]. 尽管MRI对恶性肿瘤的敏感性确实高于诊断性乳腺X线摄影，但现有证据不支持在乳腺X线或超声检查未发现相应可疑病变的情况下，对可触及乳腺肿块使用MRI检查\[129-131]。导管原位癌（DCIS）在静脉对比增强MRI中通常表现为非肿块样强化（60%），但也可能呈现为肿块（31%）或局灶性强化（9%）\[59]。乳腺MRI上DCIS的形态学特征与强化动力学显著相关：非肿块样强化更倾向于表现为中等持续型动力学，而局灶性强化或肿块则多表现为快速平台型或流出型动力学（P\<0.05）\[59]。小于1.5cm的DCIS病灶更易呈现快速初始强化（P=0.004）\[59]。钙化与非钙化DCIS在乳腺MRI上表现相似\[59]。鉴于文献报道乳腺X线摄影可能低估DCIS的病变范围，乳腺MRI对于DCIS患者的评估可能具有特殊价值\[58]。
* 检查项目: CT Chest With IV Contrast / CT胸部(增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0017 / R:CR000466
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明: There is no evidence to support the use of CT chest with IV contrast for initial imaging for suspected local recurrence based on symptoms, physical examination, or laboratory value in patients with history of breast conservation therapy for DCIS. 目前尚无证据支持对接受过DCIS保乳治疗的患者，基于症状、体格检查或实验室检查结果怀疑局部复发时，采用静脉注射对比剂的胸部CT作为初始影像学检查手段。
* 检查项目: CT Chest Without IV Contrast / CT胸部(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0019 / R:CR000468
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明: There is no evidence to support the use of CT chest without IV contrast for initial imaging for suspected local recurrence based on symptoms, physical examination, or laboratory value in patients with history of breast conservation therapy for DCIS. 对于有导管原位癌保乳治疗史的患者，基于症状、体格检查或实验室检查怀疑局部复发时，尚无证据支持使用非静脉增强胸部CT作为初始影像学检查手段。
* 检查项目: CT Chest Without and With IV Contrast / CT胸部(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0018 / R:CR000467
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明: There is no evidence to support the use of CT chest without and with IV contrast for initial imaging for suspected local recurrence based on symptoms, physical examination, or laboratory value in patients with history of breast conservation therapy for DCIS. 对于有导管原位癌保乳治疗史的患者，基于症状、体格检查或实验室检查怀疑局部复发时，尚无证据支持初始影像学检查采用胸部CT平扫加增强扫描。
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000472
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no evidence to support the use of MRI breast without IV contrast for initial imaging for suspected local recurrence based on symptoms, physical examination, or laboratory value in patients with history of breast 目前尚无证据支持对具有乳腺癌病史的患者，基于症状、体格检查或实验室检查结果怀疑局部复发时，将无静脉注射对比剂的乳腺MRI作为初始影像学检查手段。
* 检查项目: FDG-PET Breast Dedicated / PET/CT局部(胸部)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0016 / R:CR000469
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no evidence to support the use of FDG-PET breast dedicated for initial imaging for suspected local recurrence based on symptoms, physical examination, or laboratory value in patients with history of breast conservation therapy for DCIS. 目前尚无证据支持对曾接受保乳治疗的导管原位癌患者，基于症状、体格检查或实验室检查怀疑局部复发时，使用FDG-PET乳腺专用显像作为初始影像学检查手段。
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000473
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no evidence to support the use of sestamibi MBI for initial imaging for suspected local recurrence based on symptoms, physical examination, or laboratory value in patients with history of breast conservation therapy for DCIS. 没有证据支持对有导管原位癌保乳治疗史的患者，基于症状、体格检查或实验室检查怀疑局部复发时，使用司他比锝MBI作为初始影像学检查手段。
* 检查项目: Image-Guided Core Biopsy Breast / 影像引导下乳腺穿刺活检术
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0013 / R:CR000470
  * 证据强度: LimitedReferences
  * Adult RRL: Varies
  * Peds RRL: Varies
  * 推荐说明: There is no evidence to support the use of image-guided core biopsy breast for initial imaging for suspected local recurrence based on symptoms, physical examination, or laboratory value in patients with history of breast conservation therapy for DCIS. If suspicious lesions are identified on mammography and US, image-guided CNB can be beneficial over fine-needle aspiration (FNA) \[127]. 对于有导管原位癌保乳治疗史的患者，若基于症状、体格检查或实验室指标怀疑局部复发，目前尚无证据支持将影像引导下的空心针穿刺活检作为初始影像学检查手段。若在乳腺X线摄影和超声检查中发现可疑病灶，影像引导下的空心针穿刺活检可能比细针穿刺抽吸活检更具优势\[127]。
* 检查项目: Image-Guided Fine Needle Aspiration Breast / 影像引导下乳腺细针穿刺抽吸
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0014 / R:CR000471
  * 证据强度: LimitedReferences
  * Adult RRL: Varies
  * Peds RRL: Varies
  * 推荐说明: There is no evidence to support the use of image-guided FNA breast for initial imaging for suspected local recurrence based on symptoms, physical examination, or laboratory value in patients with history of breast conservation therapy for DCIS. If suspicious lesions are identified on mammography and US, image-guided CNB can be beneficial over FNA \[127]. 目前尚无证据支持对曾接受保乳治疗的导管原位癌患者，基于症状、体格检查或实验室检查结果怀疑局部复发时，采用影像引导下细针抽吸活检作为初始影像学检查手段。若乳腺X线摄影和超声检查发现可疑病灶，影像引导下空芯针活检可能比细针抽吸更具优势\[127]。

##### S0064 Variant: Variant 6:  Adult. Suspected local recurrence based on symptoms, physical examination, or laboratory value in patient with history of mastectomy for DCIS. Initial imaging. | 成人。有DCIS乳房切除术史患者，基于症状、体格检查或实验室值疑似局部复发。初始影像学检查。

检查推荐列表：

* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0003 / R:CR000474
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: If there are symptoms suggesting a local recurrence such as a palpable mass or focal pain, US is used after diagnostic mammography (if warranted) for a full evaluation, This section was previously described in the ACR Appropriateness Criteria ® topics on “ Palpable Breast Masses ” \[125] and “ Breast Pain ” \[126]. 如出现提示局部复发的症状，如可触及肿块或局部疼痛，在诊断性乳腺X线摄影（如适用）后使用超声进行全面评估。此部分内容先前已在ACR适宜性标准®专题“可触及乳腺肿块”\[125]和“乳腺疼痛”\[126]中阐述。
* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 2
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000475
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no evidence to support the use of breast MRI without and with IV contrast as the initial imaging test for evaluation of suspected recurrence in a patient with history of mastectomy for DCIS. Although MRI does have a higher sensitivity for malignancy than diagnostic mammography, evidence does not support the use of MRI in cases of a palpable breast mass without corresponding suspicious finding on mammography or US \[129-131]. 目前尚无证据支持在既往因导管原位癌接受乳房切除术的患者中，将非增强及增强乳腺MRI作为评估疑似复发的初始影像学检查。尽管MRI对恶性肿瘤的敏感性确实高于诊断性乳腺X线摄影，但证据不支持在乳腺X线摄影或超声检查未发现相应可疑病变的可触及乳腺肿块病例中使用MRI\[129-131]。
* 检查项目: CT Chest With IV Contrast / CT胸部(增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0017 / R:CR000476
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明: There is no evidence to support the use of CT chest with IV contrast as the initial imaging test for evaluation of suspected local recurrence in a patient with history of mastectomy for DCIS. 无证据支持将静脉注射对比剂的胸部CT作为评估有DCIS乳房切除术病史患者疑似局部复发的初始影像学检查。
* 检查项目: CT Chest Without IV Contrast / CT胸部(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0019 / R:CR000478
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明: There is no evidence to support the use of CT chest without IV contrast as the initial imaging test for evaluation of suspected local recurrence in a patient with history of mastectomy for DCIS. 无证据支持将非静脉注射对比剂的胸部CT作为初始影像学检查，用于评估有DCIS乳房切除术病史患者疑似局部复发的情况。
* 检查项目: CT Chest Without and With IV Contrast / CT胸部(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0018 / R:CR000477
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明: There is no evidence to support the use of CT chest without and with IV contrast as the initial imaging test for evaluation of suspected local recurrence in a patient with history of mastectomy for DCIS. 无证据支持将非静脉造影和静脉造影胸部CT作为评估有DCIS乳房切除术病史患者疑似局部复发的初始影像学检查。
* 检查项目: Digital Breast Tomosynthesis Diagnostic / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000479
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no evidence to support the use of DBT to evaluate suspected local recurrence in the setting of mastectomy unless the local recurrence suspected is in the axillary region or the patient has a history of breast reconstruction. 目前尚无证据支持使用数字乳腺断层合成摄影（DBT）评估乳房切除术后疑似局部复发的情况，除非疑似复发位于腋窝区域或患者有乳房重建史。
* 检查项目: Mammography Diagnostic / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000479
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no evidence to support the use of diagnostic mammography to evaluate suspected local recurrence in the setting of mastectomy unless the local recurrence suspected is in the axillary region or the patient has a history of breast reconstruction. 目前尚无证据支持在乳房切除术后使用诊断性乳腺X线摄影评估疑似局部复发，除非疑似复发位于腋窝区域或患者有乳房重建史。
* 检查项目: Mammography With IV Contrast / MG双侧乳腺钼靶导管造影
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0004 / R:CR000484
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no evidence to support the use of mammography with IV contrast to evaluate suspected local recurrence in the setting of mastectomy unless the local recurrence suspected is in the axillary region or the patient has a history of breast reconstruction. 没有证据支持在乳房切除术后使用静脉造影乳腺X线摄影评估疑似局部复发，除非疑似复发位于腋窝区域或患者有乳房重建史。
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000485
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no evidence to support the use of breast MRI without IV in evaluating the suspected local recurrence in the setting of mastectomy. 无证据支持在评估乳房切除术后疑似局部复发时使用不注射静脉造影剂的乳腺MRI。
* 检查项目: FDG-PET/CT Skull Base to Mid-Thigh / PET/CT躯干
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0020 / R:CR000480
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明: There is no evidence to support the use of FDG-PET/CT as the intial imaging test for evaluation of suspected local recurrence in the setting of mastectomy. 目前尚无证据支持将FDG-PET/CT作为评估乳腺切除术后疑似局部复发的初始影像学检查手段。
* 检查项目: Image-Guided Biopsy Chest / 影像引导下穿刺活检(胸部)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0021 / R:CR000481
  * 证据强度: ModerateReferences
  * Adult RRL: Varies
  * Peds RRL: Varies
  * 推荐说明: There is no relevant literature to support US-guided sampling as the initial imaging test for suspected local recurrence in a patient with a history of mastectomy for DCIS. US-guided biopsy is usually the next study performed when chest wall imaging is suspicious for local recurrence. US-guided biopsy is a minimally invasive procedure to obtain tissue for pathologic confirmation. US-guided CNB has increasing replaced FNA \[132]. Pooled analysis show that the sensitivity of CNB is higher than that of FNA a negative result does not exclude carcinoma. The reported false-negative rate for US-guided sampling is ≤2% \[133] . 目前尚无相关文献支持将超声引导下取样作为既往因DCIS接受乳房切除术患者疑似局部复发的初始影像学检查。当胸壁影像学检查提示可疑局部复发时，通常后续会进行超声引导下活检。超声引导下活检是一种微创操作，可获取组织进行病理学确认。超声引导下空芯针活检已逐渐取代细针抽吸活检\[132]。汇总分析显示空芯针活检的敏感性高于细针抽吸活检，但阴性结果不能排除癌变。文献报道超声引导下取样的假阴性率≤2%\[133]。
* 检查项目: Image-Guided Fine Needle Aspiration Chest / 影像引导下胸部细针穿刺抽吸
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0022 / R:CR000482
  * 证据强度: ModerateReferences
  * Adult RRL: Varies
  * Peds RRL: Varies
  * 推荐说明: There is no relevant literature to support US-guided sampling as the initial imaging test for suspected local recurrence in a patient with a history of mastectomy for DCIS. US-guided biopsy is usually the next study performed when chest wall imaging is suspicious for local recurrence. US-guided biopsy is a minimally invasive procedure to obtain tissue for pathologic confirmation. US-guided CNB has increasing replaced FNA \[132]. Pooled analysis show that the sensitivity of CNB is higher than that of FNA (87% versus 74%) and the specificity of CNB is similar to that of FNA cytology (98% versus 96%) \[132] . Ho wever, a negative result does not exclude carcinoma. The reported false-negative rate for US-guided sampling is ≤2% \[133] . 目前尚无相关文献支持将超声引导下取样作为曾接受DCIS乳房切除术患者疑似局部复发的首选影像学检查。当胸壁影像学检查提示局部复发可能时，通常需进一步行超声引导下活检。该微创操作可获取组织样本进行病理学确诊。超声引导下空芯针活检（CNB）已逐步取代细针抽吸（FNA）\[132]。汇总分析显示CNB的敏感性高于FNA（87% vs 74%），而特异性与FNA细胞学检查相当（98% vs 96%）\[132]。但阴性结果不能完全排除恶性肿瘤。文献报道超声引导下取样的假阴性率≤2%\[133]。

##### S0065 Variant: Variant 7:  Adult. Known DCIS with microinvasion found on prior mammography, ultrasound, or MRI during initial evaluation. Axillary evaluation needed. Next imaging study. | 成人 已知导管原位癌伴微浸润（既往乳腺X线摄影、超声或MRI初诊发现）需行腋窝评估 下一步影像学检查

检查推荐列表：

* 检查项目: CT Chest With IV Contrast / CT胸部(增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0017 / R:CR000486
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明: There is no evidence to support the use of CT chest with IV contrast in axillary evaluation of DCIS with microinvasion. 无证据支持在伴微浸润的导管原位癌腋窝评估中使用静脉注射对比剂的胸部CT检查。
* 检查项目: CT Chest Without IV Contrast / CT胸部(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0019 / R:CR000488
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明: There is no evidence to support the use of CT chest without IV contrast in axillary evaluation of DCIS with 目前尚无证据支持在DCIS腋窝评估中使用无静脉注射对比剂的胸部CT。
* 检查项目: CT Chest Without and With IV Contrast / CT胸部(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0018 / R:CR000487
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明: There is no evidence to support the use of CT chest without and with IV contrast in axillary evaluation of DCIS with microinvasion. 没有证据支持在伴微浸润的导管原位癌腋窝评估中使用无静脉注射对比剂和静脉注射对比剂的胸部CT检查。
* 检查项目: Digital Breast Tomosynthesis Diagnostic / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000489
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no evidence to support the use of DBT in axillary evaluation of DCIS with microinvasion. 没有证据支持在伴有微浸润的导管原位癌腋窝评估中使用数字乳腺断层合成技术。
* 检查项目: Mammography With IV Contrast / MG双侧乳腺钼靶导管造影
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0004 / R:CR000492
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no evidence to support the use of mammography with IV contrast in axillary evaluation of DCIS with microinvasion. 目前尚无证据支持在伴微浸润的导管原位癌腋窝评估中使用静脉造影乳腺X线摄影。
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000494
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no evidence to support the use of breast MRI without IV contrast in axillary evaluation of DCIS with microinvasion. 无证据支持在伴微浸润的导管原位癌腋窝评估中使用无静脉对比剂的乳腺MRI。
* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000493
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no evidence to support the use of breast MRI without and with IV contrast in axillary evaluation of DCIS with microinvasion. 目前尚无证据支持在伴微浸润的导管原位癌腋窝评估中使用无静脉注射对比剂及静脉注射对比剂的乳腺MRI检查。
* 检查项目: FDG-PET/CT Whole Body / PET/CT躯干
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0020
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明: There is no evidence to support the use of FDG-PET/CT whole body in axillary evaluation of DCIS with microinvasion. 目前尚无证据支持在伴微浸润的导管原位癌腋窝评估中使用FDG-PET/CT全身扫描。
* 检查项目: Lymphoscintigraphy Axilla / SPECT淋巴显像(腋窝)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0024 / R:CR000491
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no evidence to support the use of axillary lymphoscintigraphy in axillary evaluation of DCIS with microinvasion. 没有证据支持在伴微浸润的导管原位癌腋窝评估中使用腋窝淋巴显像术。
* 检查项目: US-Guided Core Biopsy Axillary Node / US腋窝淋巴结介入超声检查
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0025 / R:CR000496
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support US-guided sampling for axillary lymph node evaluation in axillary evaluation of DCIS with microinvasion. 目前尚无相关文献支持在伴微浸润的导管原位癌腋窝评估中采用超声引导下取样进行腋窝淋巴结评估。
* 检查项目: US-Guided Fine Needle Aspiration Biopsy Axillary Node / US腋窝淋巴结介入超声检查
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0025 / R:CR000496
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support US-guided sampling for axillary lymph node evaluation in axillary evaluation of DCIS with microinvasion. 目前尚无相关文献支持在伴微浸润的导管原位癌腋窝评估中采用超声引导下取样进行腋窝淋巴结评估。
* 检查项目: US Axilla / US腋窝淋巴结常规超声检查
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0012 / R:CR000495
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no evidence to support the use of US in axillary evaluation of DCIS with microinvasion. 没有证据支持在伴有微浸润的导管原位癌腋窝评估中使用超声检查。

##### S0066 Variant: Variant 8:  Adult. Known DCIS without microinvasion found on prior mammography, ultrasound, or MRI during initial evaluation. Axillary evaluation needed. Next imaging study. | 已知导管原位癌无微浸润，既往乳腺X线摄影、超声或MRI初始评估发现，需行腋窝评估，下一步影像学检查。

检查推荐列表：

* 检查项目: CT Chest With IV Contrast / CT胸部(增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0017 / R:CR000498
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明: There is no evidence to support the use of CT chest with IV contrast in axillary evaluation of DCIS without microinvasion. 没有证据支持在无微浸润的导管原位癌腋窝评估中使用静脉注射对比剂的胸部CT检查。
* 检查项目: CT Chest Without IV Contrast / CT胸部(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0019 / R:CR000500
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明: There is no evidence to support CT of the chest without IV contrast in axillary evaluation of DCIS without microinvasion. 对于无微浸润的导管原位癌（DCIS）腋窝评估，无证据支持在不使用静脉造影剂的情况下进行胸部CT检查。
* 检查项目: CT Chest Without and With IV Contrast / CT胸部(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0018 / R:CR000499
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明: There is no evidence to support the use of CT of the chest without and with IV contrast in axillary evaluation of DCIS without microinvasion. 无证据支持在无微浸润的导管原位癌腋窝评估中使用无和有静脉注射对比剂的胸部CT检查。
* 检查项目: Digital breast tomosynthesis diagnostic / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000501
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明:
* 检查项目: Mammography With IV Contrast / MG双侧乳腺钼靶导管造影
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0004 / R:CR000504
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no evidence to support mammography with IV contrast in axillary evaluation of DCIS without microinvasion. 无证据支持在无微浸润的导管原位癌腋窝评估中使用静脉造影剂进行乳腺X线摄影。
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000506
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no evidence to support noncontract breast MRI in axillary evaluation of DCIS without microinvasion. 无证据支持在无微浸润的导管原位癌腋窝评估中使用非对比增强乳腺MRI。
* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000505
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is limited evidence to support breast MRI without and with IV contrast in axillary evaluation of DCIS without microinvasion. A study consisting of 682 patients with DCIS with or without preoperative breast MRI evaluation and who underwent breast surgery were recruited from a single institution. Of those, 386 patients had complete imaging and pathologic information. The results demonstrated that contrast-enhanced breast MRI had a 53.8% sensitivity, 77.8% specificity, 14.9% positive predictive value, 95.9% negative predictive value, and 76.2% accuracy to predict axillary lymph node metastasis in preoperative DCIS patients. In addition, in MRI node-negative breast cancer patients with an MRI tumor size \<3 cm, the negative predictive value was 96.4%, and all these false- negative cases were N1 \[139]. 支持在无微浸润的导管原位癌（DCIS）腋窝评估中使用无和有静脉对比剂的乳腺MRI证据有限。一项研究纳入了来自单一机构的682例DCIS患者，无论术前是否接受乳腺MRI评估并接受了乳腺手术。其中386例患者拥有完整的影像学和病理学信息。结果显示，在术前DCIS患者中，对比增强乳腺MRI预测腋窝淋巴结转移的敏感性为53.8%，特异性为77.8%，阳性预测值为14.9%，阴性预测值为95.9%，准确率为76.2%。此外，在MRI肿瘤大小\<3 cm且MRI淋巴结阴性的乳腺癌患者中，阴性预测值为96.4%，所有假阴性病例均为N1\[139]。
* 检查项目: FDG-PET/CT Whole Body / PET/CT躯干
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0020
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明: There is no evidence to support FDG-PET/CT of the whole body in axillary evaluation of DCIS without microinvasion. 无证据支持在无微浸润的导管原位癌（DCIS）腋窝评估中使用全身FDG-PET/CT检查。
* 检查项目: Lymphoscintigraphy Axilla / SPECT淋巴显像(腋窝)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0024 / R:CR000503
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no evidence to support the use of axillary lymphoscintigraphy in axillary evaluation of DCIS without microinvasion. 没有证据支持在无微浸润的导管原位癌腋窝评估中使用腋窝淋巴显像术。
* 检查项目: US-Guided Core Biopsy Axillary Node / US腋窝淋巴结介入超声检查
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0025 / R:CR000508
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no evidence to support US-guided sampling for axillary lymph node evaluation of DCIS without microinvasion. 无证据支持对无微浸润的导管原位癌进行超声引导下腋窝淋巴结取样评估。
* 检查项目: US-Guided Fine Needle Aspiration Biopsy Axillary Node / US腋窝淋巴结介入超声检查
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0025 / R:CR000508
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no evidence to support US-guided sampling for axillary lymph node evaluation of DCIS without microinvasion. 无证据支持对无微浸润的导管原位癌进行超声引导下腋窝淋巴结取样评估。
* 检查项目: US Axilla / US腋窝淋巴结常规超声检查
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0012 / R:CR000507
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no evidence to support US in axillary evaluation of DCIS without microinvasion. 没有证据支持超声用于无微浸润的导管原位癌腋窝评估。

#### T0011 Imaging of Invasive Breast Cancer | 浸润性乳腺癌影像学检查

* 主题编码: T0011

##### S0067 Variant: Variant 1:  Newly diagnosed. Clinical stage I-IIA (early stage) breast cancer at presentation. Evaluation for locoregional disease (includes invasive ductal carcinoma \[IDC], or invasive lobular carcinoma \[ILC], or not otherwise specified \[NOS]). | 新诊断，就诊时为临床IIIA期（早期）乳腺癌，评估局部区域疾病（包括浸润性导管癌、浸润性小叶癌或非特指型）。

检查推荐列表：

* 检查项目: Digital Breast Tomosynthesis Diagnostic / MG双侧乳腺钼靶
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0010 / R:CR000510
  * 证据强度: StrongReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Diagnostic mammography and US together can assess for extent of disease and tumor size. These imaging tests are usually already completed as part of the diagnostic workup (prior to pathological diagnosis). However, mammography is limited by breast density. In a prospective study of 111 consecutive women with newly diagnosed breast cancer, sensitivity of 2-D mammography for malignancy decreased from 100% in breasts that are almost entirely fatty to 45% in extremely dense breasts \[22]. In addition, 2-D mammography was more sensitive than US in detecting ductal carcinoma in situ (DCIS) and less sensitive in detecting ILC. Digital breast tomosynthesis (DBT) shows a higher overall sensitivity, compared with 2-D mammography, with a similar specificity. Overall sensitivity for DBT was 88.2% compared with 78.3% for 2-D mammography \[23]. DBT also has a higher sensitivity for detecting multifocal, multicentric, and contralateral breast cancer \[24,25]. The improved diagnostic performance of DBT over 2-D mammography in breast cancer staging was limited to women The correlation between mammographic size and pathologic size is variable. Some studies show mammographic size to be superior to US \[26], whereas others show it to be inferior in the case of invasive lobular histology \[27]. At least some of this variation may be related to tumor subtype. Mammography shows a higher correlation with pathologic size for DCIS and HER2/neu-negative invasive cancers and a lower correlation for hormone receptor– negative and HER2/neu-positive invasive cancers compared with US \[27]. The accuracy of DBT in assessing tumor size was 70.4% compared with 60.2% on 2-D mammography \[28]. However, The Screening with Tomosynthesis Or standard Mammography-2 (STORM-2) trial showed that DBT tended to overestimate tumor size in women with dense breasts, compared with those with nondense breasts; this was more likely to impact management in women with larger tumors \[29]. Despite the limitations of mammography in women with dense breasts, breast density was not a predictor of positive margins or conversion to mastectomy \[30]. However, 2-D mammography is limited in detecting and measuring the size of ILC, which often presents as architectural distortion and uncommonly has associated calcifications \[31] . Multiple studies have shown DBT to be superior to digital mammography (DM) alone in ILC detection, with the differential performance between DM/DBT and DM greatest in ILC when compared with IDC \[32]. Therefore, it follows that DBT is also more accurate than DM in evaluating extent of disease for this subtype, which is commonly multicentric, multifocal, and sometimes bilateral. Still, DBT can underestimate the true pathologic extent of ILC \[33], so MRI may be warranted in this subtype, as discussed below. In a retrospective study of 904 women with breast cancer (n = 97 ILC) imaged with mammography ± US, 38.8% of women with ILC undergoing breast-conserving surgery required re-excision compared with 22.3% with IDC \[34]. 诊断性乳腺摄影联合超声可评估疾病范围和肿瘤大小。这些影像学检查通常作为诊断性评估的一部分（在病理诊断前）已完成。但乳腺摄影受乳腺密度限制：一项对111例连续新诊断乳腺癌患者的前瞻性研究显示，二维乳腺摄影对恶性肿瘤的敏感性从几乎完全脂肪型乳腺的100%降至极度致密型乳腺的45%\[22]。此外，二维乳腺摄影对导管原位癌（DCIS）的检测敏感性高于超声，而对浸润性小叶癌（ILC）的敏感性较低。与二维乳腺摄影相比，数字乳腺断层合成（DBT）总体敏感性更高且特异性相近：DBT总体敏感性为88.2%，二维乳腺摄影为78.3%\[23]。DBT对多灶性、多中心性及对侧乳腺癌的检测敏感性也更高\[24,25]。DBT在乳腺癌分期中优于二维乳腺摄影的诊断效能仅限于特定人群。乳腺摄影大小与病理大小的相关性存在变异：部分研究显示其优于超声\[26]，而在浸润性小叶组织学类型中则较差\[27]。这种差异至少部分与肿瘤亚型相关：与超声相比，乳腺摄影对DCIS和HER2/neu阴性浸润癌的病理大小相关性更高，而对激素受体阴性和HER2/neu阳性浸润癌的相关性较低\[27]。DBT评估肿瘤大小的准确率为70.4%，二维乳腺摄影为60.2%\[28]。然而STORM2试验显示，与非致密乳腺相比，DBT易高估致密乳腺患者的肿瘤大小，这种差异更可能影响较大肿瘤患者的治疗决策\[29]。尽管乳腺摄影在致密乳腺患者中存在局限，乳腺密度并非切缘阳性或转行乳房切除术的预测因子\[30]。但二维乳腺摄影在检测和测量ILC大小方面存在局限——ILC常表现为结构扭曲且较少伴钙化\[31]。多项研究显示DBT在ILC检测方面优于单纯数字乳腺摄影（DM），且DM/DBT与单纯DM的差异效能在于ILC检测时较浸润性导管癌（IDC）更为显著\[32]。因此DBT在评估该亚型（常为多中心性、多灶性且有时为双侧）疾病范围时亦较DM更准确。但DBT仍可能低估ILC的真实病理范围\[33]，故该亚型可能需要MRI评估（如下文所述）。一项对904例接受乳腺摄影±超声检查的乳腺癌患者（含97例ILC）的回顾性研究显示，38.8%接受保乳手术的ILC患者需要再次切除，而IDC患者仅为22.3%\[34]。
* 检查项目: Mammography Diagnostic / MG双侧乳腺钼靶
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0010 / R:CR000510
  * 证据强度: StrongReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Diagnostic mammography and US together can assess for extent of disease and tumor size. These imaging tests are usually already completed as part of the diagnostic workup (prior to pathological diagnosis). However, mammography is limited by breast density. In a prospective study of 111 consecutive women with newly diagnosed entirely fatty to 45% in extremely dense breasts \[22]. In addition, 2-D mammography was more sensitive than US in detecting DCIS and less sensitive in detecting ILC. DBT shows a higher overall sensitivity, compared with 2-D mammography, with similar specificity. Overall sensitivity for DBT was 88.2% compared with 78.3% \[23]. DBT has a higher sensitivity for detecting multifocal, multicentric, and contralateral breast cancer \[24,25]. The improved diagnostic performance of DBT over 2-D mammography in breast cancer staging was limited to women with nondense breasts in 1 study \[24], but not others \[25]. The correlation between mammographic size and pathologic size is variable. Some studies demonstrate the assessment of size with mammography to be superior to US \[26], whereas others show it to be inferior \[46]. At least some of this variation may be related to tumor subtype. Mammography shows a higher correlation with pathologic size for DCIS and HER2/neu-negative invasive cancers and a lower correlation for hormone receptor–negative and HER2/neu-positive invasive cancers compared with US \[27]. The accuracy of DBT in assessing tumor size was 70.4% compared with 60.2% on 2-D mammography \[28]. However, the STORM-2 trial showed that DBT tended to overestimate tumor size in women with dense breasts, compared with those with nondense breasts; this difference was more likely to impact management in women with larger tumors \[29]. Despite the limitations of mammography in women with dense breasts, breast density was not a predictor of positive margins or conversion to mastectomy \[30]. However, 2-D mammography is limited in detecting and measuring the size of ILC, which often presents as architectural distortion and uncommonly has associated calcifications \[31] . Multiple studies have shown DBT to be superior to DM alone in ILC detection, with the differential performance between DM/DBT and DM greatest in ILC when compared with IDC \[32]. Therefore, it follows that DBT is also more accurate than DM in evaluating the extent of disease for this subtype, which is commonly multicentric, multifocal, and sometimes bilateral. Still, DBT can underestimate the true pathologic extent of ILC \[33], so MRI may be warranted in this subtype, as discussed below. Supporting this, in a retrospective study of 904 women with breast cancer (n = 97 ILC), imaged with mammography ± US, 38.8% of women with ILC undergoing breast-conserving surgery required re-excision compared with 22.3% with IDC \[34]. Due to patient positioning constraints, 2-D mammography and DBT have limited value for evaluating the axilla. In a single-institution retrospective study of 3,944 patients with breast cancer, mammography improved the sensitivity 诊断性乳腺X线摄影与US联合应用可评估疾病范围和肿瘤大小。这些影像学检查通常已在诊断性评估（病理诊断前）中完成。然而乳腺X线摄影受乳腺密度限制。一项针对111名连续新诊断女性的前瞻性研究显示，乳腺密度从完全脂肪型至极致密型占比达45%\[22]。此外，二维乳腺X线摄影检测DCIS的敏感性高于US，而检测ILC的敏感性较低。与二维乳腺X线摄影相比，DBT显示出更高的总体敏感性，且特异性相当。DBT的总体敏感性为88.2%，而二维乳腺X线摄影为78.3%\[23]。DBT在检测多灶性、多中心性及对侧乳腺癌方面具有更高敏感性\[24,25]。一项研究显示DBT相较于二维乳腺X线摄影在乳腺癌分期中诊断性能的提升仅限于非致密乳腺女性\[24]，但其他研究未证实此结论\[25]。乳腺X线摄影测量尺寸与病理尺寸的相关性存在差异。部分研究表明乳腺X线摄影评估尺寸优于US\[26]，而其他研究显示其劣于US\[46]。这种差异至少部分与肿瘤亚型相关。与US相比，乳腺X线摄影对DCIS和HER2/neu阴性浸润癌的病理尺寸相关性更高，而对激素受体阴性和HER2/neu阳性浸润癌的相关性较低\[27]。DBT评估肿瘤尺寸的准确率为70.4%，而二维乳腺X线摄影为60.2%\[28]。然而STORM2试验显示，与非致密乳腺女性相比，DBT倾向于高估致密乳腺女性的肿瘤尺寸；这种差异更可能影响较大肿瘤女性的治疗决策\[29]。尽管乳腺X线摄影在致密乳腺女性中存在局限性，但乳腺密度并非阳性切缘或转为乳房切除术的预测因子\[30]。然而二维乳腺X线摄影在检测和测量ILC尺寸方面存在局限，ILC常表现为结构扭曲且较少伴钙化\[31]。多项研究显示DBT在ILC检测方面优于单独DM，DM/DBT与单独DM的性能差异在ILC中较IDC更为显著\[32]。因此DBT在评估该亚型疾病范围方面亦较DM更准确，该亚型常为多中心性、多灶性且有时为双侧性。尽管如此，DBT仍可能低估ILC的真实病理范围\[33]，故该亚型可能需要MRI评估（如下文所述）。一项针对904名乳腺癌女性（含97例ILC）的回顾性研究支持此观点：接受乳腺X线摄影±US检查后，38.8%的ILC患者保乳手术需再次切除，而IDC患者为22.3%\[34]。由于患者体位限制，二维乳腺X线摄影和DBT对腋窝评估价值有限。一项针对3,944名乳腺癌患者的单中心回顾性研究显示，乳腺X线摄影提高了敏感性。
* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0003 / R:CR000512
  * 证据强度: StrongReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: Diagnostic mammography and US together can assess for extent of disease and tumor size. These imaging tests are usually already completed as part of the diagnostic workup (prior to pathological diagnosis). The sensitivity of US for detecting cancer ranges from 79% to 94% \[22,25,104,105]. The addition of DBT to US improved sensitivity for detecting both primary breast cancer and multicentric and multifocal disease, from 82.6% (nondense) and 91.6% (dense) with US alone to 97.7% with combined DBT and US \[106]. However, DBT and mammography have limited added value over US alone for initial evaluation in women \<40 years of age \[105]. Although bilateral US use in women with primary breast cancer to evaluate for multicentric and multifocal disease shows a lower sensitivity than MRI (85.1% versus 71.1%), US showed higher accuracy and specificity than MRI (67.6% versus 39.3% and 69.2% versus 60.2%, respectively), suggesting that bilateral US may be an acceptable alternative to MRI for locoregional staging \[57]. When compared with DM alone, supplemental US more accurately depicted the extent of disease needing wider excision in 17 of 96 (18%) breasts for which conservation was anticipated, corresponding to 17 of 30 (57%) breasts with mammographically occult disease \[22]. Based on mammography/clinical examination, 2% to 3% of patients have synchronous bilateral cancer \[107]. This risk for bilateral synchronous cancer is increased in patients less than 55 years of age or in those diagnosed with invasive lobular subtypes \[108]. In 1 series with 9% contralateral synchronous malignancy, mammography detected 60%, US detected 80%, and MRI detected 90% (with the remainder detected on follow-up imaging) \[22]. In addition to its role in the initial diagnostic workup, US is important in the secondary evaluation of a suspicious finding on MRI in the setting of evaluation of disease extent. US sensitivity and NPV are higher than those of DBT \[109]. Compared with DBT, US showed a lower specificity (98.1% versus 78.9%) and similar PPV (66.7% versus 52.2%). However, a meta-analysis of second-look US following a suspicious finding on MRI showed heterogeneity in US performance, with the detection rate ranging from 22.6% to 82.1% (pooled detection rate 57.5%) and an 87.8% pooled NPV \[110]. Therefore, a negative US is insufficient to obviate the need for an MRI biopsy in this setting. There is no evidence supporting US as an accurate method for determining disease extent of those diagnosed with ILC subtype. Conventional imaging with mammography and/or US can significantly underestimate the extent of study \[113], and a different study showed that the greatest discrepancy between tumor size and pathologic size using US measurements was for the ILC subtype \[26]. 诊断性乳腺X线摄影与US联合应用可评估疾病范围和肿瘤大小。这些影像学检查通常已在诊断性评估（病理诊断前）中完成。US检测癌症的敏感性范围为79%至94%\[22,25,104,105]。在US基础上增加DBT可将原发性乳腺癌及多中心多灶性病变的检测敏感性从单独US的82.6%（非致密）和91.6%（致密）提升至DBT联合US的97.7%\[106]。然而对于40岁以下女性的初始评估，DBT和乳腺X线摄影较单独US的附加价值有限\[105]。虽然双侧US用于原发性乳腺癌女性评估多中心多灶性病变的敏感性低于MRI（85.1%对71.1%），但US显示出比MRI更高的准确性和特异性（分别为67.6%对39.3%和69.2%对60.2%），表明双侧US可能作为MRI局部区域分期的可接受替代方案\[57]。与单独DM相比，补充US在96例预期保乳的乳房中更准确描绘了17例（18%）需扩大切除的疾病范围，对应30例乳腺X线摄影隐匿病变中的17例（57%）\[22]。基于乳腺X线摄影/临床检查，2%至3%的患者存在双侧同步癌\[107]。55岁以下患者或被诊断为浸润性小叶亚型者双侧同步癌风险增加\[108]。在一个对侧同步恶性病变占比9%的系列研究中，乳腺X线摄影检出率为60%，US为80%，MRI为90%（其余通过随访影像检出）\[22]。除初始诊断评估外，US在MRI可疑发现的二次评估（疾病范围评估场景）中至关重要。US的敏感性和NPV高于DBT\[109]。与DBT相比，US显示出较低的特异性（98.1%对78.9%）和相似的PPV（66.7%对52.2%）。然而对
* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 7
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0005 / R:CR000513
  * 证据强度: StrongReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: MRI breast is useful for detecting additional cancers in the ipsilateral or contralateral breast \[16,55], particularly in women with dense breasts \[23,56,57]. A meta-analysis of 22 studies investigated MRI screening of the contralateral breast in women with newly diagnosed breast cancer. This meta-analysis reported contralateral malignancies that were detected by MRI in 131 of 3,253 women. Thus, the summary estimate for incremental cancer detection rate was 4.1%. In studies in which pathologic tumor stage was reported, all but 2 tumors were in situ or stage I, and of biopsy in 9.3% of women (95% confidence interval \[CI], 5.8%-14.7%) with PPV for malignancy of 47.9% (95% CI, 31.8%-64.6%). Where reported, 35.1% of MRI-detected cancers were DCIS (mean size = 6.9 mm) and 64.9% were invasive cancers (mean size = 9.3 mm) \[58]. MRI can accurately assess tumor size for preoperative planning \[50,59-61]. In a study involving 343 tumors, size measurements of cancers on breast MRI were within 5 mm of pathological size in 88% of patients \[60]. Still, other studies using mastectomy specimens have shown that MRI underestimates primary tumor size in 21% and overestimates primary tumor size in 24% of cases \[62]. MRI also overestimated the number of invasive lesions by 19% and underestimated the number of invasive lesions in 28% in the same study \[62]. These data underscore the importance of using biopsy to pathologically confirm MRI findings instead of relying on them to alter surgical planning, especially when the MRI finding is nonmass enhancement \[63]. In addition to tumor size assessment, some studies show a reduction in re-excision after preoperative MRI \[64-68]. For example, in a study of 991 women, preoperative MRI changed the surgical procedure in 25% (157/626) of cases. In 81% (127/157), MRI benefited some patients, as otherwise occult carcinomas were removed (n = 122) and further biopsy prevented (n = 5) \[67]. In this trial, the rate of mastectomy did not differ between patients undergoing preoperative MRI and those who did not. A recent multinational observational study at 27 centers also found that subjects receiving MR as part of routine clinical care had a significantly lower reoperation rate after breast conservation (8.5% versus 11.7%, P \< .001) \[69]. However, other large multicenter studies, such as the comparative effectiveness of MRI in breast cancer (COMICE) trial, showed the addition of MRI to conventional imaging was not significantly associated with a reduced reoperation rate, with 153 (19%) needing reoperation in the MRI group versus 156 (19%) in the non-MRI group (odds ratio \[OR], 0.96; 95% CI, 0.75-1.24; P = .77) \[70]. Although the findings are important, limitations from the COMICE trial are also noted, such as its inclusion of patients from several small centers where technical factors and varying degree of experience among interpreting radiologists could have influenced the MRI results. It is also not clear that the data from the MRI was incorporated into surgical 乳腺 MRI 可用于检测同侧或对侧乳腺的额外癌灶 \[16,55]，尤其适用于致密型乳腺女性 \[23,56,57]。一项纳入 22 项研究的荟萃分析探讨了新诊断乳腺癌患者对侧乳腺的 MRI 筛查。该分析显示，在 3,253 例女性中，MRI 检测出 131 例对侧恶性肿瘤，增量癌症检出率的汇总估计值为 4.1%。在报告病理肿瘤分期的研究中，除 2 个肿瘤外，其余均为原位癌或 I 期癌；活检率为 9.3%（95% 置信区间 \[CI]，5.8%–14.7%），恶性阳性预测值为 47.9%（95% CI，31.8%–64.6%）。据报告，MRI 检出癌症中 35.1% 为导管原位癌（平均大小 = 6.9 mm），64.9% 为浸润癌（平均大小 = 9.3 mm）\[58]。MRI 可准确评估肿瘤大小以指导术前规划 \[50,59–61]。一项涉及 343 个肿瘤的研究显示，88% 患者的乳腺 MRI 癌症尺寸测量与病理大小差异在 5 mm 以内 \[60]。但其他使用乳房切除标本的研究表明，MRI 在 21% 的病例中低估原发肿瘤大小，在 24% 的病例中高估原发肿瘤大小 \[62]。同一研究中，MRI 还高估浸润性病灶数量 19%，低估 28% \[62]。这些数据强调需通过活检病理确认 MRI 结果而非依赖其改变手术计划，尤其当 MRI 表现为非肿块样强化时 \[63]。除肿瘤大小评估外，部分研究显示术前 MRI 可降低再次切除率 \[64–68]。例如，一项针对 991 例女性的研究中，术前 MRI 改变了 25%（157/626）病例的手术方式；其中 81%（127/157）患者获益，包括切除 otherwise 隐匿癌灶（n = 122）和避免进一步活检（n = 5）\[67]。该试验中，接受与未接受术前 MRI 患者的乳房切除术率无差异。近期一项在 27 个中心开展的多国观察性研究也发现，接受 MRI 作为常规临床护理的受试者保乳术后再手术率显著更低（8.5% 对比 11.7%，P \< .001）\[69]。然而，其他大型多中心研究如乳腺癌 MRI 比较有效性（COMICE）试验显示，在常规影像基础上增加 MRI 并未显著降低再手术率：MRI 组 153 例（19%）需再手术，非 MRI 组 156 例（19%）（优势比 \[OR]，0.96；95% CI，0.75–1.24；P = .77）\[70]。尽管这些发现重要，但 COMICE 试验也存在局限性，例如纳入多家小型中心的患者，其技术因素和放射科医师解读经验差异可能影响 MRI 结果，且尚不明确 MRI 数据是否被整合用于手术决策。
* 检查项目: Mammography With IV Contrast / MG双侧乳腺钼靶导管造影
  * 评分: 5
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0004 / R:CR000514
  * 证据强度: StrongReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Several retrospective studies have compared the sensitivity and specificity of CEM with conventional 2-D and 3-D mammography, US, and MRI. Overall, CEM and MRI are superior to DM and DM/DBT imaging \[47]. The sensitivities between CEM and MRI are comparable, with some studies showing improved sensitivities with CEM \[48] and some showing MRI to be superior \[49,50]. Overall sensitivities ranged from 92% to 100% \[16,49,51-53], including CEM detecting 92.3% of satellite masses and up to 100% of contralateral cancers \[28]. CEM and MRI show similar abilities to estimate tumor size ( r = 0.72-0.89 versus 0.65-0.84), but studies have shown an improved positive predictive value (PPV) of CEM (52%-93%) compared with MRI (28-60%) \[16,49,53]. Despite increased specificity over MR, limitations of contrast mammography in determining disease extent include evaluation of the axilla and other nodal groups as well as chest wall involvement \[47], and there is evidence against using CEM to determine disease extent in lobular cancer, due to lower conspicuity \[54]. 多项回顾性研究对比了对比增强乳腺摄影（CEM）与传统二维、三维乳腺摄影、超声及磁共振成像的敏感性与特异性。总体而言，CEM与MRI的诊断效能优于数字化乳腺摄影（DM）及数字化乳腺断层合成摄影（DM/DBT）\[47]。CEM与MRI的敏感性相当，部分研究显示CEM敏感性更优\[48]，亦有研究表明MRI更具优势\[49,50]。综合敏感性范围为92%至100%\[16,49,51-53]，其中CEM可检出92.3%的卫星病灶及高达100%的对侧乳腺癌\[28]。CEM与MRI在评估肿瘤大小方面表现相似（相关系数r=0.72-0.89 vs 0.65-0.84），但研究显示CEM的阳性预测值（52%-93%）优于MRI（28%-60%）\[16,49,53]。尽管相较MRI具有更高特异性，对比增强乳腺摄影在评估疾病范围时存在局限性，包括对腋窝淋巴结、其他淋巴结组及胸壁受累的评估\[47]。有证据表明由于显示清晰度较低，CEM不适用于小叶癌的疾病范围判定\[54]。
* 检查项目: US Axilla / US腋窝淋巴结常规超声检查
  * 评分: 5
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0012 / R:CR000515
  * 证据强度: StrongReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: This section was previously described in the ACR Appropriateness Criteria ® topic on “ Imaging of the Axilla ” \[88]. The Z0011 trial showed that in women with tumor size \<5 cm and no clinically palpable nodes, ≤2 positive axillary nodal macrometastases on sentinel lymph node biopsy can avoid axillary nodal dissection without compromising survival \[89]. US is the most established noninvasive imaging test for assessing the axilla following a clinically or imaging detected suspicious lymph node. US features associated with a higher likelihood of malignancy include short-axis lymph node size >1 cm, cortical thickness of >0.3 cm, and an absence of a fatty hilum \[90-93]. There is a wide range of reported sensitivity and specificity for axillary US, and none of these imaging features are specific enough to avoid the need for histologic sampling. The sensitivity ranges from 26.4% to 94%, and the specificity ranges from 53% to 98% \[94-97]. Axillary US alone has a relatively low NPV to rule out metastatic disease \[36,98]. A meta-analysis of 21 studies showed that US combined with needle biopsy improved the sensitivity from 61% to 79% \[99-101]. US-guided core needle biopsy was superior to US-guided FNA in a meta-analysis of 1,353 patients with newly diagnosed invasive breast carcinoma, with a reported sensitivity of 88% for core biopsy and 74% for FNA \[102]. A xillary US and an MRI performed similarly (sensitivity of 99.1% versus 97.4% and specificity 15.4% versus 15.4%, respectively) in evaluating axillary lymph nodes. Despite this performance, approximately 14% of women with breast cancer and negative imaging for axillary metastasis ultimately have metastatic disease on sentinel lymph node biopsy \[103]. 该部分内容此前已在ACR适宜性标准®关于“腋窝影像学”的主题中有所阐述\[88]。Z0011试验表明，对于肿瘤大小\<5厘米且无临床可触及淋巴结的女性患者，前哨淋巴结活检显示≤2个阳性腋窝淋巴结大转移灶时，可避免腋窝淋巴结清扫术而不影响生存率\[89]。超声是评估临床或影像学发现可疑淋巴结后腋窝最成熟的非侵入性影像学检查方法。与恶性可能性较高的超声特征包括淋巴结短轴直径>1厘米、皮质厚度>0.3厘米以及无脂肪门结构\[90-93]。腋窝超声的敏感性和特异性报道范围较广，但这些影像学特征均不足以特异性避免组织学取样需求。敏感性范围从26.4%至94%，特异性范围从53%至98%\[94-97]。单独使用腋窝超声排除转移性疾病的阴性预测值相对较低\[36,98]。一项包含21项研究的荟萃分析显示，超声联合穿刺活检可将敏感性从61%提高至79%\[99-101]。在一项针对1,353例新诊断浸润性乳腺癌患者的荟萃分析中，超声引导下空心针活检优于超声引导下细针穿刺，报道敏感性分别为88%（空心针活检）和74%（细针穿刺）\[102]。腋窝超声与MRI在评估腋窝淋巴结时表现相似（敏感性分别为99.1% vs
* 检查项目: CT chest abdomen pelvis with IV contrast / CT胸部(增强),CT全腹部(增强),CT盆腔(增强)
  * 评分: 2
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0027 / R:CR000516
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明:
* 检查项目: CT chest abdomen pelvis without and with IV contrast / CT胸部(平扫+增强),CT全腹部(平扫+增强),CT盆腔(平扫+增强)
  * 评分: 2
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0028 / R:CR000517
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢☢ 10-30 mSv \[ped]
  * 推荐说明:
* 检查项目: FDG-PET/CT Skull Base to Mid-Thigh / PET/CT躯干
  * 评分: 2
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0020 / R:CR000518
  * 证据强度: StrongReferences
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明: FDG-PET/CT has limited sensitivity for subcentimeter lesions. For this reason, it is seldom used for determining locoregional extent in the breast. Nevertheless, some studies have evaluated the use of PET/CT for detecting the primary tumor and estimating tumor size. From these studies, the overall sensitivity for detecting the primary tumor was 77% to 94% \[38-40]. The sensitivity of PET/CT is lower (59%) when the tumor is ≤1 cm \[41]. PET/CT is inferior at estimating T stage compared with MRI (T-stage accuracy is 68% with PET/CT versus 82% with MRI, P \< .05). Specificity ranged from 94% to 100% \[38,39]. Additionally, PET/CT failed to identify additional lesions in up to 57% of patients with multicentric or multifocal disease \[40]. PET/CT has the potential to have greater sensitivity than US for axillary staging because it uses a functional measurement instead of an anatomic determination (eg, cortical thickness, loss of fatty hilum) as criteria for determining suspicion for metastatic disease \[42]. Surgical studies show that 21% to 33% of T1 and 45% to 60% T2 tumors with normal appearing lymph nodes have metastatic disease on pathological examination \[43]. Thus, studies have queried whether a functional measurement might be better. One study retrospectively evaluated PET/CT in 826 consecutive patients with breast cancer and showed a sensitivity and specificity of 74.7% and 83,4%, respectively, for identifying metastatic disease. Studies show a negative predictive value (NPV) from 87% to 88% \[39,44]. Other studies show the sensitivity and specificity for detecting lymph node metastasis as 79% and 100%, respectively \[38]. However, Sohn et al \[45] showed a higher sensitivity for US plus fine-needle aspiration (FNA) at determining lymph node status than PET/CT (83% versus 80%, respectively). Despite extensive scientific investigation, given the results above and the Z0011 trial, the role of PET/CT in determining locoregional extent is likely nominal. FDG-PET/CT对亚厘米病灶的敏感性有限，因此很少用于确定乳腺的局部区域范围。不过，一些研究评估了PET/CT在检测原发肿瘤和评估肿瘤大小方面的应用。这些研究显示，检测原发肿瘤的总体敏感性为77%至94%\[38-40]。当肿瘤≤1 cm时，PET/CT的敏感性较低（59%）\[41]。与MRI相比，PET/CT在评估T分期方面较差（PET/CT的T分期准确率为68%，而MRI为82%，P \< 0.05）。特异性范围为94%至100%\[38,39]。此外，在多中心或多灶性疾病的患者中，PET/CT未能识别额外病灶的比例高达57%\[40]。PET/CT在腋窝分期方面可能比超声具有更高的敏感性，因为它采用功能测量而非解剖学标准（如皮质厚度、脂肪门消失）作为判断转移性疾病的依据\[42]。外科研究表明，在病理检查中，21%至33%的T1肿瘤和45%至60%的T2肿瘤（淋巴结外观正常）存在转移性疾病\[43]。因此，研究探讨功能测量是否更具优势。一项研究回顾性评估了826例连续乳腺癌患者的PET/CT结果，显示检测转移性疾病的敏感性和特异性分别为74.7%和83.4%。研究显示阴性预测值（NPV）为87%至88%\[39,
* 检查项目: CT chest abdomen pelvis without IV contrast / CT胸部(平扫),CT全腹部(平扫),CT盆腔(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0030 / R:CR000520
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明:
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000521
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no evidence to support the use of noncontrast breast MRI in evaluating extent of disease. 无证据支持使用非对比增强乳腺MRI评估疾病范围。
* 检查项目: Bone Scan Whole Body / SPECT全身骨显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0029 / R:CR000519
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明: There is no evidence to support the use of Tc-99m bone scan whole body to evaluate for locoregional disease. 没有证据支持使用锝-99m骨扫描全身评估来诊断局部区域性疾病。

##### S0068 Variant: Variant 2:  Newly diagnosed. Clinical stage I-IIA (early stage) breast cancer at presentation. Evaluation for distant disease (includes IDC, or ILC, or NOS). | 新诊断，就诊时为临床IIIA期（早期）乳腺癌，评估远处转移（包括浸润性导管癌、浸润性小叶癌或非特指型）。

检查推荐列表：

* 检查项目: CT chest abdomen pelvis with IV contrast / CT胸部(增强),CT全腹部(增强),CT盆腔(增强)
  * 评分: 2
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0027 / R:CR000523
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明:
* 检查项目: CT chest abdomen pelvis without and with IV contrast / CT胸部(平扫+增强),CT全腹部(平扫+增强),CT盆腔(平扫+增强)
  * 评分: 2
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0028 / R:CR000524
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢☢ 10-30 mSv \[ped]
  * 推荐说明:
* 检查项目: FDG-PET/CT Skull Base to Mid-Thigh / PET/CT躯干
  * 评分: 2
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0020 / R:CR000525
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明: According to the ABIM/ASCO, ESMO, and SEOM guidelines, there is insufficient evidence to routinely use FDG- PET/CT to evaluate for distant disease in asymptomatic women with early stage breast cancer \[128-130]. NCCN guidelines recommend chest, abdomen, and pelvic CT as an additional test prior to preoperative systemic therapy to evaluate for distant disease if the tumor size is >2 cm (T2) or there are positive lymph nodes, or the tumor size is >1 cm (T1c) and HER2+, or there is triple-negative disease \[126]. Although not definitive, and not currently recommended in the guidelines above, there is evidence that PET/CT may be useful in early stage breast cancer \[133]. A recent study of 196 subjects \[134] tested the utility of PET/CT in breast cancer and found the overall yield of unsuspected distant metastases was 14% (n = 27), including 0% for stage IIA, 13% for stage IIB (10/79), 22% for stage IIIA (9/41), 17% for stage IIIB (5/30), and 37% for stage IIIC (3/8). In another study of 303 patients, PET/CT demonstrated unknown metastatic disease in 4.9% (15/303), 0.8% in stage IIA, and 9.8% in stage IIB \[135]. Finally, Groheux et al \[136] performed a prospective study of 254 women with breast cancer, and PET/CT found unsuspected metastatic disease in 2.3% of stage IIA and 10.7% in stage IIB \[128]. The performance of PET/CT was independent of cancer subtype, as shown in other studies on stage IIB disease \[137]. Finally, a recent meta-analysis of 4,276 patients (29 studies) also found 11% (95% CI, 3%-22%) of patients with stage I and 20% (95% CI, 16%-24%) of patients with stage II breast cancer changed disease stage or management plan (including up or downstaging) with PET/CT \[13]. Thus, there is some evidence to consider this test, even in early breast cancer, if the immunohistochemical subtype is HER2+/TN or the disease is locally advanced as described above. 根据ABIM/ASCO、ESMO和SEOM指南，目前尚无充分证据支持常规使用FDG-PET/CT评估无症状早期乳腺癌患者的远处转移\[128-130]。NCCN指南建议，当肿瘤>2cm（T2）或存在淋巴结阳性，或肿瘤>1cm（T1c）且HER2阳性，或三阴性乳腺癌时，可在术前系统治疗前通过胸腹盆CT进行远处转移评估\[126]。尽管现有证据尚不充分且未被上述指南推荐，但研究表明PET/CT可能对早期乳腺癌具有应用价值\[133]。一项纳入196例受试者的最新研究\[134]显示，PET/CT检出意外远处转移的总率为14%（27例），其中IIA期0%、IIB期13%（10/79）、IIIA期22%（9/41）、IIIB期17%（5/30）、IIIC期37%（3/8）。另一项303例患者的研究中，PET/CT检出未知转移灶比例为4.9%（15/303），IIA期0.8%，IIB期9.8%\[135]。Groheux等\[136]的前瞻性研究（254例）表明，PET/CT在IIA期和IIB期分别检出2.3%和10.7%的隐匿转移\[128]。多项研究证实，PET/CT的检测效能与癌症亚型无关\[137]。一项纳入
* 检查项目: Bone Scan Whole Body / SPECT全身骨显像
  * 评分: 2
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0029 / R:CR000522
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明: Bone is the most common site for breast cancer metastasis; up to 70% of women with stage IV disease have bone metastasis, with the predilection for bone metastases not applying to basal-like tumors \[117]. Up to 13.6% of women diagnosed with early stage breast cancer will develop bone metastasis within 15 years of diagnosis \[122], even if the parent tumor is low grade \[123]. Tc-99m bone scans detect early bone metastasis because of the new bone formation occurring at these sites \[124] and have a 98% sensitivity for detecting early bone metastasis in symptomatic patients. However, bone scan is not helpful for asymptomatic women with newly diagnosed early stage breast cancer due to the low prevalence of metastasis (\<1%) at initial diagnosis \[125]. Whole body bone scans are performed in up to 35% of women with newly diagnosed breast cancer despite National Comprehensive Cancer Network (NCCN) guidelines recommending against routine staging in asymptomatic women with early stage breast cancer \[125,126]. The unnecessary use of this imaging test and the further evaluation of false-positive findings can result in treatment delay \[127]. There is no evidence to use whole body bone scan in the evaluation of distant disease in stage I to IIA breast cancer. 骨是乳腺癌最常见的转移部位；高达70%的IV期患者会发生骨转移，但基底样肿瘤除外\[117]。即使原发肿瘤为低级别\[123]，仍有高达13.6%的早期乳腺癌患者在确诊后15年内会出现骨转移\[122]。锝-99m骨扫描能通过检测转移灶的新骨形成来早期发现骨转移\[124]，对有症状患者的早期骨转移检出灵敏度达98%。但由于初诊时转移发生率低(\<1%)\[125]，骨扫描对无症状的早期乳腺癌新确诊患者并无帮助。尽管美国国家综合癌症网络(NCCN)指南不建议对无症状早期乳腺癌患者进行常规分期检查\[125,126]，但仍有高达35%的新确诊患者接受了全身骨扫描。这种影像学检查的过度使用及假阳性结果的进一步评估可能导致治疗延迟\[127]。目前没有证据支持在I-IIA期乳腺癌远处转移评估中使用全身骨扫描。
* 检查项目: CT chest abdomen pelvis without IV contrast / CT胸部(平扫),CT全腹部(平扫),CT盆腔(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0030 / R:CR000526
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明:
* 检查项目: Digital Breast Tomosynthesis Diagnostic / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000527
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no evidence to support the use of DBT to evaluate distant disease. 没有证据支持使用DBT评估远处疾病。
* 检查项目: Mammography Diagnostic / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000527
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no evidence to support the use of diagnostic mammography to evaluate distant disease. 没有证据支持使用诊断性乳腺X线摄影来评估远处疾病。
* 检查项目: Mammography With IV Contrast / MG双侧乳腺钼靶导管造影
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0004 / R:CR000529
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no evidence to support the use of diagnostic mammography with IV contrast to evaluate distant disease. 没有证据支持使用静脉注射造影剂的诊断性乳腺X线摄影来评估远处疾病。
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000531
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no evidence to support the use of noncontrast breast MRI in evaluating extent of disease. 无证据支持使用非对比增强乳腺MRI评估疾病范围。
* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000530
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no evidence to support the use of MRI breast to evaluate distant disease. 没有证据支持使用乳腺磁共振成像评估远处疾病。
* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0003 / R:CR000533
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no evidence to support the use of US breast to evaluate distant disease. 没有证据支持使用超声检查乳房来评估远处疾病。
* 检查项目: US Axilla / US腋窝淋巴结常规超声检查
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0012 / R:CR000532
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no evidence to support the use of US axilla to evaluate distant disease. 没有证据支持使用腋窝超声评估远处疾病。

##### S0069 Variant: Variant 3:  Newly diagnosed. Clinical stage IIB-III (late stage) breast cancer at presentation. Evaluation for locoregional disease (includes IDC, or ILC, or NOS). | 初诊临床分期为IIBIII期（晚期）乳腺癌，评估局部区域疾病（包括浸润性导管癌、小叶癌或非特殊类型癌）。

检查推荐列表：

* 检查项目: Mammography Diagnostic / MG双侧乳腺钼靶
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0010 / R:CR000536
  * 证据强度: StrongReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Diagnostic mammography and US together can assess for extent of disease and tumor size. These imaging tests are usually already completed as part of the diagnostic workup (prior to pathological diagnosis). However, mammography is limited by breast density. In a prospective study of 111 consecutive women with newly diagnosed breast cancer, the sensitivity of 2-D mammography for malignancy decreased from 100% in breasts that are almost entirely fatty to 45% in extremely dense breasts \[22]. In addition, 2-D mammography was more sensitive in detecting DCIS and less sensitive, compared with US, in detecting ILC. DBT shows higher overall sensitivity, compared with 2-D mammography, with similar specificity. Overall sensitivity for DBT was 88.2% compared with 78.3% \[23]. DBT has higher sensitivity for detecting multifocal, multicentric, and contralateral breast cancer than 2-D mammography alone \[24,25]. The improved diagnostic performance of DBT over 2-D mammography in breast cancer staging was limited to women with nondense breasts in 1 study \[24], but not others \[25]. The correlation between mammographic size and pathologic size is variable. Some studies demonstrate that the assessment of size with mammography to be superior to US \[26], whereas others show it to be inferior \[46]. At least some of this variation may be related to tumor subtype. Mammography shows a higher correlation with pathologic size for DCIS and HER2/neu-negative invasive cancers and a lower correlation for hormone receptor–negative and HER2/neu-positive invasive cancers compared with US \[27]. The accuracy of DBT for assessing tumor size was 70.4% compared with 60.2% on 2-D mammography \[28]. However, the STORM-2 trial showed that DBT tended to overestimate tumor size in women with dense breasts, compared with those with nondense breasts; this was more likely to impact management in women with larger tumors \[29]. Despite the limitations of mammography in women with dense breasts, breast density was not a predictor of positive margins or conversion to mastectomy \[30]. However, 2-D mammography is limited in detecting and measuring the size of ILC, which often presents as architectural distortion and uncommonly has associated calcifications \[31] . Multiple studies have shown DBT to be superior to DM alone in ILC detection, with the differential performance between DM/DBT and DM greatest in ILC compared with IDC \[32]. Therefore, it follows that DBT is also more accurate than DM in evaluating extent of disease for this subtype, which is commonly multicentric, multifocal, and sometimes bilateral. Still, DBT can underestimate the true pathologic extent of ILC \[33], so MRI may be warranted in this subtype, as discussed below. Supporting this, in a retrospective study of 904 women with breast cancer (n = 97 ILC) imaged with mammography ± US, 38.8% of women with ILC undergoing breast-conserving surgery required re-excision compared with 22.3% with IDC \[34]. Due to patient positioning constraints, 2-D mammography and DBT have limited value for evaluating the axilla. In 诊断性乳腺X线摄影与超声联合应用可评估疾病范围和肿瘤大小。这些影像学检查通常已在诊断性评估（病理诊断前）中完成。然而乳腺X线摄影受乳腺密度限制。一项针对111例连续新诊断乳腺癌患者的前瞻性研究显示，二维乳腺X线摄影对恶性肿瘤的敏感性从几乎完全脂肪型乳腺的100%降至极度致密型乳腺的45%\[22]。此外，与超声相比，二维乳腺X线摄影检测导管原位癌（DCIS）的敏感性更高，而检测浸润性小叶癌（ILC）的敏感性较低。与二维乳腺X线摄影相比，数字乳腺断层合成（DBT）总体敏感性更高且特异性相当。DBT总体敏感性为88.2%，而二维乳腺X线摄影为78.3%\[23]。DBT检测多灶性、多中心性及对侧乳腺癌的敏感性高于单独二维乳腺X线摄影\[24,25]。一项研究显示DBT相较于二维乳腺X线摄影在乳腺癌分期中的诊断性能提升仅限于非致密乳腺女性\[24]，但其他研究未证实此结论\[25]。乳腺X线摄影测量尺寸与病理尺寸的相关性存在差异。部分研究表明乳腺X线摄影评估尺寸优于超声\[26]，而其他研究显示其劣于超声\[46]。这种差异至少部分与肿瘤亚型相关。与超声相比，乳腺X线摄影对DCIS和HER2/neu阴性浸润癌的病理尺寸相关性更高，而对激素受体阴性和HER2/neu阳性浸润癌的相关性较低\[27]。DBT评估肿瘤尺寸的准确率为70.4%，而二维乳腺X线摄影为60.2%\[28]。然而STORM2试验显示，与非致密乳腺女性相比，DBT倾向于高估致密乳腺女性的肿瘤尺寸；这种情况更可能影响较大肿瘤女性的治疗决策\[29]。尽管乳腺X线摄影在致密乳腺女性中存在局限性，乳腺密度并非阳性切缘或转为乳房切除术的预测因子\[30]。但二维乳腺X线摄影在检测和测量ILC尺寸方面存在局限，ILC常表现为结构扭曲且较少伴钙化\[31]。多项研究显示DBT在ILC检测方面优于单独数字乳腺X线摄影（DM），DM/DBT与单独DM的性能差异在ILC中比浸润性导管癌（IDC）更显著\[32]。因此DBT在评估该亚型疾病范围时也较DM更准确，该亚型常为多中心性、多灶性且有时为双侧性。尽管如此，DBT仍可能低估ILC的真实病理范围\[33]，故该亚型可能需要MRI评估（如下文所述）。一项针对904例乳腺癌女性（含97例ILC）的回顾性研究支持此观点：接受乳腺X线摄影±超声检查后，38.8%的ILC患者接受保乳手术需再次切除，而IDC患者仅为22.3%\[34]。由于患者体位限制，二维乳腺X线摄影和DBT对腋窝评估价值有限。
* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0003 / R:CR000535
  * 证据强度: StrongReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: Diagnostic mammography and US together can assess for extent of disease and tumor size. These imaging tests are usually already completed as part of the diagnostic workup (prior to pathological diagnosis). The sensitivity of US for detecting cancer ranges from 79% to 94% \[22,25,104,105]. The addition of DBT to US improved sensitivity for detecting both primary breast cancer and multicentric and multifocal disease, from 82.6% (nondense) and 91.6% (dense) with US alone to 97.7% with combined DBT and US \[106]. However, DBT and mammography have limited added value over US alone for initial evaluation in women \<40 years of age \[105]. Although bilateral US use in women with primary breast cancer to evaluate for multicentric and multifocal disease shows lower sensitivity to MRI (85.1% versus 71.1%), US showed higher accuracy and specificity than MRI (67.6% versus 39.3% and 69.2% versus 60.2%, respectively), suggesting that bilateral US may be an acceptable alternative to MRI for locoregional staging \[57]. When compared with DM alone, supplemental US more accurately depicted extent of disease needing wider excision in 17 of 96 (18%) breasts for which conservation was anticipated, corresponding to 17 of 30 (57%) patients have synchronous bilateral cancer \[107]. This risk of synchronous bilateral malignancy is increased for patients less than 55 years of age or those with diagnosis of invasive lobular subtype \[108]. In 1 series with 9% contralateral synchronous malignancy, mammography detected 60%, US detected 80%, and MRI detected 90% (with the remainder detected on follow-up imaging) \[22]. In addition to its role in the initial diagnostic workup, US is important in the secondary evaluation of a suspicious finding on MRI in the setting of evaluation for disease extent. US sensitivity and NPV are higher than DBT \[109]. Compared with DBT, US showed a lower specificity (98.1% versus 78.9%) and a similar PPV (66.7% versus 52.2%). However, a meta-analysis of second-look US following a suspicious finding on MRI showed heterogeneity in US performance, with the detection rate ranging from 22.6% to 82.1% (pooled detection rate 57.5%) and an 87.8% pooled NPV \[110]. Therefore, a negative US is insufficient to obviate the need for an MRI biopsy in this setting. There is no evidence supporting US as an accurate method for determining disease extent in those diagnosed with the ILC subtype. Conventional imaging with mammography and/or US can significantly underestimate the span of ILC \[26,111-114]. For example, US specifically underestimated ILC tumor size by 27% (95% CI, 17%-37%) in a study \[113], and a different study showed that the greatest discrepancy between tumor size and pathologic size using US measurements was for those with the ILC subtype \[26]. 诊断性乳腺X线摄影和超声（US）联合使用可评估疾病范围和肿瘤大小。这些影像学检查通常作为诊断检查的一部分（在病理诊断之前）已完成。超声检测癌症的敏感性范围为79%至94%\[22,25,104,105]。在US基础上加用数字乳腺断层合成（DBT）提高了检测原发性乳腺癌以及多中心和多灶性病变的敏感性，从单独使用US的82.6%（非致密乳腺）和91.6%（致密乳腺）提高到DBT与US联合的97.7%\[106]。然而，对于40岁以下女性的初始评估，DBT和乳腺X线摄影相对于单独US的附加价值有限\[105]。虽然在原发性乳腺癌女性中使用双侧US评估多中心和多灶性病变的敏感性低于MRI（85.1%对71.1%），但US显示出比MRI更高的准确性和特异性（分别为67.6%对39.3%和69.2%对60.2%），表明双侧US可能是MRI用于局部区域分期的一个可接受的替代方案\[57]。与单独数字乳腺X线摄影（DM）相比，补充性US更准确地描绘了96例预期保乳手术乳房中17例（18%）需要更广泛切除的疾病范围，对应30例患者中17例（57%）存在双侧同步癌\[107
* 检查项目: Digital Breast Tomosynthesis Diagnostic / MG双侧乳腺钼靶
  * 评分: 8
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0010 / R:CR000536
  * 证据强度: StrongReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Diagnostic mammography and US together can assess for extent of disease and tumor size. These imaging tests are usually already completed as part of the diagnostic workup (prior to pathological diagnosis). However, mammography is limited by breast density. In a prospective study of 111 consecutive women with newly diagnosed breast cancer, sensitivity of 2-D mammography for malignancy decreased from 100% in breasts that are almost entirely fatty to 45% in extremely dense breasts \[22]. In addition, 2-D mammography was more sensitive than US in detecting DCIS and less sensitive at detecting ILC. DBT shows higher overall sensitivity, compared with 2-D mammography, with similar specificity. Overall sensitivity for DBT was 88.2% compared with 78.3% for 2-D mammography \[23]. DBT also has a higher sensitivity for detecting multifocal, multicentric, and contralateral breast cancer \[24,25]. The improved diagnostic performance of DBT over 2-D mammography was limited to women with nondense breasts in 1 study \[24], but not others \[25]. The correlation between mammographic size and pathologic size is variable. Some studies demonstrate that the assessment of size with mammography to be superior to US \[26], whereas others show it to be inferior \[46]. At least some of this variation may be related to tumor subtype. Mammography shows a higher correlation with pathologic size for DCIS and HER2/neu-negative invasive cancers and a lower correlation for hormone receptor–negative and HER2/neu-positive invasive cancers compared with US \[27]. The accuracy for DBT for assessing tumor size was 70.4% compared with 60.2% on 2-D mammography \[28]. However, the STORM-2 trial showed that DBT tended to overestimate tumor size in women with dense breasts, compared with those with nondense breasts; this difference was more likely to impact management in women with larger tumors \[29]. Despite the limitations of mammography in women with dense breasts, breast density was not a predictor of positive margins or conversion to mastectomy \[30]. However, 2-D mammography is limited in detecting and measuring the size of ILC, which often presents as architectural distortion and uncommonly has associated calcifications \[31] . Multiple studies have shown DBT to be superior to DM alone in ILC detection, with the differential performance between DM/DBT and DM greatest in ILC when compared with patients diagnosed with IDC \[32]. Therefore, it follows that DBT is also more accurate than DM in evaluating extent of disease for this cancer subtype, which is commonly multicentric, multifocal, and sometimes bilateral. Still, DBT can underestimate the true pathologic extent of ILC \[33], so MRI may be warranted in this subtype, as discussed below. Supporting this, in a retrospective study of 904 women with breast cancer (n = 97 ILC) imaged with mammography ± US, 38.8% of women with ILC undergoing breast-conserving surgery required re-excision compared with 22.3% with IDC \[34]. Due to patient positioning constraints, 2-D mammography and DBT have limited value for evaluating the axilla. In 诊断性乳腺X线摄影和超声联合应用可评估疾病范围和肿瘤大小。这些影像学检查通常已作为诊断检查（病理诊断前）的一部分完成。然而，乳腺X线摄影受乳腺密度限制。一项针对111例连续新诊断乳腺癌女性的前瞻性研究中，二维乳腺X线摄影对恶性肿瘤的敏感性从几乎完全脂肪型乳腺的100%降至极度致密型乳腺的45%\[22]。此外，二维乳腺X线摄影在检测导管原位癌（DCIS）时比超声更敏感，而在检测浸润性小叶癌（ILC）时敏感性较低。与二维乳腺X线摄影相比，数字乳腺断层合成（DBT）显示出更高的总体敏感性，且特异性相似。DBT的总体敏感性为88.2%，而二维乳腺X线摄影为78.3%\[23]。DBT在检测多灶性、多中心性及对侧乳腺癌方面也具有更高敏感性\[24,25]。一项研究显示DBT相较于二维乳腺X线摄影的诊断性能提升仅限于非致密乳腺女性\[24]，但其他研究未证实此结论\[25]。乳腺X线摄影测量大小与病理大小的相关性存在差异。部分研究表明乳腺X线摄影评估大小优于超声\[26]，而其他研究显示其在浸润性小叶组织学类型中较差\[27]。这种差异至少部分与肿瘤亚型相关。与超声相比，乳腺X线摄影对DCIS和HER2/neu阴性浸润癌的病理大小相关性更高，而对激素受体阴性和HER2/neu阳性浸润癌的相关性较低\[27]。DBT评估肿瘤大小的准确率为70.4%，二维乳腺X线摄影为60.2%\[28]。然而，断层合成或标准乳腺X线摄影2（STORM2）试验表明，与非致密乳腺女性相比，DBT倾向于高估致密乳腺女性的肿瘤大小；这种情况更可能影响较大肿瘤女性的治疗决策\[29]。尽管乳腺X线摄影在致密乳腺女性中存在局限性，乳腺密度并非阳性切缘或转为乳房切除术的预测因子\[30]。但二维乳腺X线摄影在检测和测量ILC大小方面存在局限，ILC常表现为结构扭曲且较少伴钙化\[31]。多项研究显示DBT在ILC检测方面优于单独数字乳腺X线摄影（DM），与浸润性导管癌（IDC）患者相比，DM/DBT与DM在ILC中的性能差异最大\[32]。因此，DBT在评估这种常为多中心性、多灶性且有时为双侧性的癌症亚型的疾病范围方面也较DM更准确。尽管如此，DBT可能低估ILC的真实病理范围\[33]，故该亚型可能需要MRI检查，如下文所述。一项针对904例乳腺癌女性（含97例ILC）的回顾性研究支持此观点，该研究采用乳腺X线摄影±超声成像，显示接受保乳手术的ILC女性中38.8%需要再次切除，而IDC女性为22.3%\[34]。由于患者体位限制，二维乳腺X线摄影和DBT对腋窝评估价值有限。
* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 8
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0005 / R:CR000537
  * 证据强度: StrongReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: MRI breast is useful for detecting additional cancers in the ipsilateral and contralateral breast \[16,55], particularly in women with dense breasts \[23,56,57]. A meta-analysis of 22 studies investigated MRI screening of the contralateral breast in women with newly diagnosed breast cancer. The study reported contralateral malignancies that were detected by MRI in 131 of 3,253 women. Thus, the summary estimate for incremental cancer detection rate was 4.1%. In studies in which pathologic tumor stage was reported, all but 2 tumors were in situ or stage I, and of those 2 tumors, 1 was a node-negative ILC (42 mm). Summary estimates were as follows: MRI-directed additional biopsy in 9.3% of women (95% CI, 5.8%-14.7%) with PPV for malignancy of 47.9% (95% CI, 31.8%- 64.6%). Where reported, 35.1% of MRI-detected cancers were DCIS (mean size = 6.9 mm) and 64.9% were invasive cancers (mean size = 9.3 mm) \[58]. MRI can accurately assess tumor size for preoperative planning \[50,59-61]. In a study involving 343 tumors, size measurements of cancers on breast MRI were within 5 mm of pathological size in 88% of patients \[60]. Still, other studies using mastectomy specimens have shown that MRI underestimates primary tumor size in 21% and overestimates primary tumor size in 24% of cases. MRI also overestimated the number of invasive lesions by 19% and underestimated the number of invasive lesions in 28% in the same study \[62]. These data underscore the importance of using biopsy to pathologically confirm MRI findings before using them to alter surgical planning, especially when the MRI finding is nonmass enhancement \[63]. In addition to tumor size assessment, some studies show a reduction in re-excision after preoperative MRI \[64-68]. For example, in a study of 991 women, preoperative MRI changed the surgical procedure in 25% (157/626) of cases. In 81% (127/157), MRI was beneficial for the patients, as otherwise occult carcinomas were removed (n = 122) or further biopsy could be prevented (n = 5) \[67]. In this trial, the rate of mastectomy did not differ between patients undergoing preoperative MRI and those who did not. A recent multinational observational study at 27 centers also found that subjects receiving MR as part of routine clinical care had a significantly lower reoperation rate after breast conservation (8.5% versus 11.7%, P \< .001) \[69]. However, other large multicenter studies, such as the COMICE trial, showed the addition of MRI to conventional imaging was not significantly associated with a reduced reoperation rate, with 153 (19%) needing reoperation in the MRI group versus 156 (19%) in the non-MRI group, (OR, 0.96; 95% CI, 0.75-1.24; P = .77) \[70]. Although the findings are important, limitations from the COMICE trial are also noted, such as its inclusion of patients from several small centers where technical factors and varying degree of experience among interpreting radiologists could have influenced the MRI results. It is also not clear that the data from the MRI were incorporated into surgical planning, and nearly 7% of the group assigned MRI乳腺成像可用于检测同侧及对侧乳腺的附加癌灶\[16,55]，尤其适用于致密型乳腺女性\[23,56,57]。一项包含22项研究的荟萃分析探讨了新诊断乳腺癌女性对侧乳腺的MRI筛查。研究显示在3,253名女性中，MRI检测出131例对侧恶性肿瘤。因此，增量癌症检出率的汇总估计值为4.1%。在报告病理肿瘤分期的研究中，除2个肿瘤外均为原位癌或I期肿瘤；该2个肿瘤中，1例为淋巴结阴性的浸润性小叶癌（42 mm）。汇总估计值如下：9.3%的女性接受MRI引导下的附加活检（95% CI, 5.8%14.7%），恶性病变阳性预测值为47.9%（95% CI, 31.8%64.6%）。据报告，MRI检出癌症中35.1%为导管原位癌（平均尺寸=6.9 mm），64.9%为浸润癌（平均尺寸=9.3 mm）\[58]。MRI可准确评估肿瘤尺寸以指导术前规划\[50,5961]。一项涉及343个肿瘤的研究显示，88%患者的乳腺癌MRI尺寸测量与病理尺寸差异在5 mm以内\[60]。但其他采用乳房切除标本的研究表明，MRI在21%的病例中低估原发肿瘤尺寸，在24%的病例中高估原发肿瘤尺寸。同一研究中，MRI对浸润性病灶数量的高估率和低估率分别为19%和28%\[62]。这些数据强调了在根据MRI结果更改手术方案前（特别是当MRI表现为非肿块样强化时）采用活检进行病理确认的重要性\[63]。除肿瘤尺寸评估外，部分研究显示术前MRI可降低再次切除率\[
* 检查项目: FDG-PET/CT Skull Base to Mid-Thigh / PET/CT躯干
  * 评分: 7
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0020 / R:CR000538
  * 证据强度: ModerateReferences
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明: FDG-PET/CT is helpful in evaluating locoregional disease in patients with stage IIB to III breast cancer. Locoregional spread refers to disease spread to the draining regional lymph node basins. Although this usually refers to the ipsilateral axilla, regional spread can also be to the infraclavicular (level III axillary), supraclavicular, and internal mammary/parasternal nodal basins \[2]. Contralateral lymph node involvement is classified as distant (stage IV) disease in the absence of synchronous contralateral breast malignancy \[2]. When used to evaluate locoregional extent of disease, there was a change in stage or management in 20% of stage II and 34% of stage III disease \[13-15,138,139]. NCCN guidelines recommend PET/CT as an optional additional test prior to preoperative systemic therapy if the tumor size is ≥2 cm, or there are positive lymph nodes, or the tumor size is >1 cm with HER2+ or triple-negative disease \[126]. FDG-PET/CT有助于评估IIB至III期乳腺癌患者的局部区域病变。局部区域扩散指病灶转移至引流区域淋巴结群，通常累及同侧腋窝，但也可扩散至锁骨下（III级腋窝）、锁骨上及内乳/胸骨旁淋巴结群\[2]。若无对侧乳腺同时性恶性肿瘤，对侧淋巴结受累则归类为远处（IV期）转移\[2]。用于评估局部区域病变范围时，20%的II期和34%的III期患者的分期或治疗方案发生改变\[13-15,138,139]。NCCN指南建议，若肿瘤≥2cm或存在淋巴结阳性，或肿瘤>1cm且HER2阳性或三阴性时，可将PET/CT作为术前系统治疗的备选附加检查\[126]。
* 检查项目: US Axilla / US腋窝淋巴结常规超声检查
  * 评分: 7
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0012 / R:CR000539
  * 证据强度: StrongReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: This section was previously described in the ACR Appropriateness Criteria ® topic on “ Imaging of the Axilla ” \[88]. The Z0011 trial showed that in women with tumor size \<5 cm and no clinically palpable nodes, ≤2 positive axillary nodal macrometastases on sentinel lymph node biopsy can avoid axillary nodal dissection without compromising survival \[89]. US is the most established noninvasive imaging test for assessing the axilla following a clinically or imaging detected suspicious lymph node. US features associated with a higher likelihood of malignancy include short-axis lymph node size >1 cm, cortical thickness of >0.3 cm, and absence of a fatty hilum \[90-93]. There is a wide range of reported sensitivity and specificity for axillary US, and none of these imaging features are specific enough to avoid the need for histologic sampling. The sensitivity ranges from 26.4% to 94%, and the specificity ranges from 53% to 98% \[94-97]. Although axillary US alone has a relatively low NPV to rule out metastatic disease \[36,98], axillary imaging is significantly more likely to identify metastatic disease in patients with pN2-3 disease compared with low volume burden (ie, those eligible for axillary preservation according to the Z0011 trial). Therefore, detection of nodal disease can help identify patients who would benefit from neoadjuvant systemic therapy to help downstage and de-escalate their axillary surgery and avoid axillary lymph node dissection. However, imaging is less sensitive in detecting invasive lobular cancer metastasis compared with ductal type \[140]. A meta-analysis of 21 studies showed that US combined with needle biopsy improved the sensitivity from 61% to 79% \[99-101]. US- guided core needle biopsy was superior to US-guided FNA in a meta-analysis of 1,353 patients with newly diagnosed invasive breast carcinoma, with a reported sensitivity of 88% for core biopsy and 74% for FNA \[102]. A xillary US and an MRI performed similarly at evaluating axillary lymph nodes in an additional study \[103]. In a meta-analysis of 9,232 cases of preoperative axillary staging procedures in 9,212 patients with breast cancer, preoperative axillary US-guided biopsy was able to identify approximately 50% of women with axillary involvement, but the false-negative rate was 25% \[141]. An additional meta-analysis reported similar findings \[100]. The NCCN does recommend consideration of axillary US, with marker placement if biopsy is performed, prior to preoperative systemic therapy \[126]. 本变体包括采用MRI评估肝转移性疾病，以及腹盆腔MRI评估肝外转移性疾病。ACR适宜性标准® 14 直肠癌分期与疾病监测 多数研究显示，静脉注射常规细胞外钆剂增强MRI检测结直肠肝转移的敏感性相较于CT具有可比性或更优\[98,99]。在脂肪肝背景及新辅助治疗后，MRI检测肝转移的准确性高于CT\[98,99,126]。近年许多研究聚焦于肝胆特异性对比剂增强MRI与DWI的获益\[127134]。一项针对242例接受结直肠肝转移手术切除患者
* 检查项目: Mammography With IV Contrast / MG双侧乳腺钼靶导管造影
  * 评分: 5
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0004 / R:CR000540
  * 证据强度: StrongReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Several retrospective studies have compared the sensitivity and specificity of CEM with conventional 2-D and 3-D mammography, US, and MRI. Overall, CEM and MRI are superior to DM and DM/DBT imaging \[47]. The \[48], and some showing MRI to be superior \[49,50]. Overall sensitivities ranged from 92% to 100% \[16,49,51-53], including CEM detecting 92.3% of satellite masses and up to 100% of contralateral cancers \[28]. CEM and MRI show similar abilities to estimate tumor size ( r , 0.72-0.89 versus 0.65-0.84), but studies have shown improved PPV of CEM (52%-93%) compared with MRI (28-60%) \[16,49,53]. Despite increased specificity over MR, limitations of contrast mammography in determining disease extent include evaluation of the axilla and other nodal groups as well as chest wall involvement \[47], and there is evidence against using CEM to determine disease extent in lobular cancer, due to lower conspicuity \[54]. 多项回顾性研究比较了对比增强乳腺X线摄影（CEM）与传统二维和三维乳腺X线摄影、超声及MRI的敏感性和特异性。总体而言，CEM和MRI优于数字乳腺X线摄影（DM）及DM/数字乳腺断层合成（DBT）成像\[47]。部分研究显示CEM与MRI性能相当\[48]，部分研究表明MRI更优\[49,50]。总体敏感性范围在92%至100%之间\[16,49,5153]，包括CEM检测出92.3%的卫星灶和高达100%的对侧癌症\[28]。CEM和MRI在评估肿瘤大小方面表现相似（相关系数r分别为0.720.89与0.650.84），但研究显示CEM的阳性预测值（PPV）（52%93%）优于MRI（28%60%）\[16,49,53]。尽管相比MR特异性更高，对比增强乳腺X线摄影在确定疾病范围方面存在局限性，包括对腋窝及其他淋巴结群评估以及胸壁侵犯的判断\[47]，且有证据表明由于其显着性较低，不推荐使用CEM确定小叶癌的疾病范围\[54]。
* 检查项目: CT chest abdomen pelvis with IV contrast / CT胸部(增强),CT全腹部(增强),CT盆腔(增强)
  * 评分: 2
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0027 / R:CR000541
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明:
* 检查项目: CT chest abdomen pelvis without and with IV contrast / CT胸部(平扫+增强),CT全腹部(平扫+增强),CT盆腔(平扫+增强)
  * 评分: 2
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0028 / R:CR000542
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢☢ 10-30 mSv \[ped]
  * 推荐说明:
* 检查项目: CT chest abdomen pelvis without IV contrast / CT胸部(平扫),CT全腹部(平扫),CT盆腔(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0030 / R:CR000544
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明:
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000545
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no evidence to support the use of noncontrast breast MRI in evaluating extent of disease. 无证据支持使用非对比增强乳腺MRI评估疾病范围。
* 检查项目: Bone Scan Whole Body / SPECT全身骨显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0029 / R:CR000543
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明: There is no evidence to support the use of bone scan whole body for determining locoregional disease. 没有证据支持使用全身骨扫描来确定局部区域性疾病。

##### S0070 Variant: Variant 4:  Newly diagnosed. Clinical stage IIB-III (late stage) breast cancer at presentation. Evaluation for distant disease. IDC or ILC that is ER+/HER2-. | 新诊断，就诊时为临床IIBIII期（晚期）乳腺癌，评估远处转移，ER阳性/HER2阴性浸润性导管癌或浸润性小叶癌。

检查推荐列表：

* 检查项目: FDG-PET/CT Skull Base to Mid-Thigh / PET/CT躯干
  * 评分: 8
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0020 / R:CR000546
  * 证据强度: StrongReferences
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明: There is a large body of evidence that FDG-PET/CT is useful to detect metastatic disease in stage IIB to III breast cancer \[136-139,149-158]. This is important because patients with locoregional breast malignancy have 5-year survival rates of 76% to 99%, but for patients with distant metastases, 5-year survival rates decreases to 20% to 28% \[159]. The sensitivity, specificity, PPV, NPV, and accuracy of PET/CT in identifying metastatic disease in this population are 100%, 96%, 80%, 100%, and 97%, respectively \[41]. The false-positive rate of PET/CT was 19%. In comparison with CT and other modalities, 80% of patients with distant disease had the metastases exclusively identified on PET/CT \[41]. Groheux et al \[136] investigated 254 patients and found previously unknown metastases in 1 of 44 (2%) women with stage IIA breast cancer, 6 of 56 (11%) women with stage IIB cancer, 11 of 63 (18%) women with stage IIIA cancer, 27 of 74 (37%) women with stage IIIB cancer, and 8 of 17 (47%) women with stage IIIC cancer. PET/CT has especially high yields in patients newly diagnosed at \<40 years of age, revealing distant metastases in 17% of asymptomatic stage IIB \[155]. PET/CT modified staging between 14% and 28% of patients with late-stage disease, regardless of tumor receptor status \[138,139]. In a study of 163 women, PET/CT and whole body bone scan demonstrated concordance in identifying osseous metastases in 81% of cases. Also, PET/CT had the added benefit of detecting extraosseous metastasis in 62% of patients with osseous metastasis. Of those patients with extraosseous metastases, 6% had equivocal and 42% had negative bone scans \[160]. The sensitivity and specificity for PET/CT in the detection of distant metastases is higher than conventional imaging, with a 97% sensitivity and 91% specificity versus an 86% sensitivity and 67% specificity ( P = .009 and P \< .001, respectively) \[161]. However, PET/CT has limited sensitivity for ILC \[162]. NCCN guidelines recommend FDG-PET/CT as an optional additional test prior to preoperative systemic therapy to evaluate for distant disease if the tumor size is >2 cm (T2) or there are positive lymph nodes, or the tumor size is >1 cm (T1c) and HER2+, or there is triple-negative disease \[126]. 有大量证据表明，FDGPET/CT 可用于检测 IIB 期至 III 期乳腺癌的转移性疾病 \[136139,149158]。这一点很重要，因为局部区域性乳腺恶性肿瘤患者的 5 年生存率为 76% 至 99%，但对于远处转移患者，5 年生存率下降至 20% 至 28% \[159]。PET/CT 在该人群中识别转移性疾病的敏感性、特异性、PPV、NPV 和准确度分别为 100%、96%、80%、100% 和 97% \[41]。PET/CT 的假阳性率为 19%。与 CT 和其他检查方式相比，80% 的远处疾病患者其转移灶仅在 PET/CT 上被发现 \[41]。Groheux 等人 \[136] 调查了 254 名患者，发现在 44 名 IIA 期乳腺癌女性中有 1 名 (2%)、56 名 IIB 期癌症女性中有 6 名 (11%)、63 名 IIIA 期癌症女性中有 11 名 (18%)、74 名 IIIB 期癌症女性中有 27 名 (37%) 以及 17 名 IIIC 期癌症女性中有 8 名 (47%) 存在先前未知的转移灶。PET/CT 在年龄小于 40 岁的新诊断患者中检出率尤其高，在 17% 的无症状 IIB 期患者中发现了远处转移 \[155]。PET/CT 改变了 14% 至 28% 的晚期疾病患者的分期，且与肿瘤受体状态无关 \[138,139]。在一项针对 163 名女性的研究中，PET/CT 和全身骨扫描在识别骨转移方面的一致性达到 81% 的病例。此外，PET/CT 还具有额外优势，即在 62% 的骨转移患者中检测出骨外转移。在这些骨外转移患者中，6% 的患者骨扫描结果不确定，42% 的患者骨扫描结果为阴性 \[160]。PET/CT 检测远处转移的敏感性和特异性高于常规影像学检查，其敏感性和特异性分别为 97% 和 91%，而常规影像学检查的敏感性和特异性分别为 86% 和 67%（P 值分别为 .009 和 \< .001）\[161]。然而，PET/CT 对浸润性小叶癌 (ILC) 的敏感性有限 \[162]。NCCN 指南推荐将 FDGPET/CT 作为术前全身治疗前的一项可选附加检查，用于评估远处疾病，条件是肿瘤大小 ≥ 2 cm (T2) 或存在淋巴结阳性，或肿瘤大小 ≥ 1 cm (T1c) 且 HER2+，或存在三阴性疾病 \[126]。
* 检查项目: CT chest abdomen pelvis with IV contrast / CT胸部(增强),CT全腹部(增强),CT盆腔(增强)
  * 评分: 7
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0027 / R:CR000548
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明: CT of the chest, abdomen, and pelvis with intravenous contrast is usually appropriate for the initial staging evaluation of a patient with newly diagnosed clinical stage IIB-III, ER+/HER2- invasive ductal or lobular carcinoma to assess for distant metastatic disease. This comprehensive cross-sectional imaging is indicated due to the elevated risk of occult metastases associated with this advanced clinical stage at presentation, which directly impacts therapeutic planning. The procedure provides essential evaluation of the thorax, abdomen, and pelvis for metastatic involvement in organs such as the lungs, liver, adrenal glands, and bones, while also assessing nodal disease beyond the axilla. While highly sensitive for detecting macrometastases, its limitations include lower sensitivity for subcentimeter lesions, peritoneal carcinomatosis, and bone marrow metastases without cortical destruction. The use of intravenous contrast is necessary for optimal characterization of visceral organs and vascular structures. This study should be performed as part of the initial diagnostic workup prior to definitive treatment decision-making. 对于新诊断的临床IIB-III期、ER+/HER2-浸润性导管癌或小叶癌患者，使用静脉对比剂进行胸部、腹部和盆腔CT检查通常适用于初步分期评估，以评估远处转移性疾病。由于该晚期临床分期在就诊时存在隐匿性转移的高风险，并直接影响治疗计划，因此需要进行这种全面的横断面成像检查。该程序可对胸部、腹部和盆腔进行基本评估，检查肺、肝、肾上腺和骨骼等器官的转移受累情况，同时评估腋窝以外的淋巴结疾病。虽然其对检测大转移灶具有高度敏感性，但其局限性包括对亚厘米病灶、腹膜癌病和无皮质破坏的骨髓转移的敏感性较低。使用静脉对比剂对于内脏器官和血管结构的最佳表征是必要的。该研究应作为明确治疗决策前初始诊断检查的一部分进行。
* 检查项目: Bone Scan Whole Body / SPECT全身骨显像
  * 评分: 7
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0029 / R:CR000547
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明: Bone is the most common site for breast cancer metastasis; up to 70% of women with stage IV disease have bone metastasis, with the predilection for bone metastases not applying to basal-like tumors \[117]. Up to 13.6% of women diagnosed with early stage breast cancer will develop bone metastasis within 15 years of diagnosis \[122], even if the parent tumor is low grade \[123]. Tc-99m bone scans detect early bone metastasis because of the new bone formation occurring at these sites \[124] and have a 98% sensitivity for detecting early bone metastasis in symptomatic patients. The sensitivity of whole body bone scans for detecting bone metastases in patients with late-stage breast cancer ranges from 62% to 100%, regardless of tumor subtype \[143]. Studies using bone scans to stage women with late- stage disease have shown the prevalence of osseous metastases ranging from 4.7% to 45% \[144]. A study by Chu et al \[145] on 256 women with N2/N3 disease showed a metastatic workup for asymptomatic patients was only indicated with T3 or T4 primary lesions. For patients with T0, T1, and T2 diseases, the incidence of stage IV disease was 0%, 0%, and 6%, respectively. The incidence increased with higher T stage; 22% for T3 and 36% for T4 Several studies comparing bone scan performance with CT and PET have been performed in women presenting with late-stage disease \[144]. Some studies have shown up to 17.1% of women with extraosseous metastasis on CT had negative or inconclusive bone scans. One of the benefits of whole body bone scans is the detection of metastasis in the peripheral skeleton, areas not included by CT chest, abdomen, and pelvis with IV contrast. However, the presence of peripheral metastasis almost always (>99%) occurs in the context of extraosseous or central osseous metastasis, and detection of additional peripheral metastases does not typically result in a change in management \[144,146]. 骨是乳腺癌最常见的转移部位；高达70%的IV期女性患者存在骨转移，但这种骨转移倾向不适用于基底样肿瘤\[117]。高达13.6%的早期乳腺癌女性患者在诊断后15年内会发生骨转移\[122]，即使原发肿瘤为低分级\[123]。Tc99m骨扫描可检测早期骨转移，因为这些部位会发生新骨形成\[124]，其对有症状患者早期骨转移的检测敏感性达98%。全身骨扫描对晚期乳腺癌患者骨转移的检测敏感性范围为62%至100%，且与肿瘤亚型无关\[143]。使用骨扫描对晚期女性患者进行分期的研究显示，骨转移的患病率在4.7%至45%之间\[144]。Chu等人\[145]一项针对256名N2/N3疾病女性的研究表明，对无症状患者进行转移性检查仅适用于T3或T4原发灶病变。对于T0、T1和T2疾病患者，IV期疾病的发生率分别为0%、0%和6%。发生率随T分期的升高而增加；T3为22%，T4为36%。多项研究在晚期疾病女性患者中比较了骨扫描与CT和PET的性能\[144]。一些研究表明，高达17.1%的CT发现骨外转移的女性患者，其骨扫描结果为阴性或不确定\[144]。全身骨扫描的优势之一是可检测外周骨骼中的转移灶，这些区域未被静脉对比增强的胸部、腹部和盆腔CT所覆盖。然而，外周转移的存在几乎总是（99%）发生在骨外或中央骨转移的背景下，且检测到额外的外周转移通常不会导致治疗方案的改变\[144,146]。
* 检查项目: CT chest abdomen pelvis without IV contrast / CT胸部(平扫),CT全腹部(平扫),CT盆腔(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0030 / R:CR000550
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明:
* 检查项目: CT chest abdomen pelvis without and with IV contrast / CT胸部(平扫+增强),CT全腹部(平扫+增强),CT盆腔(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0028 / R:CR000549
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢☢ 10-30 mSv \[ped]
  * 推荐说明:
* 检查项目: Digital Breast Tomosynthesis Diagnostic / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000551
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no evidence to support the use of DBT to evaluate for distant disease. 没有证据支持使用数字乳腺断层合成（DBT）来评估远处疾病。
* 检查项目: Mammography diagnostic / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000551
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明:
* 检查项目: Mammography With IV Contrast / MG双侧乳腺钼靶导管造影
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0004 / R:CR000553
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no evidence to support the use of mammography with IV contrast to evaluate distant disease. 没有证据支持使用静脉造影乳腺X线摄影来评估远处疾病。
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000555
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no evidence to support the use of noncontrast breast MRI in evaluating extent of disease. 无证据支持使用非对比增强乳腺MRI评估疾病范围。
* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000554
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no evidence to support the use of MRI breast without and with IV contrast to evaluate for distant disease. 无证据支持使用无静脉注射对比剂及静脉注射对比剂的乳腺MRI来评估远处疾病。
* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0003 / R:CR000557
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no evidence to support the use of US breast to evaluate for distant disease. 没有证据支持使用超声检查乳房来评估远处疾病。
* 检查项目: US Axilla / US腋窝淋巴结常规超声检查
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0012 / R:CR000556
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no evidence to support the use of US axilla to evaluate for distant disease. 没有证据支持使用腋窝超声评估远处疾病。

##### S0071 Variant: Variant 5:  Newly diagnosed. Clinical stage IIB-III (late stage) breast cancer at presentation. Evaluation for distant disease. IDC or ILC that is HER2+ or triple negative (ER, PR, and HER2-). | 初诊临床分期为IIBIII期（晚期）乳腺癌，评估远处转移，HER2阳性或三阴性（ER、PR及HER2阴性）的浸润性导管癌或小叶癌。

检查推荐列表：

* 检查项目: CT chest abdomen pelvis with IV contrast / CT胸部(增强),CT全腹部(增强),CT盆腔(增强)
  * 评分: 8
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0027 / R:CR000558
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明: CT of the chest, abdomen, and pelvis with intravenous contrast is usually appropriate for the evaluation of distant metastatic disease in patients with newly diagnosed clinical stage IIB-III invasive ductal carcinoma (IDC) or invasive lobular carcinoma (ILC) that is either HER2-positive or triple-negative (ER-, PR-, HER2-). This recommendation is based on the high risk of occult metastases associated with these late-stage, biologically aggressive tumor subtypes at initial presentation. The procedure provides a comprehensive survey of common metastatic sites, including the lungs, liver, and bones, which is essential for accurate staging and subsequent treatment planning. The use of intravenous contrast is necessary to optimize lesion detection and characterization within the chest, abdomen, and pelvis. It is important to recognize that while CT is highly sensitive for detecting macrometastases in solid organs, it has limitations in evaluating certain sites, such as the brain or bones, for which additional dedicated imaging may be required based on clinical suspicion. This staging examination is a critical component of the initial workup to determine the extent of disease and guide appropriate systemic therapy. 对于新诊断的临床IIB-III期、HER2阳性或三阴性（ER-、PR-、HER2-）浸润性导管癌（IDC）或浸润性小叶癌（ILC）患者，使用静脉注射对比剂进行胸部、腹部和盆腔CT检查对于评估远处转移性疾病通常是合适的。该建议基于这些晚期、生物学侵袭性肿瘤亚型在初次就诊时具有较高的隐匿性转移风险。该检查可对常见转移部位（包括肺、肝和骨骼）进行全面评估，这对于准确分期和后续治疗计划至关重要。使用静脉对比剂对于优化胸部、腹部和盆腔内病变的检测和表征是必要的。必须认识到，虽然CT对于检测实质器官中的大转移灶高度敏感，但在评估某些部位（如大脑或骨骼）方面存在局限性，可能需要根据临床怀疑进行额外的专项影像学检查。该分期检查是初步评估的重要组成部分，用于确定疾病范围并指导适当的全身治疗。
* 检查项目: FDG-PET/CT Skull Base to Mid-Thigh / PET/CT躯干
  * 评分: 8
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0020 / R:CR000559
  * 证据强度: StrongReferences
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明: NCCN guidelines recommend PET/CT as an optional additional test prior to preoperative systemic therapy if the tumor size is greater than T2, or there are positive lymph nodes, any HER2+, or triple-negative disease \[126]. There is a large body of evidence that FDG-PET/CT is useful to detect metastatic disease in stage IIB to III breast cancer \[136-139,149-158]. This is important because patients with locoregional breast malignancy have 5-year survival rates of 76% to 99%, but for patients with distant metastases, 5-year survival rates decreases to 20% to 28% \[159]. The sensitivity, specificity, PPV, NPV, and accuracy of PET/CT in identifying metastatic disease in this population are 100%, 96%, 80%, 100%, and 97%, respectively \[41]. The false-positive rate of PET/CT was 19%. In comparison with CT and other modalities, 80% of patients with distant disease had the metastases exclusively identified on PET/CT \[41]. Groheux et al \[136] investigated 254 patients and found previously unknown metastases in 1 of 44 (2%) women with stage IIA breast cancer, 6 of 56 (11%) women with stage IIB cancer, 11 of 63 (18%) women with stage IIIA cancer, 27 of 74 (37%) women with stage IIIB cancer, and 8 of 17 (47%) women with stage IIIC cancer. PET/CT has especially high yields in the case of patients newly diagnosed at \<40 years of age, revealing distant metastases in 17% of asymptomatic patients with stage IIB breast cancer \<40 years of age \[155]. PET/CT modified staging between 14% and 28% of patients with late-stage disease, regardless of tumor receptor status \[138,139]. In a study of 163 women, PET/CT and whole body bone scan demonstrated concordance in identifying osseous metastases in 81% of cases. Also, PET/CT had the added benefit of detecting extraosseous metastasis in 62% of patients with osseous metastasis. Of those patients with extraosseous metastases, 6% had equivocal and 42% had negative bone scans \[160]. The sensitivity and specificity for PET/CT in the detection of distant metastases is higher than conventional imaging, with a 97% sensitivity and 91% specificity versus an 86% sensitivity and 67% specificity, respectively ( P = .009 and P \< .001, respectively) \[161]. However, PET/CT has limited sensitivity for ILC \[162]. NCCN guidelines recommend PET/CT as an optional additional test prior to preoperative systemic therapy to evaluate for distant disease if the tumor size is >2 cm (T2) or there are positive lymph nodes, or tumor size is >1 cm (T1c) and HER2+, or there is triple-negative disease \[126], because these subtypes tend to be more aggressive with earlier spread to extraosseous locations compared with other molecular subtypes as described above. NCCN 指南推荐，若肿瘤大小超过 T2、存在淋巴结阳性、任何 HER2+ 或三阴性乳腺癌，可考虑将 PET/CT 作为术前系统治疗的备选附加检查 \[126]。大量证据表明，FDGPET/CT 有助于检测 IIB 至 III 期乳腺癌的转移性疾病 \[136139,149158]。这一点至关重要，因为局部区域性乳腺癌患者的 5 年生存率为 76% 至 99%，而远处转移患者的 5 年生存率降至 20% 至 28% \[159]。PET/CT 在该人群中识别转移性疾病的敏感性、特异性、PPV、NPV 和准确度分别为 100%、96%、80%、100% 和 97% \[41]。PET/CT 的假阳性率为 19%。与 CT 及其他检查方式相比，80% 的远处转移患者其转移灶仅通过 PET/CT 识别 \[41]。Groheux 等 \[136] 研究了 254 例患者，发现在 44 例 IIA 期乳腺癌女性中有 1 例（2%）、56 例 IIB 期中有 6 例（11%）、63 例 IIIA 期中有 11 例（18%）、74 例 IIIB 期中有 27 例（37%）、17 例 IIIC 期中有 8 例（47%）存在先前未知的转移灶。PET/CT 在年龄小于 40 岁的新诊断患者中检出率尤其高，在无症状的 IIB 期乳腺癌且年龄小于 40 岁的患者中，有 17% 发现了远处转移 \[155]。PET/CT 改变了 14% 至 28% 的晚期疾病患者的分期，且与肿瘤受体状态无关 \[138,139]。一项针对 163 名女性的研究中，PET/CT 和全身骨扫描在识别骨转移方面的一致性为 81%。此外，PET/CT 还具有额外优势，即在 62% 的骨转移患者中检测出骨外转移。在这些骨外转移患者中，6% 的骨扫描结果不明确，42% 为阴性 \[160]。PET/CT 检测远处转移的敏感性和特异性高于常规影像学检查，其敏感性为 97%，特异性为 91%，而常规影像学分别为 86% 和 67%（P 值分别为 0.009 和 \<0.001）\[161]。然而，PET/CT 对浸润性小叶癌（ILC）的敏感性有限 \[162]。NCCN 指南推荐，若肿瘤大小为 2 cm（T2）或存在淋巴结阳性，或肿瘤大小为 1 cm（T1c）且 HER2+，或为三阴性乳腺癌，可考虑将 PET/CT 作为术前系统治疗前评估远处疾病的备选附加检查 \[126]，因为这些亚型往往更具侵袭性，且如上所述，相比其他分子亚型更早发生骨外转移。
* 检查项目: Bone Scan Whole Body / SPECT全身骨显像
  * 评分: 7
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0029 / R:CR000560
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明: Bone is the most common site for breast cancer metastasis; up to 70% of women with stage IV disease have bone metastasis, with the predilection for bone metastases not applying to basal-like tumors \[117]. Up to 13.6% of women diagnosed with early stage breast cancer will develop bone metastasis within 15 years of diagnosis \[122], even if the parent tumor is low grade \[123]. Tc-99m bone scans detect early bone metastasis because of the new bone formation occurring at these sites \[124] and have a 98% sensitivity for detecting early bone metastasis in symptomatic patients. The sensitivity of whole body bone scans for detecting bone metastases in patients with late-stage breast cancer ranges from 62% to 100%, regardless of tumor subtype \[143]. Studies using bone scans to stage women with late- stage disease have shown the prevalence of osseous metastases ranging from 4.7% to 45% \[144]. A study by Chu et al \[145] on 256 women with N2/N3 disease showed a metastatic workup for asymptomatic patients was only indicated with T3 or T4 primary lesions. For patients with T0, T1, and T2 diseases, the incidence of stage IV disease was 0%, 0%, and 6%, respectively. The incidence increased with higher T stage; 22% for T3 and 36% for T4 tumors. Several studies comparing bone scan performance with CT and PET have been performed in women presenting with late-stage disease \[144]. Some studies have shown up to 17.1% of women with extraosseous metastasis on CT had negative or inconclusive bone scans \[144]. One of the benefits of whole body bone scans is the detection of However, the presence of peripheral metastasis almost always (>99%) occurs in the context of extraosseous or central osseous metastasis, and detection of additional peripheral metastases does not typically result in a change in management \[144,146]. 骨是乳腺癌最常见的转移部位；高达70%的IV期女性患者存在骨转移，但这种骨转移倾向不适用于基底样肿瘤\[117]。高达13.6%的早期乳腺癌女性患者在诊断后15年内会发生骨转移\[122]，即使原发肿瘤为低分级\[123]。Tc99m骨扫描可检测早期骨转移，因为这些部位会发生新骨形成\[124]，其对有症状患者早期骨转移的检测敏感性达98%。全身骨扫描对晚期乳腺癌患者骨转移的检测敏感性范围为62%至100%，且与肿瘤亚型无关\[143]。使用骨扫描对晚期女性患者进行分期的研究显示，骨转移的患病率在4.7%至45%之间\[144]。Chu等人\[145]一项针对256名N2/N3疾病女性的研究表明，对无症状患者进行转移性检查仅适用于T3或T4原发灶病变。对于T0、T1和T2疾病患者，IV期疾病的发生率分别为0%、0%和6%。发生率随T分期的升高而增加；T3为22%，T4肿瘤为36%。多项研究在晚期疾病女性患者中比较了骨扫描与CT和PET的性能\[144]。一些研究表明，高达17.1%的CT发现骨外转移的女性患者，其骨扫描结果为阴性或不确定\[144]。全身骨扫描的优势之一是可检测外周骨骼中的转移灶，然而，外周转移的存在几乎总是（99%）发生在骨外或中央骨转移的背景下，且检测到额外的外周转移通常不会导致治疗方案的改变\[144,146]。
* 检查项目: MRI Head Without and With IV Contrast / MR颅脑(平扫+增强)
  * 评分: 3
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0031 / R:CR000561
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: The cumulative incidence of brain metastasis across all stages and subtypes of breast cancer ranges from 5.1% to 9.1% \[163,164]. However, the incidence increases to 14.2% in patients with other metastases \[163]. In a single study of 968 patients with brain metastasis, Martin et al \[165] found a higher incidence proportion among hormone receptor–negative, HER2+ (1.1%), and triple-negative (0.7%) subtypes. In patients with known metastasis to any extracranial site, the incidence increased to 11.5% and 11.4%, respectively. The incidence of brain metastases was also higher among Black women, possibly due to later stage at diagnosis (OR, 1.27; 95% CI, 1.06-1.53; P = .01). Currently, the NCCN and ASCO do not recommend routine screening for brain metastasis using MRI because there is no evidence of improved survival \[126,166]. 乳腺癌各分期和亚型中脑转移的累积发生率为5.1%至9.1%\[163,164]。但在合并其他转移灶的患者中，该比例上升至14.2%\[163]。Martin等\[165]对968例脑转移患者的研究显示，激素受体阴性/HER2阳性（1.1%）和三阴性（0.7%）亚型的发生率更高。在已知存在颅外转移的患者中，这两个亚型的脑转移发生率分别增至11.5%和11.4%。黑人女性脑转移发生率更高（OR=1.27，95%CI 1.06-1.53，P=0.01），可能与诊断时分期较晚有关。目前NCCN和ASCO均不推荐常规MRI筛查脑转移，因缺乏改善生存期的证据\[126,166]。
* 检查项目: CT chest abdomen pelvis without IV contrast / CT胸部(平扫),CT全腹部(平扫),CT盆腔(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0030 / R:CR000563
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明:
* 检查项目: CT chest abdomen pelvis without and with IV contrast / CT胸部(平扫+增强),CT全腹部(平扫+增强),CT盆腔(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0028 / R:CR000562
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢☢ 10-30 mSv \[ped]
  * 推荐说明:
* 检查项目: Digital Breast Tomosynthesis Diagnostic / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000564
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no evidence to support the use of DBT to evaluate for distant disease. 没有证据支持使用数字乳腺断层合成（DBT）来评估远处疾病。
* 检查项目: Mammography diagnostic / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000564
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明:
* 检查项目: Mammography With IV Contrast / MG双侧乳腺钼靶导管造影
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0004 / R:CR000566
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no evidence to support the use of mammography with IV contrast to evaluate for distant disease. 没有证据支持使用静脉造影乳腺X线摄影来评估远处疾病。
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000568
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no evidence to support the use of noncontrast breast MRI in evaluating the extent of disease. 无证据支持使用非对比增强乳腺MRI评估疾病范围。
* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000567
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no evidence to support the use of MRI breast without and with IV contrast to evaluate for distant disease. 无证据支持使用无静脉注射对比剂及静脉注射对比剂的乳腺MRI来评估远处疾病。
* 检查项目: MRI Head Without IV Contrast / MR颅脑(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0032 / R:CR000569
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no evidence to support the use of MRI head without IV contrast to evaluate for distant disease. 无证据支持使用无静脉注射对比剂的头部MRI来评估远处疾病。
* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0003 / R:CR000571
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no evidence to support the use of US breast to evaluate for distant disease. 没有证据支持使用超声检查乳房来评估远处疾病。
* 检查项目: US Axilla / US腋窝淋巴结常规超声检查
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0012 / R:CR000570
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no evidence to support the use of US axilla to evaluate for distant disease. 没有证据支持使用腋窝超声评估远处疾病。

##### S0072 Variant: Variant 6:  Surveillance. Regardless of clinical stage of breast cancer at time of original presentation. Evaluation for local recurrence in patient with history of BCT. | 监测。无论初诊时乳腺癌临床分期如何。评估既往保乳治疗史患者的局部复发。

检查推荐列表：

* 检查项目: Digital Breast Tomosynthesis Diagnostic / MG双侧乳腺钼靶
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0010 / R:CR000572
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: The most widely accepted guidelines regarding the surveillance of asymptomatic women with a history of breast cancer come from 2 national organizations: ASCO and NCCN \[172,173]. Both organizations state that routine surveillance with an annual mammogram can detect an in-breast recurrence or a new primary breast cancer in women with an average risk for recurrence. However, there is institutional variation on the frequency (every 6 months versus annual) and time period (1-5 years post-BCT) for surveillance after BCT. There is also variation on whether to include women in the screening versus diagnostic patient populations, in which women in the diagnostic population wait for possible additional imaging needed to reach a final assessment prior to leaving the imaging facility. The sensitivity of mammography is decreased due to post-treatment changes from surgery and radiation therapy, and some institutions prefer closer follow-up after BCT to assess changes due to radiation and surgery and potentially detect local recurrences earlier than on annual follow-up imaging. A single-institution study of 2,329 women following BCT showed that a 6- month interval for surveillance detected a higher proportion of local recurrences at an earlier stage compared with annual surveillance \[174]. In a single-institution study of 789 asymptomatic women after BCT, 1.2% had cancer underwent routine mammographic screening a year after treatment (n = 620) \[175]. However, earlier diagnosis did not result in a difference in local and distant disease-free survival. In summary, there is insufficient evidence demonstrating superior outcomes with diagnostic versus screening mammography for breast cancer surveillance. Expert consensus is to perform an annual diagnostic examination for the first 3 years, followed by routine annual screening, due to the increased complexity of interpretation from postsurgical and postradiation changes \[176] and the increased risk of recurrence in the first 3 years following treatment \[177-180]. There have been multiple studies evaluating the performance of DM versus DBT for surveillance. Chikarmane et al \[181] compared tomosynthesis with 2-D mammography in women with a personal history of breast cancer treated with lumpectomy and mastectomy. They reported a significant decrease in recall rate (7.9% versus 10.1%, respectively) and increased sensitivity (92.3% versus 90.0%, respectively) with tomosynthesis with no significant difference in the cancer detection rate (6.1 versus 6.0 per 1,000 women screened, respectively) or PPV (12.0% versus 6.4%, respectively). These changes in interpretive performance were similar regardless of whether the women underwent breast-conserving surgery or mastectomy. There is evidence that mammography alone may not be sufficient for surveillance in this population. In a large study involving 32,331 women with a history of breast cancer undergoing 117,971 surveillance mammographic examinations (112,269 digital mammographic examinations and 5,702 DBT examinations), surveillance 关于无症状乳腺癌病史女性监测最广泛接受的指南来自两个国家组织：ASCO和NCCN\[172,173]。两个组织均指出，年度乳腺X线摄影常规监测可检测平均复发风险女性的乳腺内复发或新发原发性乳腺癌。但各机构在保乳术后监测频率（每6个月 versus 年度）和监测时长（保乳术后15年）方面存在差异。在将患者归类为筛查人群 versus 诊断人群方面也存在差异——诊断人群需在离开影像科室前等待可能需要的额外影像学检查以完成最终评估。因手术和放疗后治疗改变会降低乳腺X线摄影的敏感性，部分机构倾向于在保乳术后采用更密切的随访，以评估放疗和手术所致变化，并可能比年度随访影像学检查更早发现局部复发。一项针对2,329名保乳术后女性的单机构研究表明，6个月间隔的监测相比年度监测能发现更高比例的早期局部复发\[174]。另一项针对789名保乳术后无症状女性的单机构研究显示，治疗后6个月时间点确诊癌症的比例为1.2%（n=169），而治疗后一年接受常规乳腺X线筛查的女性中癌症检出率为0.6%（n=620）\[175]。但更早的诊断并未导致局部和远处无病生存率的差异。总之，目前缺乏充分证据表明诊断性 versus 筛查性乳腺X线摄影在乳腺癌监测中具有更优的结局。专家共识建议首次3年进行年度诊断性检查，随后转为常规年度筛查，原因是术后和放疗后改变增加了影像解读的复杂性\[176]，且治疗后前3年复发风险增高\[177180]。多项研究评估了DM versus DBT的监测性能。Chikarmane等\[181]比较了断层合成摄影与二维乳腺X线摄影在有乳腺癌个人史（接受肿块切除术和乳房切除术治疗）女性中的应用。他们报道断层合成摄影显著降低了召回率（分别为7.9% versus 10.1%）并提高了敏感性（分别为92.3% versus 90.0%），但癌症检出率（分别为每1000名筛查女性6.1例 versus 6.0例）或PPV（分别为12.0% versus 6.4%）无显著差异。无论女性接受保乳手术还是乳房切除术，这些解读性能的变化均相似。有证据表明单用乳腺X线摄影可能不足以对该人群进行监测。一项大型研究纳入32,331名有乳腺癌病史的女性共接受117,971次监测性乳腺X线检查（
* 检查项目: Mammography Diagnostic / MG双侧乳腺钼靶
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0010 / R:CR000572
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: The most widely accepted guidelines regarding the surveillance of asymptomatic women with a history of breast cancer come from 2 national organizations: ASCO and NCCN \[172,173]. Both organizations state that routine surveillance with an annual mammogram can detect an in-breast recurrence or a new primary breast cancer in women with an average risk for recurrence. However, there is institutional variation on the frequency (every 6 months versus annual) and time period (1-5 years diagnostic patient populations, in which women in the diagnostic population wait for possible additional imaging needed to reach a final assessment prior to leaving the imaging facility. The sensitivity of mammography is decreased due to post-treatment changes from surgery and radiation therapy, and some institutions prefer closer follow-up after BCT to assess changes due to radiation and surgery and potentially detect local recurrences earlier than annual follow-up. A single-institution study of 2,329 women following BCT showed that a 6-month interval for surveillance detected a higher proportion of local recurrences at an earlier stage compared with annual surveillance \[174]. In a single-institution study of 789 asymptomatic women after BCT, 1.2% had cancer diagnosed at the 6-month timepoint following treatment (n = 169), and 0.6% had cancer detected in women who underwent routine mammographic screening a year after treatment (n = 620) \[175]. However, earlier diagnosis did not result in a difference in local and distant disease-free survival. In summary, there is insufficient evidence demonstrating superior outcomes with diagnostic versus screening mammography for breast cancer surveillance. Expert consensus is to perform an annual diagnostic examination for the first 3 years, followed by routine annual screening, due to the increased complexity of interpretation from postsurgical and postradiation changes \[176] and the increased risk of recurrence in the first 3 years following treatment \[177-180]. There is evidence that mammography alone may not be sufficient for surveillance in this population. In a large study involving 32,331 women with a history of breast cancer undergoing 117,971 surveillance mammographic examinations (112,269 digital mammographic examinations and 5,702 DBT examinations), surveillance mammography performance in the detection of interval cancers was inferior to established screening mammography benchmarks \[182], with the main limitation of this study being the relative low proportion of DBT examinations because DBT does detect more cancer than DM alone \[183]. Women \<50 years of age at primary breast cancer diagnosis appear to be at highest risk of a missed interval cancer using surveillance mammography \[184]. These data suggest a need for evolving evidence-based surveillance recommendations on supplemental screening. 关于无症状乳腺癌病史女性监测最广泛接受的指南来自两个国家组织：ASCO和NCCN\[172,173]。两个组织均指出，年度乳腺X线摄影常规监测可检测平均复发风险女性的乳腺内复发或新发原发性乳腺癌。但各机构在保乳术后监测频率（每6个月 versus 年度）和监测时长（15年）方面存在差异。在将患者归类为筛查人群 versus 诊断人群方面也存在差异——诊断人群需在离开影像科室前等待可能需要的额外影像学检查以完成最终评估。因手术和放疗后治疗改变会降低乳腺X线摄影的敏感性，部分机构倾向于在保乳术后采用更密切的随访，以评估放疗和手术所致变化，并可能比年度随访更早发现局部复发。一项针对2,329名保乳术后女性的单机构研究表明，6个月间隔的监测相比年度监测能发现更高比例的早期局部复发\[174]。另一项针对789名保乳术后无症状女性的单机构研究显示，治疗后6个月时间点确诊癌症的比例为1.2%（n=169），而治疗后一年接受常规乳腺X线筛查的女性中癌症检出率为0.6%（n=620）\[175]。但更早的诊断并未导致局部和远处无病生存率的差异。总之，目前缺乏充分证据表明诊断性 versus 筛查性乳腺X线摄影在乳腺癌监测中具有更优的结局。专家共识建议首次3年进行年度诊断性检查，随后转为常规年度筛查，原因是术后和放疗后改变增加了影像解读的复杂性\[176]，且治疗后前3年复发风险增高\[177180]。有证据表明单用乳腺X线摄影可能不足以对该人群进行监测。一项大型研究纳入32,331名有乳腺癌病史的女性共接受117,971次监测性乳腺X线检查（112,269次数字乳腺X线检查和5,702次DBT检查），发现监测性乳腺X线摄影对间期癌的检测性能低于既定的筛查性乳腺X线摄影基准\[182]，该研究主要局限在于DBT检查比例相对较低，而DBT确实比单独DM能检测更多癌症\[183]。原发性乳腺癌诊断时年龄\<50岁的女性采用监测性乳腺X线摄影时间期癌漏诊风险最高\[184]。这些数据表明需要制定基于循证医学的补充筛查监测建议。
* 检查项目: Mammography Screening / MG双侧乳腺钼靶
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0010 / R:CR000572
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: The most widely accepted guidelines regarding the surveillance of asymptomatic women with a history of breast cancer come from 2 national organizations: ASCO and NCCN \[172,173]. Both organizations state that routine surveillance with an annual mammogram can detect an in-breast recurrence or a new primary breast cancer in women with an average risk for recurrence. However, there is institutional variation on the frequency (every 6 months versus annual) and time period (1-5 years post-BCT) for surveillance after BCT. There is also variation on whether to include women in the screening versus diagnostic patient populations, in which women in the diagnostic population wait for possible additional imaging needed to reach a final assessment prior to leaving the imaging facility, whereas women in the screening population could leave after their standard views are performed. The sensitivity of mammography is decreased due to post- treatment changes from surgery and radiation therapy, and some institutions prefer closer follow-up after BCT to assess changes due to radiation and surgery and potentially detect local recurrences earlier than on annual follow- up imaging. A single-institution study of 2,329 women following BCT showed that a 6-month interval for surveillance detected a higher proportion of local recurrences at an earlier stage compared with annual surveillance \[174]. In a single-institution study of 789 asymptomatic women after BCT, 1.2% had cancer diagnosed at the 6- month timepoint following treatment (n = 169), and 0.6% had cancer detected in women who underwent routine mammographic screening a year after treatment (n = 620) \[175]. However, earlier diagnosis did not result in a difference in local and distant disease-free survival. In summary, there is insufficient evidence demonstrating superior outcomes with diagnostic versus screening mammography for breast cancer surveillance. Expert consensus is to perform an annual diagnostic examination for the first 3 years, followed by routine annual screening, due to the increased complexity of interpretation from postsurgical and postradiation changes \[176] and the increased risk of recurrence in the first 3 years following treatment \[177-180]. 关于无症状乳腺癌病史女性监测最广泛接受的指南来自两个国家组织：ASCO和NCCN\[172,173]。两个组织均指出，年度乳腺X线摄影常规监测可检测平均复发风险女性的乳腺内复发或新发原发性乳腺癌。但保乳术后监测频率（每6个月 versus 年度）和持续时间（保乳术后15年）存在机构差异。在将女性纳入筛查人群 versus 诊断人群方面也存在差异——诊断人群女性需在离开影像科室前等待可能需要的额外影像学检查以完成最终评估，而筛查人群女性在完成标准投照后即可离开。由于手术和放疗后的治疗改变，乳腺X线摄影的敏感性降低，部分机构倾向于保乳术后更密切随访，以评估放疗和手术所致变化，并可能比年度随访影像检查更早发现局部复发。一项针对2,329名保乳术后女性的单机构研究表明，6个月间隔监测相比年度监测能发现更高比例的早期局部复发\[174]。另一项针对789名保乳术后无症状女性的单机构研究显示，治疗后6个月时间点确诊癌症的比例为1.2%（n=169），而治疗后一年接受常规乳腺X线筛查的女性中癌症检出率为0.6%（n=620）\[175]。但更早诊断并未导致局部和远处无病生存率的差异。总之，目前缺乏充分证据表明诊断性 versus 筛查性乳腺X线摄影在乳腺癌监测中具有更优结局。专家共识建议首次3年进行年度诊断性检查，之后转为常规年度筛查，原因是术后和放疗后改变增加了影像解读复杂性\[176]，且治疗后前3年复发风险更高\[177180]。
* 检查项目: Digital Breast Tomosynthesis Screening / MG双侧乳腺钼靶(筛查)
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0001 / R:CR000573
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: The most widely accepted guidelines regarding the surveillance of asymptomatic women with a history of breast cancer come from 2 national organizations: ASCO and NCCN \[172,173]. Both organizations state that routine surveillance with an annual mammogram can detect an in-breast recurrence or a new primary breast cancer in women with an average risk for recurrence. However, there is institutional variation on the frequency (every 6 months versus annual) and time period (1-5 years post-BCT) for surveillance after BCT. There is also variation on whether to include women in the screening versus diagnostic patient populations, in which women in the diagnostic population wait for possible additional imaging needed to reach a final assessment prior to leaving the imaging facility, whereas women in the screening population could leave after their standard views are performed. The sensitivity of mammography is decreased due to post- treatment changes from surgery and radiation therapy, and some institutions prefer closer follow-up after BCT to assess changes due to radiation and surgery and potentially detect local recurrences earlier than on annual follow- up imaging. A single-institution study of 2,329 women following BCT showed that a 6-month interval for surveillance detected a higher proportion of local recurrences at an earlier stage, compared with annual surveillance \[174]. In a single-institution study of 789 asymptomatic women after BCT, 1.2% had cancer diagnosed at the 6- month timepoint following treatment (n = 169) and 0.6% had cancer detected in women who underwent routine mammographic screening a year after treatment (n = 620) \[175]. However, earlier diagnosis did not result in a difference in local and distant disease-free survival. In summary, there is insufficient evidence demonstrating superior outcomes with diagnostic versus screening mammography for breast cancer surveillance. Expert consensus is to perform an annual diagnostic examination for the first 3 years, followed by routine annual screening, due to the increased complexity of interpretation from postsurgical and post radiation changes \[176] and the increased risk of recurrence in the first 3 years following treatment \[177-180]. 关于无症状乳腺癌病史女性监测最广泛接受的指南来自两个国家组织：ASCO和NCCN\[172,173]。两个组织均指出，年度乳腺X线摄影常规监测可检测平均复发风险女性的乳腺内复发或新发原发性乳腺癌。但保乳术后监测频率（每6个月 versus 年度）和持续时间（保乳术后15年）存在机构差异。在将女性纳入筛查人群 versus 诊断人群方面也存在差异——诊断人群女性需在离开影像科室前等待可能需要的额外影像学检查以完成最终评估，而筛查人群女性在完成标准投照后即可离开。由于手术和放疗后的治疗改变，乳腺X线摄影的敏感性降低，部分机构倾向于保乳术后更密切随访，以评估放疗和手术所致变化，并可能比年度随访影像检查更早发现局部复发。一项针对2,329名保乳术后女性的单机构研究表明，6个月间隔
* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 6
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0005 / R:CR000576
  * 证据强度: StrongReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: For most breast cancer survivors, there is insufficient evidence for or against the use of breast MRI to detect disease recurrence in women of average risk. However, the ACR recommends annual surveillance with breast MRI in women with a personal history of breast cancer and dense breast tissue, or those diagnosed before age 50 \[186]. This ACR recommendation is partially due to data showing that women with a personal history of premenopausal breast cancer benefited from MRI screening \[187]. Data from the Breast Cancer Surveillance Consortium (BCSC) showed that, compared with mammography, MRI identified more cancers (10.8 versus 8.2 per 1,000 women screened) at the expense of a higher biopsy rate (10.1% versus 4.0%). However, multivariate models showed no difference in interval cancer detection rate or sensitivity (61.4% versus 70.3%, respectively) \[188]. Wernli et al \[188] also found that surveillance breast MRI leads to higher biopsy rate (OR, 2.2; 95% CI, 1.9-2.7; P \< .001) and cancer detection rate (OR, 1.7; 95% CI, 1.1-2.7; P = .03) than mammography alone. However, there were no differences in sensitivity (OR, 1.1; 95% CI, 0.4-2.9; P = .84) or interval cancer rate (OR, 1.1; 95% CI, 0.6-2.2; P = .70) compared with mammography. Single-institutional studies at academic centers evaluating MRI for surveillance report sensitivities between 75% to 100% \[189-193]. The cancer detection rate ranges from 1% to 2.9% for women whose only risk factor is a personal history of breast cancer \[190-192]. However, this increases to 5.4% in patients with a personal history of breast cancer and dense breasts \[194]. Another study from the BCSC group showed that women with a personal history of breast cancer undergoing MRI had a 2-fold increase in biopsy rate per 1,000 screening episodes (57.1% versus 23.6%) and lower cancer yield (267.6 versus 404.6 per 1,000 episodes with biopsy) than following mammography \[195]. Most recently, a meta-analysis from 2000-2019 evaluating MRI as a screening modality in 8,338 women with a history of breast cancer (12,335 MRI examinations) found insufficient data to recommend for or against MRI as a surveillance examination in addition to mammographic screening \[196]. Cancer detection rates of a second breast cancer by MRI were 8 to 20 per 1,000 examinations, but the sensitivity range was from 61% to 100%, with BI- RADS benchmark for MRI screening of at least 80%. Thus, clinical performance benchmarks have not been met in this population. Still, with the exception of the study on the BCSC cohort, other studies did not account for patient characteristics that could increase risk, such as premenopausal status, breast density, mutation status, or family history, through adjustment, stratification, or descriptive analysis. 对于大多数乳腺癌幸存者而言，目前缺乏充分证据支持或反对使用乳腺MRI检测平均风险女性的疾病复发。然而，ACR建议对有个人乳腺癌史且乳腺组织致密或50岁前确诊的女性进行年度乳腺MRI监测\[186]。ACR这一推荐部分基于数据显示有绝经前乳腺癌个人史的女性可从MRI筛查中获益\[187]。乳腺癌监测联盟（BCSC）数据显示，与乳腺X线摄影相比，MRI能检测出更多癌症（每1000名受检女性中10.8例对8.2例），但代价是更高的活检率（10.1%对4.0%）。多变量模型显示间期癌检出率或敏感性无差异（分别为61.4%对70.3%）\[188]。Wernli等\[188]还发现监测性乳腺MRI比单独乳腺X线摄影导致更高活检率（OR=2.2；95%CI：1.92.7；P\<0.001）和癌症检出率（OR=1.7；95%CI：1.12.7；P=0.03），但敏感性（OR=1.1；95%CI：0.42.9；P=0.84）或间期癌发生率（OR=1.1；95%CI：0.62.2；P=0.70）无差异。学术中心评估MRI监测效能的单机构研究报告敏感性介于75%至100%\[189193]。仅具有个人乳腺癌史风险因素的女性癌症检出率为1%至2.9%\[190192]，但在有个人乳腺癌史且乳腺致密的患者中增至5.4%\[194]。BCSC另一研究显示，有个人乳腺癌史接受MRI的女性每1000次筛查的活检率增加2倍（57.1%对23.6%），且癌症检出效能低于乳腺X线摄影（每1000次活检中267.6例对404.6例）\[195]。最新一项20002019年纳入8338名有乳腺癌史女性（12335次MRI检查）的荟萃分析发现，缺乏足够数据支持或反对在乳腺X线摄影筛查基础上加用MRI监测\[196]。MRI对第二原发乳腺癌的检出率为每1000次检查8至20例，但敏感性范围61%至100%，未达到MRI筛查BIRADS标准至少80%的基准性能。除BCSC队列研究外，其他研究未通过调整、分层或描述性分析考虑可能增加风险的患者特征（如绝经前状态、乳腺密度、基因突变状态或家族史）。
* 检查项目: Mammography With IV Contrast / MG双侧乳腺钼靶导管造影
  * 评分: 5
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0004 / R:CR000577
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: A large study (n = 858) comparing the use of mammography with IV contrast to 2-D mammography showed an increase in the sensitivity of cancer detection from 50% to 87.5% with minimal changes to the specificity (97.1% versus 93.7%, respectively) and PPV (25.0% versus 20.9%, respectively) \[185]. This study cohort included a large portion of women with a personal history of breast cancer (40.2%) and women with dense breasts (77.5%), although no information is given about the time since breast cancer diagnosis or stage at presentation in the surveillance 一项大型研究（n=858）比较使用静脉注射对比剂的乳腺摄影与二维乳腺摄影，结果显示癌症检测敏感性从50%提升至87.5%，特异性（分别为97.1%与93.7%）和阳性预测值（分别为25.0%与20.9%）变化微小\[185]。该研究队列包含大量有个人乳腺癌史（40.2%）和致密乳腺（77.5%）的女性，但未提供乳腺癌诊断后的时间或监测就诊时的分期信息。
* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 2
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0003 / R:CR000578
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is limited evidence to support the use of US breast for surveillance in women with history of BCT. A single study in Asian patients with a personal history of breast cancer treated with breast-conserving surgery or mastectomy showed diagnostic performances for the sensitivity, specificity, PPV, and accuracy of US of 95.8%, 97.8%, 27.1%, and 97.9% after BCS and 42.9%, 97.5%, 9.4%, and 97.2% after mastectomy \[197]. There is additional evidence that whole breast US, as an adjunct to screening mammography in all women with dense breasts, detects additional 0.3 to 7.7 cancers per 1,000 at the expense of 11.7 to 106.6 biopsies per 1,000 women \[198]. Although useful as a general supplemental screening tool, these limited data do not support US breast as supplemental screening after breast cancer conservation, with more data needed to determine how postoperative changes and fat necrosis specific to this population might impact specificity and sensitivity. 目前支持对保乳治疗（BCT）病史女性采用超声进行监测的证据有限。一项针对亚洲乳腺癌患者（曾接受保乳手术或乳房切除术）的研究显示：保乳术后超声诊断的敏感性、特异性、阳性预测值及准确率分别为95.8%、97.8%、27.1%和97.9%；乳房切除术后则分别为42.9%、97.5%、9.4%和97.2%\[197]。另有证据表明，在致密型乳腺女性中，全乳超声作为乳腺X线筛查的辅助手段，每1000例可额外检出0.3-7.7例癌症，但需付出每1000例女性11.7-106.6次活检的代价\[198]。尽管超声作为常规补充筛查工具具有价值，但这些有限数据不支持将其作为保乳术后的补充筛查手段，需更多数据评估该人群特有的术后改变和脂肪坏死对特异性和敏感性的影响。
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000580
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no evidence to support the use of noncontrast breast MRI in evaluating extent of disease. 无证据支持使用非对比增强乳腺MRI评估疾病范围。
* 检查项目: FDG-PET/CT Skull Base to Mid-Thigh / PET/CT躯干
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0020 / R:CR000579
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明: There is no literature to support the use of FDG-PET/CT to evaluate local recurrence of breast cancer. 目前尚无文献支持使用FDG-PET/CT评估乳腺癌局部复发。

##### S0073 Variant: Variant 7:  Surveillance. Regardless of clinical stage of breast cancer at time of original presentation. Evaluation for local recurrence in patient with history of mastectomy. | 监测。无论初诊时乳腺癌临床分期如何。评估既往乳房切除术史患者的局部复发。

检查推荐列表：

* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 5
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0005 / R:CR000581
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: High-risk women with mastectomies may benefit from MRI surveillance of their remaining breast. In a small study evaluating MRI in women with a unilateral mastectomy, the cancer detection rate was 10 per 1,000 in the asymptomatic mastectomy side, and these cancers would have otherwise been undetected until symptomatic because screening mammography is not performed after mastectomy. In this population, surveillance MR had a sensitivity of 66.7%, a specificity of 99.2%, a PPV of 57.1%, and an NPV of 99.5%. Larger studies are needed to assess the utility of surveillance MR in the setting of mastectomy \[201]. 接受乳房切除术的高风险女性可能受益于对剩余乳房的MRI监测。一项针对单侧乳房切除术后女性进行MRI评估的小型研究显示，无症状切除侧乳房的癌症检出率为每1000人中10例，这些癌症若不通过MRI监测将无法被发现直至出现症状，因为乳房切除术后不再进行筛查性乳腺X线摄影。在该人群中，监测MRI的敏感性为66.7%，特异性为99.2%，阳性预测值（PPV）为57.1%，阴性预测值（NPV）为99.5%。需要更大规模研究来评估乳房切除术后MRI监测的效用\[201]。
* 检查项目: Digital Breast Tomosynthesis Diagnostic / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000582
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no evidence to support the use of DBT to evaluate for recurrence after mastectomy in an asymptomatic patient. 没有证据支持在无症状患者中使用数字乳腺断层合成摄影（DBT）评估乳房切除术后复发情况。
* 检查项目: Mammography Diagnostic / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000582
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no evidence to support the use of diagnostic mammography to evaluate for recurrence after mastectomy in asymptomatic women. 没有证据支持对无症状女性在乳房切除术后使用诊断性乳腺X线摄影来评估复发。
* 检查项目: Mammography Screening / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000582
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no evidence to support the use of screening mammography to evaluate for recurrence after mastectomy. 没有证据支持使用筛查性乳腺X线摄影来评估乳房切除术后的复发情况。
* 检查项目: Digital breast tomosynthesis screening / MG双侧乳腺钼靶(筛查)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0001 / R:CR000583
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明:
* 检查项目: Mammography With IV Contrast / MG双侧乳腺钼靶导管造影
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0004 / R:CR000587
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no evidence to support the use of CEM to evaluate for recurrence after mastectomy in asymptomatic women. 没有证据支持使用对比增强乳腺X线摄影（CEM）来评估无症状女性乳房切除术后的复发情况。
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000588
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no evidence to support the use of noncontrast breast MRI in surveillance. 无证据支持在监测中使用非对比增强乳腺MRI。
* 检查项目: FDG-PET/CT Skull Base to Mid-Thigh / PET/CT躯干
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0020 / R:CR000584
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明: In asymptomatic patients with a history of breast cancer who received treatment for curative intent, there is no role for imaging to screen for locoregional recurrences with FDG-PET/CT skull base to mid-thigh. ASCO, NCCN, and ESMO all recommend against the routine use of imaging to screen for distant disease recurrence \[172,173,200]. 对于以治愈为目的接受治疗的无症状乳腺癌病史患者，采用FDG-PET/CT（颅底至大腿中部）筛查局部区域复发并无临床价值。ASCO、NCCN和ESMO均不建议常规使用影像学检查筛查远处疾病复发\[172,173,200]。
* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0003 / R:CR000589
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is limited evidence to support the use of US breast for surveillance in the women with history of mastectomy. 现有证据不足以支持对曾接受乳房切除术的女性使用超声进行监测。

##### S0074 Variant: Variant 8:  Suspected local recurrence of breast cancer based on symptoms, physical examination, or laboratory value in patient with history of BCT. Regardless of clinical stage at time of original presentation. | 基于症状、体格检查或实验室值，疑似乳腺癌局部复发，患者有保乳治疗史。无论初次就诊时的临床分期如何。

检查推荐列表：

* 检查项目: Digital Breast Tomosynthesis Diagnostic / MG双侧乳腺钼靶
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0010 / R:CR000590
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Mammography can assist in monitoring women with a history of breast cancer and evaluating for suspicion of local recurrence. Diagnostic DBT improves lesion characterization in noncalcified lesions when compared with conventional mammographic workup \[202]. The performance of DM versus DBT has not been determined for symptomatic imaging specifically in the post-BCT population. 乳腺X线摄影有助于监测有乳腺癌病史的女性并评估疑似局部复发的情况。与传统乳腺X线检查相比，诊断性数字乳腺断层合成成像（DBT）可提高非钙化病灶的特征分析能力\[202]。目前尚未明确数字乳腺摄影（DM）与DBT在保乳术后人群症状性成像中的具体表现差异。
* 检查项目: Mammography Diagnostic / MG双侧乳腺钼靶
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0010 / R:CR000590
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Mammography can assist in monitoring women with a history of breast cancer and evaluating for suspicion of local recurrence. Diagnostic DBT improves lesion characterization in noncalcified lesions when compared with conventional mammographic workup \[202]. The performance of DM versus DBT has not been determined for symptomatic imaging specifically in the post-BCT population. 乳腺X线摄影有助于监测有乳腺癌病史的女性并评估疑似局部复发的情况。与传统乳腺X线检查相比，诊断性数字乳腺断层合成成像（DBT）可提高非钙化病灶的特征分析能力\[202]。目前尚未明确数字乳腺摄影（DM）与DBT在保乳术后人群症状性成像中的具体表现差异。
* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 8
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0003 / R:CR000592
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: In the setting of symptoms suggesting a local recurrence such as a palpable mass or focal pain, US is used after diagnostic mammography for a full evaluation, as per the ACR Appropriateness Criteria ® topics on “ Palpable Breast Masses ” \[207] and “ Breast Pain ” \[208]. US breast may be helpful to further evaluate women with suspected recurrence unless the findings on mammography corresponding to the physical examination finding are classic for a benign etiology (eg, fat necrosis). 在出现提示局部复发的症状（如可触及肿块或局部疼痛）时，根据美国放射学会适用性标准®关于"可触及乳腺肿块"\[207]和"乳腺疼痛"\[208]的主题，超声检查在诊断性乳腺X线摄影后用于全面评估。除非乳腺X线摄影检查结果与体检发现相符且符合典型良性病因（如脂肪坏死），否则乳腺超声可能有助于进一步评估疑似复发的女性患者。
* 检查项目: Mammography With IV Contrast / MG双侧乳腺钼靶导管造影
  * 评分: 5
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0004 / R:CR000593
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There are limited data on the use of CEM in breast cancer surveillance. Sorin et al \[203] did show a high incremental cancer detection rate (13.1 cancers per 1,000 women) when mammography with IV contrast replaced DM in patients with a personal history of breast cancer or with an intermediate lifetime risk. US (targeted and whole breast) increased the number of women needing biopsy from 80 to 134 without detecting additional malignancy. 关于对比增强乳腺X线摄影（CEM）在乳腺癌监测中的应用数据有限。Sorin等人\[203]的研究显示，对于有乳腺癌个人史或中等终生风险的女性，采用静脉注射对比剂的乳腺X线摄影替代数字乳腺X线摄影（DM）时，其增量癌症检出率较高（每1000名女性中检出13.1例癌症）。超声检查（靶向及全乳）使需要活检的女性人数从80例增至134例，但未检出额外恶性肿瘤。
* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 5
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0005 / R:CR000594
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: Although MRI does have greater sensitivity for malignancy than diagnostic mammogram alone, this use serves to detect asymptomatic disease. If there is a finding on the mammogram or US, then workup may be performed based on the most suspicious finding identified during the standard diagnostic workup. A mammographic finding can be sampled using tomosynthesis or stereotactic biopsy, and a sonographic finding can be sampled using US-guided biopsy. If mammogram and US are unrevealing, MRI is not useful as a problem-solving test, and, therefore, further in cases of a palpable breast mass without corresponding suspicious finding on mammography or US. In a study, 2 of 82 patients were subsequently diagnosed with malignancy with PPV of 25% \[204], and in another, 3 of 167 women with PPV of 13% \[205]. Finally, a third study starting with 22,004 women with palpable abnormalities demonstrated 9,334 with negative mammogram and/or US. Thirty-one of these patients underwent subsequent MRI, with 8 subsequent biopsies and no malignancies found \[206]. 尽管 MRI 对恶性肿瘤的敏感性确实高于单独诊断性乳腺 X 线摄影，但其用途在于检测无症状疾病。若乳腺 X 线摄影或超声发现异常，则可根据标准诊断检查中最可疑的发现进行进一步评估。乳腺 X 线摄影发现可通过断层合成或立体定向活检取样，超声发现可通过超声引导活检取样。若乳腺 X 线摄影和超声未发现异常，MRI 作为问题解决性检查并无用处，因此不推荐用于可触及乳腺肿块但乳腺 X 线摄影或超声无相应可疑发现的情况。一项研究中，82 例患者中有 2 例后续诊断为恶性肿瘤，阳性预测值为 25% \[204]；另一项研究中，167 名女性中有 3 例，阳性预测值为 13% \[205]。最后，第三项研究从 22,004 名有可触及异常的女性开始，其中 9,334 名乳腺 X 线摄影和/或超声结果为阴性。这些患者中有 31 例接受了后续 MRI，其中 8 例进行了后续活检，未发现恶性肿瘤 \[206]。
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000596
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no role for noncontrast MRI in the setting of suspected local recurrence based on signs and symptoms. 对于基于症状和体征怀疑局部复发的病例，非增强MRI无应用价值。
* 检查项目: FDG-PET/CT Skull Base to Mid-Thigh / PET/CT躯干
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0020 / R:CR000595
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明: There is no evidence to support the use of FDG-PET/CT to evaluate for locoregional recurrence after BCT. 目前尚无证据支持使用FDG-PET/CT评估保乳治疗后的局部区域复发。

##### S0075 Variant: Variant 9:  Suspected local recurrence of breast cancer based on symptoms, physical examination, or laboratory value in patient with history of mastectomy. Regardless of clinical stage at time of original presentation. | 基于症状、体格检查或实验室值，疑似乳腺癌局部复发，患者有乳房切除术史。无论初次就诊时的临床分期如何。

检查推荐列表：

* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0003 / R:CR000597
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: In the setting of symptoms suggesting a local recurrence such as a palpable mass or focal pain, US is used after diagnostic mammography (if indicated) for a full evaluation, as per the ACR Appropriateness Criteria ® topics on “ Palpable Breast Masses ” \[207] and “ Breast Pain ” \[208]. 在出现提示局部复发的症状（如可触及肿块或局部疼痛）时，根据美国放射学会适用性标准®关于“可触及乳腺肿块”\[207]和“乳腺疼痛”\[208]的主题建议，超声检查应在诊断性乳腺X线摄影（如适用）后进行，以完成全面评估。
* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 3
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000598
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: Although breast MR has been evaluated in the setting of asymptomatic screening after mastectomy, there is insufficient evidence to support the use of MR as a problem-solving tool after a negative mammogram (axillary finding/reconstructed breast) and/or US. Therefore, management should be based on clinical suspicion rather than additional imaging. 尽管乳房磁共振成像（MR）已在乳房切除术后无症状筛查中得到评估，但目前证据不足以支持在乳腺X线摄影（腋窝发现/重建乳房）和/或超声检查阴性后使用MR作为问题解决工具。因此，处理应基于临床怀疑而非额外影像学检查。
* 检查项目: Digital Breast Tomosynthesis Diagnostic / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000599
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no evidence to support the use of DBT to evaluate suspected local recurrence in the setting of mastectomy unless the local recurrence suspected is in the axillary region or the patient has a history of breast reconstruction. 目前尚无证据支持使用数字乳腺断层合成摄影（DBT）评估乳房切除术后疑似局部复发的情况，除非疑似复发位于腋窝区域或患者有乳房重建史。
* 检查项目: Mammography Diagnostic / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000599
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no evidence to support the use of mammography to evaluate suspected local recurrence in the setting of mastectomy unless the local recurrence suspected is in the axillary region or the patient has a history of breast reconstruction. 目前尚无证据支持在乳房切除术后使用乳腺X线摄影评估疑似局部复发，除非疑似复发部位位于腋窝区域或患者有乳房重建史。
* 检查项目: Mammography With IV Contrast / MG双侧乳腺钼靶导管造影
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0004 / R:CR000602
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no evidence to support the use of mammography with IV contrast to evaluate suspected local recurrence in the setting of mastectomy unless the local recurrence suspected is in the axillary region or the patient has a history of breast reconstruction. 没有证据支持在乳房切除术后使用静脉造影乳腺X线摄影评估疑似局部复发，除非疑似复发位于腋窝区域或患者有乳房重建史。
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000603
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no evidence to support the use of noncontrast breast MRI in evaluating disease suspected recurrence. 无证据支持使用非对比增强乳腺MRI评估疑似疾病复发。
* 检查项目: FDG-PET/CT Skull Base to Mid-Thigh / PET/CT躯干
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0020 / R:CR000600
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明: There is no evidence to support the use of FDG-PET/CT to evaluate suspected local recurrence in the setting of mastectomy. 目前尚无证据支持在乳房切除术后使用FDG-PET/CT评估疑似局部复发。

##### S0076 Variant: Variant 10:  Surveillance. Regardless of clinical stage of breast cancer at time of original presentation. Evaluation for distant metastatic disease. | 监测。无论初诊时乳腺癌临床分期如何。评估远处转移性疾病。

检查推荐列表：

* 检查项目: CT chest abdomen pelvis with IV contrast / CT胸部(增强),CT全腹部(增强),CT盆腔(增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0027 / R:CR000605
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明:
* 检查项目: CT chest abdomen pelvis without IV contrast / CT胸部(平扫),CT全腹部(平扫),CT盆腔(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0030 / R:CR000607
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明:
* 检查项目: CT chest abdomen pelvis without and with IV contrast / CT胸部(平扫+增强),CT全腹部(平扫+增强),CT盆腔(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0028 / R:CR000606
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢☢ 10-30 mSv \[ped]
  * 推荐说明:
* 检查项目: Digital Breast Tomosynthesis Diagnostic / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000608
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no evidence to support the use of DBT in asymptomatic women for surveillance of distant metastatic disease. 没有证据支持使用数字乳腺断层合成技术（DBT）对无症状女性进行远处转移性疾病的监测。
* 检查项目: Mammography Diagnostic / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000608
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no evidence to support the use of mammography to evaluate suspected distant metastatic disease unless the recurrence suspected is in the axillary region. 除非怀疑复发部位在腋窝区域，否则没有证据支持使用乳腺X线摄影评估疑似远处转移性疾病。
* 检查项目: MRI Head Without IV Contrast / MR颅脑(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0032 / R:CR000612
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no evidence supporting the use of MRI head without IV contrast in asymptomatic women for surveillance. 无证据支持对无症状女性使用无静脉注射造影剂的头部MRI进行监测。
* 检查项目: MRI Head Without and With IV Contrast / MR颅脑(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0031 / R:CR000611
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no evidence supporting the use of MRI head without and with IV contrast in asymptomatic women for surveillance. In asymptomatic patients with a history of breast cancer who received treatment for curative intent, there is no role for imaging to screen for distant recurrences. The ASCO, NCCN, ESMO, and ESO all recommend against the routine use of imaging to screen for distant disease recurrence \[126,128,209,210]. 目前尚无证据支持对无症状女性使用无静脉注射对比剂及增强MRI进行监测。对于已接受根治性治疗的无症状乳腺癌患者，影像学检查在筛查远处复发方面并无作用。美国临床肿瘤学会（ASCO）、美国国家综合癌症网络（NCCN）、欧洲肿瘤内科学会（ESMO）及欧洲肿瘤学院（ESO）均不建议常规采用影像学检查筛查远处疾病复发\[126,128,209,210]。
* 检查项目: FDG-PET/CT Skull Base to Mid-Thigh / PET/CT躯干
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0020 / R:CR000609
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明: In asymptomatic patients with a history of breast cancer who received treatment for curative intent, there is no evidence to support the use of FDG-PET/CT for surveillance of distant metastatic disease. The ASCO, NCCN, ESMO, and ESO all recommend against the routine use of imaging to screen for distant disease recurrence \[126,128,209,210]. 对于以治愈为目的接受治疗的无症状乳腺癌病史患者，目前无证据支持使用FDG-PET/CT进行远处转移病灶监测。美国临床肿瘤学会（ASCO）、美国国家综合癌症网络（NCCN）、欧洲肿瘤内科学会（ESMO）及欧洲肿瘤学院（ESO）均不建议常规采用影像学检查筛查远处疾病复发\[126,128,209,210]。
* 检查项目: Bone Scan Whole Body / SPECT全身骨显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0029 / R:CR000604
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明: In asymptomatic patients with a history of breast cancer who received treatment for curative intent, there is no evidence to support the use of bone scan whole body for surveillance of distant metastatic disease. The ASCO, NCCN, ESMO, and ESO all recommend against the routine use of imaging to screen for distant disease recurrence 对于有乳腺癌病史且已接受以治愈为目的的治疗的无症状患者，无证据支持使用全身骨扫描来监测远处转移性疾病。ASCO、NCCN、ESMO 和 ESO 均不建议常规使用影像学检查来筛查远处疾病复发。
* 检查项目: US Axilla / US腋窝淋巴结常规超声检查
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0012 / R:CR000613
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no evidence supporting the use of US axilla in asymptomatic women for surveillance of distant metastatic disease. 没有证据支持对无症状女性使用腋窝超声来监测远处转移性疾病。

##### S0077 Variant: Variant 11:  Suspected distant recurrence of breast cancer based on symptoms, physical examination, or laboratory value. Regardless of clinical stage at time of original presentation. | 基于症状、体格检查或实验室值疑似乳腺癌远处复发。无论初次就诊时的临床分期如何。

检查推荐列表：

* 检查项目: CT chest abdomen pelvis with IV contrast / CT胸部(增强),CT全腹部(增强),CT盆腔(增强)
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0027 / R:CR000615
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明: CT chest abdomen pelvis with IV contrast is usually appropriate for patients with suspected distant recurrence of breast cancer based on symptoms, physical examination findings, or abnormal laboratory values, regardless of the original clinical stage at presentation. This comprehensive cross-sectional imaging modality provides high sensitivity for detecting metastatic disease in the thorax, abdomen, and pelvis, including common sites such as the lungs, liver, bones, and lymph nodes. The use of intravenous contrast is essential for optimal characterization of soft tissue lesions and vascular structures, improving diagnostic accuracy for metastatic involvement. This examination is particularly valuable for evaluating symptomatic patients or those with biochemical evidence of recurrence, as it can confirm metastatic disease, assess the extent of involvement, and guide subsequent management decisions. However, it should be noted that CT has limitations in detecting certain types of metastases, particularly those involving the brain or bones, which may require additional dedicated imaging. The procedure should be performed in accordance with standardized protocols to ensure consistent image quality and interpretation. 对于基于症状、体格检查或实验室值怀疑乳腺癌远处复发的患者，无论原始临床分期如何，静脉注射对比剂的胸部、腹部和盆腔CT检查通常是合适的。这种全面的横断面成像方式对检测胸部、腹部和盆腔的转移性疾病具有高敏感性，包括肺、肝、骨和淋巴结等常见部位。静脉注射对比剂的使用对于软组织病变和血管结构的最佳表征至关重要，可提高转移性病变的诊断准确性。该检查对于评估有症状患者或有生化证据复发的患者特别有价值，因为它可以确认转移性疾病、评估受累范围并指导后续管理决策。但应注意，CT在检测某些类型的转移方面存在局限性，特别是涉及脑或骨的转移，可能需要额外的专用成像检查。该程序应按照标准化方案执行，以确保一致的图像质量和解读。
* 检查项目: Bone Scan Whole Body / SPECT全身骨显像
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0029 / R:CR000614
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明: In the setting of suspected distant recurrence, bone scan along with chest, abdomen, and pelvis CT is recommended by the NCCN \[126]. 在疑似远处复发的病例中，NCCN建议进行骨扫描及胸部、腹部和盆腔CT检查\[126]。
* 检查项目: FDG-PET/CT Skull Base to Mid-Thigh / PET/CT躯干
  * 评分: 8
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0020 / R:CR000616
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明: In symptomatic patients with a history of breast cancer who received treatment for curative intent, PET/CT can be used to evaluate for recurrence according to NCCN guidelines \[126]. 对于有乳腺癌病史且以治愈为目的接受治疗的有症状患者，根据NCCN指南\[126]，PET/CT可用于评估复发情况。
* 检查项目: MRI Head Without and With IV Contrast / MR颅脑(平扫+增强)
  * 评分: 7
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0031 / R:CR000617
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: The cumulative incidence of secondary breast cancer brain metastases among a US-based population of patients with primary breast cancer was 9.1% (95% CI, 8.5%-9.8%) and the prevalence was 11.7% (95% CI, 11.0%-12.4%) in a study including any patient with a breast cancer diagnosis \[164]. In a single study of 968 patients with brain metastasis, Martin et al \[165] found a higher incidence among hormone receptor–negative, HER2+ (1.1%), and triple-negative (0.7%) subtypes. In patients with known metastasis to any extracranial site, the incidence increased to 11.5% and 11.4%, respectively. The incidence of brain metastases was also higher among Black women, possibly due to later stage at diagnosis (OR, 1.27; 95% CI, 1.06-1.53; P = .01). In the setting of symptoms concerning for brain metastases (headache, nausea, vomiting), a CT head with IV contrast or MRI head with and without IV contrast may be helpful, as detailed in the ACR Appropriateness Criteria ® topic on “ Headache ” \[211]. 一项纳入所有乳腺癌确诊患者的研究显示，美国原发性乳腺癌患者继发脑转移的累积发生率为9.1%（95%CI 8.5%-9.8%），患病率为11.7%（95%CI 11.0%-12.4%）\[164]。Martin等\[165]对968例脑转移患者的单中心研究发现，激素受体阴性/HER2阳性（1.1%）和三阴性（0.7%）亚型发生率更高。在已知存在颅外转移的患者中，发生率分别升至11.5%和11.4%。黑人女性脑转移发生率更高（OR 1.27，95%CI 1.06-1.53，P=0.01），可能与诊断分期较晚有关。当出现脑转移相关症状（头痛、恶心、呕吐）时，参照ACR适用性标准中"头痛"\[211]专题建议，可行静脉造影头部CT或平扫+增强头部MRI检查。
* 检查项目: CT chest abdomen pelvis without IV contrast / CT胸部(平扫),CT全腹部(平扫),CT盆腔(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0030 / R:CR000619
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明:
* 检查项目: CT chest abdomen pelvis without and with IV contrast / CT胸部(平扫+增强),CT全腹部(平扫+增强),CT盆腔(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0028 / R:CR000618
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢☢ 10-30 mSv \[ped]
  * 推荐说明:
* 检查项目: MRI Head Without IV Contrast / MR颅脑(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0032 / R:CR000620
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no evidence supporting the use of MRI head without IV contrast in symptomatic women for the detection of distant disease. 无证据支持对有症状女性使用无静脉造影剂的头部MRI来检测远处疾病。

#### T0012 Imaging of the Axilla | 腋窝影像学检查

* 主题编码: T0012

##### S0078 Variant: Variant 1:  Female. New palpable, unilateral, axillary lump. Initial imaging of the axilla. | 女性，新发可触及单侧腋窝肿块，腋窝初始影像学检查。

检查推荐列表：

* 检查项目: US Axilla / US腋窝淋巴结常规超声检查
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0012 / R:CR000621
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: Multiple studies support the use of US to characterize findings in the axilla \[36,37]. The most common etiology, besides normal tissue, is adenopathy from benign or malignant disease, typically of lymphatic or mammary origin. In addition, accessory breast tissue and both benign and cancerous lesions within accessory tissue can be seen \[36]. If a suspicious US finding or mass is identified, US-guided biopsy can be performed for definitive diagnosis, even if the malignancy rate may be low in a woman with palpable axillary mass and no other signs of malignancy \[37]. 多项研究支持使用超声评估腋窝病变特征\[36,37]。除正常组织外，最常见的病因是良恶性疾病引起的淋巴结肿大，通常源于淋巴系统或乳腺组织。此外，还可观察到副乳组织及其中的良恶性病变\[36]。若超声发现可疑病灶或肿块，即使可触及腋窝肿块的女性恶性率较低且无其他恶性征象，仍可进行超声引导活检以明确诊断\[37]。
* 检查项目: Digital Breast Tomosynthesis Diagnostic / MG双侧乳腺钼靶
  * 评分: 4
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0010 / R:CR000622
  * 证据强度: StrongReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is insufficient data to support the use of DBT as the single initial imaging test for an axillary palpable mass, even though a portion or all of the axillary mass may be visible on DBT. If there is a personal history of breast cancer or clinical suspicion of axillary tail breast carcinoma, DBT, as an adjunct test to axillary US, can provide a global assessment of the ipsilateral breast and also assess for other suspicious findings such as microcalcifications associated with the palpable axillary mass. DBT allows better characterization of lesions and addresses some of the If the unilateral axillary mass is suspicious for metastatic adenopathy from a primary breast cancer or occult breast cancer, the reported data from multicenter trials for DBT use in this population, in addition to digital mammography, was associated with an increased primary breast cancer detection rate compared with digital mammogram alone \[28] . DBT, in addition to digital mammography, demonstrated best performance gains in women ages 40 to 49 years \[29] . 即使数字乳腺断层合成（DBT）可能显示部分或全部腋窝肿块，仍缺乏足够数据支持将其作为腋窝可触及肿块的单一初始影像学检查。若有乳腺癌个人史或临床怀疑腋尾区乳腺癌，DBT作为腋窝超声的辅助检查，可提供同侧乳腺的整体评估，并检测其他可疑表现（如与可触及腋窝肿块相关的微钙化）。DBT能更好地表征病变特征，并解决部分局限性。若单侧腋窝肿块疑似原发性乳腺癌或隐匿性乳腺癌的转移性淋巴结病变，多中心试验数据显示：在此人群中使用DBT联合数字乳腺X线摄影，相较于单独使用数字乳腺X线摄影，可提高原发性乳腺癌检出率\[28]。在40至49岁女性中，DBT联合数字乳腺X线摄影展现出最显著的效能提升\[29]。
* 检查项目: Mammography Diagnostic / MG双侧乳腺钼靶
  * 评分: 4
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0010 / R:CR000622
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is insufficient data to support the use of mammography as the initial imaging test for an axillary palpable mass, even though pathologically enlarged nodes may be seen as dense enlarged nodes or masses on the mediolateral or mediolateral-oblique projection of a mammogram. However, if there is a personal history of breast cancer or clinical suspicion of axillary tail breast carcinoma or metastatic adenopathy from a breast primary, then mammography as an adjunct test to axillary US can provide global assessment of the ipsilateral breast and identify other suspicious findings such as microcalcifications associated with the palpable mass. 目前尚无足够数据支持将乳腺X线摄影作为腋窝可触及肿块的初始影像学检查手段，尽管病理增大的淋巴结可能在乳腺X线摄影的内外侧位或内外斜位投照中显示为致密增大的淋巴结或肿块。然而，若患者有乳腺癌个人史或临床怀疑为腋尾乳腺癌或乳腺原发灶转移性淋巴结病变，则乳腺X线摄影作为腋窝超声的辅助检查，可对同侧乳腺进行全面评估，并识别其他可疑表现（如与可触及肿块相关的微钙化灶）。
* 检查项目: MRI breast without and with IV contrast / MR乳腺(平扫+增强)
  * 评分: 2
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000624
  * 证据强度: StrongReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明:
* 检查项目: CT chest abdomen pelvis with IV contrast / CT胸部(增强),CT全腹部(增强),CT盆腔(增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0027 / R:CR000625
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明:
* 检查项目: CT chest abdomen pelvis without IV contrast / CT胸部(平扫),CT全腹部(平扫),CT盆腔(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0030 / R:CR000627
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明:
* 检查项目: CT chest abdomen pelvis without and with IV contrast / CT胸部(平扫+增强),CT全腹部(平扫+增强),CT盆腔(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0028 / R:CR000626
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢☢ 10-30 mSv \[ped]
  * 推荐说明:
* 检查项目: MRI breast without IV contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000629
  * 证据强度: StrongReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明:
* 检查项目: FDG-PET/CT Skull Base to Mid-Thigh / PET/CT躯干
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0020 / R:CR000628
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明: FDG-PET/CT is not beneficial for assessing an axillary mass of unknown etiology as the initial imaging assessment because of its low yield to detect an occult primary malignancy without first confirming that the unilateral axillary mass is of malignant etiology \[30,31]. Less than 1% of breast cancers initially present as axillary adenopathy \[32,33]. If FDG-PET/CT incidentally detects an FDG-avid lymph node, then axillary US is helpful to characterize the nodal morphology and guide biopsy, if warranted. FDG-PET/CT不推荐作为评估不明原因腋窝肿块的首选影像学检查方法，因为在未首先确认单侧腋窝肿块为恶性病因的情况下，其检测隐匿性原发恶性肿瘤的检出率较低\[30,31]。仅有不足1%的乳腺癌最初表现为腋窝淋巴结肿大\[32,33]。若FDG-PET/CT偶然发现FDG高摄取淋巴结，则腋窝超声有助于评估淋巴结形态特征并在必要时引导活检。
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000630
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of Tc-99m sestamibi molecular breast imaging (MBI) for assessing a unilateral palpable axillary mass. 目前尚无相关文献支持使用锝-99m甲氧基异丁基异腈（Tc-99m sestamibi）分子乳腺成像（MBI）评估单侧可触及腋窝肿块。

##### S0079 Variant: Variant 2:  Female. New palpable, bilateral, axillary lump. Initial imaging of the axilla. | 女性，新发可触及双侧腋窝肿块，腋窝初始影像学检查。

检查推荐列表：

* 检查项目: US Axilla / US腋窝淋巴结常规超声检查
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0012 / R:CR000631
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: The differential diagnosis of bilateral axillary masses is broad and includes normal variants (eg, accessory breast, ectopic breast tissue, lactational changes), infectious or nonmalignant etiologies (eg, reactive adenopathy from mastitis, granulomas, lipomas), and malignancies (eg, lymphoma, leukemia, metastatic breast cancer). Axillary US can determine if the mass is solid or cystic. Management of the finding varies depending on the sonographic appearance. For example, lipomas require no further evaluation, whereas enlarged lymph nodes may require biopsy unless clinical history provides a reasonable explanation \[20,37]. Mammography is also often performed to detect a primary breast carcinoma as the cause of the axillary adenopathy \[40,41]. Initial imaging with an US of the axilla’s is appropriate in the setting of a new palpable, bilateral, axillary lump. 双侧腋窝肿块的鉴别诊断范围广泛，包括正常变异（如副乳、异位乳腺组织、哺乳期改变）、感染性或非恶性病因（如乳腺炎引起的反应性淋巴结肿大、肉芽肿、脂肪瘤）以及恶性肿瘤（如淋巴瘤、白血病、转移性乳腺癌）。腋窝超声可判断肿块为实性或囊性。根据超声表现，处理方式各异。例如，脂肪瘤无需进一步评估，而肿大的淋巴结除非临床病史能合理解释，否则可能需要活检\[20,37]。乳腺X线摄影也常用于检测原发性乳腺癌是否为腋窝淋巴结肿大的原因\[40,41]。对于新出现的可触及双侧腋窝肿块，首选腋窝超声检查是合适的。
* 检查项目: Digital Breast Tomosynthesis Diagnostic / MG双侧乳腺钼靶
  * 评分: 3
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000632
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is insufficient data to support the use of DBT as the initial imaging test for evaluating bilateral palpable axillary masses even though a portion of the axillary region can be visualized on DBT. DBT can provide global assessment of the breasts as well as assess for microcalcifications associated with the axillary mass(es). NCCN guidelines suggest that a diagnostic mammogram and/or DBT may complement axillary US by evaluating the breast 目前尚无足够数据支持将数字乳腺断层合成（DBT）作为评估双侧可触及腋窝肿块的首选影像学检查，尽管DBT可显示部分腋窝区域。DBT能提供乳腺的整体评估，并检测与腋窝肿块相关的微钙化。NCCN指南指出诊断性乳腺X线摄影和/或DBT可通过乳腺评估补充腋窝超声检查。
* 检查项目: Mammography Diagnostic / MG双侧乳腺钼靶
  * 评分: 3
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000632
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is insufficient data to support the use of mammography as the initial imaging test for evaluating bilateral palpable axillary masses, even though a portion of the axillary region can be visualized on mammography. NCCN guidelines also suggest that a diagnostic mammogram and/or DBT may complement axillary US by providing a global evaluation of the breast for underlying lesions in the setting of patients presenting with axillary lymphadenopathy \[7,21]. However, the choice of the imaging modality varies based on the patient’s age, clinical presentation or situation, and patient’s risk factors for breast cancer. 目前数据不足以支持将乳腺X线摄影作为评估双侧可触及腋窝肿块的首选影像学检查方法，尽管部分腋窝区域可通过乳腺X线摄影显像。NCCN指南同时指出，对于表现为腋窝淋巴结病的患者，诊断性乳腺X线摄影和/或数字乳腺断层合成摄影（DBT）可通过对乳腺进行全面评估以发现潜在病灶，从而作为腋窝超声的补充检查手段\[7,21]。然而，影像学检查方式的选择需根据患者年龄、临床表现或具体情况以及乳腺癌危险因素进行个体化调整。
* 检查项目: CT chest abdomen pelvis with IV contrast / CT胸部(增强),CT全腹部(增强),CT盆腔(增强)
  * 评分: 2
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0027 / R:CR000634
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明:
* 检查项目: CT chest abdomen pelvis without IV contrast / CT胸部(平扫),CT全腹部(平扫),CT盆腔(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0030 / R:CR000636
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明:
* 检查项目: CT chest abdomen pelvis without and with IV contrast / CT胸部(平扫+增强),CT全腹部(平扫+增强),CT盆腔(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0028 / R:CR000635
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢☢ 10-30 mSv \[ped]
  * 推荐说明:
* 检查项目: MRI breast without IV contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000639
  * 证据强度: StrongReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明:
* 检查项目: MRI breast without and with IV contrast / MR乳腺(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000638
  * 证据强度: StrongReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明:
* 检查项目: FDG-PET/CT Skull Base to Mid-Thigh / PET/CT躯干
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0020 / R:CR000637
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明: There is no relevant literature to support the use of FDG-PET/CT as the initial imaging test for bilateral axillary adenopathy even though FDG-PET/CT can detect the axillary lymphadenopathy as well as other lymphadenopathy in the neck, chest, abdomen, and pelvis. In one series of breast cancer patients, FDG-PET/CT was significantly more accurate than US (75% versus 62%) for the detection of axillary lymph node metastases, but there was no difference in sensitivity (54% versus 38%) \[38]. Incidental axillary FDG uptake on PET/CT may require further evaluation with mammography, DBT, and US, followed by possible image-guided biopsy. 目前尚无相关文献支持将FDG-PET/CT作为双侧腋窝淋巴结肿大的初始影像学检查手段，尽管FDG-PET/CT可检测腋窝淋巴结肿大以及颈部、胸部、腹部和盆腔的其他淋巴结肿大。在一组乳腺癌患者系列研究中，FDG-PET/CT检测腋窝淋巴结转移的准确率显著高于超声检查（75%对62%），但敏感性无显著差异（54%对38%）\[38]。PET/CT检查中偶然发现的腋窝FDG摄取可能需进一步通过乳腺X线摄影、数字乳腺断层合成成像（DBT）和超声评估，必要时进行影像引导下活检。
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000640
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of Tc-99m sestamibi MBI as the initial imaging of patients presenting with bilateral palpable axillary masses. 目前尚无相关文献支持将锝-99m甲氧基异丁基异腈（MIBI）显像作为双侧可触及腋窝肿块患者的首选影像学检查方法。

##### S0080 Variant: Variant 3:  Female. Newly diagnosed breast cancer, 2 cm or less, with clinical node-negative. Initial imaging of the axilla following diagnostic mammography or DBT. | 女性，新诊断乳腺癌，≤2 cm，临床淋巴结阴性，诊断性乳腺X线摄影或DBT后腋窝初始影像学检查。

检查推荐列表：

* 检查项目: US Axilla / US腋窝淋巴结常规超声检查
  * 评分: 5
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0012 / R:CR000641
  * 证据强度: StrongReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: Axillary US is often performed in early-stage breast cancer patients since the Z0011 trial showed that early-stage cancer and low nodal burden minimizes surgical morbidity because patients can undergo SLNB rather than ALND without compromising survival \[5]. However, there are currently differences in opinion on the use of preoperative axillary US and controversy regarding its routine use in staging clinically node-negative breast cancer patients. One point of view is that a positive axillary US with biopsy proven nodal involvement may commit the patients to ALND who could have received SLN surgery if the Z0011 inclusion criteria were met. The Z0011 inclusion criteria involve histologically confirmed invasive breast carcinoma of ≤5 cm clinically with no palpable adenopathy and an SLN-containing breast cancer on frozen section, touch preparation, or hematoxylin-eosin staining on permanent section, with \<3 positive nodes on SLNB \[5]. The other point of view supporting preoperative axillary US argues that the finding of an abnormal axillary node on axillary US followed by percutaneous biopsy confirmation would help to identify those patients with higher second surgery. One study supporting the utilization of preoperative axillary US from a single center reported that only 3% to 5% of patients had an abnormal axillary US yet met the Z0011 criteria (ie, ALND was not necessary in these patients with preoperative abnormal axillary US). Other studies also supporting the use of preoperative axillary US even in patients who meet Z0011 criteria argue that axillary US can help identify patients with unsuspected extensive nodal disease, thereby removing them from consideration for unindicated SLNB \[56-58]. Patients with negative preoperative axillary US and SLNB had fewer positive nodes, smaller nodal metastases, and lower extranodal extension on final pathology \[58]. US-guided biopsy of any suspicious axillary node either via fine-needle aspiration (FNA) or core biopsy is commonly performed when preoperative axillary US is done. The sensitivity of US-guided biopsy is variable with a wide range of 52% to 90%, whereas the specificity is higher, ranging from 98% to 100% \[59-63]. 腋窝US常在早期乳腺癌患者中进行，因为Z0011试验表明，早期癌症和低淋巴结负荷可最小化手术发病率，因为患者可以接受SLNB而非ALND而不影响生存\[5]。然而，目前对于术前腋窝US的使用存在意见分歧，关于其在临床淋巴结阴性乳腺癌患者分期中常规使用的争议。一种观点认为，腋窝US阳性且活检证实淋巴结受累可能使本可接受SLN手术的患者（若符合Z0011纳入标准）被迫进行ALND。Z0011纳入标准包括组织学证实浸润性乳腺癌≤5 cm、临床无可触及淋巴结病变、SLN冰冻切片、印片或永久切片苏木精伊红染色显示乳腺癌，且SLNB阳性淋巴结\<3个\[5]。另一种支持术前腋窝US的观点认为，腋窝US发现异常淋巴结并经皮活检确认有助于识别那些需要二次手术的患者。一项支持术前腋窝US的单中心研究报告称，仅3%至5%的患者腋窝US异常却符合Z0011标准（即这些术前腋窝US异常的患者不需要ALND）。其他
* 检查项目: MRI breast without and with IV contrast / MR乳腺(平扫+增强)
  * 评分: 3
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000642
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明:
* 检查项目: CT chest abdomen pelvis with IV contrast / CT胸部(增强),CT全腹部(增强),CT盆腔(增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0027 / R:CR000643
  * 证据强度: ModerateReferences
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明:
* 检查项目: CT chest abdomen pelvis without IV contrast / CT胸部(平扫),CT全腹部(平扫),CT盆腔(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0030 / R:CR000645
  * 证据强度: ModerateReferences
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明:
* 检查项目: CT chest abdomen pelvis without and with IV contrast / CT胸部(平扫+增强),CT全腹部(平扫+增强),CT盆腔(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0028 / R:CR000644
  * 证据强度: ModerateReferences
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢☢ 10-30 mSv \[ped]
  * 推荐说明:
* 检查项目: MRI breast without IV contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000647
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明:
* 检查项目: FDG-PET/CT Skull Base to Mid-Thigh / PET/CT躯干
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0020 / R:CR000646
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明: According to the breast cancer guidelines, such as NCCN, European Society for Medical Oncology, Spanish Society of Medical Oncology, and National Institute for Health and Care Excellence, FDG-PET/CT is not routinely performed for staging of early-stage breast cancer in the absence of symptoms (see the ACR Appropriateness Criteria ® topic on “ Stage I Breast Cancer: Initial Workup and Surveillance for Local Recurrence and Distant Metastases in Asymptomatic Women ” \[46] for further guidance). FDG-PET/CT is commonly performed when there are equivocal or suspicious findings on standard staging studies and for staging locally advanced breast cancer or metastatic disease from breast cancer \[7,48]. The rationale is that FDG-PET/CT cannot replace SLNB even though this imaging test can visualize the entire axillary region and can detect distant metastases. A meta-analysis of 25 studies compared the accuracy of FDG-PET/CT with SLNB and reported that the performance of FDG-PET/CT was inferior to SLNB despite its high specificity of 94% in axillary lymph node assessment (95% confidence interval \[CI], 91%–96 %) \[49]. The use of FDG-PET in assessing axillary lymph node status in a newly diagnosed breast cancer of ≤2 cm is not supported by current data in patients who do not have clinical node positive disease. 根据美国国家综合癌症网络（NCCN）、欧洲肿瘤内科学会、西班牙肿瘤内科学会及英国国家卫生与临床优化研究所的乳腺癌指南，对于无症状的早期乳腺癌患者，不推荐常规使用FDG-PET/CT进行分期（具体可参考美国放射学会适宜性标准中关于"I期乳腺癌：无症状女性局部复发和远处转移的初始检查与监测"的专题\[46]）。FDG-PET/CT通常用于标准分期检查结果不明确或可疑时，以及局部晚期乳腺癌或乳腺癌转移病灶的分期\[7,48]。其依据在于：尽管FDG-PET/CT可显示整个腋窝区域并检测远处转移，但不能替代前哨淋巴结活检（SLNB）。一项纳入25项研究的荟萃分析比较了FDG-PET/CT与SLNB的准确性，结果显示在腋窝淋巴结评估中，FDG-PET/CT虽具有94%的高特异性（95%置信区间\[CI]为91%-96%），但其整体性能仍逊于SLNB\[49]。现有数据不支持对临床淋巴结阴性、新诊断肿瘤≤2cm的乳腺癌患者使用FDG-PET评估腋窝淋巴结状态。
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000648
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of Tc-99m sestamibi MBI for staging of the axilla in breast cancer patients. 目前尚无相关文献支持使用锝-99m甲氧基异丁基异腈（MIBI）对乳腺癌患者腋窝进行分期。

##### S0081 Variant: Variant 4:  Female. Newly diagnosed breast cancer, 2 cm or less, with clinical node-positive. Initial imaging of the axilla following diagnostic mammography or DBT. | 女性，新诊断乳腺癌，≤2 cm，临床淋巴结阳性，诊断性乳腺X线摄影或DBT后腋窝初始影像学检查。

检查推荐列表：

* 检查项目: US Axilla / US腋窝淋巴结常规超声检查
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0012 / R:CR000649
  * 证据强度: StrongReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: US is the most established noninvasive imaging test for assessing the axilla. Benign lymph nodes can often be differentiated from malignant nodes based on size, morphology, and vascularity, although there is a wide range of reported sensitivity and specificity for axillary US. The reported sensitivity can range from 26.4% to 94% and specificity from 53% to 98% \[58,81,82]. Axillary US alone has a relatively low NPV and sensitivity to be useful as a predictor of axillary nodal burden \[83,84]. When combined with needle biopsy, however, the sensitivity improves from 61% to 79% in a meta-analysis of 21 studies \[54,62,85]. US-guided core needle biopsy was superior to US- guided FNA in a meta-analysis of 1,353 patients with newly diagnosed invasive breast carcinoma, with a reported sensitivity of 88% for core biopsy and 74% for FNA \[86]. US features associated with a higher likelihood of malignancy include short-axis lymph node size >1 cm, cortical thickness of >0.3cm, and absence of a fatty hilum \[87-90]. However, these imaging features are not specific enough to avoid the need for histologic sampling. Since the Z0011 trial, there continues to be variability in incorporating axillary US into practice. Those in favor of performing axillary US routinely argue that >3 abnormal nodes or a positive axillary lymph node on needle biopsy warrant ALND rather than SLNB because these patients tend to have a high nodal tumor burden \[58,91]. Those not in favor of performing axillary US recommend proceeding with SLNB, even if the preoperative US identify malignant-appearing lymph node(s) because the specificity of US is relatively low. 超声是评估腋窝最成熟的非侵入性影像学检查。良性淋巴结通常可根据大小、形态和血管分布与恶性淋巴结区分，但腋窝超声报告的敏感性和特异性差异较大。敏感性报道范围为26.4%至94%，特异性为53%至98%\[58,81,82]。单独使用腋窝超声的阴性预测值和敏感性相对较低，难以作为腋窝淋巴结负荷的预测指标\[83,84]。然而，联合穿刺活检时，21项研究的荟萃分析显示敏感性从61%提升至79%\[54,62,85]。在1,353例新诊断浸润性乳腺癌患者的荟萃分析中，超声引导空芯针活检优于超声引导细针穿刺，报道敏感性分别为88%和74%\[86]。与恶性可能性较高的超声特征包括淋巴结短轴>1cm、皮质厚度>0.3cm及脂肪门缺失\[87-90]。但这些影像特征特异性不足，仍需组织学取样。自Z0011试验以来，临床实践中腋窝超声的应用仍存在差异。支持常规行腋窝超声的学者认为，若发现>3枚异常淋巴结或穿刺活检阳性，应行腋窝淋巴结清扫而非前哨淋巴结活检，因这类患者通常具有较高淋巴结肿瘤负荷\[58,91]。反对常规行腋窝超声的学者则建议直接行前哨淋巴结活检，即使术前超声发现可疑恶性淋巴结，因超声特异性相对较低。
* 检查项目: MRI breast without and with IV contrast / MR乳腺(平扫+增强)
  * 评分: 5
  * 适宜性: May be appropriate (Disagreement) / 可能适宜（存在争议）
  * 编码: P:PR0005 / R:CR000650
  * 证据强度: Expert OpinionReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: MRI breast without and with IV contrast may be appropriate for the initial imaging of the axilla in a female with newly diagnosed breast cancer (2 cm or less) and clinical node-positive status following diagnostic mammography or DBT. While MRI provides superior soft tissue contrast and can offer detailed evaluation of axillary lymph nodes, its role in this specific scenario is characterized by panel disagreement. The procedure may be considered to further characterize suspicious nodes identified on initial imaging or to provide additional anatomic detail; however, it should not replace tissue sampling for definitive nodal staging. Key considerations include the potential for false positives, which could lead to unnecessary biopsies, and the need to correlate MRI findings with clinical assessment. The decision to utilize MRI should be made on a case-by-case basis, weighing its benefits against its limitations and the availability of alternative diagnostic methods. 对于新诊断乳腺癌（2厘米或以下）且临床淋巴结阳性的女性，在诊断性乳腺X线摄影或DBT后进行腋窝初始成像时，使用带和不带静脉注射对比剂的乳腺MRI可能是合适的。尽管MRI提供卓越的软组织对比度并能详细评估腋窝淋巴结，但专家小组对此特定情景中的作用存在分歧。该程序可考虑用于进一步表征初始成像中发现的可疑淋巴结或提供额外的解剖细节；然而，它不应取代用于明确淋巴结分期的组织采样。关键考虑因素包括可能导致不必要活检的假阳性潜力，以及需要将MRI发现与临床评估相关联。使用MRI的决定应基于个案评估，权衡其益处与局限性以及替代诊断方法的可用性。
* 检查项目: CT chest abdomen pelvis with IV contrast / CT胸部(增强),CT全腹部(增强),CT盆腔(增强)
  * 评分: 2
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0027 / R:CR000651
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明:
* 检查项目: FDG-PET/CT Skull Base to Mid-Thigh / PET/CT躯干
  * 评分: 2
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0020 / R:CR000652
  * 证据强度: StrongReferences
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明: FDG-PET/CT is a valuable modality with potential to impact clinical management of patients with newly diagnosed locally advanced disease, monitoring treatment response in patients with known metastatic breast cancer, and for detection of recurrent disease. FDG-PET/CT is not suggested for routine systemic staging in T0 to T3, N0 to 1, M0 breast cancer patients without signs or symptoms of metastatic disease. A meta-analysis of 25 studies demonstrates the inferiority of FDG-PET/CT to SLNB for evaluation of the axilla \[49]. FDG-PET/CT has high specificity of 90% to 100% for detecting lymph node metastases but variable sensitivity ranging from 48% to 87% \[67-71]. FDG uptake by an axillary node does not always represent a true positive metastatic node \[72]. Single-center studies proposed certain imaging features that may be predictive of axillary metastases or predicts recurrent risk, such as higher maximum standardized uptake value (SUV max ) of the primary breast tumor, higher SUV max of the axillary nodes, and axillary node-to-primary tumor SUV max ratio \[73-76]. However, other investigators reported that no FDG-PET/CT features were associated with any predictive factors for axillary metastases \[77,78]. The tumor size within the metastatic node was associated with positive FDG- PET/CT finding in one retrospective study of 156 breast cancer patients \[78]. In summary, FDG-PET/CT is usually not appropriate as the initial imaging of the axilla following diagnostic mammography or DBT in women newly diagnosed breast cancer, ≤2 cm, with clinical node-positive disease. FDG-PET/CT是一种有价值的检查手段，可能影响新诊断局部晚期疾病患者的临床管理、监测已知转移性乳腺癌患者的治疗反应以及检测疾病复发。对于T0至T3、N0至1、M0且无转移性疾病体征或症状的乳腺癌患者，不建议常规使用FDG-PET/CT进行全身分期。一项包含25项研究的荟萃分析表明，在评估腋窝淋巴结方面，FDG-PET/CT不如前哨淋巴结活检（SLNB）\[49]。FDG-PET/CT检测淋巴结转移的特异性较高（90%至100%），但敏感性差异较大（48%至87%）\[67-71]。腋窝淋巴结的FDG摄取并不总是代表真正的阳性转移淋巴结\[72]。单中心研究提出某些影像特征可能预测腋窝转移或复发风险，如原发乳腺肿瘤的最大标准化摄取值（SUVmax）较高、腋窝淋巴结的SUVmax较高以及腋窝淋巴结与原发肿瘤的SUVmax比值\[73-76]。然而，其他研究者报告称，FDG-PET/CT特征与腋窝转移的任何预测因素均无关联\[77,78]。在一项针对156例乳腺癌患者的回顾性研究中，转移淋巴结内的肿瘤大小与FDG-PET/CT阳性结果相关\[78]。总之，对于新诊断乳腺癌（肿瘤≤2 cm）且临床淋巴结阳性的女性，在诊断性乳腺X线摄影或数字乳腺
* 检查项目: CT chest abdomen pelvis without IV contrast / CT胸部(平扫),CT全腹部(平扫),CT盆腔(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0030 / R:CR000654
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明:
* 检查项目: CT chest abdomen pelvis without and with IV contrast / CT胸部(平扫+增强),CT全腹部(平扫+增强),CT盆腔(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0028 / R:CR000653
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢☢ 10-30 mSv \[ped]
  * 推荐说明:
* 检查项目: MRI breast without IV contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000655
  * 证据强度: ModerateReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明:
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000656
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature supporting the routine use of Tc-99m sestamibi MBI for staging of the axilla in breast cancer patients. 目前尚无相关文献支持常规使用锝-99m甲氧基异丁基异腈（MIBI）显像技术对乳腺癌患者进行腋窝分期。

##### S0082 Variant: Variant 5:  Female. Newly diagnosed breast cancer, greater than 2 cm, with clinical node-negative. Initial imaging of the axilla following diagnostic mammography or DBT. | 女性，新诊断乳腺癌，2 cm，临床淋巴结阴性，诊断性乳腺X线摄影或DBT后腋窝初始影像学检查。

检查推荐列表：

* 检查项目: US Axilla / US腋窝淋巴结常规超声检查
  * 评分: 6
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0012 / R:CR000657
  * 证据强度: StrongReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: SLNB is currently the standard of care for axillary staging in early clinically node-negative breast cancer. However, if axillary node involvement is proven by percutaneous biopsy of a suspicious node detected by axillary US or another imaging modality, which more often may be the case for women with a known breast cancer ≥2 cm, this would lead to ALND rather than SLNB \[6,92,96]. However, there are currently differences in opinion on the use of preoperative axillary US and controversy regarding its routine use in staging clinically node-negative breast cancer patients. One point of view is that a positive axillary US with biopsy-proven nodal involvement may commit the patients to ALND who could have received SLN surgery if the Z0011 inclusion criteria were met. The Z0011 inclusion criteria involve histologically confirmed invasive breast carcinoma of ≤5 cm clinically with no palpable adenopathy and one or two SLNs containing breast cancer on frozen section, touch preparation, or hematoxylin-eosin staining on permanent section, with \<3 positive nodes on SLNB \[5]. The other point of view supporting preoperative axillary US argues that the finding of an abnormal axillary node on axillary US followed by percutaneous biopsy confirmation would help to identify those patients with higher tumor burden \[54,55], and these patients would benefit from proceeding directly to ALND. This approach avoids the need for a second surgery. One study, supporting the utilization of preoperative axillary US from a single center, reported that only 3% to 5% of patients had an abnormal axillary US and met the Z0011 criteria (ie, ALND was not necessary in these patients with preoperative abnormal axillary US). Other studies also supporting the addition of preoperative axillary US to the management of patients who met Z0011 criteria argue that axillary US can help identify patients with more extensive nodal disease who meet the Z0011 criteria \[56-58]. Patients with negative preoperative axillary US and SLN had fewer positive nodes, smaller nodal metastases, and lower extranodal US-guided biopsy of any suspicious axillary node either via FNA or core biopsy is commonly performed when preoperative axillary US is done. The sensitivity of US-guided biopsy is variable with a wide range of 52% to 90%, whereas the specificity is higher, ranging from 98% to 100% \[59-63]. 前哨淋巴结活检目前是临床早期淋巴结阴性乳腺癌腋窝分期的标准诊疗方案。然而，若经腋窝超声或其他影像学检查发现可疑淋巴结并通过经皮活检证实腋窝淋巴结受累（此类情况更常见于已知乳腺癌≥2 cm的女性患者），则需行腋窝淋巴结清扫术而非前哨淋巴结活检\[6,92,96]。但目前对于术前腋窝超声的应用仍存在意见分歧，且其作为临床淋巴结阴性乳腺癌患者常规分期手段存在争议。一种观点认为，腋窝超声阳性且经活检证实淋巴结受累的患者，若符合Z0011试验入组标准本可接受前哨淋巴结手术，却因上述检查结果而接受了腋窝淋巴结清扫术。Z0011入组标准包括：组织学确诊的浸润性乳腺癌临床直径≤5 cm、无可触及淋巴结肿大、1或2枚前哨淋巴结经冰冻切片、印片或石蜡切片苏木精伊红染色显示乳腺癌浸润，且前哨淋巴结活检阳性淋巴结数\<3枚\[5]。另一种支持术前腋窝超声的观点认为，腋窝超声发现异常淋巴结并经经皮活检证实，有助于识别肿瘤负荷较高的患者\[54,55]，这些患者可直接从腋窝淋巴结清扫术中获益。该方法避免了二次手术。一项支持术前腋窝超声的单中心研究报道，仅3%至5%的患者存在腋窝超声异常且符合Z0011标准（即这些术前腋窝超声异常的患者无需行腋窝淋巴结清扫术）。其他支持对符合Z0011标准患者加用术前腋窝超声的研究认为，腋窝超声有助于识别符合Z0011标准但淋巴结病变更广泛的患者\[5658]。术前腋窝超声阴性且前哨淋巴结阴性患者的阳性淋巴结数更少、淋巴结转移灶更小、结外浸润率更低。术前腋窝超声检查时，通常会对可疑腋窝淋巴结行超声引导下细针抽吸或空心针活检。超声引导活检的敏感性差异较大（52%至90%），特异性较高（98%至100%）\[5963]。
* 检查项目: MRI breast without and with IV contrast / MR乳腺(平扫+增强)
  * 评分: 5
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0005 / R:CR000658
  * 证据强度: ModerateReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: MRI breast without and with IV contrast may be appropriate for the initial imaging of the axilla in a female with newly diagnosed breast cancer greater than 2 cm and clinically node-negative disease following diagnostic mammography or DBT. While not a primary modality for axillary staging, MRI can provide valuable adjunctive information regarding the morphology and enhancement characteristics of axillary lymph nodes, potentially identifying suspicious features warranting further evaluation. Its utility is primarily in the comprehensive locoregional assessment of the primary tumor, where it may incidentally offer supplementary axillary visualization. However, MRI should not replace dedicated axillary ultrasound for nodal assessment, as ultrasound remains the standard initial imaging technique for evaluating clinically negative axillae. The decision to employ MRI should be based on specific clinical circumstances and the need for additional characterization of the primary breast malignancy, with the understanding that its role in axillary imaging is secondary and complementary. 对于新诊断大于2厘米、临床淋巴结阴性乳腺癌的女性，在诊断性乳腺X线摄影或数字乳腺断层合成摄影后，进行无和有静脉注射对比剂的乳腺MRI作为腋窝初始成像可能是合适的。虽然MRI不是腋窝分期的首选方式，但可提供关于腋窝淋巴结形态和强化特征的有价值辅助信息，可能识别出需要进一步评估的可疑特征。其主要效用在于对原发肿瘤进行全面区域评估，可能附带提供补充性腋窝可视化。然而，MRI不应取代专用的腋窝超声进行淋巴结评估，因为超声仍是评估临床阴性腋窝的标准初始成像技术。使用MRI的决定应基于特定临床情况和对原发乳腺恶性肿瘤额外特征描述的需求，并理解其在腋窝成像中的作用是次要和补充性的。
* 检查项目: CT chest abdomen pelvis with IV contrast / CT胸部(增强),CT全腹部(增强),CT盆腔(增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0027 / R:CR000659
  * 证据强度: ModerateReferences
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明:
* 检查项目: CT chest abdomen pelvis without IV contrast / CT胸部(平扫),CT全腹部(平扫),CT盆腔(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0030 / R:CR000661
  * 证据强度: ModerateReferences
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明:
* 检查项目: CT chest abdomen pelvis without and with IV contrast / CT胸部(平扫+增强),CT全腹部(平扫+增强),CT盆腔(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0028 / R:CR000660
  * 证据强度: ModerateReferences
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢☢ 10-30 mSv \[ped]
  * 推荐说明:
* 检查项目: MRI breast without IV contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000663
  * 证据强度: ModerateReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明:
* 检查项目: FDG-PET/CT Skull Base to Mid-Thigh / PET/CT躯干
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0020 / R:CR000662
  * 证据强度: StrongReferences
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明: FDG-PET/CT is not routinely performed for pretreatment imaging of the axilla and is not useful in staging newly diagnosed breast cancer \[7]. Given that nodal metastases are often subcentimeter in size, FDG-PET/CT has poor sensitivity for axillary nodal metastases as compared with SLNB \[93]. FDG-PET/CT is more helpful in detecting clinically occult extra-axillary locoregional nodes, such as supraclavicular or internal mammary nodes. FDG- PET/CT identification of unsuspected regional nodal or distant metastases can be useful in locally advanced breast cancer or inflammatory breast cancer and can substantially change the patient’s stage \[94,95]. FDG-PET/CT不常规用于腋窝治疗前成像，对新诊断乳腺癌的分期无益\[7]。鉴于淋巴结转移灶通常小于1厘米，与SLNB相比，FDG-PET/CT对腋窝淋巴结转移的敏感性较差\[93]。FDG-PET/CT更有助于检测临床隐匿的腋窝外区域淋巴结，如锁骨上或内乳淋巴结。FDG-PET/CT发现意外区域淋巴结或远处转移对局部晚期乳腺癌或炎性乳腺癌具有临床价值，可能显著改变患者分期\[94,95]。
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000664
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature supporting the routine use of sestamibi MBI for staging of the axilla in breast cancer patients. 目前尚无相关文献支持常规使用司他比锝MBI对乳腺癌患者腋窝进行分期。

##### S0083 Variant: Variant 6:  Female. Newly diagnosed breast cancer, greater than 2 cm, with clinical node-positive. Initial imaging of the axilla following diagnostic mammography or DBT (prior to treatment). | 女性，新诊断乳腺癌，2 cm，临床淋巴结阳性，诊断性乳腺X线摄影或DBT后腋窝初始影像学检查（治疗前）。

检查推荐列表：

* 检查项目: US Axilla / US腋窝淋巴结常规超声检查
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0012 / R:CR000665
  * 证据强度: StrongReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: Axillary US is typically performed for assessing nodal disease in patients with newly diagnosed breast carcinoma and palpable adenopathy \[7,92]. In a retrospective series of 1,287 breast cancer patients who had preoperative axillary US-FNA followed by SLNB or ALND, the group with axillary US-FNA had a higher number of metastatic axillary lymph nodes than those with micro- or macrometastatic nodal disease on SLNB. This suggests that patients with US visible nodal disease, confirmed by axillary US-FNA, have more extensive nodal involvement \[60]. Positive axillary US, confirmed with biopsy, helps to identify patients with higher tumor burden \[54,55], and as such, these patients can proceed directly to ALND. However, axillary US is not able to detect all metastatic nodes and therefore cannot replace SLNB or ALND \[58]. It is well known that negative axillary US with or without biopsy does not rule out nodal disease \[58]. The sensitivity of US-guided biopsy also has variable sensitivity ranging from 52% to 90%, whereas the specificity is higher, ranging from 98% to 100% \[59-63]. For many cases, axillary US can differentiate patients with high lymph node tumor burden from patients with low lymph node tumor burden, suggesting that those with positive axillary nodes on percutaneous biopsy should have ALND rather than SLNB, especially because the Z0011 criteria do not apply to patients with clinically palpable adenopathy. Axillary US features favoring nodal metastases include cortical thickness of >0.3 cm and absence of a fatty hilum, a finding with a high positive predictive value (PPV) of 90% to 93% \[103-105] . 腋窝超声通常用于评估新诊断乳腺癌患者及可触及淋巴结病变的淋巴结疾病\[7,92]。一项回顾性研究纳入1,287例术前接受腋窝超声细针穿刺（US-FNA）后行前哨淋巴结活检（SLNB）或腋窝淋巴结清扫（ALND）的乳腺癌患者，结果显示腋窝US-FNA阳性组的转移性腋窝淋巴结数量显著多于SLNB检出微转移或宏转移的病例。这表明经腋窝US-FNA证实存在超声可见淋巴结病变的患者，其淋巴结受累范围更广泛\[60]。活检证实的阳性腋窝超声结果有助于识别肿瘤负荷较高的患者\[54,55]，此类患者可直接进行ALND。但腋窝超声无法检出所有转移性淋巴结，因此不能替代SLNB或ALND\[58]。需注意的是，无论是否联合活检，腋窝超声阴性结果均不能排除淋巴结转移\[58]。超声引导活检的敏感度存在较大差异（52%-90%），而特异度较高（98%-100%）\[59-63]。多数情况下，腋窝超声可区分高淋巴结肿瘤负荷与低负荷患者，提示经皮活检证实腋窝淋巴结阳性的患者应接受ALND而非SLNB——尤其考虑到Z0011标准不适用于临床可触及淋巴结病变的患者。提示淋巴结转移的超声特征包括皮质厚度＞0.3cm及脂肪门缺失，该征象的阳性预测值高达90%-93%\[
* 检查项目: MRI breast without and with IV contrast / MR乳腺(平扫+增强)
  * 评分: 5
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0005 / R:CR000667
  * 证据强度: ModerateReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: MRI breast without and with IV contrast may be appropriate for the initial imaging of the axilla in a female with newly diagnosed breast cancer greater than 2 cm and clinical node-positive disease, following diagnostic mammography or DBT and prior to treatment. While not a primary modality for axillary staging, it can provide valuable adjunctive information regarding the extent of nodal involvement and assist in treatment planning. The procedure may help characterize suspicious nodes identified on other imaging modalities and evaluate for additional sites of disease. However, its utility is limited by variable specificity for nodal metastasis, and findings should not replace histopathologic confirmation. MRI is most appropriately used when its results are anticipated to influence surgical or systemic therapy decisions. The inherent limitations, including potential for false positives and overestimation of disease burden, must be considered in clinical context. 对于新诊断大于2厘米且临床淋巴结阳性的乳腺癌女性患者，在诊断性乳腺X线摄影或DBT之后、治疗之前，进行无和有静脉注射对比剂的乳腺MRI作为腋窝初始成像可能是合适的。虽然它不是腋窝分期的首选方式，但可以提供关于淋巴结受累范围的宝贵辅助信息，并协助制定治疗计划。该程序可能有助于表征其他成像方式发现的可疑淋巴结，并评估是否存在其他疾病部位。然而，其效用受限于对淋巴结转移的可变特异性，且发现不应取代组织病理学确认。当预期MRI结果会影响手术或全身治疗决策时，其使用最为合适。必须结合临床背景考虑其固有局限性，包括假阳性和高估疾病负担的可能性。
* 检查项目: FDG-PET/CT Skull Base to Mid-Thigh / PET/CT躯干
  * 评分: 5
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0020 / R:CR000666
  * 证据强度: StrongReferences
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明: FDG-PET/CT may be useful in the staging of newly diagnosed advanced breast cancer given a higher likelihood of extra-axillary metastatic disease or distant disease \[94,95]. It has been proposed that if a primary breast tumor is >2 cm and has a high SUV max , there is a higher probability of axillary nodal metastases \[73,99]. In addition to assisting in the staging of advanced breast cancer, FDG-PET/CT may be beneficial in staging patients with T1 stage breast cancer, particularly those with triple negative or human epidermal growth factor receptor 2 (HER2) positive breast cancer with clinical node positive disease because there is a higher prevalence of nodal disease and distant metastases \[71]. In order to assess response to neoadjuvant therapy, comparing pretreatment nodal FDG uptake to subsequent midtreatment or post-treatment FDG uptake is essential and also can be used to identify those at a higher risk of recurrence \[100-102]. 鉴于新诊断晚期乳腺癌患者存在较高概率的腋窝外转移或远处转移\[94,95]，FDG-PET/CT可能有助于疾病分期。有研究提出，若原发乳腺肿瘤>2cm且SUV最大值较高，则存在腋窝淋巴结转移的可能性更大\[73,99]。除辅助晚期乳腺癌分期外，FDG-PET/CT对T1期乳腺癌患者的分期也有裨益，特别是三阴性或人表皮生长因子受体2(HER2)阳性且临床淋巴结阳性的患者，因其具有更高的淋巴结转移和远处转移发生率\[71]。为评估新辅助治疗疗效，比较治疗前与治疗中或治疗后淋巴结FDG摄取情况至关重要，该方法还可用于识别复发高风险患者\[100-102]。
* 检查项目: CT chest abdomen pelvis with IV contrast / CT胸部(增强),CT全腹部(增强),CT盆腔(增强)
  * 评分: 4
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0027 / R:CR000668
  * 证据强度: StrongReferences
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明: CT chest abdomen pelvis with IV contrast may be appropriate for the initial imaging of the axilla in a female with newly diagnosed breast cancer greater than 2 cm and clinical node-positive disease following diagnostic mammography or DBT, prior to treatment. This modality can provide valuable information regarding the extent of locoregional disease, including detailed assessment of axillary lymph nodes, and is particularly useful for detecting distant metastases in the chest, abdomen, and pelvis, which is a critical component of staging in node-positive patients. However, its role in axillary staging is secondary to dedicated axillary ultrasound with fine-needle aspiration biopsy, which remains the primary method for nodal evaluation. The use of CT should be considered when there is a clinical suspicion for advanced disease or distant metastases, and it may guide treatment planning by identifying extra-axillary involvement. Limitations include radiation exposure, the need for intravenous contrast, and the potential for false-positive or false-negative findings in lymph node assessment. The decision to utilize CT should be made in the context of multidisciplinary discussion, weighing the potential benefits against the risks and considering the overall clinical presentation. 对于新诊断的乳腺癌大于2厘米且临床淋巴结阳性的女性患者，在诊断性乳腺X线摄影或数字乳腺断层合成（DBT）后进行初始腋窝成像，在治疗前，CT胸部腹部盆腔增强扫描可能是合适的。该模态可提供关于局部区域疾病范围的有价值信息，包括对腋窝淋巴结的详细评估，并且在检测胸部、腹部和盆腔的远处转移方面特别有用，这是淋巴结阳性患者分期的重要组成部分。然而，其在腋窝分期中的作用次于专用的腋窝超声引导下细针穿刺活检，后者仍是淋巴结评估的主要方法。当临床怀疑晚期疾病或远处转移时，应考虑使用CT，并且它可能通过识别腋窝外受累来指导治疗计划。局限性包括辐射暴露、需要静脉注射造影剂，以及在淋巴结评估中可能出现假阳性或假阴性结果。使用CT的决定应在多学科讨论的背景下做出，权衡潜在益处与风险，并考虑整体临床表现。
* 检查项目: CT chest abdomen pelvis without and with IV contrast / CT胸部(平扫+增强),CT全腹部(平扫+增强),CT盆腔(平扫+增强)
  * 评分: 2
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0028 / R:CR000669
  * 证据强度: StrongReferences
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢☢ 10-30 mSv \[ped]
  * 推荐说明:
* 检查项目: CT chest abdomen pelvis without IV contrast / CT胸部(平扫),CT全腹部(平扫),CT盆腔(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0030 / R:CR000670
  * 证据强度: StrongReferences
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明:
* 检查项目: MRI breast without IV contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000671
  * 证据强度: ModerateReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明:
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000672
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature supporting the use of Tc-99m sestamibi MBI for staging of the axilla in clinically node-positive breast cancer patients. 目前尚无相关文献支持在临床淋巴结阳性乳腺癌患者中使用锝-99m甲氧基异丁基异腈（MIBI）进行腋窝分期。

##### S0084 Variant: Variant 7:  Female. Breast cancer, greater than 2 cm in size, at mid-treatment of neoadjuvant chemotherapy, with initial clinical node-negative disease but now presenting with new palpable axillary lump. Imaging of the axilla at mid-treatment. | 女性，乳腺癌，肿瘤大小2 cm，新辅助化疗治疗中，初始临床淋巴结阴性，目前出现新发可触及腋窝肿块，治疗中腋窝影像学检查。

检查推荐列表：

* 检查项目: US Axilla / US腋窝淋巴结常规超声检查
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0012 / R:CR000673
  * 证据强度: ModerateReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: Despite the limited literature addressing the use of axillary US for assessing a new palpable axillary lump during midtreatment, axillary US may be useful in this scenario because of its noninvasive nature. If the axillary US finding is uncertain, biopsy can be performed \[86]. A small single-center study looking at the role of midtreatment axillary US in 159 patients of mixed breast cancer subtypes observed that US performed better for residual axillary nodal tumor burden than for residual index breast cancer and provided more consistent results across different cancer subtypes \[109]. 尽管关于在治疗中期使用腋窝超声评估新出现的可触及腋窝肿块的文献有限，但由于其无创性，腋窝超声在此情况下可能有用。如果腋窝超声结果不确定，可以进行活检\[86]。一项针对159例混合乳腺癌亚型患者的小型单中心研究观察了治疗中期腋窝超声的作用，发现超声在评估残留腋窝淋巴结肿瘤负荷方面优于评估残留原发乳腺癌，且在不同癌症亚型中提供的结果更为一致\[109]。
* 检查项目: Digital Breast Tomosynthesis Diagnostic / MG双侧乳腺钼靶
  * 评分: 3
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000674
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: DBT allows visualization of axillary level I nodal regions but does not fully assess the axilla. Although not typically used for axillary evaluation, DBT may be helpful in evaluating for progression of the primary breast malignancy. DBT可显示腋窝I级淋巴结区域，但无法全面评估腋窝情况。虽然通常不用于腋窝评估，但DBT可能有助于评估原发性乳腺恶性肿瘤的进展情况。
* 检查项目: MRI breast without and with IV contrast / MR乳腺(平扫+增强)
  * 评分: 3
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000675
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明:
* 检查项目: CT chest abdomen pelvis with IV contrast / CT胸部(增强),CT全腹部(增强),CT盆腔(增强)
  * 评分: 2
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0027 / R:CR000676
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明:
* 检查项目: CT chest abdomen pelvis without and with IV contrast / CT胸部(平扫+增强),CT全腹部(平扫+增强),CT盆腔(平扫+增强)
  * 评分: 2
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0028 / R:CR000677
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢☢ 10-30 mSv \[ped]
  * 推荐说明:
* 检查项目: Mammography Diagnostic / MG双侧乳腺钼靶
  * 评分: 2
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000674
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Similar to DBT, mammography does not visualize the entire axilla and is not useful for assessing an axillary lump. 与DBT类似，乳腺X线摄影无法显示整个腋窝区域，因此对评估腋窝肿块无临床价值。
* 检查项目: CT chest abdomen pelvis without IV contrast / CT胸部(平扫),CT全腹部(平扫),CT盆腔(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0030 / R:CR000679
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明:
* 检查项目: MRI breast without IV contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000681
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明:
* 检查项目: FDG-PET/CT Skull Base to Mid-Thigh / PET/CT躯干
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0020 / R:CR000680
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明: There is no relevant literature to support the use of FDG-PET/CT for assessing a new palpable axillary mass during midtreatment of NAC. 目前尚无相关文献支持使用FDG-PET/CT评估新辅助化疗期间新出现的可触及腋窝肿块。
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000682
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature supporting the use of Tc-99m sestamibi MBI for assessing a new palpable axillary lump during midtreatment of NAC. 目前尚无相关文献支持在NAC治疗中期使用Tc-99m甲氧基异丁基异腈（MBI）评估新出现的可触及腋窝肿块。

##### S0085 Variant: Variant 8:  Female. Breast cancer, greater than 2 cm in size, clinical node-negative. Imaging of the axilla after completion of neoadjuvant chemotherapy. | 女性，乳腺癌，肿瘤大小2 cm，临床淋巴结阴性，新辅助化疗完成后腋窝影像学检查。

检查推荐列表：

* 检查项目: MRI breast without and with IV contrast / MR乳腺(平扫+增强)
  * 评分: 5
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0005 / R:CR000683
  * 证据强度: StrongReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: MRI breast without and with IV contrast may be appropriate for imaging the axilla in a clinically node-negative female with a breast cancer greater than 2 cm after completion of neoadjuvant chemotherapy. This modality can provide valuable information on the post-treatment status of the axilla by assessing for residual abnormal lymph nodes, as it offers high soft-tissue contrast and can detect morphological changes and patterns of contrast enhancement suggestive of persistent disease. However, its use for this specific purpose should be considered with caution, as MRI is not the primary modality for axillary staging and its accuracy in evaluating the axilla after neoadjuvant therapy can be influenced by treatment-induced changes, such as fibrosis, which may mimic or obscure residual malignancy. The decision to utilize MRI should be made in the context of the overall clinical scenario and in conjunction with other established axillary assessment methods, recognizing that it serves as an adjunct rather than a replacement for standard techniques like ultrasound. 对于临床淋巴结阴性、肿瘤大于2厘米的女性乳腺癌患者，在完成新辅助化疗后，使用不注射和注射静脉对比剂的乳腺MRI对腋窝进行成像可能是合适的。该模态可通过评估残留异常淋巴结，提供有关腋窝治疗后状态的有价值信息，因为它具有较高的软组织对比度，并能检测提示持续疾病的形态学变化和对比剂增强模式。然而，对此特定用途的使用应谨慎考虑，因为MRI并非腋窝分期的首要模态，且其在新辅助治疗后评估腋窝的准确性可能受到治疗引起的变化（如纤维化，可能模拟或掩盖残留恶性肿瘤）的影响。使用MRI的决定应在整体临床情境中做出，并与其它已建立的腋窝评估方法结合使用，认识到其是标准技术（如超声）的辅助手段而非替代品。
* 检查项目: US Axilla / US腋窝淋巴结常规超声检查
  * 评分: 5
  * 适宜性: May be appropriate (Disagreement) / 可能适宜（存在争议）
  * 编码: P:PR0012 / R:CR000684
  * 证据强度: Expert OpinionReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: The role of axillary US to assess the axilla after NAC remains controversial \[7]. Most of the data from multicenter trials involve patients with initial clinical node-positive disease \[129,130]. These studies, evaluating SLNB after NAC, report that the accuracy rates of SLNB are acceptable. With the variable sensitivity and specificity of axillary US, even in combination with percutaneous biopsy, axillary US is not able to replace SLNB. Therefore, axillary US may not assess axillary response after chemotherapy. 新辅助化疗（NAC）后超声评估腋窝的作用仍存在争议\[7]。多中心试验的数据大多涉及初始临床淋巴结阳性的患者\[129,130]。这些评估NAC后前哨淋巴结活检（SLNB）的研究报告显示，SLNB的准确率是可接受的。由于腋窝超声的敏感性和特异性存在差异，即使结合经皮活检，腋窝超声也无法替代SLNB。因此，腋窝超声可能无法评估化疗后的腋窝反应。
* 检查项目: Digital Breast Tomosynthesis Diagnostic / MG双侧乳腺钼靶
  * 评分: 2
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000685
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There are no data to support the use of DBT to image the axilla after completion of NAC in patients with initial clinical node-negative disease and no new clinical concern or palpable axillary lump. For assessment of the primary breast tumor, one prospective study of 51 stage II and III breast cancer patients reported that MRI and DBT outperformed mammography and whole-breast US in the prediction of pathologic complete response \[113]. However, this study cannot be extrapolated to axillary nodal disease. 目前尚无数据支持在初始临床淋巴结阴性且无新发临床问题或可触及腋窝肿块的患者完成新辅助化疗后，使用数字乳腺断层合成成像（DBT）对腋窝进行成像。对于原发乳腺肿瘤的评估，一项针对51例II期和III期乳腺癌患者的前瞻性研究显示，在预测病理完全缓解方面，磁共振成像（MRI）和DBT优于乳腺X线摄影和全乳超声\[113]。然而，该研究结果不能外推至腋窝淋巴结疾病的评估。
* 检查项目: Mammography Diagnostic / MG双侧乳腺钼靶
  * 评分: 2
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000685
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Mammography can reliably be used to assess response of a primary breast malignancy to NAC. However, it is less useful in assessing axillary nodal response to therapy given that the axilla is incompletely visualized. 乳腺X线摄影可可靠地用于评估原发性乳腺恶性肿瘤对新辅助化疗（NAC）的反应。然而，由于腋窝区域显像不完全，其在评估腋窝淋巴结对治疗反应方面的作用较为有限。
* 检查项目: CT chest abdomen pelvis with IV contrast / CT胸部(增强),CT全腹部(增强),CT盆腔(增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0027 / R:CR000687
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明:
* 检查项目: CT chest abdomen pelvis without IV contrast / CT胸部(平扫),CT全腹部(平扫),CT盆腔(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0030 / R:CR000689
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明:
* 检查项目: CT chest abdomen pelvis without and with IV contrast / CT胸部(平扫+增强),CT全腹部(平扫+增强),CT盆腔(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0028 / R:CR000688
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢☢ 10-30 mSv \[ped]
  * 推荐说明:
* 检查项目: MRI breast without IV contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000691
  * 证据强度: StrongReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明:
* 检查项目: FDG-PET/CT Skull Base to Mid-Thigh / PET/CT躯干
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0020 / R:CR000690
  * 证据强度: ModerateReferences
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明: There are limited data to support the use of FDG-PET/CT for assessing response of nodal disease from breast cancer following completion of NAC. Most studies report changes in size and SUV measurements of the index breast carcinoma or distant metastases. Four meta-analyses of FDG-PET/CT in detecting residual breast disease reported a pooled sensitivity of 81% to 84% and a specificity of 66% to 79% \[114-118]. FDG-PET/CT is limited by the lack of consensus for standard criteria to measure response of the index tumor or nodal disease, and SUV measurements underestimating the amount of residual disease when the residual tumor size is small. In one meta-analysis, 4 of 19 studies reported a pooled sensitivity of 92% and an NPV of 88% in predicting regional lymph node response but with NAC response, a negative FDG-PET/CT does not guarantee that the final pathology is also negative, especially if the residual tumor is of low to moderate grade \[119,120]. A recent report from the National Cancer Database of 33,162 patients concluded that a breast-only response from a node-only response or both breast and nodal response had different prognoses, which also varied with tumor subtypes \[112]. Given the limited data, FDG-PET/CT is not currently performed post-NAC to restage the axilla. 支持使用FDGPET/CT评估乳腺癌新辅助化疗（NAC）后淋巴结反应的数据有限。多数研究报道的是原发乳腺癌或远处转移灶的尺寸和SUV测量值变化。四项关于FDGPET/CT检测乳腺癌残留病灶的荟萃分析报道的汇总敏感性为81%至84%，特异性为66%至79%\[114118]。FDGPET/CT的局限性在于缺乏测量原发肿瘤或淋巴结反应的标准共识标准，且当残留肿瘤尺寸较小时，SUV测量值会低估残留病灶量。一项荟萃分析中，19项研究中的4项报道预测区域淋巴结反应的汇总敏感性为92%，阴性预测值（NPV）为88%，但对于NAC反应，FDGPET/CT阴性并不能保证最终病理也为阴性，尤其当残留肿瘤为低至中等级别时\[119,120]。国家癌症数据库一项涉及33,162例患者的最新报告得出结论，仅乳腺反应与仅淋巴结反应或乳腺和淋巴结均反应具有不同的预后，且随肿瘤亚型而异\[112]。鉴于数据有限，目前不常规在NAC后使用FDGPET/CT对腋窝进行再分期。
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000692
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature supporting the use of Tc-99m sestamibi MBI for assessing response after treatment with NAC. 目前尚无相关文献支持使用锝-99m甲氧基异丁基异腈（MBI）评估新辅助化疗（NAC）后的治疗反应。

##### S0086 Variant: Variant 9:  Female. Breast cancer, greater than 2 cm in size, clinical node-positive. Imaging of the axilla after completion of neoadjuvant chemotherapy and prior to surgery. | 女性，乳腺癌，肿瘤大小2 cm，临床淋巴结阳性，新辅助化疗完成后且手术前腋窝影像学检查。

检查推荐列表：

* 检查项目: US Axilla / US腋窝淋巴结常规超声检查
  * 评分: 8
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0012 / R:CR000693
  * 证据强度: StrongReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: Because of its noninvasive nature, axillary US may evaluate for residual axillary nodal disease despite its PPV of 60% to 81%, NPV of 43% to 74%, and specificity of 37% to 92% \[138]. However, the sensitivity of US (71%) for prediction of residual nodal metastatic disease was higher than that of clinical examination and MRI/PET in most studies \[139]. Limited data have suggested that the sensitivity of axillary US is higher for some subtypes such as triple negative breast cancer (69%) and HER2 positive breast cancer (71%) \[140,141]. In the Z1071 prospective trial consisting of clinical T0-T4, N1-N2, and M0 of 611 patients, the post-NAC US features predictive of residual nodal disease included continued loss of the fatty hilum, cortical thickness of ≥0.3 cm, and a decrease in lymph node size \[87]. However, a normal axillary US does not exclude pathological nodal disease \[142]. The absence of a fatty hilum can be an indication for performing a biopsy \[88,143]. A clip placed at the time of biopsy prior to NAC can help to reduce the FNR of SLNB \[8,10]. However, the clipped node is not the SLN in 23% of cases based on a single-center prospective study \[8]. The detection rate after radioactive seed placement was 97% \[138]. 由于无创性特点，腋窝超声可用于评估残余腋窝淋巴结病变，尽管其阳性预测值为60%-81%、阴性预测值为43%-74%、特异性为37%-92%\[138]。但多数研究表明，超声预测残余淋巴结转移的敏感性（71%）高于临床检查和MRI/PET\[139]。有限数据显示，腋窝超声对三阴性乳腺癌（69%）和HER2阳性乳腺癌（71%）等亚型的敏感性更高\[140,141]。在纳入611例临床分期T0-T4/N1-N2/M0患者的Z1071前瞻性试验中，新辅助化疗后预测残余淋巴结病变的超声特征包括持续存在的门部脂肪消失、皮质厚度≥0.3cm及淋巴结体积缩小\[87]。但正常腋窝超声结果不能排除病理性淋巴结转移\[142]。门部脂肪消失可作为活检指征\[88,143]。新辅助化疗前活检时放置定位夹可降低前哨淋巴结活检的假阴性率\[8,10]，但单中心前瞻性研究显示23%病例中标记淋巴结并非前哨淋巴结\[8]。放射性粒子标记后的检出率达97%\[138]。
* 检查项目: MRI breast without and with IV contrast / MR乳腺(平扫+增强)
  * 评分: 5
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0005 / R:CR000694
  * 证据强度: StrongReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: MRI breast without and with IV contrast may be appropriate for imaging the axilla in a female with a breast cancer greater than 2 cm and clinical node-positive status after completion of neoadjuvant chemotherapy and prior to surgery. This modality can provide valuable information regarding the treatment response of known axillary metastases, potentially identifying residual disease or confirming a complete pathologic response. The use of intravenous contrast allows for the assessment of residual nodal enhancement, which may correlate with viable tumor. However, MRI has limitations in specificity, as post-treatment inflammatory changes can mimic residual malignancy, and microscopic disease may not be detectable. The findings should be interpreted in conjunction with the clinical context and may inform surgical planning, but they do not replace the need for histopathologic evaluation, which remains the standard for determining axillary nodal status. 对于完成新辅助化疗后、手术前，患有大于2厘米且临床淋巴结阳性乳腺癌的女性患者，使用静脉注射对比剂的乳腺MRI检查腋窝可能是合适的。该方式可提供有关已知腋窝转移治疗反应的有价值信息，可能识别残留病变或确认完全病理缓解。静脉对比剂的使用允许评估残留淋巴结强化，这可能与存活肿瘤相关。然而，MRI在特异性方面存在局限性，因为治疗后炎症变化可能模拟残留恶性肿瘤，且微观病变可能无法检测。结果应结合临床背景进行解读，并可能为手术规划提供信息，但不能替代组织病理学评估，后者仍是确定腋窝淋巴结状态的标准。
* 检查项目: Digital Breast Tomosynthesis Diagnostic / MG双侧乳腺钼靶
  * 评分: 3
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000695
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There are no data to support the use of DBT to image the axilla after completion of NAC in patients with initial clinical node-positive disease pre-NAC and who have no clinical suspicion of disease progression or new axillary nodal disease. When comparing mammography to DBT, one prospective study of 51 stage II and III breast cancer patients reported that MRI and DBT outperformed mammography and whole-breast US in the prediction of pathologic complete response \[113]. Unfortunately, this cannot be extrapolated to axillary nodal disease because DBT does not completely visualize the entire axilla. DBT may be useful in selected cases after NAC because it may identify response within a clipped node and provide a means for image guided localization \[131]. 目前尚无数据支持在完成新辅助化疗（NAC）后，对初始临床淋巴结阳性且无临床怀疑疾病进展或新发腋窝淋巴结病变的患者使用数字乳腺断层合成（DBT）进行腋窝成像。一项针对51例II期和III期乳腺癌患者的前瞻性研究显示，在预测病理完全缓解方面，磁共振成像（MRI）和DBT优于乳腺X线摄影和全乳超声\[113]。然而，这一结论不能推广至腋窝淋巴结病变，因为DBT无法完整显示整个腋窝结构。对于特定NAC后病例，DBT可能通过识别标记淋巴结内的治疗反应并提供影像引导定位手段而具有应用价值\[131]。
* 检查项目: FDG-PET/CT Skull Base to Mid-Thigh / PET/CT躯干
  * 评分: 3
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0020 / R:CR000696
  * 证据强度: ModerateReferences
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明: FDG-PET/CT is widely used to assess response to therapy, despite the lack of consensus on the criteria for determining response. The reported pooled sensitivity for FDG-PET/CT is 71% to 88% and specificity is 69% to 79.3% \[117,120,132,133]. Most of the studies do not specifically report on response of the regional lymph nodes. In one meta-analysis of four studies involving 920 patients, the sensitivity of FDG-PET/CT for regional lymph node response assessment is 92% \[118]. In another meta-analysis of 987 abstracts, only four were eligible for analysis, yielding a PPV between 40% and 100% \[134]. The timing of FDG-PET/CT is critical and varies between studies, with some investigators demonstrating FDG- PET/CT has more accuracy during NAC (after first or second cycles of chemotherapy) than after NAC, whereas MRI performed better at the end of NAC \[118,133]. MRI had higher sensitivity in predicting the pathologic response after NAC in 13 studies involving 575 patients, and FDG-PET/CT had a higher specificity in these same 13 studies involving 618 patients \[132]. Currently, there is lack of consensus that early response detected by imaging tests translates into improved overall outcomes. A negative FDG-PET/CT during or after NAC does not necessarily correlate with final pathological node-negative disease, as demonstrated in one series of 206 patients \[119]. SUV values may underestimate or overestimate response when the residual tumor is small. Some investigators have reported SUV max \<2.5 as negative \[120], whereas others demonstrated that the change in SUV before and after NAC or change between the pre-NAC FDG-PET/CT examination and the examination performed after the first or second cycle of NAC were better predictors of response \[134-136]. Despite the research, there is no accurate noninvasive test to replace SLNB or ALND at this time. However, one benefit of using FDG-PET/CT is that this examination can also evaluate other sites of metastases in a single study \[102]. A search for a noninvasive restaging technique for identifying patients with axillary complete response is ongoing. 尽管缺乏确定疗效标准的共识，FDG PET/CT 被广泛用于评估治疗反应。FDG PET/CT 报告的汇总敏感性为 71% 至 88%，特异性为 69% 至 79.3% \[117,120,132,133]。大多数研究并未特别报告区域淋巴结的反应。一项包含 4 项研究、涉及 920 名患者的荟萃分析显示，FDG PET/CT 评估区域淋巴结反应的敏感性为 92% \[118]。另一项对 987 篇摘要进行的荟萃分析中，仅有 4 篇符合分析条件，得出的阳性预测值（PPV）在 40% 至 100% 之间 \[134]。FDG PET/CT 的检查时机至关重要，且各研究间存在差异；一些研究者证明，FDG PET/CT 在新辅助化疗（NAC）期间（第一或第二周期化疗后）比 NAC 结束后更准确，而 MRI 在 NAC 结束时表现更好 \[118,133]。在涉及 575 名患者的 13 项研究中，MRI 在预测 NAC 后病理反应方面具有更高的敏感性；而在涉及 618 名患者的这同样的 13 项研究中，FDG PET/CT 具有更高的特异性 \[132]。目前，缺乏共识表明影像学检查检测到的早期反应能转化为改善的总体结局。如一项包含 206 名患者的系列研究所证明 \[119]，NAC 期间或之后 FDG PET/CT 结果为阴性并不一定与最终的病理淋巴结阴性疾病相关。当残留肿瘤较小时，SUV 值可能会低估或高估反应。一些研究者报告 SUVmax \<2.5 视为阴性 \[120]，而其他研究者证明，NAC 前后 SUV 的变化，或 NAC 前 FDG PET/CT 检查与第一或第二周期 NAC 后检查之间的 SUV 变化，是更好的反应预测指标 \[134136]。尽管有这些研究，目前尚无准确的无创检测方法可替代前哨淋巴结活检（SLNB）或腋窝淋巴结清扫（ALND）。然而，使用 FDG PET/CT 的一个好处是，该检查也能在一次研究中评估其他部位的转移 \[102]。寻找一种无创的再分期技术以识别腋窝完全缓解患者的研究正在进行中。
* 检查项目: Mammography Diagnostic / MG双侧乳腺钼靶
  * 评分: 2
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000695
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Mammography can reliably be used to assess response of a primary breast malignancy to NAC. However, it is less useful in assessing axillary nodal response to therapy given that the axilla is incompletely visualized. 乳腺X线摄影可可靠地用于评估原发性乳腺恶性肿瘤对新辅助化疗（NAC）的反应。然而，由于腋窝区域显像不完全，其在评估腋窝淋巴结对治疗反应方面的作用较为有限。
* 检查项目: CT chest abdomen pelvis with IV contrast / CT胸部(增强),CT全腹部(增强),CT盆腔(增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0027 / R:CR000698
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明:
* 检查项目: CT chest abdomen pelvis without IV contrast / CT胸部(平扫),CT全腹部(平扫),CT盆腔(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0030 / R:CR000700
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明:
* 检查项目: CT chest abdomen pelvis without and with IV contrast / CT胸部(平扫+增强),CT全腹部(平扫+增强),CT盆腔(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0028 / R:CR000699
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢☢ 10-30 mSv \[ped]
  * 推荐说明:
* 检查项目: MRI breast without IV contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000701
  * 证据强度: StrongReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明:
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000702
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature supporting the use of Tc-99m sestamibi MBI for assessing response after treatment with NAC. 目前尚无相关文献支持使用锝-99m甲氧基异丁基异腈（MBI）评估新辅助化疗（NAC）后的治疗反应。

##### S0087 Variant: Variant 10:  Female. Newly diagnosed locally recurrent breast cancer. Initial imaging of the axilla following diagnostic mammography or DBT. | 女性，新诊断局部复发性乳腺癌，诊断性乳腺X线摄影或DBT后腋窝初始影像学检查。

检查推荐列表：

* 检查项目: US Axilla / US腋窝淋巴结常规超声检查
  * 评分: 6
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0012 / R:CR000703
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: US can be used to evaluate the axilla in patients with newly diagnosed recurrent breast cancer after BCS, after mastectomy, or with suspicion of recurrent nodal disease in the axilla. Diagnostic mammogram and/or DBT to evaluate for in-breast recurrent disease has also been shown to be helpful \[154]. Axillary US can also provide guidance for percutaneous biopsy of any suspicious nodes because it influences potential surgical approach (SLNB versus full ALND). 超声可用于评估新诊断的乳腺癌患者在保乳手术后、乳房切除术后或怀疑腋窝淋巴结复发的腋窝情况。诊断性乳腺X线摄影和/或数字乳腺断层合成技术（DBT）也被证明有助于评估乳腺内复发疾病\[154]。腋窝超声还可为任何可疑淋巴结的经皮活检提供指导，因为这会影响潜在的手术方式选择（前哨淋巴结活检与全腋窝淋巴结清扫术）。
* 检查项目: MRI breast without and with IV contrast / MR乳腺(平扫+增强)
  * 评分: 5
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0005 / R:CR000705
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: MRI breast without and with IV contrast may be appropriate for the initial imaging of the axilla in a female with newly diagnosed locally recurrent breast cancer following diagnostic mammography or DBT. While mammography and ultrasound remain the primary modalities for axillary evaluation, contrast-enhanced MRI can provide valuable supplemental information in this specific clinical scenario. It offers superior soft tissue contrast and can help delineate the extent of recurrent disease, assess for multifocality, and evaluate involvement of axillary lymph nodes. The procedure may be particularly useful when there is a discrepancy between clinical findings and conventional imaging or when planning surgical management. However, its use should be considered in the context of the patient's overall clinical picture, as MRI may not be necessary in all cases of local recurrence. Limitations include potential false positives, cost, and the requirement for intravenous contrast administration. The decision to utilize MRI should be made through multidisciplinary discussion, weighing its potential benefits against its constraints for the individual patient. 对于诊断性 mammography 或 DBT 后新诊断局部复发性乳腺癌女性的腋窝初始成像，使用和不使用静脉对比剂的乳腺 MRI 可能是合适的。虽然 mammography 和超声仍然是腋窝评估的主要方式，但在此特定临床场景中，对比增强 MRI 可以提供有价值的补充信息。它具有卓越的软组织对比度，有助于描绘复发性疾病的范围、评估多灶性以及评估腋窝淋巴结的受累情况。当临床发现与常规成像存在差异或计划手术管理时，该程序可能特别有用。然而，其使用应考虑患者的整体临床情况，因为并非所有局部复发病例都需要 MRI。局限性包括潜在的假阳性、成本以及需要静脉注射对比剂。使用 MRI 的决定应通过多学科讨论做出，权衡其对个体患者的潜在益处与限制。
* 检查项目: FDG-PET/CT Skull Base to Mid-Thigh / PET/CT躯干
  * 评分: 5
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0020 / R:CR000704
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明: FDG-PET/CT may be ordered concurrently at the time of the locally recurrent breast cancer diagnosis to rule out distant metastatic disease and for pretreatment planning. PET/CT is helpful in identifying unsuspected regional nodal disease or distant metastases in certain situations such as in patients with locally advanced breast cancer and inflammatory breast cancer \[7]. In a meta-analysis of 26 studies involving 1,752 patients with suspected recurrent breast cancer, the pooled sensitivity for FDG-PET/CT was 90% and specificity was 81%; FDG-PET/CT is more accurate than PET alone \[155]. The authors noted that the studies were heterogeneous, and therefore the analysis had limitations. In-breast recurrent disease versus chest wall or nodal recurrent disease was not specified \[155]. 在诊断局部复发性乳腺癌时，可同步进行FDG-PET/CT检查以排除远处转移性疾病并用于治疗前规划。PET/CT有助于在某些情况下（如局部晚期乳腺癌和炎性乳腺癌患者）发现未预料到的区域淋巴结病变或远处转移\[7]。一项纳入26项研究、共1,752例疑似复发性乳腺癌患者的荟萃分析显示，FDG-PET/CT的综合敏感性为90%，特异性为81%；FDG-PET/CT比单独PET检查更准确\[155]。作者指出这些研究存在异质性，因此分析存在局限性。研究未具体区分乳腺内复发与胸壁或淋巴结复发的情况\[155]。
* 检查项目: CT chest abdomen pelvis with IV contrast / CT胸部(增强),CT全腹部(增强),CT盆腔(增强)
  * 评分: 2
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0027 / R:CR000706
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明:
* 检查项目: CT chest abdomen pelvis without and with IV contrast / CT胸部(平扫+增强),CT全腹部(平扫+增强),CT盆腔(平扫+增强)
  * 评分: 2
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0028 / R:CR000707
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢☢ 10-30 mSv \[ped]
  * 推荐说明:
* 检查项目: CT chest abdomen pelvis without IV contrast / CT胸部(平扫),CT全腹部(平扫),CT盆腔(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0030 / R:CR000708
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明:
* 检查项目: MRI breast without IV contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000709
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明:
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000710
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature supporting the use of Tc-99m sestamibi MBI for imaging the axilla in patients with newly diagnosed recurrent disease. 目前尚无相关文献支持使用锝-99m甲氧基异丁基异腈（MIBI）显像技术对新诊断复发疾病患者的腋窝进行成像检查。

##### S0088 Variant: Variant 11:  Female. Suspicious axillary node on mammography or ultrasound. Next imaging study. | 女性，乳腺X线摄影或超声检查发现可疑腋窝淋巴结，下一步影像学检查。

检查推荐列表：

* 检查项目: US-Guided Core Biopsy Axillary Node / US腋窝淋巴结介入超声检查
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0025 / R:CR000711
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: US-guided biopsy (either core needle biopsy or FNA) may provide a diagnosis for morphologically abnormal lymph nodes detected on imaging. In a meta-analysis of 1,353 patients from 6 studies, US-guided core needle biopsy was superior to US-guided FNA in diagnosing axillary nodal metastases with reported pooled sensitivity of 88% versus 74%, respectively. Both US-guided core needle biopsy and FNA had a high specificity of 100% \[86]. Complications such as pain, hematoma, and bruising were higher with core needle biopsy than FNA. 超声引导下活检（粗针穿刺或细针抽吸）可为影像学发现的形态异常淋巴结提供诊断依据。一项纳入6项研究共1353例患者的荟萃分析显示，超声引导粗针穿刺在诊断腋窝淋巴结转移方面优于细针抽吸，汇总敏感度分别为88%和74%。两种方法均具有100%的高特异度\[86]。粗针穿刺的疼痛、血肿及瘀斑等并发症发生率高于细针抽吸。
* 检查项目: US-Guided Fine Needle Aspiration Biopsy Axillary Node / US腋窝淋巴结介入超声检查
  * 评分: 8
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0025 / R:CR000711
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: US-guided FNA biopsy is a reliable procedure associated with minimal complications. In a meta-analysis of 31 studies, US-guided FNA improved the median sensitivity of US from 61% to 79% and specificity from 82.0% to 100% \[62]. In another publication of 3,781 breast cancer patients, the sensitivity and specificity of axillary US alone were 59% and 89%, respectively. The specificity improved to 100% when axillary US was combined with FNA. FNA resulted in sensitivity, specificity, PPV, NPV, and accuracy of 52%, 100%, 100%, 74.8%, and 80%, respectively \[63]. The decision to perform FNA or core biopsy of a suspicious axillary node is not standardized and depends on provider choice and patient factors. 超声引导下细针穿刺活检（US-guided FNA）是一种可靠的操作，并发症极少。一项包含31项研究的荟萃分析显示，超声引导下细针穿刺活检将超声检查的中位灵敏度从61%提高至79%，特异度从82.0%提升至100%\[62]。另一项针对3,781例乳腺癌患者的研究表明，单独腋窝超声检查的灵敏度和特异度分别为59%和89%。当腋窝超声联合细针穿刺活检时，特异度提升至100%。细针穿刺活检的灵敏度、特异度、阳性预测值、阴性预测值及准确率分别为52%、100%、100%、74.8%和80%\[63]。目前对可疑腋窝淋巴结行细针穿刺或空心针活检的选择尚未标准化，需结合操作者判断及患者个体因素决定。
* 检查项目: MRI breast without and with IV contrast / MR乳腺(平扫+增强)
  * 评分: 5
  * 适宜性: May be appropriate (Disagreement) / 可能适宜（存在争议）
  * 编码: P:PR0005 / R:CR000713
  * 证据强度: Expert OpinionReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: MRI breast without and with IV contrast may be appropriate for the evaluation of a suspicious axillary node identified on mammography or ultrasound. This modality can provide additional soft tissue characterization of the node and may help identify an occult primary breast carcinoma, particularly in cases where conventional imaging is equivocal or negative. However, its use in this specific scenario is subject to disagreement among experts, reflecting variability in clinical practice and the lack of robust evidence to universally support or refute its role. The decision to proceed with MRI should be made on a case-by-case basis, considering factors such as patient history, physical examination findings, and the specific features of the node. It is important to note that MRI does not replace tissue diagnosis, and any suspicious findings should be confirmed with histopathological evaluation. The procedure's utility may be limited by availability, cost, and the potential for false-positive or false-negative results. 对于在乳腺X线摄影或超声检查中发现可疑腋窝淋巴结的患者，使用不注射和注射静脉对比剂的乳腺MRI可能适用。该模态可提供淋巴结的额外软组织特征，并可能有助于识别隐匿性原发性乳腺癌，特别是在常规影像学检查结果不明确或阴性的情况下。然而，其在此特定场景中的应用存在专家分歧，反映了临床实践的差异性以及缺乏有力证据普遍支持或反驳其作用。是否进行MRI检查应逐案决定，需考虑患者病史、体格检查结果及淋巴结的具体特征等因素。需要注意的是，MRI不能替代组织学诊断，任何可疑发现均应通过组织病理学评估确认。该程序的实用性可能受到可用性、成本以及假阳性或假阴性结果的潜在限制。
* 检查项目: FDG-PET/CT Skull Base to Mid-Thigh / PET/CT躯干
  * 评分: 3
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0020 / R:CR000714
  * 证据强度: ModerateReferences
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明: Less than 1% of breast cancers initially present as axillary adenopathy \[32,33]. Historically, mammography, US, and breast MRI have helped to identify the primary malignancy in patients with pathologic axillary adenopathy from unknown primary. However, mammography and US have relatively low sensitivity for detecting the primary breast lesion \[31,159]. The addition of breast MRI has improved sensitivity \[160] because MRI is able to detect the primary breast lesion in 36% to 86% of cases \[39]. Although PET/CT can be helpful in identifying the site of an unknown primary, for breast cancer, there are little data to support its routine use. 仅有不到1%的乳腺癌病例以腋窝淋巴结转移为首发表现\[32,33]。传统上，乳腺X线摄影、超声和乳腺MRI有助于病理确诊腋窝淋巴结转移但原发灶不明的患者寻找原发恶性肿瘤。然而，乳腺X线摄影和超声对原发乳腺病灶的检出敏感性相对较低\[31,159]。联合乳腺MRI可提高检出率\[160]，因为MRI能在36%-86%的病例中发现原发乳腺病灶\[39]。虽然PET/CT有助于识别原发灶不明肿瘤的部位，但对于乳腺癌而言，目前缺乏支持其常规应用的数据依据。
* 检查项目: CT chest abdomen pelvis with IV contrast / CT胸部(增强),CT全腹部(增强),CT盆腔(增强)
  * 评分: 2
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0027 / R:CR000715
  * 证据强度: ModerateReferences
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明:
* 检查项目: CT chest abdomen pelvis without IV contrast / CT胸部(平扫),CT全腹部(平扫),CT盆腔(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0030 / R:CR000717
  * 证据强度: ModerateReferences
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明:
* 检查项目: CT chest abdomen pelvis without and with IV contrast / CT胸部(平扫+增强),CT全腹部(平扫+增强),CT盆腔(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0028 / R:CR000716
  * 证据强度: ModerateReferences
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢☢ 10-30 mSv \[ped]
  * 推荐说明:
* 检查项目: MRI breast without IV contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000718
  * 证据强度: StrongReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明:
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000719
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature supporting the use of Tc-99m sestamibi MBI for imaging the axilla in patients with suspicious axillary nodes detected on mammography and US. 目前尚无相关文献支持使用锝-99m甲氧基异丁基异腈（MBI）对乳腺X线摄影和超声检查发现可疑腋窝淋巴结的患者进行腋窝成像。

##### S0089 Variant: Variant 12:  Female. Suspicious axillary node on any other imaging modality (excluding mammography and ultrasound). Next imaging study. | 女性，其他影像学检查（乳腺X线摄影和超声除外）发现可疑腋窝淋巴结，下一步影像学检查。

检查推荐列表：

* 检查项目: Digital Breast Tomosynthesis Diagnostic / MG双侧乳腺钼靶
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0010 / R:CR000720
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: When a suspicious lymph node is identified on imaging, correlation with clinical history and physical examination is essential to guide management. If a breast primary is of concern, mammography and DBT can assist in identifying the breast primary. At least one study has shown that DBT is superior to full-field digital mammography for detection of subtle architectural distortion \[161]. 当影像学检查发现可疑淋巴结时，必须结合临床病史和体格检查以指导治疗。若考虑乳腺原发灶可能，乳腺X线摄影和数字乳腺断层合成成像（DBT）有助于识别乳腺原发灶。至少有一项研究表明，对于细微结构扭曲的检出，DBT优于全视野数字化乳腺X线摄影\[161]。
* 检查项目: US Axilla / US腋窝淋巴结常规超声检查
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0012 / R:CR000721
  * 证据强度: StrongReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: If mammogram or DBT identifies a primary breast malignancy, then axillary US after mammogram and/or DBT may evaluate the nodal size, nodal cortical, and hilar morphology. The sensitivity and specificity for axillary US for differentiating benign from malignant nodes is variable, with reported sensitivity ranging from 26% to 94% and specificity from 53% to 98% \[58]. Axillary US alone has relatively low NPV and sensitivity and therefore is not a reliable predictor of axillary nodal burden \[83,84]. When combined with needle biopsy, however, the sensitivity improves from 61% to 79% in a meta-analysis of 21 studies \[54,62,85]. Some US features that are more likely to be associated with malignancy include short-axis diameter >1 cm, cortical thickness >0.3 cm, and absence of a fatty hilum \[87-90]. The absence of a fatty hilum has the highest PPV (90% to 93%) for malignancy \[103,104]. A suspicious node on US warrants percutaneous biopsy because a positive axillary US helps to identify those patients at risk for higher tumor burden \[54,55]. However, a negative axillary US with or without biopsy does not rule out nodal disease \[58]. 若乳腺X线摄影或数字乳腺断层合成摄影（DBT）发现原发性乳腺恶性肿瘤，后续进行的腋窝超声检查可评估淋巴结大小、皮质及门部形态学特征。腋窝超声鉴别良恶性淋巴结的敏感度与特异度存在较大差异，文献报道其敏感度为26%-94%，特异度为53%-98%\[58]。单纯腋窝超声检查的阴性预测值（NPV）和敏感度相对较低，因此不能可靠预测腋窝淋巴结转移负荷\[83,84]。但联合穿刺活检时，21项研究的荟萃分析显示其敏感度可从61%提升至79%\[54,62,85]。更具恶性倾向的超声特征包括：短轴直径＞1cm、皮质厚度＞0.3cm及脂肪门消失\[87-90]，其中脂肪门消失对恶性肿瘤的阳性预测值（PPV）最高（90%-93%）\[103,104]。超声发现可疑淋巴结需行经皮活检，因阳性腋窝超声结果有助于识别高肿瘤负荷风险患者\[54,55]。但阴性腋窝超声结果（无论是否联合活检）不能排除淋巴结转移\[58]。
* 检查项目: Mammography Diagnostic / MG双侧乳腺钼靶
  * 评分: 8
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0010 / R:CR000720
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: When a suspicious lymph node is identified on imaging, other than mammography or DBT, correlation with clinical history and physical examination is essential to guide further imaging. If a breast primary is of concern, mammography and/or DBT may assist in identifying a primary breast malignancy. Mammography is not optimal for evaluating the axilla. Valente et al \[162] found that mammography has a high FNR in the detection of axillary metastatic lymphadenopathy. 当在影像学检查（乳腺X线摄影或数字乳腺断层合成摄影除外）中发现可疑淋巴结时，必须结合临床病史和体格检查以指导进一步影像学评估。若考虑乳腺原发灶可能，乳腺X线摄影和/或数字乳腺断层合成摄影有助于识别原发性乳腺恶性肿瘤。乳腺X线摄影对腋窝评估效果欠佳——Valente等\[162]研究发现，该技术检测腋窝转移性淋巴结病变具有较高的假阴性率。
* 检查项目: US-Guided Fine Needle Aspiration Biopsy Axillary Node / US腋窝淋巴结介入超声检查
  * 评分: 5
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0025 / R:CR000724
  * 证据强度: ModerateReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: US-guided FNA of an axillary node is a well-tolerated low-risk procedure that can accurately confirm metastatic disease in a suspicious lymph node. Although a recent meta-analysis of 1,353 patients showed that US-guided core needle biopsy is superior to US-guided FNA \[86], FNA does have a role in diagnosing patients with suspicious lymphadenopathy, especially if a patient is unable to discontinue anticoagulants. On-site cytopathologist is not a common practice even though immediate pathology assessment for inadequate sampling is very beneficial because inadequate sampling rates can occur in 5% to 10% of cases \[163-165]. 超声引导下腋窝淋巴结细针穿刺抽吸术是一种耐受性良好、风险较低的操作，能准确确认可疑淋巴结的转移性疾病。尽管近期一项纳入1,353例患者的荟萃分析显示超声引导下空心针活检优于超声引导下细针穿刺\[86]，但细针穿刺在可疑淋巴结病变诊断中仍具价值，尤其适用于无法停用抗凝药物的患者。虽然现场细胞病理学评估对采样不足（发生率5%-10%\[163-165]）具有显著益处，但该操作模式尚未成为常规实践。
* 检查项目: US-Guided Core Biopsy Axillary Node / US腋窝淋巴结介入超声检查
  * 评分: 5
  * 适宜性: May be appropriate (Disagreement) / 可能适宜（存在争议）
  * 编码: P:PR0025 / R:CR000724
  * 证据强度: Expert OpinionReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: Based on a meta-analysis of 1,353 patients with newly diagnosed breast cancer, US-guided core needle biopsy is superior to US-guided FNA with a reported sensitivity of 88% for core biopsy and 74% for FNA \[86]. The overall sensitivity of US-guided biopsy ranges from 52% to 90%, whereas the specificity ranges from 98% to 100% \[59- 基于一项针对1,353例新诊断乳腺癌患者的荟萃分析，超声引导空心针活检优于超声引导细针抽吸活检，报道的空心针活检敏感性为88%，细针抽吸活检为74%\[86]。超声引导活检的总体敏感性范围为52%至90%，而特异性范围为98%至100%\[59]。

#### T0013 Male Breast Cancer Screening | 男性乳腺癌筛查

* 主题编码: T0013

##### S0090 Variant: Variant 1:  Adult male. Breast cancer screening. Higher-than-average risk. | 成人男性。乳腺癌筛查。高于平均风险。

检查推荐列表：

* 检查项目: Mammography Screening / MG双侧乳腺钼靶
  * 评分: 7
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0010
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There are limited but emerging data supporting screening in high-risk men, with routine mammographic screening approaching similar cancer detection rates compared with women of average risk in standard population-based mammographic screening programs \[19]. There are no randomized controlled trials evaluating screening mammography for men at elevated risk of breast cancer. In a retrospective study of 1,869 men with higher-than- average risk (ages 18-96 years; median 55 years) undergoing digital mammography or DBT to screen for breast cancer, the cancer detection rate was 18 per 1,000, with a sensitivity of 100%, a specificity 95%, and a positive predictive value of biopsy of 50%. The use of DBT was limited to only 46 examinations (2.2%). Mammography has been shown to be highly sensitive in men \[12], likely secondary to most men having nondense breast tissue. Many of the mammograms performed for men in this clinical scenario are ordered as diagnostic because screening mammography is commonly ordered only for cisgender women. Therefore, although most high-risk men undergo annual mammography as a “diagnostic” examination, for this discussion and for the purposes of this appropriateness criteria, the modality of “screening” is being used to describe “surveillance” mammography in asymptomatic patients. The imaging interval (annual versus biennial) or the age to start surveillance has not been well researched. In 1 study comparing screening mammography in asymptomatic men at elevated risk relative to diagnostic mammography in symptomatic men, the average size of cancers detected at screening were significantly smaller and significantly more likely to be node negative (1.2 cm versus 2.1 cm average size and 0% versus 58% nodal involvement, respectively) \[12]. These data suggest that screening or surveillance mammography in men of elevated risk may indeed prove useful. Because axillary nodal positivity is the strongest surrogate marker for systemic metastatic risk, the ability of screening mammography to detect breast malignancies with a markedly lower rate of nodal involvement is indicative of a probable benefit from screening mammography in men of elevated risk. The first guidelines published in 2020 by ASCO recommend men with a known deleterious BRCA 1 or 2 mutation at least receive a baseline mammogram \[20]. Men with a personal history of breast cancer should continue at least to receive annual ipsilateral mammography after treatment (formed as a strong recommendation with low evidence), and men with personal history of breast cancer and a known deleterious genetic mutation should receive bilateral annual mammography (formed as a moderate recommendation with low evidence) \[3]. The NCCN guidelines currently recommend that men with a BRCA2 or BRCA1 gene mutation consider getting annual screening mammograms starting at age 50 or 10 years before the earliest known male breast cancer diagnosis in the family (whichever comes first). NCCN guidelines acknowledge that there are “only minimal data” to support screening 目前支持对高风险男性进行筛查的数据有限但逐渐增多，常规乳腺X线筛查的癌症检出率已接近标准人群乳腺X线筛查项目中一般风险女性的水平\[19]。目前尚无评估乳腺X线摄影对乳腺癌高风险男性筛查效果的随机对照试验。一项回顾性研究纳入1,869名高于平均风险的男性（年龄1896岁；中位年龄55岁），通过数字乳腺X线摄影或DBT进行乳腺癌筛查，癌症检出率为每1000人18例，敏感性达100%，特异性为95%，活检阳性预测值为50%。其中仅46次检查（2.2%）使用了DBT。乳腺X线摄影对男性具有高度敏感性\[12]，这可能与大多数男性乳腺组织非致密性有关。在此临床情境中，许多男性乳腺X线检查被列为诊断性检查，因为筛查性乳腺X线摄影通常仅针对顺性别女性开展。因此，尽管大多数高风险男性每年接受的是"诊断性"乳腺X线检查，但基于本次讨论及适用标准制定目的，本文件使用"筛查"这一术语来描述无症状患者的"监测性"乳腺X线检查。影像学检查间隔（年度或双年度）或开始监测的年龄尚未得到充分研究。一项研究比较了无症状高风险男性的筛查性乳腺X线摄影与有症状男性的诊断性乳腺X线摄影，发现筛查检出癌症的平均尺寸显著更小且淋巴结阴性概率显著更高（平均尺寸分别为1.2厘米 vs 2.1厘米，淋巴结受累率分别为0% vs 58%）\[12]。这些数据表明对高风险男性进行筛查或监测性乳腺X线摄影确实可能具有价值。由于腋窝淋巴结阳性是系统性转移风险的最强替代标志物，筛查性乳腺X线摄影能够以显著更低的淋巴结受累率检测乳腺恶性肿瘤，表明高风险男性可能从筛查中获益。2020年ASCO发布的首部指南建议已知BRCA1或2有害突变的男性至少接受基线乳腺X线检查\[20]。有乳腺癌个人史的男性治疗后应继续至少每年接受同侧乳腺X线检查（形成强推荐低证据等级建议），而有乳腺癌个人史且已知有害基因突变的男性应接受双侧年度乳腺X线检查（形成中等推荐低证据等级建议）\[3]。NCCN指南目前建议BRCA2或BRCA1基因突变男性考虑从50岁或比家族中最早确诊男性乳腺癌年龄提前10年开始（以先到者为准）每年进行筛查性乳腺X线摄影。NCCN指南承认支持筛查的数据"极为有限"。
* 检查项目: Digital Breast Tomosynthesis Screening / MG双侧乳腺钼靶(筛查)
  * 评分: 7
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0001 / R:CR000725
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There are limited but emerging data supporting screening digital breast tomosynthesis (DBT) in high-risk men, with routine mammographic screening approaching similar cancer detection rates compared with women of average risk in standard population-based mammographic screening programs \[19]. There are no randomized controlled trials evaluating screening mammography for men at elevated risk of breast cancer. In a retrospective study of 1,869 men with higher-than-average risk (ages 18-96 years; median 55 years) undergoing digital mammography or DBT to screen for breast cancer, the cancer detection rate was 18 per 1,000, with a sensitivity of 100%, a specificity 95%, and a positive predictive value of biopsy of 50%. The use of DBT was limited to only 46 examinations (2.2%). Mammography has been shown to be highly sensitive in men \[12], likely secondary to most men having nondense breast tissue. Many of the mammograms performed for men in this clinical scenario are ordered as diagnostic because screening mammography is commonly ordered only for cisgender women. Therefore, although most high-risk men undergo annual mammography as a “diagnostic” examination, for this discussion and for the purposes of this appropriateness criteria, the modality of “screening” is being used to describe “surveillance” mammography in asymptomatic patients. The imaging interval (annual versus biennial) or the age to start screening has not been well researched. In one study comparing screening mammography in asymptomatic men at elevated risk relative to diagnostic mammography in symptomatic men, the average size of cancers detected at screening were significantly smaller and significantly more likely to be node negative (1.2 cm versus 2.1 cm average size and 0% versus 58% nodal involvement, respectively) \[12]. These data suggest that screening or surveillance mammography in men of elevated risk may indeed prove useful. Because axillary nodal positivity is the strongest surrogate marker for systemic metastatic risk, the ability of screening mammography to detect breast malignancies with a markedly lower rate of nodal involvement is indicative of a probable benefit from screening mammography in men of elevated risk. The first guidelines published in 2020 by ASCO recommend men with a known deleterious BRCA1 or BRCA2 mutation at least receive a baseline mammogram \[20]. Men with a personal history of breast cancer should continue to receive annual ipsilateral mammography after treatment (formed as a strong recommendation with low evidence), and men with a personal history of breast cancer and a known deleterious genetic mutation should receive bilateral annual mammography (formed as a moderate recommendation with low evidence) \[3]. The NCCN guidelines currently recommend that men with a BRCA1 or BRCA2 germline mutation consider getting annual screening mammograms starting at age 50 or 10 years before the earliest known male breast cancer diagnosis in the family (whichever comes first). NCCN guidelines acknowledge that there are “only minimal data” to support screening 支持高危男性进行筛查性数字乳腺断层合成（DBT）的数据有限但不断涌现，常规 mammographic 筛查的癌症检出率接近标准人群 mammographic 筛查项目中平均风险女性的水平\[19]。目前无随机对照试验评估对乳腺癌风险升高男性的筛查 mammography。一项回顾性研究纳入1,869例高于平均风险的男性（年龄1896岁；中位55岁）接受数字 mammography 或 DBT 筛查乳腺癌，癌症检出率为每1,000人18例，敏感性100%，特异性95%，活检阳性预测值50%。DBT使用仅限于46次检查（2.2%）。Mammography 在男性中显示出高敏感性\[12]，可能源于大多数男性乳腺组织非致密。本临床场景中许多男性 mammography 检查以诊断性方式开具，因筛查 mammography 通常仅针对顺性别女性。因此，尽管大多数高危男性每年接受 mammography 作为“诊断性”检查，但为本适当性标准讨论之目的，“筛查”一词用于描述无症状患者的“监测” mammography。影像学间隔（每年或每两年）或开始筛查年龄尚未充分研究。一项研究比较无症状高风险男性的筛查 mammography 与有症状男性的诊断 mammography，筛查检出癌症的平均尺寸显著更小且更可能淋巴结阴性（平均尺寸1.2 cm对比2.1 cm，淋巴结受累
* 检查项目: Mammography With IV Contrast / MG双侧乳腺钼靶导管造影
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0004 / R:CR000727
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of mammography with intravenous (IV) contrast for breast cancer screening in this clinical setting. 目前尚无相关文献支持在该临床情况下使用静脉注射造影剂的乳腺X线摄影进行乳腺癌筛查。
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000730
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support the use of MRI breast without IV contrast for breast cancer screening in this clinical setting. The ASCO guidelines state breast MRI is not routinely recommended in men with breast cancer (formed as a moderate recommendation with low evidence) \[3]. 目前尚无相关文献支持在此临床情境下使用无静脉对比剂的乳腺MRI进行乳腺癌筛查。美国临床肿瘤学会（ASCO）指南指出，男性乳腺癌患者不常规推荐乳腺MRI检查（该建议为中等强度推荐，证据等级较低）\[3]。
* 检查项目: MRI Breast Without IV Contrast Abbreviated / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000730
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support the use of MRI breast without IV contrast abbreviated for breast cancer screening in this clinical setting. The ASCO guidelines state breast MRI is not routinely recommended in men with 目前尚无相关文献支持在此临床情境下使用无静脉注射对比剂的简化乳腺 MRI 进行乳腺癌筛查。ASCO 指南指出，不常规推荐对男性患者进行乳腺 MRI 检查。
* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000728
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support the use of MRI breast without and with IV contrast for breast cancer screening in this clinical setting. The ASCO guidelines state breast MRI is not routinely recommended in men with breast cancer (formed as a moderate recommendation with low evidence) \[3]. 目前尚无相关文献支持在此临床情况下使用无静脉注射对比剂及增强MRI进行乳腺癌筛查。美国临床肿瘤学会（ASCO）指南指出，男性乳腺癌患者不常规推荐乳腺MRI检查（该建议为中等强度推荐，证据等级较低）\[3]。
* 检查项目: MRI Breast Without and With IV Contrast Abbreviated / MR乳腺(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000728
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support the use of MRI breast without and with IV contrast abbreviated for breast cancer screening in this clinical setting. The ASCO guidelines state breast MRI is not routinely recommended in men with breast cancer (formed as a moderate recommendation with low evidence) \[3]. 目前尚无相关文献支持在此临床情境下使用无静脉对比剂及静脉对比剂增强的简化乳腺MRI进行乳腺癌筛查。ASCO指南指出，男性乳腺癌患者不常规推荐乳腺MRI检查（形成中等推荐强度，证据等级较低）\[3]。
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000732
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of sestamibi molecular breast imaging (MBI) for breast cancer screening in this clinical setting. 目前尚无相关文献支持在此临床背景下使用司他比锝分子乳腺成像（MBI）进行乳腺癌筛查。
* 检查项目: US breast / US乳腺常规超声检查
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0003 / R:CR000733
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明:

##### S0091 Variant: Variant 2:  Adult male. Breast cancer screening. Average risk. | 成人男性。乳腺癌筛查。平均风险。

检查推荐列表：

* 检查项目: Mammography Screening / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support mammographic screening in this clinical setting. No standard screening regimen for breast cancer has been recommended in the average-risk man \[21]. 目前尚无相关文献支持在此临床情况下进行乳腺X线筛查。对于平均风险的男性，尚未推荐标准的乳腺癌筛查方案\[21]。
* 检查项目: Digital Breast Tomosynthesis Screening / MG双侧乳腺钼靶(筛查)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0001 / R:CR000734
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the DBT screening in this clinical setting. No standard screening regimen for breast cancer has been recommended in the average-risk man \[21]. 目前尚无相关文献支持在此临床情况下使用数字乳腺断层合成（DBT）进行筛查。对于平均风险的男性，尚未推荐标准的乳腺癌筛查方案\[21]。
* 检查项目: Mammography With IV Contrast / MG双侧乳腺钼靶导管造影
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0004 / R:CR000736
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support screening mammography with IV contrast in this clinical setting. No standard screening regimen for breast cancer has been recommended in the average-risk man \[21]. 目前尚无相关文献支持在该临床情况下使用静脉造影剂进行乳腺X线筛查。对于平均风险的男性，尚未推荐标准的乳腺癌筛查方案\[21]。
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000739
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support breast MRI screening without IV contrast in this clinical setting. No standard screening regimen for breast cancer has been recommended in the average-risk man \[21]. 目前尚无相关文献支持在此临床情况下进行无静脉对比剂的乳腺MRI筛查。对于平均风险男性，尚未推荐标准的乳腺癌筛查方案\[21]。
* 检查项目: MRI Breast Without IV Contrast Abbreviated / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000739
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support abbreviated breast MRI screening without IV contrast in this clinical setting. No standard screening regimen for breast cancer has been recommended in the average-risk man \[21]. 目前尚无相关文献支持在此临床情况下使用无静脉对比剂的简化乳腺MRI筛查。对于平均风险男性，尚未推荐标准的乳腺癌筛查方案\[21]。
* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000737
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support breast MRI screening without and with IV contrast in this clinical setting. No standard screening regimen for breast cancer has been recommended in the average-risk man \[21]. 目前尚无相关文献支持在此临床情况下进行不注射和注射静脉造影剂的乳腺MRI筛查。对于平均风险男性，尚未推荐标准的乳腺癌筛查方案\[21]。
* 检查项目: MRI Breast Without and With IV Contrast Abbreviated / MR乳腺(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000737
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support abbreviated breast MRI screening without and with IV contrast in this clinical setting. No standard screening regimen for breast cancer has been recommended in the average-risk man \[21]. 目前尚无相关文献支持在此临床情况下使用无静脉注射对比剂和含静脉注射对比剂的简化乳腺MRI筛查。对于平均风险男性，尚未推荐标准的乳腺癌筛查方案\[21]。
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000741
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support sestamibi MBI screening in this clinical setting. No standard screening regimen for breast cancer has been recommended in the average-risk man \[21]. 目前尚无相关文献支持在此临床背景下使用司他比锝MBI进行筛查。对于平均风险的男性，尚未推荐标准的乳腺癌筛查方案\[21]。
* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0003 / R:CR000742
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support the breast US screening in this clinical setting. No standard screening regimen for breast cancer has been recommended in the average-risk man \[21]. 目前尚无相关文献支持在此临床情况下进行乳腺超声筛查。对于平均风险的男性，尚未推荐标准的乳腺癌筛查方案\[21]。

##### S0092 Variant: Variant 3:  Adult male, younger than 25 years of age. Breast cancer screening. Any risk. | \<25岁男性。乳腺癌筛查。任何风险。

检查推荐列表：

* 检查项目: Mammography Screening / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support mammographic screening in this clinical setting. 目前尚无相关文献支持在此临床情况下进行乳腺X线筛查。
* 检查项目: Digital Breast Tomosynthesis Screening / MG双侧乳腺钼靶(筛查)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0001 / R:CR000743
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support DBT screening in this clinical setting. 目前尚无相关文献支持在此临床情境下进行DBT筛查。
* 检查项目: Mammography With IV Contrast / MG双侧乳腺钼靶导管造影
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0004 / R:CR000745
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support screening mammography with IV contrast in this clinical setting. 目前尚无相关文献支持在此临床情况下使用静脉造影剂进行乳腺X线筛查。
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000748
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support screening breast MRI without IV contrast in this clinical setting. 目前尚无相关文献支持在此临床情况下进行无需静脉注射对比剂的乳腺MRI筛查。
* 检查项目: MRI Breast Without IV Contrast Abbreviated / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000748
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support abbreviated screening breast MRI without IV contrast in this clinical setting. 目前尚无相关文献支持在此临床情况下使用无静脉对比剂的简化乳腺MRI筛查方案。
* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000746
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support screening breast MRI without and with IV contrast in this clinical setting. 目前尚无相关文献支持在此临床情况下进行无静脉注射对比剂和有静脉注射对比剂的乳腺MRI筛查。
* 检查项目: MRI Breast Without and With IV Contrast Abbreviated / MR乳腺(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000746
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support screening abbreviated breast MRI without and with IV contrast in this clinical setting. 目前尚无相关文献支持在此临床情况下进行无静脉注射对比剂和含静脉注射对比剂的简化乳腺MRI筛查。
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000750
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support screening sestamibi MBI in this clinical setting. 目前尚无相关文献支持在此临床情况下进行甲氧基异丁基异腈（MIBI）核素扫描筛查。
* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0003 / R:CR000751
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support breast US screening in this clinical setting. 目前尚无相关文献支持在此临床情况下进行乳腺超声筛查。

#### T0014 Monitoring Response to Neoadjuvant Systemic Therapy for Breast Cancer | 乳腺癌新辅助全身治疗疗效监测

* 主题编码: T0014

##### S0093 Variant: Variant 1:  Adult female or male or transfeminine (male-to-female) or transmasculine (female-to-male). Known breast cancer. Initial determination of tumor size and extent within the breast prior to neoadjuvant chemotherapy. Initial imaging. | 成人女性或男性或跨性别女性（男跨女）或跨性别男性（女跨男）。已知乳腺癌。新辅助化疗前初次确定肿瘤大小及乳腺内范围。初始影像学检查。

检查推荐列表：

* 检查项目: Digital Breast Tomosynthesis Diagnostic / MG双侧乳腺钼靶
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0010 / R:CR000752
  * 证据强度: StrongReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Mammography, ultrasound (US), and MRI are complementary modalities for assessing primary tumor size before treatment because they are reliable tools to determine tumor size at diagnosis \[1,11-15]. Mammography and US are the two main modalities for assessing primary tumor size before treatment because they are reliable tools to determine tumor size at diagnosis \[11-15]. Mammography is most accurate for ductal and low-grade malignancies and less accurate for invasive lobular cancers and higher-grade lesions \[11-16]. Digital breast tomosynthesis (DBT) addresses some of the limitations encountered with standard mammographic views. In addition to planar images, DBT creates thin-section reconstructed images, which decreases the lesion- masking effect of overlapping normal tissue. In the screening setting, some authors found the advantages of DBT to be especially pronounced in patients \<50 years of age \[17,18], in patients with dense breasts \[17,19], and with lesion types including spiculated masses, \[20] asymmetries \[21], and architectural distortion \[22]. DBT is also useful in the diagnostic setting, improving lesion characterization \[22-25] in noncalcified lesions compared with conventional mammography. A prospective study of 166 patients with breast cancer compared digital mammography (DM) to combined DM plus DBT for accuracy of local tumor staging. They demonstrated better accuracy of DM plus DBT for detecting additional ipsilateral and contralateral disease in patients with nondense breasts \[26]. A retrospective study of 222 cancers demonstrated that pathologic response to NAC was less likely with the baseline mammographic finding of spiculation \[27]. Because of the presence of dense tissue in up to 50% of patients, obscured margins may limit evaluation of the extent of disease \[28]. Therefore, mammography or DBT is most often combined with other modalities, such as US or MRI, to guide clinical management. 乳腺X线摄影、超声和MRI是评估治疗前原发肿瘤大小的互补检查手段，因其在诊断时能可靠测定肿瘤大小\[1,11-15]。乳腺X线摄影和超声作为治疗前评估原发肿瘤的两大主要检查方法，在诊断时具有可靠的肿瘤大小测定价值\[11-15]。乳腺X线摄影对导管癌和低度恶性肿瘤最为准确，而对浸润性小叶癌和高级别病变的准确性较低\[11-16]。数字乳腺断层合成摄影（DBT）解决了标准乳腺摄影视图的部分局限性。除平面图像外，DBT还能生成薄层重建图像，减少正常组织重叠对病灶的遮蔽效应。在筛查场景中，部分学者发现DBT的优势在50岁以下患者\[17,18]、致密型乳腺患者\[17,19]以及表现为毛刺状肿块\[20]、不对称影\[21]和结构扭曲\[22]的病灶中尤为显著。DBT在诊断场景中也具有应用价值，与传统乳腺X线摄影相比，能改善非钙化性病灶的特征分析\[22-25]。一项针对166例乳腺癌患者的前瞻性研究比较了数字乳腺X线摄影（DM）与DM联合DBT在局部肿瘤分期准确性上的差异，结果显示在非致密型乳腺患者中，DM联合DBT对检测同侧及对侧附加病灶具有更高准确性\[26]。一项包含222例癌症的回顾性研究表明，
* 检查项目: Mammography Diagnostic / MG双侧乳腺钼靶
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0010 / R:CR000752
  * 证据强度: StrongReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Mammography, US, and MRI are complementary modalities for assessing primary tumor size before treatment because they are reliable tools to determine tumor size at diagnosis \[1,11-15]. Mammography is most accurate for ductal and low-grade malignancies and less accurate for invasive lobular cancers and higher-grade lesions \[11-16]. DBT addresses some of the limitations encountered with standard mammographic views. In addition to planar images, DBT creates thin-section reconstructed images, which decreases the lesion-masking effect of overlapping normal tissue. In the screening setting, some authors found the advantages of DBT to be especially pronounced in patients \<50 years of age \[17,18], in patients with dense breasts \[17,19], and with lesion types including spiculated masses \[20] and asymmetries \[21]. DBT can also be useful in the diagnostic setting, improving lesion A prospective study of 166 patients with breast cancer compared DM to combined DM plus DBT for accuracy of local tumor staging. They demonstrated better accuracy of DM plus DBT for detecting additional ipsilateral and contralateral disease in patients with nondense breasts \[26]. A retrospective study of 222 cancers demonstrated that pathologic response to NAC was less likely with the baseline mammographic finding of spiculation \[27]. Because of the presence of dense tissue in up to 50% of patients, obscured margins may limit evaluation of the extent of disease \[28]. Therefore, mammography or DBT is most often combined with other modalities, such as US or MRI, to guide clinical management. 乳腺X线摄影、超声和MRI是评估治疗前原发肿瘤大小的互补检查手段，因其是确诊时确定肿瘤大小的可靠工具\[1,1115]。乳腺X线摄影对导管癌和低度恶性肿瘤最准确，对浸润性小叶癌和高级别病变准确性较低\[1116]。数字乳腺断层合成摄影解决了标准乳腺投照体位的部分局限性。除平面图像外，数字乳腺断层合成摄影生成薄层重建图像，减少重叠正常组织对病灶的遮蔽效应。在筛查环境中，部分学者发现数字乳腺断层合成摄影的优势在\<50岁患者\[17,18]、致密型乳腺患者\[17,19]以及伴有毛刺状肿块\[20]和非对称性改变\[21]等病灶类型中尤为显著。数字乳腺断层合成摄影在诊断场景中亦具价值，可改善病灶特征评估。一项针对166例乳腺癌患者的前瞻性研究比较了数字乳腺X线摄影与数字乳腺X线摄影联合数字乳腺断层合成摄影对局部肿瘤分期的准确性，证实联合检查对非致密型乳腺患者检测同侧及对侧附加病灶具有更优准确性\[26]。一项针对222例癌症的回顾性研究显示，基线乳腺X线摄影发现毛刺征象者对新辅助化疗的病理学反应可能性较低\[27]。由于高达50%患者存在致密组织，模糊边缘可能限制疾病范围的评估\[28]。因此，乳腺X线摄影或数字乳腺断层合成摄影多与超声或MRI等其他检查联合应用以指导临床管理。
* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0005 / R:CR000754
  * 证据强度: StrongReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: MRI is complementary to mammography and US for assessing tumor size before treatment. MRI permits evaluation of a viable tumor before and after NAC by detecting changes in tumor vascularity \[31]. There is substantial evidence to support the routine use of contrast-enhanced MRI to stage, monitor early response, and assess for residual and recurrent disease given the overall high sensitivity and relatively high specificity of this technique \[1]. Dynamic contrast-enhanced MRI is a sensitive tool to determine extent of disease in the breast, especially in young patients (\<50 years of age), with sensitivity approaching 90% and specificity ranging between 50% and 97% \[1,32]. To accurately evaluate for response to NAC, a pretreatment MRI must be obtained to serve as a baseline for comparison. MRI is particularly useful in the assessment of multifocal and multicentric disease, which is often underestimated on both mammography and US \[28]. In fact, multifocal and multicentric disease are detected in up to 16% of patients on staging MRI according to a study by Houssami et al \[33]. A prospective study of 216 patients demonstrated that size determination on MRI was superior to clinical examination in predicting pathologic response both before, during, and after completion of NAC \[31]. The enhancement pattern on the pretreatment MRI also indicates how reliable this technique will be in evaluating response. Nonmass enhancement on the pretreatment MRI has been shown to reveal a scattered cell pattern more commonly on posttreatment imaging, thereby making assessment of residual disease more difficult \[34]. However, when a mass with well-defined margins is seen, MRI can more accurately predict the amount of residual disease on posttreatment imaging \[34]. In addition, several studies have shown that MRI is more accurate than mammography and US in defining disease extent for invasive lobular cancer \[32,35,36]. MRI can reliably assess the chest wall because pectoral or intercostal muscle enhancement correlates well with invasion \[37]. Finally, several studies have shown that up to 3% of patients have unsuspected contralateral disease at the time of initial diagnosis and MRI has been proven effective in detecting such contralateral disease \[38]. MRI是评估治疗前肿瘤大小的乳腺X线摄影和US的补充手段。MRI通过检测肿瘤血管性变化，可在NAC前后评估活性肿瘤\[31]。鉴于该技术整体高敏感性和相对较高的特异性，有充分证据支持常规使用对比增强MRI进行分期、监测早期反应及评估残留与复发疾病\[1]。动态对比增强MRI是确定乳腺疾病范围的敏感工具，尤其对年轻患者（\<50岁），敏感性接近90%，特异性介于50%至97%\[1,32]。为准确评估NAC反应，必须获取治疗前MRI作为对比基线。MRI在评估多灶性和多中心性疾病方面特别有用，这两种情况在乳腺X线摄影和US中常被低估\[28]。事实上，根据Houssami等\[33]的研究，分期MRI检测到多灶性和多中心性疾病的患者比例高达16%。一项216例患者的前瞻性研究显示，在预测NAC前、中及完成后的病理反应方面，MRI的大小测定优于临床检查\[31]。治疗前MRI的强化模式也预示了该技术评估反应的可信度。治疗前MRI的非肿块强化在治疗后影像中更常显示为散在细胞模式，从而使残留疾病评估更困难\[34]。然而，当观察到边界清晰的肿块时，MRI能更准确预测治疗后影像上的残留疾病量\[34]。此外，多项研究表明，在界定浸润性小叶癌疾病范围方面，MRI比乳腺X线摄影和US更准确\[32,35,36]。MRI可可靠评估胸壁，因为胸肌或肋间肌强化与侵袭密切相关\[37]。最后，多项研究显示高达3%的患者在初诊时存在未被怀疑的对侧疾病，而MRI已被证明可有效检测此类对侧疾病\[38]。
* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0003 / R:CR000755
  * 证据强度: StrongReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: Mammography, US, and MRI are complementary modalities for assessing primary tumor size before treatment because they are reliable tools to determine tumor size at diagnosis \[1,11-15]. US is more accurate in measuring tumor size than clinical breast examination or mammography. It is most often performed in conjunction with 乳腺X线摄影、超声和MRI是评估治疗前原发肿瘤大小的互补检查手段，因其是确诊时确定肿瘤大小的可靠工具\[1,1115]。超声在测量肿瘤大小方面较临床乳腺检查或乳腺X线摄影更为准确，通常与乳腺X线摄影联合实施。
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 2
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000756
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: A few institutions routinely image newly diagnosed breast cancer with molecular breast imaging (MBI) using Tc- 99m sestamibi, which is also sometimes referred to as scintimammography. This functional imaging technique reflects cell metabolism by accumulating in active mitochondrial cells. A prospective study of 90 patients found the longest dimension of the cancer measured on MRI was within 1 cm of that on MBI in 72% of cases and concluded that MBI may be an option for patients with contraindication to MRI \[40,41]. However, there is insufficient literature to support the routine use of sestamibi MBI in initial imaging evaluation of tumor size and extent in the breast before NAC. 少数机构常规采用锝-99m司他比单光子发射计算机断层显像（分子乳腺成像，MBI）对初诊乳腺癌进行成像检查，该技术有时也被称为乳腺闪烁成像。这种功能成像技术通过在线粒体活跃的细胞中积聚来反映细胞代谢活性。一项针对90例患者的前瞻性研究发现，72%的病例中MRI测量的肿瘤最大径与MBI结果差异在1厘米以内，研究结论认为对于存在MRI禁忌证的患者，MBI可作为替代检查方案\[40,41]。但目前尚无充分文献支持在乳腺癌新辅助化疗前的初始影像学评估中，常规应用司他比MBI来评估肿瘤大小及乳腺受累范围。
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000758
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: A small study of 71 patients with MRI before and after treatment found no significant difference in lesion size interpretation on unenhanced versus enhanced MRI sequences \[39]. However, there is insufficient literature to support the use of MRI without intravenous (IV) contrast in initial imaging evaluation of tumor size and extent in the breast before NAC. 一项针对71例患者治疗前后MRI的小型研究发现，在未增强与增强MRI序列上对病灶大小的判读无显著差异\[39]。然而，目前文献尚不足以支持在NAC前初始影像评估乳腺肿瘤大小和范围时使用无静脉注射对比剂的MRI检查。
* 检查项目: FDG-PET/CT Skull Base to Mid-Thigh / PET/CT躯干
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0020 / R:CR000757
  * 证据强度: StrongReferences
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明: Fluorine-18-2-fluoro-2-deoxy-D-glucose (FDG)-PET/CT has a low sensitivity for detection of primary breast cancer because of the low spatial resolution of the scanners and the relatively low FDG uptake of both invasive lobular cancers and low-grade malignancies \[29,30]. As a result, this modality is not routinely used for pretreatment imaging of the primary breast tumor. 氟-18-2-氟-2-脱氧-D-葡萄糖（FDG）-PET/CT对原发性乳腺癌的检出敏感性较低，这是由于扫描仪的空间分辨率不足，且浸润性小叶癌和低度恶性肿瘤的FDG摄取相对较低\[29,30]。因此，该检查方式不常规用于原发性乳腺肿瘤的术前影像学评估。

##### S0094 Variant: Variant 2:  Adult female or male or transfeminine (male-to-female) or transmasculine (female-to-male). Known breast cancer. Imaging of the breast after initiation or completion of neoadjuvant chemotherapy. Initial imaging. | 成人女性或男性或跨性别女性（男跨女）或跨性别男性（女跨男）。已知乳腺癌。新辅助化疗开始后或完成后的乳腺影像学检查。初始影像学检查。

检查推荐列表：

* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0005 / R:CR000759
  * 证据强度: StrongReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: MRI is a functional imaging technique that permits evaluation of a viable tumor before and after NAC by detecting changes in tumor vascularity \[31]. There is substantial evidence to support the routine use of MRI to stage, monitor early response, and assess for residual and recurrent disease, given the overall high sensitivity and relatively high specificity of this technique \[1]. However, MRI can overestimate as well as underestimate the amount of residual tumor after completion of therapy. Multiple studies show that dynamic contrast-enhanced MRI is the optimal imaging tool to determine disease response, with sensitivity approaching 90%, specificity ranging from 60 to 100%, and an accuracy of approximately 91% \[31,32,35,36,43,63-66]. MRI is particularly helpful in patients with documented multifocal and multicentric tumors on the pretreatment study, despite the fact that MRI underestimates disease extent in up to 18% of cases \[67,68]. However, there is a lack of consensus in the literature on the optimal imaging interval to assess response to therapy. Tumor measurements on MRI more accurately predict residual tumor and pathologic response than clinical assessment, a finding corroborated in several studies \[69-71], with volume measurements performing better than tumor diameter early in treatment after the first cycle of chemotherapy \[31]. In a prospective clinical trial of 138 patients, longest diameter on posttreatment MRI was superior to both mammography and clinical breast examination in detecting residual disease. MRI tumor volume was also shown to predict recurrence free survival in a trial of 162 patients \[72]. The ability of MRI to evaluate disease response is variable on the basis of tumor subtype, being more effective for invasive lobular carcinoma, triple-negative, and HER2/neu-positive tumors and less accurate for luminal subtypes (ER and/or progesterone receptor positive, HER2/neu-positive or negative), with an overall accuracy of approximately 75% \[73-81]. A study of 208 patients suggested that patients who can safely consider breast conservation therapy after NAC have tumors \<3 cm in maximal size on pretreatment MRI, reduction in tumor size on posttreatment MRI, and more often have HER2/neu-positive or triple-negative tumors \[67,82]. When the tumor presents as diffuse nonmass enhancement on the pretreatment MRI or is of low nuclear grade, MRI is less helpful in assessing response to therapy \[83]. In addition, tumors presenting initially as nonmass enhancement more likely presented as scattered foci within an area of fibrosis on posttreatment MRI, making prediction of residual disease challenging \[34,84]. Finally, there is some evidence that certain chemotherapeutic agents, such as ER modulators, antiangiogenic agents, and taxane-based therapies, may alter perfusion to the breasts, limiting the ability of MRI to accurately predict residual tumor after chemotherapy, most often leading to disease underestimation \[85,86]. Studies demonstrate that adding diffusion-weighted imaging helps predict response for some tumor subtypes. In a MRI是一种功能性成像技术，可通过检测肿瘤血管性变化来评估新辅助化疗前后存活肿瘤的情况\[31]。鉴于该技术总体敏感性较高且特异性相对较高，有充分证据支持常规使用MRI进行分期、监测早期反应以及评估残留和复发性疾病\[1]。然而，MRI既可能高估也可能低估治疗完成后的残留肿瘤量。多项研究表明，动态对比增强MRI是评估疾病反应的最佳成像工具，其敏感性接近90%，特异性范围为60%至100%，准确度约为91%\[31,32,35,36,43,6366]。对于治疗前检查已证实为多灶性和多中心性肿瘤的患者，MRI尤其有帮助，尽管其在高达18%的病例中低估疾病范围\[67,68]。然而，文献中关于评估治疗反应的最佳成像间隔缺乏共识。MRI的肿瘤测量比临床评估更准确地预测残留肿瘤和病理反应，这一发现在多项研究中得到证实\[6971]，且在化疗第一个周期后的治疗早期，体积测量优于肿瘤直径测量\[31]。在一项纳入138例患者的前瞻性临床试验中，治疗后MRI的最长直径在检测残留疾病方面优于乳腺X线摄影和临床乳腺检查。一项162例患者的试验也显示MRI肿瘤体积可预测无复发生存\[72]。MRI评估疾病反应的能力因肿瘤亚型而异，对浸润性小叶癌、三阴性和HER2/neu阳性肿瘤更有效，而对管腔亚型（ER和/或孕激素受体阳性，HER2/neu阳性或阴性）准确性较低，总体准确度约为75%\[7381]。一项208例患者的研究表明，新辅助化疗后可安全考虑保乳治疗的患者，其治疗前MRI肿瘤最大径\<3 cm，治疗后MRI显示肿瘤缩小，且更多为HER2/neu阳性或三阴性肿瘤\[67,82]。当肿瘤在治疗前MRI上表现为弥漫性非肿块样强化或为低核级时，MRI对评估治疗反应的帮助较小\[83]。此外，最初表现为非肿块样强化的肿瘤在治疗后MRI上更可能表现为纤维化区域内的散在灶，使得残留疾病的预测具有挑战性\[34,84]。最后，有证据表明某些化疗药物（如ER调节剂、抗血管生成药物和紫杉烷类药物）可能改变乳腺灌注，限制MRI准确预测化疗后残留肿瘤的能力，最常导致低估疾病\[85,86]。研究表明，加入扩散加权成像有助于预测某些肿瘤亚型的反应。
* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 8
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0003 / R:CR000760
  * 证据强度: StrongReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: US is a reliable modality for determining tumor size, especially if the residual tumor measures >7 mm \[100,101]. A decrease in tumor vascularity does appear to correlate with response \[28]. In 2 studies, US predicted residual tumor size accurately in 60% to 80% of patients, compared with 32% to 71% for mammography \[102,103]. In a study by Keune et al \[104], the absence of residual disease on both mammography and US correlated with a pCR in 80% of patients. Although pretreatment tumor stiffness as determined by shear-wave elastography has shown strong correlation with response to therapy, there is insufficient data to support its routine use at this time \[105,106]. In addition, there is insufficient data to support the routine use of contrast-enhanced US, although some early research suggests that changes in the time-intensity curves may reliably predict response to therapy \[107,108]. 超声是评估肿瘤大小的可靠方法，尤其当残余肿瘤＞7mm时\[100,101]。肿瘤血管减少确实与治疗反应相关\[28]。两项研究显示超声预测残余肿瘤大小的准确率达60%-80%，而乳腺X线摄影仅为32%-71%\[102,103]。Keune等\[104]的研究表明，乳腺X线摄影和超声均未检出残余病灶的患者中80%达到病理完全缓解。虽然剪切波弹性成像测得的治疗前肿瘤硬度与治疗反应呈强相关，但目前数据尚不足以支持其常规应用\[105,106]。此外，尽管早期研究表明时间-强度曲线的变化可能可靠预测治疗反应，但增强超声的常规应用仍缺乏足够数据支持\[107,108]。
* 检查项目: Digital Breast Tomosynthesis Diagnostic / MG双侧乳腺钼靶
  * 评分: 7
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0010 / R:CR000761
  * 证据强度: StrongReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Although mammography, DBT, and US are reliable for determining tumor size at diagnosis \[11-15], changes within the tumor secondary to NAC may be difficult to evaluate after treatment is initiated. It is well known that tumoral changes related to necrosis, fragmentation, and fibrosis make it difficult for mammography, DBT, and US to accurately determine residual tumor burden \[43,44]. In a retrospective study of 445 patients who underwent NAC, mammography was 94% sensitive and 50% specific for predicting residual disease in the breast. In cases presenting as mass lesions, 95% of masses decreased in mammographic size with treatment. However, there was correlation between mammographic size and surgical pathology in only 60% of cases \[45]. One study found that if >50% of the margin of the primary lesion was mammographically visible at baseline, posttreatment mammographic imaging was a reliable tool for determining lesion size \[28,46]. In a study of 56 patients, mammography was 79% sensitive and 77% specific in predicting residual disease after therapy, performing better than clinical breast examination \[47]. The extent of calcifications on mammography after therapy does not correlate well with residual tumor burden and is overestimated in up to 45% of patients \[48-50]. Therefore, it is not a reliable marker of remaining viable tumor. In a study including 139 patients with baseline mammographic calcifications, residual calcifications were present on all posttreatment mammograms \[45]. Estrogen receptor (ER)-positive tumors are more likely than ER-negative tumors to have residual malignant calcifications on mammography after treatment, whereas triple-negative tumors are the least likely to have residual malignant calcifications after therapy, suggesting that different tumor subtypes may warrant different approaches \[48,51]. There is no relevant literature specifically comparing the performance of DBT to mammography after initiation or completion of NAC. 虽然乳腺X线摄影、数字乳腺断层合成（DBT）和超声（US）在诊断时确定肿瘤大小方面具有可靠性\[11-15]，但新辅助化疗（NAC）引发的肿瘤内部变化在治疗开始后可能难以评估。众所周知，与坏死、碎裂和纤维化相关的肿瘤改变使得乳腺X线摄影、DBT和US难以准确评估残余肿瘤负荷\[43,44]。一项针对445例接受NAC患者的回顾性研究显示，乳腺X线摄影预测乳腺残留病变的敏感性为94%，特异性为50%。对于表现为肿块病变的病例，95%的肿块在治疗后乳腺X线摄影尺寸缩小，但仅60%的病例中乳腺X线摄影尺寸与手术病理结果具有相关性\[45]。有研究发现，若基线时原发病灶>50%的边缘在乳腺X线摄影中可见，则治疗后乳腺X线成像可作为评估病灶大小的可靠工具\[28,46]。一项纳入56例患者的研究表明，乳腺X线摄影预测治疗后残留病变的敏感性为79%，特异性为77%，其表现优于临床乳腺检查\[47]。治疗后乳腺X线摄影显示的钙化范围与残余肿瘤负荷相关性不佳，且在高达45%的患者中被高估\[48-50]，因此不能作为存活肿瘤的可靠标志物。一项包含139例基线乳腺X线钙化患者的研究显示，所有治疗后乳腺X线图像均存在残余钙化\[45]。雌激素受体（ER
* 检查项目: Mammography Diagnostic / MG双侧乳腺钼靶
  * 评分: 7
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0010 / R:CR000761
  * 证据强度: StrongReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Although mammography and US are reliable for determining tumor size at diagnosis \[11-15], changes within the tumor, secondary to NAC, may be difficult to evaluate after treatment is initiated. It is well known that tumoral changes related to necrosis, fragmentation, and fibrosis make it difficult for mammography, DBT, and US to accurately determine residual tumor burden \[43,44]. In a retrospective study of 445 patients who underwent NAC, mammography was 94% sensitive and 50% specific for predicting residual disease in the breast. In cases presenting as mass lesions, most masses (95%) decreased in mammographic size with treatment. However, there was correlation between mammographic size and surgical pathology in only 60% of cases \[45]. One study found that if >50% of the margin of the primary lesion was mammographically visible at baseline, posttreatment mammographic imaging was a reliable tool for determining lesion size \[28,46]. In a study of 56 patients, mammography was 79% sensitive and 77% specific in predicting residual disease after therapy, performing better than clinical breast examination \[47]. The extent of calcifications on mammography after therapy does not correlate well with residual tumor burden and is overestimated in up to 45% of patients \[48-50]. Therefore, it is not a reliable marker of remaining viable tumor. on all posttreatment mammograms \[45]. ER-positive tumors are more likely than ER-negative tumors to have residual malignant calcifications on mammography after treatment, whereas triple-negative tumors are the least likely to have residual malignant calcifications after therapy, suggesting that different tumor subtypes may warrant different approaches \[48,51]. There is no relevant literature specifically comparing the performance of DBT to mammography after initiation of completion of NAC. 虽然 mammography 和 US 在诊断时确定肿瘤大小方面可靠\[1115]，但继发于 NAC 的肿瘤内部变化在治疗开始后可能难以评估。众所周知，与坏死、碎裂和纤维化相关的肿瘤变化使得 mammography、DBT 和 US 难以准确判断残余肿瘤负荷\[43,44]。一项对445例接受NAC患者的回顾性研究中，mammography预测乳腺残留病变的敏感性为94%，特异性为50%。在以肿块病变呈现的病例中，大多数肿块（95%）经治疗后 mammography 尺寸缩小。然而，仅60%的病例中 mammography 尺寸与手术病理学存在相关性\[45]。一项研究发现，若基线时原发病灶50%的边缘在 mammography 可见，则治疗后 mammography 成像是确定病变大小的可靠工具\[28,46]。一项针对56例患者的研究显示，mammography预测治疗后残留病变的敏感性为79%，特异性为77%，其表现优于临床乳腺检查\[47]。治疗后 mammography 上钙化范围与残余肿瘤负荷相关性不佳，且在高达45%的患者中被高估\[4850]。因此，它并非可靠的有活性肿瘤残留标志物\[45]。ER阳性肿瘤比ER阴性肿瘤更可能在治疗后 mammography 上残留恶性钙化，而三阴性肿瘤治疗后残留恶性钙化的可能性最低，这表明不同肿瘤亚型可能需要不同的评估策略\[48,51]。目前尚无专门比较DBT与mammography在NAC开始后或完成后的表现的相关文献。
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000764
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: A small study of 71 patients with MRI before and after treatment found no significant difference in lesion size interpretation on unenhanced versus enhanced MRI sequences \[39]. However, there is insufficient literature to support the use of MRI without IV contrast of the breast in initial imaging evaluation of tumor size and extent in the breast after initiation or completion of chemotherapy. 一项针对71例患者治疗前后MRI检查的小型研究发现，在非增强与增强MRI序列上病灶大小的判读无显著差异\[39]。然而，目前文献证据不足以支持在化疗开始或结束后对乳腺肿瘤大小及范围进行初始影像学评估时采用无静脉对比剂的MRI检查。
* 检查项目: FDG-PET/CT Skull Base to Mid-Thigh / PET/CT躯干
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0020 / R:CR000763
  * 证据强度: StrongReferences
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明: Because of its relatively low specificity, PET/CT is not routinely used for posttreatment imaging of the primary breast tumor and is typically only used in combination with other imaging modalities to monitor treatment response \[52-54] . Two meta-analyses found posttreatment PET/CT sensitivities of 77% to 84% and specificities of 66% to 78% for predicting response to therapy \[52,54]. In a study by Bassa et al \[55], PET was able to accurately predict residual disease in only 75% of cases, compared with 88% for US. However, PET may have use in assessing early response to therapy, with a study in 47 patients showing that a >50% to 60% reduction in FDG uptake after one cycle of therapy correlated with a pCR \[56]. PET imaging may be more helpful for certain tumor subtypes. Three studies showed that PET/CT can reliably detect early response and predict residual disease in HER2/neu-positive tumors \[57-59], and a \<42% decrease in radioisotope uptake in triple-negative tumors correlates with poor response and outcome \[60]. Lobular cancers are less FDG avid, making assessment challenging \[61,62]. 由于特异性相对较低，PET/CT不常规用于原发性乳腺癌的术后影像学评估，通常仅与其他影像学检查联合用于监测治疗反应\[52-54]。两项荟萃分析显示，治疗后PET/CT预测治疗反应的敏感性为77%-84%，特异性为66%-78%\[52,54]。Bassa等\[55]的研究表明，PET准确预测残留病灶的准确率仅为75%，而超声为88%。但PET在评估早期治疗反应方面可能具有价值，一项针对47例患者的研究显示，治疗一个周期后FDG摄取下降>50%-60%与病理完全缓解相关\[56]。PET成像对某些肿瘤亚型可能更具价值。三项研究表明，PET/CT可可靠检测HER2/neu阳性肿瘤的早期反应并预测残留病灶\[57-59]，而三阴性肿瘤放射性同位素摄取下降\<42%与治疗反应差及不良预后相关\[60]。小叶癌对FDG亲和力较低，这使得评估更具挑战性\[61,62]。
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000765
  * 证据强度: StrongReferences
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: In a study of 20 patients who underwent imaging with Tc-99m sestamibi, reduction in tumor size correlated reliably A small study of 62 patients also showed that high uptake after chemotherapy predicts poor survival \[96]. In one study of 122 patients, breast-specific gamma imaging had sensitivity of 74% and specificity of 72% for detection of residual tumor after chemotherapy, but it underestimated the amount of residual disease for tumors of luminal subtype \[97]. In a small study of 49 patients with locally advanced breast cancer, MBI did not accurately predict response to therapy \[98]. In a prospective study of 90 patients, posttreatment MBI had a higher false-negative rate than MRI (41% versus 18%) for predicting pathologic response \[41]. A retrospective study of 114 patients demonstrated that posttreatment MBI had a lower sensitivity than MRI for detecting residual tumor (70% versus 83%). However, MBI was more specific than MRI in determining CR (90% versus 60%) \[99]. At present, there is insufficient literature to support the routine use of Sestamibi MBI in imaging of the breast after initiation or completion of NAC. 一项20例患者行Tc99m甲氧异腈显像的研究显示，肿瘤缩小与显像结果具有可靠相关性。一项62例患者的小型研究亦表明化疗后高摄取提示生存预后较差\[96]。122例患者的研究显示，乳腺专用伽马成像检测化疗后残余肿瘤的敏感性为74%，特异性为72%，但对管腔亚型肿瘤的残余病灶范围存在低估\[97]。一项49例局部晚期乳腺癌患者的小型研究中，MBI未能准确预测治疗反应\[98]。90例患者的前瞻性研究显示，治疗后MBI预测病理反应的假阴性率高于MRI（41% vs 18%）\[41]。114例患者的回顾性研究证明，治疗后MBI检测残余肿瘤的敏感性低于MRI（70% vs 83%），但确定完全缓解的特异性高于MRI（90% vs 60%）\[99]。目前尚无足够文献支持在新辅助化疗开始或完成后常规使用甲氧异腈MBI进行乳腺成像。

##### S0095 Variant: Variant 3:  Adult female or male or transfeminine (male-to-female) or transmasculine (female-to-male). Known breast cancer, clinically node-negative. Axillary evaluation prior to neoadjuvant chemotherapy. Initial imaging. | 成人女性或男性或跨性别女性（男跨女）或跨性别男性（女跨男）。已知乳腺癌，临床淋巴结阴性。新辅助化疗前腋窝评估。初始影像学检查。

检查推荐列表：

* 检查项目: US Axilla / US腋窝淋巴结常规超声检查
  * 评分: 7
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0012 / R:CR000766
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: Current National Comprehensive Cancer Network practice guidelines recommend considering axillary US and possible biopsy before starting NAC, even in clinically node-negative patients \[115,116]. Assessment of the axilla before and after NAC with US can help guide surgical management. US permits routine visualization of stage I and II nodes. By identifying subclinical metastases in clinically node-negative patients, US-guided fine-needle aspiration (FNA) or core needle biopsy (CNB) may select patients who require axillary lymph node dissection \[116]. However, a study of 402 patients with a clinically negative axilla demonstrated that half of patients with abnormal lymph nodes on pretreatment imaging did not require axillary lymph node dissection \[116]. Therefore, pretreatment imaging of the axilla in clinically node-negative patients remains controversial \[4]. 现行美国国家综合癌症网络临床实践指南建议，即使在临床淋巴结阴性患者中，开始新辅助化疗前也应考虑行腋窝超声检查及必要时的活检\[115,116]。新辅助化疗前后通过超声评估腋窝状态有助于指导手术方案制定。超声可常规显示I期和II期淋巴结。对于临床淋巴结阴性患者，超声引导下细针穿刺抽吸(FNA)或空心针穿刺活检(CNB)能检出亚临床转移灶，从而筛选出需行腋窝淋巴结清扫术的患者\[116]。但一项针对402例临床腋窝阴性患者的研究表明，治疗前影像学显示淋巴结异常的患者中，半数最终无需接受腋窝淋巴结清扫\[116]。因此，对于临床淋巴结阴性患者是否需常规进行治疗前腋窝影像学评估仍存在争议\[4]。
* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 2
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000767
  * 证据强度: StrongReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is robust evidence to support MRI for determining the extent of disease in the breast, both before and after NAC \[1,4,31,32,35,36,43,63-66]. Although the axillary lymph nodes are included on MRI, it is only moderately sensitive for the detection of axillary nodal metastasis before and after therapy \[4,112,113]. Therefore, MRI is not Although breast MRI can identify stage I–III and internal mammary lymph nodes, it is only moderately sensitive for detection of nodal metastases \[113]. In a prospective trial of stage I–III breast cancer patients undergoing NAC, MRI was only 65% sensitive for predicting metastases before therapy \[113]. A prospective study of 45 patients found pretreatment MRI to be 97% sensitive and 50% specific in predicting axillary lymph biopsy results \[114]. 有充分证据支持在NAC治疗前后使用MRI确定乳腺疾病范围\[1,4,31,32,35,36,43,6366]。虽然MRI扫描包含腋窝淋巴结，但其在治疗前后检测腋窝淋巴结转移的敏感性仅为中等水平\[4,112,113]。尽管乳腺MRI可识别IIII期及内乳淋巴结，但其对淋巴结转移检测的敏感性一般\[113]。一项针对接受NAC的IIII期乳腺癌患者的前瞻性试验显示，MRI对治疗前转移预测的敏感性仅为65%\[113]。一项包含45例患者的前瞻性研究发现，治疗前MRI预测腋窝淋巴结活检结果的敏感性为97%，特异性为50%\[114]。
* 检查项目: Digital Breast Tomosynthesis Diagnostic / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000768
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of DBT in the initial imaging evaluation of the axilla before NAC. Mammography or DBT is performed for initial diagnosis of the primary breast cancer. This procedure incompletely images the axilla, although pathologically enlarged stage I and II nodes may be included on the lateral and mediolateral oblique projections. 目前尚无相关文献支持在NAC前对腋窝进行初始影像学评估时使用DBT。乳腺X线摄影或DBT主要用于原发性乳腺癌的初步诊断。该检查对腋窝的成像不完整，尽管在侧位和内外斜位投照中可能包含病理学增大的I期和II期淋巴结。
* 检查项目: Mammography Diagnostic / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000768
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of diagnostic mammography in initial imaging evaluation of the axilla before NAC. Mammography or DBT is performed for initial diagnosis of the primary breast cancer. This procedure incompletely images the axilla, although pathologically enlarged stage I and II nodes may be included on the lateral and mediolateral oblique projections. 目前尚无相关文献支持在新辅助化疗（NAC）前对腋窝进行初始影像学评估时采用诊断性乳腺X线摄影。乳腺X线摄影或数字乳腺断层合成（DBT）主要用于原发性乳腺癌的初始诊断。该检查对腋窝的成像不完整，但侧位和内外斜位投照可能包含病理学增大的I期和II期淋巴结。
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000771
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support the use of MRI breast without IV contrast in initial imaging evaluation of the axilla before NAC. 目前尚无相关文献支持在新辅助化疗前腋窝初始影像学评估中使用无静脉对比剂的乳腺MRI检查。
* 检查项目: FDG-PET/CT Skull Base to Mid-Thigh / PET/CT躯干
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0020 / R:CR000769
  * 证据强度: StrongReferences
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明: FDG-PET/CT is not routinely used for initial imaging of the clinically node-negative axilla before NAC because of its low sensitivity and specificity for detecting nodal disease \[4]. In several studies on detection of nodal disease, including a multicenter study of 360 patients, PET had disparate sensitivities (43%-79%) and specificities (66%-93%), possibly related to differences in tumor size in patient populations \[109,110]. Given these limitations, surgical sampling of the axillary nodes remains the standard of care. However, when an FDG-avid axillary node is seen on a pretreatment PET/CT scan, this is highly predictive of metastasis \[111]. FDG-PET/CT不常规用于新辅助化疗前临床淋巴结阴性腋窝的初始影像学评估，因其对淋巴结病变检测的敏感性和特异性较低\[4]。在多项关于淋巴结病变检测的研究中（包括一项360例患者的多中心研究），PET显示出不同的敏感性（43%-79%）和特异性（66%-93%），这可能与患者群体中肿瘤大小的差异有关\[109,110]。鉴于这些局限性，腋窝淋巴结手术取样仍是标准诊疗方法。然而，若治疗前PET/CT扫描发现FDG高摄取腋窝淋巴结，则高度提示转移\[111]。
* 检查项目: US-Guided Core Biopsy Axillary Node / US腋窝淋巴结介入超声检查
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0025 / R:CR000772
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no evidence to support US-guided sampling as the initial imaging test for axillary lymph node evaluation. However, US-guided axillary lymph node sampling is typically the next study performed when axillary imaging is suspicious for metastatic disease. Overall, US-guided biopsy offers a minimally invasive option to obtain histopathologic proof of axillary nodal involvement for suspicious findings, although a negative biopsy does not reliably exclude metastatic disease, and therefore surgical pathology remains the reference standard. When US- guided biopsy confirms metastatic disease in pathologic-appearing nodes, it can obviate the need for pretreatment sentinel node biopsy, because the completion of axillary surgery is typically performed after therapy \[2,117]. 目前尚无证据支持将超声引导下取样作为腋窝淋巴结评估的初始影像学检查。然而，当腋窝影像学检查怀疑转移性疾病时，超声引导下腋窝淋巴结取样通常是下一步进行的检查。总体而言，对于可疑发现，超声引导活检为获取腋窝淋巴结受累的组织病理学证据提供了一种微创选择，但阴性活检结果并不能可靠排除转移性疾病，因此手术病理学仍是金标准。当超声引导活检证实病理表现淋巴结中存在转移性疾病时，可避免治疗前哨淋巴结活检的需要，因为腋窝手术通常在治疗后完成\[2,117]。
* 检查项目: US-Guided Fine Needle Aspiration Biopsy Axillary Node / US腋窝淋巴结介入超声检查
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0025 / R:CR000772
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no evidence to support US-guided sampling as the initial imaging test for axillary lymph node evaluation. However, US-guided axillary lymph node sampling is typically the next study performed when axillary imaging is suspicious for metastatic disease. Overall, US-guided FNA offers a minimally invasive option to obtain histopathologic proof of axillary nodal involvement for suspicious findings, although a negative biopsy does not reliably exclude metastatic disease, and therefore surgical pathology remains the reference standard. When US- guided biopsy confirms metastatic disease in pathologic-appearing nodes, it can obviate the need for pretreatment sentinel node biopsy, because the completion of axillary surgery is typically performed after therapy \[2,117]. 目前尚无证据支持将超声引导下取样作为评估腋窝淋巴结的初始影像学检查。然而，当腋窝影像学检查怀疑转移性疾病时，超声引导下腋窝淋巴结取样通常是下一步进行的检查。总体而言，对于可疑发现，超声引导下细针穿刺活检提供了一种微创选择以获取腋窝淋巴结受累的组织病理学证据，但阴性活检结果并不能可靠排除转移性疾病，因此手术病理学仍是金标准。当超声引导活检证实病理表现淋巴结中存在转移性疾病时，可避免治疗前哨淋巴结活检的需要，因为腋窝手术通常在治疗后完成\[2,117]。

##### S0096 Variant: Variant 4:  Adult female or male or transfeminine (male-to-female) or transmasculine (female-to-male). Known breast cancer, clinically node-positive. Axillary evaluation prior to neoadjuvant chemotherapy. Initial imaging. | 成人女性或男性或跨性别女性（男跨女）或跨性别男性（女跨男）。已知乳腺癌，临床淋巴结阳性。新辅助化疗前腋窝评估。初始影像学检查。

检查推荐列表：

* 检查项目: US Axilla / US腋窝淋巴结常规超声检查
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0012 / R:CR000774
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: Axillary US is routinely performed for pretreatment evaluation of a clinically positive axilla \[4]. Current National Comprehensive Cancer Network practice guidelines recommend axillary US and possible biopsy before starting systemic therapy \[115]. US-guided FNA or CNB can confirm and mark metastatic disease. When US-guided biopsy confirms metastatic disease in pathologic-appearing nodes, it can obviate the need for pretreatment sentinel node biopsy because the completion of axillary surgery is typically performed after therapy \[2,117]. Placing a biopsy clip to mark the metastatic lymph node before therapy can also help guide the type of axillary restaging surgery following NAC \[119]. 腋窝超声检查常规用于临床阳性腋窝的预处理评估\[4]。目前美国国家综合癌症网络实践指南建议在开始全身治疗前进行腋窝超声检查及可能的活检\[115]。超声引导下细针穿刺或空芯针活检可确认并标记转移病灶。当超声引导活检证实病理表现淋巴结中存在转移性疾病时，可避免预处理前哨淋巴结活检的需要，因为腋窝手术通常在治疗后完成\[2,117]。治疗前放置活检夹标记转移淋巴结还有助于指导新辅助化疗后腋窝再分期手术的类型\[119]。
* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 5
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0005 / R:CR000776
  * 证据强度: StrongReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: MRI does not always include the entire axilla and is not routinely used solely for evaluation of axillary lymph nodes. However, contrast-enhanced MRI may be useful for monitoring the breast and axillary response in clinically node- positive patients \[4]. MRI is only moderately sensitive for detection of axillary nodal metastasis before and after therapy \[4,112,113]. Although breast MRI does not always include the entire axilla, it often images stage I–III and internal mammary lymph nodes. In a prospective trial of stage I–III breast cancer patients undergoing NAC, MRI was only 65% sensitive for predicting metastases before therapy \[113]. A prospective study of 45 patients found pretreatment MRI to be 97% sensitive and 50% specific in predicting axillary lymph biopsy results \[114]. MRI并不总是包括整个腋窝区域，且不常规单独用于评估腋窝淋巴结。然而，对于临床淋巴结阳性患者，增强MRI可能有助于监测乳腺及腋窝的治疗反应\[4]。MRI在治疗前后检测腋窝淋巴结转移的敏感性仅为中等水平\[4,112,113]。虽然乳腺MRI不一定覆盖整个腋窝，但常可显示I-III期及内乳区淋巴结。一项针对接受新辅助化疗的I-III期乳腺癌患者的前瞻性试验显示，MRI对治疗前转移灶的预测敏感性仅为65%\[113]。另一项45例患者的前瞻性研究发现，治疗前MRI预测腋窝淋巴结活检结果的敏感性为97%，特异性为50%\[114]。
* 检查项目: FDG-PET/CT Skull Base to Mid-Thigh / PET/CT躯干
  * 评分: 5
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0020 / R:CR000775
  * 证据强度: StrongReferences
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明: FDG-PET/CT may be useful for staging and restaging clinically node-positive patients undergoing NAC \[4]. In node-positive patients, the decrease in standardize uptake value from pre- to posttreatment scans can be used to monitor response and help predict pCR \[116]. This possibly may lead to less aggressive axillary surgery upon completion of chemotherapy rather than complete lymph node dissection \[118]. In several studies on detection of nodal disease, including a multicenter study of 360 patients, PET had disparate sensitivities (43%-79%) and specificities (66%-93%), possibly related to differences in tumor size in patient populations \[109,110]. Given these limitations, surgical sampling of the axillary nodes remains the standard of care. However, when an FDG-avid axillary node is seen on a pretreatment PET/CT scan, this is highly predictive of FDG PET/CT可能有助于对接受新辅助化疗的临床淋巴结阳性患者进行分期和再分期\[4]。对于淋巴结阳性患者，治疗前后扫描标准化摄取值降低可用于监测反应并帮助预测病理学完全缓解\[116]。这可能使化疗完成后采用侵袭性较小的腋窝手术而非完全淋巴结清扫\[118]。在多项淋巴结疾病检测研究中，包括一项360例患者的多中心研究，PET表现出不同的敏感性（43%79%）和特异性（66%93%），可能与患者群体肿瘤大小差异有关\[109,110]。鉴于这些局限性，腋窝淋巴结手术取样仍是标准诊疗。然而，当治疗前PET/CT扫描显示FDG高摄取腋窝淋巴结时，这高度提示
* 检查项目: Digital Breast Tomosynthesis Diagnostic / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000777
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of DBT in the initial imaging evaluation of the axilla before NAC. Mammography or DBT is performed for initial diagnosis of the primary breast cancer. This procedure incompletely images the axilla, although pathologically enlarged stage I and II nodes may be included on the lateral and mediolateral oblique projections. 目前尚无相关文献支持在NAC前对腋窝进行初始影像学评估时使用DBT。乳腺X线摄影或DBT主要用于原发性乳腺癌的初步诊断。该检查对腋窝的成像不完整，尽管在侧位和内外斜位投照中可能包含病理学增大的I期和II期淋巴结。
* 检查项目: Mammography Diagnostic / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000777
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of diagnostic mammography in initial imaging evaluation of the axilla before NAC. Mammography or DBT is performed for initial diagnosis of the primary breast cancer. This procedure incompletely images the axilla, although pathologically enlarged stage I and II nodes may be included on the lateral and mediolateral oblique projections. 目前尚无相关文献支持在新辅助化疗（NAC）前对腋窝进行初始影像学评估时采用诊断性乳腺X线摄影。乳腺X线摄影或数字乳腺断层合成（DBT）主要用于原发性乳腺癌的初始诊断。该检查对腋窝的成像不完整，但侧位和内外斜位投照可能包含病理学增大的I期和II期淋巴结。
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000779
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support the use of MRI breast without IV contrast in initial imaging evaluation of the axilla before NAC. 目前尚无相关文献支持在新辅助化疗前腋窝初始影像学评估中使用无静脉对比剂的乳腺MRI检查。
* 检查项目: US-Guided Core Biopsy Axillary Node / US腋窝淋巴结介入超声检查
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0025 / R:CR000780
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no evidence to support US-guided sampling as the initial imaging test for axillary lymph node evaluation. However, US-guided axillary lymph node sampling is typically the next study performed when axillary imaging is suspicious for metastatic disease. Overall, US-guided biopsy offers a minimally invasive option to obtain histopathologic proof of axillary nodal involvement for suspicious findings, although a negative biopsy does not reliably exclude metastatic disease, and therefore surgical pathology remains the reference standard. When US- guided biopsy confirms metastatic disease in pathologic-appearing nodes, it can obviate the need for pretreatment sentinel node biopsy, because the completion of axillary surgery is typically performed after therapy \[2,117]. 目前尚无证据支持将超声引导下取样作为腋窝淋巴结评估的初始影像学检查。然而，当腋窝影像学检查怀疑转移性疾病时，超声引导下腋窝淋巴结取样通常是下一步进行的检查。总体而言，对于可疑发现，超声引导活检为获取腋窝淋巴结受累的组织病理学证据提供了一种微创选择，但阴性活检结果并不能可靠排除转移性疾病，因此手术病理学仍是金标准。当超声引导活检证实病理表现淋巴结中存在转移性疾病时，可避免治疗前哨淋巴结活检的需要，因为腋窝手术通常在治疗后完成\[2,117]。
* 检查项目: US-Guided Fine Needle Aspiration Biopsy Axillary Node / US腋窝淋巴结介入超声检查
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0025 / R:CR000780
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no evidence to support US-guided sampling as the initial imaging test for axillary lymph node evaluation. However, US-guided axillary lymph node sampling is typically the next study performed when axillary imaging is suspicious for metastatic disease. Overall, US-guided FNA offers a minimally invasive option to obtain histopathologic proof of axillary nodal involvement for suspicious findings, although a negative biopsy does not reliably exclude metastatic disease, and therefore surgical pathology remains the reference standard. When US- guided biopsy confirms metastatic disease in pathologic-appearing nodes, it can obviate the need for pretreatment sentinel node biopsy, because the completion of axillary surgery is typically performed after therapy \[2,117]. 目前尚无证据支持将超声引导下取样作为评估腋窝淋巴结的初始影像学检查。然而，当腋窝影像学检查怀疑转移性疾病时，超声引导下腋窝淋巴结取样通常是下一步进行的检查。总体而言，对于可疑发现，超声引导下细针穿刺活检提供了一种微创选择以获取腋窝淋巴结受累的组织病理学证据，但阴性活检结果并不能可靠排除转移性疾病，因此手术病理学仍是金标准。当超声引导活检证实病理表现淋巴结中存在转移性疾病时，可避免治疗前哨淋巴结活检的需要，因为腋窝手术通常在治疗后完成\[2,117]。

##### S0097 Variant: Variant 5:  Adult female or male or transfeminine (male-to-female) or transmasculine (female-to-male). Known breast cancer, clinically node-negative. Axillary evaluation after completion of neoadjuvant chemotherapy, axilla not previously evaluated. Initial imaging. | 成人女性或男性或跨性别女性（男跨女）或跨性别男性（女跨男）。已知乳腺癌，临床淋巴结阴性。新辅助化疗完成后腋窝评估，腋窝既往未评估。初始影像学检查。

检查推荐列表：

* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 2
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000783
  * 证据强度: StrongReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: The current literature evaluates performance of posttreatment MRI evaluation of the axilla only in the setting of baseline pretreatment imaging and/or clinically node-positive patients, as described below. These data cannot necessarily be extrapolated to initial imaging after completion of therapy in the absence of pretreatment axillary evaluation. MRI of the axilla is only 38% to 61% sensitive for detection of residual disease after NAC \[112,113]; therefore, surgical sampling is the standard of care \[114,120-122]. In a retrospective study of 135 clinically node-positive patients after NAC, MRI had a low negative predictive value (NPV) of 26% for predicting axillary disease when a positive MRI was defined by node >1 cm, cortex >3 mm, loss of hilum, or irregular contour \[121]. In a retrospective study of 269 node-positive patients, posttreatment MRI was only 38% sensitive, 76% specific, and 58% accurate in predicting the pathology of the sentinel lymph node (SLN). In a prospective study of 45 patients, 35 of whom were node-positive, there was no association between posttreatment axillary MRI and surgical pathology; MRI had a high false negative rate (46%), low sensitivity (55%), and specificity (63%) \[114]. 现有文献仅在基线治疗前影像学和/或临床淋巴结阳性患者背景下评估治疗后腋窝MRI的表现，如下所述。这些数据未必能外推至治疗完成后缺乏治疗前腋窝评估的初始影像学检查。对于新辅助化疗（NAC）后残留病灶的检测，腋窝MRI的敏感性仅为38%至61%\[112,113]；因此手术取样仍是标准诊疗方案\[114,120-122]。一项针对135例NAC后临床淋巴结阳性患者的回顾性研究显示，当阳性MRI定义为淋巴结>1cm、皮质>3mm、门部结构消失或轮廓不规则时，MRI预测腋窝病变的阴性预测值（NPV）低至26%\[121]。另一项269例淋巴结阳性患者的回顾性研究表明，治疗后MRI在预测前哨淋巴结（SLN）病理状态的敏感性仅38%，特异性76%，准确率58%。一项45例患者（其中35例为淋巴结阳性）的前瞻性研究显示，治疗后腋窝MRI与手术病理无相关性；MRI具有高假阴性率（46%）、低敏感性（55%）和特异性（63%）\[114]。
* 检查项目: FDG-PET/CT Skull Base to Mid-Thigh / PET/CT躯干
  * 评分: 2
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0020 / R:CR000782
  * 证据强度: StrongReferences
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明: PET/CT is not routinely used for evaluation of the axilla after NAC as data are limited \[4]. In several studies on detection of nodal disease, including a multicenter study of 360 patients, PET had disparate sensitivities (43%-79%) and specificities (66%-93%), possibly related to differences in tumor size in patient populations \[109,110]. Given these limitations, this modality is not particularly useful to evaluate the axilla, and surgical sampling of the axillary nodes remains the standard of care. However, when an FDG-avid axillary node is seen on a pretreatment PET/CT scan, this is highly predictive of metastasis \[111]. In addition, in node-positive tumors, PET/CT can be used to monitor response and possibly lead to sentinel node biopsy upon completion of chemotherapy rather than full axillary dissection \[118]. PET/CT不常规用于新辅助化疗后腋窝评估，因相关数据有限\[4]。多项关于淋巴结病变检测的研究（包括一项360例患者的多中心研究）显示，PET灵敏度差异显著（43%-79%），特异性波动较大（66%-93%），可能与研究人群的肿瘤大小差异有关\[109,110]。鉴于这些局限性，该检查对腋窝评估价值有限，手术淋巴结取样仍是标准方案。但若治疗前PET/CT显示FDG高摄取腋窝淋巴结，则高度提示转移\[111]。此外，对于淋巴结阳性肿瘤，PET/CT可用于监测治疗效果，在化疗完成后可能引导实施前哨淋巴结活检而非全腋窝清扫\[118]。
* 检查项目: US Axilla / US腋窝淋巴结常规超声检查
  * 评分: 2
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0012 / R:CR000784
  * 证据强度: StrongReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: US is not typically performed for initial evaluation of the axilla after initiation of NAC, and the current literature does not specifically evaluate this scenario. The literature on posttreatment axillary US predicting residual nodal disease evaluates patients with established node-positive disease before therapy, as described below. These data cannot necessarily be extrapolated to initial imaging after therapy in the absence of pretreatment axillary evaluation. No imaging test can reliably detect residual nodal disease after NAC, and therefore surgical sampling is the standard of care. In established node-positive patients after therapy, axillary US only demonstrates moderate sensitivity (53%-86%) and specificity (78%) for detecting residual disease with an NPV ranging from 46% to 90% \[112,123,124]. Therefore, surgical sampling of axillary lymph nodes after therapy remains the standard of care. In a retrospective study of 408 clinically node-positive breast cancer patients treated with NAC, the strongest predictor for residual axillary disease was preoperative US showing axillary lymphadenopathy, defined as axial cortical thickness >3.5 mm or loss of the hilum \[125]. The prospective clinical Z1071 trial included 611 patients with US after NAC; US features associated with residual disease included increased cortical thickness (mean 3.5 US通常不用于NAC开始后腋窝的初始评估，并且当前文献并未专门评估这种情况。关于治疗后腋窝US预测残留淋巴结病变的文献评估的是治疗前已确诊淋巴结阳性的患者，如下所述。这些数据不一定能外推至缺乏治疗前腋窝评估情况下治疗后的初始成像。没有任何影像学检查能够可靠地检测NAC后的残留淋巴结病变，因此手术取样是护理标准。在治疗后已确诊的淋巴结阳性患者中，腋窝US对于检测残留病变仅显示出中等敏感性（53%86%）和特异性（78%），NPV范围从46%到90%\[112,123,124]。因此，治疗后腋窝淋巴结的手术取样仍然是护理标准。在一项对408例接受NAC治疗的临床淋巴结阳性乳腺癌患者的回顾性研究中，残留腋窝病变的最强预测因素是术前US显示腋窝淋巴结病，定义为腋窝皮质厚度≥3.5毫米或门部结构消失\[125]。前瞻性临床Z1071试验纳入了611例NAC后接受US检查的患者；与残留病变相关的US特征包括皮质增厚（平均3.5
* 检查项目: Digital Breast Tomosynthesis Diagnostic / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000785
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Mammography or DBT is performed for initial diagnosis of the primary breast cancer. This procedure incompletely images the axilla, although pathologically enlarged stage I and II nodes may be included on the lateral and mediolateral oblique projections. 乳腺X线摄影或数字乳腺断层合成摄影用于原发性乳腺癌的初始诊断。该检查对腋窝成像不完全，但病理学上增大的I期和II期淋巴结可能包含在侧位和内外斜位投照中。
* 检查项目: Mammography Diagnostic / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000785
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of diagnostic mammography in initial imaging of the axilla after NAC \[4]. Mammography or DBT is performed for initial diagnosis of the primary breast cancer. This procedure incompletely images the axilla, although pathologically enlarged stage I and II nodes may be included on the lateral and mediolateral oblique projections. 目前尚无相关文献支持在NAC（新辅助化疗）后腋窝初始影像学检查中使用诊断性乳腺X线摄影\[4]。乳腺X线摄影或数字乳腺断层合成摄影（DBT）主要用于原发性乳腺癌的初始诊断。该检查对腋窝的成像不完整，尽管在侧位和内外斜位投照中可能包含病理增大的I期和II期淋巴结。
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000787
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support the use of MRI breast without IV contrast in initial imaging of the axilla after NAC. 目前尚无相关文献支持在NAC后腋窝初始影像学检查中使用无静脉对比剂的乳腺MRI。
* 检查项目: US-Guided Core Biopsy Axillary Node / US腋窝淋巴结介入超声检查
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0025 / R:CR000788
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support the use of US-guided core biopsy of axillary nodes in initial imaging of the axilla after completion of NAC. 目前尚无相关文献支持在完成新辅助化疗（NAC）后腋窝初始影像学检查中使用超声引导下腋窝淋巴结粗针穿刺活检。
* 检查项目: US-Guided Fine Needle Aspiration Biopsy Axillary Node / US腋窝淋巴结介入超声检查
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0025 / R:CR000788
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support the use of US-guided FNA of axillary nodes in initial imaging of the axilla after completion of NAC. 目前尚无相关文献支持在完成新辅助化疗后，将超声引导下腋窝淋巴结细针穿刺活检作为腋窝初始影像学检查手段。

##### S0098 Variant: Variant 6:  Adult female or male or transfeminine (male-to-female) or transmasculine (female-to-male). Known breast cancer with clinical suspicion of metastatic disease. Staging or assessment of response to neoadjuvant chemotherapy. Initial imaging. | 成人女性或男性或跨性别女性（男跨女）或跨性别男性（女跨男）。已知乳腺癌伴临床疑似转移性疾病。分期或评估新辅助化疗反应。初始影像学检查。

检查推荐列表：

* 检查项目: CT chest abdomen pelvis with IV contrast / CT胸部(增强),CT全腹部(增强),CT盆腔(增强)
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0027 / R:CR000791
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明: CT chest abdomen pelvis with IV contrast is usually appropriate for adult patients with known breast cancer and clinical suspicion of metastatic disease when staging or assessing response to neoadjuvant chemotherapy during initial imaging evaluation. This modality provides comprehensive cross-sectional assessment of thoracic, abdominal, and pelvic compartments, allowing for detection of distant metastases and evaluation of treatment response in known sites of disease. The intravenous contrast enhancement improves lesion detection and characterization, particularly for visceral organ involvement. While CT offers excellent spatial resolution and rapid acquisition, limitations include radiation exposure and potential need for additional imaging for characterization of indeterminate lesions. This technique serves as a foundational staging tool but may be supplemented by other modalities based on specific clinical concerns or findings. 对于已知乳腺癌且临床怀疑转移性疾病的成年患者，在初始影像学评估中进行新辅助化疗的分期或反应评估时，CT胸部腹部盆腔增强扫描通常是合适的。该模态提供胸、腹、盆腔的全面横断面评估，能够检测远处转移并评估已知病灶的治疗反应。静脉对比剂增强可改善病灶检测和特征描述，特别是对于内脏器官受累。虽然CT具有出色的空间分辨率和快速采集的优点，但局限性包括辐射暴露以及可能需要对不确定病灶进行额外成像以进行特征描述。该技术作为基础分期工具，可根据具体临床关注点或发现辅以其他模态。
* 检查项目: FDG-PET/CT Skull Base to Mid-Thigh / PET/CT躯干
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0020 / R:CR000792
  * 证据强度: StrongReferences
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明: Staging of patients before and after treatment typically entails either 1) FDG-PET/CT skull base to mid-thigh only or 2) bone scan in conjunction with CT chest, abdomen, and pelvis with IV contrast, depending upon institutional preference. There is no evidence to support performing all 3 studies. PET/CT combines cross-sectional imaging with tumor metabolism and has been shown to be more sensitive and accurate than conventional staging with combined CT and bone scan \[127]. Staging with PET/CT detects distant metastases with a sensitivity of 50% to 100% and a specificity of 50% to 97% in patients with advanced breast cancers, some of which were occult on conventional CT imaging. In one study by Lee et al, the detection of distant metastases occult on conventional CT imaging led to changes in clinical stage for 52% of women \[129]. Given that 8% to 14% of women with locally advanced breast cancer have distant metastatic disease at diagnosis (beyond the axillary nodes), FDG-PET/CT skull base to mid-thigh may be preferred over conventional CT imaging \[130] . In addition, several studies have shown FDG-PET/CT to be superior in detecting internal mammary and mediastinal lymphadenopathy \[129] but inferior to contrast-enhanced chest CT at detecting pulmonary metastases \[130] . Multiple studies show that PET/CT staging is more useful for stage IIIB and operable stage IIIA tumors and specific tumor subtypes including invasive ductal cancers, ER-negative and triple-negative tumors, high-grade malignancies, and those with p53 mutations \[131-133]. PET/CT staging is not as useful for low-grade malignancies or invasive lobular cancers because of the overall low isotope uptake \[134]. 治疗前后的患者分期通常采用以下两种方式之一：1) 仅进行颅底至大腿中段的FDG-PET/CT检查；2) 骨扫描联合静脉增强胸部、腹部和盆腔CT检查，具体选择取决于机构偏好。目前尚无证据支持同时进行这三项检查。PET/CT将断层成像与肿瘤代谢相结合，已被证明比传统CT联合骨扫描的分期方式更敏感、更准确\[127]。在晚期乳腺癌患者中，PET/CT分期检测远处转移的敏感性为50%至100%，特异性为50%至97%，其中部分转移灶在传统CT检查中呈隐匿性。Lee等人的一项研究表明，通过PET/CT发现传统CT未能检出的隐匿性远处转移，导致52%的女性患者临床分期发生改变\[129]。鉴于8%至14%的局部晚期乳腺癌患者在确诊时已发生腋窝淋巴结以外的远处转移，颅底至大腿中段的FDG-PET/CT检查可能优于传统CT成像\[130]。此外，多项研究显示FDG-PET/CT在检测内乳和纵隔淋巴结病变方面更具优势\[129]，但在检测肺转移方面逊于增强胸部CT\[130]。大量研究表明，PET/CT分期对IIIB期和可手术IIIA期肿瘤以及特定亚型（包括浸润性导管癌、ER阴性和三阴性肿瘤、高级别恶性肿瘤及存在p53突变的肿瘤）更具临床价值\[131-
* 检查项目: Bone Scan Whole Body / SPECT全身骨显像
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0029 / R:CR000790
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明: Staging of patients before and after treatment typically entails either 1) FDG-PET/CT skull base to mid-thigh only or 2) bone scan in conjunction with CT chest, abdomen, and pelvis with IV contrast, depending upon institutional preference. There is no evidence to support performing all 3 studies. Bone scan represents one of the standard imaging tests to stage a patient with newly diagnosed breast cancer, allowing assessment of bony metastasis. PET/CT combines cross-sectional imaging with tumor metabolism and has been shown to be more sensitive and accurate than conventional staging with combined CT and bone scan \[127]. 治疗前后的患者分期通常包括以下两种方式之一：1) 仅进行颅底至大腿中段的FDG-PET/CT检查；或2) 根据医疗机构偏好，联合进行骨扫描与静脉增强的胸部、腹部及盆腔CT检查。目前无证据支持需要同时进行全部三项检查。骨扫描作为新诊断乳腺癌患者的标准影像学检查之一，可用于评估骨转移情况。PET/CT将断层成像与肿瘤代谢信息相结合，研究\[127]表明其敏感性及准确性均优于传统CT联合骨扫描的分期方法。
* 检查项目: CT chest abdomen pelvis without IV contrast / CT胸部(平扫),CT全腹部(平扫),CT盆腔(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0030 / R:CR000794
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明:
* 检查项目: CT chest abdomen pelvis without and with IV contrast / CT胸部(平扫+增强),CT全腹部(平扫+增强),CT盆腔(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0028 / R:CR000793
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢☢ 10-30 mSv \[ped]
  * 推荐说明:
* 检查项目: MRI Chest, Abdomen, Pelvis Without IV Contrast / MR胸部腹部盆腔(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0034 / R:CR000796
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support the use of MRI chest, abdomen, and pelvis without IV contrast in the initial evaluation of metastatic disease. 目前尚无相关文献支持在转移性疾病的初始评估中使用无静脉造影的胸部、腹部和盆腔MRI。
* 检查项目: MRI Chest, Abdomen, Pelvis Without and With IV Contrast / MR胸部腹部盆腔(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0033 / R:CR000795
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support the use of MRI chest, abdomen, and pelvis without and with IV contrast 目前尚无相关文献支持使用不注射及注射静脉对比剂的胸部、腹部和盆腔 MRI。

##### S0099 Variant: Variant 7:  Adult female or male or transfeminine (male-to-female) or transmasculine (female-to-male). Known axillary lymph node-positive breast cancer on prior mammography, US, or MRI. Axillary evaluation after completion of neoadjuvant chemotherapy, axilla previously evaluated. Next imaging study. | 成人女性或男性或跨性别女性（男跨女）或跨性别男性（女跨男）。既往乳腺X线摄影、US或MRI已知腋窝淋巴结阳性乳腺癌。新辅助化疗完成后腋窝评估，腋窝既往已评估。下一步影像学检查。

检查推荐列表：

* 检查项目: US Axilla / US腋窝淋巴结常规超声检查
  * 评分: 8
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0012 / R:CR000797
  * 证据强度: ModerateReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: If the axilla is imaged after NAC, US is the most useful imaging modality, although it only demonstrates moderate sensitivity (53%-86%) and specificity (78%) for detecting residual disease \[112,124]. Therefore, surgical sampling of axillary lymph nodes after therapy remains the standard of care. US permits image-guided localization of the clipped metastatic axillary lymph node if the patient is undergoing sentinel node biopsy with surgical excision of the clipped node. The axilla is most commonly imaged after NAC in patients with a clinically positive axilla before therapy \[4]. In a retrospective study of 408 clinically node-positive breast cancer patients treated with NAC, the strongest predictor of residual axillary disease was posttreatment US showing axillary lymphadenopathy, defined as axial cortical thickness >3.5 mm or loss of the hilum \[125]. The prospective clinical Z1071 trial included 611 patients with US after NAC, 238 of whom had axillary CR. US features associated with residual disease included increased cortical 若在新辅助化疗后对腋窝进行影像学评估，超声是最有效的影像学方法，但其检测残留病灶仅具有中等敏感性（53%86%）和特异性（78%）\[112,124]。因此治疗后腋窝淋巴结的手术采样仍是标准诊疗方案。若患者正接受前哨淋巴结活检及标记淋巴结手术切除，超声可实现影像引导下的标记转移性腋窝淋巴结定位。临床上治疗前腋窝阳性患者最常在新辅助化疗后接受腋窝影像学检查\[4]。一项针对408例接受新辅助化疗的临床淋巴结阳性乳腺癌患者的回顾性研究显示，治疗后超声显示腋窝淋巴结病（定义为皮质轴向厚度≥3.5mm或淋巴门结构消失）是残留腋窝病变的最强预测因子\[125]。前瞻性临床Z1071试验纳入了611例新辅助化疗后接受超声检查的患者，其中238例达到腋窝完全缓解。与残留病变相关的超声特征包括皮质增厚
* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 3
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000799
  * 证据强度: StrongReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: MRI is not routinely used for evaluation of the axilla after completion of NAC because it is only 38% to 61% sensitive for detecting residual axillary disease \[112-114,120-122]. No imaging test can reliably detect residual nodal disease after NAC, and therefore surgical sampling is the standard of care. Use of MRI for restaging the axilla in clinically node-positive patients is questionable \[4]. In a retrospective study of 135 clinically node-positive patients who underwent NAC, MRI evaluation of the axilla after treatment had a low NPV (26%) and therefore could not predict residual axillary disease when a positive MRI of the axilla was defined as node >1 cm, cortex >3 mm, loss of hilum, or irregular contour \[121]. In a retrospective study of 269 node-positive patients, postchemotherapy MRI was only 38% sensitive, 76% specific, and 58% accurate in predicting the pathology result of the SLN. In a prospective study of 45 patients, 35 of whom were node-positive, there was no association between posttreatment axillary MRI findings and surgical pathology; MRI had a high false negative rate (46%), low sensitivity (55%), and specificity (63%) \[114]. MRI不常规用于新辅助化疗（NAC）后腋窝评估，因其检测残留腋窝病灶的敏感性仅为38%至61%\[112-114,120-122]。目前尚无影像学检查能可靠检出NAC后残留淋巴结转移，因此手术取样仍是标准诊疗方案。对于临床淋巴结阳性患者，采用MRI进行腋窝再分期存在争议\[4]。一项纳入135例临床淋巴结阳性NAC患者的回顾性研究显示，治疗后腋窝MRI评估的阴性预测值较低（26%），当将阳性MRI定义为淋巴结>1cm、皮质>3mm、门部结构消失或轮廓不规则时，无法准确预测残留腋窝病灶\[121]。另一项269例淋巴结阳性患者的回顾性研究表明，化疗后MRI预测前哨淋巴结病理结果的敏感性仅38%、特异性76%、准确率58%。一项45例患者（其中35例淋巴结阳性）的前瞻性研究显示，治疗后腋窝MRI表现与手术病理无相关性，MRI假阴性率高达46%，敏感性55%，特异性63%\[114]。
* 检查项目: FDG-PET/CT Skull Base to Mid-Thigh / PET/CT躯干
  * 评分: 3
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0020 / R:CR000798
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢☢ 10-30 mSv
  * Peds RRL: ☢☢☢☢ 3-10 mSv \[ped]
  * 推荐说明: PET/CT is not routinely used to evaluate the axilla after completion of NAC. Although a few studies suggest that PET can reliably predict the response of axillary nodes early in treatment, a majority of studies show that PET has low sensitivity (63%) for detection of residual disease after NAC \[112,135]. No imaging test can reliably detect residual nodal disease after NAC, and therefore surgical sampling is the standard of care. PET/CT不常规用于新辅助化疗（NAC）后腋窝评估。尽管少数研究表明PET可在治疗早期可靠预测腋窝淋巴结反应，但多数研究显示PET对NAC后残留病灶检测敏感性较低（63%）\[112,135]。目前尚无影像学检查能可靠检测NAC后残留淋巴结病变，因此手术取样仍是标准诊疗方案。
* 检查项目: Digital Breast Tomosynthesis Diagnostic / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000800
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Although many patients undergo mammography or DBT after NAC, there is no specific evidence supporting its use in the imaging of known axillary lymph node-positive breast cancer after completion of therapy. The axilla is incompletely visualized on the mediolateral and lateral projections, thereby limiting the use of these modalities to reliably detect residual disease. 尽管许多患者在新辅助化疗后接受乳腺X线摄影或数字乳腺断层合成摄影检查，但目前尚无具体证据支持其在治疗完成后用于已知腋窝淋巴结阳性乳腺癌的影像学评估。在内外侧位和侧位投照中，腋窝区域显示不完全，因此限制了这些方法在可靠检测残留病灶方面的应用。
* 检查项目: Mammography Diagnostic / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000800
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Although many patients undergo mammography or DBT after NAC, there is no specific evidence supporting its use in the imaging of known axillary lymph node-positive breast cancer after completion of therapy \[4]. The axilla is incompletely visualized on the mediolateral and lateral projections, thereby limiting the use of these modalities to reliably detect residual disease. 尽管许多患者在NAC后接受乳腺X线摄影或DBT检查，但尚无具体证据支持其在治疗完成后用于已知腋窝淋巴结阳性乳腺癌的影像学检查\[4]。在内外侧和外侧投照位上，腋窝区域显示不完全，因此限制了这些方法在可靠检测残留病灶方面的应用。
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000802
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support the use of MRI breast without IV contrast in the imaging of known axillary lymph node-positive breast cancer after completion of NAC. 目前尚无相关文献支持在完成新辅助化疗后，对已知腋窝淋巴结阳性乳腺癌患者使用无静脉对比剂的乳腺MRI进行影像学检查。
* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0003 / R:CR000803
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support the use of breast US alone in the evaluation of known axillary lymph node- positive disease after completion of NAC. However, some studies have shown a correlation between pCR in the breast and the axilla \[136]. 目前尚无相关文献支持在完成新辅助化疗后仅使用乳腺超声评估已知腋窝淋巴结阳性病变。然而，部分研究表明乳腺与腋窝的病理完全缓解存在相关性\[136]。
* 检查项目: US-Guided Core Biopsy Axillary Node / US腋窝淋巴结介入超声检查
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0025 / R:CR000804
  * 证据强度: StrongReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support the use of US-guided core biopsy of the axillary node in imaging of known axillary lymph node-positive breast cancer after completion of NAC. No imaging test can reliably detect residual nodal disease after NAC; therefore, surgical intervention (either sentinel node biopsy or axillary dissection) is necessary after completion of treatment, provided the patient demonstrated a PR or CR warranting surgery and did not undergo axillary surgery before treatment \[112,137]. Some centers place a clip in the biopsied positive axillary node before treatment so that it can be surgically excised along with the sentinel node(s) after completion of the NAC; this procedure is sometimes referred to as targeted axillary dissection \[138]. US-guided localization of the clipped lymph node can be performed preoperatively \[139] . Excising the clipped lymph node and SLN(s) decreases the false-negative rate of SLN biopsy (SLNB) \[140]. In a study of 31 patients, 11 patients had residual axillary disease, and, in all cases, the clipped lymph node was positive \[141]. In a prospective study of 23 patients with clipped axillary metastases before NAC, the surgeon retrieved the clipped node in 22 cases, and the SLN was retrieved in only 19. The clipped node was the SLN in only 14 cases (61%). The NPV was 100% for removal of clipped and sentinel node but only 85% for SLN removal alone \[119]. 目前尚无相关文献支持在完成新辅助化疗（NAC）后，对已知腋窝淋巴结阳性乳腺癌患者行超声引导下腋窝淋巴结空心针活检以评估影像学表现。现有影像学检查均无法可靠检测NAC后残留的淋巴结病灶；因此，若患者达到部分缓解（PR）或完全缓解（CR）需接受手术且治疗前未行腋窝手术，则完成NAC后仍需进行外科干预（前哨淋巴结活检或腋窝淋巴结清扫）\[112,137]。部分医疗中心会在治疗前对活检阳性的腋窝淋巴结放置标记夹，以便NAC完成后与哨淋巴结一并手术切除；该操作有时被称为靶向腋窝淋巴结清扫术\[138]。术前可采用超声引导对标记淋巴结进行定位\[139]。切除标记淋巴结及前哨淋巴结可降低前哨淋巴结活检（SLNB）的假阴性率\[140]。一项涉及31例患者的研究显示，11例存在腋窝病灶残留的患者中，标记淋巴结均为阳性\[141]。另一项针对23例NAC前接受腋窝转移灶标记的前瞻性研究表明，外科医生成功切除22例的标记淋巴结，而前哨淋巴结仅成功切除19例。标记淋巴结与前哨淋巴结重合的病例仅14例（61%）。同时切除标记淋巴结和前哨淋巴结的阴性预测值（NPV）达100%，而单独切除前哨淋巴结的NPV仅为85%\[119]。
* 检查项目: US-Guided Fine Needle Aspiration Biopsy Axillary Node / US腋窝淋巴结介入超声检查
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0025 / R:CR000804
  * 证据强度: StrongReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support the use of US-guided FNA of the axillary node in imaging of known axillary lymph node-positive breast cancer after completion of NAC. No imaging test can reliably detect residual nodal disease after NAC; therefore, surgical intervention (either sentinel node biopsy or axillary dissection) is necessary after completion of neoadjuvant treatment, provided the patient demonstrated a PR or CR warranting surgery and did not undergo axillary surgery before treatment \[112,137]. Some centers place a clip in the biopsied positive axillary node before treatment so that it can be surgically excised along with the sentinel node(s) after completion of the NAC; this procedure is sometimes referred to as targeted axillary dissection \[138]. US-guided localization of the clipped lymph node can be performed preoperatively \[139] . Excising the clipped lymph node and SLN(s) decreases the false-negative rate of SLNB \[140]. In a study of 31 patients, 11 patients had residual axillary disease, and, in all cases, the clipped lymph node was positive \[141]. In a prospective study of 23 patients with clipped axillary metastases before NAC, the surgeon retrieved the clipped node in 22 cases, and the SLN was retrieved in only 19. The clipped node was the SLN in only 14 cases (61%). The NPV was 100% for removal of clipped and sentinel node but only 85% for SLN removal alone \[119]. 目前尚无相关文献支持在完成新辅助化疗（NAC）后，对已知腋窝淋巴结阳性的乳腺癌患者使用超声引导下细针穿刺抽吸（US-guided FNA）进行影像学评估。现有影像学检查均无法可靠检测NAC后残留的淋巴结病灶，因此在新辅助治疗完成后（前提是患者达到部分缓解或完全缓解需接受手术且治疗前未行腋窝手术）必须进行外科干预（前哨淋巴结活检或腋窝淋巴结清扫）\[112,137]。部分医疗中心会在治疗前对活检阳性的腋窝淋巴结放置标记夹，以便在NAC完成后与哨淋巴结一并手术切除，该操作有时被称为靶向腋窝淋巴结清扫术\[138]。术前可采用超声引导对标记淋巴结进行定位\[139]。切除标记淋巴结及前哨淋巴结可降低前哨淋巴结活检的假阴性率\[140]。一项涉及31例患者的研究显示，11例存在腋窝病灶残留的患者中，标记淋巴结均为阳性\[141]。另一项针对23例NAC前接受腋窝转移灶标记的前瞻性研究表明，外科医生成功切除22例患者的标记淋巴结，而前哨淋巴结仅成功切除19例。标记淋巴结与前哨淋巴结重合的病例仅14例（61%）。同时切除标记淋巴结和前哨淋巴结的阴性预测值达100%，而单独切除前哨淋巴结仅为85%\[119]。

##### S0100 Variant: Variant 8:  Adult female or male or transfeminine (male-to-female) or transmasculine (female-to-male). Known breast cancer. Axillary imaging suspicious for metastatic disease on mammography, US, or MRI during initial evaluation. Next imaging study. | 成人女性或男性或跨性别女性（男跨女）或跨性别男性（女跨男）。已知乳腺癌。初次评估中乳腺X线摄影、US或MRI提示腋窝影像疑似转移性疾病。下一步影像学检查。

检查推荐列表：

* 检查项目: US-Guided Core Biopsy Axillary Node / US腋窝淋巴结介入超声检查
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0025 / R:CR000806
  * 证据强度: StrongReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: US-guided axillary lymph node sampling is the most useful next study performed when axillary imaging is suspicious for metastatic disease \[4]. Sampling of abnormal-appearing nodes by CNB is typically performed using a 14- to 18-gauge device. Some centers place a clip in the biopsied node to facilitate future image-guided localization of the lymph node at surgical excision after completion of NAC. US-guided CNB has proven high specificity, with a moderate to high sensitivity in the detection of metastatic lymph nodes. Houssami et al \[33] published a meta-analysis of 2,874 FNA and CNB procedures and found a pooled sensitivity of 80%, a specificity of 98%, and a positive predictive value of 97%. Another meta-analysis of 1,353 patients undergoing axillary lymph node biopsy to detect metastases showed that both CNB and FNA procedures performed well, with sensitivities of 74% and 88%, respectively, and a specificity of 100% for both procedures. Complication rates with US-guided biopsies were low, although slightly higher for CNB when compared with FNA (7% versus 1%, respectively), and most commonly included pain, hematoma, and bruising \[142]. Some centers place a clip in the biopsied positive axillary node before treatment so that it can be surgically excised along with the sentinel node(s) after completion of the NAC; this procedure is sometimes referred to as targeted axillary dissection \[138]. US-guided localization of the clipped lymph node can be performed preoperatively \[139] . Excising the clipped lymph node and SLNs decreases the false-negative rate of SLNB \[26]. In a study of 31 patients, 11 patients had residual axillary disease, and, in all cases, the clipped lymph node was positive \[141]. In a prospective study of 23 patients with clipped axillary metastases before NAC, the surgeon retrieved the clipped node in 22 cases, and the SLN was retrieved in only 19. The clipped node was the SLN in only 14 cases (61%). The NPV was 100% for removal of clipped and sentinel nodes but only 85% for SLN removal alone \[119]. Overall, US-guided biopsy offers a minimally invasive option to obtain histopathologic proof of axillary nodal involvement for suspicious findings, although a negative biopsy does not reliably exclude metastatic disease, and therefore surgical pathology remains the reference standard. When US-guided biopsy confirms metastatic disease in pathologic-appearing nodes, it can obviate the need for pretreatment sentinel node biopsy because the completion of axillary surgery is typically performed after therapy \[2,117]. 当腋窝影像学检查怀疑转移性疾病时，超声引导下腋窝淋巴结取样是最有用的后续检查\[4]。对形态异常的淋巴结通常使用14至18号针具进行空芯针活检。部分中心会在完成新辅助化疗后，在已活检的淋巴结中放置标记夹，以便后续在手术切除时进行影像引导下的淋巴结定位。超声引导空芯针活检已被证明具有高特异性，以及中至高度的转移性淋巴结检测敏感性。Houssami等\[33]发表了一项包含2,874例细针抽吸和空芯针活检程序的荟萃分析，汇总敏感性为80%，特异性为98%，阳性预测值为97%。另一项针对1,
* 检查项目: US-Guided Fine Needle Aspiration Biopsy Axillary Node / US腋窝淋巴结介入超声检查
  * 评分: 8
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0025 / R:CR000806
  * 证据强度: StrongReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: US-guided axillary lymph node sampling is the most useful next study performed when axillary imaging is suspicious for metastatic disease \[4]. Sampling of abnormal-appearing lymph nodes by US-guided FNA is frequently performed with a 22- or 25-gauge needle and also requires the availability of skilled cytopathologists. False-negative rates are low (\< 2%) in experienced hands but may occur, especially with smaller metastatic deposits \[143]. Some centers place a clip in the biopsied node to facilitate future image-guided localization of the lymph node at surgical excision after completion of NAC. US-guided axillary FNA has proven high specificity, with a moderate to high sensitivity in the detection of metastatic lymph nodes. A retrospective study of 65 patients compared US-guided FNA results to final surgical pathology in patients with radiographically suspicious lymph nodes and demonstrated high sensitivity, specificity, and positive predicative value (89%, 100% and 100%, respectively) for FNA \[144]. A larger meta-analysis of 1,353 patients undergoing axillary lymph node biopsy to detect metastases showed that both FNA and CNB performed well, with sensitivities of 74% and 88%, respectively, and a specificity of 100% for both procedures. Complication rates for FNA were lower than CNB (1% versus 7%, respectively) and were most commonly pain, hematoma, and bruising \[142]. Additionally, one prospective study of combined axillary US and FNA in 315 patients with sonographically positive lymph nodes again demonstrated high sensitivity (81%), specificity (100%), and positive predictive value (100%). However, the NPV was low (50%), supporting the need for definitive surgical sampling \[145]. Some centers place a clip in the biopsied positive axillary node before treatment so that it can be surgically excised axillary dissection \[138]. US-guided localization of the clipped lymph node can be performed preoperatively \[139] . Excising the clipped lymph node and SLNs decreases the false-negative rate of SLNB \[26]. In a study of 31 patients, 11 patients had residual axillary disease, and, in all cases, the clipped lymph node was positive \[141]. In a prospective study of 23 patients with clipped axillary metastases before NAC, the surgeon retrieved the clipped node in 22 cases, and the SLN was retrieved in only 19. The clipped node was the SLN in only 14 cases (61%). The NPV was 100% for removal of clipped and sentinel node but only 85% for SLN removal alone \[119]. Overall, US-guided biopsy offers a minimally invasive option to obtain histopathologic proof of axillary nodal involvement for suspicious findings, although a negative biopsy does not reliably exclude metastatic disease, and therefore surgical pathology remains the reference standard. When US-guided biopsy confirms metastatic disease in pathologic-appearing nodes, it can obviate the need for pretreatment sentinel node biopsy because the completion of axillary surgery is typically performed after completion of therapy \[2,117]. 当腋窝影像学检查怀疑转移性疾病时，超声引导下腋窝淋巴结取样是最有用的后续检查\[4]。通常使用22或25号针进行超声引导下细针抽吸活检对异常表现的淋巴结进行取样，并且需要熟练的细胞病理学家支持。在经验丰富的操作者手中假阴性率较低（\<2%），但仍可能发生，特别是在转移灶较小时\[143]。一些中心会在活检淋巴结中放置标记夹，以便在新辅助化疗完成后手术切除时进行影像引导下的淋巴结定位。超声引导下腋窝细针抽吸活检已被证明具有高特异性，以及中等到高度的转移淋巴结检测敏感性。一项对65例患者的回顾性研究将超声引导下细针抽吸活检结果与影像学可疑淋巴结患者的最终手术病理学进行了比较，显示细针抽吸活检具有高敏感性、特异性和阳性预测值（分别为89%、100%和100%）\[144]。一项包含1,353例接受腋窝淋巴结活检以检测转移灶患者的更大规模荟萃分析显示，细针抽吸活检和空芯针活检均表现良好，敏感性分别为74%和88%，两种方法的特异性均为100%。细针抽吸活检的并发症率低于空芯针活检（分别为1% versus 7%），最常见的是疼痛、血肿和瘀斑\[142]。此外，一项对315例超声阳性淋巴结患者联合腋窝超声和细针抽吸活检的前瞻性研究再次证明了高敏感性（81%）、特异性（100%）和阳性预测值（100%）。然而，阴性预测值较低（50%），支持需要进行明确的手术取样\[145]。一些中心在治疗前于活检阳性的腋窝淋巴结中放置标记夹，以便在腋窝清扫术中手术切除\[138]。术前可进行超声引导下标记淋巴结的定位\[139]。切除标记淋巴结和前哨淋巴结可降低前哨淋巴结活检的假阴性率\[26]。在一项涉及31例患者的研究中，11例患者有残留腋窝疾病，且所有病例中标记淋巴结均为阳性\[141]。在一项对23例新辅助化疗前放置标记的腋窝转移患者的前瞻性研究中，外科医生在22例中取出了标记淋巴结，而仅19例中取出了前哨淋巴结。仅14例（61%）中标记淋巴结即为前哨淋巴结。联合切除标记淋巴结和前
* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 2
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000808
  * 证据强度: StrongReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support the use of MRI breast with IV contrast in the further evaluation of axillary There is robust evidence to support MRI for determining extent of disease in the breast, both before and after NAC \[1,4,31,32,35,36,43,63-66]. Although the axillary lymph nodes are included on MRI, it is only moderately sensitive for detection of axillary nodal metastasis before and after therapy \[4,112,113]. 目前尚无相关文献支持使用增强 MRI 乳腺检查对腋窝进行进一步评估。有充分证据表明，MRI 可用于确定乳腺癌新辅助化疗（NAC）前后的疾病范围\[1,4,31,32,35,36,43,6366]。虽然 MRI 扫描范围包含腋窝淋巴结，但其在治疗前后检测腋窝淋巴结转移的敏感性仅为中等水平\[4,112,113]。
* 检查项目: Digital Breast Tomosynthesis Diagnostic / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000809
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of DBT in further evaluation of axillary imaging suspicious for metastatic disease. Mammography or DBT is performed for initial diagnosis of the primary breast cancer. This procedure incompletely images the axilla, although pathologically enlarged stage I and II nodes may be included on the lateral and mediolateral oblique projections. 目前尚无相关文献支持使用数字乳腺断层摄影（DBT）对疑似转移性疾病的腋窝影像进行进一步评估。乳腺X线摄影或DBT主要用于原发性乳腺癌的初始诊断。该检查对腋窝的成像不完整，尽管在侧位和内外斜位投照中可能包含病理学上增大的I期和II期淋巴结。
* 检查项目: Mammography Diagnostic / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000809
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of diagnostic mammography in further evaluation of axillary imaging suspicious for metastatic disease. Mammography or DBT is performed for initial diagnosis of the primary breast cancer. This procedure incompletely images the axilla, although pathologically enlarged stage I and II nodes may be included on the lateral and mediolateral oblique projections. 目前尚无相关文献支持在进一步评估疑似转移性疾病的腋窝影像时使用诊断性乳腺X线摄影。乳腺X线摄影或数字乳腺断层合成（DBT）主要用于原发性乳腺癌的初步诊断。该检查对腋窝的成像不完整，尽管在侧位和中外斜位投照中可能包含病理增大的I期和II期淋巴结。
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000811
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support the use of MRI breast without IV contrast in the further evaluation of imaging suspicious for metastatic disease. 目前尚无相关文献支持在疑似转移性疾病的进一步影像学评估中使用无静脉对比剂的乳腺MRI检查。

#### T0015 Palpable Breast Masses | 可触及乳腺肿块

* 主题编码: T0015

##### S0101 Variant: Variant 1:  Adult female, 40 years of age or older. Palpable breast mass. Initial imaging. | 女性成人，≥40岁，可触及乳腺肿块，初始影像学检查。

检查推荐列表：

* 检查项目: Digital Breast Tomosynthesis Diagnostic / MG双侧乳腺钼靶
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0010 / R:CR000812
  * 证据强度: StrongReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Diagnostic digital breast tomosynthesis (DBT) should be used for initial imaging evaluation. A small radio-opaque marker is placed on the skin over the palpable finding to identify its location. Several prior studies have shown the diagnostic accuracy of DBT is equivalent to or better than supplemental diagnostic mammographic views in the workup of women with clinical signs and symptoms and in women recalled from screening \[11-14]. The added features of planar imaging and thin-section reconstructions allow further assessment of potential false-positive findings. In a recent study, DBT provided similarly accurate diagnostic results as compared with digital mammography (DM) in women with palpable breast masses for detecting breast cancer using either combination DM with DBT (DM/DBT) or DM alone \[15]. Several small studies, which specifically included women presenting with clinical symptoms including palpable lumps, demonstrated increased accuracy on combination DM/DBT compared with DM alone \[13,16,17]. Additionally, it was demonstrated that DBT may improve lesion detection and characterization with higher conspicuity scores as compared with conventional DM imaging, particularly for cancers presenting as spiculated masses and distortions \[17]. 诊断性数字乳腺断层合成（DBT）应作为初始影像学评估手段。在可触及病灶的皮肤表面放置小型不透X线标记物以定位其位置。多项前期研究表明，对于出现临床症状的女性及筛查召回女性的检查中，DBT的诊断准确性与补充诊断性乳腺X线摄影相当或更优\[11-14]。其平面成像与薄层重建的附加功能可进一步评估潜在的假阳性发现。近期一项研究显示，在可触及乳腺肿块女性中，无论采用DBT联合数字乳腺X线摄影（DM/DBT）或单独DM，DBT对乳腺癌检测的诊断准确性均与DM相当\[15]。多项专门纳入包括可触及肿块等临床症状女性的小型研究表明，与单独DM相比，DM/DBT联合检查可提高诊断准确性\[13,16,17]。此外，研究证实与传统DM成像相比，DBT可提高病灶检出率和特征描述能力，尤其对表现为毛刺状肿块及结构扭曲的癌症具有更高的显像评分\[17]。
* 检查项目: Mammography Diagnostic / MG双侧乳腺钼靶
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0010 / R:CR000812
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Mammography should be using for initial imaging of a palpable breast mass in women ≥40 years of age. It is performed under the direct supervision of a radiologist and usually consists at a minimum of craniocaudal and mediolateral oblique views of each breast, enabling screening of the entire breast for additional lesions. The mammogram may only include the ipsilateral breast if the patient has had a recent bilateral mammogram (within the last 3 to 6 months). A small radio-opaque marker is placed on the skin over the palpable finding to identify its location. Spot compression views obtained with or without magnification or tangential views are often obtained to specifically evaluate the clinical finding. Supplemental mammographic views may also be needed to clarify the features or location of a mammographic lesion, including craniocaudal exaggerated, cleavage, step-oblique, and 90° lateral views. In several series evaluating palpable breast abnormalities \[18-20], the sensitivity of mammography alone was 86% modality may be particularly useful in women with almost entirely fatty breasts, in which mammography alone was shown to have a high sensitivity (96%) and specificity (93%) in the evaluation of palpable breast masses \[22]. 乳腺X线摄影应用于≥40岁女性可触及乳腺肿块的初始影像学检查。该检查在放射科医师直接监督下进行，通常至少包括每侧乳腺的头尾位和内外斜位投照，能够对整个乳腺进行额外病灶筛查。若患者近期（过去3至6个月内）已行双侧乳腺X线摄影，则可仅拍摄同侧乳腺。需在可触及病灶表面的皮肤放置小型不透X线标记物以定位其位置。常采用点压摄影（伴或不伴放大）或切线位投照以特异性评估临床发现。可能需要补充投照体位以明确乳腺X线病灶的特征或位置，包括头尾位外延位、乳沟位、阶梯斜位和90°侧位。多项评估可触及乳腺异常的研究系列\[1820]显示，单纯乳腺X线摄影的敏感性为86%。该检查对几乎完全脂肪型乳腺的女性尤其有效，研究\[22]表明单纯乳腺X线摄影对此类人群可触及乳腺肿块的评估具有高敏感性（96%）和特异性（93%）。
* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 5
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0003 / R:CR000814
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: US may be considered as an initial means of imaging if the patient has had a recent negative mammogram within the past 6 months. In a study of women presenting with a palpable breast mass with a negative mammogram within the previous 6 to 12 months, US detected a finding in 50.3% of 311 cases, whereas repeat mammography detected a change in 12.9% of cases \[21]. US is more frequently used following DBT/mammography in this age group \[2,26] (see Variants 2, 3, and 5). The negative predictive value of mammography with US in the context of a palpable mass ranges from 97.4% to 100% \[7-9]. 若患者在过去6个月内乳腺X线检查结果为阴性，可考虑将超声作为初始影像学检查手段。一项针对近期（6-12个月内）乳腺X线检查阴性但触及乳腺肿块女性的研究表明，在311例病例中超声检出异常占50.3%，而重复乳腺X线检查仅发现12.9%的病例存在变化\[21]。该年龄段更常在DBT/乳腺X线检查后使用超声\[2,26]（参见方案2、3和5）。对于可触及肿块患者，乳腺X线联合超声检查的阴性预测值范围为97.4%至100%\[7-9]。
* 检查项目: Mammography Screening / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000812
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: In women presenting with signs or symptoms, including a palpable breast mass, screening mammography is not useful as the initial imaging study. Screening mammography is provided to women without signs or symptoms of breast disease. 对于出现体征或症状（包括可触及的乳房肿块）的女性，筛查性乳腺X线摄影不宜作为初始影像学检查手段。筛查性乳腺X线摄影适用于无乳腺疾病体征或症状的女性群体。
* 检查项目: Digital Breast Tomosynthesis Screening / MG双侧乳腺钼靶(筛查)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0001 / R:CR000815
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: In women presenting with signs or symptoms, including a palpable breast mass, screening DBT, with or without DM, is not useful as the initial imaging study. Screening mammography is provided to women without signs or symptoms of breast disease. 对于出现体征或症状（包括可触及的乳房肿块）的女性，筛查数字乳腺断层合成（DBT）联合或不联合数字乳腺X线摄影（DM）作为初始影像学检查并无临床价值。筛查性乳腺X线摄影适用于无乳腺疾病体征或症状的女性。
* 检查项目: MRI breast without IV contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000821
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明:
* 检查项目: MRI breast without and with IV contrast / MR乳腺(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000820
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明:
* 检查项目: FDG-PET Breast Dedicated / PET/CT局部(胸部)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0016 / R:CR000816
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of fluorine-18-2-fluoro-2-deoxy-D-glucose (FDG)-PET breast dedicated in the initial evaluation of a woman presenting with a palpable mass \[2]. 目前尚无相关文献支持在女性出现可触及肿块初步评估时使用氟-18-2-氟-2-脱氧-D-葡萄糖（FDG）专用乳腺PET检查\[2]。
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000822
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of Tc-99m sestamibi molecular breast imaging (MBI) in the initial evaluation of a woman presenting with a palpable mass. 目前尚无相关文献支持在女性可触及肿块的初步评估中使用锝-99m甲氧基异丁基异腈（Tc-99m sestamibi）分子乳腺成像（MBI）。
* 检查项目: Image-Guided Core Biopsy Breast / 影像引导下乳腺穿刺活检术
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0013 / R:CR000817
  * 证据强度: Expert Consensus
  * Adult RRL: Varies
  * Peds RRL: Varies
  * 推荐说明: There is no relevant literature to support the use of image-guided core biopsy in the initial evaluation of a woman presenting with a palpable mass. Because many breast masses may not exhibit distinctive physical findings, imaging evaluation is necessary in almost all patients ≥40 years of age to characterize the palpable lesion and screen the remainder of each breast for additional lesions. It is preferable for imaging to occur before biopsy because changes related to the biopsy may confuse, alter, obscure, and/or limit image interpretation. However, negative imaging evaluation should not deter biopsy when a strongly suspicious finding is present on physical examination. There is no relevant literature to support the use of image-guided core biopsy in the initial evaluation of women ≥40 years of age with palpable mass. 目前尚无相关文献支持在初次评估可触及肿块女性患者时使用影像引导下的空心针穿刺活检。由于许多乳腺肿块可能缺乏特征性体格检查表现，几乎所有40岁及以上患者均需进行影像学评估，以明确可触及肿块的性质并对双侧乳腺其余部位进行筛查以发现其他病变。活检前进行影像学检查更为可取，因为活检相关改变可能混淆、改变、掩盖和/或限制影像学解读。然而，当体格检查存在高度可疑发现时，阴性影像学评估结果不应妨碍活检的进行。目前尚无相关文献支持对40岁及以上可触及肿块女性患者的初次评估采用影像引导下的空心针穿刺活检。
* 检查项目: Image-Guided Fine Needle Aspiration Breast / 影像引导下乳腺细针穿刺抽吸
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0014 / R:CR000818
  * 证据强度: Expert Consensus
  * Adult RRL: Varies
  * Peds RRL: Varies
  * 推荐说明: There is no relevant literature to support the use of image-guided fine needle aspiration (FNA) in the initial evaluation of a woman presenting with a palpable mass. Because many breast masses may not exhibit distinctive physical findings, imaging evaluation is necessary in almost all cases to characterize the palpable lesion and screen the remainder of each breast for additional lesions. It is preferable for imaging to occur before biopsy because changes related to the biopsy may confuse, alter, obscure, and/or limit image interpretation. There is no relevant literature to support the use of the use of image-guided FNA biopsy (FNAB) in the initial evaluation of women ≥40 years of age with palpable mass. 目前尚无相关文献支持在初次评估女性可触及肿块时采用影像引导下的细针穿刺抽吸术（FNA）。由于许多乳腺肿块可能缺乏特异性体格检查表现，绝大多数病例仍需通过影像学检查来明确可触及病灶的特征，并对双侧乳腺其余部位进行额外病灶筛查。建议在活检前完成影像学检查，因为活检相关改变可能导致影像解读出现混淆、改变、模糊和/或受限。针对40岁及以上女性可触及肿块的初次评估，尚无相关文献支持采用影像引导下的细针穿刺活检（FNAB）。

##### S0102 Variant: Variant 2:  Adult female, 40 years of age or older. Palpable breast mass. Mammography findings are suspicious or highly suggestive of malignancy (BI-RADS 4 or 5). Next imaging study. | 成人女性，≥40岁，可触及乳腺肿块，乳腺X线摄影检查结果可疑或高度提示恶性（BIRADS 4或5类），下一步影像学检查。

检查推荐列表：

* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0003 / R:CR000823
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: US may be helpful in characterizing a suspicious mammographic finding \[33]. In a study of women presenting with palpable breast thickening, the sensitivity of diagnostic mammography for invasive cancer detection was 60%, whereas the sensitivity of US alone was 100% \[34]. Breast US should be performed using a high-resolution, real-time linear array scanner with an adjustable focal zone and a transducer with a minimum center frequency of 12 MHz \[35]. Some mammographers also perform screening US of the remainder of the ipsilateral breast and the contralateral breast in the setting of a suspicious finding \[33]. If there is no sonographic correlate for a suspicious mammographic finding, tissue sampling (stereotactic biopsy) should be guided by the suspicious mammographic finding. If there is no sonographic correlate for a suspicious DBT finding, tissue sampling (tomosynthesis-guided biopsy) should be guided by the suspicious DBT finding. 超声可能有助于鉴别可疑的乳腺X线摄影发现\[33]。在一项针对可触及乳腺增厚女性的研究中，诊断性乳腺X线摄影对浸润性癌检测的敏感性为60%，而单独使用超声的敏感性为100%\[34]。乳腺超声检查应使用具有可调聚焦区的高分辨率实时线阵扫描仪，换能器中心频率至少为12 MHz\[35]。部分乳腺影像医师在发现可疑病变时，还会对同侧乳腺剩余部分及对侧乳腺进行筛查性超声检查\[33]。若可疑乳腺X线摄影发现无超声对应表现，应以乳腺X线摄影可疑发现指导组织取样（立体定位活检）。若可疑DBT（数字乳腺断层合成）发现无超声对应表现，应以DBT可疑发现指导组织取样（断层合成引导活检）。
* 检查项目: MRI breast without IV contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000828
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明:
* 检查项目: MRI breast without and with IV contrast / MR乳腺(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000827
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明:
* 检查项目: FDG-PET Breast Dedicated / PET/CT局部(胸部)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0016 / R:CR000824
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of FDG-PET breast dedicated as the next step in evaluating a palpable mass in the context of a suspicious mammographic finding \[2]. 目前尚无相关文献支持在乳腺X线摄影检查结果可疑的情况下，将FDG-PET乳腺专用显像作为评估可触及肿块的下一步检查手段\[2]。
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000829
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of the use of Tc-99m sestamibi MBI as the next step in evaluating a palpable mass in the context of a suspicious mammographic finding. 目前尚无相关文献支持在乳腺X线摄影检查结果可疑的情况下，将锝-99m甲氧基异丁基异腈（MIBI）显像作为触诊肿块评估的后续检查手段。
* 检查项目: Image-Guided Core Biopsy Breast / 影像引导下乳腺穿刺活检术
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0013 / R:CR000825
  * 证据强度: LimitedReferences
  * Adult RRL: Varies
  * Peds RRL: Varies
  * 推荐说明: It is preferable for imaging to occur before biopsy because changes related to the biopsy may confuse, alter, obscure, and/or limit image interpretation. If a mammographically suspicious lesion is identified that correlates with the palpable mass, US is recommended as the next step in evaluation before image-guided core biopsy is pursued. However, the lack of sonographic correlate should not deter biopsy of a suspicious mammographic or DBT abnormality in this setting. Core biopsy is superior to FNAB in terms of sensitivity, specificity, and correct histological grading of palpable masses \[27]. In addition, core biopsy allows for ready evaluation of tumor receptor status. When a mammographically or DBT-detected suspicious lesion is identified that correlates with a palpable mass, biopsy is warranted. If a lesion is only identified on mammography or DBT, mammographically or DBT- guided core biopsy may be pursued \[28,29]. If the lesion can be seen with US, US-guided biopsy may be pursued \[30]. At image-guided biopsy, a marker clip is placed, and a postbiopsy diagnostic mammogram confirms that the US and mammographic findings correlate. Similarly, a postbiopsy DBT confirms that the US and DBT findings correlate. US-guided core biopsy is also usually more easily tolerated because of a lack of breast compression and may allow biopsy of lesions difficult to access stereotactically (eg, far posterior lesions or axillary lesions) \[30]. 影像学检查最好在活检前进行，因为活检相关改变可能干扰、改变、掩盖和/或限制影像学判读。若发现与可触及肿块对应的乳腺X线可疑病灶，建议在影像引导下空心针活检前先进行超声评估。但在此情况下，缺乏超声对应表现不应妨碍对乳腺X线或数字乳腺断层合成摄影（DBT）可疑异常的活检。对于可触及肿块，空心针活检在敏感性、特异性及正确组织学分级方面均优于细针抽吸活检\[27]。此外，空心针活检便于评估肿瘤受体状态。当乳腺X线或DBT检测到与可触及肿块对应的可疑病灶时，应进行活检。若病灶仅在乳腺X线或DBT上显现，可采用乳腺X线或DBT引导下空心针活检\[28,29]。若病灶可通过超声显示，则可行超声引导下活检\[30]。影像引导活检时应放置标记夹，活检后诊断性乳腺X线摄影需确认超声与乳腺X线表现相符。同理，活检后DBT需确认超声与DBT表现一致。超声引导空心针活检通常耐受性更佳（因无需压迫乳房），且可对立体定位困难的病灶（如位置深在或腋窝病灶）进行活检\[30]。
* 检查项目: Image-Guided Fine Needle Aspiration Breast / 影像引导下乳腺细针穿刺抽吸
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0014 / R:CR000826
  * 证据强度: LimitedReferences
  * Adult RRL: Varies
  * Peds RRL: Varies
  * 推荐说明: It is preferable for imaging to occur before biopsy because changes related to the biopsy may confuse, alter, obscure, and/or limit image interpretation. If a mammographically suspicious lesion is identified that correlates with the palpable mass, US is recommended as the next step in evaluation before image-guided FNA is pursued. However, the lack of sonographic correlate should not deter biopsy of a suspicious mammographic or DBT abnormality in this setting. Core biopsy is superior to FNAB in terms of sensitivity, specificity, and correct histological grading of palpable masses \[27]. In addition, core biopsy allows for ready evaluation of tumor receptor status. An additional consideration of FNAB over a core biopsy may be the faster turnover time for a pathology diagnosis without a difference in time to treatment \[31]. At US-guided FNA, a marker clip is placed and a postprocedure mammogram confirms that the US and mammographic findings correlate. Similarly, a postprocedure DBT confirms that the US 影像学检查宜在活检前进行，因为活检相关改变可能干扰、改变、掩盖和/或限制影像学解读。若发现与可触及肿块对应的乳腺X线可疑病变，建议在影像引导下细针抽吸活检前先行超声评估。但在此情况下，缺乏超声对应征象不应阻碍对乳腺X线或数字乳腺断层合成摄影可疑异常的活检。就可触及肿块而言，空心针活检在敏感性、特异性及正确组织学分级方面优于细针抽吸活检\[27]。此外，空心针活检便于评估肿瘤受体状态。选择细针抽吸活检的另一考量可能是病理诊断周转时间更快，且不影响治疗启动时间\[31]。超声引导下细针抽吸活检时需放置标记夹，术后乳腺X线摄影确认超声与乳腺X线表现对应关系。同理，术后数字乳腺断层合成摄影需确认超声——

##### S0103 Variant: Variant 3:  Adult female, 40 years of age or older. Palpable breast mass. Diagnostic mammography, DBT, and US findings are probably benign (BI-RADS 3). Next imaging study. | 女性成人，≥40岁，可触及乳腺肿块，诊断性乳腺X线摄影、DBT和US检查结果可能良性（BIRADS 3类），下一步影像学检查。

检查推荐列表：

* 检查项目: Image-Guided Core Biopsy Breast / 影像引导下乳腺穿刺活检术
  * 评分: 3
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0013 / R:CR000830
  * 证据强度: LimitedReferences
  * Adult RRL: Varies
  * Peds RRL: Varies
  * 推荐说明: If a palpable mass has probably benign features as identified on mammogram and/or US, imaging follow-up may be appropriate. However, if a mass is new on imaging or increasing by >20% in volume or >20% in each diameter in a 6-month period, the mass is considered suspicious, and image-guided biopsy is recommended \[36]. Core biopsy is superior to FNAB in terms of sensitivity, specificity, and correct histological grading of palpable masses \[27]. In addition, there are certain cases in which biopsy may be performed even on probably benign lesions. For example, BI-RADS 3 lesions in high-risk patients, patients awaiting organ transplant, patients with known synchronous cancers, or patients trying to get pregnant may be appropriate for tissue sampling. In addition, situations in which biopsy may alleviate extreme patient anxiety may prompt tissue sampling \[30,37]. If an image-guided biopsy is pursued, a marker clip is placed and a postbiopsy mammogram/DBT confirms that the clip placement and mammographic/DBT findings correlate. 若乳腺X线摄影和/或超声检查显示可触及肿块可能为良性特征，影像学随访可能是合适的。然而，若影像学检查发现新发肿块，或在6个月内体积增长超过20%或各径线增长超过20%，则该肿块视为可疑，建议进行影像引导下活检\[36]。对于可触及肿块，核心活检在敏感性、特异性及正确组织学分级方面均优于细针穿刺活检\[27]。此外，某些情况下即使病变可能为良性也可能需要活检，例如高风险患者的BI-RADS 3类病变、等待器官移植的患者、已知存在同步癌症的患者或计划妊娠的患者可能适合进行组织取样。另外，若活检能显著缓解患者极度焦虑的情况，也可考虑进行组织取样\[30,37]。若实施影像引导下活检，需放置标记夹并术后行乳腺X线摄影/数字乳腺断层合成摄影（DBT）以确认标记夹位置与影像学表现相符。
* 检查项目: Image-Guided Fine Needle Aspiration Breast / 影像引导下乳腺细针穿刺抽吸
  * 评分: 2
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0014 / R:CR000831
  * 证据强度: LimitedReferences
  * Adult RRL: Varies
  * Peds RRL: Varies
  * 推荐说明: If a palpable mass has probably benign features as identified on mammogram and/or US, imaging follow-up may be appropriate. However, if a mass is new on imaging or increasing by >20% in volume or >20% in each diameter in a 6-month period, image-guided biopsy is recommended \[36]. In addition, there are certain cases in which biopsy may be performed even on probably benign lesions. For example, BI-RADS 3 lesions in high-risk patients, patients awaiting organ transplant, patients with known synchronous cancers, or patients trying to get pregnant may be appropriate for tissue sampling. In addition, situations in which biopsy may alleviate extreme patient anxiety may prompt tissue sampling \[30,37]. Large series have demonstrated core biopsy is superior to FNAB in terms of sensitivity, specificity, and correct histological grading of palpable masses \[27]. In addition, core biopsy allows for ready evaluation of tumor receptor status. FNAB; however, may allow a faster turnover time as compared with core biopsy for a pathology diagnosis without a difference in time to treatment \[31]. At image-guided FNA, a marker clip is placed and a postprocedure mammogram/DBT confirms that the marker clip and mammographic/DBT findings correlate. 若乳腺X线摄影和/或超声检查显示可触及肿块可能为良性特征，影像学随访可能是合适的。然而，若影像学检查发现新发肿块，或在6个月内体积增长超过20%或各径线增长超过20%，则建议进行影像引导下活检\[36]。此外，某些情况下即使病变可能为良性也可能需要活检。例如，高风险患者的BI-RADS 3类病变、等待器官移植的患者、已知存在同步癌症的患者或计划怀孕的患者可能适合进行组织取样。另外，活检可能缓解患者极度焦虑的情况也可促使进行组织取样\[30,37]。大型研究系列表明，对于可触及肿块，核心活检在敏感性、特异性及正确组织学分级方面优于细针抽吸活检（FNAB）\[27]。此外，核心活检便于评估肿瘤受体状态。然而，与核心活检相比，FNAB可能缩短病理诊断的周转时间，但治疗开始时间无差异\[31]。在影像引导下进行FNA时，需放置标记夹，并在术后通过乳腺X线摄影/数字乳腺断层合成摄影（DBT）确认标记夹与影像学表现相符。
* 检查项目: MRI breast without IV contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000834
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明:
* 检查项目: MRI breast without and with IV contrast / MR乳腺(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000833
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明:
* 检查项目: FDG-PET Breast Dedicated / PET/CT局部(胸部)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0016 / R:CR000832
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of FDG-PET breast dedicated as the next step in evaluating a palpable mass in the context of a probably benign mammographic finding for women ≥40 years of age \[2]. 目前尚无相关文献支持在40岁及以上女性乳腺X线摄影检查结果可能为良性但触及肿块的情况下，将专用乳腺FDG-PET作为下一步评估手段\[2]。
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000835
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of the use of Tc-99m sestamibi MBI as the next step in evaluating a palpable mass in the context of a probably benign mammographic finding for women ≥40 years of age. 目前尚无相关文献支持在40岁及以上女性乳腺X线检查结果可能为良性但触及肿块的情况下，将锝-99m甲氧基异丁基异腈（MIBI）显像作为下一步评估手段。

##### S0104 Variant: Variant 4:  Adult female, 40 years of age or older. Palpable breast mass. Mammography findings are benign (BI-RADS 2) at the site of palpable mass. Next imaging study. | 女性成人，≥40岁，可触及乳腺肿块，乳腺X线摄影检查于可触及肿块处显示良性表现（BIRADS 2类），下一步影像学检查。

检查推荐列表：

* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 5
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0003 / R:CR000836
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: When the mammogram shows a definite benign mass (eg, lymph node, hamartoma, lipoma, calcified fibroadenoma, or oil cyst), US is not necessary as long as the benign mass identified on mammography is a definitive correlate of the clinical finding. If correlation between the mammographic finding and the palpable lesion is uncertain, US is useful. US is preferably targeted specifically to the palpable finding \[33]. When both mammography and US are negative or benign in the evaluation of a palpable breast mass, the negative predictive value exceeds 97% \[8,9,38]. Together, these imaging modalities can be reassuring when the physical examination is not highly suspicious and clinical follow-up is planned. However, a suspicious physical examination should prompt biopsy regardless of benign imaging findings \[38]. 当乳腺X线摄影显示明确的良性肿块（如淋巴结、错构瘤、脂肪瘤、钙化性纤维腺瘤或油性囊肿）时，只要X线检查所见的良性肿块与临床检查结果明确对应，则无需进行超声检查。若X线检查结果与可触及肿块的相关性不确定，超声检查则具有应用价值。建议超声检查应针对性针对可触及的病灶进行\[33]。在评估可触及乳腺肿块时，若乳腺X线摄影和超声检查结果均为阴性或良性，其阴性预测值超过97%\[8,9,38]。当体格检查未高度怀疑恶性且计划进行临床随访时，这两种影像学检查结果可提供可靠依据。然而，若体格检查结果可疑，即使影像学检查显示良性，也应立即进行活检\[38]。
* 检查项目: MRI breast without IV contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000841
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明:
* 检查项目: MRI breast without and with IV contrast / MR乳腺(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000840
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明:
* 检查项目: FDG-PET Breast Dedicated / PET/CT局部(胸部)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0016 / R:CR000837
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of FDG-PET breast dedicated as the next step in evaluating a palpable mass in the context of a benign mammographic finding \[2]. 目前尚无相关文献支持在乳腺X线检查结果为良性的情况下，将FDG-PET乳腺专用显像作为评估可触及肿块的下一步检查手段\[2]。
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000842
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of Tc-99m sestamibi MBI as the next step in evaluating a palpable mass in the context of a benign mammographic finding. 目前尚无相关文献支持在乳腺X线检查结果为良性的情况下，将锝-99m甲氧基异丁基异腈（MIBI）显像作为评估可触及肿块的后续检查手段。
* 检查项目: Image-Guided Core Biopsy Breast / 影像引导下乳腺穿刺活检术
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0013 / R:CR000838
  * 证据强度: Expert Consensus
  * Adult RRL: Varies
  * Peds RRL: Varies
  * 推荐说明: There is no relevant literature to support the use of image-guided core biopsy breast as the next step in evaluating a palpable mass in the context of a benign mammographic finding. 目前尚无相关文献支持在乳腺X线检查结果为良性的情况下，将影像引导下空心针穿刺活检作为评估可触及肿块的下一步检查手段。
* 检查项目: Image-Guided Fine Needle Aspiration Breast / 影像引导下乳腺细针穿刺抽吸
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0014 / R:CR000839
  * 证据强度: Expert Consensus
  * Adult RRL: Varies
  * Peds RRL: Varies
  * 推荐说明: There is no relevant literature to support the use of image-guided FNAB as the next step in evaluating a palpable mass in the context of a benign mammographic finding. However, image-guided aspiration can be considered for symptomatic relief of a palpable simple cyst. 目前尚无相关文献支持在乳腺影像学检查结果为良性时，将影像引导下的细针抽吸活检作为评估可触及肿块的下一步措施。然而，对于可触及的单纯性囊肿，可考虑采用影像引导下的抽吸术以缓解症状。

##### S0105 Variant: Variant 5:  Adult female, 40 years of age or older. Palpable breast mass. Mammography findings are negative (BI-RADS 1). Next imaging study. | 成人女性，≥40岁，可触及乳腺肿块，乳腺X线摄影检查结果阴性（BIRADS 1类），下一步影像学检查。

检查推荐列表：

* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0003 / R:CR000843
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: A major advantage of US is the ability to directly correlate the clinical and imaging findings. The use of multiple modalities in diagnosing palpable masses has been advocated as a measure to increase the true-positive rate. In 3 series evaluating palpable breast abnormalities \[18-20], the sensitivity of mammography was 86% to 91%. The addition of US detects 93% to 100% of cancers \[8,9,19]. The addition of US to mammography may also improve detection of a benign etiology for a palpable finding and may also identify lesions that are mammographically occult \[26]. In a series, 40% of benign palpable masses were identified only on US \[20]. In another study of 375 palpable masses in 320 women, 68.8% of the masses (n = 258) were only identified with US and were typically oval (n = 275, 73.3%) and hypoechoic (n = 336 in 372 US examinations, 90.3%) \[39]. When both mammography and US are negative or benign in the evaluation of a palpable breast mass, the negative predictive value is very high, more than 97% \[8,9,38,40]. Together, these imaging modalities can be reassuring when the physical examination is not highly suspicious and clinical follow-up is planned. If almost entirely fatty tissue is identified in the palpable region of concern, US may not be necessary \[2]. In a study that included 323 palpable masses in 271 women with almost entirely fatty tissue on diagnostic mammography, mammography alone yielded a negative predictive value of 99.6% \[22]. Of the 294 (91%) of women with almost entirely fatty breasts who also underwent targeted US for the evaluation of palpable symptoms, US yielded 11 false- positives and 8 benign correlates at sites with no mammographic findings \[22]. 超声检查的一大优势在于能够直接将临床表现与影像学结果相关联。为提高真阳性率，推荐采用多模态成像技术诊断可触及肿块。在三项评估可触及乳腺异常的研究\[18-20]中，乳腺X线摄影的敏感性为86%至91%。联合超声检查可使癌症检出率达到93%至100%\[8,9,19]。乳腺X线摄影联合超声检查还能提高对可触及病变良性病因的检出率，并可发现X线摄影隐匿性病灶\[26]。有研究显示，40%的良性可触及肿块仅通过超声检出\[20]。另一项针对320名女性375个可触及肿块的研究表明，68.8%的肿块（n=258）仅通过超声发现，这些肿块多呈椭圆形（n=275，73.3%）和低回声（372次超声检查中n=336，90.3%）\[39]。当乳腺X线摄影和超声检查对可触及乳腺肿块的评估结果均为阴性或良性时，阴性预测值极高，超过97%\[8,9,38,40]。在体格检查无明显可疑且计划临床随访的情况下，这两种影像学检查方法联合应用可提供可靠依据。若在可疑触诊区域发现几乎全为脂肪组织，则可能无需进行超声检查\[2]。一项纳入271名女性323个可触及肿块的研究显示，诊断性乳腺X线摄影显示几乎全为脂肪组织时，单独
* 检查项目: MRI breast without IV contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000848
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明:
* 检查项目: MRI breast without and with IV contrast / MR乳腺(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000847
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明:
* 检查项目: FDG-PET Breast Dedicated / PET/CT局部(胸部)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0016 / R:CR000844
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of FDG-PET breast dedicated as the next step in the evaluation of a woman presenting with a negative mammogram and a palpable mass \[2]. 目前尚无相关文献支持将FDG-PET乳腺专用显像作为乳腺钼靶检查阴性但可触及肿块女性患者的下一步评估手段\[2]。
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000849
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of the use of Tc-99m sestamibi MBI as the next step in the evaluation of a woman presenting with a negative mammogram and a palpable mass. 目前尚无相关文献支持将锝-99m甲氧基异丁基异腈（MBI）显像作为乳腺X线摄影阴性但可触及肿块女性患者的后续评估手段。
* 检查项目: Image-Guided Core Biopsy Breast / 影像引导下乳腺穿刺活检术
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0013 / R:CR000845
  * 证据强度: LimitedReferences
  * Adult RRL: Varies
  * Peds RRL: Varies
  * 推荐说明: There is no relevant literature to support the use of image-guided core biopsy as the next step in the evaluation of a woman presenting with a negative mammogram and a palpable mass. US should be performed, and if a suspicious correlate is identified, then US-guided core biopsy is recommended. However, a suspicious physical examination should prompt biopsy guided by palpation, regardless of negative imaging findings \[38]. 目前尚无相关文献支持对乳腺X线摄影阴性但可触及肿块的女性采用影像引导下空心针活检作为下一步评估手段。应进行超声检查，若发现可疑相关病变，则推荐超声引导下空心针活检。然而，对于体检高度可疑的病例，即使影像学检查结果为阴性，也应考虑触诊引导下的活检\[38]。
* 检查项目: Image-Guided Fine Needle Aspiration Breast / 影像引导下乳腺细针穿刺抽吸
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0014 / R:CR000846
  * 证据强度: LimitedReferences
  * Adult RRL: Varies
  * Peds RRL: Varies
  * 推荐说明: There is no relevant literature to support the use of image-guided FNAB as the next step in the evaluation of a woman presenting with a negative mammogram and a palpable mass. US should be performed, and if a suspicious correlate is identified, then US-guided core biopsy is recommended. However, a suspicious physical examination should prompt biopsy guided by palpation, regardless of negative imaging findings \[38]. 目前尚无相关文献支持对乳腺X线摄影阴性但可触及肿块的女性患者采用影像引导下的细针抽吸活检作为下一步评估手段。应进行超声检查，若发现可疑相关病变，则推荐超声引导下的空心针活检。然而，对于体检可疑的病例，即使影像学检查结果为阴性，也应立即进行触诊引导下的活检\[38]。

##### S0106 Variant: Variant 6:  Adult female, younger than 30 years of age. Palpable breast mass. Initial imaging. | 成人女性，\<30岁，可触及乳腺肿块，初始影像学检查。

检查推荐列表：

* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0003 / R:CR000850
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: The probability of a woman developing breast cancer increases with age; a woman has a 1 in 53 chance of developing invasive breast cancer from birth to age 49 years compared with a 1 in 15 chance at ≥70 years of age \[47]. Diagnostic mammography is useful as the initial examination in the evaluation of a palpable breast finding for women aged ≥40 years of age. However, because of the low incidence of breast cancer (\<1%) in younger women, their imaging evaluation differs from that performed for older patients \[41-44]. In addition, most benign lesions in young women are not visualized on mammography \[41,43], and US is therefore used as the initial imaging modality in younger women. US is preferably targeted specifically to the palpable finding \[33]. As with all age-related guidelines, pertinent clinical factors such as family history should be used to determine appropriate patient care. 女性罹患乳腺癌的概率随年龄增长而上升：从出生至49岁期间患病风险为1/53，而70岁以上人群风险升至1/15\[47]。对于40岁以上女性，诊断性乳腺X线摄影可作为触诊异常的首选检查手段。但由于年轻女性乳腺癌发病率较低（\<1%），其影像学评估方案与年长患者存在差异\[41-44]。此外，年轻女性多数良性病变在乳腺X线摄影中不可见\[41,43]，因此超声检查成为该人群的首选影像学方法，建议针对触诊异常部位进行针对性扫描\[33]。与所有年龄相关指南相同，临床决策应结合家族史等相关因素综合判断。
* 检查项目: Digital Breast Tomosynthesis Diagnostic / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000851
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Because of the low incidence of breast cancer (\<1%) in younger women, the recommended initial imaging differs from older patients \[41-44]. Younger women tend to have relatively denser breast tissue \[45], which is associated with decreased mammographic/DBT sensitivity \[46]. DBT is not useful as the initial imaging modality in younger women. 由于年轻女性乳腺癌发病率较低（\<1%），其初始影像学检查方案与年长患者有所不同\[41-44]。年轻女性乳腺组织密度通常相对较高\[45]，这会导致乳腺X线摄影/数字乳腺断层合成（DBT）的敏感性下降\[46]。因此，DBT不推荐作为年轻女性的首选影像学检查手段。
* 检查项目: Mammography Diagnostic / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000851
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Because of the low incidence of breast cancer (\<1%) in younger women, the recommended initial imaging differs from older patients \[41-44]. Younger women tend to have relatively denser breast tissue \[45], which is associated with decreased mammographic/DBT sensitivity \[46]. Most benign lesions in young women are not visualized on mammography \[41,43]. Diagnostic mammography is not useful as the initial imaging modality in younger women. 由于年轻女性乳腺癌发病率较低（\<1%），其推荐的初始影像学检查方式与年长患者有所不同\[41-44]。年轻女性乳腺组织通常较为致密\[45]，这会导致乳腺X线摄影/数字乳腺断层合成摄影的敏感性降低\[46]。年轻女性大多数良性病变在乳腺X线摄影中不可见\[41,43]。诊断性乳腺X线摄影不宜作为年轻女性的首选影像学检查手段。
* 检查项目: Mammography Screening / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000851
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: In women presenting with signs or symptoms, including a palpable breast mass, screening mammography is not useful as the initial imaging study. Screening mammography is provided to women without signs or symptoms of 对于出现体征或症状（包括可触及乳腺肿块）的女性，筛查性乳腺X线摄影不宜作为初始影像学检查。筛查性乳腺X线摄影适用于无体征或症状的女性。
* 检查项目: Digital Breast Tomosynthesis Screening / MG双侧乳腺钼靶(筛查)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0001 / R:CR000852
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: In women presenting with signs or symptoms, including a palpable breast mass, screening DBT, with or without DM, is not useful as the initial imaging study. Screening mammography is provided to women without signs or symptoms of breast disease. 对于出现体征或症状（包括可触及的乳房肿块）的女性，筛查数字乳腺断层合成（DBT）联合或不联合数字乳腺X线摄影（DM）作为初始影像学检查并无临床价值。筛查性乳腺X线摄影适用于无乳腺疾病体征或症状的女性。
* 检查项目: MRI breast without IV contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000859
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明:
* 检查项目: MRI breast without and with IV contrast / MR乳腺(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000858
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明:
* 检查项目: FDG-PET Breast Dedicated / PET/CT局部(胸部)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0016 / R:CR000853
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of FDG-PET breast dedicated as the initial imaging workup in women \<30 years of age with a palpable mass \[2]. 目前尚无相关文献支持将FDG-PET乳腺专用显像作为30岁以下可触及肿块女性的初始影像学检查手段\[2]。
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000860
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of the use of Tc-99m sestamibi MBI as the initial imaging workup in women \<30 years of age with a palpable mass. 目前尚无相关文献支持将锝-99m甲氧基异丁基异腈（MIBI）显像作为30岁以下可触及肿块女性的初始影像学检查手段。
* 检查项目: Image-Guided Core Biopsy Breast / 影像引导下乳腺穿刺活检术
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0013 / R:CR000854
  * 证据强度: Expert Consensus
  * Adult RRL: Varies
  * Peds RRL: Varies
  * 推荐说明: There is no relevant literature to support the use of image-guided core biopsy as the initial imaging workup in women \<30 years of age with a palpable mass. 目前尚无相关文献支持将影像引导下核心针活检作为30岁以下女性可触及肿块的初始影像学检查方法。
* 检查项目: Image-Guided Fine Needle Aspiration Breast / 影像引导下乳腺细针穿刺抽吸
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0014 / R:CR000855
  * 证据强度: Expert Consensus
  * Adult RRL: Varies
  * Peds RRL: Varies
  * 推荐说明: There is no relevant literature to support the use of image-guided FNAB as the initial imaging workup in women \<30 years of age with a palpable mass. 目前尚无相关文献支持将影像引导下的细针抽吸活检作为30岁以下可触及肿块女性的初始影像学检查手段。

##### S0107 Variant: Variant 7:  Adult female, younger than 30 years of age. Palpable breast mass. US findings are suspicious or highly suggestive of malignancy (BI-RADS 4 or 5). Next imaging study. | 成人女性，\<30岁，可触及乳腺肿块，超声检查结果可疑或高度提示恶性（BIRADS 4或5类），下一步影像学检查。

检查推荐列表：

* 检查项目: Image-Guided Core Biopsy Breast / 影像引导下乳腺穿刺活检术
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0013 / R:CR000861
  * 证据强度: LimitedReferences
  * Adult RRL: Varies
  * Peds RRL: Varies
  * 推荐说明: If a suspicious mass has been identified on US, tissue sampling (US guided) is warranted. It may be appropriate to proceed directly to image-guided biopsy if a palpable lesion has suspicious features on US followed by placement of a biopsy clip. If US findings are particularly worrisome for malignancy, diagnostic mammography or DBT may be performed prior to tissue sampling to delineate disease extent (eg, calcifications extending beyond the margins of the US-identified solid mass) and identify any additional suspicious findings in the ipsilateral or contralateral breast. Core-needle biopsy has been shown in large series to be superior to FNA in terms of sensitivity, specificity, and correct histological grading \[27]. Some practices have had good results using FNAB, but this may be facility specific, and a lower threshold for radiologic-pathologic discordance may need to be applied \[50,51]. 若超声检查发现可疑肿块，则需进行超声引导下的组织取样。若可触及的病灶在超声下呈现可疑特征，随后放置活检夹，可直接进行影像引导下的活检。若超声结果高度提示恶性可能，组织取样前可进行诊断性乳腺X线摄影或数字乳腺断层合成摄影（DBT），以明确病变范围（如钙化延伸超出超声所见的实性肿块边缘）并发现同侧或对侧乳腺的其他可疑病灶。大量研究显示，空心针活检在敏感性、特异性及正确组织学分级方面均优于细针抽吸活检\[27]。部分机构采用细针抽吸活检（FNAB）取得良好效果，但这可能因设施而异，需降低影像学与病理学结果不一致的判定阈值\[50,51]。
* 检查项目: Digital Breast Tomosynthesis Diagnostic / MG双侧乳腺钼靶
  * 评分: 8
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0010 / R:CR000862
  * 证据强度: StrongReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: DBT may be useful in a woman \<30 years of age with a suspicious sonographic finding that correlates to a palpable mass. DBT may demonstrate findings not readily detected at US (calcifications or subtle architectural distortion); this may provide a more accurate assessment of the extent of disease in the ipsilateral breast and can identify contralateral lesions as well. In addition, DBT may have relatively high diagnostic accuracy in dense breast tissue, often encountered in younger patients \[48,49]. 对于30岁以下超声检查发现可疑病变且与可触及肿块相关的女性，DBT可能具有一定价值。DBT可显示超声不易发现的征象（钙化灶或细微结构扭曲），从而更准确评估同侧乳腺病变范围，并识别对侧病灶。此外，DBT在致密型乳腺组织（常见于年轻患者）中具有相对较高的诊断准确性\[48,49]。
* 检查项目: Mammography Diagnostic / MG双侧乳腺钼靶
  * 评分: 7
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0010 / R:CR000862
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Mammography may be useful in a woman \<30 years of age with a suspicious sonographic finding that correlates to a palpable mass. If US findings are particularly worrisome for malignancy, mammography diagnostic or diagnostic DBT would usually be performed before tissue sampling to identify any additional suspicious findings and/or delineate the extent of disease (eg, calcifications extending beyond the margins of the US-identified solid mass) in the ipsilateral breast. Mammography diagnostic is recommended as a prebiopsy assessment in cases in which cancer is strongly suspected clinically \[41]. 对于30岁以下女性，若超声检查发现可疑病变且与可触及肿块相关，乳腺X线摄影可能有帮助。若超声表现高度提示恶性可能，通常在组织取样前进行乳腺X线诊断摄影或诊断性数字乳腺断层合成（DBT），以识别同侧乳房内其他可疑病灶和/或明确病变范围（例如超出超声所发现实性肿块边缘的钙化灶）。当临床高度怀疑癌症时，推荐将乳腺X线诊断摄影作为活检前评估手段\[41]。
* 检查项目: Image-Guided Fine Needle Aspiration Breast / 影像引导下乳腺细针穿刺抽吸
  * 评分: 5
  * 适宜性: May be appropriate (Disagreement) / 可能适宜（存在争议）
  * 编码: P:PR0014 / R:CR000864
  * 证据强度: Expert OpinionReferences
  * Adult RRL: Varies
  * Peds RRL: Varies
  * 推荐说明: If a suspicious mass has been identified on US, tissue sampling (US guided) is warranted. It may be appropriate to proceed directly to image-guided biopsy if a palpable lesion has suspicious features on US. If US findings are particularly worrisome for malignancy, diagnostic mammography or DBT may be performed before tissue sampling to delineate disease extent (eg, calcifications extending beyond the margins of the US-identified solid mass) and identify any additional suspicious findings in the ipsilateral or contralateral breast. Core-needle biopsy has been shown in large series to be superior to FNA in terms of sensitivity, specificity, and correct histological grading \[27]. Some practices have had good results using FNAB, but this may be facility specific, and a lower threshold for radiologic-pathologic discordance may need to be applied \[50,51]. US-guided FNAB may be preferred over core 若超声检查发现可疑肿块，则需进行超声引导下组织取样。若可触及病灶在超声上呈现可疑特征，直接进行影像引导下活检可能是合适的。若超声表现高度怀疑恶性，可在组织取样前进行诊断性乳腺X线摄影或数字乳腺断层融合成像，以明确病变范围（例如钙化延伸至超声发现的实性肿块边界之外）并识别同侧或对侧乳腺的任何其他可疑发现。大型系列研究显示，核心针活检在敏感性、特异性及正确组织学分级方面均优于细针抽吸活检\[27]。部分医疗机构采用细针抽吸活检取得良好结果，但这可能因机构而异，且需采用更低的影像病理不符阈值\[50,51]。超声引导下细针抽吸活检可能优于核心针活检。
* 检查项目: Mammography Screening / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000862
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: In women presenting with signs or symptoms, including a palpable breast mass, screening mammography is not useful as the next imaging study. Screening mammography is provided to women without signs or symptoms of breast disease. 对于出现体征或症状（包括可触及的乳房肿块）的女性，筛查性乳腺X线摄影不宜作为下一步影像学检查手段。筛查性乳腺X线摄影适用于无乳腺疾病体征或症状的女性。
* 检查项目: Digital Breast Tomosynthesis Screening / MG双侧乳腺钼靶(筛查)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0001 / R:CR000865
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: In women presenting with signs or symptoms, including a palpable breast mass, screening DBT, with or without DM, is not useful as the next imaging study. Screening mammography is provided to women without signs or symptoms of breast disease. 对于出现体征或症状（包括可触及的乳房肿块）的女性，无论是否联合数字乳腺X线摄影（DM），筛查性数字乳腺断层合成（DBT）作为后续影像学检查均无临床价值。筛查性乳腺X线摄影适用于无乳腺疾病体征或症状的女性。
* 检查项目: MRI breast without IV contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000869
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明:
* 检查项目: MRI breast without and with IV contrast / MR乳腺(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000868
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明:
* 检查项目: FDG-PET Breast Dedicated / PET/CT局部(胸部)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0016 / R:CR000866
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of FDG-PET breast dedicated as the next step in evaluating a palpable mass with suspicious sonographic features in women \<30 years of age \[2]. 目前尚无相关文献支持将FDG-PET乳腺专用显像作为30岁以下女性超声检查提示可疑的可触及肿块的下一步评估手段\[2]。
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000870
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of the use of Tc-99m sestamibi MBI as the next step in evaluating a palpable mass with suspicious sonographic features in women \<30 years of age. 目前尚无相关文献支持将锝-99m甲氧基异丁基异腈（MIBI）显像作为30岁以下女性超声检查可疑可触及肿块的下一步评估手段。

##### S0108 Variant: Variant 8:  Adult female, younger than 30 years of age. Palpable breast mass. US findings probably benign (BI-RADS 3). Next imaging study. | 女性，\<30岁，可触及乳腺肿块，超声检查结果可能良性（BIRADS 3），下一步影像学检查

检查推荐列表：

* 检查项目: Digital Breast Tomosynthesis Diagnostic / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000871
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: If a correlate for a palpable mass has been identified on US and is probably benign, there is no indication for DBT to further evaluate the palpable mass in women \<30 years of age. 若超声检查已发现可触及肿块的对应病灶且可能为良性，则30岁以下女性无需进行数字乳腺断层摄影（DBT）进一步评估该可触及肿块。
* 检查项目: Mammography Diagnostic / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000871
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: If a correlate for a palpable mass has been identified on US and is probably benign, there is no indication for 如果在超声检查中已发现可触及肿块的对应物且可能为良性，则无指征进行
* 检查项目: Mammography Screening / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000871
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: In women presenting with signs or symptoms, including a palpable breast mass, screening mammography is unnecessary for imaging surveillance. Screening mammography is provided to women without signs or symptoms of breast disease. 对于出现体征或症状（包括可触及的乳房肿块）的女性，无需通过筛查性乳腺X线摄影进行影像学监测。筛查性乳腺X线摄影适用于无乳腺疾病体征或症状的女性。
* 检查项目: Digital Breast Tomosynthesis Screening / MG双侧乳腺钼靶(筛查)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0001 / R:CR000872
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: In women presenting with signs or symptoms, including a palpable breast mass, screening DBT, with or without DM, is unnecessary for imaging surveillance. Screening mammography is provided to women without signs or symptoms of breast disease. 对于出现体征或症状（包括可触及的乳房肿块）的女性，无需采用数字乳腺断层合成摄影（DBT）联合或不联合数字乳腺X线摄影（DM）进行影像学监测。乳腺筛查性X线摄影适用于无乳腺疾病体征或症状的女性。
* 检查项目: MRI breast without IV contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000879
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明:
* 检查项目: MRI breast without and with IV contrast / MR乳腺(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000878
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明:
* 检查项目: FDG-PET Breast Dedicated / PET/CT局部(胸部)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0016 / R:CR000873
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of FDG-PET breast dedicated in women \<30 years of age with probably benign sonographic findings in the setting of a palpable mass \[2]. 目前尚无相关文献支持在30岁以下女性可触及肿块且超声检查结果可能为良性的情况下使用FDG-PET乳腺专用成像\[2]。
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000880
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of the use of Tc-99m sestamibi MBI in women \<30 years of age with probably benign sonographic findings in the setting of a palpable mass. 目前尚无相关文献支持在30岁以下女性中，针对超声检查结果可能为良性且伴有可触及肿块的情况下使用锝-99m甲氧基异丁基异腈（MBI）显像。
* 检查项目: Image-Guided Core Biopsy Breast / 影像引导下乳腺穿刺活检术
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0013 / R:CR000874
  * 证据强度: LimitedReferences
  * Adult RRL: Varies
  * Peds RRL: Varies
  * 推荐说明: If a palpable mass has probably benign features as identified on US, US follow-up is recommended. However, image-guided core biopsy may be performed after complete imaging assessment in some cases. For example, BI- RADS 3 lesions in high-risk patients, patients awaiting organ transplant, patients with known synchronous cancers, or patients trying to get pregnant may be appropriate for biopsy instead of imaging follow-up. In addition, situations in which biopsy may alleviate extreme patient anxiety may prompt tissue sampling and a biopsy marker clip should be placed \[30]. 若超声检查发现可触及肿块可能为良性特征，建议进行超声随访。但在某些情况下，经完整影像学评估后可考虑行影像引导下空心针穿刺活检。例如：高危患者的BI-RADS 3类病灶、等待器官移植的患者、已知存在同步性癌症的患者或计划妊娠的患者可能更适合活检而非影像随访。此外，对于活检可能缓解患者极度焦虑的情况，可考虑实施组织取样，并应放置活检标记夹\[30]。
* 检查项目: Image-Guided Fine Needle Aspiration Breast / 影像引导下乳腺细针穿刺抽吸
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0014 / R:CR000875
  * 证据强度: LimitedReferences
  * Adult RRL: Varies
  * Peds RRL: Varies
  * 推荐说明: If a palpable mass has probably benign features as identified on US, US follow-up is recommended. Image-guided FNAB may be performed after complete imaging assessment in some cases. For example, BI-RADS 3 lesions in high-risk patients, patients awaiting organ transplant, patients with known synchronous cancers, or patients trying to get pregnant may be appropriate for tissue sampling. In addition, situations in which biopsy may alleviate extreme patient anxiety may prompt tissue sampling, and a biopsy marker clip should be placed \[30]. However, large series demonstrate that core biopsy is superior to FNAB in terms of sensitivity, specificity, and correct histological grading of palpable masses \[27]. In addition, core biopsy allows for ready evaluation of tumor receptor status. US-guided FNAB may be preferred in rare situations (lesion abuts an implant). 若超声检查发现可触及肿块可能为良性特征，建议进行超声随访。部分病例在完成影像学评估后可考虑行影像引导下细针抽吸活检（FNAB）。例如：高危患者的BI-RADS 3类病灶、等待器官移植的患者、已知存在同步性癌症的患者或备孕患者可能适合进行组织取样。此外，当活检可能缓解患者极度焦虑时也可实施组织取样，并应放置活检标记夹\[30]。但大型系列研究表明，对于可触及肿块而言，空心针活检在敏感性、特异性及正确组织学分级方面均优于细针抽吸活检\[27]。此外，空心针活检可便捷评估肿瘤受体状态。仅在特殊情况下（如病灶毗邻植入物）可优先考虑超声引导下细针抽吸活检。

##### S0109 Variant: Variant 9:  Adult female, younger than 30 years of age. Palpable breast mass. US findings benign (BI-RADS 2). Next imaging study. | 女性，\<30岁，可触及乳腺肿块，超声检查结果良性（BIRADS 2），下一步影像学检查

检查推荐列表：

* 检查项目: Digital Breast Tomosynthesis Diagnostic / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000881
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: If a benign entity has been found on US and is the definitive correlate for a palpable mass, there is no role for further evaluation with diagnostic DBT in women \<30 years of age. 如果在超声检查中发现良性病变且与可触及肿块明确相关，则30岁以下女性无需进一步进行诊断性数字乳腺断层摄影（DBT）评估。
* 检查项目: Mammography Diagnostic / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000881
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: If a benign entity has been found on US and is the definitive correlate for a palpable mass, there is no role for further evaluation with diagnostic mammography in women \<30 years of age. 若超声检查发现良性病变且与可触及肿块明确相关，则30岁以下女性无需进一步行诊断性乳腺X线摄影检查。
* 检查项目: Mammography Screening / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000881
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: In women presenting with signs or symptoms, including a palpable breast mass, screening mammography is unnecessary for confirmation of benignity. Screening mammography is provided to women without signs or symptoms of breast disease. 对于出现体征或症状（包括可触及的乳房肿块）的女性，无需通过筛查性乳腺X线摄影来确认良性病变。筛查性乳腺X线摄影适用于无乳腺疾病体征或症状的女性。
* 检查项目: Digital Breast Tomosynthesis Screening / MG双侧乳腺钼靶(筛查)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0001 / R:CR000882
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: In women presenting with signs or symptoms, including a palpable breast mass, screening DBT, with or without DM, is unnecessary for confirmation of benignity. Screening mammography is provided to women without signs or symptoms of breast disease. 对于出现体征或症状（包括可触及的乳房肿块）的女性，无需通过筛查数字乳腺断层合成摄影（DBT）（无论是否联合数字乳腺X线摄影（DM））来确认良性。筛查性乳腺X线摄影适用于无乳腺疾病体征或症状的女性。
* 检查项目: MRI breast without IV contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000889
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明:
* 检查项目: MRI breast without and with IV contrast / MR乳腺(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000888
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明:
* 检查项目: FDG-PET Breast Dedicated / PET/CT局部(胸部)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0016 / R:CR000883
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: If a benign entity has been found on US and is the definitive correlate for a palpable mass, there is no role for FDG- PET breast dedicated in women \<30 years of age \[2]. 如果在超声检查中发现良性病变且与可触及肿块明确相关，则对于30岁以下女性无需进行FDG-PET乳腺专用检查\[2]。
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000890
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: If a benign entity has been found on US and is the definitive correlate for a palpable mass, there is no evidence for Tc-99m sestamibi MBI in women \<30 years of age. 若超声检查发现良性病变且与可触及肿块明确相关，则30岁以下女性无需进行锝-99m甲氧基异丁基异腈乳腺显像检查。
* 检查项目: Image-Guided Core Biopsy Breast / 影像引导下乳腺穿刺活检术
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0013 / R:CR000884
  * 证据强度: LimitedReferences
  * Adult RRL: Varies
  * Peds RRL: Varies
  * 推荐说明: If a benign entity has been found on US and is the definitive correlate for a palpable mass, there is no role for tissue sampling. The likelihood of a palpable mass in a young woman that is benign on both clinical examination and US resulting in a cancer is extremely low; one study prospectively evaluating US-guided core biopsy in 248 young women \<25 years of age with clinically benign masses and predominantly benign findings found no cancers in this group \[52]. 若超声检查发现良性病变且与可触及肿块明确相关，则无需进行组织取样。年轻女性出现临床检查和超声均显示良性的可触及肿块，其恶变概率极低；一项前瞻性研究对248例25岁以下临床良性肿块（以良性表现为主）患者行超声引导下空心针活检，该组未发现癌症病例\[52]。
* 检查项目: Image-Guided Fine Needle Aspiration Breast / 影像引导下乳腺细针穿刺抽吸
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0014 / R:CR000885
  * 证据强度: Expert Consensus
  * Adult RRL: Varies
  * Peds RRL: Varies
  * 推荐说明: If a benign entity has been found on US and is the definitive correlate for a palpable mass, there is no role for image- guided FNAB in women \<30 years of age. 如果在超声检查中发现良性病变，并且与可触及的肿块明确相关，则对于30岁以下的女性无需进行影像引导下的细针抽吸活检。

##### S0110 Variant: Variant 10:  Adult female, younger than 30 years of age. Palpable breast mass. US findings negative (BI-RADS 1). Next imaging study. | 女性，\<30岁，可触及乳腺肿块，超声检查结果阴性（BIRADS 1），下一步影像学检查

检查推荐列表：

* 检查项目: Digital Breast Tomosynthesis Diagnostic / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000891
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: DBT is not useful unless the clinical findings are suspicious. DBT or mammography diagnostic is recommended as age, if physical examination is highly suspicious and DBT and US are negative, tissue sampling with core biopsy or surgical biopsy is warranted. 除非临床发现可疑，否则DBT无用。如果体格检查高度可疑且DBT和US为阴性，则推荐进行DBT或诊断性乳腺X线摄影（按年龄），并需要进行核心活检或手术活检的组织取样。
* 检查项目: Mammography Diagnostic / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000891
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Mammography is not useful unless the clinical findings are suspicious. Mammography is recommended as a prebiopsy assessment in cases in which cancer is strongly suspected clinically \[41]. If a mammographic correlate to a suspicious finding is identified, then stereotactic biopsy is recommended. As with women ≥40 years of age, if physical examination is highly suspicious and mammography and US are negative, tissue sampling with core biopsy or surgical biopsy is warranted. 除非临床发现可疑，否则乳腺X线摄影并无用处。对于临床高度怀疑癌症的病例，推荐将乳腺X线摄影作为活检前评估手段\[41]。若在可疑发现中识别出乳腺X线摄影相关征象，则推荐进行立体定位活检。与≥40岁女性相同，若体格检查高度可疑而乳腺X线摄影和超声检查均为阴性时，必须进行空心针穿刺活检或手术活检获取组织样本。
* 检查项目: Mammography Screening / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000891
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: In women presenting with signs or symptoms, including a palpable breast mass, screening mammography is not useful as the next imaging study. Screening mammography is provided to women without signs or symptoms of breast disease. 对于出现体征或症状（包括可触及的乳房肿块）的女性，筛查性乳腺X线摄影不宜作为下一步影像学检查手段。筛查性乳腺X线摄影适用于无乳腺疾病体征或症状的女性。
* 检查项目: Digital Breast Tomosynthesis Screening / MG双侧乳腺钼靶(筛查)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0001 / R:CR000892
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: In women presenting with signs or symptoms, including a palpable breast mass, screening DBT, with or without DM, is not useful as the next imaging study. Screening mammography is provided to women without signs or symptoms of breast disease. 对于出现体征或症状（包括可触及的乳房肿块）的女性，无论是否联合数字乳腺X线摄影（DM），筛查性数字乳腺断层合成（DBT）作为后续影像学检查均无临床价值。筛查性乳腺X线摄影适用于无乳腺疾病体征或症状的女性。
* 检查项目: MRI breast without IV contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000899
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明:
* 检查项目: MRI breast without and with IV contrast / MR乳腺(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000898
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明:
* 检查项目: FDG-PET Breast Dedicated / PET/CT局部(胸部)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0016 / R:CR000893
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of the use of FDG-PET breast dedicated in women \<30 years of age with negative US findings \[2]. 目前尚无相关文献支持对30岁以下超声检查结果阴性的女性使用FDG-PET乳腺专用检查\[2]。
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000900
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of the use of Tc-99m sestamibi MBI in women \<30 years of age with negative US findings. 目前尚无相关文献支持在超声检查结果阴性的30岁以下女性中使用锝-99m甲氧基异丁基异腈（MBI）。
* 检查项目: Image-Guided Core Biopsy Breast / 影像引导下乳腺穿刺活检术
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0013 / R:CR000894
  * 证据强度: Expert Consensus
  * Adult RRL: Varies
  * Peds RRL: Varies
  * 推荐说明: There is no relevant literature to support the use of the use of image-guided core biopsy in women \<30 years of age with negative US findings. 目前尚无相关文献支持对超声检查结果阴性的30岁以下女性使用影像引导下的空心针穿刺活检。
* 检查项目: Image-Guided Fine Needle Aspiration Breast / 影像引导下乳腺细针穿刺抽吸
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0014 / R:CR000895
  * 证据强度: Expert Consensus
  * Adult RRL: Varies
  * Peds RRL: Varies
  * 推荐说明: There is no relevant literature to support the use of the use of image-guided FNAB in women \<30 years of age with negative US findings. 目前尚无相关文献支持对超声检查结果阴性的30岁以下女性使用影像引导下的细针抽吸活检。

##### S0111 Variant: Variant 11:  Adult female, 30 to 39 years of age. Palpable breast mass. Initial imaging. | 女性成人，30至39岁，可触及乳腺肿块，初始影像学检查。

检查推荐列表：

* 检查项目: Digital Breast Tomosynthesis Diagnostic / MG双侧乳腺钼靶
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0010 / R:CR000901
  * 证据强度: StrongReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Diagnostic mammography, DBT, or US can be useful as initial imaging for women 30 to 39 years of age with a palpable breast mass. DBT may demonstrate subtle architectural distortion or calcifications, findings not readily detected by US. DBT and diagnostic mammography can also provide more information regarding the extent of disease and the presence of additional findings in the ipsilateral breast \[22]. In the absence of DBT data for women 30 to 39 years of age, the utility of DBT can be extrapolated from the diagnostic mammography data. Mammography has been shown to add clinical value for women ≥30 years of age with a palpable breast mass. Mammographic sensitivity is dependent on the tumor size on palpation, ranging from 78% for a palpable tumor size of ≤2 cm to 97% for a palpable tumor size between 2 and 5 cm \[53]. DBT provided similarly accurate diagnostic results as compared to DM in women with palpable breast masses \[15]. Several small studies that specifically included women presenting with clinical symptoms including palpable lumps demonstrated increased accuracy on combination DM/DBT compared with DM alone \[13,16,17]. In one recent study, mammography contributed to the workup of palpable malignant masses in 16.7% of cases in women 30 to 39 years of age \[54]. 对于30至39岁有可触及乳腺肿块的女性，诊断性乳腺X线摄影、数字乳腺断层合成（DBT）或超声可作为初始影像学检查。DBT可显示细微的结构扭曲或钙化，这些征象在超声检查中不易被发现。DBT与诊断性乳腺X线摄影还能提供更多关于病变范围及同侧乳腺是否存在其他异常的信息\[22]。若无30至39岁女性的DBT数据，可从诊断性乳腺X线摄影数据推知DBT的效用。研究证实，乳腺X线摄影对≥30岁有可触及乳腺肿块的女性具有临床价值。其敏感性取决于触诊肿瘤大小：可触及肿瘤≤2cm时敏感性为78%，2-5cm时可达97%\[53]。针对可触及乳腺肿块女性，DBT与全视野数字化乳腺摄影（DM）的诊断准确性相当\[15]。多项纳入有临床症状（包括可触及肿块）女性患者的小型研究表明，联合DM/DBT较单独DM诊断准确性更高\[13,16,17]。近期一项研究显示，在30至39岁女性中，乳腺X线摄影对16.7%的可触及恶性肿块病例的诊疗具有贡献\[54]。
* 检查项目: Mammography Diagnostic / MG双侧乳腺钼靶
  * 评分: 8
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0010 / R:CR000901
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Diagnostic mammography, DBT, or US can be useful as initial imaging for women 30 to 39 years of age with a palpable breast mass. Mammography has been shown to add clinical value for women ≥30 years of age with a palpable breast mass. Mammographic sensitivity is dependent on the tumor size on palpation, ranging from 78% for a palpable tumor size of ≤2 cm to 97% for a palpable tumor size between 2 and 5 cm \[53]. In one recent study, it was demonstrated that in 16.7% of cases in women 30 to 39 years of age, mammography contributed in the workup of malignant palpable masses \[54]. For example, mammography revealed calcifications that extended outside of the mass or associated satellite lesions. The overall contribution of diagnostic mammography for palpable breast masses is the characterization of benign disease, evaluating the overall extent of disease and assessing the remainder of the ipsilateral breast \[22]. One study of 1,208 women 30 to 39 years of age presenting with focal breast symptoms found a higher sensitivity for US compared with mammography (95.7% versus 60.9%) but with a similar specificity (89.2% and 94.4%, respectively), negative predictive value (99.9% and 99.2%, respectively), and positive predictive value (13.2% and 18.4%, respectively) \[40]. 对于30至39岁有可触及乳腺肿块的女性，诊断性乳腺X线摄影、数字乳腺断层合成摄影（DBT）或超声可作为初始影像学检查手段。研究表明，乳腺X线摄影对≥30岁有可触及肿块女性具有临床价值，其敏感性取决于触诊肿瘤大小：可触及肿瘤≤2cm时敏感性为78%，2-5cm时可达97%\[53]。近期研究显示，在30-39岁女性中，16.7%的恶性可触及肿块病例通过乳腺X线摄影获得重要诊断信息\[54]，例如发现肿块外钙化灶或伴随卫星病灶。诊断性乳腺X线摄影的核心价值在于：鉴别良性病变、评估病变整体范围及检查同侧乳腺其余部位\[22]。一项针对1,208名30-39岁局灶性乳腺症状女性的研究发现，超声较乳腺X线摄影具有更高敏感性（95.7% vs 60.9%），但两者特异性（89.2%与94.4%）、阴性预测值（99.9%与99.2%）及阳性预测值（13.2%与18.4%）相近\[40]。
* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 8
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0003 / R:CR000903
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: Diagnostic mammography, DBT, or US can be useful as initial imaging for women 30 to 39 years of age with a palpable breast mass. Most benign lesions in young women are not visualized on mammography \[41,43], and US is therefore frequently used as the initial imaging modality in younger women. The criterion for “young” has historically been considered \<30 years of age. However, the risk of breast cancer remains relatively low for women 30 to 39 years of age. The sensitivity of US may be higher than mammography for women \<40 years of age \[53]. One study of 1,208 women 30 to 39 years of age presenting with focal breast symptoms found higher sensitivity for US compared with mammography (95.7% versus 60.9%), with similar specificity (89.2% and 94.4%, respectively) \[40]. US is a reasonable initial imaging study for women \<40 years of age, with a low threshold for using mammography if the clinical examination or other risk factors are concerning. If the mass has probably benign US features, then short-term interval follow-up with US only may be appropriate. If a suspicious mass is identified on US in this group, bilateral mammography is useful. 对于30至39岁有可触及乳腺肿块的女性，诊断性乳腺X线摄影、数字乳腺断层合成摄影（DBT）或超声可作为初始影像学检查手段。年轻女性中大多数良性病变在乳腺X线摄影中不可见\[41,43]，因此超声常被用作年轻女性的首选影像学检查方式。传统上“年轻”的标准被界定为30岁以下。然而30至39岁女性的乳腺癌风险仍相对较低。对于40岁以下女性，超声的敏感性可能高于乳腺X线摄影\[53]。一项针对1,208名30至39岁出现局部乳腺症状女性的研究发现，与乳腺X线摄影相比，超声具有更高的敏感性（95.7%对60.9%），特异性则相近（分别为89.2%和94.4%）\[40]。对于40岁以下女性，超声是合理的初始影像学检查选择，若临床检查或其他危险因素存在疑虑，应降低采用乳腺X线摄影的阈值。若肿块超声特征倾向良性，仅采用超声进行短期随访可能是合适的。若该人群超声检查发现可疑肿块，则双侧乳腺X线摄影具有重要价值。
* 检查项目: Mammography Screening / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010 / R:CR000901
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: In women presenting with signs or symptoms, including a palpable breast mass, screening mammography is not useful as the initial imaging study. Screening mammography is provided to women without signs or symptoms of breast disease. 对于出现体征或症状（包括可触及的乳房肿块）的女性，筛查性乳腺X线摄影不宜作为初始影像学检查手段。筛查性乳腺X线摄影适用于无乳腺疾病体征或症状的女性群体。
* 检查项目: Digital Breast Tomosynthesis Screening / MG双侧乳腺钼靶(筛查)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0001 / R:CR000904
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: In women presenting with signs or symptoms, including a palpable breast mass, screening DBT, with or without DM, is not useful as the initial imaging study. Screening mammography is provided to women without signs or 对于出现体征或症状（包括可触及乳腺肿块）的女性，筛查性DBT（无论是否联合DM）不宜作为初始影像学检查。筛查性乳腺X线摄影适用于无体征或症状的女性。
* 检查项目: MRI breast without IV contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000910
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明:
* 检查项目: MRI breast without and with IV contrast / MR乳腺(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000909
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明:
* 检查项目: FDG-PET Breast Dedicated / PET/CT局部(胸部)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0016 / R:CR000905
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of the use of FDG-PET breast dedicated in the initial evaluation of women 30 to 39 years of age with a palpable mass \[2]. 目前尚无相关文献支持在30至39岁女性可触及肿块的初步评估中使用FDG-PET乳腺专用成像\[2]。
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000911
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of Tc-99m sestamibi MBI in the initial evaluation of women 30 to 39 years of age with palpable mass. 目前尚无相关文献支持在30至39岁可触及肿块女性的初步评估中使用锝-99m甲氧基异丁基异腈（MBI）。
* 检查项目: Image-Guided Core Biopsy Breast / 影像引导下乳腺穿刺活检术
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0013 / R:CR000906
  * 证据强度: Expert Consensus
  * Adult RRL: Varies
  * Peds RRL: Varies
  * 推荐说明: There is no relevant literature to support the use of the use of image-guided core biopsy in the initial evaluation of women 30 to 39 years of age with a palpable mass. 目前尚无相关文献支持在30至39岁女性可触及肿块的初步评估中使用影像引导下的空心针穿刺活检。
* 检查项目: Image-Guided Fine Needle Aspiration Breast / 影像引导下乳腺细针穿刺抽吸
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0014 / R:CR000907
  * 证据强度: Expert Consensus
  * Adult RRL: Varies
  * Peds RRL: Varies
  * 推荐说明: There is no relevant literature to support the use of the use of image-guided FNAB in the initial evaluation of women 30 to 39 years of age with a palpable mass. 目前尚无相关文献支持在30至39岁女性可触及肿块的初步评估中使用影像引导下的细针抽吸活检。

#### T0016 Supplemental Breast Cancer Screening Based on Breast Density | 基于乳腺密度的补充性乳腺癌筛查

* 主题编码: T0016

##### S0112 Variant: Variant 1:  Adult female. Supplemental breast cancer screening. Average risk. Nondense breasts. | 成人女性，乳腺癌补充筛查，平均风险，非致密型乳腺。

检查推荐列表：

* 检查项目: Digital Breast Tomosynthesis Screening / MG双侧乳腺钼靶(筛查)
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0001 / R:CR000912
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Screening mammography has been shown to reduce mortality by approximately 30% to 40% \[3,4]. It is most sensitive in women with nondense tissue. In DBT the x-ray tube moves in an arc obtaining multiple low-dose mammographic images that are reconstructed into 2-D images. The additional information from varying angles aims to reduce summation shadows and overlapping structures to maximize visibility \[2]. The retrospective Population-based Research Optimizing Screening Through Personalized Regimens (PROSPR) consortium review evaluated more than 180,000 women; approximately 130,000 were screened with digital mammography (DM) and 50,000 with DBT. Women with nondense tissue accounted for 64% of the cohort as compared with 36% with dense tissue. A statistically significant increase in CDR was found in women with both nondense tissue (1.7/1,000) and dense tissue (2.27/1,000) screened with DBT. Cancers tended to be smaller, lymph node negative, and less biologically aggressive \[9]. Li et al \[10] reviewed several studies comparing DBT with 2- D mammography in Europe and the United States and found the pooled CDR to be statistically significant in both nondense and dense tissue. Another advantage of DBT is a reduction in recall rate with improved specificity. A few studies have demonstrated this benefit with the reduction ranging between 15% to 63% in observational, retrospective studies in the United States \[11,12]. In a retrospective cohort study evaluating multiple screening rounds, Sprague et al \[13] found no difference in the interval cancer rate between DBT and DM. The randomized prospective Tomosynthesis Mammographic Imaging Screening Trial (TMIST) trial comparing DBT with 2-D mammography is currently active. 乳腺X线筛查已被证实可将死亡率降低约30%至40%\[3,4]。该技术对非致密型乳腺组织女性最为敏感。在数字乳腺断层合成摄影(DBT)中，X射线管沿弧线运动获取多幅低剂量乳腺图像，经重建生成二维影像。通过多角度采集的附加信息可减少叠加阴影与结构重叠，从而最大化病灶可视性\[2]。基于人群的回顾性研究"个体化方案优化筛查项目(PROSPR)"联盟评估了超过18万名女性，其中约13万接受数字乳腺X线摄影(DM)筛查，5万接受DBT筛查。非致密型乳腺组织女性占队列64%，致密型占36%。统计显示，DBT筛查组中非致密型(1.7/1000)与致密型(2.27/1000)乳腺组织的癌症检出率(CDR)均显著提高，且检出肿瘤更小、淋巴结阴性率更高、生物学侵袭性更低\[9]。Li等\[10]综述了欧美多项比较DBT与二维乳腺摄影的研究，发现无论非致密或致密型乳腺组织，其汇总CDR均具有统计学显著性。DBT另一优势是通过提升特异性降低召回率。美国多项观察性回顾研究显示该获益幅度达15%-63%\[11,12]。Sprague等\[13]在评估多轮筛查的回顾
* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 3
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0003 / R:CR000913
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: Screening breast US can be performed using hand-held (HHUS) or automated (ABUS) techniques. Although the sensitivity of mammography in nondense tissue approaches 90%, it can be as low as 30% in women with extremely dense tissue \[17]. Screening US offers improved the sensitivity and interval cancer detection particularly in women with dense tissue. In women with nondense tissue, the Japan Strategic Anti-cancer Randomized Trial (J-START) trial demonstrated increased cancer detection, but this was not supported in 2 other large cohort studies \[18]. Although studies have demonstrated increased CDR with the addition of screening US to mammography, this comes at the at the expense of low biopsy PPVs and high false-positive rates including a high rate of short-term follow-up recommendations \[7,19]. No added benefit of screening US has been found in women who undergo MRI breast or AB-MRI screening \[20]. 乳腺筛查超声可采用手持式（HHUS）或自动化（ABUS）技术实施。虽然乳腺X线摄影对非致密组织的敏感性接近90%，但在乳腺组织极度致密的女性中其敏感性可低至30%\[17]。筛查超声能提高敏感性并改善间期癌检出率，尤其对致密型乳腺女性。日本抗癌战略随机试验（J-START）显示，非致密乳腺女性中超声可提升癌症检出率，但另两项大型队列研究未支持该结论\[18]。尽管研究表明在乳腺X线摄影基础上联合超声筛查可提高癌症检出率（CDR），但代价是活检阳性预测值（PPV）较低、假阳性率较高（包括短期随访建议率升高）\[7,19]。对于已接受乳腺MRI或AB-MRI筛查的女性，超声筛查未显示额外获益\[20]。
* 检查项目: Mammography With IV Contrast / MG双侧乳腺钼靶导管造影
  * 评分: 2
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0004 / R:CR000914
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support CEM screening in average-risk women with nondense breast tissue. CEM uses a dual-energy technique to acquire 8 standard mammographic images after the administration of intravenous (IV) iodinated contrast material. Four low-energy images mimic a conventional 2-D mammogram. The additional 4 diagnostic recombined images show contrast enhancement, which offers morphologic and functional assessment to identify malignancies. CEM has been valuable in evaluating abnormalities in the diagnostic setting \[14], however, recent literature has indicated that it may play a beneficial role in screening women with dense tissue at an intermediate risk of developing breast cancer or those seeking an alternative supplemental screening modality to MRI \[15]. 目前尚无相关文献支持对乳腺组织非致密的中等风险女性进行对比增强乳腺X线摄影（CEM）筛查。CEM采用双能技术，在静脉注射碘对比剂后获取8张标准乳腺X线图像，其中4张低能图像模拟传统二维乳腺摄影，另外4张诊断性重组图像可显示对比剂强化，提供形态学和功能学评估以识别恶性肿瘤。CEM在诊断性检查中评估异常病变具有重要价值\[14]，但最新文献表明，该技术可能对乳腺组织致密的中等风险女性筛查具有积极作用，或可作为磁共振成像（MRI）的替代补充筛查手段\[15]。
* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 2
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000915
  * 证据强度: ModerateReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There are limited data to support the use of breast MRI in average-risk women with nondense breast tissue. Kuhl et al \[16] demonstrated a CDR of 15.5 per 1,000 with a high specificity (97.1%) and positive predictive value (PPV) 支持在平均风险且非致密乳腺组织女性中使用乳腺MRI的数据有限。Kuhl等\[16]的研究显示其癌症检出率（CDR）为每1000人15.5例，具有高特异性（97.1%）和阳性预测值（PPV）。
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000918
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature regarding the use of MRI breast without IV contrast for supplemental screening in average-risk women with nondense breasts. 目前尚无相关文献支持对非致密乳腺的平均风险女性使用无静脉对比剂的乳腺MRI进行补充筛查。
* 检查项目: MRI Breast Without IV Contrast Abbreviated / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000918
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature regarding the use of AB-MRI breast without IV contrast for supplemental screening in average-risk women with nondense breasts. 目前尚无相关文献支持在不使用静脉对比剂的情况下，采用AB-MRI乳腺检查对非致密型乳腺的平均风险女性进行补充筛查。
* 检查项目: MRI Breast Without and With IV Contrast Abbreviated / MR乳腺(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000915
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature regarding the use of AB-MRI without and with IV contrast for supplemental screening in average-risk women with nondense breasts. 目前尚无相关文献探讨在非致密乳腺的平均风险女性中，不使用和使用静脉对比剂的AB-MRI作为补充筛查手段的效果。
* 检查项目: FDG-PET Breast Dedicated / PET/CT局部(胸部)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0016 / R:CR000916
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature regarding the use of FDG-PET breast dedicated for supplemental screening in average-risk women with nondense breasts. 目前尚无关于使用FDG-PET乳腺专用显像对非致密乳腺平均风险女性进行补充筛查的相关文献。
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000920
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature regarding the use of Tc-99m sestamibi MBI for supplemental screening in average- risk women with nondense breasts. This modality is not yet widely used in clinical practice. 目前尚无关于使用锝-99m甲氧基异丁基异腈（MBI）对非致密型乳腺平均风险女性进行补充筛查的相关文献报道。该检查方法尚未在临床实践中广泛应用。

##### S0113 Variant: Variant 2:  Adult female. Supplemental breast cancer screening. Average risk. Heterogeneously dense breasts. | 成人女性，乳腺癌补充筛查，平均风险，不均匀致密型乳腺。

检查推荐列表：

* 检查项目: Digital Breast Tomosynthesis Screening / MG双侧乳腺钼靶(筛查)
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0001 / R:CR000921
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Screening mammography has been shown to reduce mortality by approximately 30% to 40% \[3,4]. It is most sensitive in women with nondense tissue. Women with heterogeneously and extremely dense tissue, who can comprise up to half of screening-aged women in the United States, may not receive the same benefit from mammography alone because sensitivity can be reduced by 30% to 48% in extremely dense tissue \[17]. In DBT, the x-ray tube moves in an arc obtaining multiple low-dose mammographic images that are reconstructed into 2-D images. The additional information from varying angles aims to reduce summation shadows and overlapping structures to maximize visibility \[2]. The retrospective PROSPR consortium review evaluated more than 180,000 women; approximately 130,000 were screened with DM and 50,000 with DBT. Women with nondense tissue accounted for 64% of the cohort as compared with 36% with dense tissue. A statistically significant increase in CDR was found in women with both nondense tissue (1.7/1,000) and dense tissue (2.27/1,000) screened with DBT. Cancers tended to be smaller, lymph node negative, and less biologically aggressive \[9]. Li et al \[10] reviewed several studies comparing DBT with 2- D mammography in Europe and the United States and found the pooled CDR to be statistically significant in both nondense and dense tissue. However, Berg et al \[20] found the greatest increase in CDR to be in women with heterogeneously dense breasts. No significant increase in detection was identified in women with extremely dense tissue \[20], highlighting the need for other methods of supplemental screening in this population. Another advantage of DBT is a reduction in recall rate with improved specificity. A few studies have demonstrated this benefit, with the reduction ranging between 15% to 63% in observational, retrospective studies in the United States \[11,12]. In a retrospective cohort study evaluating multiple screening rounds, Sprague et al \[13] found no difference in the interval cancer rate between DBT and DM. The randomized prospective TMIST trial comparing 筛查性乳腺X线摄影已被证明可降低约30%至40%的死亡率\[3,4]。其对非致密组织女性的敏感性最高。在美国，具有异质性和极度致密组织的女性可能占筛查适龄女性的一半，但她们可能无法仅从乳腺X线摄影中获得同等益处，因为在极度致密组织中敏感性可能降低30%至48%\[17]。在DBT中，X射线管沿弧线运动，获取多个低剂量乳腺影像，并重建为2D图像。来自不同角度的附加信息旨在减少叠加阴影和重叠结构，以最大化可视性\[2]。回顾性PROSPR联盟研究评估了超过180,000名女性；约130,000名接受了DM筛查，50,000名接受了DBT筛查。非致密组织女性占队列的64%，而致密组织女性占36%。在采用DBT筛查的女性中，非致密组织（1.7/1,000）和致密组织（2.27/1,000）的CD
* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 5
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0005 / R:CR000922
  * 证据强度: ModerateReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There are data to support the use of breast MRI in average-risk women with heterogeneously dense breasts. Kuhl et al \[16] demonstrated a CDR of 15.5 per 1,000 with a high specificity (97.1%) and PPV (35.7%) in average-risk women of all breast densities . In a review of 22 randomized clinical trials and observational prospective studies, supplemental MRI had a CDR of 19.9 per 1,000 as compared with 4.5 per 1000 (HHUS) and 3.2 per 1,000 (DBT) in average- and intermediate- risk women with dense tissue \[17]. 现有数据支持对具有不均匀致密乳腺组织的平均风险女性使用乳腺MRI检查。Kuhl等\[16]的研究表明，在所有乳腺密度的平均风险女性中，MRI的癌症检出率（CDR）为每1000人15.5例，同时具有较高的特异性（97.1%）和阳性预测值（35.7%）。一项针对22项随机临床试验和前瞻性观察研究的综述显示，在具有致密组织的平均风险和中危女性中，补充MRI的CDR为每1000人19.9例，而手持超声（HHUS）和数字乳腺断层摄影（DBT）分别为每1000人4.5例和3.2例\[17]。
* 检查项目: MRI Breast Without and With IV Contrast Abbreviated / MR乳腺(平扫+增强)
  * 评分: 5
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0005 / R:CR000922
  * 证据强度: StrongReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: The standard MRI protocol uses multiple sequences to identify malignancy and characterize benign breast findings requiring longer magnet and interpretation times. The protocol for AB-MRI is variable and even customizable, however, all protocols use a limited number of images to highlight findings in the early postcontrast phase. This technique maximizes cancer detection while reducing the time burden on the patient and the radiologist. Negative studies can be quickly interpreted, reducing physician workload. Lawson et al \[23] found no statistical difference when comparing the sensitivity of standard MRI with AB-MRI (100% to 88.9%). This is consistent with findings from Kuhl et al \[24], Baxter et al \[19], and others \[25,26]. The EA1141 trial demonstrated a CDR (invasive and ductal carcinoma in situ \[DCIS]) of 15.2 per 1,000 examinations with AB-MRI compared with 6.2 per 1,000 examinations with DBT in average-risk women with dense tissue \[27]. The specificity of AB-MRI was reduced when compared with DBT (87% versus 97%). Clinicians should be aware that baseline imaging may result in benign biopsies or short-term interval follow-ups \[28]. Weinstein et al \[29] reported a CDR of 27.4 per 1,000 in a retrospective review of average-risk women previously screened with DBT. 标准MRI方案采用多序列扫描以识别恶性病变并定性良性乳腺发现，但需占用更长的磁共振扫描及判读时间。而AB-MRI方案具有可变性甚至可定制性，其共同特点是仅采用有限数量的图像突出显示早期增强后阶段的异常表现。该技术在最大化癌症检出率的同时，显著降低了患者和放射科医师的时间负担。阴性结果可快速完成判读，从而减轻医师工作量。Lawson等\[23]研究发现标准MRI与AB-MRI的敏感性无统计学差异（100%对比88.9%），该结论与Kuhl等\[24]、Baxter等\[19]及其他学者\[25,26]的研究结果一致。EA1141试验数据显示，在乳腺致密的平均风险女性中，AB-MRI的癌症检出率（浸润性癌和导管原位癌\[DCIS]）为15.2‰，而数字乳腺断层合成摄影（DBT）为6.2‰\[27]。但与DBT相比，AB-MRI的特异性有所降低（87%对比97%）。临床医师需注意基线成像可能导致良性病变活检或短期随访\[28]。Weinstein等\[29]回顾性研究显示，既往接受DBT筛查的平均风险女性中，AB-MRI的癌症检出率达27.4‰。
* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 5
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0003 / R:CR000924
  * 证据强度: StrongReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: Screening breast US can be performed using HHUS or ABUS techniques. Although the sensitivity of mammography in nondense tissue approaches 90%, it can be as low as 30% in women with extremely dense tissue \[17]. Screening US offers improved sensitivity and interval cancer detection, particularly in women with dense tissue. A statistically significant CDR of an additional 3.0 per 1,000 breast cancers was identified in average-risk women with dense tissue in a secondary review of the J-START \[33,34]. Additionally, a significant decrease was observed in the interval cancer rate (0.5 per 1,000 compared with 2.0 per 1,000 in the control group). In women with nondense tissue, the J-START trial demonstrated increased cancer detection as well, but this was not supported in 2 other large cohort studies \[18]. The prospective, multicenter ASTOUND-2 (adjunct screening with tomosynthesis or US in women with mammography-negative dense breasts) trial conducted in screening women with dense tissue found 4.9 per 1,000 additional cancers with HHUS as compared with 2.8 per 1,000 with DBT, although the former had more false-positives \[35]. Although studies have demonstrated increased CDR with the addition of screening US to mammography, this comes at the expense of low biopsy PPVs and high false-positive rates including a high rate of short-term follow-up recommendations \[7,19]. No added benefit of screening US has been found in women who undergo MRI breast or AB-MRI screening \[20]. In women with elevated risk only due to breast density, supplemental screening US could be considered \[7]. 乳腺筛查超声可采用手持式超声（HHUS）或自动乳腺全容积超声（ABUS）技术进行。虽然乳腺X线摄影对非致密组织的敏感性接近90%，但在乳腺组织极度致密的女性中可低至30%\[17]。筛查超声能提高敏感性及间期癌检出率，尤其对致密乳腺组织女性。J-START研究的二次分析显示，在平均风险且乳腺组织致密的女性中，超声筛查可额外检出3.0例/1000例乳腺癌（具有统计学显著性）\[33,34]，同时间期癌发生率显著降低（0.5例/1000例，对照组为2.0例/1000例）。J-START试验表明超声对非致密组织女性同样增加癌症检出，但另两项大型队列研究未支持该结论\[18]。针对致密乳腺组织女性的前瞻性多中心ASTOUND-2试验（采用断层合成或超声辅助筛查乳腺X线阴性致密乳腺）发现，HHUS额外检出4.9例/1000例癌症，而数字乳腺断层合成（DBT）为2.8例/1000例，但前者假阳性率更高\[35]。尽管研究证实联合超声筛查可提高癌症检出率，但代价是活检阳性预测值较低、假阳性率较高（包括大量短期随访建议）\[7,19]。对于已接受乳腺MRI或AB-MRI筛查的女性，超声
* 检查项目: Mammography With IV Contrast / MG双侧乳腺钼靶导管造影
  * 评分: 2
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0004 / R:CR000925
  * 证据强度: StrongReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support CEM screening in average-risk women with heterogeneously dense breast tissue. CEM uses a dual-energy technique to acquire 8 standard mammographic images after the administration of IV iodinated contrast material. Four low-energy images mimic a conventional 2-D mammogram. The additional 4 diagnostic recombined images demonstrate contrast enhancement, which offers morphologic as well as functional assessment to identify malignancies. CEM has been valuable in evaluating abnormalities in the diagnostic setting \[14], however, recent literature has indicated that it may play a beneficial role in screening women with dense tissue at an intermediate risk of developing breast cancer or those seeking an alternative supplemental screening modality to MRI \[15]. The CDR in screening studies has ranged from 8.6 to 13.1 cancers per 1,000 screening examinations \[21,22], although most of these were conducted retrospectively at a single institution. CEM offers a higher sensitivity compared with mammography, with the benefit statistically significant in women with dense breast tissue \[21]. The Contrast Mammography Enhanced Imaging Screening Trial (CMIST) is currently enrolling intermediate- risk women with dense breasts to participate in a prospective study comparing DBT and CEM. 目前尚无相关文献支持对乳腺组织致密的中等风险女性进行对比增强乳腺X线摄影（CEM）筛查。CEM采用双能量技术，在静脉注射碘对比剂后获取8张标准乳腺X线图像，其中4张低能量图像模拟传统二维乳腺X线片，另外4张诊断性重组图像可显示对比剂强化，从而通过形态学和功能学评估识别恶性肿瘤。CEM在诊断性检查中对评估异常病变具有重要价值\[14]，但最新研究表明，该技术可能对乳腺组织致密的中等乳腺癌风险女性、或寻求替代MRI补充筛查方案的群体具有潜在益处\[15]。筛查研究显示其癌症检出率（CDR）为每1000例检查8.6-13.1例\[21,22]，但多数为单机构回顾性研究。与常规乳腺X线摄影相比，CEM具有更高敏感性，且对致密乳腺组织女性的优势具有统计学意义\[21]。目前正在开展的对比增强乳腺成像筛查试验（CMIST）正招募乳腺致密的中等风险女性，进行数字乳腺断层合成摄影（DBT）与CEM的前瞻性对比研究。
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000927
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature regarding the use of MRI breast without IV contrast for supplemental screening in average-risk women with heterogeneously dense breasts. 目前尚无相关文献支持对具有不均匀致密乳腺组织的平均风险女性使用无静脉对比剂的乳腺MRI进行补充筛查。
* 检查项目: MRI Breast Without IV Contrast Abbreviated / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000927
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature regarding the use of AB-MRI breast without IV contrast for supplemental screening in average-risk women with heterogeneously dense breasts. 目前尚无相关文献支持在不使用静脉对比剂的情况下，采用AB-MRI乳腺检查对具有不均匀致密乳腺组织的平均风险女性进行补充筛查。
* 检查项目: FDG-PET Breast Dedicated / PET/CT局部(胸部)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0016 / R:CR000926
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature regarding the use of FDG-PET breast dedicated for supplemental screening in average-risk women with heterogeneously dense breasts. 目前尚无关于使用FDG-PET乳腺专用显像对具有不均匀致密乳腺的平均风险女性进行补充筛查的相关文献。
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000929
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: Currently, there is insufficient evidence to support the use of Tc-99m sestamibi MBI as a supplemental screening exam in average-risk women with heterogeneously dense tissue, however, there are emerging data. At present, barriers include lack of incidence around screening, longer examination times, and limited studies addressing the spectrum of breast densities and risk \[7]. MBI is a nuclear medicine study that uses the IV injection of Tc-99m sestamibi to identify mitotically active areas within breast tissue, ideally differentiating malignant tumors from background parenchyma. Although breast- zinc telluride detectors to obtain a functional imaging study, which takes approximately 40 minutes \[30]. The prospective study (1,585 women) by Rhodes et al \[31] and a retrospective study (1,696 women) by Shermis et al \[32] reported a CDR of 7.7 to 8.8 per 1,000 in women with dense breasts. Preliminary data from the Density Molecular Breast Imaging and Tomosynthesis to Eliminate the Reservoir of Undetected Cancers (MATTERS) trial, comparing DBT and MBI, found 7 cancers in 537 women, 6 of which were found by MBI only. All were invasive. The incremental CDR of MBI was 9.3 per 1,000 \[31]. 目前尚无充分证据支持将Tc99m司他比MBI作为中等风险致密乳腺女性的补充筛查手段，但新兴数据正在积累。当前应用障碍包括筛查相关发病率数据缺乏、检查时间较长、以及针对乳腺密度谱和风险的研究有限\[7]。MBI是一种核医学检查，通过静脉注射Tc99m司他比识别乳腺组织中有丝分裂活跃区域，从而区分恶性肿瘤与背景实质。尽管乳腺碲锌镉探测器可获得功能成像检查，耗时约40分钟\[30]。Rhodes等\[31]的前瞻性研究（1,585名女性）与Shermis等\[32]的回顾性研究（1,696名女性）报道致密乳腺女性的癌症检出率（CDR）为7.78.8‰。MATTERS试验初步数据对比DBT与MBI，在537名女性中发现7例癌症，其中6例仅由MBI检出，均为浸润癌。MBI的增量CDR达9.3‰\[31]。

##### S0114 Variant: Variant 3:  Adult female. Supplemental breast cancer screening. Average risk. Extremely dense breasts. | 成人女性，乳腺癌补充筛查，平均风险，致密型乳腺。

检查推荐列表：

* 检查项目: Digital Breast Tomosynthesis Screening / MG双侧乳腺钼靶(筛查)
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0001 / R:CR000930
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Screening mammography has been shown to reduce mortality by approximately 30% to 40% \[3,4]. It is most sensitive in women with nondense tissue. Women with heterogeneously and extremely dense tissue, who can comprise up to half of screening-aged women in the United States, may not receive the same benefit from mammography alone because sensitivity can be reduced by 30% to 48% in extremely dense tissue \[17]. In DBT, the x-ray tube moves in an arc obtaining multiple low-dose mammographic images that are reconstructed into 2-D images. The additional information from varying angles aims to reduce summation shadows and overlapping structures to maximize visibility \[2]. The retrospective PROSPR consortium review evaluated more than 180,000 women; approximately 130,000 were screened with DM and 50,000 with DBT. Women with nondense tissue accounted for 64% of the cohort as compared with 36% with dense tissue. A statistically significant increase in CDR was found in women with both nondense tissue (1.7/1,000) and dense tissue (2.27/1,000) screened with DBT. Cancers tended to be smaller, lymph node negative, and less biologically aggressive \[9]. Li et al \[10] reviewed several studies comparing DBT with 2- D mammography in Europe and the United States and found the pooled CDR to be statistically significant in both nondense and dense tissue. However, Berg et al \[20] found the greatest increase in CDR to be in women with heterogeneously dense breasts. No significant increase in detection was identified in women with extremely dense tissue \[20], highlighting the need for other methods of supplemental screening in this population. Another advantage of DBT is a reduction in recall rate with improved specificity. A few studies have demonstrated this benefit, with the reduction ranging between 15% to 63% in observational, retrospective studies in the United States \[11,12]. In a retrospective cohort study evaluating multiple screening rounds, Sprague et al \[13] found no difference in the interval cancer rate between DBT and DM. The randomized prospective TMIST trial comparing DBT with 2-D mammography is currently active. 筛查性乳腺X线摄影已被证明可将死亡率降低约30%至40%\[3,4]。其在非致密组织女性中敏感性最高。在美国，异质性和极度致密组织女性可占筛查适龄女性的半数，她们可能无法从单纯乳腺X线摄影中获得同等获益，因为在极度致密组织中敏感性可降低30%至48%\[17]。在DBT中，X射线管沿弧线运动获取多个低剂量乳腺图像，并重建为2D图像。来自不同角度的附加信息旨在减少叠加阴影和重叠结构以最大化可视性\[2]。回顾性PROSPR联盟研究评估了超过180,000名女性；约130,000名接受DM筛查，50,000名接受DBT筛查。非致密组织女性占队列的64%，而致密组织女性占36%。在DBT筛查的非致密组织（1.7/1,000）和致密组织（2.27/1,000）女性中均发现CDR有统计学显著增加。癌症往往更小、淋巴结阴性且生物学侵袭性更低\[9]。Li等\[10]回顾了欧洲和美国多项比较DBT与2D乳腺X线摄影的研究，发现合并CDR在非致密和致密组织中均具有统计学显著性。然而，Berg等\[20]发现CDR的最大增幅出现在异质性致密乳腺女性中。在极度致密组织女性中未发现检测率的显著增加\[20]，这凸显了该人群需要其他补充筛查方法。DBT的另一优势是通过提高特异性降低召回率。美国的多项观察性回顾性研究\[11,12]证明了这一益处，降低幅度在15%至63%之间。在一项评估多轮筛查的回顾性队列研究中，Sprague等\[13]发现DBT与DM的间期癌发生率无差异。比较DBT与2D乳腺X线摄影的随机前瞻性TMIST试验目前正在进行中。
* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 7
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0005 / R:CR000931
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: The Dense Tissue and Early Breast Neoplasm Screening (DENSE) trial is a Dutch multicenter, randomized trial in which supplemental MRI identified an additional 16.5 cancers per 1,000 screened in women of all risk stratification \[36]. Additionally, the interval cancer rate of the MRI group was 0.8 per 1,000 compared with the control group, 5.0 per 1,000, suggesting a mortality benefit. In the second round of screening, the false-positive rate dropped to 26.3 per 1,000 from 79.8 per 1,000, and the incremental CDR was 5.8 per 1,000 \[37]. Given the superior detection rate of MRI compared with DBT or US in women with dense breasts, the European Society of Breast Imaging now recommends supplemental screening with MRI in women with extremely dense breast tissue, regardless of risk \[38]. 《致密乳腺组织与早期乳腺肿瘤筛查（DENSE）试验》是一项荷兰多中心随机研究，该研究表明补充性MRI检查在所有风险分层女性中可额外检出16.5例/1000例乳腺癌\[36]。此外，MRI筛查组的间期癌发生率为0.8例/1000例，显著低于对照组的5.0例/1000例，提示其具有降低死亡率的优势。在第二轮筛查中，假阳性率从79.8例/1000例降至26.3例/1000例，增量癌症检出率为5.8例/1000例\[37]。鉴于MRI对致密型乳腺女性的检出率优于数字乳腺断层摄影（DBT）或超声检查，欧洲乳腺影像学会现建议对乳腺组织极度致密的女性进行MRI补充筛查，无需考虑其风险等级\[38]。
* 检查项目: MRI Breast Without and With IV Contrast Abbreviated / MR乳腺(平扫+增强)
  * 评分: 7
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0005 / R:CR000931
  * 证据强度: StrongReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: The standard MRI protocol uses multiple sequences to identify malignancy and characterize benign breast findings requiring longer magnet and interpretation times. The protocol for AB-MRI is variable and even customizable, however, all protocols use a limited number of images to highlight findings in the early postcontrast phase. This technique maximizes cancer detection while reducing the time burden on the patient and the radiologist. Negative studies can be quickly interpreted, reducing physician workload. Lawson et al \[23] found no statistical difference when comparing the sensitivity of standard MRI with AB-MRI (100% to 88.9%). This is consistent with findings from Kuhl et al \[24], Baxter et al \[19], and others \[25,26]. The EA1141 trial demonstrated a CDR (invasive and DCIS) of 15.2 per 1,000 examinations with AB-MRI compared with 6.2 per 1,000 examinations with DBT in average-risk women with dense tissue \[27]. The specificity of AB-MRI was reduced when compared with DBT (87% versus 97%). Clinicians should be aware that baseline imaging may result in benign biopsies or short-term interval follow-ups \[28]. Weinstein et al \[29] reported a CDR of 27.4 per 1,000 in a retrospective review of average- risk women previously screened with DBT. 标准MRI方案采用多序列成像以识别恶性病变并定性需长期磁共振检查与判读的良性乳腺表现。而AB-MRI方案具有可变性甚至可定制化，但所有方案均采用有限数量的图像突出显示早期增强后阶段的异常表现。该技术在最大化癌症检出率的同时，减轻了患者和放射科医师的时间负担。阴性结果可快速判读，从而降低医师工作量。Lawson等\[23]研究发现标准MRI与AB-MRI的灵敏度无统计学差异（100%对比88.9%）。该结果与Kuhl等\[24]、Baxter等\[19]及其他学者\[25,26]的研究结论一致。EA1141试验显示，在乳腺致密的平均风险女性中，AB-MRI的癌症检出率（浸润性癌和导管原位癌）为每1000次检查15.2例，而数字乳腺断层合成摄影（DBT）为6.2例\[27]。与DBT相比，AB-MRI的特异性有所降低（87%对比97%）。临床医师需注意基线成像可能导致良性病变活检或短期间隔随访\[28]。Weinstein等\[29]回顾性研究发现，既往接受DBT筛查的平均风险女性中，AB-MRI的癌症检出率达每1000次检查27.4例。
* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 5
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0003 / R:CR000933
  * 证据强度: StrongReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: Screening breast US can be performed using HHUS or ABUS techniques. Although the sensitivity of mammography in nondense tissue approaches 90%, it can be as low as 30% in women with extremely dense tissue \[17]. Screening US offers improved sensitivity and interval cancer detection particularly in women with dense tissue. A statistically significant CDR of an additional 3.0 per 1,000 breast cancers was identified in average-risk women with dense tissue in a secondary review of the J-START \[33,34]. Additionally, a significant decrease was observed in the interval cancer rate (0.5 per 1,000 compared with 2.0 per 1,000 in the control group). In women with nondense tissue, the J-START trial demonstrated increased cancer detection as well, but this was not supported in 2 other large cohort studies \[18]. The prospective, multicenter ASTOUND-2 trial conducted in screening women with dense tissue found 4.9 per 1,000 additional cancers with HHUS as compared with 2.8 per 1,000 with DBT, although the former had more false-positives \[35]. Although studies have demonstrated increased CDR with the addition of screening US to mammography, this comes at the expense of low biopsy PPVs and high false-positive rates including a high rate of short-term follow-up recommendations \[7,19]. No added benefit of screening US has been found in women who undergo MRI breast or AB-MRI screening \[20]. In women with elevated risk only due to breast density, supplemental screening US could be considered \[7]. 乳腺筛查超声可采用手持式超声（HHUS）或自动乳腺全容积扫描（ABUS）技术进行。虽然乳腺X线摄影对非致密组织的敏感性接近90%，但在乳腺组织极度致密的女性中可低至30%\[17]。筛查超声能提高敏感性并改善间期癌检出率，尤其对致密乳腺组织女性。J-START研究的二次分析显示，在平均风险且乳腺致密的女性中，超声筛查可额外检出3.0例/1000例乳腺癌（具有统计学显著性）\[33,34]，同时观察到间期癌发生率显著降低（0.5例/1000例，对照组为2.0例/1000例）。J-START试验表明超声对非致密组织女性同样增加癌检出率，但另外两项大型队列研究未支持该结论\[18]。针对致密乳腺女性的前瞻性多中心ASTOUND-2试验发现，HHUS较数字乳腺断层合成摄影（DBT）额外检出4.9例/1000例（DBT为2.8例/1000例），但前者假阳性率更高\[35]。尽管研究证实超声联合乳腺X线筛查可提高癌检出率，但需以较低的活检阳性预测值和高假阳性率为代价，包括大量短期随访建议\[7,19]。对于已接受乳腺MRI或AB-MRI筛查的女性，超声筛查未显示额外获益\[20]。仅因乳腺
* 检查项目: Mammography With IV Contrast / MG双侧乳腺钼靶导管造影
  * 评分: 2
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0004 / R:CR000934
  * 证据强度: StrongReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support CEM screening in average-risk women with extremely dense breast tissue. CEM uses a dual-energy technique to acquire 8 standard mammographic images after the administration of IV iodinated contrast material. Four low-energy images mimic a conventional 2-D mammogram. The additional 4 diagnostic recombined images demonstrate contrast enhancement, which offers morphologic as well as functional assessment to identify malignancies. CEM has been valuable in evaluating abnormalities in the diagnostic setting \[14], however, recent literature has indicated that it may play a beneficial role in screening women with dense tissue at an intermediate risk of developing breast cancer or those seeking an alternative supplemental screening modality to MRI \[15]. The CDR in screening studies has ranged from 8.6 to 13.1 cancers per 1,000 screening examinations \[21,22], although most of these were conducted retrospectively at a single institution. CEM offers a higher sensitivity compared with mammography, with the benefit statistically significant in women with dense breast tissue \[21]. The CMIST is currently enrolling intermediate-risk women with dense breasts to participate in a prospective study comparing DBT and CEM. 目前尚无相关文献支持对乳腺组织极度致密的平均风险女性进行对比增强乳腺X线摄影（CEM）筛查。CEM采用双能量技术，在静脉注射碘对比剂后获取8张标准乳腺X线图像，其中4张低能量图像模拟传统二维乳腺X线片，另外4张诊断性重组图像可显示对比剂强化，提供形态学和功能学评估以识别恶性肿瘤。CEM在诊断性评估异常病变方面具有重要价值\[14]，但最新研究表明，该技术可能对中危致密乳腺女性的筛查具有积极作用，或可作为MRI替代的补充筛查手段\[15]。筛查研究显示其癌症检出率（CDR）为每1000例检查8.6-13.1例\[21,22]，但多数为单一机构的回顾性研究。与常规乳腺X线摄影相比，CEM具有更高的敏感性，且对致密乳腺女性的获益具有统计学意义\[21]。目前CMIST研究正在招募中危致密乳腺女性参与一项比较DBT与CEM的前瞻性研究。
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000936
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature regarding the use of MRI breast without IV contrast for supplemental screening in average-risk women with extremely dense breasts. 目前尚无相关文献支持对乳腺组织极度致密的平均风险女性使用无静脉注射对比剂的MRI进行补充筛查。
* 检查项目: MRI Breast Without IV Contrast Abbreviated / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000936
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature regarding the use of AB-MRI breast without IV contrast for supplemental screening in average-risk women with extremely dense breasts. 目前尚无关于在不使用静脉对比剂的情况下，采用AB-MRI乳腺检查对乳腺极度致密的平均风险女性进行补充筛查的相关文献。
* 检查项目: FDG-PET Breast Dedicated / PET/CT局部(胸部)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0016 / R:CR000935
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature regarding the use of FDG-PET breast dedicated for supplemental screening in 目前尚无相关文献探讨将FDGPET乳腺专用显像用于补充筛查的价值。
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000938
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: Currently, there is insufficient evidence to support the use of Tc-99m sestamibi MBI as a supplemental screening examination in average-risk women with extremely dense tissue, however, there are emerging data. At present, barriers include lack of incidence around screening, longer examination times, and limited studies addressing the spectrum of breast densities and risk \[7]. MBI is a nuclear medicine study that uses the IV injection of Tc-99m sestamibi to identify mitotically active areas within breast tissue, ideally differentiating malignant tumors from background parenchyma. Although BSGI uses single detector sodium iodide cameras, MBI employs dual-head cadmium zinc telluride detectors to obtain a functional imaging study, which takes approximately 40 minutes \[30]. The prospective study (1,585 women) by Rhodes et al \[31] and a retrospective study (1,696 women) by Shermis et al \[32] reported a CDR of 7.7 to 8.8 per cancers in 537 women, 6 of which were found by MBI only. All were invasive. The incremental CDR of MBI was 9.3 per 1,000 \[31]. 目前尚无充分证据支持将Tc99m甲氧基异丁基异腈MBI作为乳腺组织极度致密的平均风险女性的补充筛查手段，但已有新兴数据。当前障碍包括缺乏筛查相关发病率数据、检查时间较长以及针对乳腺密度谱和风险的研究有限\[7]。MBI是一种核医学检查，通过静脉注射Tc99m甲氧基异丁基异腈识别乳腺组织内有丝分裂活跃区域，从而理想地区分恶性肿瘤与背景实质。虽然BSGI使用单探头碘化钠相机，但MBI采用双探头碲锌镉探测器获取功能成像检查，耗时约40分钟\[30]。Rhodes等\[31]的前瞻性研究（1,585名女性）和Shermis等\[32]的回顾性研究（1,696名女性）报告在537名女性中检出率为每千例7.7至8.8例癌症，其中6例仅经MBI发现。所有均为浸润癌。MBI的增量检出率为每千例9.3例\[31]。

##### S0115 Variant: Variant 4:  Adult female. Supplemental breast cancer screening. Intermediate risk. Nondense breasts. | 成人女性 辅助性乳腺癌筛查 中等风险 非致密乳腺

检查推荐列表：

* 检查项目: Digital Breast Tomosynthesis Screening / MG双侧乳腺钼靶(筛查)
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0001 / R:CR000939
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Screening mammography has been shown to reduce mortality by approximately 30% to 40% \[3,4]. It is most sensitive in women with nondense tissue. In DBT, the x-ray tube moves in an arc obtaining multiple low-dose mammographic images that are reconstructed into 2-D images. The additional information from varying angles aims to reduce summation shadows and overlapping structures to maximize visibility \[2]. The retrospective PROSPR consortium review evaluated more than 180,000 women; approximately 130,000 were screened with DM and 50,000 with DBT. Women with nondense tissue accounted for 64% of the cohort as compared with 36% with dense tissue. A statistically significant increase in CDR was found in women with both nondense tissue (1.7/1,000) and dense tissue (2.27/1,000) screened with DBT. Cancers tended to be smaller, lymph node negative, and less biologically aggressive \[9]. Li et al \[10] reviewed several studies comparing DBT with 2- D mammography in Europe and the United States and found the pooled CDR to be statistically significant in both nondense and dense tissue. Another advantage of DBT is a reduction in recall rate with improved specificity. A few studies have demonstrated this benefit with the reduction ranging between 15% to 63% in observational, retrospective studies in the United States \[11,12]. In a retrospective cohort study evaluating multiple screening rounds, Sprague et al \[13] found no difference in the interval cancer rate between DBT and DM. The randomized prospective TMIST trial comparing DBT with 2-D mammography is currently active. 乳腺X线筛查已被证实可降低约30%至40%的死亡率\[3,4]，其对非致密型乳腺组织女性的检测灵敏度最高。在数字乳腺断层合成摄影（DBT）中，X射线管沿弧线运动获取多幅低剂量乳腺影像，经重建生成二维图像。这种多角度采集的附加信息旨在减少叠加阴影与结构重叠，从而最大化病灶可视性\[2]。PROSPR联盟回顾性研究评估了超过18万女性，其中约13万接受数字乳腺摄影（DM）筛查，5万接受DBT筛查。非致密型乳腺组织女性占队列64%，致密型占36%。统计显示，DBT筛查使非致密型组织女性的癌症检出率（CDR）显著提升至1.7‰，致密型组织提升至2.27‰，且检出肿瘤更趋小型化、淋巴结阴性率更高、生物学侵袭性更低\[9]。Li等\[10]综述欧美多项DBT与二维乳腺摄影对比研究，发现无论非致密或致密组织，其汇总CDR均具统计学显著性。DBT另一优势是通过提升特异性降低召回率，美国多项观察性回顾研究显示其降幅达15%-63%\[11,12]。Sprague等\[13]在多轮筛查的回顾性队列研究中发现DBT与DM的间期癌发生率无差异。目前正在进行的TMIST随机前瞻
* 检查项目: MRI Breast Without and With IV Contrast Abbreviated / MR乳腺(平扫+增强)
  * 评分: 5
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0005 / R:CR000941
  * 证据强度: StrongReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is limited relevant specific literature regarding the use of AB-MRI without and with IV contrast for supplemental screening in intermediate-risk women with nondense breasts. However, given the multiplicity of studies that demonstrate similar diagnostic accuracy between full protocol MRI and AB-MRI \[23-28], the benefit may be comparable in certain patient populations. 关于在中风险非致密乳腺女性中使用无和有静脉对比剂的AB-MRI进行补充筛查的相关具体文献有限。然而，鉴于多项研究表明完整方案MRI与AB-MRI具有相似的诊断准确性\[23-28]，在某些患者群体中其获益可能相当。
* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 5
  * 适宜性: May be appropriate (Disagreement) / 可能适宜（存在争议）
  * 编码: P:PR0005 / R:CR000941
  * 证据强度: Expert OpinionReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: A retrospective review by Sippo et al \[3] demonstrated similar CDRs in the high-risk group (BRCA mutation carrier/history of chest radiation therapy \[RT]), compared with the intermediate-risk group (personal history/high- risk lesion). The CDR for BRCA/RT was 26 per 1,000 as compared with 12 per 1,000 (personal history) and 15 per 1,000 (high-risk lesion). The group with elevated risk from family history alone did not show a similar benefit. The groups were not stratified by breast density. A review of several single-institution retrospective studies conducted by Bahl \[39] in women with intermediate risk with varying breast densities demonstrated CDRs ranging between 11-16/1000. Women with a history of ALH or ADH did not benefit as greatly as women with LCIS. Sippo等人的回顾性研究\[3]显示，高风险组（BRCA突变携带者/胸部放射治疗\[RT]史）与中风险组（个人病史/高风险病变）的癌症检出率（CDR）相似。BRCA/RT组的CDR为每1000人26例，而个人病史组为每1000人12例，高风险病变组为每1000人15例。仅因家族史而风险升高的组别未显示出类似的获益。研究未按乳腺密度进行分层。Bahl\[39]对多项单机构回顾性研究的综述表明，在不同乳腺密度的中风险女性中，CDR范围为每1000人11-16例。有ALH或ADH病史的女性获益不如有LCIS病史的女性显著。
* 检查项目: Mammography With IV Contrast / MG双侧乳腺钼靶导管造影
  * 评分: 3
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0004 / R:CR000942
  * 证据强度: StrongReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: CEM uses a dual-energy technique to acquire 8 standard mammographic images after the administration of IV iodinated contrast material. Four low-energy images mimic a conventional 2-D mammogram. The additional 4 diagnostic recombined images demonstrate contrast enhancement, which offers morphologic as well as functional \[14], however, recent literature has indicated that it may play a beneficial role in screening women with dense tissue at an intermediate risk of developing breast cancer or those seeking an alternative supplemental screening modality to MRI \[15]. The CDR in screening studies has ranged from 8.6 to 13.1 cancers per 1,000 screening examinations \[21,22], although most of these were conducted retrospectively at a single institution. In an observational, retrospective study evaluating diagnostic accuracy of lobular neoplasia, CEM had a sensitivity of 100% and a specificity of 88% \[41]. 对比增强乳腺X线摄影采用双能量技术，在静脉注射碘对比剂后获取8张标准乳腺图像。其中4张低能量图像模拟传统二维乳腺X线片，另外4张诊断性重组图像显示对比剂强化，同时提供形态学和功能学信息\[14]。然而近期文献表明，该技术可能对致密乳腺组织且中危乳腺癌风险女性、或寻求MRI替代补充筛查方案者具有积极作用\[15]。筛查研究中的癌症检出率为每1000次筛查检查8.6至13.1例\[21,22]，但多数为单机构回顾性研究。一项评估小叶肿瘤诊断准确性的观察性回顾研究显示，对比增强乳腺X线摄影的敏感性为100%，特异性为88%\[41]。
* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 3
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0003 / R:CR000943
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: Screening breast US can be performed using HHUS or ABUS techniques. Although the sensitivity of mammography in nondense tissue approaches 90%, it can be as low as 30% in women with extremely dense tissue \[17]. In women with nondense tissue, the J-START trial demonstrated increased cancer detection, but this was not supported in 2 other large cohort studies \[18]. Although studies have demonstrated increased CDR with the addition of screening US to mammography, this comes at the expense of low biopsy PPVs and high false-positive rates including a high rate of short-term follow-up recommendations \[7,19]. No added benefit of screening US has been found in women who undergo MRI breast or AB-MRI screening \[20]. 乳腺筛查超声可采用手持超声（HHUS）或自动乳腺超声（ABUS）技术进行。虽然乳腺X线摄影对非致密组织的敏感性接近90%，但在乳腺组织极度致密的女性中可低至30%\[17]。J-START试验证实非致密组织女性中癌症检出率有所提升，但另外两项大型队列研究未支持该结论\[18]。尽管研究表明在乳腺X线摄影基础上增加筛查超声可提高癌症检出率（CDR），但代价是活检阳性预测值（PPV）较低、假阳性率较高（包括短期随访建议率高）\[7,19]。对于接受乳腺MRI或AB-MRI筛查的女性，尚未发现筛查超声能带来额外获益\[20]。
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000945
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature regarding the use of MRI breast without IV contrast for supplemental screening in intermediate-risk women with nondense breasts. 目前尚无关于在不使用静脉对比剂的情况下，对中等风险且乳腺组织非致密的女性进行乳腺MRI补充筛查的相关文献。
* 检查项目: MRI Breast Without IV Contrast Abbreviated / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000945
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature regarding the use of AB-MRI breast without IV contrast for supplemental screening in intermediate-risk women with nondense breasts. 目前尚无关于在不使用静脉对比剂的情况下，采用AB-MRI乳腺检查对中等风险且乳腺组织非致密女性进行补充筛查的相关文献。
* 检查项目: FDG-PET Breast Dedicated / PET/CT局部(胸部)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0016 / R:CR000944
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature regarding the use of FDG-PET breast dedicated for supplemental screening in intermediate-risk women with nondense breasts. 目前尚无关于使用FDG-PET乳腺专用显像对中等风险非致密乳腺女性进行补充筛查的相关文献。
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000947
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature regarding the use of Tc-99m sestamibi MBI for supplemental screening in intermediate-risk women with nondense breasts. This modality is not yet widely used in clinical practice. 目前尚无关于使用锝-99m甲氧基异丁基异腈（MBI）对中等风险非致密型乳腺女性进行补充筛查的相关文献报道。该检查方法尚未在临床实践中广泛应用。

##### S0116 Variant: Variant 5:  Adult female. Supplemental breast cancer screening. Intermediate risk. Heterogeneously dense breasts. | 成人女性 辅助性乳腺癌筛查 中等风险 不均匀致密乳腺

检查推荐列表：

* 检查项目: Digital Breast Tomosynthesis Screening / MG双侧乳腺钼靶(筛查)
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0001 / R:CR000948
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Screening mammography has been shown to reduce mortality by approximately 30% to 40% \[3,4]. It is most sensitive in women with nondense tissue. Women with heterogeneously and extremely dense tissue, who can comprise up to half of screening-aged women in the United States, may not receive the same benefit from In DBT, the x-ray tube moves in an arc obtaining multiple low-dose mammographic images that are reconstructed into 2-D images. The additional information from varying angles aims to reduce summation shadows and overlapping structures to maximize visibility \[2]. The retrospective PROSPR consortium review evaluated more than 180,000 women; approximately 130,000 were screened with DM and 50,000 with DBT. Women with nondense tissue accounted for 64% of the cohort as compared with 36% with dense tissue. A statistically significant increase in CDR was found in women with both nondense tissue (1.7/1,000) and dense tissue (2.27/1,000) screened with DBT. Cancers tended to be smaller, lymph node negative, and less biologically aggressive \[9]. Li et al \[10] reviewed several studies comparing DBT with 2- D mammography in Europe and the United States and found the pooled CDR to be statistically significant in both nondense and dense tissue. However, Berg et al \[20] found the greatest increase in CDR to be in women with heterogeneously dense breasts. No significant increase in detection was identified in women with extremely dense tissue \[20], highlighting the need for other methods of supplemental screening in this population. Another advantage of DBT is a reduction in recall rate with improved specificity. A few studies have demonstrated this benefit with the reduction ranging between 15% to 63% in observational, retrospective studies in the United States \[11,12]. In a retrospective cohort study evaluating multiple screening rounds, Sprague et al \[13] found no difference in the interval cancer rate between DBT and DM. The randomized prospective TMIST trial comparing DBT with 2-D mammography is currently active. 筛查性乳腺X线摄影已被证实可降低约30%至40%的死亡率\[3,4]。其对非致密乳腺组织女性的敏感性最高。在美国占筛查年龄女性半数以上的异质致密及极度致密组织女性，可能无法从单纯乳腺X线摄影中获得同等收益。在数字乳腺断层合成摄影中，X射线管沿弧线运动获取多个低剂量乳腺影像并重建为二维图像。多角度提供的附加信息旨在减少叠加阴影和结构重叠以最大化可视性\[2]。回顾性PROSPR联盟研究评估了超过18万名女性，其中约13万人接受数字乳腺X线摄影筛查，5万人接受断层合成摄影筛查。非致密组织女性占队列的64%，致密组织女性占36%。统计学显示断层合成摄影在非致密组织女性（1.7/1000）和致密组织女性（2.27/1000）中均显著提高了癌症检出率。检出的癌症往往更小、淋巴结阴性且生物学侵袭性更低\[9]。Li等\[10]综述了欧美多项比较断层合成摄影与二维乳腺X线摄影的研究，发现非致密与致密组织的汇总癌症检出率均存在统计学显著差异。然而Berg等\[20]发现癌症检出率的最大增幅出现在异质致密乳腺女性中，极度致密组织女性未发现显著提高\[20]，这凸显了该人群需要其他补充筛查方法。断层合成摄影的另一优势是通过提升特异性降低召回率。美国多项观察性回顾研究显示召回率降幅达15%至63%\[11,12]。Sprague等\[13]在评估多轮筛查的回顾性队列研究中发现断层合成摄影与数字乳腺X线摄影的间期癌发生率无差异。目前正在开展比较断层合成摄影与二维乳腺X线摄影的随机前瞻性TMIST试验。
* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 7
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0005 / R:CR000949
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: A retrospective review by Sippo et al \[3] demonstrated similar CDRs in the high-risk group (BRCA mutation carrier/history of chest RT), compared with the intermediate-risk group (personal history/high-risk lesion). The CDR for BRCA/RT was 26 per 1,000 as compared with 12 per 1,000 (personal history) and 15 per 1,000 (high-risk lesion). The group with elevated risk from family history alone did not show a similar benefit. The groups were not stratified by breast density. In a review of 22 randomized clinical trials and observational prospective studies, supplemental MRI had a CDR of 19.9 per 1,000 versus 4.5 per 100 HHUS versus 3.2 per 1,000 DBT in average- and intermediate-risk women with dense tissue \[17]. In women with a higher than average risk of developing breast cancer and dense tissue, supplemental screening with breast MRI is advised \[7]. Sippo等人的回顾性研究\[3]显示，高风险组（BRCA突变携带者/胸部放疗史）与中风险组（个人病史/高风险病变）的癌症检出率(CDR)相近。BRCA/RT组的CDR为每1000例26例，而个人病史组为每1000例12例，高风险病变组为每1000例15例。仅因家族史导致风险升高的组别未显示出类似获益。研究未按乳腺密度进行分层。在对22项随机临床试验和前瞻性观察研究的综述中，对于乳腺组织致密的平均风险和中风险女性，补充MRI的CDR为每1000例19.9例，而手持超声(HHUS)为每1000例4.5例，数字乳腺断层摄影(DBT)为每1000例3.2例\[17]。对于乳腺癌风险高于平均水平且乳腺组织致密的女性，建议采用乳腺MRI进行补充筛查\[7]。
* 检查项目: MRI Breast Without and With IV Contrast Abbreviated / MR乳腺(平扫+增强)
  * 评分: 7
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0005 / R:CR000949
  * 证据强度: StrongReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: The standard MRI protocol uses multiple sequences to identify malignancy and characterize benign breast findings requiring longer magnet and interpretation times. The protocol for AB-MRI is variable and even customizable, however, all protocols use a limited number of images to highlight findings in the early postcontrast phase. This technique maximizes cancer detection while reducing the time burden on the patient and the radiologist. Negative studies can be quickly interpreted, reducing physician workload. Lawson et al \[23] found no statistical difference when comparing the sensitivity of standard MRI with AB-MRI (100% to 88.9%). This is consistent with findings from Kuhl et al \[24], Baxter et al \[19], and others \[25,26]. The EA1141 trial demonstrated a CDR (invasive and DCIS) of 15.2 per 1,000 examinations with AB-MRI compared with 6.2 per 1,000 examinations with DBT in (87% versus 97%). Clinicians should be aware that baseline imaging may result in benign biopsies or short-term interval follow-ups \[28]. Weinstein et al \[29] reported a CDR of 27.4 per 1,000 in a retrospective review of average- risk women previously screened with DBT. 标准MRI方案使用多个序列识别恶性肿瘤并表征良性乳腺病变，需要更长的磁共振扫描和判读时间。ABMRI方案多变甚至可定制，但所有方案均使用有限数量的图像突出显示早期增强后阶段的发现。该技术最大程度提高癌症检出率，同时减少患者和放射科医师的时间负担。阴性研究可快速判读，减轻医师工作量。Lawson等\[23]发现标准MRI与ABMRI的敏感性无统计学差异（100%对比88.9%）。这与Kuhl等\[24]、Baxter等\[19]及其他研究者\[25,26]的结果一致。EA1141试验显示ABMRI的癌症检出率（浸润性癌和导管原位癌）为每1,000次检查15.
* 检查项目: Mammography With IV Contrast / MG双侧乳腺钼靶导管造影
  * 评分: 5
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0004 / R:CR000951
  * 证据强度: StrongReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: CEM uses a dual-energy technique to acquire 8 standard mammographic images after the administration of IV iodinated contrast material. Four low-energy images mimic a conventional 2-D mammogram. The additional 4 diagnostic recombined images demonstrate contrast enhancement, which offers morphologic as well as functional assessment to identify malignancies. CEM has been valuable in evaluating abnormalities in the diagnostic setting \[14], however, recent literature has indicated that it may play a beneficial role in screening women with dense tissue at an intermediate risk of developing breast cancer or those seeking an alternative supplemental screening modality to MRI \[15]. The CDR in screening studies has ranged from 8.6 to 13.1 cancers per 1,000 screening examinations \[21,22], although most of these were conducted retrospectively at a single institution. CEM offers a higher sensitivity compared with mammography, with the benefit statistically significant in women with dense breast tissue \[21]. The CMIST is currently enrolling intermediate-risk women with dense breasts to participate in a prospective study comparing DBT and CEM. 对比增强乳腺X线摄影（CEM）采用双能技术，在静脉注射碘对比剂后获取8幅标准乳腺影像。其中4幅低能图像模拟传统二维乳腺X线片，另外4幅诊断性重组图像可显示对比剂强化，提供形态学与功能学双重评估以识别恶性肿瘤。CEM在诊断性检查中对异常病变评估具有重要价值\[14]。最新研究表明，该技术对中等乳腺癌风险且致密型乳腺女性的筛查，或需替代MRI补充筛查方案的人群可能具有优势\[15]。筛查研究显示其癌症检出率（CDR）为每1000例检查8.6-13.1例\[21,22]，但多数为单机构回顾性研究。相较于传统乳腺X线摄影，CEM具有更高敏感性，且对致密型乳腺女性的优势具有统计学意义\[21]。目前CMIST研究正在招募中等风险致密型乳腺女性，开展一项比较数字乳腺断层合成（DBT）与CEM的前瞻性研究。
* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 5
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0003 / R:CR000952
  * 证据强度: StrongReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: Screening breast US can be performed using HHUS or ABUS techniques. Although the sensitivity of mammography in nondense tissue approaches 90%, it can be as low as 30% in women with extremely dense tissue \[17]. Screening US offers improved sensitivity and interval cancer detection particularly in women with dense tissue. A statistically significant CDR of an additional 3.0 per 1,000 breast cancers was identified in average-risk women with dense tissue in a secondary review of the J-START \[33,34]. Additionally, a significant decrease was observed in the interval cancer rate (0.5 per 1,000 as compared with 2.0 per 1,000 in the control group). In women with nondense tissue, the J-START trial demonstrated increased cancer detection as well, but this was not supported in 2 other large cohort studies \[18]. The prospective, multicenter ASTOUND-2 trial conducted in screening women with dense tissue found 4.9 per 1,000 additional cancers with HHUS as compared with 2.8 per 1,000 with DBT, although the former had more false-positives \[35]. Although studies have demonstrated increased CDR with the addition of screening US to mammography, this comes at the expense of low biopsy PPVs and high false-positive rates including a high rate of short-term follow-up recommendations \[7,19]. No added benefit of screening US has been found in women who undergo MRI breast or AB-MRI screening \[20]. In women with an elevated risk of breast cancer and dense tissue who cannot undergo supplemental screening with MRI, breast US could be considered \[7]. 乳腺筛查超声可采用手持式超声（HHUS）或自动乳腺全容积扫描（ABUS）技术进行。虽然乳腺X线摄影对非致密组织的敏感性接近90%，但在乳腺组织极度致密的女性中可低至30%\[17]。筛查超声能提高敏感性并改善间期癌检出率，尤其对致密型乳腺女性更具优势。J-START研究的二次分析显示，在平均风险且乳腺致密的女性中，超声筛查可额外检出3.0例/1000例乳腺癌（具有统计学显著性）\[33,34]，同时观察到间期癌发生率显著降低（0.5例/1000例，对照组为2.0例/1000例）。J-START试验在非致密乳腺女性中也观察到癌症检出率提升，但另外两项大型队列研究未支持该结论\[18]。针对致密型乳腺女性的前瞻性多中心ASTOUND-2试验发现，HHUS较数字乳腺断层合成摄影（DBT）可多检出4.9例/1000例癌症（DBT为2.8例/1000例），但前者假阳性率更高\[35]。尽管研究表明在乳腺X线摄影基础上联合超声筛查可提高癌症检出率，但需以较低的活检阳性预测值（PPV）和较高的假阳性率为代价，包括更多短期随访建议\[7,19]。对于已接受乳腺MRI或快速乳腺MRI筛查的女性，超声
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000954
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature regarding the use of MRI breast without IV contrast for supplemental screening in intermediate-risk women with heterogeneously dense breasts. 目前尚无相关文献支持在不使用静脉造影剂的情况下，对具有不均匀致密乳腺的中等风险女性进行MRI乳腺检查作为补充筛查手段。
* 检查项目: MRI Breast Without IV Contrast Abbreviated / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000954
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature regarding the use of AB-MRI breast without IV contrast for supplemental screening in intermediate-risk women with heterogeneously dense breasts. 目前尚无关于在不使用静脉对比剂的情况下应用AB-MRI乳腺检查对具有不均匀致密乳腺的中等风险女性进行补充筛查的相关文献。
* 检查项目: FDG-PET Breast Dedicated / PET/CT局部(胸部)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0016 / R:CR000953
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature regarding the use of FDG-PET breast dedicated for supplemental screening in intermediate-risk women with heterogeneously dense breasts. 目前尚无关于使用FDG-PET乳腺专用显像对具有不均匀致密乳腺的中危女性进行补充筛查的相关文献。
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000956
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: Currently, there is insufficient evidence to support the use of Tc-99m sestamibi MBI as a supplemental screening exam in intermediate-risk women with heterogeneously dense tissue, however, there are emerging data. At present, barriers include lack of incidence around screening, longer examination times, and limited studies addressing the spectrum of breast densities and risk \[7]. MBI is a nuclear medicine study that uses the IV injection of Tc-99m sestamibi to identify mitotically active areas within breast tissue, ideally differentiating malignant tumors from background parenchyma. Although BSGI uses single detector sodium iodide cameras, MBI employs dual-head cadmium zinc telluride detectors to obtain a functional imaging study, which takes approximately 40 minutes \[30]. The prospective study (1,585 women) by Rhodes et al \[31] and a retrospective study (1,696 women) by Shermis et al \[32] reported a CDR of 7.7 to 8.8 per 1,000 in women with dense breasts. Preliminary data from the MATTERS trial, comparing DBT and MBI, found 7 cancers in 537 women, 6 of which were found by MBI only. All were invasive. The incremental CDR of MBI was 9.3 per 1,000 \[31]. 目前尚无充分证据支持将Tc-99m甲氧基异丁基异腈（MBI）作为中等风险且乳腺组织致密不均女性的补充筛查手段，但相关研究数据正在积累。当前存在的障碍包括：筛查相关发病率数据不足、检查时间较长、以及针对不同乳腺密度谱和风险水平的研究有限\[7]。MBI是一种核医学检查技术，通过静脉注射Tc-99m甲氧基异丁基异腈来识别乳腺组织中细胞分裂活跃区域，从而有效区分恶性肿瘤与背景实质组织。与采用单探头碘化钠相机的乳腺特异性伽马成像（BSGI）不同，MBI使用双头碲锌镉探测器进行功能成像检查，耗时约40分钟\[30]。Rhodes等\[31]的前瞻性研究（1,585名女性）和Shermis等\[32]的回顾性研究（1,696名女性）报告显示，在致密乳腺女性中MBI的癌症检出率（CDR）为每1,000人7.7至8.8例。MATTERS试验（比较数字乳腺断层合成摄影DBT与MBI）的初步数据显示，537名女性中发现7例癌症，其中6例仅通过MBI检出，且均为浸润性癌。MBI的增量CDR达到每1,000人9.3例\[31]。

##### S0117 Variant: Variant 6:  Adult female. Supplemental breast cancer screening. Intermediate risk. Extremely dense breasts. | 成人女性 辅助性乳腺癌筛查 中等风险 极度致密乳腺

检查推荐列表：

* 检查项目: Digital Breast Tomosynthesis Screening / MG双侧乳腺钼靶(筛查)
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0001 / R:CR000957
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Screening mammography has been shown to reduce mortality by approximately 30% to 40% \[3,4]. It is most sensitive in women with nondense tissue. Women with heterogeneously and extremely dense tissue, who can comprise up to half of screening-aged women in the United States, may not receive the same benefit from In DBT, the x-ray tube moves in an arc obtaining multiple low-dose mammographic images that are reconstructed into 2-D images. The additional information from varying angles aims to reduce summation shadows and overlapping structures to maximize visibility \[2]. The retrospective PROSPR consortium review evaluated more than 180,000 women; approximately 130,000 were screened with DM and 50,000 with DBT. Women with nondense tissue accounted for 64% of the cohort as compared with 36% with dense tissue. A statistically significant increase in CDR was found in women with both nondense tissue (1.7/1,000) and dense tissue (2.27/1,000) screened with DBT. Cancers tended to be smaller, lymph node negative, and less biologically aggressive \[9]. Li et al \[10] reviewed several studies comparing DBT with 2- D mammography in Europe and the United States and found the pooled CDR to be statistically significant in both nondense and dense tissue. However, Berg et al \[20] found the greatest increase in CDR to be in women with heterogeneously dense breasts. No significant increase in detection was identified in women with extremely dense tissue \[20], highlighting the need for other methods of supplemental screening in this population. Another advantage of DBT is a reduction in recall rate with improved specificity. A few studies have demonstrated this benefit, with the reduction ranging between 15% to 63% in observational, retrospective studies in the United States \[11,12]. In a retrospective cohort study evaluating multiple screening rounds, Sprague et al \[13] found no difference in the interval cancer rate between DBT and DM. The randomized prospective TMIST trial comparing DBT with 2-D mammography is currently active. 筛查性乳腺X线摄影已被证明可降低约30%至40%的死亡率\[3,4]。其对非致密组织女性的敏感性最高。在美国，具有异质性和极度致密组织的女性可能占筛查适龄女性的一半，但她们可能无法从DBT中获得同等益处。在DBT中，X射线管沿弧线运动，获取多个低剂量乳腺影像，并重建为2D图像。来自不同角度的附加信息旨在减少叠加阴影和重叠结构，以最大化可视性\[2]。回顾性PROSPR联盟研究评估了超过180,000名女性；约130,000名接受了DM筛查，50,000名接受了DBT筛查。非致密组织女性占队列的64%，而致密组织女性占36%。在采用DBT筛查的女性中，非致密组织（1.7/1,000）和致密组织（2.27/1,000）的CDR均出现统计学显著增加。癌症往往更小、淋巴结阴性且生物学侵袭性较低\[9]。Li等\[10]回顾了欧洲和美国多项比较DBT与2D乳腺X线摄影的研究，发现汇总CDR在非致密和致密组织中均具有统计学显著性。然而，Berg等\[20]发现CDR的最大增加出现在具有异质性致密乳房的女性中。在极度致密组织女性中未发现检测率的显著增加\[20]，这凸显了在该人群中进行其他补充筛查方法的必要性。DBT的另一个优势是通过提高特异性降低召回率。一些研究已证明这一益处，在美国的观察性回顾性研究中，降低幅度介于15%至63%之间\[11,12]。在一项评估多轮筛查的回顾性队列研究中，Sprague等\[13]发现DBT与DM的间期癌率无差异。比较DBT与2D乳腺X线摄影的随机前瞻性TMIST试验目前正在进行中。
* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 7
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0005 / R:CR000958
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: The DENSE trial is a Dutch multicenter, randomized trial in which supplemental MRI identified an additional 16.5 cancers per 1,000 screened in women of all risk stratification \[36]. Additionally, the interval cancer rate of the MRI group was 0.8 per 1,000 as compared with the control group 5.0 per 1,000, suggesting a mortality benefit. In the second round of screening, the false-positive rate dropped to 26.3 per 1,000 from 79.8 per 1,000, and the incremental CDR was 5.8 per 1,000 \[37]. Given the superior detection rate of MRI compared with DBT or US in women with dense breasts, the European Society of Breast Imaging now recommends supplemental screening with MRI in women with extremely dense breast tissue, regardless of risk \[38]. DENSE试验是一项荷兰多中心随机研究，结果显示补充MRI检查在所有风险分层女性中额外检出16.5例/1000例癌症\[36]。此外，MRI组的间期癌症发生率为0.8例/1000例，而对照组为5.0例/1000例，提示存在死亡率获益。在第二轮筛查中，假阳性率从79.8例/1000例降至26.3例/1000例，增量癌症检出率为5.8例/1000例\[37]。鉴于MRI对致密型乳腺女性的检出率优于数字乳腺断层摄影或超声，欧洲乳腺影像学会现建议对极度致密乳腺组织女性进行MRI补充筛查，不论其风险水平如何\[38]。
* 检查项目: MRI Breast Without and With IV Contrast Abbreviated / MR乳腺(平扫+增强)
  * 评分: 7
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0005 / R:CR000958
  * 证据强度: StrongReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: The standard MRI protocol uses multiple sequences to identify malignancy and characterize benign breast findings requiring longer magnet and interpretation times. The protocol for AB-MRI is variable and even customizable, however, all protocols use a limited number of images to highlight findings in the early postcontrast phase. This technique maximizes cancer detection while reducing the time burden on the patient and the radiologist. Negative studies can be quickly interpreted, reducing physician workload. Lawson et al \[23] found no statistical difference when comparing the sensitivity of standard MRI with AB-MRI (100% to 88.9%). This is consistent with findings from Kuhl et al \[24], Baxter et al \[19], and others \[25,26]. In a prospective observational reader study of 443 women Clinicians should be aware that baseline imaging may result in benign biopsies or short-term interval follow-ups \[28]. 标准MRI方案使用多个序列识别恶性肿瘤并表征良性乳腺病变，需要更长的磁共振扫描和判读时间。ABMRI方案多变甚至可定制，但所有方案均使用有限数量的图像突出显示早期增强后阶段的发现。该技术最大程度提高癌症检出率，同时减少患者和放射科医师的时间负担。阴性研究可快速判读，减轻医师工作量。Lawson等\[23]发现标准MRI与ABMRI的敏感性无统计学差异（100%对比88.9%）。这与Kuhl等\[24]、Baxter等\[19]及其他研究者\[25,26]的结果一致。在一项涉及443名女性的前瞻性观察性读者研究中，临床医师应意识到基线成像可能导致良性活检或短期间隔随访\[28]。
* 检查项目: Mammography With IV Contrast / MG双侧乳腺钼靶导管造影
  * 评分: 6
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0004 / R:CR000960
  * 证据强度: StrongReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: CEM uses a dual-energy technique to acquire 8 standard mammographic images after the administration of IV iodinated contrast material. Four low-energy images mimic a conventional 2-D mammogram. The additional 4 diagnostic recombined images demonstrate contrast enhancement, which offers morphologic as well as functional assessment to identify malignancies. CEM has been valuable in evaluating abnormalities in the diagnostic setting \[14], however, recent literature has indicated that it may play a beneficial role in screening women with dense tissue at an intermediate risk of developing breast cancer or those seeking an alternative supplemental screening modality to MRI \[15]. The CDR in screening studies has ranged from 8.6 to 13.1 cancers per 1,000 screening examinations \[21,22], although most of these were conducted retrospectively at a single institution. CEM offers a higher sensitivity compared with mammography, with the benefit statistically significant in women with dense breast tissue \[21]. The CMIST is currently enrolling intermediate-risk women with dense breasts to participate in a prospective study comparing DBT and CEM. In an observational, retrospective study evaluating diagnostic accuracy of lobular neoplasia, CEM had a sensitivity of 100% and a specificity of 88% \[41]. 对比增强乳腺X线摄影（CEM）采用双能量技术，在静脉注射碘对比剂后获取8幅标准乳腺影像。其中4幅低能量图像模拟传统二维乳腺X线片，另外4幅诊断性重组图像可显示对比剂强化，提供形态学与功能学双重评估以识别恶性肿瘤。CEM在诊断性检查中评估异常病变具有重要价值\[14]，最新研究表明其对中等乳腺癌风险且乳腺组织致密的女性筛查，或需替代MRI补充筛查方案的群体可能具有优势\[15]。筛查研究显示其癌症检出率（CDR）为每1000例检查8.6-13.1例\[21,22]，但多数为单机构回顾性研究。相较于传统乳腺X线摄影，CEM具有更高敏感性，对致密乳腺组织女性的统计学获益尤为显著\[21]。目前CMIST研究正在招募中等风险且乳腺致密的女性，开展DBT与CEM的前瞻性对照研究。一项评估小叶肿瘤诊断准确性的回顾性观察性研究显示，CEM的敏感性和特异性分别达100%和88%\[41]。
* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 5
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0003 / R:CR000961
  * 证据强度: StrongReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: Screening breast US can be performed using HHUS or ABUS techniques. Although the sensitivity of mammography in nondense tissue approaches 90%, it can be as low as 30% in women with extremely dense tissue \[17]. Screening US offers improved sensitivity and interval cancer detection, particularly in women with dense tissue. A statistically significant CDR of an additional 3.0 per 1,000 breast cancers was identified in average-risk women with dense tissue in a secondary review of the J-START \[33,34]. Additionally, a significant decrease was observed in the interval cancer rate (0.5 per 1,000 compared with 2.0 per 1,000 in the control group). In women with nondense tissue, the J-START trial demonstrated increased cancer detection as well, but this was not supported in 2 other large cohort studies \[18]. The prospective, multicenter ASTOUND-2 trial conducted in screening women with dense tissue found 4.9 per 1,000 additional cancers with HHUS as compared with 2.8 per 1,000 with DBT, although the former had more false-positives \[35]. Although studies have demonstrated increased CDR with the addition of screening US to mammography, this comes at the expense of low biopsy PPVs and high false-positive rates including a high rate of short-term follow-up recommendations \[7,19]. No added benefit of screening US has been found in women who undergo MRI breast or AB-MRI screening \[20]. In women with an elevated risk of breast cancer and dense tissue who cannot undergo supplemental screening with MRI, breast US could be considered \[7]. 乳腺筛查超声可采用手持超声（HHUS）或自动乳腺全容积超声（ABUS）技术进行。虽然乳腺X线摄影对非致密组织的敏感性接近90%，但在乳腺组织极度致密的女性中可低至30%\[17]。筛查超声能提高敏感性及间期癌检出率，尤其对致密乳腺组织女性。J-START研究的二次分析显示，在平均风险但乳腺组织致密的女性中，超声筛查可额外检出3.0例/1000例乳腺癌（具有统计学显著性）\[33,34]，同时观察到间期癌发生率显著降低（0.5例/1000例，对照组为2.0例/1000例）。J-START试验在非致密组织女性中也观察到癌症检出率提升，但另外两项大型队列研究未支持该结论\[18]。针对致密乳腺女性的前瞻性多中心ASTOUND-2试验发现，HHUS较数字乳腺断层合成摄影（DBT）可多检出4.9例/1000例癌症（DBT为2.8例/1000例），但前者假阳性率更高\[35]。尽管研究证实超声联合乳腺X线摄影可提高癌症检出率，但代价是活检阳性预测值较低、假阳性率较高（包括短期随访建议率较高）\[7,19]。对于已接受乳腺MRI或快速乳腺MRI筛查的女性，未发现超声筛查具有额外获益\[20]。
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000963
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature regarding the use of MRI breast without IV contrast for supplemental screening in intermediate-risk women with extremely dense breasts. 目前尚无相关文献支持在不使用静脉对比剂的情况下，对乳腺组织极度致密的中危女性进行MRI乳腺检查作为补充筛查手段。
* 检查项目: MRI Breast Without IV Contrast Abbreviated / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000963
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature regarding the use of AB-MRI breast without IV contrast for supplemental screening in intermediate-risk women with extremely dense breasts. 目前尚无相关文献探讨在不使用静脉对比剂的情况下，采用AB-MRI乳腺检查对乳腺极度致密的中等风险女性进行补充筛查的效果。
* 检查项目: FDG-PET Breast Dedicated / PET/CT局部(胸部)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0016 / R:CR000962
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature regarding the use of FDG-PET breast dedicated for supplemental screening in intermediate-risk women with extremely dense breasts. 目前尚无关于使用FDG-PET乳腺专用显像对极高密度乳腺的中危女性进行补充筛查的相关文献。
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000965
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: Currently, there is insufficient evidence to support the use of Tc-99m sestamibi MBI as a supplemental screening exam in intermediate-risk women with extremely dense tissue, however, there are emerging data. At present, barriers include lack of incidence around screening, longer examination times, and limited studies addressing the spectrum of breast densities and risk \[7]. MBI is a nuclear medicine study that uses the IV injection of Tc-99m sestamibi to identify mitotically active areas within breast tissue, ideally differentiating malignant tumors from background parenchyma. Although BSGI uses single detector sodium iodide cameras, MBI employs dual-head cadmium zinc telluride detectors to obtain a functional imaging study, which takes approximately 40 minutes \[30]. The prospective study (1,585 women) by Rhodes et al \[31] and a retrospective study (1,696 women) by Shermis et al \[32] reported a CDR of 7.7 to 8.8 per 1,000 in women with dense breasts. Preliminary data from the MATTERS trial, comparing DBT and MBI, found 7 cancers in 537 women, 6 of which were found by MBI only. All were invasive. The incremental CDR of MBI was 9.3 per 1,000 \[31]. 目前尚无充分证据支持将Tc-99m甲氧异腈（MBI）作为致密乳腺组织中等风险女性的补充筛查手段，但相关研究数据正在积累。当前限制因素包括：筛查相关发病率数据不足、检查时间较长、以及针对不同乳腺密度谱与风险关系的研究有限\[7]。MBI是一种核医学检查技术，通过静脉注射Tc-99m甲氧异腈来识别乳腺组织中具有有丝分裂活性的区域，从而有效区分恶性肿瘤与背景实质组织。与采用单探头碘化钠相机的乳腺特异性伽马成像（BSGI）不同，MBI采用双探头碲锌镉探测器进行功能成像检查，耗时约40分钟\[30]。Rhodes等\[31]的前瞻性研究（1,585名女性）和Shermis等\[32]的回顾性研究（1,696名女性）报告显示，在致密乳腺女性中MBI的癌症检出率（CDR）为每1,000人7.7-8.8例。MATTERS试验（比较数字乳腺断层合成摄影与MBI）的初步数据显示，537名女性中发现7例癌症，其中6例仅通过MBI检出，且均为浸润性癌。MBI的增量CDR达到每1,000人9.3例\[31]。

##### S0118 Variant: Variant 7:  Adult female. Supplemental breast cancer screening. High risk. Nondense or dense breasts. | 成人女性 辅助性乳腺癌筛查 高风险 非致密或致密乳腺

检查推荐列表：

* 检查项目: Digital Breast Tomosynthesis Screening / MG双侧乳腺钼靶(筛查)
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0001 / R:CR000966
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Screening mammography has been shown to reduce mortality by approximately 30% to 40% \[3,4]. It is most sensitive in women with nondense tissue. Women with heterogeneously and extremely dense tissue, who can comprise up to half of screening-aged women in the United States, may not receive the same benefit from In DBT, the x-ray tube moves in an arc obtaining multiple low-dose mammographic images that are reconstructed into 2-D images. The additional information from varying angles aims to reduce summation shadows and overlapping structures to maximize visibility \[2]. The retrospective PROSPR consortium review evaluated more than 180,000 women; approximately 130,000 were screened with DM and 50,000 with DBT. Women with nondense tissue accounted for 64% of the cohort as compared with 36% with dense tissue. A statistically significant increase in CDR was found in women with both nondense tissue (1.7/1,000) and dense tissue (2.27/1,000) screened with DBT. Cancers tended to be smaller, lymph node negative, and less biologically aggressive \[9]. Li et al \[10] reviewed several studies comparing DBT with 2- D mammography in Europe and the United States and found the pooled CDR to be statistically significant in both nondense and dense tissue. However, Berg et al \[20] found the greatest increase in CDR to be in women with heterogeneously dense breasts. No significant increase in detection was identified in women with extremely dense tissue, highlighting the need for other methods of supplemental screening in this population. Another advantage of DBT is a reduction in recall rate with improved specificity. A few studies have demonstrated this benefit with the reduction ranging between 15% to 63% in observational, retrospective studies in the United States \[11,12]. In a retrospective cohort study evaluating multiple screening rounds, Sprague et al \[13] found no difference in the interval cancer rate between DBT and DM. The randomized prospective TMIST trial comparing DBT with 2-D mammography is currently active. 筛查性乳腺X线摄影已被证明可降低约30%至40%的死亡率\[3,4]。其对非致密组织女性的敏感性最高。在美国，具有异质性和极度致密组织的女性可能占筛查适龄女性的一半，但她们可能无法从DBT中获得同等益处。在DBT中，X射线管沿弧线运动，获取多个低剂量乳腺影像，并重建为2D图像。来自不同角度的附加信息旨在减少叠加阴影和重叠结构，以最大化可视性\[2]。回顾性PROSPR联盟研究评估了超过180,000名女性；约130,000名接受了DM筛查，50,000名接受了DBT筛查。非致密组织女性占队列的64%，而致密组织女性占36%。在采用DBT筛查的女性中，非致密组织（1.7/1,000）和致密组织（2.27/1,000）的CDR均出现统计学显著增加。癌症往往更小、淋巴结阴性且生物学侵袭性较低\[9]。Li等\[10]回顾了欧洲和美国多项比较DBT与2D乳腺X线摄影的研究，发现汇总CDR在非致密和致密组织中均具有统计学显著性。然而，Berg等\[20]发现CDR的最大增加出现在具有异质性致密乳房的女性中。在极度致密组织女性中未发现检测率的显著增加\[20]，这凸显了在该人群中进行其他补充筛查方法的必要性。DBT的另一个优势是通过提高特异性降低召回率。一些研究已证明这一益处，在美国的观察性回顾性研究中，降低幅度介于15%至63%之间\[11,12]。在一项评估多轮筛查的回顾性队列研究中，Sprague等\[13]发现DBT与DM的间期癌率无差异。比较DBT与2D乳腺X线摄影的随机前瞻性TMIST试验目前正在进行中。
* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0005 / R:CR000967
  * 证据强度: ModerateReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: American Cancer Society and NCCN guidelines support the use of annual breast MRI in high-risk individuals regardless of breast density. MRI has the highest CDR of all modalities (8.2-15.9 per 1,000 for MRI alone), and in the high-risk population, sensitivity is not affected by breast density \[5]. Sippo et al \[3] demonstrated a CDR of 26 per 1,000 in the BRCA/RT group with a high PPV of 41%. In a multicenter, prospective trial the sensitivity of MRI (91%) was greater than US (52%) or mammography plus US (63%) in the high-risk population \[42]. 美国癌症协会和NCCN指南支持对高风险人群进行年度乳腺MRI检查，无论乳腺密度如何。MRI是所有检查方式中检出率最高的（单独MRI检查为每1000人8.2-15.9例），在高风险人群中，其敏感性不受乳腺密度影响\[5]。Sippo等\[3]的研究显示，BRCA/RT组的检出率达到每1000人26例，阳性预测值高达41%。一项多中心前瞻性试验表明，在高风险人群中，MRI的敏感性（91%）高于超声（52%）或乳腺X线摄影联合超声（63%）\[42]。
* 检查项目: MRI Breast Without and With IV Contrast Abbreviated / MR乳腺(平扫+增强)
  * 评分: 7
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0005 / R:CR000967
  * 证据强度: StrongReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: The standard MRI protocol uses multiple sequences to identify malignancy and characterize benign breast findings requiring longer magnet and interpretation times. The protocol for AB-MRI is variable and even customizable, however, all protocols use a limited number of images to highlight findings in the early postcontrast phase. This technique maximizes cancer detection while reducing the time burden on the patient and the radiologist. Negative studies can be quickly interpreted, reducing physician workload. Lawson et al \[23] found no statistical difference when comparing the sensitivity of standard MRI with AB-MRI (100% to 88.9%). This is consistent with findings from Kuhl et al \[24], Baxter et al \[19], and others \[25,26]. In a retrospective review of 568 high-risk women by Harvey et al \[43], no difference was identified in CDR (12.3/1,000) when comparing abbreviated and full protocol 标准MRI方案使用多个序列识别恶性肿瘤并表征良性乳腺病变，需要更长的磁共振扫描和判读时间。ABMRI方案多变甚至可定制，但所有方案均使用有限数量的图像突出显示早期增强后阶段的发现。该技术最大程度提高癌症检出率，同时减少患者和放射科医师的时间负担。阴性研究可快速判读，减轻医师工作量。Lawson等\[23]发现标准MRI与ABMRI的敏感性无统计学差异（100%对比88.9%）。这与Kuhl等\[24]、Baxter等\[19]及其他研究者\[25,26]的结果一致。在Harvey等\[43]对568名高风险女性的回顾性分析中，比较简化方案与完整方案时未发现癌症检出率（CDR）存在差异（12.3/1,000）。
* 检查项目: Mammography With IV Contrast / MG双侧乳腺钼靶导管造影
  * 评分: 5
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0004 / R:CR000969
  * 证据强度: StrongReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: CEM uses a dual-energy technique to acquire 8 standard mammographic images after the administration of IV iodinated contrast material. Four low-energy images mimic a conventional 2-D mammogram. The additional 4 diagnostic recombined images demonstrate contrast enhancement, which offers morphologic as well as functional assessment to identify malignancies. CEM has been valuable in evaluating abnormalities in the diagnostic setting \[14], however, recent literature has indicated that it may play a beneficial role in screening women with dense tissue at an intermediate risk of developing breast cancer or those seeking an alternative supplemental screening modality to MRI \[15]. The CDR in screening studies has ranged from 8.6 to 13.1 cancers per 1,000 screening examinations \[21,22], although most of these were conducted retrospectively at a single institution. CEM offers a higher sensitivity compared with mammography, with the benefit statistically significant in women with dense breast tissue \[21]. The CMIST is currently enrolling intermediate-risk women with dense breasts to participate in a prospective study comparing DBT and CEM. Although in a single-institution, prospective study, Lawson et al \[23] found the sensitivity of standard and AB-MRI to be higher, and CEM reduced recall rates and had a higher PPV when compared with MRI or AB-MRI. 对比增强乳腺X线摄影（CEM）采用双能量技术，在静脉注射碘对比剂后获取8张标准乳腺X线图像。其中4张低能量图像模拟传统二维乳腺X线摄影，另外4张诊断性重组图像可显示对比剂强化，提供形态学与功能学双重评估以识别恶性肿瘤。CEM在诊断性检查中对评估异常病变具有重要价值\[14]。最新研究表明，该技术对中等乳腺癌风险且乳腺组织致密的女性筛查具有积极作用，亦可作为磁共振成像（MRI）替代的补充筛查手段\[15]。筛查研究显示其癌症检出率（CDR）为每1000例检查8.6-13.1例\[21,22]，但多数为单机构回顾性研究。相较于传统乳腺X线摄影，CEM具有更高敏感性，且对致密乳腺组织女性的优势具有统计学意义\[21]。目前CMIST研究正在招募中等风险且乳腺致密的女性，开展比较数字乳腺断层合成（DBT）与CEM的前瞻性研究。Lawson等\[23]的单机构前瞻性研究发现：标准MRI和 abbreviated MRI（AB-MRI）的敏感性更高，但与MRI或AB-MRI相比，CEM能降低召回率并提高阳性预测值（PPV）。
* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 5
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0003 / R:CR000970
  * 证据强度: StrongReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: Screening breast US can be performed using HHUS or ABUS techniques. Although the sensitivity of mammography in nondense tissue approaches 90%, it can be as low as 30% in women with extremely dense tissue \[17]. Screening US offers improved sensitivity and interval cancer detection particularly in women with dense tissue. A statistically significant CDR of an additional 3.0 per 1,000 breast cancers was identified in average-risk women with dense tissue in a secondary review of the J-START \[33,34]. Additionally, a significant decrease was observed in the interval cancer rate (0.5 per 1,000 compared with 2.0 per 1,000 in the control group). In women with nondense tissue, the J-START trial demonstrated increased cancer detection as well, but this was not supported in 2 other large cohort studies \[18]. The prospective, multicenter ASTOUND-2 trial conducted in screening women with dense tissue found 4.9 per 1,000 additional cancers with HHUS as compared with 2.8 per 1,000 with DBT, although the former had more false-positives \[35]. Although studies have demonstrated increased CDR with the addition of screening US to mammography, this comes at the expense of low biopsy PPVs and high false-positive rates including a high rate of short-term follow-up recommendations \[7,19]. No added benefit of screening US has been found in women who undergo MRI breast or AB-MRI screening \[20]. In women with an elevated risk of breast cancer and dense tissue who cannot undergo supplemental screening with MRI, breast US could be considered \[7]. 乳腺筛查超声可采用手持超声（HHUS）或自动乳腺全容积超声（ABUS）技术进行。虽然乳腺X线摄影对非致密组织的敏感性接近90%，但在乳腺组织极度致密的女性中可低至30%\[17]。筛查超声能提高敏感性并改善间期癌检出率，尤其对致密型乳腺女性具有优势。J-START研究的二次分析显示，在平均风险且乳腺组织致密的女性中，超声筛查可额外检出3.0/1000例乳腺癌，具有统计学显著性\[33,34]。此外，间期癌发生率显著降低（0.5/1000 vs 对照组2.0/1000）。J-START试验在非致密组织女性中也观察到癌症检出率提升，但另外两项大型队列研究未支持该结论\[18]。针对致密型乳腺女性的前瞻性多中心ASTOUND-2试验发现，HHUS较数字乳腺断层合成摄影（DBT）可多检出4.9/1000例癌症（DBT为2.8/1000），但前者假阳性率更高\[35]。尽管研究表明在乳腺X线摄影基础上增加超声筛查可提高癌症检出率，但需以较低的活检阳性预测值和高假阳性率为代价，包括更高比例的短期随访建议\[7,19]。对于已接受乳腺MRI或快速乳腺MRI筛查的女性，超声筛查未显示额外获益\[20]。对于乳腺癌风险升高且
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000972
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature regarding the use of MRI breast without IV contrast for supplemental screening in high-risk women with nondense or dense breasts. 目前尚无相关文献支持在不使用静脉对比剂的情况下，对高风险女性（无论乳腺密度高低）进行乳腺MRI补充筛查。
* 检查项目: MRI Breast Without IV Contrast Abbreviated / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000972
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature regarding the use of AB-MRI breast without IV contrast for supplemental screening in high-risk women with nondense or dense breasts. 目前尚无关于在不使用静脉对比剂的情况下，采用AB-MRI乳腺检查对非致密或致密乳腺的高风险女性进行补充筛查的相关文献。
* 检查项目: FDG-PET Breast Dedicated / PET/CT局部(胸部)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0016 / R:CR000971
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature regarding the use of FDG-PET breast dedicated for supplemental screening in high- risk women with nondense and dense breasts. 目前尚无关于使用FDG-PET乳腺专用显像对非致密型及致密型乳腺高风险女性进行补充筛查的相关文献。
* 检查项目: Sestamibi MBI / SPECT心脏显像
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0009 / R:CR000974
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢☢ 1-10 mSv
  * Peds RRL:
  * 推荐说明: Currently, there is insufficient evidence to support the use of Tc-99m sestamibi MBI as a supplemental screening exam in high-risk women with nondense and dense breast tissue, however, there are emerging data. At present, barriers include lack of incidence around screening, longer examination times, and limited studies addressing the spectrum of breast densities and risk \[7]. MBI is a nuclear medicine study that uses the IV injection of Tc-99m sestamibi to identify mitotically active areas within breast tissue, ideally differentiating malignant tumors from background parenchyma. Although BSGI uses single detector sodium iodide cameras, MBI employs dual-head cadmium zinc telluride detectors to obtain a functional imaging study, which takes approximately 40 minutes \[30]. The prospective study (1585 women) by Rhodes et al \[31] and a retrospective study (1696 women) by Shermis et al \[32] reported a CDR of 7.7 to 8.8 per 1,000 in women with dense breasts. Preliminary data from the MATTERS trial, comparing DBT and MBI, found 7 cancers in 537 women, 6 of which were found by MBI only. All were invasive. The incremental CDR of MBI was 9.3 per 1,000 \[31]. 目前尚无充分证据支持将Tc-99m甲氧基异丁基异腈（MBI）作为高风险女性（无论乳腺组织致密与否）的补充筛查手段，但相关研究数据正在积累。当前限制因素包括：筛查相关发病率数据不足、检查时间较长、以及针对不同乳腺密度谱和风险水平的研究有限\[7]。MBI是一种核医学检查技术，通过静脉注射Tc-99m甲氧基异丁基异腈来识别乳腺组织中细胞分裂活跃区域，理论上可区分恶性肿瘤与正常腺体组织。与使用单探头碘化钠相机的乳腺特异性伽马成像（BSGI）不同，MBI采用双头碲锌镉探测器进行功能成像检查，耗时约40分钟\[30]。Rhodes等\[31]的前瞻性研究（1585名女性）和Shermis等\[32]的回顾性研究（1696名女性）报告显示，在致密乳腺女性中MBI的癌症检出率（CDR）为每1000人7.7-8.8例。MATTERS试验（比较数字乳腺断层合成摄影与MBI）的初步数据显示：537名女性中发现7例癌症，其中6例仅通过MBI检出，且均为浸润性癌。MBI的增量癌症检出率达每1000人9.3例\[31]。

#### T0017 Transgender Breast Cancer Screening | 跨性别乳腺癌筛查

* 主题编码: T0017

##### S0119 Variant: Variant 1:  Breast cancer screening. Transfeminine (male-to-female) patient, 40 years of age or older with past or current hormone use equal to or greater than 5 years. Average-risk patient. | 乳腺癌筛查。跨性别女性（男跨女）患者，年龄≥40岁，目前或既往激素使用≥5年。平均风险患者。

检查推荐列表：

* 检查项目: Mammography Screening / MG双侧乳腺钼靶
  * 评分: 6
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0010
  * 证据强度: StrongReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There are no relevant data on the use of digital mammography for breast cancer screening of transgender individuals in this clinical setting. Furthermore, no longitudinal data exist on screening transgender women for breast cancer with imaging. However, limited data on transgender individuals, along with extrapolated data from cisgender studies, suggest that digital mammography or DBT is helpful to screen for breast cancer in transgender women. A Dutch cohort study of 3,489 transgender patients showed an increased risk of breast cancer in transgender women receiving gender-affirming hormone therapy compared with cisgender men (SIR: 46.7, 95% CI: 27.2–75.4) but not compared with cisgender women (SIR: 0.3, 95% CI: 0.2–0.4) \[2]. The risk of breast cancer increased over a relatively short hormone duration (median 18 years, range 7–37 years). Two previous studies concluded that the was increased in transgender women who received hormone treatment (31.4 per 100,000 person-years compared with 1.2 per 100,000 person-years for cisgender men and 170 per 100,000 person-years for cisgender women) \[1]. Any conclusions drawn from the existing literature are significantly limited by inconsistent dose and length of exposure to hormones as well as small sample size and relatively short duration of follow-up. Large prospective cisgender studies have shown that exogenous hormones, in particular estrogen and progestin, increase breast cancer risk in cisgender postmenopausal females \[18-20], which could support a role for screening in this clinical setting. Additionally, in cisgender males, high estrogen levels associated with certain conditions, such as Klinefelter syndrome, liver disease, testicular dysfunction, and obesity, are recognized risk factors for developing breast cancer \[21]. In the absence of definitive data on the risk of breast cancer in this clinical setting, some transgender health experts and professional societies have established guidelines recommending screening mammography in transgender women with ≥5 years of hormone use. However, the current recommendations range from annual or biennial mammograms starting at age 50 from the UCSF and Fenway Health to screening transgender women with the same frequency as that of cisgender women beginning at age 40 from the Endocrine Society \[10]. 目前缺乏在该临床背景下使用数字乳腺X线摄影对跨性别个体进行乳腺癌筛查的相关数据。此外，尚无通过影像学对跨性别女性进行乳腺癌筛查的纵向数据。然而，有限的跨性别个体数据以及顺性别研究的外推数据表明，数字乳腺X线摄影或DBT有助于对跨性别女性进行乳腺癌筛查。一项针对3,489名跨性别患者的荷兰队列研究显示，接受性别肯定激素治疗的跨性别女性与顺性别男性相比乳腺癌风险升高（标准化发病率比SIR：46.7，95% CI：27.2–75.4），但与顺性别女性相比风险较低（SIR：0.3，95% CI：0.2–0.4）\[2]。乳腺癌风险在相对较短的激素治疗期内即出现升高（中位时间18年，范围737年）。先前两项研究认为其风险与顺性别男性相当，但接受激素治疗的跨性别女性发病率确实
* 检查项目: Digital Breast Tomosynthesis Screening / MG双侧乳腺钼靶(筛查)
  * 评分: 6
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0001 / R:CR000975
  * 证据强度: StrongReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no relevant data on the use of digital breast tomosynthesis (DBT) for breast cancer screening of transgender individuals in this clinical setting. Furthermore, no longitudinal data exist on screening transgender women for breast cancer with imaging. However, limited data on transgender individuals along with extrapolated data from cisgender studies suggest that digital mammography or DBT may be helpful to screen for breast cancer in transgender women. A Dutch cohort study of 3,489 transgender patients showed an increased risk of breast cancer in transgender women receiving gender-affirming hormone therapy compared with cisgender men (standardized incidence ratio \[SIR]: 46.7, 95% confidence interval \[CI]: 27.2–75.4) but not compared with cisgender women (SIR: 0.3, 95% CI: 0.2–0.4) \[2]. The risk of breast cancer increased over a relatively short hormone duration (median 18 years, range 7–37 years). Three previous studies concluded that the risk of breast cancer in transgender women is comparable with that of cisgender men \[1,3,18]; however, the incidence was increased in transgender women who received hormone treatment (31.4 per 100,000 person-years compared with 1.2 per 100,000 person-years for cisgender men and 170 per 100,000 person-years for cisgender women) \[1]. Any conclusions drawn from the existing literature are significantly limited by inconsistent dose and length of exposure to hormones as well as small sample size and relatively short duration of follow-up. Large prospective cisgender studies have shown that exogenous hormones, in particular estrogen and progestin, increase breast cancer risk in cisgender postmenopausal females \[18-20], which could support a role for screening in this clinical setting. Additionally, in cisgender males, high estrogen levels associated with certain conditions, such as Klinefelter syndrome, liver disease, testicular dysfunction, and obesity, are recognized risk factors for developing breast cancer \[21]. In the absence of definitive data on the risk of breast cancer in this clinical setting, some transgender health experts and professional societies have established guidelines recommending screening mammography in transgender women with ≥5 years of hormone use. However, the current recommendations range from annual or biennial mammograms starting at age 50 from the UCSF and Fenway Health to screening transgender women with the same frequency as cisgender women beginning at age 40 from the Endocrine Society \[10]. In addition to planar images, DBT allows for creation and viewing of thin-section reconstructed images that decrease the lesion-masking effect of overlapping normal tissue, thereby decreasing false-positive recalls as well as improving cancer detection rates (CDRs) in breast cancer screening. 目前尚无关于在此临床背景下使用数字乳腺断层合成（DBT）对跨性别个体进行乳腺癌筛查的相关数据。此外，亦缺乏通过影像学方法对跨性别女性进行乳腺癌筛查的纵向数据。然而，基于跨性别个体的有限数据及从顺性别研究中推断的数据提示，数字乳腺X线摄影或DBT可能有助于跨性别女性的乳腺癌筛查。一项荷兰队列研究纳入3,489名跨性别患者，结果显示接受性别肯定激素治疗的跨性别女性与顺性别男性相比乳腺癌风险升高（标准化发病率比\[SIR]：46.7，95%置信区间\[CI]：27.2–75.4），但与顺性别女性相比风险较低（SIR：0.3，95% CI：0.2–0.4）\[2]。乳腺癌风险在相对较短的激素用药时间内即出现升高（中位时间18年，范围7–37年）。先前三项研究得出结论称跨性别女性的乳腺癌风险与顺性别男性相当\[1,3,18]；但接受激素治疗的跨性别女性发病率有所升高（每10万人年31.4例，而顺性别男性为每10万人年1.2例，顺性别女性为每10万人年170例）\[1]。现有文献得出的任何结论均受到激素暴露剂量和时长不一致、样本量小以及随访时间相对较短的显著限制。大型前瞻性顺性别研究表明，外源性激素（特别是雌激素和孕激素）会增加顺性别绝经后女性的乳腺癌风险\[18–20]，这支持在此临床背景下进行筛查的必要性。此外，在顺性别男性中，与某些疾病（如克氏综合征、肝病、睾丸功能障碍和肥胖）相关的高雌激素水平是公认的乳腺癌发生风险因素\[21]。在此临床背景下缺乏乳腺癌风险的明确数据的情况下，部分跨性别健康专家及专业学会已制定指南，建议对激素使用时间≥5年的跨性别女性进行筛查性乳腺X线摄影。然而，当前推荐方案存在差异：从加州大学旧金山分校和芬威健康推荐的50岁起每年或每两年一次乳腺X线摄影，到内分泌学会推荐的40岁起以与顺性别女性相同的频率进行筛查\[10]。除平面图像外，DBT可生成并显示薄层重建图像，减少正常组织重叠对病灶的遮蔽效应，从而降低假阳性召回率并提高乳腺癌筛查的癌症检出率（CDR）。
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000978
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support the use of MRI breast without IV contrast for screening in this clinical setting. However, transgender women may have breast implants placed for augmentation. For evaluation of implants and for discussion of the evidence regarding screening for implant rupture, please see the ACR Appropriateness Criteria ® topic on “ Breast Implant Evaluation ” \[17]. 目前尚无相关文献支持在此临床情况下使用无静脉对比剂的乳腺MRI进行筛查。然而，跨性别女性可能因隆胸手术植入了乳房假体。关于假体评估及假体破裂筛查证据的讨论，请参阅ACR适宜性标准®专题"乳房假体评估"\[17]。
* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000977
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is insufficient evidence to support the use of MRI breast without and with intravenous (IV) contrast to screen for breast cancer in this clinical setting. However, MRI screening may have limited use in patients who have undergone direct injection of particles such as silicone, mineral oil, liquid paraffin, or petroleum jelly to augment the breasts because fibrosis and injection granulomas can obscure the breast tissue on mammography and ultrasound (US). Hence, contrast-enhanced breast MRI is the preferred modality for breast cancer detection in patients who have undergone breast augmentation with free-particle injections \[4,10]. 目前证据不足以支持在此临床情况下使用无静脉注射（IV）对比剂及增强MRI进行乳腺癌筛查。但对于曾接受硅胶、矿物油、液体石蜡或凡士林等颗粒物直接注射隆乳的患者，由于纤维化和注射性肉芽肿可能导致乳腺X线摄影和超声检查难以清晰显示乳腺组织，MRI筛查可能具有一定应用价值。因此，对于接受游离颗粒注射隆乳的患者，增强乳腺MRI是检测乳腺癌的首选检查方式\[4,10]。
* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0003 / R:CR000979
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is insufficient evidence to support screening with US breast in this clinical setting. A small study of screening whole-breast US in 50 transgender women found no cancers \[11]. The majority of patients were on estrogen therapy (94%) and had no family history of breast cancer (88%). However, the lack of incremental cancer detection may be secondary to the small sample size. 目前尚无充分证据支持在此临床情况下采用超声筛查乳房。一项针对50名跨性别女性进行全乳超声筛查的小型研究未发现癌症病例\[11]。大多数患者正在接受雌激素治疗（94%）且无乳腺癌家族史（88%）。但癌症检出率未增加可能与样本量较小有关。

##### S0120 Variant: Variant 2:  Breast cancer screening. Transfeminine (male-to-female) patient, 25 to 30 years of age or older with past or current hormone use equal to or greater than 5 years. Higher-than-average risk (patient with personal history of breast cancer or chest irradiation at 10 to 30 years of age, patient with genetic predisposition to breast cancer, patient with family history of breast or ovarian cancer, and untested patient with first-degree relative with genetic predisposition to breast cancer). | 乳腺癌筛查。跨性别女性（男跨女）患者，年龄≥25至30岁，目前或既往激素使用≥5年。风险高于平均水平（既往乳腺癌史或10至30岁胸部放疗史，乳腺癌遗传易感性，乳腺癌或卵巢癌家族史，以及未检测的一级亲属有乳腺癌遗传易感性）。

检查推荐列表：

* 检查项目: Mammography Screening / MG双侧乳腺钼靶
  * 评分: 7
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0010
  * 证据强度: StrongReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There are no relevant data on the use of digital mammography for breast cancer screening of transgender individuals in this clinical setting. Furthermore, no longitudinal data on screening transgender women for breast cancer with imaging exist. However, limited data on transgender individuals, along with extrapolated data from cisgender studies, suggest that digital mammography or DBT is helpful to screen for breast cancer in higher-than-average- risk transgender women. A Dutch cohort study of 3,489 transgender patients showed an increased risk of breast cancer in transgender women receiving gender-affirming hormone therapy compared with cisgender men (SIR: 46.7, 95% CI: 27.2–75.4) but not compared with cisgender women (SIR: 0.3, 95% CI: 0.2–0.4) \[2]. The risk of breast cancer increased over a relatively short hormone duration (median 18 years, range 7–37 years). Three previous studies concluded that the risk of breast cancer in transgender women is comparable with that of cisgender men \[1,3,18]; however, the incidence was increased in transgender women who received hormone treatment (31.4 per 100,000 person-years compared with 1.2 per 100,000 person-years for cisgender men and 170 per 100,000 person-years for cisgender women) \[1]. Any conclusions drawn from the existing literature are significantly limited by inconsistent dose and length of exposure to hormones as well as small sample size and relatively short duration of follow-up. Large prospective cisgender studies have shown that exogenous hormones, in particular estrogen and progestin, increase breast cancer risk in cisgender postmenopausal females \[18-20], which could support a role for screening in this clinical setting. Although the relative risk of breast cancer associated with exogenous hormone therapy in transfeminine patients remains to be clearly defined, data extrapolated from cisgender men support screening mammography in this clinical setting. One retrospective study of cisgender men at increased risk of breast cancer (ages 18–96 years; median: 55 years) showed a CDR of 18 per 1,000 screening mammograms, including a subset performed with DBT \[22]. The use of DBT was limited to only 46 studies (2.2%). A smaller retrospective cohort study and 3 case reports also support screening higher-than-average-risk cisgender men for breast cancer \[22-24]. Recognized risk factors for the development of breast cancer in cisgender men include personal history of breast cancer, genetic predisposition (ie, BRCA mutations, Ashkenazi descent), previous radiation exposure, family history of breast or ovarian cancer, and elevated estrogen levels (ie, Klinefelter’s syndrome, obesity, etc) \[21-23]. Because of a paucity In the absence of definitive data, some transgender health experts and professional societies recommend digital mammography or DBT to screen for breast cancer in transgender women with higher-than-average risk of breast cancer ( [https://transcare.ucsf.edu/guidelines/breast-cancer-women](https://transcare.ucsf.edu/guidelines/breast-cancer-women) ). There is no consensus on the age at which to 目前尚无关于在此临床背景下使用数字乳腺X线摄影对跨性别个体进行乳腺癌筛查的相关数据。此外，也不存在通过影像学方法对跨性别女性进行乳腺癌筛查的纵向数据。然而，有限的跨性别个体数据以及从顺性别研究中推断的数据表明，数字乳腺X线摄影或数字乳腺断层合成（DBT）有助于对高风险跨性别女性进行乳腺癌筛查。一项针对3,489名跨性别患者的荷兰队列研究显示，与顺性别男性相比，接受性别肯定激素治疗的跨性别女性患乳腺癌的风险增加（标准化发病率比SIR：46.7，95% CI：27.2–75.4），但与顺性别女性相比则风险较低（SIR：0.3，95% CI：0.2–0.4）\[2]。乳腺癌风险的增加发生在相对较短的激素用药时间内（中位时间18年，范围737年）。先前的三项研究得出结论，跨性别女性的乳腺癌风险与顺性别男性相当\[1,3,18]；然而，接受激素治疗的跨性别女性发病率有所增加（每10万人年31.4例，而顺性别男性为每10万人年1.2例，顺性别女性为每10万人年170例）\[1]。现有文献得出的任何结论都受到激素暴露剂量和时间长短不一致、样本量小以及随访时间相对较短的显著限制。大型前瞻性顺性别研究表明，外源性激素，特别是雌激素和孕激素，会增加顺性别绝经后女性的乳腺癌风险\[1820]，这可以支持在此临床背景下进行筛查的作用。尽管与跨女性患者使用外源性激素治疗相关的乳腺癌相对风险仍有待明确，但从顺性别男性推断的数据支持在此临床背景下进行筛查性乳腺X线摄影。一项针对乳腺癌风险增加的顺性别男性（年龄1896岁；中位年龄55岁）的回顾性研究显示，癌症检出率（CDR）为每1000次筛查性乳腺X线摄影18例，其中包括一部分使用DBT进行的研究\[22]。DBT的使用仅限于46项研究（2.2%）。一项规模较小的回顾性队列研究和3份病例报告也支持对高风险顺性别男性进行乳腺癌筛查\[2224]。公认的顺性别男性发生乳腺癌的风险因素包括个人乳腺癌病史、遗传易感性（即BRCA突变、德系犹太人血统）、既往放射线暴露、乳腺癌或卵巢癌家族史以及雌激素水平升高（即克兰费尔特综合征、肥胖等）\[2123]。由于缺乏明确数据，一些跨性别健康专家和专业学会建议使用数字乳腺X线摄影或DBT对乳腺癌风险高于平均水平的跨性别女性进行筛查（[https://transcare.ucsf.edu/guidelines/breastcancerwomen）。关于开始筛查的年龄尚未达成共识。](https://transcare.ucsf.edu/guidelines/breastcancerwomen%EF%BC%89%E3%80%82%E5%85%B3%E4%BA%8E%E5%BC%80%E5%A7%8B%E7%AD%9B%E6%9F%A5%E7%9A%84%E5%B9%B4%E9%BE%84%E5%B0%9A%E6%9C%AA%E8%BE%BE%E6%88%90%E5%85%B1%E8%AF%86%E3%80%82)
* 检查项目: Digital Breast Tomosynthesis Screening / MG双侧乳腺钼靶(筛查)
  * 评分: 7
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0001 / R:CR000980
  * 证据强度: StrongReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There are no relevant data on the use of DBT for breast cancer screening of transgender individuals in this clinical setting. Furthermore, no longitudinal data on screening transgender women for breast cancer with imaging exist. However, limited data on transgender individuals, along with extrapolated data from cisgender studies, suggest that digital mammography or DBT is helpful to screen for breast cancer in higher-than-average-risk transgender women. A Dutch cohort study of 3,489 transgender patients showed an increased risk of breast cancer in transgender women receiving gender-affirming hormone therapy compared with cisgender men (SIR: 46.7, 95% CI: 27.2–75.4) but not compared with cisgender women (SIR 0.3: 95% CI: 0.2–0.4) \[2]. The risk of breast cancer increased over a relatively short hormone duration (median 18 years, range 7–37 years). Three previous studies concluded that the risk of breast cancer in transgender women is comparable with that of cisgender men \[1,3,18]; however, the incidence was increased in transgender women who received hormone treatment (31.4 per 100,000 person-years compared with 1.2 per 100,000 person-years for cisgender men and 170 per 100,000 person-years for cisgender women) \[1]. Any to hormones as well as small sample size and relatively short duration of follow-up. Large prospective cisgender studies have shown that exogenous hormones, in particular estrogen and progestin, increase breast cancer risk in cisgender postmenopausal females \[18-20], which could support a role for screening in this clinical setting. Although the relative risk of breast cancer associated with exogenous hormone therapy in transfeminine patients remains to be clearly defined, data extrapolated from cisgender men support screening mammography in this clinical setting. One retrospective study of cisgender men at increased risk of breast cancer (ages 18–96 years; median: 55 years) showed a CDR of 18 per 1,000 screening mammograms, including a subset performed with DBT \[22]. The use of DBT was limited to only 46 studies (2.2%). A smaller retrospective cohort study and 3 case reports also support screening higher-than-average-risk cisgender men for breast cancer \[22-24]. Recognized risk factors for the development of breast cancer in cisgender men include personal history of breast cancer, genetic predisposition (ie, Breast Cancer gene \[BRCA] mutations, Ashkenazi descent), previous radiation exposure, family history of breast or ovarian cancer, and elevated estrogen levels (ie, Klinefelter’s syndrome, obesity, etc) \[21-23]. Because of a paucity of data, a finer classification of breast cancer risk in this patient population is not currently possible. In the absence of definitive data, some transgender health experts and professional societies recommend digital mammography or DBT to screen for breast cancer in transgender women with higher-than-average risk of breast cancer ( [https://transcare.ucsf.edu/guidelines/breast-cancer-women](https://transcare.ucsf.edu/guidelines/breast-cancer-women) ). There is no consensus on the age at which to 目前缺乏在该临床背景下使用数字乳腺断层合成（DBT）对跨性别个体进行乳腺癌筛查的相关数据。此外，尚无通过影像学对跨性别女性进行乳腺癌筛查的纵向数据。然而，有限的跨性别个体数据以及顺性别研究的外推数据表明，数字乳腺X线摄影或DBT有助于对高风险跨性别女性进行乳腺癌筛查。一项针对3,489名跨性别患者的荷兰队列研究显示，接受性别肯定激素治疗的跨性别女性与顺性别男性相比乳腺癌风险升高（标准化发病率比SIR：46.7，95% CI：27.2–75.4），但与顺性别女性相比风险较低（SIR：0.3，95% CI：0.2–0.4）\[2]。乳腺癌风险在相对较短的激素治疗期内即出现升高（中位时间18年，范围737年）。先前三项研究认为跨性别女性的乳腺癌风险与顺性别男性相当\[1,3,18]；但接受激素治疗的跨性别女性发病率确实升高（每10万人年31.4例，而顺性别男性为1.2例，顺性别女性为170例）\[1]。现有文献得出的任何结论均受到激素暴露剂量和时长不一致、样本量小以及随访时间相对较短的显著限制。大型前瞻性顺性别研究表明，外源性激素（特别是雌激素和孕激素）会增加顺性别绝经后女性的乳腺癌风险\[1820]，这支持在该临床背景下开展筛查。尽管外源性激素治疗对跨性别女性的乳腺癌相对风险尚待明确，但来自顺性别男性的外推数据支持在此临床背景下进行筛查性乳腺X线摄影。一项针对高风险顺性别男性（年龄1896岁；中位年龄55岁）的回顾性研究显示，每1000次筛查性乳腺X线摄影的癌症检出率（CDR）为18例，其中包括一部分使用DBT进行的检查\[22]。DBT的使用仅限于46次检查（2.2%）。一项规模较小的回顾性队列研究和3份病例报告也支持对高风险顺性别男性进行乳腺癌筛查\[2224]。公认的顺性别男性乳腺癌危险因素包括个人乳腺癌病史、遗传易感性（即乳腺癌基因\[BRCA]突变、德系犹太人血统）、既往放射线暴露、乳腺癌或卵巢癌家族史以及雌激素水平升高（即克兰费尔特综合征、肥胖等）\[2123]。由于数据匮乏，目前无法对该患者群体的乳腺癌风险进行更精细的分类。在缺乏确定性数据的情况下，一些跨性别健康专家和专业学会建议对高于平均风险的跨性别女性采用数字乳腺X线摄影或DBT进行乳腺癌筛查（[https://transcare.ucsf.edu/guidelines/breastcancerwomen）。关于开始筛查的年龄尚未达成共识。](https://transcare.ucsf.edu/guidelines/breastcancerwomen%EF%BC%89%E3%80%82%E5%85%B3%E4%BA%8E%E5%BC%80%E5%A7%8B%E7%AD%9B%E6%9F%A5%E7%9A%84%E5%B9%B4%E9%BE%84%E5%B0%9A%E6%9C%AA%E8%BE%BE%E6%88%90%E5%85%B1%E8%AF%86%E3%80%82)
* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 3
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000982
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is insufficient evidence to support the use of MRI breast without and with IV contrast to screen for breast cancer in this clinical setting. However, MRI screening may have limited use in patients who have undergone direct injection of particles, such as silicone, mineral oil, liquid paraffin, or petroleum jelly, to augment the breasts because fibrosis and injection granulomas can obscure the breast tissue on mammography and US. Hence, contrast-enhanced breast MRI is the preferred modality for breast cancer detection in patients who have undergone breast augmentation with free-particle injections \[4,10]. For evaluation of implants and for discussion of the evidence regarding screening for implant rupture, please see the ACR Appropriateness Criteria ® topic on “ Breast Implant Evaluation ” \[17]. 目前尚无充分证据支持在该临床情况下使用无静脉注射对比剂及静脉注射对比剂的乳腺MRI进行乳腺癌筛查。然而，对于曾接受过直接注射颗粒物（如硅胶、矿物油、液体石蜡或凡士林）以隆乳的患者，MRI筛查可能有一定局限性，因为纤维化和注射性肉芽肿可能使乳腺组织在乳腺X线摄影和超声检查中难以辨认。因此，对于接受过游离颗粒注射隆乳的患者，增强乳腺MRI是检测乳腺癌的首选方法\[4,10]。关于植入物评估及植入物破裂筛查证据的讨论，请参阅ACR适宜性标准®专题“乳腺植入物评估”\[17]。
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000983
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support the use of MRI breast without IV contrast for screening in this clinical setting. However, transgender women may have breast implants placed for augmentation. For evaluation of implants and for discussion of the evidence regarding screening for implant rupture, please see the ACR Appropriateness Criteria ® topic on “ Breast Implant Evaluation ” \[17]. 目前尚无相关文献支持在此临床情况下使用无静脉对比剂的乳腺MRI进行筛查。然而，跨性别女性可能因隆胸手术植入了乳房假体。关于假体评估及假体破裂筛查证据的讨论，请参阅ACR适宜性标准®专题"乳房假体评估"\[17]。
* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0003 / R:CR000984
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support the use of US for breast cancer screening in this clinical setting. 目前尚无相关文献支持在该临床情况下使用超声进行乳腺癌筛查。

##### S0121 Variant: Variant 3:  Breast cancer screening. Transfeminine (male-to-female) patient with no hormone use (or hormone use less than 5 years) at any age. Average-risk patient. | 乳腺癌筛查。跨性别女性（男跨女），未使用激素（或激素使用\<5年），任何年龄，平均风险人群。

检查推荐列表：

* 检查项目: Mammography Screening / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of DBT for breast cancer screening in this clinical setting. In the absence of identifiable risk factors for breast cancer, general screening has no role because of an overall low prevalence of disease. The lifetime risk of breast cancer in transfeminine patients with no hormone use and no significant risk factors is considered to be equivalent to the average risk in cisgender men, which is 0.1% (compared with 12.4% in the average-risk cisgender female) \[1,26]. 目前尚无相关文献支持在此临床背景下使用数字乳腺断层合成（DBT）进行乳腺癌筛查。由于乳腺癌总体患病率较低，在缺乏可识别的乳腺癌危险因素的情况下，常规筛查并无意义。未使用激素且无显著危险因素的跨性别女性患者，其终生乳腺癌风险被认为与顺性别男性的平均风险相当，即0.1%（相比之下，平均风险顺性别女性为12.4%）\[1,26]。
* 检查项目: Digital Breast Tomosynthesis Screening / MG双侧乳腺钼靶(筛查)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0001 / R:CR000985
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of DBT for breast cancer screening in this clinical setting. In the absence of identifiable risk factors for breast cancer, general screening has no role because of an overall low prevalence of disease. The lifetime risk of breast cancer in transfeminine patients with no hormone use and no significant risk factors is considered to be equivalent to the average risk in cisgender men, which is 0.1% (compared with 12.4% in the average-risk cisgender female) \[1,26]. 目前尚无相关文献支持在此临床背景下使用数字乳腺断层合成（DBT）进行乳腺癌筛查。由于乳腺癌总体患病率较低，在缺乏可识别的乳腺癌危险因素的情况下，常规筛查并无意义。未使用激素且无显著危险因素的跨性别女性患者，其终生乳腺癌风险被认为与顺性别男性的平均风险相当，即0.1%（相比之下，平均风险顺性别女性为12.4%）\[1,26]。
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000988
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support the use of MRI breast without IV contrast for screening in this clinical setting. However, transgender women may have breast implants placed for augmentation. For evaluation of implants and for discussion of the evidence regarding screening for implant rupture, please see the ACR Appropriateness Criteria ® topic on “ Breast Implant Evaluation ” \[17]. 目前尚无相关文献支持在此临床情况下使用无静脉对比剂的乳腺MRI进行筛查。然而，跨性别女性可能因隆胸手术植入了乳房假体。关于假体评估及假体破裂筛查证据的讨论，请参阅ACR适宜性标准®专题"乳房假体评估"\[17]。
* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000987
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support the use of MRI breast without and with IV contrast to screen for breast cancer in this clinical setting. 目前尚无相关文献支持在此临床情况下使用无静脉注射对比剂及静脉注射对比剂的乳腺MRI进行乳腺癌筛查。
* 检查项目: US breast / US乳腺常规超声检查
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0003 / R:CR000989
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明:

##### S0122 Variant: Variant 4:  Breast cancer screening. Transfeminine (male-to-female) patient, 25 to 30 years of age or older with no hormone use (or hormone use less than 5 years). Higher-than-average risk (patient with personal history of breast cancer or chest irradiation at 10 to 30 years of age, patient with genetic predisposition to breast cancer, patient with family history of breast or ovarian cancer, and untested patient with first-degree relative with genetic predisposition to breast cancer). | 乳腺癌筛查。跨性别女性（男跨女），≥25至30岁，未使用激素（或激素使用\<5年），高于平均风险（既往乳腺癌史或10至30岁期间胸部放疗史、乳腺癌遗传易感性、乳腺癌或卵巢癌家族史、未检测但一级亲属有乳腺癌遗传易感性）。

检查推荐列表：

* 检查项目: Mammography Screening / MG双侧乳腺钼靶
  * 评分: 5
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0010
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There are no relevant data on the use of digital mammography for breast cancer screening of transgender individuals in this clinical setting. Furthermore, no longitudinal data on screening transgender women for breast cancer with imaging exist. However, limited data from risk-comparable cisgender men suggest that screening mammography or DBT may be beneficial in this clinical setting. A retrospective study of 1,869 cisgender men with higher-than- average risk (ages 18–96 years; median: 55 years) reported a CDR of 18 per 1,000 examinations using digital mammography or DBT to screen for breast cancer \[22]. A smaller retrospective cohort study and 3 case reports also support screening higher-than-average-risk cisgender men for breast cancer \[22,23]. Recognized risk factors for the development of breast cancer in cisgender men include personal history of breast cancer, genetic predisposition (ie, BRCA mutations, Ashkenazi descent), previous radiation exposure, family history of breast or ovarian cancer, and elevated estrogen levels (ie, Klinefelter’s syndrome, obesity, etc) \[21-23]. Because of a paucity of data, a finer classification of breast cancer risk in this patient population is not currently possible. 目前尚无关于数字乳腺X线摄影在此临床情境下用于跨性别者乳腺癌筛查的相关数据。此外，也不存在通过影像学筛查跨性别女性乳腺癌的纵向研究数据。然而，来自风险水平相当顺性别男性的有限数据表明，在此临床情境下采用乳腺X线摄影或数字乳腺断层合成技术（DBT）筛查可能具有获益价值。一项针对1,869名高于平均风险的顺性别男性（年龄18-96岁；中位数：55岁）的回顾性研究显示，采用数字乳腺X线摄影或DBT筛查乳腺癌的检出率为每1000次检查18例\[22]。另一项规模较小的回顾性队列研究和3份病例报告也支持对高于平均风险的顺性别男性进行乳腺癌筛查\[22,23]。已确认的顺性别男性乳腺癌风险因素包括：个人乳腺癌病史、遗传易感性（如BRCA基因突变、德系犹太人血统）、既往放射线暴露、乳腺癌或卵巢癌家族史以及雌激素水平升高（如克兰费尔特综合征、肥胖等）\[21-23]。由于数据不足，目前尚无法对该患者群体进行更精确的乳腺癌风险分级。
* 检查项目: Digital Breast Tomosynthesis Screening / MG双侧乳腺钼靶(筛查)
  * 评分: 5
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0001 / R:CR000990
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There are no relevant data on the use of DBT for breast cancer screening of transgender individuals in this clinical setting. Furthermore, no longitudinal data on screening transgender women for breast cancer with imaging exist. However, limited data from risk-comparable cisgender men suggest that screening mammography or DBT may be beneficial in this clinical setting. A retrospective study of 1,869 cisgender men with higher-than-average risk (ages 18–96 years; median 55 years) reported a CDR of 18 per 1,000 examinations using digital mammography or DBT to screen for breast cancer \[22]. The use of DBT was limited to only 46 studies (2.2%). A smaller retrospective cohort study and 3 case reports also support screening higher-than-average-risk cisgender men for breast cancer \[22,23]. Recognized risk factors for the development of breast cancer in cisgender men include personal history of breast cancer, genetic predisposition (ie, BRCA mutations, Ashkenazi descent), previous radiation exposure, family history of breast or ovarian cancer, and elevated estrogen levels (ie, Klinefelter’s syndrome, obesity, etc) \[21-23]. Because of a paucity of data, a finer classification of breast cancer risk in this patient population is not currently possible. In addition to planar images, DBT allows for creation and viewing of thin-section reconstructed images that decrease the lesion-masking effect of overlapping normal tissue, thereby decreasing false-positive recalls as well as improving CDR in breast cancer screening. 目前尚无关于在此临床背景下使用数字乳腺断层合成（DBT）对跨性别个体进行乳腺癌筛查的相关数据。此外，也不存在通过影像学筛查跨性别女性乳腺癌的纵向数据。然而，来自风险相当顺性别男性的有限数据表明，在此临床背景下进行乳腺X线摄影或DBT筛查可能有益。一项针对1,869名高于平均风险的顺性别男性（年龄18-96岁；中位55岁）的回顾性研究报道，采用数字乳腺X线摄影或DBT筛查乳腺癌的检出率（CDR）为每1000次检查18例\[22]。其中DBT的使用仅限于46次检查（2.2%）。另一项规模较小的回顾性队列研究和3份病例报告也支持对高于平均风险的顺性别男性进行乳腺癌筛查\[22,23]。公认的顺性别男性乳腺癌风险因素包括：个人乳腺癌病史、遗传易感性（如BRCA突变、德系犹太人血统）、既往放射线暴露、乳腺癌或卵巢癌家族史以及雌激素水平升高（如克氏综合征、肥胖等）\[21-23]。由于数据不足，目前尚无法对该患者群体的乳腺癌风险进行更精细的分类。除平面图像外，DBT还能生成并查看薄层重建图像，减少正常组织重叠对病灶的遮蔽效应，从而降低假阳性召回率并提高乳腺癌筛查的检出率。
* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 2
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000992
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is insufficient evidence to support the use of MRI breast without and with IV contrast to screen for breast cancer in this clinical setting. However, MRI screening may have limited use in patients who have undergone direct injection of particles, such as silicone, mineral oil, liquid paraffin, or petroleum jelly, to augment the breasts because fibrosis and injection granulomas can obscure the breast tissue on mammography and US. Hence, contrast-enhanced breast MRI is the preferred modality for breast cancer detection in patients who have undergone breast augmentation with free-particle injections \[4,10]. For evaluation of implants and for discussion of the evidence regarding screening for implant rupture, please see the ACR Appropriateness Criteria ® topic on “ Breast Implant Evaluation ” \[17]. 目前尚无充分证据支持在该临床情况下使用无静脉注射对比剂及静脉注射对比剂的乳腺MRI进行乳腺癌筛查。然而，对于曾接受过直接注射颗粒物（如硅胶、矿物油、液体石蜡或凡士林）以隆乳的患者，MRI筛查可能有一定局限性，因为纤维化和注射性肉芽肿可能使乳腺组织在乳腺X线摄影和超声检查中难以辨认。因此，对于接受过游离颗粒注射隆乳的患者，增强乳腺MRI是检测乳腺癌的首选方法\[4,10]。关于植入物评估及植入物破裂筛查证据的讨论，请参阅ACR适宜性标准®专题“乳腺植入物评估”\[17]。
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000993
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support the use of MRI breast without IV contrast for screening in this clinical setting. However, transgender women may have breast implants placed for augmentation. For evaluation of implants and for discussion of the evidence regarding screening for implant rupture, please see the ACR Appropriateness Criteria ® topic on “ Breast Implant Evaluation ” \[17]. 目前尚无相关文献支持在此临床情况下使用无静脉对比剂的乳腺MRI进行筛查。然而，跨性别女性可能因隆胸手术植入了乳房假体。关于假体评估及假体破裂筛查证据的讨论，请参阅ACR适宜性标准®专题"乳房假体评估"\[17]。
* 检查项目: US breast / US乳腺常规超声检查
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0003 / R:CR000994
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明:

##### S0123 Variant: Variant 5:  Breast cancer screening. Transmasculine (female-to-male) patient with bilateral mastectomies (“top surgery”) at any age and any risk. | 乳腺癌筛查。跨性别男性（女跨男）患者，任何年龄行双侧乳房切除术（“胸部手术”），任何风险。

检查推荐列表：

* 检查项目: Mammography Screening / MG双侧乳腺钼靶
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0010
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of digital mammography for breast cancer screening in this clinical setting. 目前尚无相关文献支持在此临床情境下使用数字乳腺X线摄影进行乳腺癌筛查。
* 检查项目: Digital Breast Tomosynthesis Screening / MG双侧乳腺钼靶(筛查)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0001 / R:CR000995
  * 证据强度: Expert Consensus
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: There is no relevant literature to support the use of DBT for breast cancer screening in this clinical setting. 目前尚无相关文献支持在此临床背景下使用数字乳腺断层合成技术（DBT）进行乳腺癌筛查。
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR000998
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support the use of MRI without IV contrast for breast cancer screening in this clinical setting. 目前尚无相关文献支持在此临床情况下使用无静脉对比剂的MRI进行乳腺癌筛查。
* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR000997
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support the use of MRI breast without and with IV contrast for breast cancer screening in this clinical setting. 目前尚无相关文献支持在此临床情况下使用无静脉注射对比剂及静脉注射对比剂的乳腺MRI进行乳腺癌筛查。
* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0003 / R:CR000999
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support the use of US for breast cancer screening in this clinical setting. In cisgender women with a personal history of breast cancer, a few small and retrospective studies report utility in surveillance with US after mastectomy \[28]. For a discussion of screening after mastectomy in high-risk patients, please see the ACR Appropriateness Criteria ® topic on “ Imaging after Mastectomy and Breast Reconstruction ” \[28]. 目前尚无相关文献支持在此临床背景下使用超声进行乳腺癌筛查。对于有乳腺癌个人史的顺性别女性，少数小型回顾性研究报道了乳房切除术后超声监测的效用\[28]。关于高风险患者乳房切除术后筛查的讨论，请参阅美国放射学会适宜性标准®专题“乳房切除术及乳房重建术后影像学检查”\[28]。

##### S0124 Variant: Variant 6:  Breast cancer screening. Transmasculine (female-to-male) patient with reduction mammoplasty or no chest surgery, 40 years of age or older. Average-risk patient (less than 15% lifetime risk of breast cancer). | 乳腺癌筛查。跨性别男性（女跨男）患者行乳房缩小成形术或无胸部手术，年龄≥40岁。平均风险患者（终生乳腺癌风险\<15%）。

检查推荐列表：

* 检查项目: Mammography Screening / MG双侧乳腺钼靶
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0010
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Annual screening with digital mammography or DBT is recommended in this clinical setting to screen for breast cancer beginning at age 40 and continuing while life expectancy exceeds 5 to 7 years because transmasculine patients without top surgery have breast cancer risk similar with cisgender women. Please see the ACR Appropriateness Criteria ® topic on “ Breast Cancer Screening ” \[25]. 在此临床情况下，建议从40岁开始每年进行数字乳腺X线摄影或数字乳腺断层合成摄影（DBT）筛查乳腺癌，并持续至预期寿命超过5至7年，因为未接受胸部手术的跨男性患者乳腺癌风险与顺性别女性相似。具体请参阅美国放射学会（ACR）适宜性标准中关于“乳腺癌筛查”的主题\[25]。
* 检查项目: Digital Breast Tomosynthesis Screening / MG双侧乳腺钼靶(筛查)
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0001 / R:CR001000
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Annual screening with digital mammography or DBT is recommended in this clinical setting to screen for breast cancer beginning at age 40 and continuing while life expectancy exceeds 5 to 7 years because transmasculine patients without top surgery have breast cancer risk similar with cisgender women. Please see the ACR Appropriateness Criteria ® topic on “ Breast Cancer Screening ” \[25]. In addition to planar images, DBT allows for creation and viewing of thin-section reconstructed images that decrease the lesion-masking effect of overlapping normal tissue, thereby decreasing false-positive recalls as well as improving CDR in breast cancer screening. 在此临床背景下，建议从40岁开始并持续至预期寿命超过5至7年期间，每年采用数字乳腺X线摄影或数字乳腺断层合成摄影（DBT）进行乳腺癌筛查，因为未接受胸部手术的跨男性患者具有与顺性别女性相似的乳腺癌风险。具体请参阅ACR适宜性标准®中关于"乳腺癌筛查"的主题\[25]。除平面图像外，DBT技术可生成并观察薄层重建图像，减少正常组织重叠对病灶的遮蔽效应，从而降低假阳性召回率并提高乳腺癌筛查的癌症检出率（CDR）。
* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 2
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0003 / R:CR001002
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is insufficient evidence to support the use of US for breast cancer screening of average-risk patients with nondense breast tissue \[25,29]. Dense breast tissue lowers the sensitivity of mammography and increases breast cancer risk when compared with fatty breasts \[25,30]. In patients with dense breasts and no additional risk factors, breast US may be useful as an adjunct to mammography for incremental cancer detection \[25,31]; however, the increased risk of a false-positive examination should be considered in the decision \[25,32-34]. 现有证据不足以支持对平均风险且乳腺组织非致密的患者使用超声进行乳腺癌筛查\[25,29]。与脂肪型乳腺相比，致密乳腺组织会降低乳腺X线摄影的敏感性并增加乳腺癌风险\[25,30]。对于乳腺致密但无其他危险因素的患者，乳腺超声可作为乳腺X线摄影的辅助手段以提高癌症检出率\[25,31]；但决策时需考虑假阳性检查结果风险增加的问题\[25,32-34]。
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR001004
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support the use of MRI without IV contrast for breast cancer screening in this clinical setting. 目前尚无相关文献支持在此临床情况下使用无静脉对比剂的MRI进行乳腺癌筛查。
* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0005 / R:CR001003
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is no relevant literature to support the use of MRI breast without and with IV contrast for breast cancer 目前尚无相关文献支持使用无静脉注射对比剂及增强乳腺 MRI 进行乳腺癌筛查。

##### S0125 Variant: Variant 7:  Breast cancer screening. Transmasculine (female-to-male) patient with reduction mammoplasty or no chest surgery, 30 years of age or older. Intermediate risk (patient with personal history of breast cancer, lobular neoplasia, atypical ductal hyperplasia, or 15% to 20% lifetime risk of breast cancer). | 乳腺癌筛查。跨性别男性（女跨男）患者行乳房缩小成形术或无胸部手术，年龄≥30岁。中危（患者有乳腺癌、小叶肿瘤、非典型导管增生既往史，或终生乳腺癌风险15%至20%）。

检查推荐列表：

* 检查项目: Mammography Screening / MG双侧乳腺钼靶
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0010
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Annual screening with digital mammography or DBT is recommended in this clinical setting as it is for risk- comparable cisgender women with high-risk lesions, such as lobular neoplasia or atypical ductal hyperplasia, beginning at diagnosis but not before 30 years of age \[25,35]. Transmasculine patients with a personal history of breast cancer are recommended to have mammography every 12 months because their breast cancer risk is similar to cisgender women \[25,35]. The sensitivity of mammography decreases with increasing density. For a discussion of breast cancer screening in intermediate-risk patients, please see the ACR Appropriateness Criteria ® topic on “ Breast Cancer Screening ” \[25]. 在此临床背景下，建议每年进行数字乳腺X线摄影或数字乳腺断层合成（DBT）筛查，这与具有高风险病变（如小叶肿瘤或不典型导管增生）且风险相当的顺性别女性相同，筛查应从确诊时开始但不早于30岁\[25,35]。有乳腺癌个人史的跨男性患者建议每12个月进行一次乳腺X线检查，因其乳腺癌风险与顺性别女性相似\[25,35]。乳腺X线摄影的敏感性随乳腺密度增加而降低。关于中风险患者乳腺癌筛查的讨论，请参阅ACR适宜性标准®专题“乳腺癌筛查”\[25]。
* 检查项目: Digital Breast Tomosynthesis Screening / MG双侧乳腺钼靶(筛查)
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0001 / R:CR001005
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Annual screening with digital mammography or DBT is recommended in this clinical setting as it is for risk- comparable cisgender women with high-risk lesions, such as lobular neoplasia or atypical ductal hyperplasia, beginning at diagnosis but not before 30 years of age \[25,35]. Transmasculine patients with a personal history of breast cancer are recommended to have mammography every 12 months because their breast cancer risk is similar to cisgender women \[25,35]. The sensitivity of mammography decreases with increasing density. DBT can address some of the limitations encountered with standard digital mammography. In addition to planar images, DBT allows for creation and viewing of thin-section reconstructed images that decrease the lesion-masking effect of overlapping normal tissue, thereby decreasing false-positive recalls as well as improving CDR in breast cancer screening. Please see the ACR Appropriateness Criteria ® topic on “ Breast Cancer Screening ” \[25]. 在此临床背景下，建议每年进行数字乳腺X线摄影或数字乳腺断层合成摄影（DBT）筛查，这与具有高风险病变（如小叶肿瘤或不典型导管增生）且风险相当的顺性别女性筛查方案一致，应从确诊后开始但不宜早于30岁\[25,35]。有乳腺癌个人史的跨男性患者建议每12个月进行一次乳腺X线检查，因其乳腺癌风险与顺性别女性相似\[25,35]。乳腺X线摄影的敏感度会随乳腺密度增加而降低。DBT可弥补标准数字乳腺X线摄影的部分局限性。除平面图像外，DBT还能生成并显示薄层重建图像，减少正常组织重叠对病灶的遮蔽效应，从而降低假阳性召回率并提高乳腺癌筛查的癌症检出率。详见ACR适用性标准®专题《乳腺癌筛查》\[25]。
* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 5
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0005 / R:CR001007
  * 证据强度: LimitedReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: Studies of cisgender females with intermediate risk for breast cancer support the use of screening breast MRI with IV contrast in certain subsets of the population, including patients with a history of lobular neoplasia \[25,36,37] or a personal history of breast cancer \[25,38,39]. For a discussion of breast cancer screening in intermediate-risk patients, please see the ACR Appropriateness Criteria ® topic on “ Breast Cancer Screening ” \[25]. 针对乳腺癌中等风险的顺性别女性研究支持在特定人群中使用静脉注射对比剂的乳腺MRI筛查，包括有小叶性肿瘤病史\[25,36,37]或个人乳腺癌病史的患者\[25,38,39]。关于中等风险患者乳腺癌筛查的讨论，请参阅ACR适宜性标准®专题"乳腺癌筛查"\[25]。
* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 5
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0003 / R:CR001008
  * 证据强度: StrongReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: In patients with dense breasts and increased risk of breast cancer, supplementing screening mammography with 对于致密乳腺且乳腺癌风险增高的患者，补充筛查性乳腺X线摄影可结合
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR001009
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is insufficient evidence to support the use of MRI breast without IV contrast for breast cancer screening in this clinical setting. 现有证据不足以支持在该临床情况下使用无静脉对比剂的乳腺MRI进行乳腺癌筛查。

##### S0126 Variant: Variant 8:  Breast cancer screening. Transmasculine (female-to-male) patient with reduction mammoplasty or no chest surgery, 25 to 30 years of age or older. High risk (patient with genetic predisposition to breast cancer or untested patient with a first-degree relative with genetic predisposition to breast cancer, patient with a history of chest irradiation between 10 to 30 years of age, patient with 20% or greater lifetime risk of breast cancer). | 乳腺癌筛查。跨性别男性（女跨男）患者，乳房缩小成形术或无胸部手术，年龄≥25至30岁。高风险（乳腺癌遗传易感性或未检测的一级亲属有乳腺癌遗传易感性，10至30岁胸部放疗史，终生乳腺癌风险≥20%）。

检查推荐列表：

* 检查项目: Mammography Screening / MG双侧乳腺钼靶
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0010
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Annual screening with digital mammography or DBT is recommended in this clinical setting as it is for risk- comparable cisgender women beginning 8 years after radiation therapy but not before age 25 for patients who received mantle radiation between 10 and 30 years of age \[25,42]. In transmasculine patients with familial breast cancer risk, an annual screening mammogram is recommended starting 10 years earlier than the affected relative’s age at diagnosis but not before 30 years of age, as their breast cancer risk is similar to cisgender women \[25,35]. 在此临床情况下，建议每年进行数字乳腺X线摄影或数字乳腺断层合成（DBT）筛查，这与风险相当的顺性别女性相同——从放射治疗结束后8年开始（但对于在10至30岁期间接受斗篷野放疗的患者不早于25岁）\[25,42]。对于具有家族性乳腺癌风险的跨男性患者，建议从比患病亲属确诊年龄早10年开始（但不早于30岁）每年进行乳腺X线筛查，因其乳腺癌风险与顺性别女性相似\[25,35]。
* 检查项目: Digital Breast Tomosynthesis Screening / MG双侧乳腺钼靶(筛查)
  * 评分: 9
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0001 / R:CR001010
  * 证据强度: LimitedReferences
  * Adult RRL: ☢☢  0.1-1mSv
  * Peds RRL:
  * 推荐说明: Annual screening with digital mammography or DBT is recommended in this clinical setting as it is for risk- comparable cisgender women beginning 8 years after radiation therapy but not before age 25 for patients who received mantle radiation between 10 and 30 years of age \[25,42]. In transmasculine patients with familial breast cancer risk, an annual screening mammogram is recommended starting 10 years earlier than the affected relative’s age at diagnosis but not before 30 years of age, as their breast cancer risk is similar to cisgender women \[25,35]. The sensitivity of mammography decreases with increasing density. DBT can address some of the limitations encountered with standard digital mammography. In addition to planar images, DBT allows for creation and viewing of thin-section reconstructed images that decrease the lesion-masking effect of overlapping normal tissue, thereby decreasing false-positive recalls as well as improving CDR in breast cancer screening. Please see the ACR Appropriateness Criteria ® topic on “ Breast Cancer Screening ” \[25]. 在此临床背景下，建议每年进行数字乳腺X线摄影或数字乳腺断层合成（DBT）筛查，这与风险相当的顺性别女性相同——从放射治疗结束后8年开始（但接受斗篷野放疗且年龄在10至30岁之间的患者不应早于25岁）\[25,42]。对于具有家族性乳腺癌风险的跨男性患者，建议从比患病亲属确诊年龄早10年开始（但不早于30岁）每年进行乳腺X线筛查，因其乳腺癌风险与顺性别女性相似\[25,35]。乳腺X线摄影的敏感性随乳腺密度增加而降低，而DBT可弥补标准数字乳腺X线摄影的部分局限性。除平面图像外，DBT还能生成并显示薄层重建图像，减少正常组织重叠对病灶的遮蔽效应，从而降低假阳性召回率并提高乳腺癌检出率（CDR）。详见ACR适宜性标准®专题《乳腺癌筛查》\[25]。
* 检查项目: MRI Breast Without and With IV Contrast / MR乳腺(平扫+增强)
  * 评分: 8
  * 适宜性: Usually appropriate / 通常适宜
  * 编码: P:PR0005 / R:CR001012
  * 证据强度: StrongReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: Evidence from studies of high-risk cisgender women supports the use of MRI breast with IV contrast for breast cancer screening in this clinical setting because transmasculine patients have breast cancer risk similar to cisgender women. Breast MRI in a high-risk population has a higher sensitivity than mammography, and the combination of mammography and MRI in this population has the highest sensitivity (92.7% compared with 52% for US and mammography combined) \[25,43-50]. For this reason, MRI is recommended as an adjunct to screening DBT or mammography. For a discussion of breast cancer screening in high-risk patients, please see the ACR Appropriateness Criteria ® topic on “ Breast Cancer Screening ” \[25]. 针对高风险顺性别女性的研究证据支持在该临床情境下使用静脉注射对比剂的乳腺MRI进行乳腺癌筛查，因为跨男性患者的乳腺癌风险与顺性别女性相似。在高风险人群中，乳腺MRI的敏感性高于乳腺X线摄影，而乳腺X线摄影与MRI联合应用时敏感性最高（达92.7%，而超声与乳腺X线摄影联合仅为52%）\[25,43-50]。因此，建议将MRI作为筛查性数字乳腺断层合成摄影（DBT）或乳腺X线摄影的辅助手段。关于高风险患者乳腺癌筛查的详细讨论，请参阅ACR适宜性标准®专题"乳腺癌筛查"\[25]。
* 检查项目: US Breast / US乳腺常规超声检查
  * 评分: 5
  * 适宜性: May be appropriate / 可能适宜
  * 编码: P:PR0003 / R:CR001013
  * 证据强度: StrongReferences
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: Screening breast US may be helpful in this clinical setting because transmasculine patients have breast cancer risk similar to cisgender women. Mammography alone does not perform as well as mammography plus supplemental 在此临床背景下筛查性乳腺超声可能具有价值，因为跨男性患者的乳腺癌风险与顺性别女性相似。单纯乳腺X线摄影的性能不如乳腺X线摄影联合补充性筛查。
* 检查项目: MRI Breast Without IV Contrast / MR乳腺(平扫)
  * 评分: 1
  * 适宜性: Usually not appropriate / 通常不适宜
  * 编码: P:PR0007 / R:CR001014
  * 证据强度: Expert Consensus
  * Adult RRL: O 0 mSv
  * Peds RRL: O 0 mSv \[ped]
  * 推荐说明: There is insufficient evidence to support the use of MRI breast without IV contrast for breast cancer screening in this clinical setting. 现有证据不足以支持在该临床情况下使用无静脉对比剂的乳腺MRI进行乳腺癌筛查。
